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Just the Facts in Critical Care represents the essential material contained in
Principles of Critical Care, 3rd Edition, published in 2005. Just the Facts was
created to guide intensive care physicians, internists, anesthesiologists, sur-
geons, emergency physicians, and others who care for critically ill patients.
Following roughly the framework of “Principles,” this work provides essential
information in a readily accessible format. Much of the background material
and detail present in the larger text has been omitted in favor of facts vital to
the clinician confronted with an acutely ill patient or the physician studying for
board certification examinations. Just the Facts is not intended to be compre-
hensive or to replace the larger text, so each chapter refers the reader seeking
additional detail to more complete information in “Principles.”
In Critical Care, time is of the essence, a fact we took to heart in creating
this work. Each chapter begins with a brief overview of the topic. The material
is then divided into a highly organized structure, emphasized by a bullet-point
style. Key points in recognition, diagnosis, evaluation, monitoring, therapy, and
prognosis are clearly stated. Figures and tables, most created expressly for this
work, serve to convey maximal information at a glance. Together, these fea-
tures make for chapters that can be scanned quickly for maximum efficiency.
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1 ASSESSMENT OF THE
CRITICALLY ILL PATIENT
Vidya Krishnan
KEY POINTS
• Begin with a brief but careful history and directed
examination, seeking acute life-threats.
• Vital signs, neck veins, oximetry, and chest radiography
are particularly valuable diagnostic aids in the initial
evaluation.
• Severity of illness scores may guide initial therapy and
provide a rough guide to prognosis.
• Quickly liberate the patient from excessive early
interventions so that there are not more treatments
than diseases.
• Seek to identify the patient who may be dying and
follow advance directives when available.
INITIAL ASSESSMENT
• Critical illness involves respiratory failure, hemody-
namic instability, or other acute threat to life or limb.
The initial assessment and management of the criti-
cally ill patient is crucial in the course of the patient’s
care. Exemplary critical care management involves the
careful balance of the institution of rapid diagnostic
and therapeutic interventions and development of a
rational and compassionate management plan based on
the therapeutic goals. The acquisition of the skills nec-
essary to achieve this balance is a lifelong learning
process.
• Advance directives. The formulation of a therapeutic
plan should be guided by the patient’s wishes for resus-
citation and intubation. The presence of a “living will”
does not obviate the need to discuss with the patient’s
significant others about the direction of therapy.
• Primary survey. Basic life support and advanced life
support protocols provide a guide to initiating a patent
airway, ensuring adequate ventilation, and managing
circulation.
• Secondary survey. The role of clinical excellence,
by obtaining a careful medical history, physical
examination, and laboratory testing, is to elucidate
the nature of the patient’s current disease, and to
formulate a rational diagnostic and therapeutic
plan. A thorough compilation of the patient’s med-
ical history is often the most helpful information in
directing further management of the critically ill
patient.
 Sources of information include the patient, his/her
significant others, medical records, and prior radio-
logic studies and laboratory values.
 Particular attention to the patient’s health and activ-
ities preceding the acute event may contribute to
defining the current pathophysiologic state.
 The physical examination will provide information
regarding the patient’s current condition. The fol-
lowing list is a guideline of physical findings to
evaluate, and is by no means exhaustive:
 Vital signs
• Hypothermia and hyperthermia may be a sign of
infection or inflammation.
• Heart rate is usually elevated, but exceptions
include beta-blocker use, hypoglycemia, and
cardiac disease.
• Blood pressure may be initially normal, due to
compensatory mechanism, or deranged.
• Respiratory rate abnormalities may reflect dis-
turbances in acid-base status.
• Pain (“the fifth vital sign”) may direct medical
attention to trauma or the source of infection.
 Skin. Findings may include sweat, dry, altered tem-
perature, decreased capillary refill, cyanosis, pale,
duskiness, ecchymoses or purpura, erythema, or
rash.
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 Cardiovascular
• Murmurs may represent valvular abnormalities,
and should be compared to previous examinations
for determination of whether this is a new finding.
• Jugular venous distention may represent ele-
vated right heart pressures. Flattened neck veins
may signify hypovolemia.
• Absence or reduced peripheral pulses may sig-
nify inadequate perfusion.
 Pulmonary
• Rales could be a sign of an alveolar filling process
(such as edema or infection).
• Absence of breath sounds or wheezing may sig-
nify an obstruction or pneumothorax.
 Gastrointestinal
• Shock may result in intestinal ileus or ischemia,
pancreatitis, or acalculous cholecystitis.
• Bleeding may occur anywhere along the intes-
tinal tract, and when heme is present in gastric
contents or feces, hemorrhage may be contribut-
ing to the acute state.
 Renal. Oliguria may represent obstruction, inade-
quate renal perfusion, or intrinsic renal disease.
Polyuria may occur paradoxically with acute
tubular necrosis or in a hyperosmolar state.
 Neurologic. The level of consciousness and pres-
ence of reflexes are assessable even when the
patient cannot assist the examiner.
SCORING SEVERITY OF ILLNESS
• Severity-of-illness scoring systems (Table 1-1). Scoring
systems give a quantification of the severity of illness
that may assist in determining prognosis of individual
patients in order to assist families and caregivers in
making decisions about ICU care. However, in some
studies the accuracy of prediction of outcomes from
scoring systems is not greater than that of the individ-
ual clinician’s judgment.
FORMULATE A WORKING DIAGNOSIS
• Based on the history and physical examination find-
ings, hypotheses should be formulated concerning the
mechanisms responsible for each main problem and a
differential diagnosis should be generated. Laboratory
testing and radiologic evaluations are tools to be used
to confirm or refute the clinical hypotheses. Some
common tools used in the evaluation of the critically
ill patient include the following:
 Arterial blood gas results can give insight into the
patient’s oxygenation, ventilation, and metabolic status.
 Pulse oximetry will give an indication of oxygenation,
but may be uninterpretable in the presence of poor
peripheral circulation, deranged arterial hemoglobin-
carrying capacity, or carbon monoxide poisoning.
 Chest radiography is a useful tool to diagnose tho-
racic pathology and to confirm proper intervention
techniques (e.g., endotracheal tubes and central
venous access placement, development of pneu-
mothorax or hemothorax).
 Complete blood counts, basic chemistry panels,
liver and renal function tests, cardiac enzymes, and
coagulation pathway tests may all be helpful in the
confirmation of clinical hypotheses.
 Urinary analysis may reveal an active sediment con-
sistent with acute tubular necrosis, hemorrhage, or
infection.
 Body fluid and tissue cultures assist in the diagnosis
of infection and can direct therapy when specific
pathogenic organisms are identified.
• Experienced critical care physicians recognize that the
assessment and management of critically ill patients
extend beyond the implementation of diagnostic and
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TABLE 1-1 Comparison of Severity-of-Illness Scoring Systems
SCORING SYSTEM DESCRIPTION DISEASE-SPECIFIC SIGNIFICANCE
Acute Physiology and Chronic It uses age, type of admission, chronic health Yes APACHE II is the most commonly used
Health Evaluation (APACHE) evaluation, and 12 physiologic variables clinical severity-of-illness scoring
(Acute Physiology Score or APS) to predict system in North America
hospital mortality. The 12 physiologic 
variables are defined as the most abnormal 
values during the 24 h after ICU admission
Mortality Probability Models It is the only scoring system that was derived No Instead of a numeric score, the MPM II
(MPM) at ICU admission and can therefore be used yields a direct probability of survival
at ICU admission
Simplified Acute Physiology The probability of hospital mortality is  No
Score II (SAPS) calculated from the score
Sequential Organ Failure No Independent of the initial values, an
Assessment (SOFA) increase in the SOFA score during
the first 48 h of ICU admission predicts
a mortality rate of at least 50%
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therapeutic interventions. Students of critical care
management should keep in mind these additional
clinical pearls.
 Liberate the patient from interventions, so that there
are not more treatments than diagnoses. One of the
consequences of protocol-driven resuscitations and
fast-paced clinical decision processes observed in the
management of ICU patients, is that the recovered
patient has excessive and unnecessary treatments.
Adverse events are associated with nearly all interven-
tions, and the balance of positive and negative effects
should be repeatedly evaluated. The approach of the
critical care team should be frequent (at least daily)
assessment of the need for interventions, and removal
of unnecessary and potentially toxic interventions.
 Define therapeutic goals and seek the least interven-
tion to achieve each. It is often helpful to concretely
identify the therapeutic goals for a patient, so that
the management plan will be focused to achieve
these goals. Invasive and prolonged resuscitation
efforts are inappropriate in a patient whose goals
have been altered from cure to comfort.
 Communicate with the patient and his/her family.
Family and patient meetings are necessary to intro-
duce the critical care physician and the health care
team, to communicate patient status, to obtain consent
for anticipated interventions, and to answer questions
and alleviate anxiety that naturally accompanies criti-
cal illness of one’s self or significant others.
BIBLIOGRAPHY
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2 AIRWAY MANAGEMENT
Nuala Meyer
KEY POINTS
• Bag-mask ventilation is a life-saving skill.
• Prior to endotracheal intubation, the operator should
assess the patient’s disease, anatomy, and cardiovas-
cular stability with particular attention to cervical
spine stability, intracranial pressure, and drug con-
traindications.
• Esophageal intubation must be recognized promptly.
• Hypotension commonly complicates endotracheal
intubation.
• A dislodged, freshly-placed tracheostomy tube should
generally not be reinserted emergently—instead,
insert an endotracheal tube through the mouth, then
attempt open the tracheostomy wound.
BAG-MASK VENTILATION
• The first skill that any physician or respiratory thera-
pist should master is the ability to successfully mask
ventilate an awake or somnolent patient. When done
correctly, mask ventilation can allow time for a more
careful, well-planned intubation, and can avoid pre-
cipitating hemodynamic instability. The hallmarks of
mask ventilation are:
 Forming an adequate seal between the patient’s skin
and the Ambu-bag
 Jaw-thrust maneuver to elevate the tongue away
from the epiglottis
 Steady breath support with 100% FiO2, ideally aug-
menting the patient’s own breathing efforts without
hyperventilation
• Bag-mask ventilation can be performed either by a solo
practitioner who can skillfully seal the mask and pro-
vide jaw thrust with one hand while delivering breaths
with the other, or by two practitioners: one to control
the mask and jaw, and another to deliver breaths.
INDICATIONS FOR INTUBATION
• The indications for intubation and mechanical ventila-
tion are many and varied. They can be broadly catego-
rized as involving one of the following four systems:
airway disease, pulmonary disease, circulatory disease,
and neurologic disease (Table 2-1).
 Airway disease encompasses problems with airway
support: for example, airway narrowing by edema
or tumor; pharyngeal instability (e.g., facial frac-
tures); depressed mental status causing inability to
protect airway or clear secretions; or paralyzed
vocal cords causing a functional airway obstruction.
TABLE 2-1 Indications for Intubation
INDICATION 
FOR INTUBATION EXAMPLE
Airway disease Tracheal obstruction with tumor, laryngeal
edema
Pulmonary disease Hypoxemia, chronic obstructive pulmonary
disease (COPD) exacerbation, opioid 
overdose
Circulatory disease Shock, sepsis, cardiac arrest
Neurologic disease Loss of gag reflex, increased ICPs
 Pulmonary disease refers to acute hypoxemic respi-
ratory failure (low arterial oxygen saturation), venti-
latory failure from an increased work of breathing or
airway obstruction, or hypoventilation from weak-
ness, drugs, or central nervous system (CNS) causes.
 Circulatory disease can require intubation in cases
of shock, sepsis, or cardiopulmonary arrest. In this
instance, intubation and mechanical ventilation may
decrease the proportion of cardiac output expended
on the respiratory muscles, and decrease the body’s
oxygen consumption or VO2.
 Neurologic disease, such as elevated intracranial
pressure (ICP) requiring hyperventilation or altered
consciousness with loss of gag reflex, also benefits
from elective intubation.
• Finally, intubation may be imperative in the transport
of an unstable critically ill patient, for instance, to a
radiologic procedure or between hospitals.
ASSESSMENT OF THE PATIENT PRIOR
TO INTUBATION
• When called to intubate a critically ill patient, an
expeditious but thorough assessment of the patient’s
underlying disease, airway anatomy, and cardiopul-
monary status should be reviewed prior to intubation.
Physicians should perform a risk assessment of the
following conditions:
 Anatomic impediments to intubation or to direct
laryngoscopy; have a plan for urgent tracheostomy
prior to attempting intubation.
 Cervical instability, such as in rheumatoid arthri-
tis or cervical fracture
 Poor mouth opening
 Short neck or large tongue
 Tumor, edema, or infection encroaching on the
airway
 Mallampati classification
 Neurologic factors which should necessitate IV gen-
eral anesthesia for intubation.
 Elevated ICP
 Intracranial bleeding, arteriovenous malformation
(AVM), or aneurysm
 Aspiration risk—cricoid pressure (the Sellick
maneuver) may be helpful.
 NPO (nothing by mouth) status
 Pregnancy
 Gastroparesis
 Obesity
 Pulmonary risk—certain patients cannot be reliably
bag-mask ventilated, and should have rapid intuba-
tion with institution of mechanical ventilation.
 Bronchoconstriction
 Severe refractory hypoxemia
 Cardiovascular risk:
 Ischemia risk—laryngoscopy and endotracheal
intubation often produce myocardial ischemia in
at-risk patients. Such patients may be best man-
aged with awake intubation with aggressive topi-
cal anesthesia.
 Hypovolemia—intubation and positive pressure
ventilation will augment the hemodynamic effects
of hypovolemia, and hypotension may be precipi-
tated. Patients with suspected hypovolemia should
be rapidly volume expanded with intravenous
fluid once the decision is made to intubate.
 Dysrhythmias may be observed in patients with
structurally abnormal hearts.
 Coagulation risk factors:
 Thrombocytopenia or coagulopathy are relative
contraindications to nasotracheal intubation, lest
epistaxis be severe.
 Contraindications to succinylcholine:
 Hyperkalemia
 Malignant hyperthermia
 History of burns, crush injury, or spinal cord injury
EQUIPMENT AND PREPARATION
• When planning intubation of a critically ill patient, the
following should be immediately available and ready
for use by the anesthesiology team:
 Functioning IV line
 Monitors: pulse oximeter, blood pressure cuff or
arterial line, ECG, and, if possible end-tidal CO2
monitor/capnograph
 Suction with Yankauer
 Ambu-bag
 Ventilator
• Establishment of an artificial airway is a skill obtained
with significant amounts of training. Use of many of
the drugs listed below should be reserved to physicians
well versed in the management of a difficult airway.
The physician or team performing intubation will need
access to the following additional equipment:
 Laryngoscope with functioning light × 2
 Assortment of blades (Macintosh and Miller)
 Variety of endotracheal tubes (ETT) of different sizes
 Malleable metal stylet
 Stethoscope
 Drugs
 Topical anesthetics: viscous lidocaine, benzocaine
or lidocaine spray
 Glycopyrrolate: dries the mouth to improve visu-
alization
 Paralytics: rocuronium or succinylcholine
 IV anesthetic agents: lidocaine, midazolam, fen-
tanyl, thiopental, etomidate, propofol, or ketamine
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• A thorough review of intubation procedures is beyond
the scope of this book, but can be found in numerous
anesthesiology textbooks.
PHYSIOLOGIC CHANGES ASSOCIATED
WITH INTUBATION
• The presence of an artificial airway and mechanical
ventilation provokes certain predictable physiologic
consequences (Box 2-1).
 ETT cause increased airways resistance.
 An 8.0 mm tube causes a 20% increase in airway
resistance; a 7.0 mm tube has almost twice this
resistance.
 Inspissated mucus or respiratory secretions can
further decrease the diameter of the ETT, causing
increased resistance.
 Tracheal intubation can trigger bronchospasm in
certain individuals, especially patients with asthma.
 Mechanical ventilation usually changes intrathoracic
pressure from negative to positive, which may impair
venous return and thus decrease cardiac output.
 Mechanical ventilation may abolish stimuli such as
hypoxia, hypercarbia, and dyspnea which may have
contributed to an increased level of endogenous cat-
echolamines; the abolition of these stimuli can
sometimes cause a fall in blood pressure or heart
rate commensurate with the fall in catechols.
 Patients with small airways obstruction—asthma
and emphysema—are at risk for auto-PEEP (positive
end-expiratory pressure), in which the lungs are
unable to return to their functional residual capacity
(FRC), due to their need for a long expiratory time.
Patients are especially prone to this phenomenon
during vigorous Ambu-bag ventilation, where tidal
volumes are not readily apparent. High levels of
PEEP, whether from auto-PEEP or extrinsically from
the ventilator, can increase the pulmonary vascular
resistance and diminish versus return, thus produc-
ing hypotension.
COMPLICATIONS OF INTUBATION
AND MECHANICAL VENTILATION
• Intubation of critically ill patients in the ICU is often
necessary but can be fraught with danger. Some more
common complications encountered, which should be
fresh in one’s mind when evaluating a patient postin-
tubation, are:
 Right mainstem intubation; all ETT placements
must be confirmed by chest radiograph shortly after
placement
 Esophageal intubation
 This can be minimized with the routine use of
end-tidal CO2 monitors to confirm gas exchange
after intubation.
 Breath sounds should always be confirmed once
the ETT is in place.
 End-tidal CO2 monitoring is notoriously unreli-
able in the setting of cardiac arrest/absent circula-
tion, and occasionally in children with severe
bronchospasm.
 Gastric aspiration
 Dental injury and aspiration of teeth
 Tracheal or esophageal lacerations
 Vocal cord trauma
 Impaired swallowing
 Dysrhythmias
 Premature ventricular contractions (PVCs), ven-
tricular tachycardia, and ventricular fibrillation in
patients susceptible to these rhythms.
 Bradycardia can be observed in young patients
with high vagal tone.
 Death
 Death occurs around the time of intubation in
approximately 3% of critically ill patients.
 Death may be a consequence of airway manipula-
tion, or may speak to the severity of illness in
patients requiring intubation.
TRACHEOSTOMY
• Tracheostomy may be indicated in evolving upper
airway obstructions such as angioedema, epiglottitis/
supraglottic abscess, bilateral vocal cord paralysis, or
tumor encroachment on the trachea. It is also the
preferred route to provide long-term mechanical ven-
tilation. Tracheostomy is used to treat patients who are
unable to handle their airway secretions, and finally,
may be the best method to liberate patients from pro-
tracted mechanical ventilation.
• Benefits of tracheostomy include:
 Easier and safer access to the mouth than patients with
orotracheal tubes; this allows better oral hygiene.
Increased airways resistance
Bronchospasm
Increased intrathoracic pressures
Decreased venous return
Decreased cardiac output
Hypotension
Auto-PEEP
BOX 2-1 Physiologic Changes Associated 
with Mechanical Ventilation
 More comfortable than orotracheal intubation; facil-
itates eventual phonation and eating.
 Less airway trauma over time; in general, patients
who will require mechanical ventilation for more
than 2 weeks will benefit from tracheostomy.
 Reduces anatomic dead space, thus increasing the
alveolar ventilation for every given minute ventila-
tion. This allows patients with chronic weakness or
chronically high ventilatory demand to have effec-
tive ventilation with a decreased workload.
COMPLICATIONS OF TRACHEOSTOMY
• Immediate:
 Hemorrhage—neck hematomas can compress or
deviate the trachea
 Malpositioning
 Pneumothorax/pneumomediastinum
• Long-term:
 Irritation or erosion of trachea into esophagus (tra-
cheoesophageal fistula)
 Tracheal stenosis/tracheal malacia
• In the event that a freshly placed tracheostomy
becomes dislodged, do not attempt to replace the tra-
cheostomy! Doing so carries great risk of dissecting
into the soft tissues of the neck, and failing to ade-
quately ventilate the patient. Instead, mask-ventilate
the patient while you call anesthesia or reintubate the
patient endotracheally.
• Airway management skills take a great deal of time
and practice to master. The optimal place for training
in this regard is in the operating room, guided by
experienced anesthesiologists. Because critically ill
patients do not tolerate multiple attempts at establish-
ing adequate ventilation, these skills are best learned
in the elective setting and then translated to the ICU.
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3 RESUSCITATION
Steven Q. Davis
KEY POINTS
• Survival to discharge after cardiac arrest is still an
uncommon event.
• Early response and use of ACLS protocols is the key
to patient survival.
• Patients at risk for sudden cardiac death should be
evaluated for automatic internal cardiac defibrillators
(AICDs).
EPIDEMIOLOGY
• Overall, 44% of 14,720 adult in-hospital cardiac arrest
victims had a return of spontaneous circulation, but
only 17% survived to hospital discharge.
• Ventricular fibrillation (VF) was the initial lethal
rhythm in 16% of victims, of whom 34% survived to
discharge.
• The survival numbers for out-of-hospital arrests are
much lower.
PREVENTION
• Patients frequently exhibit signs and symptoms of dete-
rioration up to 12 hours before they suffer an arrest.
• These may include:
 Vital sign changes
 Progressive hypotension
 Tachycardia
 Hypothermia
 Hypoxemia
 Tachypnea
 Mental status changes
 Progressive dyspnea
PROGNOSIS
• The most important intervention is the rapid applica-
tion of advanced cardiac life support (ACLS) proto-
cols, particularly early defibrillation.
• Time from notification of the arrest to first shock ide-
ally should be <5 minutes.
• This principle has lead to the development and public
availability of automatic external defibrillators (AEDs)
for first responders.
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TREATMENT
• Treatment of an arrested patient begins with the ABCs
(Airway, Breathing, and Circulation). A practitioner
of critical care should be familiar with all ACLS
guidelines for cardiac arrest and resuscitation.
• Calling for immediate assistance is very important. A
successful resuscitation is usually a team effort.
• A clear “leader” or “runner” for the code needs to be
established. One person is in charge of orders and
directing the team, while other members of the team
focus on the needed activities.
 Airway management
 Intravenous access
 Chest compressions
 Drug administration
 Transcribing and recording
 Family counseling
• Initially, the airway should be managed with a bag-
valve-mask to ensure the airway is patent. A skilled
operator well versed in bagging while maintaining a
patent airway should perform this. The airway should
then be secured with an endotracheal tube as soon as
is feasible.
• 100% FiO2 should be delivered via either the bag-
valve-mask or the endotracheal tube.
• As a general rule, the radial pulse disappears at a pres-
sure of 80 mmHg, the femoral at 70, and the carotid at
60. If the carotid pulse cannot be felt, compressions
should be initiated at a rate of 100 beats per minute
with a depth of 1–2 in. Attention should be paid to the
quality of compressions as they are often inadequate.
• End-tidal carbon dioxide measurement (capnography) can
be used to assess the adequacy of the circulation (either
native or via compressions). A low (<10 mmHg) end-tidal
carbon dioxide level portends a dismal prognosis.
• Large bore IV access should be obtained as soon as
possible.
 If a large bore central catheter is chosen, the optimal site
is the femoral vein, since other sites will be difficult due
to chest compressions and airway management.
 A triple lumen catheter is not a large bore catheter.
 If a central catheter is not possible, 14–18 gauge
peripheral IV access is acceptable.
• Once an IV access is established, the patient should
receive at least 500–1000 cc of normal saline or lac-
tated Ringer over a few minutes (wide open, not on an
infusion pump).
• If an intravenous catheter is placed during a resuscita-
tion attempt, it should be considered a nonsterile line
and removed no later than 8 hours after successful
resuscitation.
 As the patient is stabilized, sterile insertion of any
monitoring devices should be obtained. It is a “gen-
eral rule” that any device inserted during a patient
resuscitation is contaminated.
• ACLS protocols should be followed throughout the
resuscitation event, realizing that different algorithms
will be employed as the patient moves though various
arrhythmias.
• Particular attention should be given to finding a cause
for pulseless electrical activity (PEA). These include:
cardiac tamponade, drug overdose, hyperkalemia,
hypothermia, hypovolemia, hypoxia, massive pul-
monary embolism, myocardial infarction, and tension
pneumothorax. Hypovolemia and hypoxemia are the
most likely etiologies for inpatients (Box 3-1).
• When making the decision to terminate resuscitation
efforts, the team leader should verbally summarize
efforts so far, and ask for any further suggestions from
other members of the team.
• A debriefing session should occur shortly after the
resuscitation attempt, preferably while every member of
the team is still near the location of the resuscitation. If
applicable, records should be forwarded to the hospital’s
cardiopulmonary resuscitation (CPR) committee for
quality review.
• Biphasic defibrillators are becoming more prevalent.
Hospital personnel involved in resuscitation will need
to become familiar with them.
• AEDs are becoming more prevalent in the commu-
nity, and significantly reduce the time to first shock.
OTHER CONCERNS
AND INTERVENTIONS
• A new model has emerged for cardiac arrest, breaking
it down into three core components:
 Electrical (first 4 minutes)
 Circulatory (4–10 minutes)
 Metabolic phase (after 10 minutes)
Mechanical
Pulmonary embolism (e.g., clot, air, and amniotic fluid)
Pericardial tamponade
Tension pneumothorax
Myocardial infarction
Auto-PEEP
Systemic
Drug overdose
Hyperkalemia
Hypothermia
Hypovolemia
Hypoxemia
BOX 3-1 Causes of PEA Arrest: The Differential
Diagnosis for PEA
• The most important therapeutic intervention during
the electrical phase is defibrillation for VF/ventricular
tachycardia (VT).
• Somewhat in discord with the American Heart
Association guidelines, the circulatory phase appears
to be treated most effectively initially with CPR and
ventilation, then defibrillation several minutes later.
• Ischemia and reperfusion injury become apparent
during the metabolic phase. Induced hypothermia may
have a role in the treatment of this phase of arrest.
 Subjects cooled to 32–34°C after their arrest had a
survival benefit (see Chap. 69 on therapeutic
hypothermia).
• Resuscitation personnel must stay current with resus-
citation protocols (i.e., ACLS, pediatric advanced life
support [PALS], and neonatal advanced life support
[NALS]). Recommendations for pharmacologic inter-
vention change at regular intervals.
• Thrombolytic therapy should be considered if there is
a strong suspicion for pulmonary embolism as the eti-
ology for cardiac arrest.
• When having end-of-life discussions with patients
and their family, it is of paramount importance to
remember that “do not resuscitate” does NOT mean
“do not treat.”
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4 FLUID THERAPY
E. Mirnalini Mohanraj
KEY POINTS
• The need for intravenous fluids should be judged ini-
tially and reassessed frequently.
• In severe sepsis, urgent fluid resuscitation may reduce
subsequent mortality.
• Right atrial and pulmonary wedge pressures are poor
predictors of fluid responsiveness.
• Dynamic indicators, such as the inspiratory fall in
right atrial pressure (in the spontaneously breathing
patient) or the arterial pulse pressure variation (in the
passively ventilated patient), are superior to static
pressure measurements.
• Maintenance fluids are rarely appropriate, given the
large volume of obligatory fluids infused into most
critically ill patients.
• Colloids offer no advantage over crystalloids.
INTRAVENOUS FLUID THERAPY
• Several considerations should enter into every deci-
sion to employ intravenous (IV) fluid therapy in criti-
cally ill patients.
• Initially, the patients’ intravascular volume state and
their likelihood of responding to IV fluid therapy
should be assessed.
• Secondly, both the type of fluid to be used and the rate
at which the infusion occurs should be determined.
• These decisions are highly dependent on the underly-
ing disease process and severity of illness. As with all
therapies, IV fluid therapy should be individualized
on a case-by-case basis.
ASSESSMENT OF INTRAVASCULAR
VOLUME
• Historical data, physical examination, and laboratory
data should be used as the initial means of assessing
volume status. The following factors should be
addressed when performing an initial history and
physical examination:
• Historical data
 Decrease in oral intake
 Dizziness
 Syncope
 Confusion or change in mental status
 Vomiting or diarrhea
 Polyuria
 Bleeding (hematemesis, hematochezia, melena, other)
 Recent change or noncompliance with medications
• Physical examination findings
 General appearance
 Altered mental status
 Vital signs with attention to orthostatics and tachy-
cardia
 Oliguria or anuria
 Skin turgor
 Mucous membranes
 Jugular venous pressure
 Cardiac examination (tachycardia, murmurs, extra
heart sounds)
 Pulmonary examination (crackles, effusion)
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 Peripheral perfusion (capillary refill, peripheral pulses)
 Peripheral edema
 Evidence of bleeding (gross blood on rectal exami-
nation, hematemesis, hemoptysis)
• Laboratory data
 An increased blood urea nitrogen (BUN) to creati-
nine ratio of >20 may suggest acute renal insuffi-
ciency that is secondary to volume depletion. This
finding, however, is not specific as there are other
causes for an elevation of the BUN that is out of
proportion to the creatinine.
 A decreased hematocrit may be an indicator of
bleeding as a cause of volume depletion. Such a
finding should prompt re-evaluation of the patient’s
intravascular volume status and the need for trans-
fusion.
 An elevated hematocrit may be a sign of hemocon-
centration, but this finding is not specific to volume
depletion and should not be used alone as a reliable
indicator of intravascular volume.
• Central venous pressure (CVP)
 The CVP as a surrogate for right atrial pressure is
frequently used as an estimate for intravascular
volume. The relationship is poor, however, perhaps
reflecting the vagaries of ventricular dysfunction,
pericardial disease, pulmonary disease, and the
effects of positive pressure ventilation.
 Changes in the right atrial pressure may be used
during resuscitation to assess adequacy of volume
expansion (e.g., increased CVP indicates improved
intravascular status).
 A study of 33 spontaneously breathing patients
looked at the ability of the inspiratory fall in CVP to
predict fluid responsiveness. An inspiratory fall in
right atrial pressure of >1 mmHg indicated that the
patient would likely have an increase in perfusion in
response to rapidly infused saline. Those whose
CVP did not fall during inspiration did not respond
to fluid.
• Pulmonary artery catheters (PACs) have been used
to measure pulmonary capillary wedge pressure
(PCWP) as an estimation of left atrial pressure and
left ventricular end-diastolic volume and subsequently
as an estimate of intravascular volume.
• There are limitations to this practice, causing PACs to
be used less frequently as the standard for assessing
volume status. Limitations to use of PACs include the
following:
 Technical (zero, level).
 Inappropriate interpretation (i.e., failure to read at
end-expiration)
 PEEP (end-expiratory pressure) and auto-PEEP (pos-
itive end-expiratory pressure) may alter the true value.
 PCWP represents a pressure not a volume.
 PCWP is a very poor predictor of patient respon-
siveness to volume.
 Recent studies of patients with sepsis, acute respiratory
distress syndrome (ARDS), or undergoing high-risk
operative procedures have failed to confirm earlier
concerns about harm due to the catheter, but also,
without exception, have shown that patients do not
benefit from PAC-derived information.
 While further studies are underway to assess the
benefits and risks of using PACs, the current data
indicate that alternate measures of intravascular
volume may be necessary.
• Many of these traditional methods for assessing
intravascular volume are unreliable measures that do
not reflect true intravascular volume and do not indi-
cate a patient’s potential responsiveness to volume
resuscitation.
• Dynamic measures, such as the change in arterial
pulse pressure or systolic pressure during passive ven-
tilator breaths, seem much more reliable than static
measures such as the CVP or wedge pressure.
MAINTENANCE FLUIDS
• Traditionally, the continuous infusion of IV fluids was
thought to be a relatively benign intervention.
• Maintenance fluid therapy has been routinely advo-
cated for pre- and postoperative treatment as well as
for empiric treatment for patients with poor to little
oral intake while in the hospital.
• More recent data reveal that empiric use of mainte-
nance fluids without clinical evidence of intravascular
depletion puts patients at risk for multiple complica-
tions as well as increasing their mortality.
• Inappropriate volume expansion in an intravascularly
replete patient can lead to volume overload and sec-
ondary complications including third-spacing of fluid,
pulmonary edema, myocardial dysfunction, and lim-
ited diffusion of oxygen to tissues.
• Studies on surgical patients have shown that there are
correlations between postoperative weight increases
and mortality.
 A multicenter trial evaluated postoperative complica-
tions and mortality in patients randomized to either a
standard IV fluid regimen or a restricted IV fluid reg-
imen (aimed to maintain preoperative weight).
 There were significantly fewer cardiopulmonary and
tissue-healing complications in the restricted group.
• This and additional studies advocate a more cautious
approach to IV fluids and the avoidance of routine use
of maintenance fluids.
• Each patient should receive at minimum a daily
assessment of his or her intravascular and total body
volume status and IV fluid therapy for the purposes of
volume expansion should be only administered when
there is true evidence for volume depletion.
• IV maintenance fluids should not be used as a surro-
gate for enteral or parenteral nutrition.
FLUIDS IN THE CRITICALLY
ILL PATIENT
• Clinically significant volume depletion often develops
when large amounts of volume are lost via gastroin-
testinal tract, skin (burn patients), hemorrhage, or third-
space sequestration. Signs and symptoms of serious
volume loss and possible tissue ischemia may include:
 Hypotension
 Oliguria or anuria
 Altered mental status
 Renal dysfunction
 Cardiac ischemia
 Other organ system failure
 Decreased peripheral perfusion
• Rapid assessment of intravascular volume status and
rapid fluid resuscitation is necessary to avoid progres-
sion toward acute ischemic injuries and hypovolemic
shock.
• While the usefulness of traditional methods for volume
assessment (see above) should not be minimized, data
suggest these measures may be inadequate.
• An alternate technique using pulse pressure variation
(PPV) has been proposed as a means to assess intravas-
cular volume status.
 In intubated patients, the PPV with each ventilator
breath is a superior measure of intravascular volume
and a better predictor of responsiveness to fluid
therapy than right atrial pressure, systolic blood
pressure, or PCWP.
 The PPV can be easily and accurately measured in
patients with an indwelling arterial catheter.
 A study of 40 mechanically ventilated patients with
circulatory failure secondary to sepsis presented the
PPV as a simple and effective means of predicting
clinical responsiveness to fluid resuscitation.
 A PPV value of 13% or greater allowed reliable dis-
crimination between patients who would and would
not respond to fluid resuscitation.
 Reliable prediction of responsiveness to IV fluid
therapy is essential for rapid resuscitation of
patients with true volume depletion.
 PPV is an equally important predictor of nonre-
sponders to volume expansion.
 Identifying nonresponders prevents unnecessary
resuscitation that may result in volume overload and
secondary complications including third-spacing of
fluid, pulmonary edema, myocardial dysfunction,
and limited diffusion of oxygen to tissues.
CRYSTALLOID FLUIDS
• Crystalloid fluids are primarily composed of sodium
chloride (NaCl) and pass readily between the intravas-
cular and extravascular compartments.
• Administration of IV crystalloid follows the same
bodily distribution as interstitial fluids, with 75% of the
infused water and electrolytes passing to the interstitial
space and 25% remaining in the intravascular space.
• Given this pattern of distribution, patients undergoing
large volume fluid resuscitation are at high risk for
developing pulmonary and generalized interstitial
edema, particularly with a preexisting state of fluid over-
load (e.g., congestive heart failure and renal failure).
 Isotonic saline (0.9% NaCl) is the most commonly
used crystalloid fluid. It is actually slightly more
tonic and acidic than plasma; these variations are
clinically negligible. The high chloride content may
induce a hyperchloremic metabolic acidosis with
infusion of large volumes of isotonic saline.
 Lactated Ringer solution has an electrolyte compo-
sition which mimics the ionic concentrations of cal-
cium, potassium, and chloride in plasma more
closely than isotonic saline. The added lactate is
converted to bicarbonate by the liver. The intention
was for the bicarbonate to act as a buffer in patients
with metabolic acidosis; however, this effect is not a
clinically significant one. Furthermore, the added
calcium may act as a binder for many drugs and
impair both bioavailability and efficacy.
 Normosol/Plasmalyte are solutions supplemented
with magnesium and altered with buffering agents
that mimic the pH of plasma. They are not readily
available and are not superior to unbuffered solu-
tions. Similarly, IV or oral magnesium supplemen-
tation is preferred as it is more readily titratable to
individual patient laboratory abnormalities. These
solutions are contraindicated in patients with renal
failure due to the risk of causing hypermagnesemia.
 Dextrose solutions were previously used frequently
as a source of nonprotein caloric intake for criti-
cally ill patients. Complete enteral or parenteral
feeding is now the “standard of care” for providing
adequate nutrition in the intensive care unit. While
IV dextrose solutions are still beneficial in the man-
agement of glucose-deficient states, it is the least
potent volume expander of the crystalloid solu-
tions. Additionally, there are several adverse effects
including increased production of carbon dioxide,
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increased lactate production, and cell dehydration
due the infusion of a hypertonic solution.
COLLOID FLUIDS
• Colloid fluids contain large molecules that do not dif-
fuse as readily between the intravascular and extravas-
cular compartments.
• Colloid solutions are assigned a colloid oncotic pres-
sure (COP) based on molecular weight and ability to
draw fluid into the intravascular space.
 Albumin is a physiologic transport protein that is
responsible for the major oncotic pressure in plasma.
A 5% albumin solution has a COP of 20 mmHg, sim-
ilar to plasma. Approximately 50% of this solution
will remain in the intravascular compartment. A 25%
albumin solution has a COP of 70 mmHg and may
transiently increase the plasma volume by up to five
times the amount of volume infused. However, due to
the mechanism of expansion, the added volume is
drawn from the interstitial space and is not recom-
mended for volume resuscitation purposes, particu-
larly in hypovolemic patients.
 Hetastarch (6% hetastarch in isotonic saline) is a
synthetic colloid solution composed of amylopectin
molecules of varying sizes. Its COP of 30 mmHg is
slightly higher than that of 5% albumin and theoret-
ically causes a greater volume expansion. While its
half-life is 17 days, its oncotic effects last no longer
than 24 hours. Elevated amylase levels may be
expected after infusion as the enzyme is responsible
for cleavage of amylopectin prior to renal excretion.
This should resolve within 1 week. Other docu-
mented side effects include rare episodes of ana-
phylaxis and prolonged partial thromboplastin time
without associated bleeding.
 The dextrans are hyperoncotic solutions composed
of glucose polymers diluted in isotonic saline. Their
high COP (40 mmHg) was thought to induce a
larger plasma volume expansion than crystalloid
solutions, 5% albumin or hetastarch. However, the
effects are short-lived and associated with multiple
side effects including anaphylaxis, increased risk of
bleeding due to impaired platelet aggregation,
reduced activation of factor VIII, and increased fib-
rinolysis, elevated ESR, and rare renal failure.
CRYSTALLOID vs. COLLOID
• While both crystalloid and colloid solutions are used
frequently for volume resuscitation, there has been
longstanding controversy regarding the effects of
these solutions on morbidity and mortality.
• One of the strongest arguments against the use of
crystalloid fluids has been that they cause a dilutional
hypoalbuminemia that puts patients at increased risk
for developing pulmonary edema. Physiologically
speaking, this is not the case.
 Alveolar capillaries have a high permeability to
albumin and as a patient becomes hypoalbumine-
mic, there is concomitant loss of protein from the
lung interstitium.
 The oncotic pressure gradient of the alveoli and sub-
cutaneous tissue decrease in parallel and infusion of
crystalloid solutions does not pose a higher risk of
developing pulmonary edema.
• Multiple studies now indicate that there are no benefits
from using colloid rather than crystalloid solutions.
 The SAFE (Saline vs. Albumin Fluid Evaluation) Study
was a multicenter, randomized, double-blind trial that
compared mortality outcomes of medical and surgical
ICU patients. All patients were hypovolemic and
received either 4% albumin or isotonic saline. There
was no significant differences at 28 days in all-cause
deaths, single-organ or multiple-organ failure, dura-
tion in the ICU or hospital, days of renal-replacement
therapy or days of mechanical ventilation.
 A meta-analysis of 55 randomized-controlled trials
compiled data on 3504 patients treated with either
albumin or crystalloid solutions for volume expan-
sion. There was no significant difference in outcomes
or mortality.
• Given these data, crystalloid solutions are generally the
preferred agent for initial volume expansion in patients
who are not bleeding. There is no mortality benefit to
using colloid solutions and crystalloid solutions are
readily accessible and markedly less expensive.
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5 PAIN MANAGEMENT
D. Kyle Hogarth
KEY POINTS
• Almost all patients admitted to an ICU will experi-
ence some form of pain.
• Causes include any underlying disease process, trauma,
a surgical incision, an invasive procedure, the presence
of the endotracheal tube, and airway suctioning.
• The Joint Commission for Accreditation of Health
Care Organizations (JCAHO) has mandated the mon-
itoring of pain in all patients.
• Surveys of patients indicate recall of significant unre-
lieved pain in the ICU.
PAIN AND CARDIAC MORBIDITY
• The stress response from pain causes activation of the
sympathetic nervous system with increases in heart
rate, blood pressure, myocardial contractility, and
myocardial oxygen consumption.
• The stress response to pain may be enough to induce
cardiac ischemia or infarction depending on limits of
oxygen supply to the myocardium (e.g., hypotension,
anemia, and hypoxemia).
• Opioid medications can lower blood pressure and
afterload via venous and arterial dilation and can
diminish oxygen consumption by the myocardium via
a decreased heart rate through a direct sinoatrial node
effect and through sympatholysis.
PAIN AND RESPIRATORY
DYSFUNCTION
• Major abdominal and thoracic surgeries will result in
abnormal pulmonary function.
• A general rule is the closer the surgery to the
diaphragm, the more likely the pulmonary dysfunction.
• These abnormalities result from spasm and splinting
of abdominal and intercostal muscles, limited
diaphragm movement, and pain.
• Forced expired volume in one second (FEV1) and
forced vital capacity (FVC) can decline by 60% of
their preoperative level, and functional residual capac-
ity (FRC) can decline by 30% in thoracic and upper
abdominal procedures. Lower abdominal procedures
will result in 30% and 10% declines in FVC and
FEV1, respectively.
VENTILATED PATIENTS
AND PAIN CONTROL
• In ventilated patients, a frequently overlooked cause
of agitation is pain, and assessing adequacy of anal-
gesia is an important part of the continuous assess-
ment of a patient. Remember, the patient “bucking the
vent” may be in pain.
• None of the drugs commonly used for sedation pro-
vide analgesia.
• Opioid medications have demonstrated synergistic
effects with sedative drugs, particularly benzodi-
azepines, and combined use of an analgesic and seda-
tive often results in lesser doses of each.
• In some patients, an opioid analgesic alone will
achieve both pain control and tranquility.
• Almost every patient admitted to an ICU on a ventila-
tor should receive opioid medications.
ASSESSMENT OF PAIN
• Pain should be assessed and managed in all patients.
• Rating Scales for pain assessment are most often
employed as they are easy to use and have been shown
to be very reliable.
• The Visual Analog Scale is most often used, ranking
pain from extremes of “no pain” to “worst pain I have
ever had” along a horizontal scale.
• Pain can be difficult to assess in the ICU, especially if
patients are being sedated for ventilation.
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COMPLICATIONS OF PAIN CONTROL
• Ensuring the control of pain for the patient may result
in some complications. While the goal is to provide
adequate pain relief, too much opioid may increase
the likelihood of complications. For this reason, the
pain of the patient should be continuously assessed
so that the patient may remain on the optimal dose
of opioid.
• The principal concern arising from the administration
of opioids is the effect these drugs have on central res-
piratory drive. If the patient is not being mechanically
ventilated, these drugs should be administered in a
controlled setting by experienced personnel.
• Naloxone needs to be available for emergency admin-
istration in any patient receiving narcotics. However,
naloxone administration can result in pulmonary
edema, hypertension, and tachycardia.
• The continuous infusion of opioids often results in
decreased gastrointestinal motility and may interfere
with the administration of enteral nutrition. Opioids
often cause nausea as well. The use of promotility
agents, antinausea medications, and bowel stimulants
may be able to overcome these effects.
• The continuous infusion of opioids raises the possi-
bility of a patient developing a physical addiction to
these medications.
• The agitation and restlessness of a ventilated patient
during liberation from mechanical ventilation may
relate in large part to withdrawal symptoms. This
problem can affect patient populations of all ages.
• The majority of patients exhibiting withdrawal from
opioids will either have had significant exposure prior
to their critical illness, or will have received high
doses of drugs for more than 3–5 days during their
ICU management.
• The incidence of withdrawal symptoms has been shown
to increase with concurrent use of neuromuscular block-
ade and prolonged use of sedatives and analgesics.
• Concern for the development of possible addiction
should not result in the under dosing of narcotic
for pain.
METHODS OF PAIN CONTROL
• Intravenous opioids. This allows titration of the med-
ication to the desirable level that provides adequate
analgesia. Medication can be administered via as-
needed boluses or as a continuous infusion. A contin-
uous infusion often provides more relief and fewer
side effects as it avoids the peaks and troughs of drug
levels associated with boluses.
• Patient controlled analgesia (PCA). If a patient is
conscious and able to manipulate the PCA machine,
this method of analgesia is superior for pain relief.
Besides the potential psychological effect of the
patient “being in control,” the PCA has been shown to
be superior to other methods of pain control in some
studies. Overdoses are rare and are usually associated
with machine or physician errors.
• Intramuscular opioids. This is not a desirable way to
administer pain medications as the absorption of drug
can be extremely variable.
• Epidural anesthesia. It can provide complete thoracic,
abdominal, and lower extremity pain relief while min-
imizing the risk of respiratory suppression.
• Epidural anesthesia can cause hypotension, urinary
retention, and motor blockade. Rarely, spinal or
epidural hematomas can form that may lead to irre-
versible neurologic injury. Muscle weakness, pain, and
sensory deficits are usual symptoms. Hematomas occur
more often in patients with coagulation abnormalities.
• Intercostal blockade is best employed for localized
pain involving thoracic dermatomes, such as lateral
thoracotomies and rib fractures. Injection of bupiva-
caine into the intercostal space can provide relief for
6–12 hours. Pneumothorax is a rare complication of
intercostal blockade.
MEDICATIONS FOR PAIN CONTROL
• Morphine is the most commonly used medication for
pain control in the ICU. It is relatively inexpensive
and most physicians are comfortable with the drug.
• Morphine is highly soluble in water, resulting in
slower membrane penetration. Therefore, the peak
onset of morphine is around 30 minutes with effects
lasting 2–4 hours.
• Other commonly used opioid drugs include fentanyl
and hydromorphone.
• Fentanyl has a rapid onset of action, within 2–5 minutes
with an effect lasting 30–45 minutes. Fentanyl does
not cause the release of histamine.
• Meperidine should not be used in the ICU. The pro-
drug and active metabolite accumulate in patients with
renal dysfunction, a common occurrence in the criti-
cally ill. The accumulation may result in prolonged
opioid effect as well as neurotoxicity which may man-
ifest as delirium, myoclonus, and seizures (Table 5-1).
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6 SEDATION MANAGEMENT
IN THE ICU
D. Kyle Hogarth
KEY POINTS
• Most critically ill patients can be assumed to experi-
ence pain: analgesics should often be given before
sedatives.
• Sedative use is often complicated by prolonged
depression of consciousness.
• Sedative choice depends on goals, drug half-life, car-
diovascular stability, and organ (especially liver and
renal) dysfunction.
• A daily sedative interruption reduces time on the ven-
tilator and duration of ICU stay.
• The depth of sedation should be monitored objectively
and documented frequently.
INTRODUCTION
• The need for mechanical ventilation is one of the prin-
cipal reasons a patient is admitted to the intensive care
unit (ICU).
• No matter what the indication for intubation, provid-
ing the patient adequate comfort while being mechan-
ically ventilated is imperative.
• Many patients have memory of being uncomfortable
while in the ICU, but this may in part relate to inade-
quate analgesia as opposed to inadequate sedation.
• The majority of patients admitted to an ICU for
mechanical ventilation will receive one or more seda-
tive medications.
• The drugs used for sedation and analgesia in the ICU
have a broad range of half lives. Metabolism of these
drugs can be impaired as there is frequent organ fail-
ure associated with critical illness.
WHY SEDATE?
• Adequate sedation to facilitate care by the ICU team
is imperative to ensure the patient receives safe and
proper care.
• Being on a ventilator can be very anxiety provoking,
and patients on mechanical ventilation can be con-
fused and delirious, and sometimes combative and
violent.
• A patient’s need for sedating medication can be high,
depending on the indication for intubation. For
example, a patient in acute respiratory distress syn-
drome (ARDS) undergoing a strategy of permissive
hypercapnia during mechanical ventilation may
require more sedative to overcome the respiratory
drive from a climbing CO2 while a long-term emphy-
sema patient may require little or no sedation for
ventilatory failure.
• The traumatic self-removal of an endotracheal tube
puts the patient at risk for vocal cord trauma, aspira-
tion, bleeding, hypoxia, and can be life threatening.
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TABLE 5-1 Comparison of Commonly Used Intravenous Opioid Medications in the ICU
DRUG PEAK EFFECT ELIMINATION HALF-LIFE MINIMAL SUGGESTED DOSE
Morphine 30 min 2–4 h 1–4 mg bolus
1–10 mg/h infusion
Fentanyl 3 min 1–2 h 25–100 µg bolus
25–200 µg/h infusion
Hydromorphone 20 min 2–4 h 0.2–1 mg bolus
0.2–2 mg/h infusion
Pentazocine 3 min 2–3 h 30 mg bolus, no infusion
Butorphanol 5 min 3–4 h 1 mg bolus, no infusion
Ketorolac (nonsteroidal 2 h 6–8 h 30 mg bolus, no infusion
anti-inflammatory drug [NSAID])
SOURCE: Modified from Liu LL, Gropper MA. Postoperative analgesia and sedation in the adult intensive care unit: a guide to drug selection. Drugs
2003;63:755–767.
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• Unintended removal of arterial and venous catheters
can result in bleeding, interruption of medications, and
require additional procedures to replace these catheters.
• Ensuring patient comfort can minimize the need for
physical restraints. Restraints can have a negative
impact on post-ICU psychological recovery and
family members are often concerned about physical
restraints.
• While some physicians advocate complete amnesia as
a goal of sedation, this may carry adverse conse-
quences. Lack of memory of a critical illness may pre-
dispose patients to long-term psychological problems.
• In all patients receiving neuromuscular blockade
(NMB), complete and deep sedation is mandatory.
COMPLICATIONS OF SEDATION
• A common complication of sedation is drug accumu-
lation with protracted depression of central nervous
system function.
• Continuous infusion of sedation has been associated
with prolonged time on the ventilator, prolonged ICU
stays, prolonged hospital stays, increased utilization
of diagnostic procedures and imaging modalities, and
difficulty in adequately monitoring a patient’s neuro-
logic function.
• The continuous infusion of opioids and benzodi-
azepines can cause a physical addiction to these med-
ications. This problem can affect patient populations of
all ages. The majority of patients exhibiting withdrawal
from opioids and benzodiazepines will either have had
significant exposure prior to their critical illness, or
will have received high doses of drugs for more than
3–5 days during their ICU management.
MEDICATIONS FOR SEDATION
• Pain should always be assessed before the use of seda-
tives. A common cause of patient agitation and “buck-
ing the vent” is inadequate analgesia. Opioids and
benzodiazepines have synergistic effects allowing for
lower doses of both drugs to be used.
• Opioid drugs (morphine, methadone, hydromorphone,
fentanyl) are used in most critically ill patients.
Meperidine should not be used as the prodrug and
active metabolite accumulate in patients with renal dys-
function. This can result in prolonged opioid effect as
well as neurotoxicity, including delirium, myoclonus,
and seizures.
• Benzodiazepines (diazepam, lorazepam, midazolam)
are frequently used to provide anxiolysis. These drugs
provide no pain relief. Drug metabolism kinetics and
the volume of distribution of benzodiazepine drugs
change during critical illness, especially in patients
with impaired renal and hepatic function. Even drugs
considered “ultra-short-acting” when given as a single
bolus (such as midazolam) may accumulate when
given by continuous infusion or repeated bolus in the
critically ill patient.
• Propofol is an alkylphenol anesthetic that provides no
analgesia. When used concurrently with opioids,
patients may require higher analgesic dosing than
with benzodiazepines. It has a short half-life and a
rapid onset of action, but has not been shown to be
superior to other sedating agents.
• The ventilatory depression of propofol can be profound,
and it should only be used in a patient with a secured
airway or with staff immediately available to intubate.
• Propofol is insoluble in water, so it is delivered in a
lipid emulsion, which can lead to elevated triglyceride
levels. Patients on TPN must have their lipid infusion
adjusted if receiving propofol and all patients receiv-
ing propofol should have baseline, 72 hours, and then
weekly triglyceride levels measured and if significant
elevations occur, the infusion should be stopped.
• A dose of 75 µg/kg/min is a recommended maximum
to minimize the possibility of a Propofol Infusion
Syndrome: profound myocardial failure and severe
lactic acidosis.
• Haloperidol has no analgesic or amnesic properties,
and has a long half-life. Patients receiving haloperidol
demonstrate indifference to their surrounding envi-
ronment, and may even have cataleptic immobility,
making it difficult to perform pain and sedation
assessment. Haloperidol is useful for acute agitation
and treating patients with psychotic behavior, but
should not be used as a primary agent for sedation.
• Extrapyramidal effects, hypotension, and prolongation
of the QT-interval limit the usefulness of haloperidol in
the ICU. In one study, an incidence of torsades de
pointes of 3.6% was seen with haloperidol use.
• Gas anesthesia (e.g., isoflurane) is a very effective
sedative. For practical reasons related to maintaining
a closed inhalation-exhalation circuit, its use is not
routine in the ICU.
• Dexmedetomidine is a lipophilic derivative of imida-
zole, recently approved for use in the United States
that has a high affinity for α2-adrenoreceptors, with
sedative, analgesic, and sympatholytic effects.
• In early studies in the ICU and the operating room,
dexmedetomidine has been shown to reduce the quan-
tity of IV sedation, inhalation anesthesia, and IV
opioid administered, while also providing anxiolysis,
improved perioperative hemodynamic stability, and
no suppression of respiratory drive.
• While initial data regarding dexmedetomidine are
promising, the lack of large randomized trials
demonstrating decreased mechanical ventilation time
precludes recommending the routine use of this med-
ication at present (Table 6-1).
MONITORING OF SEDATION
• Early use of a spontaneous breathing trial (SBT)
reduces time spent on the ventilator. However, in
order to perform a SBT, the patient should be awake
and interactive with care providers. Patients often
receive continuous infusions of sedative medications
in the ICU, but this has been shown to lead to pro-
longed intubation and mechanical ventilation.
• Various scales to assess level of sedation have been
developed, all with the goal of permitting the bedside
clinician to adjust sedative dose to achieve adequate
but not excessive sedation. A majority of the literature
regarding sedation has used the Ramsay Sedation
Scale, developed in 1974. However, the Ramsay scale
was not originally intended to be used as a tool for
clinical monitoring, and has not been rigorously tested
for reliability and validity.
• Recently, The Richmond Agitation and Sedation
Scale (RASS) was introduced and has proven to be a
useful bedside tool in the management of sedation
(Table 6-2). This is a 10-point scale that is rated using
three well-defined steps. RASS has been validated
and shown to be reliable across multiple different
observers.
MANAGEMENT OF SEDATION
• A protocol-driven approach to mechanical ventilation
and SBTs leads to reduced time on the ventilator, but
over-sedation remained a principal reason for failure
to implement successful weaning.
• Kress and colleagues clearly demonstrated that the
daily interruption of continuous sedation decreased
the length of time on the ventilator, the time in the
ICU, and diminished the number of diagnostic tests
performed to evaluate why a patient was not waking
up once sedatives had been discontinued.
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TABLE 6-1 Comparison of Commonly Used Medications for Sedation in the ICU
DRUG PEAK EFFECT ELIMINATION HALF-LIFE MINIMAL SUGGESTED DOSE
Diazepam 3–5 min 20–40 h 5–10 mg bolus
Infusion not recommended
Midazolam 2–5 min 3–5 h 1–2 mg bolus
0.5–10 mg/h infusion
Lorazepam 2–20 min 10–20 h 1–2 mg bolus
0.5–10 mg/h infusion
Propofol 90 s 20–30 h Bolus not recommended
25–100 mg/kg/min infusion
Dexmedetomidine 60 s 2 h 1 mg/kg bolus over 10 min
0.2–0.7 mg/kg/min infusion
SOURCE: Modified from Liu LL, Gropper MA. Postoperative analgesia and sedation in the adult intensive care unit: a guide to drug
selection. Drugs 2003;63:755–767.
TABLE 6-2 Richmond Agitation–Sedation Scale
SCORE TERM DESCRIPTION
+4 Combative Overtly combative/violent. Danger to 
staff
+3 Very agitated Pulls/removes tubes or catheters.
Aggressive
+2 Agitated Nonpurposeful movement. 
Not synchronous with ventilator
+1 Restless Anxious, but movements 
not aggressive/violent
0 Alert and calm
−1 Drowsy Sustained awakening (>10 s) with eye
contact, to voice
−2 Light sedation Briefly awakens (<10 s) with eye
contact, to voice
−3 Moderate sedation Movement to voice, but no eye contact
−4 Deep sedation No response to voice. Movement 
to physical stimulation
−5 Unarousable No response to voice or physical 
stimulation
Procedure:
1. Observe patient. Calm (score zero). Do they have restless 
or agitated behavior (1–4)
2. If not alert, speak name in loud clear voice, and direct them to look
at speaker. Repeat once if necessary. Gauge response (−1 to −3)
3. If no response to voice, then physically stimulate patient. Gauge
response (−4 to −5)
SOURCE: Adapted from Sessler CN, Gosnell MS, Grap MJ, et al. The
Richmond Agitation-Sedation Scale: validity and reliability in adult
intensive care unit patients. Am J Respir Crit Care Med
2002;166:1338–1344.
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• The daily interruption protocol involved the daily
stopping of the continuous drug infusion (including
opiates) and monitoring the patient until they started
to show signs of awakening. The drugs were then
restarted at half the previous dose and were titrated at
the discretion of the bedside nurse to achieve a
Ramsay sedation score of 3–4. In comparison to rou-
tine management, the daily cessation of drug infu-
sions significantly reduced time on the ventilator and
in the ICU, and provided a valuable window of
opportunity for assessment of the patient’s neuro-
logic function (Fig. 6-1).
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7 NEUROMUSCULAR
BLOCKADE
Nuala J. Meyer
KEY POINTS
• Neuromuscular blocking drugs are used less often in
ICUs due to the frequent complication of acquired
weakness
• Neuromuscular blockers can facilitate mechanical
ventilation and improve gas exchange in some patients
• Sedatives must always be given along with neuromus-
cular blockers
• The depth of neuromuscular blockade should be mon-
itored with a peripheral nerve stimulator
MECHANISM OF ACTION
• Neuromuscular blocking agents (NMBs) block
transmission of acetylcholine (ACh) at the neuro-
muscular junction, resulting in the abolition of vol-
untary muscle control or, in simpler terms, paralysis.
At the neuromuscular junction, arrival of a nerve
impulse causes the release of ACh from presynaptic
terminals, which then crosses the junctional cleft and
stimulates the postsynaptic ACh receptors. These
postsynaptic receptors allow ions to flow through
them and depolarize the motor end plate, resulting in
muscle contraction.
NEUROMUSCULAR BLOCKADE IN THE
INTENSIVE CARE UNIT
• Neuromuscular blocking agents are commonly used
to induce a brief paralysis of the patient for intubation,
both for critically ill patients as well as those under-
going elective intubation.
• NMBs are helpful in the management of tetanus,
when chest wall rigidity limits adequate ventilation.
They are also used to prevent shivering in patients in
whom therapeutic cooling is indicated (e.g., following
cardiac arrest).
• Use of NMBs in the intensive care unit (ICU) is
limited by the frequently reported side effects and
complications of such therapy, and by the need to
Agitated patient
Provide verbal assurance
Still agitated?
Check ventilator and other devices
Still agitated?
Assess for pain
No pain
Patient calm
Adjust ventilator
remove devices
Treat pain
Sedate
FIG. 6-1 Algorithm for assessing agitated patient on the
ventilator.
continuously and carefully monitor the depth of
sedation and paralysis. Rarely, NMBs are used to
improve ventilation or oxygenation of patients in
respiratory failure in the ICU.
• NMBs must be used in conjunction with sedative
hypnotic medications with both analgesic and amnestic
qualities, and should never be used without deep
sedation.
• In the case of severe ventilatory failure, such as
status asthmaticus, paralysis with NMBs in con-
junction with heavy sedation may allow time for
bronchodilator and anti-inflammatory therapy to
begin to take effect, while improving lung compli-
ance and allowing a strategy of permissive hyper-
capnia. Neuromuscular blockade may also distribute
blood away from the muscles of respiration—which
in respiratory failure can be an enormous source for
oxygen consumption—and decrease shock associ-
ated with respiratory failure. However, as discussed
below, patients who receive both NMBs and corti-
costeroids, as is often the case in obstructive lung
disease, are at an extremely high risk for neurologic
complications.
• In hypoxemic respiratory failure such as acute respi-
ratory distress syndrome (ARDS), NMBs may be
employed to decrease oxygen consumption, facilitate
“lung-protective” ventilation which is often uncom-
fortable to the patient, and to improve venous oxygen
saturation.
COMPLICATIONS OF
NEUROMUSCULAR BLOCKADE
• The principal complication of NMBs as used in the
ICU is prolonged muscular weakness. Patients may
remain partially paralyzed for weeks despite the ces-
sation of NMBs, and may necessitate prolonged reha-
bilitation or mechanical ventilation.
• Paralysis can be due to the abnormal metabolism of
NMBs, or, more commonly, due to the effect of the
drug on the neuromuscular unit.
• Asthmatic patients receiving concomitant therapy
with NMBs and corticosteroids are at extremely high
risk for myopathy and polyneuropathy. Aminog-
lycoside antibiotics may also confer a higher risk of
myopathy.
• NMBs can produce adverse effects at both nicotinic
and muscarinic ACh receptors other than those of the
neuromuscular junction. Muscarinic blockade may
produce tachycardia and hypotension. Histamine
release may also occur, causing vasodilation, hypoten-
sion, and reflex tachycardia.
SPECIFIC NEUROMUSCULAR
BLOCKING AGENTS
• The bulk of clinically useful NMBs act by interfering
with the postsynaptic action of ACh on ACh receptors,
thereby abolishing the electrical signal from the motor
nerve to the muscle. These medicines may be further
categorized as the depolarizing blocking agents—
medicines which have agonist activity at the ACh
receptor and the nondepolarizing agents—those which
act by antagonizing or blocking ACh receptors. Both
forms of NMBs are discussed here.
SUCCINYLCHOLINE
• Succinylcholine is the one depolarizing NMB agent
currently available. As mentioned, it binds to the ACh
receptor and causes muscle contraction, similar to
ACh. However, unlike ACh, it is very slowly broken
down by acetylcholinesterase, and thus causes a per-
sistent depolarization and blockade of the neuromus-
cular junction.
 In patients with normally functioning pseudo-
cholinesterase, it causes a brief paralysis, for 2–8 min.
Patients with a homozygous deficiency of pseudo-
cholinesterase (approximately 1 in 3200 patients)
may be paralyzed for up to 8 hours.
 For intubation, a dose of 1.0–1.5 mg/kg is typically
used.
 Potential side effects of succinylcholine include ele-
vated intracranial pressure, bradycardia (severe),
malignant hyperthermia, and severe hyperkalemia.
These limitations make succinylcholine relatively
contraindicated for patients with crush injuries,
spinal cord injuries or brain injuries, renal insuffi-
ciency, muscular dystrophies, and burns.
• Nondepolarizing NMBs compete with ACh for bind-
ing at the ACh receptor. Once bound, nondepolarizing
agents inhibit the ion flux through ACh receptor, thus
prohibiting membrane depolarization and causing a
flaccid paralysis. This class has a slower onset of
action compared to succinylcholine, and a longer dura-
tion of action. Nondepolarizing NMBs can be reversed
by the administration of an acetylcholinesterase drug
such as neostigmine or edrophonium, which allows
ACh to accumulate and thus compete with the NMB
for binding to the ACh receptor.
PANCURONIUM
• Pancuronium is typically dosed as 0.08 mg/kg and has
an onset of action within 3 minutes, with a duration of
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approximately 80 minutes. For maintenance, a drip
beginning at 0.025 mg/kg/h is appropriate. Excretion
of pancuronium is both renal and biliary; its duration
of action is prolonged in patients with either renal or
hepatic insufficiency.
VECURONIUM
• Vecuronium also has a short onset of action, and a
slightly shorter duration of action, of approximately
40 minutes. It is dosed initially as 0.1 mg/kg for induc-
tion of paralysis, followed by a drip of 0.07 mg/kg/h
if a maintenance dosing schedule is necessary.
Vecuronium has minimal cardiovascular effects. Its
excretion is mainly biliary, so its elimination is pro-
longed with hepatic insufficiency or biliary obstruction.
A smaller fraction of excretion is renal, so that occa-
sionally vecuronium’s action is prolonged in patients
with renal failure.
CISATRACURIUM
• Cisatracurium, an isomer of atracurium, is among the
most frequently used NMBs in the ICU. The onset of
action for the drug is approximately 8 minutes, and its
duration of action is between 40 and 60 minutes
after one dose. Cisatracurium is typically dosed as a
0.1 mg/kg loading dose followed by a 2–3 µg/kg/min
continuous infusion. Advantages of cisatracurium
over older nondepolarizing blockers include its lack
of histamine release and its decreased production of the
metabolite laudanosine, which has been proven to pro-
voke seizures in animals at high doses. Cisatracurium is
degraded by ester hydrolysis in the plasma (Hofmann
degradation), and therefore does not require dose
adjustment in renal failure.
MONITORING THE DEPTH OF
NEUROMUSCULAR BLOCKADE
• When using any NMB agent in a maintenance fashion,
depth of paralysis should be monitored with the use of
a peripheral nerve stimulator to obtain a “train of four.”
In this setup, the nerve stimulator is set to deliver four
impulses sequentially, each at 2 Hz. Without paralysis,
four twitches of the nerve being studied—typically the
ulnar nerve—would be observed. With 90% blockade
of ACh receptors by the NMB, only one in four
twitches is visible. With 70% ACh receptor occupancy,
two to three twitches are visible.
• The goal of neuromuscular blockade is to maintain a
depth which produces two to three twitches for a train
of four.
• The use of such monitoring decreases the amount of
drug used; the recovery time after neuromuscular
blockade; and the incidence of postparalytic weakness.
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8 MONITORING THE
CARDIOVASCULAR SYSTEM
Joseph Levitt
KEY POINTS
• Multiple prospective trials, in several patient subsets,
have failed to reveal any benefit to a pulmonary artery
catheter
• Early therapy of sepsis, directed towards normalizing
the central venous oxygen saturation, improves outcome
• The adequacy of perfusion can be judged by central
venous oximetry. This method has limitations, but
these are fewer than with thermodilution cardiac
output measurement
• Fluid responsiveness is best predicted by pulse pressure
variation (for passively ventilated patients) and right
atrial pressure variation (during spontaneous breathing).
• Combined with echocardiography, these dynamic
measures can supplant the pulmonary artery catheter
• Recommendations for optimal monitoring of the car-
diovascular system remain controversial and the sub-
ject of ongoing investigation. At the center of the
controversy lie two fundamental issues:
 First is the lack of consistent evidence document-
ing safety and efficacy of invasive monitoring.
A retrospective analysis of the network fluid and
catheters treatment pulmonary artery catheter (PAC)
suggested a detrimental effect. Subsequent prospec-
tive analyses have demonstrated safety, but failed to
show a beneficial effect.
 Second, guidelines for monitoring hemodynamics
are incomplete without recommendations for how to
respond to the obtained data. Great variability in
fluid and vasoactive drug therapy exists, with little
evidence to guide current recommendations. Utility
of PACs and a liberal versus conservative fluid strat-
egy in acute respiratory distress syndrome (ARDS)
are the subjects of the recent ARDS network Fluid
and Connector Treatment Trial. An aggressive
diuretic regimen reduced time on the ventilator, but
the PAC was no better than a CVC.
MONITORING THE SEPTIC PATIENT
• Despite the existing uncertainties, early recognition and
treatment of inadequate circulation remains imperative.
Results of a recent trial of early goal-directed therapy in
sepsis suggest a role for routine and prompt placement of
a central venous catheter (CVC) in the superior vena
cava. In this trial, patients randomized to protocol-driven
therapy (goals of achieving a CVP of 8–12, MAP > 65,
and urine output > 0.5 cc/kg, with red cell transfusions
and dobutamine used to raise central venous oxygenation
> 70%) in the first 6 hours had a significantly improved
survival compared to patients receiving standard care.
• This study highlights the importance of the two main
components of invasive monitoring: measuring
venous oxygen saturation (SVO2) and assessing
intravascular volume. The mixed venous oxygen con-
tent (and, proportionately, the saturation) is related to
oxygen transport and consumption by VO2 = (CaO2 −
CVO2) × Qt (where V2 = oxygen consumption, CaO2 =
arterial oxygen content, CVO2 = venous oxygen con-
tent, and Qt = cardiac output). When oxygen delivery
is appropriate for demand, SVO2 is 70–75%.
• Lower values of SVO2 suggest impaired oxygen deliv-
ery and a quick assessment of arterial-venous oxygen
content difference can easily distinguish decreased
CaO2 (hypoxemia or anemia) from low cardiac
output. A level >75% suggests an increased ratio of
oxygen delivery to demand and while it is important
in identifying the etiology of hypotension (i.e., sepsis
and liver failure), it is probably not useful as a thera-
peutic endpoint. A large multicentered randomized-
controlled trial failed to show benefit in clinically
relevant endpoints in patients randomized to have a
supranormal SVO2. While measuring SVO2 requires a
PAC, a central venous saturation appears to be a reli-
able substitute and requires only placement of a CVC
into the superior vena cava. Thus, CVC sampling of the
SCVO2 allows qualitative assessment of cardiac output
which, unless future studies identify an optimal cardiac
output, may be just as useful as the quantitative infor-
mation obtained from a PAC.
ALTERNATINGS TO THE PAC
• The second component of invasive monitoring,
assessing intravascular filling pressures, has long been
the realm of the PAC. PACs allow measurement of the
pulmonary artery occlusion pressure (PAOP) and thus
estimation of the left ventricular end-diastolic filling
pressure, which, for many practitioners, has been the
“holy grail” of hemodynamic monitoring. However,
this focus on the PAOP as the major determinant of
cardiac output lacks appreciation of Guyton’s early
studies on the determinants of cardiac output. His
work described a cardiovascular system where the
heart serves primarily as a passive pump, with the gra-
dient between mean systemic pressure and right atrial
pressure (RAP) serving as the driving force for
venous return and thus cardiac output. Again, the
additional information derived from a PAC may not
provide a benefit over a CVC in the superior vena cava
for optimizing cardiac output. A PAC with a PAOP may
be useful diagnostically to more readily distinguishing
between left (acute myocardial infarction [MI], acute
mitral insufficiency, decompensated congestive heart
failure [CHF], and so forth) and right (pulmonary
embolism [PE], pulmonary hypertension, right ventric-
ular (RV) infarct, and so forth) heart failure. However,
combining a noninvasive transthoracic echocardiogram
with a CVC may provide equivalent data.
• Both PACs and CVCs suffer the same limitation when
attempting to assess intravascular volume: they only
measure intravascular filling pressure when what is
really needed is volume. While pressure is a reliable
surrogate for volume in most conditions, it can be
misleading in states of increased intrathoracic or
intracardiac pressure (i.e., mechanical ventilation with
high positive airway pressures, tension pneumotho-
rax, cardiac tamponade, and abdominal compartment
syndrome). In such cases, recognition of variation in
intravascular pressure with the respiratory cycle may
be more important than absolute values. In the venti-
lated patient, the rise in pleural pressure with inspira-
tion raises RAP impeding venous return and thus (with
a short lag time to allow for transit time through the
pulmonary circulation) impeding left ventricular pre-
load and stroke volume. The magnitude of this effect is
dependent on the relative position on the Starling curve
at which the heart is operating and is reflected in the
arterial pulse pressure (PP). A recent study compared
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the PAOP, RAP, change in arterial systolic pressure,
and change in PP with inspiration in passive mechani-
cally ventilated patients for utility in predicting fluid
responsiveness. A change in arterial pulse pressure
[∆PP(%) = (PP
max
− PP
min)/((PPmax + PPmin)/2)] of
>13% reliably predicted fluid responsiveness. PAOP
was the least reliable, followed closely by RAP. A
second study in ventilated but spontaneously breath-
ing patients found a fall of >1 cmH2O in RAP pre-
dicted fluid responsiveness.
• The growing recognition of the importance of assessing
intravascular volumes as opposed to pressures has also
led to increased use of echocardiography in the critical
care setting. Transthoracic echocardiography (TTE)
has sensitivity and specificity for diagnosing hemody-
namically significant pulmonary emboli and is safer to
perform on the hemodynamically unstable patient. RV
dysfunction on TTE with acute PE may also have
important prognostic and therapeutic implications.
• In summary, optimal monitoring of hemodynamics in
the critically ill remains controversial. With many old
and new technologies to choose from, more studies
demonstrating therapeutic efficacy are needed. Strict
guidelines for monitoring hemodynamics also await
future studies documenting the optimal response to
the obtainable data. For now, the early and routine
placement of a CVC with judicious interpretation of
the RAP and SCVO2 seems reasonable. Addition of
TTE to evaluate for coexisting intrinsic cardiac dys-
function may also be prudent. Recommendations
regarding routine use of a PAC are pending results of
the ongoing ARDS-NET FACCT trial.
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9 MONITORING THE
RESPIRATORY SYSTEM
Joseph Levitt
KEY POINTS
• Impending respiratory failure is often better judged at
the bedside than through blood gas measurement.
• In mechanically ventilated patients it is often not neces-
sary to normalize pH and PCO2: it may even be harmful.
• Ventilator displays of pressure and flow can guide
ventilator settings and judgments regarding the
progress of lung function.
• A daily trial of spontaneous breathing speeds libera-
tion from the ventilator.
INTRODUCTION
• The first and most important component of monitor-
ing the respiratory system is recognition of impending
respiratory failure.
• Evaluating for the presence of crackles, wheezing,
egophony, dullness to percussion, and so forth, may
assist in elucidating the etiology of respiratory dis-
tress, but is not necessary in diagnosing respiratory
failure. Pulse oximetry and blood gas sampling are
often redundant or misleading.
• Simple bedside observations can typically identify a
patient in extremis. This is often signaled by the
“tripod” position (bending forward with hands braced
on thighs), accessory muscle use, thoraco-abdominal
dyssynchrony, rapid respiratory rates (>40), and
inability to speak in short sentences. Confusion and
agitation, often with removing of oxygen mask and
IVs, are late findings. Agonal respirations are a very
late finding and predict immediate respiratory arrest.
ARTERIAL BLOOD GAS ANALYSIS
• Blood gas sampling allows accurate measurement of
the arterial pH, PaO2, and PaCO2.
• While it remains essential in evaluating the gas
exchange properties of the lung (severity of lung
injury is often determined by the PaO2/FiO2 ratio) and
acid-base status, it is often overutilized.
• Pulse oximetry provides accurate noninvasive meas-
urements of the arterial oxygen saturation in most
situations.
• Normalization of the pH and PaCO2 are often overem-
phasized in the management of respiratory failure and
should not be the primary endpoints of mechanical
ventilator settings. Furthermore, a rising PaCO2 and a
falling PaO2 are often very late findings in respiratory
failure and of limited utility in guiding therapy.
PULSE OXIMETRY
• Continuous pulse oximetry allows early detection of
hypoxemia in at-risk patients. However, despite near
ubiquitous use in ICUs and operating room, the clini-
cal benefit of routine continuous monitoring has not
been clearly established.
• Pulse oximetry is found to be accurate ± 4% at satu-
rations >90%. Accuracy at saturations below 80% is
less established. Also, distinguishing arterial blood
from venous or tissue blood requires a clear pulsatile
signal and is therefore impaired by poor perfusion
states in critically ill patients.
CAPNOMETRY
• Capnometry is defined as the measurement of expired
CO2, usually by infrared absorption. Graphic represen-
tation of expired CO2 (capnography) allows estimation
of end-tidal CO2 (PetCO2) which should approximate
PaCO2. This technology can be used in measuring res-
piratory quotients to determine adequacy of nutritional
supplementation, calculations of pulmonary dead space,
and estimations of cardiac output using the Fick equa-
tion. However, variations in ventilation-perfusion ratios
in the critically ill can lead to unreliable relationships
between PetCO2 and PaCO2.
• Capnometry is widely used to reliably differentiate
endotracheal from esophageal intubations.
AIRWAY PRESSURE MONITORING
DURING MECHANICAL VENTILATION
• When endotracheal intubation and mechanical venti-
lation are required, the ventilator can provide valuable
information in both diagnosis and management of res-
piratory failure.
• Graphic display of pressure versus time and flow
versus time waveforms give vital information about
patient-ventilator interaction.
• Readings of tidal volumes and peak and plateau pres-
sures should not be made without simultaneous con-
firmation of patient-ventilator synchrony.
• Peak airway pressure is a function of static com-
pliance of the lung and chest wall plus the resistive
component of the airway. In volume control modes,
an end-inspiratory pause briefly ceases flow after
delivering the tidal volume, eliminating the resis-
tive component of the airway pressure. This
plateau or occlusion pressure thus reflects only the
compliance of the respiratory system (lung and
chest wall) independent of airway resistance (and
any positive end-expiratory pressure [PEEP] or
auto-PEEP).
• Large gradients between peak and plateau pressures
suggest high airway resistance which could be occur-
ring at any level from the ventilator tubing, through
the endotracheal tube to large and small airways of the
bronchial tree and should help to guide therapy (i.e.,
suctioning vs. steroids and bronchodilators).
• Elevated plateau pressures suggest a noncompliant or
overdistended respiratory system, including lungs (i.e.,
pulmonary edema and fibrosis), chest wall (i.e., pneu-
mothoraces and circumferential burns), and abdomen
(i.e., obesity and abdominal compartment syndromes).
• Similarly, an expiratory pause ceases flow at end-
expiration and allows detection of auto or intrinsic
PEEP above set levels, although this maneuver
requires a very passive patient.
• Flow versus time waveforms provide readily available
information on airway resistance even in less passive
patients. Coving or scooping of the expiratory flow
suggests increased airway resistance. Failure of expi-
ratory flow to return completely to zero prior to the
subsequent breath implies at least some degree of
auto-PEEP.
• Pressure-volume curves are the subject of much
debate because of speculation that the lower inflec-
tion point of the inspiratory limb represents the
dynamic recruitment of alveolar lung units and an
upper inflection point implies overdistention of the
lung in acute respiratory distress syndrome (ARDS).
Setting PEEP to the lower inflection point may pre-
vent derecruitment of alveoli during expiration and
thus decrease shear forces experienced by alveoli
during repeated collapse and re-expansion. However,
difficulties in reliably determining the lower inflec-
tion point and lack of clinical trials demonstrating
a clinical benefit with titrating PEEP to this point
limit the use of pressure-volume curves in routine
practice.
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MONITORING FOR LIBERATION FROM
MECHANICAL VENTILATION
• Once an intubated patient’s condition has stabilized, he
or she should be screened daily for suitability for lib-
eration. Patients who are arousable, with adequate
cough and gag, without high minute ventilations, can
tolerate FiO2 levels that can be safely delivered non-
invasively at a PEEP ≤ 5, and are stable hemodynam-
ically should undergo a spontaneous breathing trial.
• Spontaneous breathing trials can be performed on a
T-piece, continuous positive airway pressure (CPAP),
or CPAP with minimal pressure support (5–7 cmH2O
depending on endotracheal tube size) and last for
30–120 minutes. Patients able to maintain a frequency
to tidal volume (in liters) ratio < 105 throughout the
trial without other signs of distress or instability
should proceed to a trial of extubation.
RESPIRATORY DRIVE AND MUSCLE
STRENGTH
• Although not routinely done, patients with unex-
plained respiratory failure or failure to liberate from
mechanical ventilation should be considered for testing
of respiratory drive and muscle strength.
• A negative inspiratory pressure (NIP) >30 cmH2O and
a forced vital capacity (FVC) >1 L are generally ade-
quate to maintain a safe minute ventilation, however,
in an individual patient, trends over time are far more
important than absolute values.
• Respiratory drive can be evaluated by measuring an
airway occlusion pressure in the first 100 ms of inspira-
tion (P 0.1). While the peak negative airway pressure a
patient can generate is a function of respiratory muscle
strength, the P 0.1 is thought to be determined by cen-
tral respiratory drive and be independent of muscle
strength.
• Finding a normal or even elevated magnitude of P 0.1
may point to unrecognized neuromuscular weakness
in a patient previously thought to have central respira-
tory failure.
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10 ASSESSMENT OF SEVERITY
OF ILLNESS
Michael Moore
KEY POINTS
• Severity-of-illness scoring systems have been devel-
oped to predict and evaluate the outcomes of groups
of critically ill patients admitted to ICUs.
• Most scoring systems have been developed using mul-
tivariate regression analysis of large clinical databases
to identify the most relevant variables related to mor-
tality with subsequent prospective validation in other
patient populations.
• The value of a predictive score in an individual patient
is limited and such scores should never be the sole
basis for recommendations regarding withdrawal of
life-sustaining treatments
• Scoring systems are most useful compared to clini-
cians’ predictions of outcomes in patients who are nei-
ther gravely ill nor have an excellent prognosis.
CHARACTERISTICS OF SCORING
SYSTEMS
• All critical care predictive scoring systems utilize
numerical values to describe the severity of a patient’s
illness.
• Scores are then assigned predicted mortalities using a
mathematical formula.
• Important principles in assessing outcome instruments:
 Scoring systems should measure an important
outcome.
 Most ICU scoring systems predict hospital mortality.
 Interest has developed in assessing long-term
mortality and functional status.
 Scoring instruments should be easy to use.
 Data collected during the routine care of the criti-
cally ill.
 Data points should be easily measured, objective,
and reproducible.
 The usefulness of any system depends on its predic-
tive accuracy.
• Characteristics used to judge the value of a predictive
system:
 Discrimination:
 Describes the accuracy of a given prediction.
 Considered discriminant if the area under the
Receiver Operating Characteristic (ROC) curve
> 0.8.
 Illustrates the discriminating ability over the
entire range of prediction scores.
 Example: Area of 0.9 means that a randomly
selected nonsurvivor will have a more severe score
than a randomly selected survivor 90% of the time.
 Calibration:
 Compares the observed mortality to the predicted
mortality within a stratum of severity.
 Example: A predictive instrument would be highly
calibrated if it were accurate at mortalities of 90%,
50%, and 20%.
 Reliability:
 Refers to the inter- and intraobserver agreement
when calculating a severity of illness score.
 A scoring system that is more subjective will be
less reliable.
 Content validity:
 Reflects the comprehensiveness of the model.
 In general, more variables in the model increase the
content validity but may decrease the reliability and
ease of use.
 Methodological rigor:
 Refers to the avoidance of bias in the development
of the model.
• All scoring systems have limitations:
 Outcomes can only be predicted in populations that
were included in the derivation data set.
 Poor application of a rigorously developed and val-
idated scoring system will decrease its usefulness.
ACUTE PHYSIOLOGIC AND CHRONIC
HEALTH EVALUATION II
• Acute physiologic and chronic health evaluation
(APACHE) II is the most widely used scoring system.
• Validated in 5813 ICU admissions from 13 U.S.
hospitals.
• APACHE II scoring:
 Disease specific.
 Score is derived from points given for age, type of
admission, chronic health evaluation, and 12 physi-
ologic variables.
 The 12 physiologic variables are defined as the most
abnormal during the first 24 hours after admission.
• Predicted death rate is computed form the weighted
sum of the APACHE II score, a variable determined
by need for emergency surgery, and the specific diag-
nostic category.
• APACHE II flaws:
 Predicted mortality is less than that observed
among patients transferred from other inpatient
facilities.
 Cannot accurately predict outcome for specific patient
subgroups, for example, liver failure and sepsis.
ACUTE PHYSIOLOGIC AND CHRONIC
HEALTH EVALUATION III
• Designed to correct many of the flaws in APACHE II.
• Derived from 17,440 admissions in 40 U.S. hospitals.
• New variables include prior treatment location and
disease requiring ICU admission.
• APACHE III score:
 Sum of 17 physiologic variables, age, and 7 poten-
tial comorbid conditions.
 Final score can vary between 0 and 300.
• Predicted death rate:
 Computed from the weighted sum of disease cate-
gory, a coefficient related to prior treatment loca-
tion, and the APACHE II score.
 78 diagnostic categories are included.
 Requires a proprietary logistic regression equation.
• Clinical information can be updated daily to provide a
dynamic predicted mortality score.
• Limitations:
 Underestimates mortality in less severely ill and
overestimates it in more severely ill patients.
 Requires a large amount of detailed physiologic data.
 Requires proprietary computer technology.
SIMPLIFIED ACUTE PHYSIOLOGIC
SCORE II
• A non-disease-specific system intended to streamline
data collection and analysis without compromising
diagnostic accuracy.
• Developed from a sample of 13,152 admissions in 12
countries.
• Score is derived from 17 variables selected by logistic
regression:
 12 categorical physiologic variables
 Age
 Type of admission
 Underlying disease
 Acquired immune deficiency syndrome
 Metastatic cancer
 Hematologic malignancy
• Predicted hospital mortality is calculated from the
simplified acute physiologic score (SAPS) II.
• Excellent discrimination and calibration.
• May be suitable for use in the intermediate care unit
setting.
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• May be less accurate in predicting mortality when
patients are admitted to the ICU for noncardiovascu-
lar disease.
MORTALITY PREDICTION MODEL II
• Developed from a sample from 19,124 ICU admis-
sions in 12 countries.
• A non-disease-specific scoring system that excluded
burn, coronary care, and cardiac surgery patients.
• Model uses 15 variables to derive a direct probability
of survival:
 Age
 Three physiologic variables
 Five acute and three chronic diagnoses
 Type of admission
 Use of cardiopulmonary resuscitation (CPR)
 Use of mechanical ventilation
• All of the variables are dichotomous (i.e., present or
absent) except for age.
• Each variable is assigned a coefficient and the sum is
entered into a published mathematical formula to cal-
culate the predicted hospital mortality.
• Excellent calibration and discrimination.
• Timing of mortality prediction model (MPM) score:
 MPM0 is calculated on ICU admission
 MPM24
 Recalculated after 24 hours by updating five
admission variables and including eight additional
variables.
 Allows comparison to other scoring systems
where the score is calculated after 24 hours in the
ICU (SAPS, APACHE).
COMPARISON OF SYSTEMS
• APACHE II, SAPS II, and MPM II all have excellent
discrimination and calibration.
• APACHE II and APACHE III have been compared in
1144 patients from the United Kingdom.
 APACHE II had better calibration and APACHE III
had better discrimination.
 Both underestimated hospital mortality with
APACHE III underestimating by a greater degree.
• Differences and limitations:
 Variables used in the models
 APACHE II variables were selected by committee
based on which variables were thought to be
important to patient outcome.
 MPM II, SAPS II, and APACHE III variables
were chosen using statistical techniques to identify
variables that were independently associated with
death.
 Data collection
 APACHE and SAPS use the worst physiologic
values measured within 24 hours of admission.
 MPM data are collected immediately on ICU
admission and can be modified after 24 hours of
hospitalization.
 APACHE III requires precise physiologic meas-
urements.
 SAPS and MPM use broader physiologic cate-
gories simplifying data collection.
 Timing of score
 APACHE II, MPM, and SAPS can only estimate
mortality on admission (MPM0) or after 24 hours
in the ICU.
 APACHE III can recalculate estimated mortality
on a daily basis.
• May have greater predictive power versus a
single projection.
• However, at least one study that provided inter-
mittently updated likelihood estimates for patient
death and disability failed to change physician
behavior or improve patient outcomes.
 Mortality calculation
 APACHE III uses proprietary computer software
to calculate predicted mortality.
 SAPS and MPM use published equations in
which the severity score is entered into equa-
tions whose solutions provide the predicted
mortalities.
 Cost
 APACHE III requires proprietary computer tech-
nology and substantial data collection.
 APACHE II score calculators are available to the
public.
 MPM and SAPS require somewhat less data and
no additional computer investment.
USE OF SEVERITY SCORES
IN THE ICU
• Severity scoring is ideally suited to the ICU:
 The ICU population is well-defined and care is well-
circumscribed.
 Evidence suggests that ICU severity of illness is the
major determinant of hospital mortality.
 There is a large range of applications in health care
management and research.
• Scoring systems in clinical research:
 Allows comparison between studies that include
heterogenous samples of critically ill patients.
 Allow clinicians to compare the studied population
to their practice.
 Scoring systems in randomized-controlled trials
have multiple functions:
 Describe severity of illness
 Assess comparability of control and treatment
groups at baseline
 Determine sample size
 Perform stratified randomization
 Determine success of randomization
• Scoring systems in ICU administration:
 Describe acuity of illness
 Assess the quality of ICU care
 APACHE scores have been used to compare open
and closed ICUs with respect to patient outcomes.
 Compare interhospital ICU mortality as an indicator
of quality
 A study using APACHE III suggested that teach-
ing hospitals have higher ICU severity and some-
what better risk-adapted patient outcomes.
 APACHE, SAPS, and MPM have been used to
identify ICUs that have higher than predicted
mortality.
 Manage some hospital resources
 Assigning severity scores to ICU patients may
identify those patients who can be placed in less
expensive settings.
• Limitations:
 ICU scoring systems are powerful research tools but
the value of a predictive score in an individual
patient or ICU may be limited.
 The databases used to derive most scoring systems
do not have sufficient statistical power to study most
disease subsets in critical care, for example, liver
failure, obstetrics, and AIDS.
 Lead time bias is well described in APACHE II
(patients transferred from other hospitals and
ICUs have a higher than predicted mortality) and
may be important in scoring systems other than
APACHE III.
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11 PULMONARY ARTERY
CATHETER
Nina M. Patel
KEY POINTS
• The PA catheter is a flow-directed catheter used to
measure intravascular pressures and oxyhemoglobin
saturations and to calculate cardiac output and various
additional hemodynamic values.
• Six randomized controlled trials in varied popula-
tions have failed to demonstrate any benefit to the use
of the PA catheter.  These devices should not be used
routinely.
• The decision to pursue invasive hemodynamic moni-
toring with a PA catheter is a clinical judgment based
on potential risks of the procedure for each individual
patient weighed against availability of noninvasive
means of hemodynamic assessment (e.g., echocardio-
graphy) and results and risks of empiric trials of ther-
apy (e.g., diuresis or volume challenge).
• Complications of a PA catheter include thrombosis,
embolism, knotting of the catheter, pulmonic valve
insufficiency, arrhythmias, endocarditis, catheter-
related sepsis, pulmonary infarction (due to persist-
ent wedging), and arterial rupture. Data from a PA
catheter can offer valuable clinical information, yet
is often misinterpreted. Proper use of a PAC
depends on complete understanding of the data
obtained.
EPIDEMIOLOGY
• 1.5 million pulmonary artery (PA) catheters are placed
per year in North America.
FORM AND FUNCTION
• The PA catheter is a flexible, flow-directed, balloon-
tipped catheter that has been utilized since the 1970s
to directly measure intravascular pressures and guide
hemodynamic assessment.
• The catheter (7 French [F]) consists of a proximal
lumen (30 cm), distal lumen (tip of catheter), thermis-
tor (to calculate cardiac output [CO]), and a 1.5 mL
inflatable balloon.
• It is inserted through an introducer (8.5 F) placed in
either the internal jugular or subclavian veins. (The
femoral and axillary veins can also be used under spe-
cial circumstances.) The distal port is connected to a
pressure transducer which records pressure waveforms
throughout catheter insertion. The transducer is
“zeroed” at the level of the phlebostatic axis (midaxil-
lary line, 4th intercostal space). This step is essential as
deviation of the transducer above or below the phlebo-
static axis will under- or overestimate pressures.
• Initially, the catheter is advanced to the level of the
right atrium (RA, approximately 10–15 cm), at which
point the balloon is inflated. The catheter is subse-
quently “floated” through the RA, right ventricle
(RV), and finally to the PA. When an adequate PA
pressure tracing is achieved, the balloon is deflated
and the catheter locked into position (Fig. 11-1).
30
20
10
0
30
20
10
0
Right atrium
Right ventricle
30
30
20
20
10
10
0
0
Pulmonary artery wedge
Pulmonary artery
Pr
es
su
re
 m
m
H
g
FIG. 11-1. Waveforms as shown during right heart catheterization.
SOURCE: Adapted from Marino PL. The ICU Book. Baltimore, MD: Williams & Wilkins; 1998:157.
• Passage of the catheter through each chamber is iden-
tified by a characteristic pressure waveform.
• During catheter insertion, patients may experience
arrhythmias. In general, these arrhythmias are tran-
sient and will resolve if the catheter is withdrawn to
the superior vena cava (SVC). In rare cases, complete
heart block or ventricular tachycardia will persist and
necessitate intervention with placement of a transve-
nous pacemaker and administration of appropriate
antiarrhythmic agents (e.g., amiodarone).
INDICATIONS
• The data procured from a PA catheter: right atrial pres-
sure (RAP), right ventricular end-diastolic pressure
(RVEDP), pulmonary artery pressure (PAP), pulmonary
artery wedge pressure (PAWP), CO, and mixed venous
oxygen saturation (SvO2), are utilized diagnostically to
differentiate among various etiologies of shock, respira-
tory failure, cardiovascular failure, and renal failure.
• In addition, the PA catheter is employed to guide
patient management through real time evaluation of
intravascular volume status and effectiveness of ther-
apeutic interventions (e.g., change in CO or SvO2
with addition of inotrope).
• The decision to pursue invasive hemodynamic moni-
toring with a PA catheter is a clinical judgment based
on potential risks of the procedure for each individual
patient weighed against availability of noninvasive
means of hemodynamic assessment (e.g., echocardio-
graphy) and/or results and risks of empiric trials of
therapy (e.g., diuresis or volume challenge).
WAVEFORMS
• Pressure waveforms transduced from the PA catheter,
in conjunction with simultaneous ECG recordings, are
valuable in characterizing normal versus pathologic
cardiac states.
• A normal atrial pressure waveform is characterized by
two ascents, the a and v waves and two descents, the
x and y descents.
• Distinctive alterations in the normal atrial pres-
sure waveform characterize a number of cardiac
disorders:
 “Cannon” a waves: atrioventricular dissociation; atrial
contraction against a closed atrioventricular valve
 Large v waves: acute mitral regurgitation, ventricu-
lar septal defect, hypervolemia
 Broad v wave + a rapid y descent: tricuspid
regurgitation
 Blunted x and y descent: pericardial tamponade;
impaired cardiac filling in diastole with subsequent
equalization of diastolic pressures
 Rapid x and y descent: constrictive pericarditis and RV
infarction; rapid ventricular filling in early diastole
• Overdamping of the catheter, catheter whip, incomplete
wedging, and overwedging can hinder acquisition of
accurate waveforms.
DATA ACQUISITION—PRESSURES,
CARDIAC OUTPUT, AND MIXED
VENOUS OXYGEN SATURATION
• The PA catheter confers ability to directly measure or
derive a number of critical hemodynamic variables.
These include: (a) intravascular pressures, (b) CO,
and (c) SvO2.
INTRAVASCULAR PRESSURES
• Respiratory variations in intrathoracic pressure are
transmitted to the vasculature and resultantly alter
intravascular pressure measurements. By convention,
measurements are taken at end-expiration at which
time the pleural pressure is least perturbed by respira-
tion. Even at end-expiration, however, the pleural
pressure may be far from its baseline value, as seen in
patients on positive end-expiratory pressure (PEEP)
(or having auto-PEEP) or when the expiratory mus-
cles are active at end-expiration as in many patients
with airflow obstruction.
• Normal ranges of intravascular pressures are:
 RA pressure: 2–8 mmHg
 RV pressure: 15–25/2–8 mmHg
 PA pressure: 15–30/4–12 mmHg
 PAWP: 2–12 mmHg
• RA pressure is equivalent to central venous pressure
(CVP) and is frequently used as a surrogate marker of
intravascular volume status.
• PAdiastolic pressure is determined by flow (Q), resist-
ance within the pulmonary vascular circuit, and the
downstream (left atrial) pressure. Under normal con-
ditions, in which the pulmonary vascular resistance
(PVR) is low, PAdiastolic pressure approximates PAWP.
However, in situations of abnormally high PVR (e.g.,
pulmonary embolism and acute respiratory distress
syndrome [ARDS]) or Q (e.g., sepsis) through the
pulmonary circuit, PAdiastolic may exceed PAWP sig-
nificantly.
• The PAWP offers valuable clinical information, yet is
often misinterpreted and as such can lead to errors in
patient management.
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 Advancing the inflated PA catheter through the PA
until complete occlusion of blood flow is achieved
derives PAWP. This creates a static column of blood
among the pulmonary arteriole, pulmonary venule,
and the left atrium. Thus, pressure transduced at the
tip of an inflated PA catheter represents pressure
transmitted from the pulmonary venule immediately
downstream of the catheter.
 PAWP is often equated with left atrial pressure or
left ventricular end-diastolic volume (LVEDV)/
preload. This is an erroneous practice; particularly
in critically ill patients, as it does not take into
account LV compliance and/or the presence of
mitral valvular abnormalities.
 PAWP is measured in West’s zone 3 lung, in which
pulmonary arterial pressure (Ppa) exceeds pul-
monary venous (Ppv) and pulmonary alveolar pres-
sures (Palv). These conditions (Ppa > Ppv > Palv)
ensure that the catheter is truly measuring intravas-
cular, as opposed to alveolar pressure. If PAWP
exceeds PAdiastolic, it is likely that the PA catheter is
not in zone 3 lung.
 PAWP reflects pulmonary venous pressure rather
than pulmonary capillary hydrostatic pressure.
CARDIAC OUTPUT
• Cardiac output calculated by thermodilution is another
hemodynamic variable derived from the PA catheter.
 The Stewart Hamilton equation utilizes the area of
decay under the temperature-time curve between
cold injectate infused at the proximal port of the PA
catheter and blood withdrawn at the distal port to
calculate flow or CO.
 Cardiac arrhythmias, tricuspid regurgitation, and
shunts can introduce significant variability into this
measurement.
MIXED VENOUS OXYGEN SATURATION
• SvO2 is the oxygen saturation of blood aspirated from
the distal port of the PA catheter.
• The normal difference between arterial oxygen satu-
ration (SaO2) and venous oxygen saturation (SvO2) is
related to oxygen consumption and CO, and normally
is 20–25%.
• SvO2 reflects roughly the adequacy of oxygen deliv-
ery to peripheral tissues.
• Decreases in SvO2 suggest either increased peripheral
oxygen consumption or decreased rate of oxygen
delivery (e.g., reduced CO, anemia, or decreased
SaO2) with subsequently increased oxygen extraction.
• One of the most essential features in using a PA
catheter is to integrate the numerous data points
derived from it to achieve an understanding of the
hemodynamic status of the patient. This is particularly
useful in classic presentations of shock:
COMPLICATIONS
• Thrombosis, embolism, knotting of the catheter, pul-
monic valve insufficiency, endocarditis, catheter-
related sepsis, pulmonary infarction (due to persistent
wedging), and PA rupture are all rare complications
that may develop while a PA catheter is in place.
• PA rupture is reported to occur infrequently at a rate
of 0.06–0.2% of PA catheter placements. However,
when this complication does occur, consequences are
severe with an estimated mortality rate of 50%.
• Catheter whip, overdamping of the system, over-
wedging, and incomplete wedging are commonly
encountered problems that can impede the acquisition
of accurate PA pressure and PAWP.
CLINICAL APPLICATIONS/
CONTROVERSIES
• The appreciable margin for error in interpretation of
PA catheter data as well as potential for complica-
tions during placement and use of the catheter have
raised concern regarding the efficacy, morbidity, and
mortality associated with PA catheter use. Three
recent randomized prospective trials have all failed
to demonstrate any benefit attributable to the
catheter.
• These data suggest that the PA catheter is not useful
when applied to general categories of patients with
shock, ARDS, or high-risk surgical status. It is
unknown whether this is related to failings of the PA
catheter or simply to the useful role of complementary
means of assessing volume state and perfusion, as dis-
cussed in other chapters, but including echocardiogra-
phy and pulse pressure variation. It also remains
possible that some subsets of patients or unusual indi-
vidual patients might benefit from the PA catheter
even though populations of patients do not.
TYPE OF
SHOCK CO SVR PAWP SvO2
Cardiogenic Decreased Increased Increased Decreased
Septic Increased Decreased Decreased Increased
Hypovolemic Decreased Increased Decreased Decreased
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12 NUTRITION IN THE
CRITICALLY ILL
Joseph Levitt
KEY POINTS
• Critical illness is often associated with hypermetabo-
lism, increased insulin resistance, accelerated lipoly-
sis, and net protein catabolism. In combination with
prolonged bedrest, these derangements can result in
severe depletion of lean body mass, impaired immune
function, impaired ventilatory reserve, and increased
infectious morbidity and mortality.
• Malnutrition is present in up to 40% of intensive care
unit (ICU) patients and is associated with an increased
mortality. Nutritional support cannot fully prevent or
reverse the metabolic alterations associated with criti-
cal illness.
• Nutritional support can improve wound healing,
decrease catabolic response to injury, improve gastroin-
testinal (GI) function, and improve clinical outcomes.
• Despite these benefits and the widespread use of
nutritional support, much controversy and variation in
practice exists over what, when, and how to feed crit-
ically ill patients.
• While many trials have addressed these questions, sig-
nificant heterogeneity in results, feeding strategies
(e.g., enteral vs. parenteral, early vs. late, positioning
of feeding tube, and content of diet), and patient
enrollment (e.g., surgical, medical, burn, trauma,
obese, and malnourished) make definitive recommen-
dations difficult.
ENTERAL VERSUS PARENTERAL
FEEDING
• While significant debate exists even over this most
fundamental question, the bulk of evidence and prac-
tice guidelines support early enteral feeding over par-
enteral feeding whenever possible. While a clear
mortality benefit has not been established by meta-
analysis, infectious complications are clearly lower
with enteral feeding.
• Potential benefits of enteral feeding include preser-
vation of gut structure and function with reduced
translocation of bacteria, as well as avoidance of
increased risks of line sepsis, immunosuppression,
hepatobiliary dysfunction, hyperglycemia, and
increased cost associated with parenteral nutrition.
• However, enteral feeding carries an increased risk of
aspiration and inability to achieve target rates of sup-
plementation due to displacement of feeding tubes,
high residuals or GI symptoms, and invasive proce-
dures or road trips from the ICU leading to frequent
interruption of feeding.
• Although not rigorously studied, generally accepted
contraindications to enteral feeding include bowel
perforation/fistula, obstruction, bowel ischemia, severe
exacerbations of inflammatory bowel disease, high
nasogastric losses, and imminent bowel resection or
endoscopy. Uncomplicated bowel anastomosis is not
a clear contraindication.
• Importantly, nasojejunal feeding improves outcome in
cases of severe pancreatitis compared to parenteral
nutrition. It is unclear if similar benefit exists for more
proximal forms of enteral nutrition but some evidence
suggests even gastric feeding is safe and is probably
preferable to parenteral nutrition if jejunal positioning
is not available.
EARLY VERSUS LATE FEEDING
• It is unclear how long critically ill patients can survive
without food. Surgical literature suggests morbidity
and mortality increase significantly with >2 weeks of
glucose infusion alone. Meta-analysis of randomized
trials show a trend toward improved mortality and
infectious complications with early (<24 or 48 hours)
enteral nutrition compared to delayed (either enteral
or parenteral) feeding. However, it is unclear how
long it is safe to withhold enteral feeding when con-
traindicated before starting parenteral feeding.
• While, some authors, in nonrandomized trials have
found increased harm associated with early aggressive
feeding, the Canadian Clinical Practice Guidelines
recommend starting enteral feeding within 24–48 hours
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of admission in all mechanically ventilated patients
without contraindications.
WHERE AND HOW MUCH TO FEED
• Many small clinical trials have found mixed results of
the benefit of small bowel versus gastric feeding.
However, meta-analyses suggest a trend toward
increased caloric intake and fewer infectious compli-
cations with small bowel feeding, which is generally
recommended when feasible.
• Importantly, even small bowel feeding dramatically
increases gastric secretions and may not significantly
reduce aspiration events. Also the association of high
gastric residual volumes and aspirations events is not
clearly established. Some authors even recommend
tolerating residual volumes up to 400–500 mL. If
these recommendations were widely followed, the
increased caloric intake associated with small bowel
feeding may diminish.
• Early achievement of target rates of enteral feeding
improved outcomes in a study of critically brain-
injured patients. While not directly translatable to
other critically ill patients, these results suggest that
strategies to maximize delivery, for example, starting
at goal rates, tolerating higher residual volumes, and
use of promotility agents (metoclopramide preferable
to erythromycin due to concerns over bacterial resist-
ance) should be considered.
• The addition of parenteral nutrition to enteral feeding
to improve caloric intake has generally been associ-
ated with worsened outcomes. However, many of
these findings may be the result of overfeeding, and
the effect of adding parenteral nutrition when enteral
feeding is poorly tolerated, is unclear. Nonetheless,
starting parenteral nutrition, before all measures to
optimize enteral feeding have been exhausted, is not
recommended.
• When parenteral nutrition is deemed necessary, short-
term (<10 days) use of hypocaloric, lipid-free formu-
las may reduce infectious complications. However,
safety in malnourished patients and longer-term use
has not been established.
• Instituting detailed nutritional protocols may also
increase rates of achieving nutritional goals and
improve clinical outcomes.
WHAT TO FEED
• In general, specialized or enhanced formulas, for
example, arginine supplemented or peptide instead of
whole protein-based diets, are expensive and have not
been shown to be beneficial in most critically ill
patients. However, small clinical trials suggest possi-
ble benefit in some areas:
 Enteral fish oils and other antioxidants may improve
outcomes in acute respiratory distress syndrome
(ARDS).
 Enteral glutamine may benefit burn and trauma
patients, while glutamine-enhanced parenteral nutri-
tion may be superior to standard formulas for criti-
cally ill patients.
 Fat-free parenteral nutrition for <10 days may
reduce infectious complications compared to stan-
dard formulas.
TIGHT GLUCOSE CONTROL
• A single large randomized prospective trial found a
significant mortality benefit with tight glucose control
(80–110 mg/dL vs. 180–200 mg/dL) in surgical ICU
patients. However, patients consisted predominantly
of elective cardiothoracic patients with low acuity
(acute physiologic and chronic health evaluation
[APACHE] II scores of 7–13) and many received
early parenteral nutrition.
• Concern exists for increased complications due to
hypoglycemia if these strict targets are extended to
more labile patients outside of a study setting. It is
also unclear if a similar benefit would be found in
nonsurgical patients not receiving parenteral nutrition.
• Nonetheless, good glycemic control should be empha-
sized in all critically ill patients, but optimal target
levels remained to be established.
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13 AN APPROACH TO SHOCK
William Schweickert
KEY POINTS
• Shock is a physiologic state characterized by a significant
reduction in tissue perfusion with resultant oxygen
deprivation. Progressive, untreated hypoperfusion
leads to the loss of cell membrane integrity, intracellular
edema, loss of intracellular contents, inadequate pH
regulation, and eventually cell death—manifesting as
end-organ damage or failure. Early recognition and
prompt treatment is necessary to prevent this cascade
of damage.
• Shock is almost always signaled by systemic hypoten-
sion (defined as a systolic blood pressure < 90 mmHg
or a mean arterial pressure < 60 mmHg) and tachy-
cardia, with commonly associated clinical features of
multiple organ system hypoperfusion including
tachypnea, oliguria, mental status changes, diaphore-
sis, and metabolic acidosis.
• Three primary types of shock states are typically rec-
ognized: hypovolemic, cardiogenic, and septic. A brief,
directed physical examination will help to recognize
these most common etiologies of shock.
• Less commonly, shock may be attributed to another
etiology, almost universally recognized by accompa-
nying historical details and adjunctive tests (beyond
complete blood counts and chemistries) which elevate
the clinical suspicion. These can be categorized under
three broad headings: high output hypotension, high
right atrial pressure hypotension, and nonresponsive
hypovolemia.
 Historical clues: food and medicine allergies, recent
changes in medications, potential acute or chronic
drug intoxication, preexisting diseases, immunosup-
pressed states, and hypercoagulable conditions.
 Important adjunctive tests: LFTs, pancreatic enzymes,
arterial lactate, cardiac enzymes, arterial blood gas,
toxicology screen, ECG, and urinalysis.
BEDSIDE ASSESSMENT OF SHOCK:
WHAT TYPE OF SHOCK IS IT?
• Step one: Is the cardiac output reduced or elevated
(Table 13-1)?
 Septic shock is strongly suggested by high cardiac
output hypotension, mediated by a primary decrease
in systemic vascular resistance (SVR) which is fre-
quently signaled by a widened pulse pressure (with
marked diastolic reduction relative to systolic pressure),
a strong apical cardiac impulse, warm extremities
with brisk nail bed return, fever or hypothermia, and
leukocytosis or leukopenia (for more details, see
Chap. 43).
 Low cardiac output indicates cardiogenic or hypov-
olemic shock. A narrow pulse pressure, reduced apical
cardiac impulse, and cool extremities with poor nail
bed return signal low cardiac output.
• Step two: If the cardiac output is low, is the heart
empty or too full (Table 13-2)?
 Cardiogenic shock is most commonly signaled by
volume overload. Findings include a large heart
with gallops or murmur, crackles on lung ausculta-
tion, elevated jugular venous pressure (JVP), and
peripheral edema. The electrocardiogram may
demonstrate ischemic changes and a chest x-ray
(CXR) may show a large cardiac silhouette with a
widened vascular pedicle, prominent azygos vein,
pulmonary edema, and upper lobe pulmonary vas-
culature. A broad differential must be entertained,
Section 2
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including systolic dysfunction (best represented by
the above findings), diastolic dysfunction, valvular
disease, and arrhythmia (for more details, see
Chap. 14).
 Hypovolemic shock may be obvious intravascular
depletion, including blood loss (indicated by
hematemesis, tarry stool, abdominal distention,
reduced hematocrit, or trauma) and dehydration
(indicated by decreased skin turgor, vomiting, diar-
rhea, or a negative fluid balance). Less commonly, it
may be the result of “central hypovolemia” or ele-
vated right atrial pressure-mediated hypotension
(see “Recognizing the less common causes,”
below).
RECOGNIZING THE LESS COMMON CAUSES
• High output hypotension (distributive shock)
 This situation involves escalated cardiac output in
the presence of reduced vascular tone and reactivity,
often associated with abnormal distribution of blood
flow. Most commonly this is the result of septic
shock; however, the differential also includes the
following:
 Liver failure: most commonly the end result of
acute decompensation (occasionally superimposed
on a chronic hepatic insufficiency), this shock is
recognized quickly by deranged liver function
tests (LFTs), and mandates testing for infectious
(viral) processes, medication/toxin abuse, and vas-
cular phenomena.
 Severe pancreatitis: similar to liver failure, this is
usually recognized by historical survey and screen-
ing serology (pancreatic enzyme levels, LFTs).
 Thyroid storm should be considered in anyone
with proptosis, goiter, recent iodine load, or access
to synthetic thyroid hormone. A screening TSH
and free thyroxine index are indicated, and early
endocrinology consultation is warranted.
 Trauma with significant systemic inflammatory
response.
 Anaphylaxis requires the appropriate clinical con-
text: drug or contact exposure, ingestion, or insect
bite. Signs and symptoms may include wheezing,
stridor, skin rash, and cyanosis.
 Others: arteriovenous fistula, Paget disease,
beriberi.
• High right atrial pressure hypotension
 In this situation, the left ventricle experiences func-
tional hypovolemia mediated by the circulatory
obstacle(s) of pulmonary hypertension and/or right
ventricular failure. The pulse pressure is narrow,
dependent edema is present; however, the lungs are
not congested.
 Pulmonary hypertension
 Pulmonary embolus suggested by the clinical
scenario (perioperative state, immobilization, throm-
bophilia), symptoms (dyspnea, chest pain, hemopt-
ysis), and physical examination (loud P2 with a
widened and fixed split of the second heart sound),
new hypoxemia without obvious parenchymal
disease, right heart strain on ECG.
 Acute-on-chronic pulmonary hypertension causes
shock in the setting of prior primary pulmonary
hypertension, recurrent pulmonary emboli, pro-
gression of collagen-vascular disease, or chronic res-
piratory failure (e.g., chronic obstructive pulmonary
disease [COPD] or pulmonary fibrosis) aggravated
in part by hypoxic pulmonary vasoconstriction.
TABLE 13-1 Shock Algorithm: Is the Cardiac Output Low?
YES NO
Pulse pressure Decreased Increased
Peripheral pulse Decreased Increased
Extremity warmth Decreased Increased
Nail bed return Decreased Increased
Heart sounds Muffled Crisp
Clinical clues Angina Increased WBC
ECG change Liver function
Working diagnosis Cardiogenic Sepsis
Hypovolemic Sepsis
Sepsis
Liver disease
Beriberi
Paget disease
Aortic insufficiency
TABLE 13-2 Shock Algorithm: Is the Heart Too Full?
YES NO
Examination S3 Dry mucous
membrane (MM)
JVD increased Decrease skin turgor
Cardiomegaly
Setting Angina Hemorrhage
Dyspnea Dehydration
Data ECG BUN/creatinine
Echo Hgb
CXR
Working diagnosis Cardiogenic Sepsis
Hypovolemic
ABBREVIATIONS: JVD, jugular venous distention; BUN, blood
urea nitrogen.
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The resultant right ventricular overload impairs
left ventricular filling, and similar to the above
“cardiogenic” shock, pulse pressure is small and
extremities are cool with peripheral edema. Oxygen
therapy, inotropic agents, and possible pulmonary
vasodilator therapy can reduce pulmonary hyper-
tension and increase cardiac output in a small but
significant proportion of patients.
 Right ventricular infarction: rarely occurs in the
absence of left ventricular injury, but may be sig-
naled by conduction disturbances (AV block), right
precordial ECG lead findings, and cardiac enzyme
elevation.
 Cardiac tamponade: the pericardial effusion is
suggested by the clinical setting (renal failure,
malignancy, chest pain), physical examination (dis-
tant heart sounds, elevated neck veins, pulsus para-
doxus), and routine investigations (CXR with
“water bottle” heart, ECG with low voltage or elec-
trical alternans). Echocardiography is a necessity—
in the interim, intravenous fluids may help to mediate
small improvements in blood pressure, while reduc-
tions in effective circulating blood volume can be
catastrophic. Tamponade physiology requires urgent
evacuation of the pericardial space (catheter or surgical
drainage).
 Other etiologies: constrictive pericarditis, tension
pneumothorax, massive pleural effusion, positive
pressure ventilation with high positive end-expiratory
pressure (PEEP), and very high intra-abdominal
pressure.
• Nonresponsive hypovolemia
 In this clinical scenario, large volumes of fluid may
be necessary to replete circulating volume, and
hypotension may persist despite such measures.
 Adrenal insufficiency: considered in patients with
history of steroid exposure (especially, recent with-
drawal), adrenal infarction or infection (e.g.,
meningococcemia and tuberculosis). Establish the
diagnosis by measuring serum cortisol and conduct
a corticotrophin stimulation test.
 Spinal shock (neurogenic shock): considered in the
setting of spinal injury with the absence of hemor-
rhage. Its hallmark is decreased vascular tone, par-
ticularly venous capacitance. Therapy is volume and
catecholamines.
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14 VENTRICULAR
DYSFUNCTION IN CRITICAL
ILLNESS
Jay Finigan
KEY POINTS
• Cardiac dysfunction is a common complication of
critical illness. 
• Disturbances of cardiac function in the ICU include
those of rate, rhythm, afterload, preload, valves, systolic
pump function, and diastolic filling. 
• While hypotension in the ICU, particularly in the setting
of sepsis, is often a problem of refractory decreases
in systemic vascular resistance (SVR), ventricular dis-
turbances are common and can contribute to increased
morbidity and mortality.
• The causes of ventricular dysfunction in the ICU are
myriad and rapid identification and correction of ven-
tricular derangements is crucial to improved mortality
in critical care. 
CARDIAC FUNCTION
• Cardiac output (CO) is the product of heart rate and
ventricular stroke volume (CO = HR × SV).
• In most critically ill patients, CO is controlled
largely by the systemic vessels, not the heart, and
determined by the mean systemic pressure, the
resistance to venous return, and the right atrial
(RA) pressure. In those with severe ventricular
dysfunction, however, it may be more helpful to
consider the cardiac determinants of SV, including
contractility, preload, and afterload. Alterations in
any of these can result in decreased ventricular
performance.
 Note that the right (RV) and left ventricle (LV) each
have a preload and afterload: RV preload is RA
pressure and afterload is pulmonary vascular imped-
ance while LV preload is LV end-diastolic pressure
and afterload is a function of outflow tract pressure
and ventricular volume.
• Contractility represents inotropic capability of the
ventricle independent of preload and afterload.
• Insufficient or excessive preload can depress ventric-
ular performance.
ASSESSMENT OF VENTRICULAR
FUNCTION
• History and physical examination can identify clues
of ventricular dysfunction.
 Distended neck veins, presence of an S3, and crack-
les suggest a failing ventricle.
 Echocardiography can rapidly and accurately assess
systolic function, diastolic function, wall motion
abnormalities, valves, and the pericardium.
• Central access can be used to measure central venous
pressure (CVP) which is a measure of RV preload.
CVP is not a measure of LV preload.
• Pulmonary artery catheters (PACs) can be used to
assess several cardiac parameters including RA pres-
sure (which represents RV preload), RV pressure, pul-
monary artery pressure (which represents RV
afterload), and pulmonary capillary wedge pressure
(PCWP) which represents LV preload.
 Early studies suggested that PACs might cause harm,
but this has not been confirmed in more recent, ran-
domized trials. On the other hand, PACs also do not
improve outcome. Multiple studies have shown that
the measured wedge pressure is a very poor predictor
of whether a patient will respond to a fluid challenge.
CAUSES OF VENTRICULAR
DYSFUNCTION
• Chronic ventricular dysfunction secondary to ischemia,
alcohol, or viral myocarditis.
• Acute ventricular dysfunction in the ICU has several
causes:
 Ischemia: Global or localized myocardial ischemia,
particularly resulting in infarction, can depress
ventricular function. Even in the setting of normal
coronary arteries, low oxygen tension can lead to
decreased contractility, CO, and coronary artery
perfusion.
 Hypocalcemia: Calcium homeostasis is critical to
cardiac function. Low serum ionized calcium leads
to decreased cardiac myocyte calcium flux and sub-
sequent depressed contractility. Causes of decreased
ionized calcium include red cell transfusions (red
cells stored in citrate which can bind calcium),
lactic acid, and bicarbonate infusion.
 Acidosis: Respiratory acidosis (PCO2 > 60 mmHg)
can result in decreased contractility and CO, while
metabolic acidosis seems to have less of an effect on
LV function.
 Drugs: Toxins such as alcohol as well as drugs such
as beta-blockers, calcium channel blockers, disopy-
ramide, and procainamide can depress contractility.
• Sepsis: Ventricular dysfunction, specifically decreased
contractility, occurs early in patients with sepsis, even
those who maintain normotension. However, after
volume loading CO is often maintained or even
increased in sepsis. This has been referred to as
“warm shock” and is marked by warm extremities and
moist skin.
 Septic patients initially manifest a depressed ejec-
tion fraction (EF) which increases over 7–10 days.
Interestingly, survivors present with ventricular
dilation and a low EF (~0.32) which increases over
time while nonsurvivors present with a higher EF
(~0.55) which remains high until death indicating
that depressed LV contractility in sepsis might be
protective.
 The cause of sepsis-induced myocardial depression
is believed to be secondary to circulating myocar-
dial depressants such as tumor necrosis factor
(TNF), nitric oxide (NO), and interleukin (IL)-6,
among others. Evidence demonstrates that coronary
hypoperfusion and ischemia are not sources of
decreased EF in sepsis.
TREATMENT
• Identify and treat reversible causes.
 Use of supplemental oxygen and red cell transfusion
to prevent or treat ischemia.
 Intravenous calcium can correct hypocalcemia.
Many measure ionized calcium levels after large red
cell transfusions (≥6 units), although it is not clear
whether calcium administration during critical ill-
ness is helpful or harmful.
 Replete other electrolytes (potassium, magnesium)
as needed.
MANAGEMENT
• Key to managing ventricular pump function in critical
illness, especially in sepsis, is to optimize preload. In
general, in the absence of cardiogenic shock, hypoten-
sion and ventricular dysfunction should be managed
first with the institution of fluids.
 According to Starling Law of the Heart, contractile
strength is a function of muscle fiber length, that is,
other things being equal, a stretched ventricle (by
increased volume) will contract more forcefully
than an unstretched ventricle. Normal end-diastolic
LV filling pressure is in the range of 10 mmHg but
a heart with depressed contractility requires higher
filling pressures to increase SV (Fig. 14-1).
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 Major limitation to volume loading is creation of pul-
monary edema which, in patients with normal albu-
min concentrations and endothelial cells, forms at
PCWP ≥ 20–25 mmHg. In patients with decreased
serum albumin and/or endothelial cell disruption
(e.g., acute respiratory distress syndrome [ARDS]),
pulmonary edema can form at lower wedge pressures.
• Afterload reduction with vasodilators (angiotensin
converting enzyme inhibitors [ACE-I], nitrates), blood
pressure permitting, will further improve ventricular
systolic function.
• Inotropic agents, such as dobutamine can boost con-
tractility and are effective adjuncts in patients with a
low CO despite adequate resuscitation. In patients
with hypotension it occasionally causes hypotension,
prompting the addition of a vasopressor.
• In cases of severe, refractory heart failure from dam-
aged myocardium, support using intra-aortic balloon
counterpulsation (IABC) can serve as a bridge to
recovery or corrective surgery. IABC aids a failing
heart in both diastole, via increased diastolic coronary
filling pressure and in systole, by decreasing cardiac
afterload.
DIASTOLIC DYSFUNCTION
• Diastolic dysfunction (DD) is a condition of decreased
SV marked by increased diastolic stiffness.
• Abnormal diastolic filling of the LV has been observed
by echocardiography in patients with hypotensive and
normotensive sepsis.
• In contrast to systolic function (see above), more severe
DD is associated with worse outcomes in sepsis.
• Therapy of DD is limited and includes identifying and
treating reversible causes (ischemia, excessive tachy-
cardia) as well as initiating standard treatment for heart
failure: afterload reduction and achieving an appropriate
end-diastolic volume with the judicious use of fluids
and diuretics. In addition, treating supraventricular
tachycardias can be important as patients with DD have
an increased reliance on the atrial contribution to end-
diastolic volume.
RIGHT VENTRICULAR DYSFUNCTION
• It is a given that the input and output of the RV and LV
must be equal and that alterations in either side can
result in clinically apparent heart failure.
• RV dysfunction is a common finding in critical care as
well as sepsis.
• In sepsis, especially if there is acute lung injury, pul-
monary vascular resistance may be elevated contribut-
ing to RV dysfunction.
• Decreased intrinsic RV contractility also contributes
to RV dysfunction in sepsis.
• Low RV EF has been associated with worse outcomes.
Similar to the situation regarding the LV, survivors
often present with lower RV EFs than nonsurvivors.
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15 RHYTHM DISTURBANCES
IN THE ICU
Susan S. Kim
KEY POINTS
• Rhythm disturbances are common in the ICU.
• In medical and surgical ICUs, dysrhythmias are markers
of critical illness more often than signals of organic
heart disease.
FIG. 14-1 Frank-Starling curve. Three different curves of con-
tractility, normal, heart failure and use of the inotropic agent such
as dobutamine. At a given level of contractility, increasing pre-
load will increase stroke volume (until the systolic function of the
heart is overwhelmed). Heart failure and inotropes cause a shift
of the curve down and to the right or up and to the left to a new
curve of contractility.
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• A 12-lead electrocardiogram, long rhythm strip, and a
systematic approach aid the diagnosis of rhythm dis-
turbances. Cardiologic consultation may be appropri-
ate in some cases.
• Tachyarrhythmias should always prompt a search for
underlying precipitants, such as hemorrhage or
hypoxemia, which might have specific remedies. ST
should almost never be treated directly.
• Unstable patients with nonsinus tachyarrhythmias
should be electrically cardioverted.
• Bradyarrhythmias may follow vagal stimulation.
• Transcutaneous and transvenous pacing, as well as
therapy delivered through an existing ICD, can be
considered in appropriate patients.
EPIDEMIOLOGY
• In a single-center study of 756 medical, cardiac, or
postoperative ICU patients, roughly one in five patients
developed a significant arrhythmia during their ICU
stay.
• Tachyarrhythmias accounted for 90% of rhythm dis-
turbance episodes.
• Atrial fibrillation (AF) affected the highest proportion
of patients (47% of patients).
• Ventricular tachycardia (VT) accounted for the highest
proportion of arrhythmia episodes (52% of episodes).
PATHOPHYSIOLOGY
• Rhythm disturbances can be divided into tach-
yarrhythmias and bradyarrhythmias.
• Tachyarrhythmias can be further divided into narrow-
complex (usually supraventricular in origin [SVT]) and
wide-complex (usually either supraventricular with
aberrant conduction or ventricular [VT]) tachycardias.
 Tachyarrhythmia mechanisms include re-entry, trig-
gered activity, increased automaticity, or a combina-
tion of these factors.
 Regardless of mechanism, both SVTs and VTs may
be stimulated by factors such as cardiac ischemia, a
hyperadrenergic state, sympathomimetic medications,
other medication toxicity, hypotension, hypoxemia,
electrolyte abnormality, catheter irritation, and acid-
base disturbance.
• Bradyarrhythmias represent sinus node dysfunction
(SND), atrioventricular block (AVB), or both.
 SND may manifest as inappropriate sinus bradycar-
dia, sinus pause, or sinus arrest.
 AVB may take the form of first-degree or type I
second-degree block (usually occurring at the level
of the AV node, usually benign) or type II second-
degree and third-degree block (usually occurring
infranodally in the His-Purkinje system, usually
pathologic).
 Both SND and AVB can stem from (a) intrinsic
nodal pathology such as is seen in older patients and
those with cardiovascular disease, (b) an external
insult such as an acid-base disturbance, electrolyte
abnormality, hypoxemia, hypotension, medication
toxicity, or increased vagal tone, or (c) a combina-
tion of intrinsic and extrinsic factors.
 AVB may also result from erosion into the AV node
by a focus of infectious endocarditis.
 Junctional rhythm is a secondary or “escape”
rhythm that occurs in response to a primary brad-
yarrhythmia such as any form of SND or AVB.
 Asystole (ventricular) represents either sinus arrest
or complete heart block with no escape rhythm.
CLINICAL FEATURES
• Tachyarrhythmias
 Sinus tachycardia (ST) is a very common rhythm in
the ICU. It is characterized by upright P waves in
lead II and gradual (vs. abrupt, such as in SVT) rises
and falls in the heart rate. ST frequently occurs in
response to a hemodynamic insult such as low stroke
volume (SV) or low systemic vascular resistance
(SVR). ST may also reflect fever, pain, or anxiety.
 Narrow-complex tachycardias (nonsinus) are usu-
ally supraventricular in origin and can represent
AF, atrial flutter (AFl), a paroxysmal supraven-
tricular tachycardia (PSVT, such as atrioventricular
nodal tachycardia [AVNRT], orthodromic re-entry
tachycardia [ORT], or atrial tachycardia [AT]), mul-
tifocal atrial tachycardia (MAT), or junctional ectopic
tachycardia (JET).
 Not uncommonly, the appearance of a wide-complex
tachycardia is generated by artifact (caused by motion,
poor lead contact, chest physical therapy, and so
forth).
 Wide-complex tachycardias can represent artifact,
supraventricular tachycardia with aberrant conduc-
tion, antidromic re-entry tachycardia, drug or elec-
trolyte imbalance, VT, or ventricular fibrillation (VF).
• Bradyarrhythmias
 In the ICU, heightened vagal tone is a common
cause of bradycardia (both SND and AVB). Factors
such as nausea, vomiting, pain, coughing, and under-
going suctioning can cause heightened vagal tone.
This autonomic input can slow or even halt sinus
node or atrioventricular nodal function. In most
instances, these episodes are self-limited and carry a
benign prognosis.
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 Bradycardia due to increased vagal tone is usually
episodic (lasting on the order of several seconds), is
gradual in onset and resolution, and is usually associ-
ated with one of the conditions noted above. For exam-
ple, vagally mediated bradycardia may manifest as
gradual sinus slowing or gradual prolongation of the PR
interval with eventual AVB (AV nodal Wenckebach).
 SND may manifest as sinus arrest, sinus pause, or
inappropriate sinus bradycardia.
 With AVB, prolonged or blocked conduction is
occurring either at the level of the AV node or infra-
nodally in the His-Purkinje system. This distinction
is important as the level of block frequently corre-
lates with the likelihood of long-term loss of AV
conduction (low and high, respectively).
 In most cases, first-degree and type I second-degree
AVB (AV nodal Wenckebach) occur at the level of
the AV node and do not lead to long-term loss of AV
conduction. A common cause of first-degree or type
I second-degree AV block is increased vagal tone
causing slowed conduction through the AV node.
 Similarly, in most cases, type II second-degree AVB
and third-degree AVB occur at the level of the His-
Purkinje system and represent fixed, structural con-
duction system disease. These forms of AVB are
associated with a high likelihood of long-term loss
of AV conduction.
DIAGNOSIS AND DIFFERENTIAL
• Whenever possible, obtain a formal 12-lead electro-
cardiogram and follow this protocol:
1. Is it a tachyarrhythmia? If yes, then proceed to #2.
If not, then go to #5
2. Rule out ST. If not ST, then go to #3
3. Rule out narrow-complex tachycardias. If not, then
go to #4
4. Wide-complex tachycardias
5. Bradyarrhythmias
• Permanent pacemakers and implantable cardioverter-
defibrillators (ICDs) may be programmed to store
supraventricular or ventricular arrhythmia events. As
such, interrogation of these devices and extraction of
those event data may assist in diagnosis.
INTENSIVE CARE UNIT CARE
• Tachyarrhythmias
 ST is frequently a compensatory hemodynamic
response; therefore, it should rarely be treated.
Rather, the underlying disorder promoting the ST
should be addressed (e.g., hypotension and fever).
 Look for an underlying trigger of the tachyarrhythmia.
 Follow advanced cardiac life support (ACLS)
guidelines.
 Cardiovert the patient if unstable.
 Adenosine at 6 and 12 mg IV doses can cause AV
block. Its half-life is a few seconds and so it should
be administered with rapid IV push followed by a
rapid flush. It may cause transient shortness of
breath and chest pressure. It is contraindicated in
asthma patients.
 Adenosine may terminate rhythms that depend on the
AV node (atrioventricular nodal re-entrant tachycardia
[AVNRT], atrioventricular re-entrant tachycardia
[AVRT]) or simply block conduction of supraven-
tricular input to the ventricles.
 Most ICDs and some pacemakers can be programmed
to deliver commanded antitachycardia pacing. ICDs
can deliver commanded internal shocks. Thus, these
implanted devices may be programmed by qualified
personnel to deliver commanded therapy to treat
tachyarrhythmias.
• Bradyarrhythmias
 Medication toxicity should start with cessation of
the offending agent and continuous cardiac teleme-
try monitoring.
 In more extreme cases with significant bradycardia
or hypotension, therapies directed at reversing toxic
effects may be applied. Beta-blocker toxicity may
be treated effectively with glucagon, calcium chan-
nel blocker toxicity with intravenous calcium, and
digoxin toxicity with digoxin-specific antibody
infusion.
 Look for extrinsic, reversible factors.
 Temporary pacing can take one of several forms:
transcutaneous pacing, transvenous pacing with an
isolated temporary pacing wire, transvenous pacing
through a pacer-port pulmonary artery catheter, and
epicardial pacing.
 Transcutaneous pacing allows for immediate, non-
invasive pacing. However, it can be painful; may not be
effective, especially in obese patients; and has less long-
term reliability than does invasive pacing. It is useful as
a short-term, temporizing measure. Pacing pads should
be placed to maximize energy delivery to the left
ventricle. Conscious patients should be sedated.
 Transvenous pacing through a pacer-port pulmonary
artery catheter can be a convenient option in a patient
with a preexisting pacer-port pulmonary artery
catheter. Because the wire is threaded through the
catheter (exiting at a port 20 cm from the catheter
tip), this method allows for more guided placement
of the wire tip into the right ventricle—an advantage,
especially, when fluoroscopy is not available. Wire
positioning, though, is subject to the stability of
catheter position.
 Transvenous pacing with an isolated temporary
pacing wire allows for more stable positioning over
time, but is most safely placed under fluoroscopic
guidance. Balloon-tipped wires are available and are
safer to place without fluoroscopy than are non-
balloon-tipped wires.
 Any transvenous pacing wire carries the risk of
myocardial perforation and consequent tamponade as
well as the risk of introducing endocardial infection.
 Patients with transvenous pacing wires should have
daily chest roentgenograms and 12-lead electrocar-
diograms to monitor positioning.
 Epicardial temporary pacing is another option, but is
mostly limited to postcardiac surgery patients who
have had epicardial wires placed intraoperatively.
Thresholds rapidly increase with these types of wires
so that by 3 days, about half no longer capture.
 Pacing is effective only if it results in myocardial
depolarization or “capture.” Capture is affected by the
vector of energy delivery (as with transcutaneous
pad placement), transvenous wire contact with the
myocardium, and amount of programmed energy deliv-
ery. The ability to capture with pacing may change over
time due to wire malpositioning or may be affected by
hypoxemia, hypotension, and acid-base status.
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16 NONINVASIVE ASSESSMENT
OF CARDIAC OUTPUT
Sascha Goonewardena
KEY POINTS
• Cardiac output is one of the most important hemody-
namic variables for the assessment of cardiac function
and for the guidance of therapy in the intensive care
setting (Table 16-1).
• The gold standard for measurement of CO is the ther-
modilution technique that involves invasive monitor-
ing with a pulmonary artery catheter. However, the
use of invasive methods to determine CO has associ-
ated risks and potential adverse outcomes. The use of
noninvasive methods to determine CO provides
intensivists with the necessary clinical information
without the potential risks associated with invasive
devices.
• Even the thermodilution technique for CO determina-
tion is susceptible to inaccuracies; intracardiac shunts,
tricuspid regurgitation, and inaccurate measurements
are the major sources of error when determining CO
using the thermodilution technique.
• Noninvasive methods to determine CO include
echocardiography with Doppler ultrasound, thoracic
bioimpedance, and the indirect Fick method.
• Each method has inherent advantages and disadvan-
tages (Table 16-2). Because of the noninvasive nature
of each method, certain assumptions are required
when utilizing each method.
• Proper utilization of noninvasive methods of CO
assessment can enable intensivists to more appropri-
ately diagnose, risk stratify, and titrate specific thera-
pies to the patient’s clinical situation.
• A major advantage of continuous CO monitoring
is that important physiologic alterations can be
detected that may not be evident with intermittent
monitoring.
ECHOCARDIOGRAPHY WITH DOPPLER
ULTRASOUND
• Echocardiography relies on high-frequency sound
waves that penetrate body tissues. As these sound
waves encounter tissues of different acoustic densi-
ties, a fraction of the emitted sound wave is reflected.
• When an ultrasound beam is directed toward a
moving target, the reflected sound wave changes its
frequency; this phenomenon is known as Doppler
shift. The magnitude of this Doppler shift is directly
proportional to the velocity of the blood flow.
• The Doppler shift equation is Fd = 2 fo/CV cos q,
where Fd represents the Doppler shift, fo is the trans-
mitted frequency, V is the velocity of the moving
blood, C is the velocity of the ultrasound in blood
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Determination of etiologies of shock
Targeting treatment strategies
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(constant), and the angle θ is the angle between the
direction of the moving blood and the transmitted
ultrasound beam.
• Echocardiography can measure ascending aortic flow
velocity and cross-sectional diameter of aortic root to
calculate cardiac output (CO).
• The velocity time integral (VTI) of blood flow is the
area under the velocity-time curve.
• Stroke volume (SV) = cross-sectional area of aortic
root × VTI. Then, by using the equation, CO = SV ×
heart rate (HR), the approximate CO can be calcu-
lated.
• Accurate estimates of CO are dependent on the accu-
rate alignment of Doppler signal with aortic blood
flow, the assumption that the aortic dimensions can be
estimated, and the assumption that aortic blood flow
is laminar.
• Deviations from these assumptions can lead to errors
of CO estimation by up to 15%.
• Transesophageal echocardiography (TEE) has improved
accuracy over transthoracic echocardiography because
of decreased deviations from the assumptions mentioned
above.
• TEE also enables intensivists to record CO continu-
ously.
• Echocardiography can provide information on a host
of hemodynamic variables in addition to CO includ-
ing an estimation of left ventricular filling pressures,
atrial interactions, and pulmonary pressures.
• Up to 25% of patients cannot be adequately imaged
using echocardiography.
THORACIC BIOIMPEDANCE
• Thoracic bioimpedance technology utilizes continu-
ous electric current stimulation to determine imped-
ance variations that are associated with physiologic
changes in the body. These variations can be utilized
to estimate the SV and CO.
• Two methods exist for performing bioimpedance
analysis of CO: thoracic electrical bioimpedance and
whole body electrical bioimpedance.
• According to Kirchov law, electric current passes
preferentially through vessels of higher conductance.
Consequently, when alternating currents of 20–100 kHz
are applied to the thorax, the currents are primarily
distributed via the extracellular fluid and the blood
vessels. Thus, with each systolic increase in the aortic
blood volume, there is a proportional increase in the
aortic electrical conductance.
• The relation between these two changes is expressed
as: ∆V/V = ∆R/R, where change in V equals the stroke
volume, V is the aortic volume immediately preceding
systole, and change in R is the systolic electrical
resistance to change, and R is the baseline resistance
of the electrical field involved.
• A potentiometer is the device used for measuring
body resistance or impedance. It is composed of two
bipolar electrodes that can be applied to any accessi-
ble part of the body.
• The Sramek-Bernstein method is the most frequently
used impedance cardiographic method since 1986.
• In general, most trials have demonstrated significant
correlation between CO with impedance cardiography
and other diagnostic methods including thermodilu-
tion; the results, however, have not always been con-
sistent. Meta-analysis of the studies in cardiac patients
comparing bioimpedance to thermodilution shows a
correlation coefficient of 0.77 (0.71–0.82).
• Most clinical trials suggest that electrical bioimpedance
is feasible and reliable in healthy volunteers; however,
the reliability and accuracy decreases in intensive care
patients.
• Limitations of thoracic electrical bioimpedance
include hemodynamically significant aortic valve
insufficiency, significant aortic dilation, aneurysm and
coarctation, significant intracardiac shunts, significant
ventricular arrhythmias, and significant pulmonary
edema.
TABLE 16-2 Comparison of Noninvasive CO Determination Techniques
METHOD ADVANTAGE DISADVANTAGE
Echocardiography with Noninvasive, can assess large Operator dependent, poor image quality 
Doppler ultrasound number of cardiac and hemodynamic in certain patient populations, and relies on 
variables in addition to CO mechanical assumptions for heart and vasculature
Thoracic Noninvasive, only requires Less reliable in critically ill patients, highly 
bioimpedance minimal equipment dependent on lead position and other mechanical variations, 
susceptible to inaccuracies when ventricular arrhythmias present
Indirect Noninvasive, continuous Less accurate at high CO, susceptible 
Fick method CO determination to small variations in VO2 and VCO2 measurements,
requires steady state conditions
• Limitations for whole body electrical bioimpedance
include hemodynamically significant aortic valve
insufficiency; significant aortic dilation; aneurysm or
coarctation; peripheral artery disease; intracardiac
shunts; restless patients, significant ventricular arrhyth-
mias; and peripheral edema.
• In addition to the above limitations, lead placement
and estimates of the volume of electrically participat-
ing tissue (VEPT) are crucial to accurate determina-
tion of CO using electrical bioimpedance technology.
INDIRECT FICK METHOD
• The Fick principle is based on the conservation of
mass. This principle states that blood flow through the
pulmonary artery is equal to the ratio of the uptake or
elimination of a gas and the difference in concentra-
tion of that gas in the blood flowing into and out of the
lungs.
• The components of the Fick principle can be deter-
mined invasively (direct method) and noninvasively
(indirect calorimetry and modified CO2 Fick method).
• The major limitations of the direct method are related
to errors in sampling and analysis, difficulty in obtain-
ing oxygen uptake continuously and reliably, and the
inability to maintain and record consistent hemody-
namic states.
• Indirect calorimetry measures O2 consumption as the
amount of O2 taken up from the respiratory gases.
This is assessed within a breathing circuit whereby
inspired and expired flow rates of O2 are measured
relative to one another, usually by means of an insol-
uble gas marker like nitrogen.
• The discrepancies between indirect calorimetry and
more invasive methods of CO determination are attrib-
uted to O2 consumption by lung tissue. In addition, very
precise calibration of measurement devices is neces-
sary to minimize variability of measured variables.
• The CO2 Fick method is noninvasive and relies on the
determination of CO2 delivery and elimination.
• Fick equation using CO2 is: Q = VCO2/CvCO2 − CaCO2,
where Q is cardiac output, VCO2 is the CO2 elimination,
and CvCO2 and CaCO2 are the mixed venous and
arterial CO2 blood contents.
• The indirect Fick method that utilizes CO2 is advanta-
geous because CO2 elimination is more easily meas-
ured than O2 uptake and estimates of arterial CO2
concentration can be made from the gas exhaled by
the lungs.
• Monitoring the CO2 partial pressure in the expired gas
and relating this measurement to the CO2 dissociation
curve can noninvasively estimate the CO2 concentra-
tion in the alveolar end-capillary blood.
• For all assessments of CO utilizing Fick principle or a
variation of the general principle require that the
patient be in a relatively steady hemodynamic state.
The patient’s being cared for in the intensive care set-
ting often violates this prerequisite.
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17 INTERPRETATION
OF HEMODYNAMIC
WAVEFORMS
Tim Floreth
KEY POINTS
• Knowledgeable interpretations of pressure waveforms
allows critical evaluation of cardiopulmonary status.
• Vascular pressures are recorded by fluid-filled plastic
tubes connecting the patient’s intravascular device to
external pressure transducers. Ensuring that the
system is working properly is of paramount impor-
tance before clinical decisions are made.
• The mean arterial pressure is superior to the systolic
pressure as an indicator of the true driving force of
blood to vital organs and, unlike the systolic pressure,
is unchanged throughout the arterial tree.
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• The pulmonary artery catheter measures pressure and
can sample blood from the right atrium, right ventri-
cle (RV), and PA. It provides an estimate of the end-
diastolic pressure of the left ventricle (LV) via the
pulmonary venous system and the left atrium. No ran-
domized trial has proven a beneficial effect of PACs
using a clinically meaningful endpoint.
INTRAVASCULAR PRESSURES
• Direct invasive monitoring is necessary in patients in
which a clinical determination of volume status is dif-
ficult to assess by examination or a specific goal of
treatment must be reached.
• Vascular pressures are recorded by fluid-filled plastic
tubes that connect the patient’s internal pressures via
catheters to the external pressure transducers.
• The Flush test (a brief flush to the catheter tubing
system) gives data to indicate whether the transducer
to recording system is intact.
• Systems can be overdamped due to bubbles in the line
and the system must be flushed. Systems can be
underdamped by the excessive length of connecting
tubing, connecting tubing with stopcocks, and high
output cardiac states.
THE ARTERIAL PRESSURE
WAVEFORMS
• The contour of the arterial pressure changes from the
proximal aorta to the distal femoral artery. As such,
the absolute systolic pressure increases and the wave-
form narrows.
• The mean arterial pressure is superior to the systolic
pressure as an indicator of the true driving force of
blood to vital organs and, unlike the systolic pressure,
is unchanged throughout the arterial tree.
• Measured mean arterial pressures are more accurate
than estimated pressures (calculated as [2 × BPdiast +
BP
syst]/3) especially when the pulse pressure is >60.
THE PULMONARY ARTERY CATHETER
• The pulmonary artery (Swan-Ganz) catheter (PAC)
measures pressures and can sample blood from the
right atrium, right ventricle (RV), and PA. It is able to
provide an estimate of the pressure of the left ventricle
(LV) via the pulmonary venous system and the left
atrium.
• The catheter is inserted into the circulation of the supe-
rior vena cava (SVC) in which pressures are similar
to the right atrium and advanced gently, allowing the
normal blood flow to guide the catheter into the cor-
rect location. Differences in waveforms and pressures
allow the operator to know where the catheter is cur-
rently located during the insertion. Figure 17-1 shows
waveform examples. In general, the right atrial (RA)
pressures and waveforms will be similar to the SVC.
Once the catheter advances to the RV, the diastolic
pressure will not change, but the systolic pressure will
increase. Visually, the waveform increases in size due
to the increased pulse pressure of the RV. As the
catheter advances into the PA, the diastolic pressure
increases and the waveform narrows. The systolic
pressure of the PA typically equals the systolic pres-
sure of the RV. The catheter is then advanced until the
mean pressure falls and (usually) the waveform damp-
ens to resemble an atrial waveform. This is the PA
occlusion (or “capillary wedge”) pressure (Ppw) that
typically is the same as the PA diastolic pressure
(6–12 mmHg).
• Knowledgeable interpretations of the pressure wave-
forms allows critical evaluation of cardiopulmonary
status via estimation of the atrial and ventricular pres-
sures. Multiple randomized trials have demonstrated
that this catheter has no impact on meaningful out-
comes (neither harmful nor helpful). For this and
other reasons, such as the ready availability of
echocardiography, use of the catheter is in substantial
decline. The many clinical uses and the primary data
used to determine various cardiopulmonary states are
outlined in Table 17-1.
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FIG. 17-1 RA pressure tracing. This schematic diagram
shows the different components of the RA pressure tracing.
A simultaneous ECG is shown to demonstrate the timing of the
different components.
SOURCE: Silvestry, F.E., Swan-Ganz catheterization interpretation
of tracings. Up to date online 14.3.
• The waveforms and data can be used to help differen-
tiate between left and right heart failure. In right heart
failure the RA pressures (Pra) will be high and the
cardiac output (Qt) will be low. Left heart dysfunction
will demonstrate elevated left ventricular end-
diastolic pressures (LVEDP) as estimated by the Ppw
and diminished cardiac output. The systemic vascular
resistance (SVR) will be elevated.
• The three classic types of hypotension can also be dif-
ferentiated based on PAC data. In hypovolemic shock,
Pra is low, Qt is low, and SVR is high. In cardiogenic
shock, Pra is high, Qt is low, and SVR is high. In vaso-
genic shock, Pra is low, Qt is high, and SVR is low.
Table 17-2 compares types of shock and their PAC
data.
SOURCES OF VARIABILITY
• “Zeroing” the catheter is performed by opening the
system to establish atmospheric pressure as zero. The
zero reference point is the intersection of the midaxil-
lary line and the fourth intercostal space and corre-
sponds to the right and left atrium in a supine patient.
Therefore, patient and bed position are also important
variables in determining correct pressure information.
WEDGE TRACING
• The wedge pressure is assumed to reflect the pressure
in the left atrium and, by inference, the LVEDP since
balloon occlusion creates a static column of blood
from the tip of the catheter, through the pulmonary
capillaries, postcapillary venules, veins, left atrium,
and to the LV. It is important to understand that
Ppw is a pressure, not a volume, and that there is a
poor correlation between measured Ppw and LVEDV,
in part because of the unpredictable compliance of
the LV.
• Like all hemodynamic pressures, Ppw should be read
at end-expiration, since this minimizes the likelihood
that respiratory muscle activity is raising or lower-
ing pressures from their passive values. Even at end-
expiration, however, respiratory muscles may be
active, especially in the sickest patients, further
complicating the assessment of ventricular preload by
the Ppw.
CARDIAC OUTPUT MEASUREMENT
• The PAC can also give measurements of cardiac
output via the indicator thermodilution method (via
thermal depression or “cold”) or the assumed Fick
method.
• In this process, cold saline is injected through the prox-
imal lumen into the RA, travels through the RV, and
finally passes into the PA where the thermistor at the
end of the catheter senses the dynamic temperature
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TABLE 17-1 Clinical Uses of PA Catheterization
Diagnostic uses Data sought
Pulmonary edema Ppw
Shock Qt and SVR; Ppw; Svo2
Oliguric renal failure Ppw, Qt
Perplexing lactic acidemia Qt, SVO2
Pulmonary hypertension Ppa, Ppad, Ppw
Cardiac disorders
Acute mitral insufficiency V wave
Ventricular septal defect O2 sat RA vs. PA
RV infarction Pra, RVEDP, Ppw
Pericardial tamponade Pra, RVEDP, Ppad, Ppw
Narrow complex RA waveform (flutter waves)
tachyarrhythmias
Wide complex RA waveform (cannon A waves)
tachyarrhythmias
Monitoring uses
Assess volume
Hypotension
Oliguria
High-risk surgical pt
Assess the effect of Ppw
on pulmonary edema
Assess therapy for shock
Cardiogenic (vasodilator,
inotrope)
Septic (volume, vasopressor,
inotrope)
Hypovolemic (volume)
Assess effects of PEEP on DO2
in ARDS
ABBREVIATION: Ppw, pulmonary wedge pressure; Qt, cardiac output;
SVR, systemic vascular resistance; SVO2, mixed venous O2 saturation;
Ppa, pulmonary artery pressure; Ppad, Ppa diastolic; Pra, right atrial
pressure; RVEDP, right ventricular end-diastolic pressure; DO2, oxygen
delivery; RV, right ventricle; RA, right atrium.
SOURCE: Adapted from Principles of Critical Care., Hall, J. et al. 3rd
edition.
TABLE 17-2 Typical PAC Data for Different Types of Shock
VASOGENIC
HYPOVOLEMIC CARDIOGENIC (SEPSIS)
RA Low High Low
pressure
Cardiac Low Low High
output
SVR High High Low
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change over time. The area under this curve is
inversely proportional to the flow rate or the cardiac
output.
• Cases where the cardiac output is inherently inaccurate
are tricuspid regurgitation (Qt is variably under- or
overestimated) and intracardiac shunts (Qt is overesti-
mated).
• Systemic and pulmonary vascular resistance can also
be calculated based on the fact that resistance is equal
to pressure change divided by flow. These are both
indirect and often inaccurate data.
RIGHT ATRIAL WAVEFORMS
• There are normally three positive and two negative
deflections in the RA waveforms of a competent tri-
cuspid valve.
• The “a” wave represents contraction during atrial sys-
tole, the “c” wave represents the small deflection during
closure of the tricuspid valve, and the “x” descent rep-
resents the decrease in RA pressure following the atrial
systolic contraction (Fig. 17-1).
• The “v” wave represents ventricular systole and pas-
sive filling of the atrium. The “y” descent occurs after
the opening of the tricuspid valve in which the RV
passively fills until the next “a” wave.
• Normal RA pressures range from 0 to 7 mmHg.
Elevations can be seen in any condition that produces a
back up of pressure due to obstruction of flow or
decrease in forward flow such as tricuspid valve disease,
pulmonic stenosis, pulmonary hypertension, RV dys-
function, pericardial disease, or left heart dysfunction.
• Tricuspid regurgitation produces elevated “v” waves
as blood is regurgitated into the RA during ventricular
systole.
• RA pressures can be elevated and approach those of the
Ppw in cardiac tamponade (“equalization of pressures”).
• Disturbances in cardiac rhythm can also be seen on
RA waveforms. Atrial fibrillation is associated with a
loss of normal “a” waves while atrial flutter may pro-
duce sawtooth “f” waves. Ventricular tachycardia,
complete heart block, and supraventricular tachycar-
dias may produce cannon “a” waves due to contrac-
tions of the atria and ventricle simultaneously against
a closed tricuspid valve.
RIGHT VENTRICULAR WAVEFORMS
• Two pressures are typically measured in the RV: the
peak right ventricular systolic pressure (15–25
mmHg) and the right ventricular end-diastolic pressure
(0–12 mmHg).
• Elevated RV systolic pressures can be seen in pul-
monary hypertension, pulmonic stenosis, and acute
pulmonary embolism. Increase in RV end-diastolic
pressure is seen in cardiomyopathy, right ventricular
ischemia, infarction, and tamponade.
PULMONARY ARTERY WAVEFORM
• The main components of the PA tracing are the systolic
(15–25 mmHg) and diastolic pressures (8–15 mmHg)
and the dicrotic notch which correlates with the closure
of the pulmonic valve.
• Elevated PA pressures occur in conditions associated
with volume overload or elevated pulmonary vascular
resistance such as left heart failure, mitral valve dis-
ease, primary lung disease, pulmonary hypertension,
or primary pulmonary hypertension.
PULMONARY ARTERIAL OCCLUSION WAVEFORM
• PA occlusion waveforms are similar to those of the
right atrium but with slightly higher pressures due to
the lower compliance of the LV compared to the RV
(6–12 mmHg).
• The “a” wave reflects atrial systole and the “x”
descent represents the fall in left atrial pressure after
the contraction. The “c” wave that would reflect mitral
closure is not visualized (Fig. 17-2)
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FIG. 17-2 Pulmonary artery wedge pressure tracing. This
schematic diagram shows the different components of the pulmonary
artery wedge pressure tracing. A simultaneous ECG is shown to
demonstrate the timing of the different components. The peak of the
“v” wave falls outside the peak of the electrocardiographic T wave.
SOURCE: Adapted from Gore JM, Alpert JS, Benntti JR, et al. Handbook
of Hemodynamic Monitoring. Boston, MA: Little, Brown & Co;1985.
• The “v” wave represents ventricular systole and atrial
filling. The “y” descent reflects the fall in left atrial
pressure after mitral valve opening.
• Elevations in the “a” wave of the Ppw are due to
resistance of flow into the LV such as with mitral
stenosis, volume overload, decreased compliance due
to myocardial infarction, or left ventricular diastolic
or systolic dysfunction. Elevations of the “v” wave of
the Ppw tracing represent mitral regurgitation.
• The Ppw is an accurate reflection of the left atrial
pressure if the tip is in zone 3 of the lungs, the area of
the lungs (below the left atrium) where the pulmonary
capillary pressure is higher than the mean alveolar
pressure. Signs that the catheter site is not in zone 3
include significant respiratory variation in the tracing,
and increases in Ppw of more than 50% of the applied
positive end-expiratory pressure (PEEP).
• When PEEP is applied, the end-expiratory lung volume
rises above functional residual capacity, raising the
pleural pressure. The effect of this on the Ppw is vari-
able, depending on the compliance of the lungs and
chest wall, as well as the degree of lung recruitment.
It is generally not advised to reduce or remove PEEP
while measuring Ppw since this may precipitate life-
threatening hypoxemia.
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18 MYOCARDIAL ISCHEMIA
James K. Min
KEY POINTS
• Many patients in the ICU for noncardiac causes are
also at risk for acute myocardial ischemia complicating
their critical illness.
• The 12-lead electrocardiogram is invaluable in the
assessment of both silent and symptomatic myocar-
dial ischemia.
• Measurement of cardiac-specific enzymes is essential
in the diagnosis of myocardial ischemia. Creatinine
kinase (CK) with MB fraction and troponin levels will
be elevated in the setting of NSTEMI or STEMI.
Troponin T is more sensitive than CK and becomes
elevated more quickly.
• Myocardial ischemia should be initially managed
with antiplatelet agents, beta blockade, nitrates, pain
control, anticoagulation, ACE inhibition, and statins.  
• A cardiologist should be consulted urgently to con-
sider interventions, such as thrombolytic drugs and
cardiac catheterization.
BACKGROUND
• There are 13 million U.S. adults with a history of
symptomatic coronary artery disease (CAD; history
of myocardial infarction or angina pectoris). Moreover,
70 million U.S. adults have some form of cardiovascular
disease.
• Many critically ill patients in the intensive care unit
(ICU) are at risk for acute myocardial ischemia.
PATHOPHYSIOLOGY
• Myocardial ischemia may occur as a manifestation of
impaired coronary blood flow or from a supply-
demand imbalance of myocardial oxygen. Acute coronary
syndromes—including unstable angina, non-ST-
elevation myocardial infarction (NSTEMI), or ST-ele-
vation myocardial infarction (STEMI)—may result as
a manifestation of myocardial ischemia, either as
result of partial or complete occlusion of an epicardial
coronary artery. Acute coronary syndromes may also
occur as a result of epicardial coronary vasospasm.
CLINICAL FEATURES OF
MYOCARDIAL ISCHEMIA
• Myocardial ischemia may be symptomatic or asymp-
tomatic. Symptomatic myocardial ischemia is most
characteristically manifested as substernal chest pain
or pressure. The location of the pain is typically on the
left side of the chest and often radiates to the left arm,
shoulder, or jaw. Less typical forms of presentation
include right-sided chest pain, epigastric discomfort,
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or interscapular soreness. Myocardial ischemia is often
associated with diaphoresis or dyspnea.
• Myocardial ischemia must be differentiated from other
syndromes that may mimic angina. These states include
dissecting aortic aneurysm, pulmonary embolism,
pericarditis, pleurisy, gastroesophageal reflux, or cos-
tochondritis.
• The physical examination, while typically insensitive,
may be helpful in diagnosing myocardial ischemia. If
the acute coronary syndrome precipitates new left
ventricular systolic dysfunction, the physical exami-
nation may reveal the presence of lung crackles,
increased jugular venous pressure (JVP), and an S3 or
S4 heart sound. The presence of a new murmur may
signal mitral regurgitation or ventricular septal defect
formation as a complication of myocardial infarction.
• Silent myocardial ischemia—which is not accompa-
nied by signs and symptoms of angina—must not be
overlooked. It is diagnosed by electrocardiography
and associated with ST-segment depression.
DIAGNOSIS OF MYOCARDIAL
ISCHEMIA
• The 12-lead electrocardiogram is invaluable in the
assessment of both silent as well as symptomatic
myocardial ischemia. Ischemia may manifest with
ST-segment depression, T-wave alterations (flattening
or inversion), or pseudonormalization of T waves
(previously inverted T waves becoming upright).
• ST-segment depression and dynamic T-wave changes
may occur in response to a host of other states unrelated
to myocardial ischemia, including drug-related causes
(such as digoxin or other vasoactive drugs), electrolyte
disturbances (such as hyperkalemia), and supraven-
tricular tachycardia (in the absence of significant
CAD).
• If total epicardial artery occlusion occurs, ST seg-
ments typically elevate. ST elevation may also occur
in pericarditis. However, in this state, the ST elevation
is typically more diffuse. Also, PR depression is often
seen during pericarditis.
• Other electrocardiographic abnormalities include QT
prolongation, Q-wave development, and poor R-wave
progression. Evolution of Q waves occurs hours after
the onset of a total epicardial coronary artery occlusion.
LABORATORY ANALYSIS OF
MYOCARDIAL ISCHEMIA
• Measurement of cardiac-specific enzymes is essential
in the diagnosis of myocardial ischemia. Creatinine
kinase (CK) with MB fraction and troponin levels will
be elevated in the setting of NSTEMI or STEMI.
Troponin T is more sensitive than CK and becomes
elevated more quickly.
• Cardiac-specific enzymes should be measured in the
critically ill patient suspected to have myocardial
ischemia and should be repeated every 6–8 hours for
24–36 hours.
• A B-type natriuretic peptide (BNP) may be useful for
determining whether symptoms are related to left ven-
tricular volume overload.
• A complete blood count is useful. An elevated white
blood cell count is sometimes seen during myocardial
ischemia, though it is relatively insensitive. Significant
anemia may be a cause of impaired myocardial supply
versus demand in the critically ill patient. Severe
thrombocytopenia (e.g., <30 mm3) may preclude the
use of certain agents such as glycoprotein IIb/IIIa
inhibitors or clopidogrel or aspirin.
• A complete metabolic panel will be useful to rule out
any significant electrolyte abnormalities. An elevated
creatinine has been associated with a poorer progno-
sis and may be useful to help stratify risk of cardiac-
related mortality. Elevated aminotransferases may
preclude the use of statin medications.
THERAPEUTIC APPROACH TO
THE PATIENT WITH MYOCARDIAL
ISCHEMIA
• Antiplatelet agents are critical for the treatment of
myocardial ischemia. Aspirin (325 mg) should be
administered immediately. If bleeding contraindica-
tions are not present, clopidogrel (300 mg initially)
should be administered.
• Beta-blockade is useful for its negative chronotropic
and inotropic properties as heart rate and contractility
are two essential characteristics of myocardial oxygen
consumption. IV metoprolol (5 mg IV initially) may
be readministered to achieve a heart rate of approxi-
mately 60 beats per minute. Beta-blockers should be
discontinued in the setting of severe hypotension.
• Nitrates are a mainstay of therapy for myocardial
ischemia. They are coronary vasodilators and reduce
preload in patients with left ventricular volume overload.
Sublingual nitroglycerin (0.4 mg) may be administered
every 5 minutes (× three times) to reduce anginal symp-
toms. If angina persists, intravenous nitroglycerin may
be initiated at a dose of 10–20 µg/min. Nitrates should
be discontinued in the setting of severe hypotension.
• Narcotic therapy is useful to reduce anginal pain. IV
morphine can be particularly helpful as it also favor-
ably affects myocardial oxygen supply.
• Intravenous heparin infusion is standard therapy for
the high-risk individual with myocardial ischemia (in
the absence of bleeding contraindication). Heparin
may be given IV initially as a bolus (5000–10,000 U)
and then continuously (1000 U/h or using a weight-
based nomogram) to achieve an activated partial
thromboplastic time (PTT) 1.5–2.5 times normal.
• High-dose statin medications have been shown to pos-
itively affect outcomes in patients with myocardial
ischemia. Atorvastatin (80 mg) can be administered
immediately during the ischemic episode.
• Angiotensin-converting enzyme (ACE) inhibitors have
also been shown to positively affect outcomes in patients
with STEMI. Intravenous or oral enalapril may be uti-
lized providing that significant hypotension is not present.
• Glycoprotein IIb/IIIa inhibitors may be useful in the
high-risk individual with NSTEMI or STEMI without
bleeding contraindication. Abciximab, tirofiban, or
eptifibatide may be administered as a bolus and then as
a continuous infusion. Consultation with a cardiologist
may be prudent before administering these agents.
• Thrombolytic therapy is beneficial in the STEMI
patient. Consultation with a cardiologist should be
obtained before administration of these agents.
• Early intravenous coronary angiography is essential in
the high-risk individual with myocardial ischemia.
Consultation with a cardiologist should be obtained
immediately to determine whether a critically ill patient
should be further evaluated with angiography and possi-
ble intervention in the cardiac catheterization laboratory.
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19 ECHOCARDIOGRAPHY
IN THE CRITICALLY 
ILL PATIENT
Steven Y. Chang
KEY POINTS
• Echocardiography allows non-invasive data to be
quickly assessed at the patient bedside. Given limita-
tions in moving critically ill patients, echocardiography
has quickly become a useful tool in the management
of ICU patients.
• Echocardiography allows evaluation of cardiac size,
function, structure, and disease of the pericardium.
• Echocardiography can provide real-time clinical
assessment of intravascular volume, response to fluids
or inotropic agents, and help manage acute right heart
syndromes.
DATA OBTAINED BY
ECHOCARDIOGRAPHY
• Cardiac chamber size and function
• Valvular structure and function
• Pericardial fluid collection
• Intracardiac masses
• Semiquantitative or qualitative information about
hemodynamics
• Directionality of blood flow
TRANSTHORACIC
ECHOCARDIOGRAPHY
AND TRANSESOPHAGEAL
ECHOCARDIOGRAPHY
• Both transthoracic echocardiography (TTE) and
transesophageal echocardiography (TEE) employ
ultrasound to examine the structure and function of
the heart, its valves, and associated great vessels.
• TTE examines the heart from the surface of the thoracic
wall.
• TEE examines the heart from the esophagus and
stomach. Because of the proximity of the esophagus
to the posterior heart, the cardiac chambers and aorta
can be well visualized.
• Advantages of TTE include: noninvasive and rela-
tively easy to perform.
• Disadvantages of TTE include: poor visualization of
heart under certain circumstances including severe
obesity, end-stage lung disease, chest wall deformi-
ties, and mechanical ventilation.
• Advantages of TEE include: improved image quality,
ability to image certain structures that cannot be visu-
alized with TTE including the left atrial appendage,
pulmonary veins, and descending aorta.
• Disadvantages of TEE include: invasive and uncomfort-
able, need for conscious sedation or intubation, aspira-
tion, small but real likelihood of esophageal perforation.
ECHO TECHNIQUES AND MODALITIES
• Motion (M-) mode—gives a view of structures along
a single line. It is especially useful for looking at
moving structures. The changes in movement of struc-
tures are plotted as a linear graph.
48 SECTION 2 • CARDIOVASCULAR DISORDERS
CHAPTER 19 • ECHOCARDIOGRAPHY IN THE CRITICALLY ILL PATIENT     49
• Two-dimensional (2-D)—gives a cross-sectional view
of the heart.
• Doppler—gives information about directionality and
velocity of blood flow. It can be used to grade the
severity of valvular disease, shunts, and even to
extrapolate hemodynamic information.
SELECT TWO-DIMENSIONAL
TRANSESOPHAGEAL
ECHOCARDIOGRAPHY VIEWS
• Orientation is determined by the position of the ultra-
sound probe (parasternal, apical, subcostal) and view
(long axis, four-chamber, five-chamber, and short
axis).
• Parasternal long axis views allow for visualization of
the left atrium (LA), right ventricle (RV), left ventri-
cle (LV), left ventricular outflow tract, aortic valve,
mitral valve, and interventricular septum.
• Depending on the level of visualization (at the aortic
valve, the mitral valve, or the papillary muscles), mul-
tiple structures can be evaluated with the parasternal
short axis view. This view is useful for comparing the
relationship of the RV and LV.
• Apical long axis views allow visualization of the LV
and its outflow tract, the ascending aorta, the aortic
valve, the mitral valve, the interventricular septum,
and the LA.
• Apical four-chamber views allow for visualization of
the four cardiac chambers, the interventricular
septum, the tricuspid valve, and the mitral valve.
• In addition to the structures mentioned for the four-
chamber view, the apical five-chamber view also
allows for visualization of the left ventricular outflow
tract, aortic valve, and proximal ascending aorta.
Occasionally, the LA appendage can be seen.
• Subcostal four-chamber views allow for examination
of the RV. Additionally, the other three chambers can
be visualized along with the interatrial septum, the
interventricular septum, the tricuspid and mitral
valves.
• Subcostal short axis views are useful for comparing
the relationship of the two ventricles.
• These different views are complementary and should
be considered together.
SELECT TRANSESOPHAGEAL
ECHOCARDIOGRAPHY VIEWS
• Similar to the TTE, orientation is determined by the
position of the ultrasound probe (transesophageal and
transgastric).
• Transesophageal four-chamber views are useful for
examining the four cardiac chambers, and the mitral
and tricuspid valves. Slight changes in position allow
for visualization of the LV outflow tract and aortic
valve.
• Transgastric views allow for imaging similar to apical
four- and five-chamber views.
REASONS FOR PERFORMING
ECHOCARDIOGRAPHY IN 
THE CRITICALLY ILL
• It can change care in a substantial number of patients.
• Cardiovascular monitoring including cardiac output
and preload (can be used independently of, or in com-
plementary fashion with information from a right
atrial or pulmonary artery catheter). For example, a
hypovolemic patient will manifest reduced ventricular
volumes and a hypercontractile state. Septic patients
may manifest reduced ejection fractions despite a
hyperdynamic state.
• Titration of medicines, especially vasoactive agents.
For example, the response to the addition of an
inotrope can be directly visualized.
• Suspected ventricular dysfunction (e.g., cardiomy-
opathies and sepsis).
• Myocardial ischemia and infarction which results in
wall motion abnormalities.
• Suspected mechanical complications after myocardial
infarction such as ventricular free wall rupture.
• Evaluation of right heart syndromes such as massive
pulmonary embolism or RV infarct. Echocardiography
can aid in determining if the RV is overfilled resulting
in an interventricular shift into the LV with resultant
poor cardiac output.
• Suspected valvular dysfunction.
• Evaluation of prosthetic valve structure and function.
• Suspected endocarditis.
• Suspected congenital or structural heart disease.
• Suspected aortic dissection.
• Exclusion of thrombus for cardioversion in atrial
fibrillation.
• Diagnoses of right-to-left and left-to-right shunting in
the setting of septal defects.
• Suspected extracardiac shunting (e.g., hepatopul-
monary syndrome).
• Suspected pericardial tamponade.
• Suspected hemodynamically compromising intracar-
diac masses.
• Evaluation of cerebrovascular accidents (CVAs) and
transient ischemic attacks (TIAs).
• Aid in evaluation of dysrhythmias.
SPECIFIC INDICATIONS 
FOR TRANSESOPHAGEAL
ECHOCARDIOGRAPHY
• Suspected endocarditis (87–93% sensitive and
91–96% specific for left-sided lesions).
• Evaluation of mitral valve disease.
• Perivalvular abscess.
• Evaluation of septal defects.
• Stratification of risk of embolism prior to cardiover-
sion for atrial fibrillation and atrial flutter.
• Diagnosis and evaluation of suspected aortic dissec-
tion (95% sensitive and 98% specific).
• Inadequate TTE (often a problem in hyperinflated,
mechanically ventilated patients).
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20 ACUTE RIGHT HEART
SYNDROMES
Steven Q. Davis
KEY POINTS
• Acute increases in PA pressures can lead to rapid right
ventricular dysfunction and decreased RV contractility
and ejection.
• Acute decompensation of the right ventricle can lead
to acute diastolic dysfunction of the left ventricle (e.g.,
“right heart failure causing left heart failure”).
• Clinical signs of acute right heart syndromes include
elevated neck veins, a pulsatile liver, peripheral edema,
a right-sided S3, and tricuspid regurgitation.
• Diagnosis of right heart dysfunction can be confirmed
quickly with bedside echocardiography.
• Therapy is directed at the underlying cause (e.g.,
treatment of the pulmonary embolism) while optimiz-
ing preload, supporting contractility, and minimizing
right ventricular afterload.
PHYSIOLOGY
• Right ventricular function deteriorates in the face of
elevated pulmonary vascular resistance or pulmonary
arterial hypertension.
• Right ventricular oxygen consumption increases sig-
nificantly with increased workload, but when coupled
with systemic hypotension, coronary perfusion to the
right ventricle will fall.
• The resultant right heart ischemia leads to decreased
right ventricular contractility and systolic ejection.
• As right heart pressures increase, the intraventricular
septum may shift to the left causing left ventricular
diastolic dysfunction, which will in turn further reduce
the coronary perfusion pressure to the right heart.
DIAGNOSIS
• A previous history of pulmonary hypertension should
alert the clinician to the possibility of acute-on-
chronic right heart dysfunction.
• Clinical signs include: elevated neck veins, a pulsatile
liver, peripheral edema, a right-sided S3 or tricuspid
regurgitation.
• Radiologic features include an enlarged pulmonary
artery or right ventricle, a Westermark sign (oligemia
of a lobe or entire lung), or a plump azygous vein.
• The electrocardiogram may show a rightward axis or
right axis deviation, right atrial enlargement, right ven-
tricular hypertrophy, right bundle branch block, right
precordial T-wave inversions, and an S1-Q3-T3 pattern.
• Echocardiographic findings may include a normally
functioning left ventricle (often with end-systolic
obliteration of the cavity), a thin-walled and poorly
contracting right ventricle, right atrial enlargement,
tricuspid insufficiency, increased pulmonary arterial
pressures, leftward shift of the intraventricular
septum, right pulmonary artery dilation, and/or loss of
respiratory variation in the inferior vena cava.
• Echocardiography should be obtained as soon as the
diagnosis of acute right heart syndrome is entertained.
SPECIFIC ETIOLOGIES
• The classic etiology of acute pulmonary hypertension
is acute pulmonary embolism. Other etiologies include
acute respiratory distress syndrome (ARDS), drug effect,
and inflammation, including sepsis.
• Chronic pulmonary hypertension may be exacerbated
by any critical illness that requires an increase in cardiac
output.
• Right ventricular infarction occurs as a result of an
inferior myocardial infarction or, less commonly, an
anterior myocardial infarction. Echocardiography can
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readily distinguish between right ventricular infarc-
tion and acute pulmonary artery hypertension.
THERAPY
• Other than therapy directed at the underlying condi-
tion (i.e., thrombolysis for pulmonary embolism), the
goals of therapy are to reduce systemic oxygen demand
while improving delivery.
• Oxygen therapy should be used to avoid alveolar hypoxic
vasoconstriction as well as to enhance arterial saturation.
• While fluids are first-line therapy for shock in general,
they may prove detrimental for patients suffering from
right heart syndrome. Additional fluid may move the
intraventricular septum further into the left ventricular
cavity. Since some patients may be volume depleted at
the time of presentation, a closely monitored fluid
challenge may be considered, paying close attention
to markers of end-organ perfusion.
• When vasoactive agents are needed, dobutamine and
norepinephrine appear to be the most effective.
• Inhaled nitric oxide may be used as a pulmonary
vasodilator.
• Ventilator management should employ the following
general strategies: give sufficient oxygen to avoid
hypoxic vasoconstriction; avoid hypercapnia; maintain
positive end-expiratory pressure (PEEP) at the lowest
level needed for adequate alveolar recruitment and oxy-
genation; and minimize auto-PEEP, and using the lowest
tidal volume necessary to maintain an acceptable PCO2.
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21 PULMONARY EMBOLISM:
THROMBUS, FAT, AIR, 
AND AMNIOTIC FLUID
Nuala J. Meyer
KEY POINTS
• Pulmonary Embolism causes approximately 25,000
deaths each year.
• Risk factors for PE include Virchow’s triad of stasis,
hypercoagulability, and vascular injury.
• PE disrupts gas exchange by creating dead space in
alveoli which are ventilated but not perfused.
• Mechanical obstruction of the pulmonary artery as
well as humoral factors released in response to
pulmonary artery thrombus increase right ventricu-
lar (RV) afterload and right ventricular oxygen con-
sumption, which can precipitate right ventricular
ischemia.
• Clinically, patients may present with nonspecific
symptoms of dyspnea, chest pain, and apprehension.
Tachypnea and tachycardia are the most common
clinical signs of PE. Hypoxemia is present in approx-
imately two-thirds of patients, so the lack of hypox-
emia cannot be relied on to exclude disease. Fever is
present in up to half of patients with PE, but is typi-
cally below 38.5°C.
• Diagnosing PE relies on one’s clinical judgment, and
diagnostic tests should be pursued either until a
firm diagnosis is reached or PE is judged to be clini-
cally unlikely. These tests include D-dimer, Doppler
venous ultrasound, V/Q scans, CT angiography, and
PA angiography. Each test has its own strengths and
weaknesses.
• Treatment for pulmonary embolism includes antico-
agulation and sometimes thrombolytics. Vena cava
interruption with a filter can be considered for those
unable to receive anticoagulation.
• Air embolism occurs when a gas (typically air) enters
the vasculature and travels to the pulmonary circula-
tion, where it causes either circulatory or respiratory
distress. The most common causes include trauma,
surgery, and intravascular catheters.
• Like PE, air embolism can acutely raise the pulmonary
arterial pressure, causing right ventricular strain and
potentially impeding venous return to the left ventricle.
In the pulmonary circulation, air emboli cause endothe-
lial injury, often triggering alveolar flooding as well as
bronchoconstriction.
• Treatment of Air Embolism focuses on preventing
further embolization and supporting the patient’s
cardiopulmonary circulation.
• The fat embolism syndrome (FES) occurs when fat
particles enter the circulation, typically from long bone
fracture, and cause lung dysfunction, neurologic changes,
and petechiae.
• Like other emboli, fat emboli may raise pulmonary
artery pressures, and cause right heart strain or failure.
Treatment is supportive.
• Amniotic fluid embolism (AFE) is thought to occur
with a frequency of 1 in approximately 30,000 births.
• Amniotic fluid embolism is typically a dramatic pres-
entation of abrupt dyspnea, hypoxemia, and hypoten-
sion, often with rapid progression to heart failure.
Pulmonary edema is common. Disseminated intravas-
cular coagulopathy (DIC) may also be present. 
• Diagnosis is clinical; sampling of pulmonary arterial
fluid for fetal tissue is neither sensitive nor specific.
Treatment is supportive.
PULMONARY THROMBOEMBOLISM
EPIDEMIOLOGY
• Pulmonary embolism (PE), whereby a thrombus frag-
ments from a deep venous thrombus and travels to the
pulmonary circulation, prompts hospitalization at a
frequency of approximately one case per 1000 persons
per year, or 200,000–300,000 U.S. annual hospitaliza-
tions. PE causes approximately 25,000 deaths each
year.
PATHOPHYSIOLOGY
• Thrombus formation begins with microthrombi at the
site of venous stasis or injury, typically in the lower
extremity. Because thrombosis impedes venous flow
and contributes to further stasis, clots may enlarge and
propagate.
• Clots which propagate into proximal deep veins in the
legs and pelvis have an increased risk of embolization,
and are responsible for the majority of significant PE.
As central venous catheterization becomes more fre-
quent, however, a small but significant proportion of
PE may be due to upper extremity thrombi.
• PE exerts its greatest effect on gas exchange and the
circulation. Gas exchange is deranged by the creation
of dead space in alveoli which are ventilated but not
perfused due to the emboli occluding pulmonary arte-
rial flow. At the same time, V/Q mismatch causes a
widening of the alveolar to arterial gradient for
oxygen ([A-a]PO2), and thus hypoxemia is present in
approximately 60% of patients. Gas exchange may
also be impaired by atelectasis.
• PE can also affect the circulation. Both the mechani-
cal obstruction of the pulmonary artery as well as
humoral factors released in response to pulmonary
artery thrombus tend to increase right ventricular
(RV) afterload and right ventricular oxygen consump-
tion, which can precipitate right ventricular ischemia.
In the most extreme cases, PE can induce cor pul-
monale, or acute right heart failure.
CLINICAL FEATURES
• Risk factors for PE include Virchow’s triad of stasis,
hypercoagulability, and vascular injury, as well as certain
clinical situations such as pregnancy/peripartum
status, orthopedic surgery (especially hip fractures or
hip or knee replacements), malignancy (especially
adenocarcinoma), and indwelling central venous
lines. Pulmonary artery catheterization was found to
be a risk factor for PE in at least one study.
• PE is famous for its varied presentation among differ-
ent patients. Dyspnea, chest pain, and apprehension
are the most common symptoms, affecting 80%, 70%,
and 60% of patients, respectively. Symptoms of deep
vein thrombosis (DVT) are present in only one-third
of patients.
• Tachypnea and tachycardia are the most common
clinical signs of PE. Hypoxemia is present in approx-
imately two-thirds of patients, so the lack of hypox-
emia cannot be relied on to exclude disease. Fever is
present in up to half of the patients with PE, but is typ-
ically below 38.5°C.
DIAGNOSIS
• In many ways, diagnosing PE relies on one’s clinical
judgment, and diagnostic tests should be pursued
either until a firm diagnosis is reached or PE is judged
to be clinically unlikely.
• Pulmonary angiography has long been considered the
gold standard for diagnosing PE. A positive study is
one in which a filling defect of a 2 mm or larger vessel
is noted on more than one view. However, pulmonary
angiography is invasive, has a reported mortality rate
of 0.2%—potentially higher in patients with pul-
monary hypertension—and necessitates intravenous
contrast.
• D-dimer, a degradation product of cross-linked fibrin,
is highly sensitive (95%) though not specific for DVT
and PE. Very low levels of D-dimer strongly argue
against PE. Unless one’s pretest probability of PE is
very high, a negative D-dimer assay should end the
workup for PE.
• Helical computed tomography (CT) angiography,
sometimes called “PE-protocol CT,” has a sensitivity
for PE ranging from 50 to 100%, and a specificity of
81 to 100%. Helical CT angiography performs better
at detecting clots larger than the subsegmental level,
as does pulmonary angiography. It seems to be as safe
to withhold anticoagulation based on a negative helical
CT angiogram as based on a negative pulmonary
angiogram.
• Ventilation-perfusion scanning can be helpful, but
again the test result can only be viewed in the context
of one’s clinical pretest probability. The test is helpful
when read as normal or high probability, in which
case the test can dictate therapy. Difficulties arise in
the majority of cases, however, if the reading is either
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low or intermediate probability, the rate of PE varies
between 16 and 40%. Thus, a V/Q scan can beget
additional testing. V/Q scanning can be technically
challenging from the ICU due to a higher probability
of underlying cardiopulmonary disease.
• Chest x-ray is frequently abnormal in PE, but many
potential patterns, including atelectasis, pleural effu-
sion, or pulmonary infarction, can be seen. Two classic
but rare findings include “Hampton hump,” a wedge-
shaped, pleural-based opacity representing pulmonary
infarction, and “Westermark sign,” detailing relative
oligemia of one lung compared to its counterpart.
• ECG, another nonspecific test, most commonly shows
sinus tachycardia. Other possible findings include
right axis deviation, right ventricular strain, or right
bundle branch block (RBBB).
• Lower extremity venous duplex studies perform
exceptionally well in patients with symptoms of prox-
imal DVT. In asymptomatic patients, Doppler studies
perform less well, and since less than half of patients
with PE have a distinct DVT at the time of PE diag-
nosis, lower extremity Doppler cannot exclude the
possibility of PE. Noninvasive leg studies may diag-
nose DVT and thus provide grounds for anticoagula-
tion, which may render inconsequential the question
of PE.
INTENSIVE CARE UNIT MANAGEMENT
• Anticoagulation is the mainstay of treatment for PE.
• Traditionally, unfractionated heparin has been used at
a dose sufficient to keep the activated partial throm-
boplastin time (aPTT) equal to or greater than 1.5
times the patient’s baseline aPTT. It is more important
to reach this threshold (≥1.5 aPTT) than to prevent the
aPTT from getting too high, as bleeding has not been
correlated with supratherapeutic levels. A typical dosing
regimen would be a bolus of heparin at 80 units/kg
of body weight, followed by a continuous infusion at
18 units/kg/h. Many weight-based dosing nomograms
are widely available. Heparin use mandates repeat
testing of the aPTT.
 Common complications of unfractionated heparin
include serious bleeding (approximately 3% of patients)
and thrombocytopenia (1–3%). Hyperkalemia,
osteoporosis, and hypersensitivity are less common
reactions.
• Low-molecular weight heparins (LMWH) are smaller
fragments of heparin which preserve heparin’s active
site. This family of medicines can be dosed once or
twice subcutaneously per day, have a more reliable
dose-response relationship compared to heparin, and
have a trend toward fewer DVT/PE recurrences and
less hemorrhage when compared to heparin. In an
uncomplicated patient with PE, LMWH should be
given first consideration.
 LMWH are cleared by renal metabolism, and dose
adjustments for renal impairment are not well-
tested. Therefore, LMWH should be reserved for
those with normal renal function.
 Complications observed with LMWH include hem-
orrhage and thrombocytopenia (<1% of patients),
but at rates lower than with heparin.
 ICU patients may be unsuitable for LMWH if they
have renal failure, morbid obesity, or a need for
ongoing invasive or urgent procedures.
• Direct thrombin inhibitors such as lepirudin or arga-
troban are not well tested in PE, but are approved for
use in patients with a history of heparin-induced
thrombocytopenia. Newer anticoagulants such as
ximelagatran and fondaparinux may be used in the
future.
• Risk stratification for patients is appropriate, as patients
with PE may range from asymptomatic to overt shock.
Echocardiography, while neither sensitive nor specific
enough for diagnosis of PE, can be helpful in deter-
mining those at highest risk for mortality and shock,
and determining which patients may require intensive
care monitoring. Echocardiographic data such as right
heart strain indicate a poorer prognosis.
• When patients with PE present with hypotension or
hypoperfusion, treatment with thrombolytic medicines—
streptokinase, urokinase, or alteplase—is warranted.
The risk of hemorrhage with these medications is as
high as 22%, and intracerebral hemorrhage may com-
plicate 3% of patients receiving thrombolysis.
Absolute contraindications to thrombolytic therapy
include hemorrhagic stroke, active intracranial hem-
orrhage, recent intracranial surgery, or recent internal
bleeding. Other bleeding risks may be compelling rel-
ative contraindications.
• Vena caval interruption devices (VCI), such as the
Greenfield filter, may be helpful when patients have
compelling contraindication to anticoagulation or if
embolization continues despite anticoagulation. Because
much of the benefits of VCI appear to be in the early
weeks following a DVT or PE, much interest has been
given to temporary VCI, which could be removed after
1–6 months. More data will be helpful in this regard.
AIR EMBOLISM
PATHOPHYSIOLOGY
• Air embolism occurs when a gas (typically air) enters
the vasculature and travels to the pulmonary circulation,
where it causes either circulatory or respiratory
distress.
• Air embolism results from the communication of air
with a blood vessel while there is a pressure gradient
favoring the movement of air into the vessel. The most
common etiologies are trauma, surgery, and intravas-
cular catheters, but the syndrome has been reported
following positive pressure ventilation or SCUBA
diving.
• Like PE, air embolism can acutely raise the pul-
monary arterial pressure, causing right ventricular
strain and potentially impeding venous return to the
left ventricle. In addition to the mechanical phenom-
ena, air embolism may also trigger cytokine release
leading to further increase in the pulmonary vascular
resistance.
• In the pulmonary circulation, air emboli cause
endothelial injury, often triggering alveolar flooding
as well as bronchoconstriction.
CLINICAL FEATURES
• Air embolism typically causes acute hypoxemic respi-
ratory failure and presents radiographically as diffuse
alveolar filling.
• Patients have increased ventilatory dead space, and
are dyspneic with high minute ventilation and low
PCO2.
• Diagnosis is clinical, and relies on a high level of
suspicion, especially in high-risk situations. Air
embolism should be strongly considered when other
causes of noncardiogenic pulmonary edema have
been excluded.
• Once further air embolization is prevented, resolution
is often swift.
INTENSIVE CARE UNIT MANAGEMENT
• Treatment focuses on preventing further embolization
and supporting the patient’s cardiopulmonary circulation.
 The source of air entry should be identified and
reversed.
 Raising the intravascular pressure (e.g., with volume
resuscitation) can lessen the gradient favoring air
entry.
 If positive pressure ventilation may be the source of
air entry, the plateau and airway pressures should be
reduced, with low tidal volumes and lower positive
end-expiratory pressure (PEEP).
 Oxygen speeds the reabsorption of air from bubbles,
so patients should receive 100% O2.
 When mechanical ventilation is necessary, manage-
ment should be similar to patients with acute respi-
ratory distress syndrome (ARDS): low tidal volumes
and plateau pressures.
 Corticosteroids may be prophylactic for air
embolism in humans, however, as the syndrome is
rare and tends to resolve rapidly, there is no role for
the routine use of steroids.
FAT EMBOLISM
PATHOPHYSIOLOGY
• The fat embolism syndrome (FES) occurs when fat
particles enter the circulation and cause lung dysfunc-
tion, neurologic changes, and petechiae.
• FES can result from trauma—especially long bone
fracture or orthopedic surgery which exposes bone
marrow to the circulation—or atraumatic, with fat
particles likely arising from lipids in the blood.
• Like other emboli, fat emboli may raise pulmonary
artery pressures, and cause right heart strain or failure.
CLINICAL FEATURES
• Classically, patients are asymptomatic for approxi-
mately 12–72 hours after the embolization occurs, and
then present similar to ARDS with a diffuse lung lesion.
In addition, there is often confusion or mental status
changes, petechiae, thrombocytopenia, and anemia.
• Retinal examination may reveal embolized fat in retinal
vessels (Purtscher retinopathy).
• Diagnosis is clinical, based on the presence of an at-risk
scenario with ARDS and neurologic manifestations.
• Fat globules in the urine, bronchoalveolar lavage fluid,
or serum are not reliably sensitive or specific.
INTENSIVE CARE UNIT MANAGEMENT
• To help prevent the FES, long bone fractures are
reduced early.
• Corticosteroids may be useful, as transthoracic
echocardiography performed in patients undergoing
specific orthopedic procedures found fewer echo-
detected emboli and less hypoxemia in patients receiving
steroids. However, as the syndrome is more commonly
mild than severe, and as steroids may increase infection
or delay wound healing, many clinicians argue against
the use of prophylactic steroids.
• Once ARDS has developed, treatment of the FES is
identical to that of all other forms of ARDS.
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AMNIOTIC FLUID EMBOLISM
PATHOPHYSIOLOGY
• Amniotic fluid embolism (AFE) is thought to occur with
a frequency of 1 in approximately 30,000 births, and
when severe causes high maternal and fetal mortality.
• AFE occurs when amniotic fluid, typically confined
to the fetal placenta, crosses the placental membrane.
For this to happen, there must be disruption of fetal
membranes, open or disrupted maternal circulation,
and a gradient favoring the entry of material from the
amnion to the mother’s veins.
• Early on, AFE is thought to cause right heart strain
and hypoxemia, much like other embolic phenomena.
However, AFE often progresses to left ventricular
dysfunction, with cardiogenic pulmonary edema.
Almost certainly, the interaction of amniotic fluid with
maternal vessels incites a humoral response which
intensifies any mechanical phenomena.
CLINICAL FEATURES
• Amniotic fluid embolism is typically a dramatic pres-
entation of abrupt dyspnea, hypoxemia, and hypoten-
sion, often with rapid progression to heart failure.
Pulmonary edema is common.
• Disseminated intravascular coagulopathy (DIC)
occurs in approximately 40% of cases, and may be the
presenting symptom in up to 15%.
• Neurologic manifestations are common, and may
progress to seizures or cerebrovascular accident.
• Diagnosis is clinical; sampling of pulmonary arterial
fluid for fetal tissue is neither sensitive nor specific.
INTENSIVE CARE UNIT MANAGEMENT
• Treatment of AFE is symptomatic, with careful mon-
itoring of coagulation parameters to exclude DIC, and
close attention to volume management and cardiac
function.
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22 PERICARDIAL DISEASE
D. Kyle Hogarth
KEY POINTS
• Pericardial disease does not always lead to altered
physiology in the patient.
• The dominant physiologic effect of significant peri-
cardial disease is lowered cardiac output. The effects
of pericardial disease on the heart result from
impaired cardiac filling, thus pericardial disease per
se does not affect systolic function. A low cardiac
output state requires prompt attention; understanding
the role pericardial disease may or may not play in the
patient’s condition can allow the clinician to properly
focus care.
• Patients with increasing effusions become “dependent”
on atrial systole in order to fill the ventricles. Atrial
flutter and fibrillation can be deadly in a patient with
a significant pericardial effusion.
• Tamponade is characterized by elevated diastolic
pressures, equal end-diastolic pressures across cham-
bers, and the absence of early filling of the ventricle
during diastole.
• Treatment of Tamponade includes fluid resuscitation
and immediate drainage of the fluid. Inotropic support
can be initiated, but there is little evidence to support
this. Mechanical ventilation can further reduce car-
diac output by impeding venous return due to the
positive thoracic pressures, but may be needed if there
is impending cardiopulmonary collapse.
HEMODYNAMIC EFFECTS 
OF PERICARDIAL DISEASE
• The effects of pericardial disease on the heart result
from impaired cardiac filling, thus pericardial disease
per se does not affect systolic function.
• Compliance of the heart is partly determined by the
pericardial tissue and the amount of pericardial fluid.
• The process causing the disease may progress rapidly
(e.g., effusion) or slowly (e.g., constriction), but the
decompensation by the patient can be acute in both
examples.
PERICARDIAL EFFUSIONS
AND TAMPONADE
• Pericardial fluid distributes evenly, and pericardial
pressure is distributed evenly across all chambers.
• As pericardial fluid accumulates, pericardial pressure
increases in relation to pericardial compliance.
• Ventricular filling occurs during late diastole in peri-
cardial effusion patients.
• Patients with increasing effusions become “dependent”
on their atrial systole in order to fill their ventricles.
Atrial flutter and fibrillation can be deadly in a patient
with a significant pericardial effusion.
• Cardiac compression by the pericardial space occurs
at 15–20 mmHg.
• In cardiac tamponade, the external pericardial pres-
sure exceeds the pressures acting to distend the cardiac
chambers. When the pressure external to the heart is
greater than the internal pressures, flow cannot occur.
As the pressure is equally distributed, an increase in
the pericardial pressure above the right atrial (RA)
pressure will result in no passive filling of the right
ventricle (RV) during diastole.
• Tamponade is characterized by elevated diastolic
pressures, equal end-diastolic pressures across cham-
bers, and the absence of early filling of the ventricle
during diastole.
CLINICAL FINDINGS IN TAMPONADE
• Sinus tachycardia.
• Elevated jugular venous pressure (JVP): The “x”
descent will be maintained. However, the “y” descent
will become absent due to limited early diastolic filling
of the ventricle.
• Pulsus paradoxus: normally, systolic blood pressure
decreases <10 mmHg on inspiration. In pulsus para-
doxus, this change is >10 mmHg on inspiration.
• Kussmaul sign: lack of decline in JVP during inspiration.
• Pericardial rub: may be present in inflammatory
causes of pericardial fluid.
DIAGNOSIS OF TAMPONADE
• Usually made clinically, especially in acute cases, but the
diagnosis is aided with various diagnostic modalities.
 ECG: will have tachycardia and low voltage, and may
have electrical alternans (beat-to-beat alteration in
the QRS complex).
 Chest x-ray (CXR): can show enlarged cardiac sil-
houette.
 Echocardiography: can show volume of fluid, car-
diac chamber collapse (especially diastolic collapse
of the right side), and “swinging” of the heart within
the large volume of fluid.
 Cardiac catheterization: pulmonary artery catheter
will show equalization of the diastolic pressures
across all chambers.
TREATMENT OF TAMPONADE
• Fluid resuscitation.
• Immediate drainage of the fluid via percutaneous
approach or surgical approach.
• Inotropic support (e.g., dobutamine), but little evi-
dence to support this.
• Mechanical ventilation should be avoided as this will
further reduce cardiac output by impeding venous
return due to the positive thoracic pressures (see
Chap. 135).
CONSTRICTIVE PERICARDITIS
• The characteristic presentation of constrictive peri-
carditis is severe right heart failure, without another
apparent cause.
• In constrictive pericarditis, the pericardial tissue has
become thickened or calcified and therefore is less
compliant.
• There is no effect on diastolic filling at low cardiac
volumes. Consequently, early filling during diastole is
not impaired. However, as filling continues and the
maximum volume allowed by the pericardial constric-
tion is reached, pressures in the chambers equalize
and filling stops. Filling is early in diastole for con-
strictive pericarditis patients.
• Observing when the ventricle fills during diastole
allows one to differentiate between tamponade and
constrictive pericarditis.
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• Echocardiography may be helpful, as there are several
echocardiographic findings associated with constric-
tive pericarditis, but none are pathognomonic.
• Pericardial thickening can be detected easily by com-
puted tomography (CT) and magnetic resonance
imaging (MRI) but is not always present, and may be
absent in 20% of patients.
• Left and right cardiac catheterization is needed for
simultaneous measurement of filling pressures in
order to aid in the diagnosis.
• Pericardiectomy is the only effective treatment.
CLINICAL FINDINGS IN CONSTRICTIVE
PERICARDITIS
• Increased JVP.
• Signs of right heart failure (peripheral edema, ascites,
hepato-jugular reflex).
• A pericardial knock may be present (essentially, an S3).
DIAGNOSTIC FINDINGS
IN CONSTRICTIVE PERICARDITIS
• No specific ECG findings, though low-voltage may be
present.
• CXR may show calcification around the heart or the
pericardium.
• Echocardiography will demonstrate increased pericar-
dial thickness and abnormal ventricular filling. The
inferior vena cava (IVC) will usually be dilated and
will not have respiratory variation in diameter. Atria
typically will be dilated.
• CT scan can demonstrate increased pericardial thickness
and calcification.
• MRI can demonstrated increased pericardial thickness.
• Cardiac catheterization will demonstrate:
 Increased RA pressures
 Increased “x” and “y” descents
 Increased RV diastolic pressures
 The “dip and plateau” or “square-root sign” on left
ventricle (LV) and RV diastolic tracings, which show
an early diastolic decrease followed by a plateau
ACUTE PERICARDITIS
• Pericarditis commonly presents with a characteristic
syndrome that includes central, pleuritic chest pain
that is worse supine and improves some with upright
positioning or leaning forward.
• A pericardial friction rub is not always present.
• The ECG is often normal or not diagnostic; diffuse ST
elevation is often not present.
• PR segment depression is very suggestive of peri-
carditis.
• The primary concern is always to distinguish pericar-
dial pain from myocardial ischemia.
• The classical symptoms of pericarditis, unassociated
with symptoms, signs, or ECG changes suggesting
ischemia or infarction, can be confidently attributed to
acute pericarditis.
• Minor elevations in cardiac enzymes, including tro-
ponin T or I, can occur in acute pericarditis.
• Treatment is with nonsteroidal anti-inflammatory
drugs (NSAIDs). If the cause of the pericarditis is
known, then specific therapy directed at that disease
should be initiated.
PURULENT PERICARDITIS
• Purulent pericarditis is a rare disease, often presenting
in the immunocompromised patient.
• It is highly fatal and requires emergent drainage.
• Purulent pericarditis is most often the result of local
spread from empyema, mediastinitis, pneumonia,
endocarditis, prior pericardiotomy, or burn injury.
• The diagnosis is made with pericardial fluid sampling.
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KEY POINTS
• There are three major etiologies of noninfectious
valvular dysfunction: (1) congenital malformations of
the valve, typically seen in young patients; (2) rheumatic
heart disease following acute rheumatic fever, classi-
cally involving the mitral valve prior to the aortic; and
(3) calcific or degenerative valvular disease, usually
involving the aortic valve of older individuals.
• Echocardiography is a useful bedside tool to evaluate
valvular abnormalities.
• Acute valvular abnormalities often require urgent sur-
gical intervention.
• Critical AS exists when the mean transvalvular pres-
sure gradient exceeds 50 mmHg, or when the calcu-
lated valve area is 0.75 cm2 or less.
• Aortic stenosis may be asymptomatic until late in
its course, but early symptoms of AS—angina and
syncope—relate to left ventricular hypertrophy.
• Aortic Insufficiency can present two ways: Acute AI
typically causes a patient to present critically ill, with
pulmonary edema, diaphoresis, cyanosis, and cardio-
genic shock. Chronic AI, in contrast, generally presents
with a gradual onset of congestive heart failure.
• Mitral stenosis occurs when the valve area is 2 cm2,
and critical MS when the valve area is 1 cm2 or less.
• To maintain normal cardiac output in the face of a nar-
rowed mitral valve area, a higher transvalvular pres-
sure gradient must be generated. Over time this leads
to chronically elevated left atrial pressure, and eventually
to elevated pulmonary venous and pulmonary arterial
pressures.
• In acute MR, for instance with rupture of the chordae,
the left atrial size is unchanged but LA pressure is
significantly and abruptly increased, resulting in
pulmonary edema. 
VALVULAR HEART DISEASE
EPIDEMIOLOGY
• Valvular heart disease is a common cause of morbid-
ity and mortality in the United States.
• Recognition of the potential complications for a
patient with disordered valves is essential when caring
for such a patient in the ICU.
• Once the most common cause for valvular heart dis-
ease, rheumatic heart disease has become relatively
rare in the western world with the routine use of
antibiotic therapy for recognized bacterial pharyngitis
and impetigo.
• Patients may still present with symptoms from valvu-
lar disease which they acquired many years earlier.
• In addition, as the population ages, degenerative valvu-
lar problems are becoming increasingly common.
AORTIC STENOSIS
ETIOLOGY
• There are three major etiologies of valvular dysfunction:
(1) congential malformations of the valve, typically
seen in young patients; (2) rheumatic heart disease
following acute rheumatic fever, classically involving
the mitral valve prior to the aortic; and (3) calcific or
degenerative valvular disease, usually involving the
aortic valve of older individuals.
PATHOPHYSIOLOGY
• 1–2% of aortic valves are estimated to be bicuspid,
making this the most common congenital heart disease.
• Bicuspid valves are subject to more stress than normal
tricuspid aortic valves, and thus are prone to earlier
calcification.
• Older adults may have senile calcification of other-
wise normal, tricuspid aortic valves.
• In either congenital or senile aortic stenosis (AS), pro-
gression of the calcification reduces valve opening,
causing an increased resistance to blood flow along
the aortic outflow tract.
• Critical AS exists when the mean transvalvular pres-
sure gradient—that is, the gradient between pressure
on the ventricular versus the aortic side of the aortic
valve—exceeds 50 mmHg, or when the calculated
valve area is 0.75 cm2 or less.
• In response to the elevated pressure gradient across
the aortic valve, the left ventricle (LV) hypertrophies,
usually causing first diastolic and later systolic dys-
function.
CLINICAL FEATURES
• Aortic stenosis may be asymptomatic until late in its
course.
• Early symptoms of AS—angina and syncope—relate
to left ventricular hypertrophy (LVH).
• Angina may occur from either decreased coronary
arterial perfusion during diastole due to the outflow
tract obstruction, or from coronary arterial disease.
• Syncope may result when an increase in LV pressure
with exertion is not accompanied by an increase in
aortic pressure, due to the fixed obstruction.
• Late in AS, LV dysfunction may occur, causing pul-
monary edema and dyspnea.
• The typical murmur of AS is a loud crescendo/
decrescendo systolic murmur heard at the base of the
heart radiating to the carotids, with a soft or absent S2
component. Carotid upstrokes may be weak and
delayed, pulsus parvus et tardus.
DIAGNOSTIC EVALUATION
• ECG typically shows LVH with repolarization abnor-
malities.
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• Chest x-ray (CXR) may show a calcified aortic valve,
and, in severe or advanced cases, an enlarged cardiac
silhouette.
• Echocardiogram reliably diagnoses AS and provides
the clinically relevant transvalvular gradient and
aortic valve area by Doppler flow. Echo is also critical
in determining the LV function for patients with AS.
• Cardiac catheterization may confirm the severity of
AS and allow measurement of the left ventricular end-
diastolic pressure, or LVEDP, often elevated in patients
with AS. In addition, patients who may undergo sur-
gical correction of their valves should be evaluated for
coronary artery disease prior to undergoing surgery.
INTENSIVE CARE UNIT MANAGEMENT
• Definitive treatment of AS requires surgery to correct
the mechanical obstruction.
• Patients with AS and decreased LV function have a
high mortality, with an estimated survival of just 1 year.
Thus, development of LV dysfunction in a patient with
critical AS is an indication for surgery as soon as med-
ically stable.
• In treating ill ICU patients with comorbid AS, the cli-
nician faces a difficult challenge. Recent evidence
supports the use of careful afterload reduction with
nitroprusside as a bridge to surgical repair in patients
with AS and decreased LV function. Dobutamine, a
positive inotrope, may also be helpful in optimizing
LV function whilst avoiding hypotension. Limited
experience with angiotensin-converting enzyme
inhibitors (ACEI) and digitalis suggest they may also
have a role in the medical management of AS.
• Percutaneous balloon aortic valvotomy, where a bal-
loon is inflated across the stenosed aortic valve to
force the leaflets apart, may be a temporizing measure
for a patient in cardiogenic shock or with need for
noncardiac surgery, but the high rate of restenosis
within 6 months precludes its recommendation as a
definitive procedure.
AORTIC INSUFFICIENCY
ETIOLOGY
• Aortic insufficiency (AI) may result from problems
with the aortic valve leaflets or from diseases of the
aortic root.
• AI can be classified as chronic or acute; acute AI can
be a life-threatening emergency.
• The most common etiologies of AI are: (1) infective
endocarditis, (2) aortic dissection, and (3) rupture or
prolapse of the aortic valve leaflet.
• The aortic valve can also be injured following blunt
chest trauma or deceleration injury.
PATHOPHYSIOLOGY
• In chronic AI, the LV gradually dilates in response to
the chronic volume overload of regurgitant flow back
into the LV during diastole. Dilation alters the usual
pressure-volume relationship of the LV, so that for any
change in volume, the pressure increase is less.
Chronic AI can thus remain compensated for some
time, until an additional strain such as ischemia or
decreased LV function causes rapid deterioration.
• In acute AI, there has been no time for the LV to
dilate. A small change in LV volume therefore causes
a large change in LVEDP, and therefore acute pul-
monary venous hypertension and congestion.
CLINICAL FEATURES
• Acute AI typically causes a patient to present critically
ill, with pulmonary edema, diaphoresis, cyanosis, and
cardiogenic shock. Patients are tachycardic, low or
normotensive with a normal pulse pressure, and a
short diastolic murmur over the base with a soft S1
and loud P2.
• Chronic AI, in contrast, generally presents with a
gradual onset of congestive heart failure.
DIAGNOSTIC EVALUATION
• In acute AI, ECG may be normal with the exception
of sinus tachycardia. Clues to acute AI on CXR may
include pulmonary edema in the presence of a normal
heart silhouette, or a widened mediastinum if the eti-
ology of AI was aortic dissection.
• In chronic AI, ECG tends to show LVH, and the CXR
often shows an enlarged cardiac silhouette with a
prominent LV, and an unfolded or dilated aorta.
• Echocardiogram, either transthoracic (TTE) or trans-
esophageal (TEE), is quite helpful in the detection and
evaluation of AI, as Doppler techniques can estimate
the severity of regurgitant flow and LV function can
be simultaneously assessed. TEE can also provide
clues to the etiology of valvular disease, demonstrating
for example aortic dissection, vegetation, or abscess
on a valve leaflet.
• Cardiac catheterization allows evaluation of the
degree of regurgitant flow, the status of the aortic root,
and the status of the coronary arteries if surgery is
planned.
INTENSIVE CARE UNIT MANAGEMENT
• Acute AI is a medical emergency, and often presents
in dramatic fashion with severe pulmonary edema. A
rapid investigation into the cause of the insuffi-
ciency—particularly looking for aortic dissection or
aortic valve endocarditis—should be sought.
• Early valve replacement should be considered when
the regurgitation is severe, and when the resultant
heart failure cannot be managed medically.
 Loop diuretics and venodilators such as sodium
nitroprusside are the mainstay of therapy, as
inotropes are typically not helpful in the setting of
an already hyperdynamic LV, and vasoconstricting
medications are relatively contraindicated as they
tend to increase the amount of regurgitation.
 Intra-aortic balloon pumps are absolutely con-
traindicated, as they worsen insufficiency.
 In aortic valve endocarditis causing severe AI, early
valve replacement has shown a decreased mortality.
However, if the heart failure can be successfully
managed medically, and if the patient is responding
to antibiotic therapy, surgery may be delayed while
the infection is treated.
• Chronic AI can be treated with long-term afterload
reduction, using medicines such as hydralazine,
ACEI, and calcium channel blockers.
• To optimize the patient’s heart function, surgery for
AI should occur before any decrement in LV function
can be demonstrated.
MITRAL STENOSIS
ETIOLOGY
• Rheumatic disease following rheumatic fever remains
the most common reason for mitral stenosis (MS), par-
ticularly in the developing world. Rarely, MS results
from severe calcification of the mitral annulus, typi-
cally in the elderly or in patients with renal failure.
PATHOPHYSIOLOGY
• In rheumatic MS, inflammation following rheumatic
fever causes fusion of the mitral commissures, the
chordae tendinae, or both. The valve gradually degen-
erates, resulting in a narrowed valve area.
 Normally, the mitral valve area is 4–6 cm2.
 Mild MS occurs when the valve area is 2 cm2, and
critical MS when the valve area is 1 cm2 or less.
• To maintain normal cardiac output in the face of a
narrowed valve area, a higher transvalvular pressure
gradient must be generated. Over time this leads to
chronically elevated left atrial pressure, and eventually
to elevated pulmonary venous and pulmonary arterial
pressures.
• MS patients are especially challenged by any increase
in heart rate, which shortens diastolic filling time and
further elevates the transvalvular gradient, thus further
exacerbating left atrial pressure overload. The left
atrium tends to dilate—placing patients at high risk
for atrial fibrillation—and its chronically elevated
pressure often causes pulmonary edema.
• Tachycardia in any form exacerbates left atrial pres-
sure overload, as diastolic filling time is shortened, and
worsens pulmonary edema.
• Eventually, long-standing MS with high left atrial
pressures will result in pulmonary hypertension, which
in turn leads to right ventricular (RV) failure.
CLINICAL FEATURES
• While patients with MS may remain asymptomatic
for many years after their acute rheumatic fever, even-
tually they tend to present with dyspnea on exertion,
atrial fibrillation, or acute pulmonary edema.
• Hemoptysis from disruption of bronchial veins—a
complication of pulmonary hypertension—may be
dramatic, and may also be precipitated by exertion.
• The dilated left atrium with atrial fibrillation is partic-
ularly prone to clot formation, and results in many
strokes in patients with MS.
• On examination, one may hear an opening snap prior
to S1, followed by a diastolic rumble at the apex. As
MS worsens, the murmur becomes louder toward end-
diastole and closer to S2.
• When pulmonary hypertension is present, the exami-
nation can reveal fixed splitting of the second heart
sound with a loud P2, RV heave, and even the Graham
Steele murmur of pulmonic insufficiency.
DIAGNOSTIC EVALUATION
• Electrocardiogram often reveals atrial fibrillation and
right ventricular hypertrophy (RVH). If sinus rhythm
is present, left atrial enlargement may be suggested by
a tall P wave.
• The CXR often shows splaying of the carina, as the
left mainstem bronchus is driven cephalad by the
dilated left atrium. The left atrial shadow is prominent
in the aortopulmonary window, and pulmonary arteries
are frequently enlarged. The mitral annulus is often
calcified and easily visible, and pulmonary edema may
be present.
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• Echocardiogram with Doppler flow is useful to study
the valve anatomy and to noninvasively obtain the
transvalvular gradient, thus judging the severity of the
lesion.
• Cardiac catheterization may confirm the severity of the
valve gradient, and right heart catheterization can esti-
mate the left atrial pressure, although a more accurate
technique is transseptal puncture of the interatrial
septum, with direct measurement of left atrial pressure.
INTENSIVE CARE UNIT MANAGEMENT
• When patients with MS present in pulmonary edema,
they should be managed with careful diuretic therapy
and aggressive rate control with either beta-blockers
or calcium channel blockers. Digoxin is considered
second-line therapy.
• Anticoagulation is essential for patients with MS and
atrial fibrillation, with a goal international normalized
ratio (INR) of 2 to 3.
• Once symptoms of MS are present, surgical or proce-
dural therapy is indicated.
 In pure rheumatic MS, the procedure of choice is
catheter balloon commissurotomy. Via a right heart
catheterization, a catheter is placed transseptally in
the left atrium and a balloon passed across the mitral
valve.
 Contraindications to balloon commissurotomy are
significant mitral regurgitation, left atrial thrombus,
or unfavorable valve morphology.
 Balloon commissurotomy is successful and has low
mortality. When the procedure is contraindicated,
surgical commissurotomy or valve replacement is
indicated.
MITRAL REGURGITATION
ETIOLOGY
• Mitral regurgitation (MR) can result from damage to
the valve leaflets, the mitral annulus, the chordae ten-
dinae, or the papillary muscles.
• The mitral valve leaflets can be damaged by rheu-
matic heart disease, trauma, infective endocarditis,
Libman-Sacks endocarditis from lupus, or myxoma-
tous degeneration from mitral valve prolapse.
• The mitral annulus suffers from either dilation—for
example, in dilated cardiomyopathies—or from calci-
fication, usually age-related.
• Ischemic heart disease, particularly acute MI, can
cause disruption of either papillary muscles or chor-
dae tendinae, and can result in acute MR. The chordae
are also occasionally damaged by infective endocardi-
tis or by mitral valve prolapse.
PATHOPHYSIOLOGY
• When regurgitant blood flows into the left atrium
during systole, the early response of the LV is to aug-
ment its cardiac output, due to increased diastolic fill-
ing and decreased systolic pressure and volume.
However, over time the LV dilates and is subjected to
higher systolic wall tension. This in turn reduces LV
performance; when the ejection fraction has fallen to
just mild LV dysfunction, a significant decrement in
LV contractility has already occurred.
• In acute MR, for instance with rupture of the chordae,
the left atrial size is unchanged but LA pressure is sig-
nificantly and abruptly increased, resulting in pul-
monary edema. In this setting, a large V wave might
be observed on pulmonary arterial catheter tracings.
• In chronic MR, by contrast, the left atrium accommo-
dates to its increased volume with dilation, and thus
avoids significant elevations in left atrial pressures.
Atrial fibrillation is common due to the massively
dilated chamber size.
CLINICAL FEATURES
• In acute MR, patients often present in florid pulmonary
edema and with low cardiac output. Frequently,
ischemia is present, and has resulted in chordae or
papillary muscle rupture.
• In chronic MR, symptoms often are absent until either
atrial fibrillation occurs or the LV function is compro-
mised.
• Critical illness, or any process elevating the systemic
vascular resistance, will dramatically worsen the
regurgitant flow, and may precipitate congestive heart
failure (CHF).
• On examination, the LV impulse is frequently later-
ally displaced.
 An S3 is often present.
 A blowing, high-pitched holosystolic murmur is
heard loudest at the apex and radiates to the axilla.
The murmur typically obliterates S1 and S2.
 MR murmurs can be distinguished from tricuspid
regurgitation (TR) in that they tend to decrease slightly
in intensity with inspiration, while the murmur
augments in TR. Dynamic LV outflow murmurs
such as idiopathic hypertrophic subaortic stenosis
are also holosystolic, but these tend to be harsher
than MR murmurs and will soften with maneuvers
that increase afterload/decrease preload (e.g.,
standing), whereas MR murmurs are louder with
such maneuvers.
DIAGNOSTIC EVALUATION
• Unless it shows evidence of myocardial ischemia, the
ECG in acute mitral regurgitation is typically normal.
In chronic MR, the ECG may show left atrial enlarge-
ment, RVH, or atrial fibrillation.
• On CXR, patients with MR have an enlarged cardiac
silhouette with LV prominence, left atrial enlargement
and, at times, mitral annular calcification.
• Echocardiogram often elucidates the etiology of
mitral regurgitation in addition to grading its severity.
• Cardiac catheterization with left ventriculogram can
effectively demonstrate MR severity and estimate LV
ejection fraction. Right heart catheterization may also
be helpful, in showing a prominent V wave which rep-
resents simultaneous filling of the left atrium by both
the pulmonary veins and by the regurgitant LV during
ventricular systole.
• Exercise testing can be an important adjunct to evalu-
ate the asymptomatic patient with chronic MR, as it
may precipitate symptoms and thus indicate a need
for surgical intervention.
INTENSIVE CARE UNIT MANAGEMENT
• Patients presenting with acute MR can be treated iden-
tically to patients with acute heart failure, with after-
load reduction (ACEI, nitroprusside, or hydralazine),
diuresis, and positive inotropes as necessary. Noninvasive
positive pressure ventilation (NIPPV) is frequently
extremely effective in treating pulmonary edema and
for further afterload reduction.
• Acute mitral regurgitation carries a high mortality;
patients should be treated aggressively and early con-
sideration for surgical intervention—for example, for
chord rupture with flail valve leaflet, papillary muscle
rupture, or valve vegetation causing acute MR—is
appropriate.
• In chronic MR, surgery for either valve repair or valve
replacement should be considered when a patient is
symptomatic. Exercise testing may elucidate an other-
wise asymptomatic patient’s complaints. In addition,
asymptomatic patients should be considered for sur-
gery when their ejection fraction falls below 50%,
their end-systolic volume index exceeds 50 mL/m2, or
when pulmonary hypertension develops.
• The decision to replace versus repair a valve often
depends on the underlying etiology of the valve dys-
function and on the valve structure.
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KEY POINTS
• Risk factors include hypertension, Marfan syndrome,
and congenital aortic anomalies.
• Aortic dissection typically presents with intense,
sharp chest pain combined with hypertension, but
symptoms can be subtle.
• Diagnosis rests on echocardiography, helical CT
angiography, or magnetic resonance imaging, and
sometimes requires aortography.
• Treatment involves urgent pain and blood pressure
control, using drugs that blunt the systolic rise in
aortic pressure (such as labetalol), followed by sur-
gery for dissections involving the ascending aorta
(type A dissection).
• Careful monitoring is required to detect complications
such as vascular occlusion, pericardial tamponade,
aortic rupture, or aortic valve insufficiency.
EPIDEMIOLOGY
• Most common emergent condition involving the aorta
with an incidence of 5–30 cases per million per year,
making it two to three times as common as rupture of
abdominal aortic aneurysm.
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• Men have two to three times greater risk of develop-
ing aortic dissection than women. Peak age of inci-
dence is 50–55 years old.
• Up to 90% of patients have hypertension at time of
presentation, with 62–78% having a history of chronic
systemic hypertension.
• Marfan syndrome is present in the majority of patients
presenting with aortic dissection under the age of 40.
PATHOPHYSIOLOGY
• A dissecting hematoma that separates the intima and
inner layers of the media from the outer medial and
adventitial layers. Most commonly initiated via a tear
in the intima that precedes either anterograde or retro-
grade, creating a false lumen. Tear is due to weakening
of the wall of the aorta (most often the medial layer),
increased shear stress, or both.
• May be complicated by rupture into the pericardial
space, or pleural space, occlusion of branching arter-
ies with consequent ischemic symptoms, or involve-
ment of the aortic valve commissures with subsequent
insufficiency.
• Table 24-1 shows dissection risk factors.
• Connective tissue diseases such as Marfan syndrome
or Ehlers-Danlos syndrome predispose to medial
degeneration.
• Secondary causes of reduced wall strength include
annuloaortic ectasia, bicuspid aortic valve, coarctation,
and pregnancy. Other causes of increased shear stress
include instrumentation of the aorta, deceleration injury
from blunt trauma, cocaine use, and abrupt discontin-
uation of a beta-blocker.
• Classified by:
 Timing: acute (<2 weeks) or chronic (>2 weeks)
 Location: type A (60%), ascending aorta is involved
(independent of site of intimal tear), or type B
(40%), only descending aorta (beyond left subcla-
vian artery)
• Mortality is highest for type A dissections.
• See Table 24-2 for classification schemes.
CLINICAL PRESENTATION
• Presentation can be subtle (diagnosis is missed in up
to 38% of patients).
• Pain is most consistent presenting complaint (95%),
located anteriorly, where it is most often retrosternal,
but occasionally epigastric, or posteriorly, when it is
usually interscapular. Almost always described as sharp,
tearing, or knifelike, with a sudden onset. It is usually
extremely intense, and may be difficult to control with
opiates.
• Patients may present with evidence of shock, with cool,
clammy periphery, ashen coloring, and depressed level
of consciousness. Elevated blood pressure (>200 mmHg
systolic) is usually present, but may be absent if dis-
section results in tamponade, aortic rupture, or severe
aortic regurgitation.
• A new murmur of aortic insufficiency is present in
50–66% of type A dissections and 25% of all patients.
• One-third of patients will present with compromised
flow to a major branch of the aorta, with the innomi-
nate artery (resulting in reduced right carotid and right
subclavian flow) being the most often affected. This
can result in the presence of a blood pressure differ-
ential between left and right brachial arteries (present
in 38% of patients), focal neurologic signs associated
with differential cerebral hypoperfusion (5–10% of
patients), and a spectrum of peripheral sensory and
motor neuropathies due to involvement of arterial
branches supplying the spinal cord.
TABLE 24-1 Risk Factors for Dissection
• Systemic hypertension
• Connective tissue disease
 Marfan syndrome
 Ehlers-Danlos syndrome
 Vasculitis
 Takayasu arteritis
 Giant-cell arteritis
 Rheumatoid arthritis
• Congenital defects
 Annuloaortic ectasia
 Bicuspid aortic valve
 Coarctation of aorta
 Turner syndrome
• Acquired risk factors
 Preexisting aortic aneurysm
 Syphilis
 Pregnancy
 Previous aortic valve replacement
 Coronary artery bypass grafting (CABG)
 Trauma
 Cocaine
TABLE 24-2 Classification of Aortic Dissections
• Daily (or Stanford) classification system
 Type A: dissection of the ascending aorta, regardless of site of initial
tear
 Type B: dissection of the descending aorta
• DeBakey classification system
 Type 1: dissection of the ascending and descending aorta
 Type 2: dissection of the ascending aorta
 Type 3: dissection of the descending aorta
• Aortic rupture is the most common cause of early
mortality with severe aortic regurgitation, the second
most common cause.
DIAGNOSIS
• A high clinical suspicion is necessary to establish the
diagnosis in many patients.
• Laboratory data are usually within normal limits in
patients with acute dissection, although leukocytosis
is sometimes seen.
• ECG is most often normal or shows left ventricular
hypertrophy, but may mimic a myocardial infarction,
especially in type A dissection if there is involvement
of one of the cusps of the coronary arteries.
• Chest x-ray may show widened mediastinum (absent
in up to 40% of type A dissections), or pleural effu-
sion (left > right, with associated apical cap).
• Appropriate diagnostic imaging is the key to diagno-
sis, but some controversy exists over the best diagnos-
tic test to most effectively diagnose aortic dissection.
Aortic angiography, computed tomography (CT)
aortic imaging, magnetic resonance imaging (MRI),
and echocardiography are all viable options.
 Echocardiography is a diagnostic modality of choice,
with transesophageal imaging superior to transthoracic
with sensitivity and specificity of >95% and >90%,
respectively.
 CT scanning is noninvasive, but is less sensitive
(83%) than angiography, but has excellent (up to
100%) specificity. Advantages include widespread
availability, noninvasiveness, and cost.
 Aortic angiography is most invasive, with sensitivity
and specificity of 85–90% and 75–95%, respectively.
 MRI is still investigational, but some studies suggest
it may have sensitivities and specificities rivaling
transesophageal echo, however, its widespread
application is limited by lack of immediate avail-
ability. Difficulty in adequately monitoring a poten-
tially critically ill patient while getting an MRI may
also limit its use.
TREATMENT
• Cardiac monitoring, with intra-arterial monitoring of
blood pressure.
• Adequate central venous access should be obtained.
• Surgical consultation is required for emergent repara-
tive surgery, which is indicated in all type A dissec-
tions, and type B dissections with rapid expansion,
impending rupture, uncontrollable pain, or evidence
of end-organ/limb ischemia. Mortality is up to 50% at
72 hours for untreated type A dissection, and 90% at
3 months, while operative mortality is 5–21%. Early
surgical management is desirable with both longer
time to operation and development of complications
leading to a worse prognosis.
• Immediate initiation of blood pressure control and
pain control with intravenous medications. Medications
that reduce the pulse pressure are preferred (labetalol,
esmolol, propranolol), but often combination therapy
with a direct-acting arterial vasodilator (nitroprusside)
is required for adequate control. Target systolic blood
pressure should be as low as 90–100 mmHg as long as
organ perfusion is maintained.
• Uncomplicated type B dissections are most often
managed medically with aggressive blood pressure
control (survival of 80%). Endovascular stent place-
ment may be a less invasive alternative to surgery in
select patient populations.
• Frequent monitoring of parameters of end-organ perfu-
sion such as pulse checks, urine output, mental status,
bowel sounds, and complete neurologic checks in an
intensive care environment allow for early detection of
progression of dissection.
• Long-term control of blood pressure is crucial to decrease
the risk of subsequent aneurismal complications.
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25 MECHANICAL CIRCULATORY
ASSIST DEVICES
Ethan L. Gundeck
KEY POINTS
• Intra-aortic balloon pumps and ventricular assist
devices are being used increasingly.
• IABPs inflate in diastole and deflate in systole,
unloading the left ventricle.
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• IABP is generally used for patients in cardiogenic
shock or at high-risk during cardiac catheterization;
vascular complications should be sought regularly.
• VAD can unload either the right or left ventricle, gen-
erally as a bridge to definitive treatment or to allow
the heart to improve (acutely or in the long-term).
• Hemorrhage is the most frequent complication of VAD.
INTRODUCTION
• Due to the aging of the U.S. population and improved
therapies for patients with heart disease, heart failure
is increasing in frequency.
• Mechanical circulatory assist devices, specifically
intra-aortic balloon pumps (IABP) and ventricular
assist devices (VAD), can offer significant benefit to
patients with (or at high-risk for) cardiogenic shock.
INTRA-AORTIC BALLOON PUMP
INTRODUCTION
• An IABP is a helium-filled balloon generally placed
in the descending aorta.
• It inflates during diastole, displacing between 30 and
50 mL of blood into the proximal aorta, and deflates
at the start of systole.
• The predominant effect is to reduce afterload, although
it may directly improve flow to the coronaries as well.
INDICATIONS
• Most common indications are to provide hemody-
namic support during or after cardiac catheterization
and for the treatment of cardiogenic shock.
• May also be used for weaning from cardiopulmonary
bypass, preoperative stabilization of high-risk patients
(left main disease, severe aortic stenosis), and treat-
ment of refractory unstable angina.
• Has been used successfully for intractable ventricular
arrhythmias and mechanical complications after
myocardial infarction (post-MI ventricular septal
defect or mitral regurgitation).
CONTRAINDICATIONS
• The major contraindication to use is aortic insuffi-
ciency (balloon inflation during diastole can greatly
exacerbate this valvular abnormality).
• Other contraindications include abdominal aortic
aneurysm or dissection; severe, bilateral peripheral
vascular disease; uncontrolled bleeding; or sepsis.
PRACTICAL CONSIDERATIONS
• May be placed through an arterial sheath (gener-
ally requires anticoagulation) or without a sheath
(the sheathless device can be used without antico-
agulation).
• Chest radiography confirms proper placement in the
descending aorta: the tip of balloon should be at the
level of the tracheal carina.
• The balloon inflates during diastole (should be timed
to the dichrotic notch of the intra-arterial wave form
displayed on the IABP console), and deflates during
the isovolumic phase of systole (generally timed to
the R wave on the ECG).
• Improper timing can cause suboptimal or even delete-
rious hemodynamic effects.
• The pump can be set to inflate in a fixed relationship
to the cardiac cycle. For example, with 1:1 timing,
the IABP synchronizes with each heartbeat, whereas
with 1:3 timing, the balloon inflates only every third
heartbeat.
• Use 1:2 or 1:3 frequency when adjusting the timing
of balloon inflation. Look for diastolic augmenta-
tion of pressure during inflation and reduced sys-
tolic and diastolic pressures during the subsequent
beat.
• Look for decrease in systolic pressure, increase in
diastolic pressure, decrease in heart rate, decrease in
wedge pressure, and increase in cardiac output (or
surrogates such as central venous oxyhemoglobin
saturation) as indicators that the IABP is having a
positive effect.
COMPLICATIONS
• Complications are divided into vascular and non-
vascular.
• Vascular complications include limb ischemia, vascular
laceration, hemorrhage, arterial dissection, spinal cord
ischemia, and visceral ischemia.
• Vascular complications are more likely in patients
with peripheral vascular disease, older age, female
gender, diabetes, hypertension, prolonged use of the
device, larger catheter size, body surface area <1.8 m2,
or cardiac index <2.2 L/min.
• Nonvascular complications include cholesterol
embolization, stroke (rare if placed properly), sepsis if
in place more than 7 days, rupture of balloon with
subsequent thrombosis, thrombocytopenia, hemolysis,
groin infection, and peripheral neuropathy.
• Limb ischemia and other complications generally
warrant prompt removal of the device.
• Lower mortality rates in IABP patients have been seen
in centers which use them more frequently.
VENTRICULAR ASSIST DEVICE
INTRODUCTION
• These mechanical pumps take over some of the func-
tion of a failing ventricle to improve hemodynamics
and end-organ perfusion.
• Can assist a failing right ventricle (RVAD), left ven-
tricle (LVAD), or both (BiVAD).
• For RVAD, blood is removed from the right atrium
and returned to the main pulmonary artery.
• For LVAD, blood is removed from either the left
atrium or apex of the left ventricle, and returned to the
ascending aorta.
• Types of VADs are divided into centrifugal, pneu-
matic pulsatile, and electric pulsatile.
• Centrifugal pumps provide nonpulsatile flow and
require anticoagulation and continuous monitoring.
These pumps are generally used only for short-term
cardiopulmonary bypass.
• Pneumatic pulsatile pumps provide pulsatile flow
with minimal trauma to blood cells. After the first few
days of placement, minimal supervision is required
for these devices, but they are somewhat bulky and
limit patient mobility.
• Electric pulsatile pumps are similar to the pneumatic
pulsatile pumps, except that they may only be used for
the left ventricle. The bulky drive console of the pneu-
matic device is replaced with a small, portable exter-
nal controller and battery pack. These devices allow
for increased patient mobility, and the possibility for
discharge to home with the device in place.
INDICATIONS AND EFFECTS
• Indications for these devices fall into three categories:
(1) temporary assistance for a failing ventricle that is
expected to recover (e.g., postcardiotomy shock); (2) as
a bridge to transplant in a ventricle that is failing to
provide adequate end-organ perfusion; or (3) for per-
manent use (so-called, “destination” therapy).
• Patients stabilized on these devices have improved 6-
minute walk times and improved oxygen consumption.
Improved histopathologic findings with long-term use
have been described as well (regression of hypertrophy,
improved fiber orientation, reversal of dilatation).
Reports exist of cardiac function improving to the point
that the device may be removed.
CONTRAINDICATIONS
• Contraindications to placement: Aortic insufficiency of
any significant degree, and severe, unrepaired mitral
stenosis. Mitral regurgitation is eliminated by a function-
ing LVAD (since ventricular afterload is completely
reduced) and is not a contraindication, nor is aortic
stenosis. Atrial and ventricular arrhythmias are generally
well tolerated. Congenital defects should be corrected
prior to VAD placement as left ventricular unloading
may uncover right-to-left shunt and hypoxemia. Bad
obstructive pulmonary disease and neurologic impair-
ment are considered contraindications as well.
COMPLICATIONS AND PRACTICAL MATTERS
• Echocardiographic findings of a functioning LVAD
include a completely decompressed left ventricle, no
aortic insufficiency, and a closed aortic valve through-
out the cardiac cycle.
• Hemorrhage is the most common major complication,
occurring in up to 30% of patients. Coagulopathies
need to be aggressively corrected.
• Right-sided failure from LVAD placement, thromboem-
bolism, infection, device malfunction, and hemolysis
are other complications.
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26 HYPERTENSIVE
ENCEPHALOPATHY
AND HYPERTENSIVE
EMERGENCIES
George W. Bell
KEY POINTS
• Hypertension is an extremely common diagnosis.
Elevated blood pressure can progress beyond stage 3
hypertension to accelerated-malignant hypertension
as well as hypertensive encephalopathy.
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• In addition, a wide range of other disease processes
can require urgent and even rapid correction of ele-
vated blood pressure (Table 26-1).
• At a given threshold, elevated blood pressure can
cause end-organ damage that may or may not be
reversible.
• The rate of increase in blood pressure is often the
determining factor of disease severity, but all
patients with a sustained diastolic blood pressure of
130 mmHg or higher should be considered for imme-
diate treatment.
• Persistently elevated blood pressure can precipitate
aggravating local and systemic effects.
• Because of its deleterious effects urgent and some-
times rapid correction of blood pressure may be
required.
• Intensive monitoring and treatment options are avail-
able depending on the clinical situation.
• Better outpatient control of hypertension likely
decreases the incidence of hypertensive emergencies.
EPIDEMIOLOGY
• Hypertension is highly prevalent in the U.S. popula-
tion, and the number of affected patients increases
with age.
• After adolescence, blacks are more likely to have
hypertension with more severe complications when
compared to income-matched whites.
• Although <1% of patients with primary hypertension
will develop accelerated-malignant phase hypertension,
more patients with primary hypertension than secondary
hypertension will present in a hypertensive crisis.
• Some causes of secondary hypertension, including
pheochromocytoma and renovascular hypertension,
are more likely to proceed to a hypertensive crisis than
primary hypertension.
CAUSES OF HYPERTENSIVE CRISES
• There are many causes of hypertensive crises, includ-
ing medical nonadherence, acute glomerulonephritis,
renal artery stenosis, pheochromocytoma, monoamine
oxidase inhibiter (MAOI) interactions, sympatheti-
cally driven drug use (cocaine), myocardial infarction,
and eclampsia.
• Previously normotensive individuals may experience
hypertensive encephalopathy at moderate blood pres-
sures if the change in pressure was acute. Such examples
include eclampsia and cocaine use.
• Myocardial ischemia, regardless of its progression to
myocardial infarction or not, often increases the
patient’s blood pressure.
PATHOPHYSIOLOGY OF HYPERTENSIVE
ENCEPHALOPATHY
• Patients can suffer acute vascular damage at different
levels of blood pressure elevation. Vascular damage
may be secondary to abnormal endothelial function
and platelet activation, as seen by elevated levels of
endothelial microparticles and circulating platelet
microparticles in severely hypertensive patients.
• Chronic hypertensive patients withstand higher pres-
sures than normotensive patients. This is due to the
fact that, over time, arterioles of hypertensive patients
respond to chronically high blood pressure by remod-
eling and developing greater wall thickness.
• In an effort to maintain constant cerebral perfusion,
arterioles adjust to the current level of blood pressure.
When blood pressure is acutely elevated, arterioles con-
strict. When blood pressure acutely decreases, arteri-
oles dilate. Together, these ensure steady cerebral
perfusion (autoregulation), a phenomenon well studied
in animal models and believed to be true in humans as
well.
• However, above a certain cut-off point, arterioles can
no longer respond to elevated pressure. At this cut-off
TABLE 26-1 Hypertensive Emergencies
Cardiac
Aortic dissection
Left ventricular failure
Myocardial infarction
Drug-related
MAOI interactions
Cocaine
Antihypertensive withdrawal
Surgical
Postoperative management (coronary artery bypass graft [CABG],
kidney transplant, vascular)
Prior to emergent surgery
Neurologic
Hypertensive encephalopathy
Intracerebral hemorrhage
Subarachnoid hemorrhage
Renal
Glomerulonephritis
Collagen vascular
Other
Pheochromocytoma
Eclampsia
Burns
Epistaxis
blood pressure, arterioles dilate. The arteriole dilation
starts in areas of less muscular vessels but progresses
globally.
• Once cerebral arterioles dilate as a result of elevated
blood pressure, cerebral hyperperfusion and extrava-
sation of fluid into the perivascular tissue occurs.
Consequently, cerebral edema, which is a hallmark of
hypertensive encephalopathy, follows.
• This cut-off point in which elevated blood pressure
causes breakthrough cerebral hyperperfusion has been
evaluated in humans. When studying cerebral perfu-
sion as a reflection of varying levels of blood pressure,
researchers identified a mean arterial pressure cut-off
value in normotensive patients of 120 mmHg. In hyper-
tensive patients, the mean arterial pressure that resulted
in cerebral hyperperfusion was 180 mmHg.
• Typically, acute vascular damage correlates with a
diastolic blood pressure of 130 mmHg or higher.
However, hypertensive encephalopathy can be seen in
normotensive patients with an acute rise in their blood
pressure to as low as 150/100 mmHg.
DIAGNOSIS AND CLINICAL FEATURES
• Patients will often present in a hypertensive crisis with
a diastolic blood pressure >140 mmHg. However,
varying levels of hypertension can cause neurologic
deficits and other end-organ damage, so it is important
to recognize the clinical features of a patient in a
hypertensive crisis.
• Patients are said to have accelerated-malignant hyper-
tension when an acute rise in blood pressure causes
retinal hemorrhage, exudates, or papilledema.
• Hypertensive encephalopathy is marked by cerebral
edema secondary to hypertension-induced cerebral
hyperperfusion.
• Patients with hypertensive encephalopathy can pres-
ent with neurologic findings of an altered level of con-
sciousness, headache, and irritability. In addition to
the global findings of confusion, somnolence, and
stupor, patients can have focal neurologic deficits as
well. Untreated hypertensive encephalopathy can
progress to coma or seizure.
• Additional organ systems affected during a hyperten-
sive crisis include the cardiac, gastrointestinal, renal,
and hematologic systems. Congestive heart failure can
occur, while the gastrointestinal involvement includes
nausea and vomiting. Renal involvement includes olig-
uria and azotemia. Occasionally, hemolysis or throm-
bocytopenia is seen.
• Some patients do not present with the above constel-
lation of symptoms despite being in a hypertensive
crisis with end-organ damage. Specifically, young
black men may not have any signs or symptoms other
than marked renal insufficiency.
• In patients with a blood pressure elevated enough to
cause hypertensive encephalopathy or accelerated-
malignant hypertension there exist other markers that
represent end-organ damage.
 Renal insufficiency can develop, marked by protein-
uria and red cells in the urine. Both azotemia and
acute oliguric renal failure can develop.
 At such high blood pressures there is also risk of
diffuse intrarenal ischemia. This diffuse intrarenal
ischemia can cause elevated plasma renin and sub-
sequent secondary aldosteronism, presenting as
hypokalemia. Besides hypokalemia, elevated renin
levels and secondary aldosteronism can exacerbate
the patient’s already high blood pressure.
 Accelerated-malignant hypertension can cause micro-
angiopathic hemolytic anemia with subsequent
schistocytes and intravascular coagulation.
NATURAL HISTORY
• Because of the vast amount of damage caused by such
elevated blood pressure, treatment should be instituted
immediately.
• Likely causes of death in the short-term include cen-
tral nervous system dysfunction, while those who sur-
vive the acute setting are more likely to later die from
renal failure or stroke.
• Prior to more effective therapy the 1-year survival of
accelerated-malignant hypertension was <25%. At
that same time the 5-year survival of poorly treated
accelerated-malignant hypertension was 1%.
• Fortunately, newer treatment options have signifi-
cantly reduced the mortality associated with acceler-
ated-malignant hypertension. The 1-year survival rate
has increased to 90%, while the 5-year survival rate
has increased to 80%.
TREATMENT OPTIONS
• With newer medications available and the appropriate
utilization of hemodialysis, patients presenting in a
hypertensive crisis have a greater chance of survival.
• Although the etiology of the hypertensive crisis is
important, treatment must often be swift even without
a known etiology. However, certain illnesses that
mimic the signs and symptoms of a hypertensive
crisis require alternative therapy and should thus be
recognized (Table 26-2).
• It is important to remember that the neurologic find-
ings of hypertensive encephalopathy can be reversed
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with early detection and appropriate treatment.
Persistently high diastolic blood pressures above
140 mmHg often require parenteral treatment. Signs
of hypertensive encephalopathy should also prompt
parenteral treatment.
• Parenteral agents include the vasodilators nitroprus-
side, nitroglycerin, nicardipine, hydralazine, enalapril,
and fenoldopam. The parenteral adrenergic inhibitors
include phentolamine, esmolol, and labetalol. In these
circumstances, patients often require parenteral
furosemide to prevent sodium and water retention,
which if left untreated will cause a recurrent rise in
blood pressure. Furosemide should only be consid-
ered in the euvolemic or hypervolemic patient, and it
often helps lower the blood pressure even further.
Special care must be taken not to give furosemide to
the hypovolemic patient with hypertensive crisis.
• Initially, blood pressure should be lowered by no more
than 25% to protect against cerebral ischemia. When
using parenteral agents, intra-arterial blood pressure
monitoring should be considered.
• Patients who do not appear in acute danger and who are
cognitively intact may be considered for oral therapy.
• Those who have suffered a stroke should not have
their blood pressure lowered too rapidly, or ischemia
can develop.
NITROPRUSSIDE
• Nitroprusside likely acts similarly to endogenous
nitric oxide with venous and arterial dilation. It has a
rapid onset and is considered first-line treatment in
severe hypertensive crises. It is especially indicated in
aortic dissection, but a drug to blunt the aortic pres-
sure rise, such as propranolol, must be used concomi-
tantly (Table 26-3).
• Its venous dilation properties can decrease cardiac pre-
load and cardiac output with subsequent tachycardia.
• When treating hypertension in patients with acute sys-
tolic dysfunction and pulmonary edema, nitroprusside
can be efficacious when used with a loop diuretic.
• Nitroprusside may increase intracranial pressure by
raising cerebral blood flow, especially when intracranial
compliance is reduced.
• Side effects include nausea, vomiting, and diaphoresis.
Muscle twitching has been noted as well.
• Thiocyanate intoxication must be monitored when
administering nitroprusside.
• The dose ranges from 0.25 to 10 mg/kg/min by intra-
venous infusion. Onset of action is nearly instantaneous
and intra-arterial blood pressure monitoring is required.
NITROGLYCERIN
• Nitroglycerin is another effective vasodilator espe-
cially useful during periods of coronary ischemia.
• The side effects include flushing, headache, tachycar-
dia, and vomiting.
• Like the vasodilator nitroprusside, nitroglycerin cou-
pled with a loop diuretic can be effective in treating
hypertension in patients with systolic dysfunction and
pulmonary edema.
• Patients must be monitored for methemoglobinemia.
• The dose is 5–100 µg/min intravenously, and its onset
is between 2 and 5 minutes.
NICARDIPINE
• This calcium antagonist is useful in preserving tissue
perfusion in patients experiencing ischemia. Nicardipine
offers a controllable reduction in blood pressure with
little chance of overcorrection and hypotension.
TABLE 26-2 Hypertensive Scenarios That Should be
Differentiated From Hypertensive Crises
Acute left ventricular failure
Renal failure
Collagen vascular diseases
Subarachnoid hemorrhage
Intracerebral hemorrhage
Thromboembolic stroke
TABLE 26-3 Preferred Treatment Options Directed
at Specific Clinical Hypertensive Situations
First-line treatment
Nitroprusside
Aortic dissection
Nitroprusside
Trimethaphan camsylate
Propranolol
Labetalol
Myocardial ischemia
Nitroprusside
Nitroglycerine
Preeclampsia/eclampsia
Hydralazine
Labetalol
Nicardipine
Nifedipine
Pheochromocytoma
Phentolamine
Cocaine-induced
Labetalol
• Side effects include flushing, headache, and tachycar-
dia. Local phlebitis has been seen.
• The dose is 5–15 mg/h intravenous infusion with an
onset of 5–10 minutes.
HYDRALAZINE
• This medication remains the treatment of choice for
preeclampsia and eclampsia.
• It can be dosed intravenously with 5 mg boluses
repeated every 20 minutes for a total of 20 mg, and its
onset is 10–20 minutes when given IV. Intramuscular
dosing at 10–50 mg IM with an onset of 20–30 minutes
is also available for hypertensive crises when intra-
venous access cannot be secured rapidly.
• Patients may experience flushing, headache, tachycardia,
vomiting, or worsening angina.
ENALAPRIL
• Enalapril is the only angiotensin-converting enzyme
(ACE) inhibitor available intravenously and may be
especially beneficial in hypertensive patients with
heart failure.
• Enalapril can be given at a range of 1.25–5 mg intra-
venously every 6 hours with onset by 15 minutes.
• Hypovolemic patients and those with renal artery
stenosis or a high renin state must be monitored
closely for dangerous decreases in blood pressure.
Patients must be monitored closely due to the variable
response of intravenous enalapril.
FENOLDOPAM
• Fenoldopam acts as a selective dopamine agonist at
the DA1 receptor. It can improve renal blood flow and
natriuresis.
• Patients may experience flushing, headache, nausea,
and tachycardia with fenoldopam administration.
• Fenoldopam should not be used for >48 hours.
• The dose of fenoldopam ranges from 0.1 to 0.3 µg/kg/
min with an onset of action in <5 minutes.
PHENTOLAMINE
• This alpha-1 antagonist is first-line therapy for treat-
ment of hypertension associated with pheochromocy-
toma.
• Flushing and tachycardia can be seen with phento-
lamine use.
• Its dose is 5–15 mg intravenously, with a quick onset
in 1–2 minutes.
ESMOLOL
• Esmolol is indicated in aortic dissection. It is given at
500 µg/kg/min for 4 minutes then dosed at 150–300
µg/kg/min intravenously. Onset of action is between 1
and 2 minutes, and hypotension must be monitored
for closely.
LABETALOL
• This adrenergic antagonist (alpha- and beta-blocker)
can be used as an adjunct in treating preeclampsia and
eclampsia. Labetalol is useful as an addition to nitro-
prusside when treating aortic dissection. It is also used
when treating hypertension during periods of acute
increased sympathetic activity such as MAOI interac-
tion, pheochromocytoma, and cocaine use (although
its use here is controversial due to the concern for
myocardial ischemia).
• Selective beta-blockade only without alpha-receptor
antagonism should be avoided in instances of
increased sympathetic activity due to the subse-
quent rise in blood pressure from unopposed alpha-
receptor stimulation absent of beta-receptor-induced
vasodilation.
• Labetalol should only be used with caution in acute
heart failure.
• A bolus of 20–80 mg should be given intravenously
every 10 minutes followed by a 2 mg/min intravenous
infusion.
• Onset of activity is typically 5–10 minutes, and patients
may experience dizziness, orthostatic hypotension, scalp
tingling, throat burning, and vomiting.
ORAL THERAPY
• Oral agents can be considered for asymptomatic
patients who are cognitively alert and in no acute
danger. Most short-acting medications can be consid-
ered, including captopril, felodipine, furosemide, and
propranolol.
• Resuming a patient’s prior oral regimen is reasonable
if the elevated blood pressure is secondary to medica-
tion withdrawal and if the prior oral regimen offered
adequate blood pressure control.
• Ischemia can result from an excessively rapid
decrease in blood pressure. For this reason liquid and
sublingual nifedipine preparations should be avoided.
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27 PATHOPHYSIOLOGY OF
ACUTE RESPIRATORY
FAILURE
Nina M. Patel
KEY POINTS
• Acute respiratory failure results from an abnormality
in gas exchange that is associated with an inability to
maintain adequate oxygenation and/or ventilation,
resulting in hypoxia and at times, hypercapnia.
• The four major classes of ARF are:
1. Type I: shunt
2. Type II: hypoventilatory
3. Type III: perioperative/atelectasis
4. Type IV: shock/hypoperfusion
OXYGEN TRANSPORT
• The movement and uptake of oxygen from lung to
tissues can be described by four major variables:
1. Arterial O2 content (CaO2)
2. Oxygen delivery (DO2)
3. Oxygen consumption (VO2)
4. Oxygen extraction ratio (O2ER)
• There are four major derangements which lead to arterial
hypoxemia:
1. Shunt, which is generally alveolar
2. Alveolar hypoventilation
3. Ventilation/perfusion (V/Q) mismatch
4. Decreased mixed venous PO2, which becomes rel-
evant when there is shunt or V/Q mismatch
ARTERIAL OXYGEN CONTENT (CaO2)
• CaO2 = 1.39 mL O2/g Hgb × [Hgb] × SaO2 + 0.003
mL/ O2/mmHg × (PaO2).
• This equation highlights a number of important
aspects of oxygen transport. First, hemoglobin
(Hgb) is a principal determinant of oxygen-carrying
capacity of blood. Second, due to the poor solubility
of oxygen in blood, PaO2 has a significantly more
limited capacity than Hgb to impact arterial O2
content.
• These principles are demonstrated graphically by the
Hgb-oxygen dissociation curve (see Fig. 27-1). As PO2
values rise to ≥60 mmHg, the Hgb saturation curve
reaches a plateau. After this point, further increases in
PaO2 minimally impact CaO2 because Hgb is already
fully saturated.
OXYGEN DELIVERY (DO2)
• DO2 (mL O2/min) = cardiac output (Q, L/min) × CaO2(mL/O2/dL).
• O2 delivery depends on both cardiac output and arte-
rial O2 content.
• Normal values for DO2: 520–570/mL/min/m.
OXYGEN CONSUMPTION (VO2)
• VO2 (mL O2/min) = Q (L/min) × 10 (dL/L) × 1.39 mL
O2/g Hgb × Hgb (g/dL) × (SaO2 − SvO2) (expressed
as fractions, not %).
• VO2 reflects peripheral oxygen uptake. This value is rel-
atively constant under normal conditions. Conversely, in
situations of increased metabolic demand (e.g., fever,
seizures), VO2 rises.
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FIG. 27-1 Hgb-oxygen dissociation curve. Depicted here is
the oxyhemoglobin dissociation curve for normal adult hemo-
globin (hemoglobin A, solid line). Note that hemoglobin is 50%
saturated with oxygen at a partial pressure of 27 mmHg (i.e.,
P50 is 27 mmHg) and is 100% saturated at a PO2 of approxi-
mately of 100 mmHg. Depicted here are curves that are “left-
shifted” (dotted line, representing increased oxygen affinity)
and “right-shifted” (dotted line, decreased oxygen affinity). The
effect of right- or left-shifting of the curve is most pronounced
at low oxygen partial pressures. In the examples shown, the
right-shifted curve means that hemoglobin can deliver approxi-
mately 70% of its attached oxygen at a PO2 of 27 mmHg. In
contrast, the left-shifted hemoglobin can deliver only about 35%
of its attached oxygen at this PO2. A high proportion of fetal
hemoglobin, which has high oxygen affinity, shifts this curve to
the left in newborns.
OXYGEN EXTRACTION RATIO (O2ER)
• O2ER = VO2/DO2.
• Under basal conditions, O2ER = 0.20–0.25, signifying
that 20–25% of delivered O2 is being consumed by
peripheral tissues. O2ER can increase to as high as
0.5–0.6 to either (a) meet oxygen requirements in face
of increased peripheral oxygen consumption (e.g.,
exercise) or (b) compensate for decreased oxygen
delivery (e.g., low output heart failure).
 A point of “critical oxygen delivery” arises when
peripheral tissues can no longer increase oxygen
extraction sufficiently to maintain VO2. When DO2
falls below the critical value, anaerobic metabolism
ensues as peripheral tissues attempt to meet energy
requirements.
• Endotracheal intubation or noninvasive ventilation
(NIV) should be considered early in all patients with
acute respiratory failure (ARF). Normally, VO2 related
to work of breathing is low. In ARF, however, VO2 can
increase substantially. Endotracheal intubation serves to
concurrently decrease VO2 related to work of breathing
and continuously deliver supplemental oxygen at an
increased FiO2.
• Optimization of CaO2 and DO2 with supplemental O2,
augmentation of cardiac output (e.g., use of inotropic
agents or crystalloid infusion), or packed red blood
cell transfusion are essential components in the man-
agement of ARF.
MECHANISMS OF HYPERCAPNIA
• The major etiologies of hypercapnia are:
1. Increased metabolic CO2 production
2. Decreased minute ventilation (VE)
3. Increased dead space ventilation (Vd)
• Arterial PCO2 is described by the equation:
 PCO2 = k × VCO2/{VE × [1 − (Vd/Vt)]}, (where k is
a constant, VCO2 is metabolic CO2 production in
mL/min, VE is total minute ventilation in L/min, Vd
is dead space volume, and Vt is tidal volume).
• In the ICU setting, increased metabolic CO2 produc-
tion is multifactorial, and can result from increased
metabolic rate or overfeeding.
• Decreased VE arises from the following situations:
1. Increased respiratory load
2. Decreased central nervous system (CNS) drive
3. Insufficient respiratory muscle strength/inadequate
neuromuscular (NMS) coupling
• Respiratory load = Pr + Pel; [(Pr = inspiratory flow ×
resistance), (Pel = volume × elastance)].
• The respiratory load of spontaneous breathing is
roughly 10 cmH2O. An average individual is capable
of generating a maximum negative inspiratory force
well above this load, at 100 cmH2O. In the setting of
airways obstruction (increased Pr) or increased lung,
chest wall, or abdominal wall elastance (increased
Pel), however, respiratory load increases signifi-
cantly. The respiratory system may not have suffi-
cient respiratory muscle strength or reserve to
overcome the increased mechanical load, hence
leading to insufficient ventilation and consequently
increased PCO2.
• Decreased CNS drive to breathe in the ICU can
develop secondary to medications (e.g., narcotics and
sedatives), toxins, and CNS injury or CNS metabolic
impairment (e.g., hypothyroidism).
• Respiratory muscle weakness/NMS uncoupling in the
ICU can occur due to primary disease (e.g., amy-
otrophic lateral sclerosis [ALS] and Guillain-Barré)
or secondary disease (e.g., severe hypophosphatemia
and drug-induced myopathy).
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• Dead space ventilation (Vd) refers to the portion of
lung that are ventilated, but not perfused. Increased Vd
can occur in a number of settings including emphy-
sema and pulmonary embolus.
TYPES OF RESPIRATORY FAILURE
TYPE I: ACUTE HYPOXEMIC 
RESPIRATORY FAILURE (AHRF)
• Severe hypoxemia, decreased PCO2 (a secondary
response, not always present when respiratory failure
is severe), and intrapulmonary shunting characterize
acute hypoxemic respiratory failure (AHRF).
• AHRF results from airspace flooding (e.g., edema
fluid, blood, and pus) with preserved perfusion but
severely compromised ventilation. Since no gas
exchange occurs, the PO2 and PCO2 of pulmonary
arterial blood supplying areas of shunt are equal to the
PO2 and PCO2 of pulmonary venous blood draining
these regions. This is termed an intrapulmonary shunt
lesion because blood flow bypasses normal gas
exchange at the alveolar-capillary interface.
• Due to the absence of gas exchange in flooded alveo-
lar units, increasing inspired O2 has little impact on
the level of hypoxemia in type I ARF.
• Positive end-expiratory pressure (PEEP) recruits flooded
alveoli for gas exchange, and is frequently utilized in the
setting of type I ARF to improve oxygenation.
TYPE II: ALVEOLAR HYPOVENTILATION
• Type II or hypoventilatory ARF presents with severe
hypercarbia resulting from decreased CO2 clearance.
In contrast to type I ARF, isolated hypoventilatory
ARF is not accompanied by severe, oxygen-refractory
hypoxemia. Rather, hypoxemia typically corrects with
modest supplemental oxygen therapy (or with improved
ventilation).
• Etiologies of type II ARF are: (1) increased Vd, (2)
increased respiratory load, (3) NMS insufficiency/
respiratory muscle weakness, (4) decreased CNS
drive, and (5) increased metabolic production of CO2.
• Evaluation includes: measurement of peak and pause
pressures on the mechanical ventilator during constant
flow, volume-preset ventilation, to evaluate for airways
obstruction or increased lung elastance; excluding
obvious metabolic derangements (e.g., electrolyte
abnormalities and hypothyroidism); examination of
caloric intake and requirements; assessment of mental
status in nonintubated patients; evaluation of medica-
tions administered (for toxicity); and vigilance in
searching for additional sources of hypoventilation
when obvious etiologies have been excluded, such as
unrecognized sleep disordered breathing.
• Supplemental oxygen therapy and treatment of the
primary etiology of alveolar hypoventilation dictate
therapeutic management of type II ARF.
TYPE III: PERIOPERATIVE ACUTE 
RESPIRATORY FAILURE
• Postoperative atelectasis, due to supine positioning,
splinting due to incisional pain and inadequate analgesia,
impaired cough and overhydration (on some occasions),
and tobacco use within 6 weeks of surgery, is the primary
etiology of type III ARF.
• The aforementioned factors work synergistically to
decrease functional residual capacity (FRC) below
increased closing volumes. The result is collapse of
dependent alveolar units.
• Surgery is not required to precipitate “perioperative”
respiratory failure, which can also be seen in medical
patients with severe obesity or ascites.
• Early institution of upright positioning, adequate
analgesia, chest physiotherapy and PEEP in intubated
patients (or mask continuous positive airway pressure
[CPAP] in those not intubated), and avoidance of
overhydration minimize the risk of developing signif-
icant postoperative atelectasis.
• If type III ARF does develop, the above factors should
be enacted immediately and, on some occasions bron-
choscopy can be attempted to clear endobronchial
secretions.
TYPE IV: HYPOPERFUSION/SHOCK
• Type IV ARF is associated with severe hypoperfusion
and an inability for Q (cardiac output) to meet the
metabolic demands of the respiratory muscles.
• Endotracheal intubation is indicated in type IV ARF
to minimize work of breathing and redirect Q from the
lungs to other organ systems. Patients can be extu-
bated on stabilization of shock/hypoperfusion, as long
as some additional cause for respiratory failure has
not developed.
CONCLUSIONS
• Acute respiratory failure in the ICU is often multifac-
torial. Identifying the primary cause(s) of ARF is crit-
ical to appropriate management of these patients.
• Assuring adequate oxygen transport and minimizing
work of breathing are essential components in the
treatment of patients with ARF.
• Expediency in liberation from mechanical ventilation
should be instituted once the type of ARF has been
identified and treated.
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28 NONINVASIVE POSITIVE
PRESSURE VENTILATION
Nathan Sandbo
KEY POINTS
• During noninvasive ventilation, a nasal mask,
oronasal mask, full facial mask, nasal pillows, or
helmet is used to couple the ventilator to the patient.
• Many patients can be ventilated effectively with non-
invasive means, especially those with exacerbations of
COPD.
• In appropriately selected patients, noninvasive venti-
lation reduces the need for intubation, lowers the inci-
dence of complications, shortens ICU stay, and
improves survival.
• Improvement is generally evident within 1 hour in
patients who will respond to noninvasive ventilation.
EPIDEMIOLOGY
• Noninvasive positive pressure ventilation (NIPPV) pro-
vides a less invasive alternative to endotracheal intuba-
tion (ETI) for the treatment of respiratory failure. Due
to the less invasive nature of this intervention, compli-
cations normally associated with ETI can be minimized,
while preserving the benefits of positive pressure
ventilation.
• Use of NIPPV has dramatically increased over the
past 15 years, as well as the indications for its use.
Benefits in selected patients include a decrease in the
need for ETI, shorter length of stay, decreased rates of
complications (such as nosocomial pneumonia), and
lower mortality rates.
TECHNICAL CONSIDERATIONS
• Positive pressure is delivered via a fitted mask in
NIPPV, rather than an endotracheal tube. Adequate
seal is required at the interface of the face and the
mask to appropriately deliver positive pressure to the
alveolar space. An oronasal mask is the primary inter-
face used, and is superior to nasal mask or cushions in
achieving adequate patient tolerance in the setting of
acute respiratory failure.
• Both traditional ventilators and newer turbine ventilators
specifically designed for NIPPV can be used. Ventilators
specifically designed for NIPPV are used for reliable
triggering despite air leaks, and are currently the pre-
ferred delivery system.
• A primary key to success is appropriate patient selec-
tion and achieving patient tolerance. An awake, spon-
taneously breathing patient who can protect the airway
is the best candidate, although chronic obstructive pul-
monary disease (COPD) patients obtunded due to ven-
tilatory failure also often respond. Patient discomfort
from claustrophobia, a tight fitting mask, and the sen-
sation of positive pressure breathing are all common
challenges which require experienced personnel to
address and correct.
• The most common ventilator setting is characterized
by the selection of both an inspiratory pressure level
(IPAP) and an expiratory pressure level (EPAP). This
correlates with a pressure support ventilator mode
with a set level of positive end-expiratory pressure
(PEEP). The two most studied strategies are continu-
ous positive airway pressure (CPAP, where IPAP =
EPAP), and bilevel positive airway pressure (BiPAP,
where IPAP > EPAP).
INDICATIONS
• Acute-on-chronic respiratory failure:
 COPD
 Sine qua non is ventilatory failure characterized
by rapid, shallow breathing. Patients experience
increased work of breathing and respiratory
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muscle fatigue due to disadvantageous respiratory
system mechanics.
 NIPPV can decrease work of breathing and
improve respiratory mechanics. This is evidenced
by improvement in tidal volumes, decreased res-
piratory rate, improved serum pH, and lowered
PCO2 within the first hour.
 Clinical evidence for use includes several
prospective randomized trials showing decreased
need for ETI (from 67 to 9% in one study), short-
ened length of stay, lower rate of complications,
and improved survival in patients with COPD.
Most studies used BiPAP settings.
• Uncomplicated hypoxemic respiratory failure:
 Both CPAP and BiPAP have been used successfully
to treat respiratory failure due to cardiogenic pul-
monary edema. Data suggest that rates of ETI, phys-
iologic parameters, and 48 hours survival are all
improved, but hospital survival was not changed.
The subgroup which has shown the most benefit is
patients with congestive heart failure (CHF) and
coexistent hypercapnia.
 In carefully selected patients, BiPAP, but not CPAP,
is of benefit for other causes of hypoxemic respira-
tory failure. Uncomplicated respiratory failure with-
out hemodynamic instability is an appropriate use of
NIPPV and confers a benefit with regard to rates of
ETI, duration of ventilation, ICU stay, and compli-
cation rate.
• Exclusions:
 Severe or complicated hypoxemic respiratory fail-
ure, shock, need for airway protection, respiratory
arrest, or coexistent organ failure.
• There is conflicting evidence regarding the role of
NIPPV for postextubation respiratory distress.
• Evolving indications include respiratory failure due to
asthma exacerbations, patients undergoing fiberoptic
bronchoscopy with marginal oxygenation, and per-
sistent weaning failure from invasive ETI.
RESPONSE
• Evaluation of clinical response to the initiation of
NIPPV is critical to the successful implementation of
this therapy. The presence of trained personnel famil-
iar with the successful strategies in initiating NIPPV
facilitates patient tolerance.
• Clinical response should be assessed in a timely fashion.
Improvement in symptoms and physiologic parameters
(respiratory rate, tidal volume, gas exchange) is usu-
ally apparent within 1 hour, with patients failing to
demonstrate improvement unlikely to benefit from a
longer trial.
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29 COMMON MODES OF
MECHANICAL VENTILATION
William Schweickert
KEY POINTS
• Consider NIV in appropriate patients before intubating.
• Ventilator modes are divided into those in which pres-
sure is set by the clinician (pressure-preset modes)
and those in which tidal volume is set (volume-preset
modes).
• Advantages for pressure-preset modes are that variable
and responsive inspiratory flow rates may be more
comfortable for some patients.
• Advantages for volume-preset modes are that a lung-
protective strategy using volume assist-control has
been demonstrated in patients with acute lung injury
and ARDS, and that respiratory system mechanics can
be most easily measured and followed.
INTRODUCTION
• Advances in technology and critical care research
have created a wide range of approaches to sup-
porting the patient in respiratory failure. The most
basic question to be asked prior to any intubation
should be the following—Can the patient be sup-
ported with NIV?
NONINVASIVE VENTILATION (NIV)
• The role of noninvasive positive pressure ventilation
(NIPPV) is rapidly increasing in clinical practice, and
should be considered as an option before intubation
and ventilation.
• Clinical scenarios that clearly warrant consideration
of such include patients with respiratory failure in the
absence of hemodynamic and neurologic compro-
mise, or more specifically, acute exacerbations of
chronic obstructive pulmonary disease, acute cardio-
genic pulmonary edema, and postoperative ventila-
tory failure.
CONVENTIONAL MODES 
OF MECHANICAL VENTILATION
• Once intubation and mechanical ventilation are an
established necessity, the next clinical question is:
Does the clinical scenario and physician experience
dictate a choice of volume-preset or pressure-preset
mode of mechanical ventilation? Categorizing
mechanical ventilation based on these headings can
assist in defining the four most common (“conven-
tional”) modes of mechanical ventilation used in clin-
ical practice. Either approach can provide full
ventilatory support or allow for substantial patient
exercise.
• All of the modes rely on a clinician-determined
inspired fraction of oxygen (FiO2) and positive end-
expiratory pressure (PEEP), used primarily to modu-
late oxygenation. These variables are discussed in
detail at the end of the chapter.
VOLUME-PRESET MODES
ASSIST-CONTROL (A/C) OR CONTROLLED
MANDATORY VENTILATION (CMV)
• The clinician sets the tidal volume (Vt), minimum res-
piratory rate (f), and inspiratory flow rate (V˙ ).
• The ventilator delivers the set tidal volume every time
a breath is triggered by the patient. The inspiratory
time (Ti), expiratory time (Te), and their ratio (I:E) are
dictated by the Vt and V˙ .
• Passive patient: If the patient’s spontaneous rate is
less than the ventilator’s set rate or if the patient is
paralyzed, the ventilator delivers tidal volumes at the
set rate.
• Active patient: Increases in the patient’s spontaneous
respiratory rate increase the minute ventilation deliv-
ered by the ventilator (i.e., the full tidal volume set is
delivered for every breath).
COMMON CLINICAL USE
• This mode is frequently applied in patients with acute
respiratory distress syndrome (ARDS), given evidence
that ventilation with low tidal volumes (≤ 6 cc/kg ideal
body weight) improves overall mortality. In general, it
is commonly used when the goal of care is to mini-
mize the work of breathing.
ADVANTAGES
• Permits the measurement of respiratory mechanics.
• Ensures adherence to low tidal volume ventilation,
even in the presence of changes in compliance of the
respiratory system.
DISADVANTAGES
• Significant elevations in ventilator pressures may
ensue in the setting of decreased respiratory compli-
ance or increased airways resistance.
• In the presence of high inspiratory effort, the patient
may trigger a second, superimposed breath, preclud-
ing rigid control of the tidal volume delivered.
• Obstructed patients can increase minute ventilation to
jeopardize exhalation time and risk-resultant PEEPi
(intrinsic PEEP).
SYNCHRONIZED INTERMITTENT MANDATORY
VENTILATION (SIMV)
• The clinician sets Vt, f, and V˙ .
• The ventilator delivers exactly that number (f) of tidal
volumes every minute, synchronizing those manda-
tory breaths with the patients’ triggering efforts.
• Passive patient: identical to A/C ventilation.
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• Active patient: Spontaneous efforts between ventilator-
delivered breaths are unassisted. The resultant (addi-
tional) breath’s Vt, V˙ , and inspiratory and expiratory
duration are determined by patient effort and respira-
tory system mechanics. Often they are quite variable,
frequently short duration and small in volume.
COMMON CLINICAL USE
• Often used to permit gradual increases in patient work
of breathing via lowering of the mandatory f and/or Vt.
However, this modality of weaning has been demon-
strated to prolong ventilator dependence.
• Often used to limit minute ventilation in deeply
sedated patients with severe airflow obstruction and
dynamic hyperinflation.
• Patients without lung disease requiring intubation, in
whom a concern for central drive cessation is
possible.
ADVANTAGES
• Respiratory mechanics can be measured on mandated,
ventilator-assisted breaths (only).
DISADVANTAGES
• Studies document inferiority as a weaning mode.
PRESSURE-PRESET MODES
PRESSURE CONTROL VENTILATION (PCV)
• The clinician sets the inspiratory pressure (Pinsp),
PEEP, f, and I:E ratio or Ti.
• The ventilator then delivers whatever flow rate and
volume are required to maintain the Pinsp for the
set Ti.
• Passive patient: Vt depends on a complex interplay
of respiratory mechanics, pressure, Ti, and dynamic
hyperinflation.
• Active patient: May demonstrate distress, unless ade-
quately sedated. Otherwise, respiratory effort can
change Vt (in either direction, depending on magni-
tude and timing of effort).
COMMON CLINICAL USE
• In ARDS patients, Palv should not exceed 30 cmH2O
in an attempt to avoid overdistention. The clinician
can rigidly adhere to that limit by setting Pinsp to a
value equaling ideal Pplat (usually ≤30); however, this
approach has not been demonstrated to protect the
lung adequately from ventilator-induced injury.
• Permits the utilization of salvage therapies for ARDS,
such as inverse ratio ventilation (IRV), in which Ti
exceeds Te.
ADVANTAGES
• May be the most comfortable mode for the patient
with high drive, since the flow rate and profile are not
limited.
DISADVANTAGES
• Increased airway resistance or decreased compliance
can result in marked hypoventilation (as resultant
volume per pressure supplied falls).
• Most physicians and respiratory therapists are not
familiar with this mode of ventilation. This becomes a
clinical setting where errors may increase.
PRESSURE SUPPORT VENTILATION (PSV)
• The clinician sets ONLY Pinsp and PEEP.
• The ventilator then delivers Pinsp whenever the
patient triggers a breath, at whatever flow is necessary
to maintain Pinsp. Inspiration is terminated when the
inspiratory flow rate falls to a threshold or fraction
of initial flow (either via cessation of patient effort or
increasing elastic recoil of the respiratory system as
Vt increases).
• Passive patient: PSV requires a central ventilatory
drive and neuromuscular coupling so this mode is not
applicable in fully passive patients.
• Active patient: The minute ventilation is determined
by the Pinsp and respiratory mechanics combined
with the patient’s respiratory rate and effort.
COMMON CLINICAL USE
• Utilized for titration of patient effort during liberation
from mechanical ventilation.
• Patients with unimpaired respiratory drive and stable
compliance of the respiratory system. Example:
patients intubated for angioedema alone.
• Deeply sedated patients with severely obstructive
airways (this requires vigilant monitoring for
apnea).
ADVANTAGES
• Improved patient comfort (compared with volume-
preset modes) and subsequent ventilator synchrony.
DISADVANTAGES
• Lack of a backup respiratory rate (f) in the event of
apnea.
• Potential decreases in minute ventilation in the event
of changes in respiratory system compliance or
resistance.
• Similar to A/C, high respiratory rates can lead to the
development of PEEPi.
• No direct measurement of respiratory system mechanics.
CONTINUOUS POSITIVE AIRWAY 
PRESSURE (CPAP)
• Not a unique mode of mechanical ventilation since the
ventilator pressure is constant (i.e., there is no inspi-
ratory assistance).
• This is used for spontaneous breathing trials, in which
the ventilatory support is minimized, while still per-
mitting accurate evaluation of respiratory rate and
tidal volume (see Chap. 33).
MIXED MODES OF VENTILATION
• Ventilators will often allow for the combination of the
above modes, most commonly the usage of SIMV
plus PSV.
• The clinician programs the SIMV as outlined above.
In addition, a Pinsp is programmed into the ventilator.
• The ventilator delivers the exact number (f) of tidal
volumes (Tv) every minute, synchronizing the manda-
tory breaths with the patient’s triggering efforts.
Spontaneous efforts between the ventilator-delivered
breaths are then augmented with the Pinsp.
• The clinical utility of this mode is unclear, but has
been applied in the following settings:
 The addition of sighs (via the SIMV—volume-
controlled breaths) to traditional PSV.
 The patient in whom central respiratory drive is not
guaranteed (e.g., central nervous system [CNS]
injury or deep sedation) and PSV is the desired
mode. The SIMV contribution will guarantee a min-
imum minute ventilation.
MODULATING OXYGENATION
FRACTION OF INSPIRED OXYGEN (FiO2)
• It is only in the intubated setting that one can truly
achieve 100% tracheal oxygen concentration.
• One of the first goals is to reduce the FiO2 to <0.6 to
minimize further lung injury (levels higher than 0.6
are generally viewed as toxic).
POSITIVE END-EXPIRATORY PRESSURE
• Positive end-expiratory pressure is best viewed as a
continuous supply of positive pressure into the respi-
ratory circuit, used to recruit alveoli (expanding col-
lapsed units and translocating fluid from flooded units
into the interstitial space) and to prevent alveolar dere-
cruitment at end-expiration. These mechanisms serve
to diminish intrapulmonary shunt and facilitate a
decrease in FiO2.
• An additional role of PEEP is to assist in the manage-
ment of patients with obstructive lung disease, in
whom PEEP can lower the inspiratory threshold load
associated with PEEPi.
• Administration of PEEP may result in hypotension sec-
ondary to a rise in pleural (and therefore, right atrial)
pressure and to increased resistance to venous return.
Significant hypotension can be treated by reducing the
PEEP temporarily and then infusing fluids or vasoac-
tive drugs to restore cardiac output.
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30 MANAGING THE
VENTILATED PATIENT
William Schweickert
KEY POINTS
• Choice of ventilator settings depends on what is
wrong with the patient.
• PEEP should be set generally no lower than 5 cmH2O
and higher in patients who require it for oxygenation
or who are obese and prone to alveolar collapse at low
values.
• When the respiratory system is normal (no intrinsic
lung or chest wall disease), nearly any mode is accept-
able as long as the patient is comfortable.
• Patients with acute lung injury (ALI) or ARDS should
be ventilated with volume assist-control with tidal
volume set at 6 cc/kg ideal body weight. Patients at risk
for ALI may also benefit from these “lung-protective”
tidal volumes.
• Patients with severe airflow obstruction should be
ventilated with modest minute ventilation (generally
<8 L/min) to reduce the risk of dangerous dynamic
hyperinflation. PEEP assists the patient with triggering.
• Patients with restrictive lung or chest wall disease
should be ventilated with small tidal volume and rapid
rates.
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OVERVIEW
• Ventilator settings vary depending on the goals of
ventilation (i.e., full rest vs. exercise), the etiology of
respiratory failure, minute ventilation needs, and the
comfort and familiarity of the physician with various
modes.
• This chapter defines the five most commonly encoun-
tered types of patients with respiratory failure and
supplies ventilatory strategies, including overall goals
and specific ventilator modes and settings.
PATIENTS WITH NORMAL RESPIRATORY
MECHANICS AND GAS EXCHANGE
• Patients with normal respiratory mechanics and gas
exchange requiring mechanical ventilation are not
uncommon. Examples of such situations include:
(1) absence of central drive to breathe (narcotic over-
dose); (2) neuromuscular weakness (amyotrophic
lateral sclerosis [ALS]); (3) upper airway obstruc-
tion (angioedema); and (4) hyperventilation therapy
(elevated intracranial pressure).
• Initial volume-preset ventilator settings include an
FiO2 of 0.5–1.0, tidal volumes of 8–12 cc/kg, respira-
tory rate of 8–12 breaths/min, and an inspiratory flow
rate of 60 L/min.
• Initial pressure-preset ventilator settings—if the patient
has an intact central respiratory drive and is not exces-
sively weak—include pressure support of roughly 10
cmH2O above positive end-expiratory pressure (PEEP),
which commonly generates tidal volumes of 1 L and
spontaneous respiratory rates around 10 breaths/min.
• Regardless of the choice of mode, the administration
of small amounts of PEEP (5 cmH2O) is often neces-
sary to prevent atelectasis.
PATIENTS WITH ACUTE HYPOXEMIC
RESPIRATORY FAILURE
• Acute hypoxemic respiratory failure (AHRF) or type I
respiratory failure is the result of alveolar filling
(with blood, pus, or edema) or alveolar collapse. The
resultant intrapulmonary shunt is characterized by
hypoxemia that is minimally responsive to oxygen
therapy.
• AHRF can be subdivided into diffuse and focal lung
lesions. Diffuse lesions may be high-pressure (hydro-
static, cardiogenic) or low-pressure (acute respiratory
distress syndrome [ARDS]) pulmonary edema. Focal
lesions are often caused by lobar pneumonia or lung
contusion.
• The goals of ventilation are to reduce intrapulmonary
shunt, to avoid toxic concentrations of oxygen, and to
select a ventilation strategy that does not propagate
further lung injury.
• Initial therapy includes supplemental oxygen therapy
in the highest concentration available—the initial
FiO2 should be 1.0 in view of the typically extreme
hypoxemia (but this can be lowered promptly in most
patients, guided by pulse oximetry).
• In diffuse lung lesions, the primary modality for
reducing intrapulmonary shunt is the administration
of PEEP, which recruits collapsed alveoli and translo-
cates fluid from flooded units, and prevents derecruit-
ment at end-expiration. PEEP may not be helpful in
focal disease such as labor pneumonia.
EXAMPLE: LOW-PRESSURE EDEMA
(ACUTE RESPIRATORY DISTRESS SYNDROME)
• Positive end-expiratory pressure should be instituted
immediately, beginning with 10 cmH2O then rapidly
adjusted to either:
 The least PEEP necessary to produce an arterial sat-
uration of 88% on an FiO2 no higher than 0.6 (the
“least PEEP” approach).
 A value of 2 cmH2O higher than the lower inflection
point of the inflation pressure-volume curve (“open-
lung approach”). This more complex method has
not been shown to be superior to the simpler “least
PEEP” method.
• The tidal volume should be 4–6 cc/kg (ideal body
weight) on volume assist-control as larger tidal vol-
umes may overdistend the lung leading to ventilator-
induced lung injury.
• Alternatively, pressure-controlled ventilation may be
used, with an inspiratory pressure adjusted (and mon-
itored) to drive tidal volumes of 6 cc/kg ideal body
weight.
• In either mode, the respiratory rate should be set at
24–36 breaths/min as long as there is little intrinsic
PEEP (PEEPi; see below).
• An occasional consequence of this ventilation strategy
is hypercapnia, which is considered preferential to
alveolar overdistention.
EXAMPLE: HIGH-PRESSURE EDEMA (CARDIOGENIC)
• Positive end-expiratory pressure should be titrated
similarly to low-pressure edema (i.e., “least PEEP”).
PEEP almost never depresses circulatory function in
these patients since the pressure driving venous return
to the heart is so high.
• Low tidal volume strategies have not been proven to
reduce mortality in this setting, but it seems reason-
able to use this approach for high-pressure pulmonary
edema.
PATIENTS WITH SEVERE AIRFLOW
OBSTRUCTION
• The primary goal of ventilation is to minimize alveolar
overdistention and limit dynamic hyperinflation in an
attempt to avoid barotrauma and impairment of cardiac
output.
• The overall result of such ventilation strategy is
diminution of the minute ventilation and subsequent
elevation of PaCO2 (levels > 40 mmHg).
• The hypercapnia, combined with preexisting 
anxiety or distress, prompt routine administration 
of (deep) sedation. Therapeutic paralysis should 
be reserved only for salvage therapy in extreme
circumstances.
• An initial FiO2 of 0.5 generally suffices, as the gas
exchange limitations are generally limited to V/Q mis-
match. If requirements are determined to be higher,
re-evaluation for alveolar filling or collapse should be
initiated.
• Ventilation should be initiated utilizing A/C mode.
The tidal volume should be small (5–7 cc/kg), and the
respiratory rate should be (relatively) lower (10–12
breaths/min).
• A peak flow of 60 L/min with a square inspiratory
waveform is recommended. Higher flow rates do little
to increase expiratory time, and lower flow rates or
decelerating inspiratory waveforms can result in pro-
longing inspiration and limiting exhalation time. This
can exacerbate auto-PEEP.
• Dynamic hyperinflation and auto-PEEP (PEEPi)
occur when insufficient time has elapsed between
inflation cycles to allow for complete expiration of
tidal volume. It may occur in any situation in which
there is a high demand for ventilation, but occurs most
commonly in cases of airflow obstruction.
• In the event of PEEPi, the respiratory rate reduction is
the most powerful means by which to increase exha-
lation time. This can usually be achieved with deep
sedation with opioid medications.
• If the patient is triggering the ventilator, incremental
PEEP should be added to reduce the work of triggering.
PEEP levels should not exceed 85% of the PEEPi to
avoid the risk of further hyperinflation.
PATIENTS WITH ACUTE-ON-CHRONIC
RESPIRATORY FAILURE (ACRF)
• Most patients are intubated after days to weeks of
progressive deterioration; as a result, most patients
will appear exhausted and sleep with minimal
sedation.
• The primary goals of ventilation include full respira-
tory muscle rest (usually for 36–72 hours).
• In stable health, these patients usually have a resting
minute ventilation of 10 L/min or less with a resultant
compensated respiratory acidosis. This should be
recreated; more aggressive mechanical ventilation risks
severe respiratory alkalosis and bicarbonate wasting by
the kidney.
• Ventilation should be initiated utilizing A/C mode
with lower tidal volumes (5–7 cc/kg) and moderate
respiratory rates (20–24 breaths/min).
• Ventilation rules regarding oxygen supplementation
and inspiratory flows and waveforms are similar to
status asthmaticus.
• Patients still experiencing increased work of breathing
or progressive hypotension should be evaluated for
PEEPi, which may require administration of PEEP,
akin to status asthmaticus.
PATIENTS WITH RESTRICTION OF THE LUNGS
OR CHEST WALLS
• Restrictive diseases of the lungs (pulmonary fibrosis),
chest wall (kyphoscoliosis), or abdomen (morbid obe-
sity, tense ascites) can progress to overt respiratory
failure, either individually or in conjunction with (even
a small) ventilatory challenge.
• Goals of ventilation include small tidal volumes and
rapid rates to minimize the hemodynamic conse-
quences of positive pressure ventilation and to reduce
the likelihood of barotrauma.
• Any reversible causes of restriction should be
immediately addressed (e.g., paracentesis for
ascites). Sitting the patient up can reduce abdominal
pressure on the diaphragm, easing the work of
breathing.
• Ventilatory approaches to achieve eucapnia may cul-
minate in excessive intrathoracic pressures, which can
compromise the circulation and subsequently evolve
into hypoxemia. The clinician must recognize this
scenario, as administration of further PEEP may aug-
ment the problem, not solve it.
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31 RESPONDING TO CRISES IN
THE VENTILATED PATIENT
William Schweickert
KEY POINTS
• Unplanned extubations occur commonly and may
precipitate an urgent crisis.
• The distressed patient or alarming ventilator is best
assessed at the bedside with attention to lung exami-
nation, tracheal position, ETT position, ability to pass
a suction catheter through the ETT, and the shape of
ventilator waveforms. A chest radiograph and arterial
blood gas should generally be obtained unless the
basis for the crisis is readily apparent.
• Endotracheal and tracheostomy tubes that appear to
be in good position may not be.
• Hypotension may signal dynamic hyperinflation,
sedative effect, tension pneumothorax, or one of the
many causes applicable to critically ill patients.
• Pressure alarming (during volume-preset ventilation)
is often caused by ETT obstruction, patient distress,
or a change in the mechanical properties of the respi-
ratory system (e.g., worse edema or obstruction).
• Low-pressure alarms often point to leaks, a failed
ETT cuff, or ventilator disconnection.
OVERVIEW
• Ventilated patients are prone to a number of medical
crises. The problem may be easy to discern (unplanned
extubation); however, a ventilator alarm may be the
only signal of the impending crisis.
• The physician’s prompt recognition of the problem is
necessitated, and this chapter should provide a system-
atic approach for responding to such warning signals.
THE OBVIOUS CRISIS: UNPLANNED
EXTUBATION
• Unplanned extubation is common in the ICU, with
reported frequency ranging from 3 to 12%. Endotracheal
tube (ETT) or tracheostomy tube securement is para-
mount. Despite attention to this detail, the loss of artifi-
cial airway may occur in the agitated or delirious patient,
or in association with patient manipulation (routine nurs-
ing care or during diagnostic studies).
• Evaluate the patient immediately, but don’t just act.
Stop and review the patient—do they truly need to
be reintubated? Evaluate the work of breathing,
oxygenation status, and the ability to protect the
airway.
• Noninvasive ventilation may be a reasonable alterna-
tive if airway protection is not an issue. However, rec-
ognize its limitations—it should only be continued if
a clear improvement is experienced within 1–2 hours
of its initiation.
• Auscultation may reveal upper airway obstruction
(stridor), which may be palliated with noninvasive
ventilation or helium-oxygen mixtures (heliox).
• In the event of tracheostomy tube dislodgement, rec-
ognize the risk of the immature tract (<2 weeks old)
which can be lost, and replacement of the trac tube
may not be feasible or safe. When in doubt, reintubate
through the nose or mouth.
• If airway protection is compromised, avoid a secondary
aspiration injury by applying cricoid pressure until the
reintubation is complete.
THE REMAINING CRISES: RESPONSE
ALGORITHM
THE PRIMARY EVALUATION—GO 
TO THE BEDSIDE!
• Inspect vital signs, the patient, and ventilator waveforms.
 Clues to patient distress may be as subtle as diaphoresis
to the obvious wide-eyed patient with limbs akimbo.
 The trachea should be midline with symmetrical rise
of the chest. Listen for bilateral equal breath sounds
(entertaining pneumothorax or collapse).
 Abdominal paradox should be evaluated with a hand
on the abdomen feeling for patient synchrony with
inspiration or forced expiration.
 The ETT should be properly secured at a proven-
safe distance at the lip.
THE PRIMARY MANEUVER
• Whenever the quality of the artificial airway or ventilator
function is in question, the patient should be removed
from the ventilator and hand-bagged with 100% oxygen.
The clinician should note the ease of bagging the patient
and the resultant rise and fall of the chest.
HYPOXEMIA
• First, rescue the patient. Immediately apply increasing
oxygen to return the saturation to ≥88% and begin the
search for the cause of the deterioration.
• Review the possible mechanisms of hypoxemia:
hypoventilation, ventilation/perfusion inequality, shunt,
decrease in the mixed venous oxygenation, insufficient
inspired oxygen, and diffusion block (rarely clinically
present).
• Hypoventilation is usually obvious, signaled by con-
comitant hypercapnia.
• Ventilation/perfusion mismatch typically causes mild
hypoxemia that is easily corrected with supplemental
oxygen. Common culprits include airway secretions
and mucous plugging, both remedied by aggressive
suctioning. Bronchoconstriction, another common
mediator, can be recognized by a high peak to plateau
airway gradient during volume-preset ventilation.
• Shunt, recognized by its relative refractoriness to
increased FiO2, may be explained by progression of
the primary cause of respiratory failure, or may impli-
cate a new process. Atelectasis, ventilator-associated
pneumonia, or pulmonary edema should be evident
when combining the physical examination and chest
x-ray. In general, diffuse lesions respond to positive
end-expiratory pressure (PEEP), while focal lesions
may require patient repositioning or maneuvers to
maximize blood flow to the nondiseased lung.
• Mixed venous desaturation is detected by analyzing a
venous blood sample, and invokes nonpulmonary
causes of hypoxemia. Reductions in cardiac output
(e.g., myocardial infarction) or hemoglobin concentra-
tion (e.g., gastrointestinal bleed) or increased systemic
oxygen consumption (e.g., fever) may be culprits.
HYPOTENSION (SOON AFTER INITIATION
OF MECHANICAL VENTILATION)
• Shock is common in the ICU, and the clinician should
have a focused approach to its diagnosis. However,
abrupt hypotension following initiation of mechanical
ventilation has several key etiologies which should be
considered early.
• The introduction of positive intrathoracic pressure
effectively reduces venous return. In addition, anes-
thetic induction agents and sedatives frequently cause
venodilation. Both of these changes may uncover rel-
ative hypovolemia or right ventricular dysfunction.
Both respond well to fluids; however, right heart dys-
function may require additive vasoactive drug admin-
istration. One approach is to infuse norepinephrine in
the abruptly deteriorating patient (works to increase
inotropy, venoconstrict, and improve coronary blood
flow to the failing right heart), while dobutamine may
be considered in the volume replete, relatively hypoten-
sive patient.
• The physical examination provides clues to the two
most common other causes: dynamic hyperinflation
and tension pneumothorax.
• Dynamic hyperinflation usually responds to the pri-
mary maneuver—by disconnecting the patient from
the ventilator, the lungs are able to decompress.
Premorbid recognition of this condition is possible
through evaluation of flow waveforms (inability to
return to baseline) or through measurement of intrinsic
PEEP. Its treatment necessitates changing ventilator
settings to produce longer exhalation time or treatment
of the underlying disease.
• Tension pneumothorax is usually signaled by unilateral
decreased breath sounds, asymmetric rise of the chest,
tracheal deviation, hypoxemia, hypotension, and
increased pressure measurements on volume-preset
ventilation. It requires immediate recognition and
needle decompression, followed by tube thoracotomy.
VENTILATOR ALARM: “HIGH PRESSURE”
• This alarm signals the presence of obstruction of the
ETT, airway, or reduced lung, chest wall, or abdominal
compliance.
• Primary risks: (1) may signal worsening clinical status,
and (2) may result in hypoventilation of the patient
(ventilator potentially cycles prematurely to expira-
tion as the upper pressure alarm is reached).
• First, perform the “primary maneuver”—manual bag-
ging will remove the ventilator from the equation.
• Difficult bag ventilation should prompt passage of a
suction catheter through the ETT. Inability to pass the
catheter confirms artificial airway obstruction.
 Proximal obstruction may be caused by the
patient biting the ETT—evident on close physical
examination—which can be remediated by bite block,
sedative, or in extremes, a short-acting neuromuscular
blocker.
 In the absence of biting, the ETT may be kinked or
occluded by desiccated secretions. Attempt reposi-
tioning the head; if there is no improvement, reintu-
bation is necessitated.
• Difficult bag ventilation with an easily passed catheter
should direct attention to patient effort. This should be
apparent on examination (usually thoracoabdominal
asynchrony), and should be treated with increasing
sedative or adjustment to ventilator parameters.
 Always review the possible reasons for the respira-
tory distress (e.g., pain, withdrawal, and progressive
shock).
• Finally, if bagging remains difficult despite adequate
sedation and relief of patient effort, the resistance may
be caused by worsening compliance of the patient’s
respiratory system. Systematically evaluate for nar-
rowing of the lower airway (bronchoconstriction),
collapse or consolidation of the lung, pleural or chest
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wall (pneumothorax) process, or abdominal (tense
ascites) pathology.
• Combining the examination with chest x-ray should
help to identify the cause. Additionally, placing the
patient back on the ventilator and measuring peak and
plateau pressures as well as auto-PEEP will further
delineate the problem.
• Ventilator dysfunction—review appropriate settings
(tidal volume, flow, inspiratory time, alarm limit),
search for fluid pooling in circuit, or any other
kinking.
VENTILATOR ALARM: “LOW INSPIRATORY
PRESSURE/LOW EXHALED TIDAL VOLUME”
• Low-pressure alarms signal inspiratory effort by the
patient, a leak, or ventilator malfunction.
• Effort, as described above, should be recognizable
immediately by the examination.
• Large persistent leaks can occur within the ventilator,
at any point of connection, including around the ETT,
or through a bronchopleural fistula.
• Bag ventilation can isolate the problem to the ventila-
tor and its tubing versus the ETT and the patient.
• If hand-bagging reveals minimal resistance, an ETT
cuff leak is likely. This can be confirmed by listen-
ing over the neck or placing a hand over the mouth.
• Chest tube and pleural drainage systems should be
interrogated for air leak, confirming bronchopleural
fistula.
PROGRESSIVE RESPIRATORY ACIDOSIS
• An increasing PaCO2 may be first recognized only as
a result of increased patient agitation. The assessment
of the arterial blood gas proves its presence. It can
result from one of three processes: (1) decreased
minute ventilation (clearance), (2) increased carbon
dioxide production, or (3) increasing dead space.
• A fall in minute ventilation can be recognized by
comparing rate and tidal volume values with those
recorded by the therapist or saved in the ventilator’s
trend monitor.
• Increased carbon dioxide production may be mediated
by such processes as fever, shivering, and agitation.
Once recognized, each one has a distinct solution.
• Increasing dead space is the most challenging. Its
presentation can be elusive, and may represent such
diverse etiologies as pulmonary embolism, excessive
PEEP, and hypovolemia. This recognition is vital, as
instinctual increases in minute ventilation may exac-
erbate the underlying problem (e.g., auto-PEEP).
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32 USING RESPIRATORY
WAVEFORMS TO ADJUST
VENTILATOR SETTINGS
Steve Mathai
KEY POINTS
• Waveform displays of flow convey rapidly important
issues of ventilator mode and patient-ventilator
interaction.
• From the pressures during volume-preset, constant flow
ventilation, one can assess the respiratory mechanical
properties.
• Patients must be passive in order to determine mechani-
cal properties. It is essential to be able to recognize
patient effort.
INTRODUCTION
• In the mechanically ventilated patient, bedside respi-
ratory graphics (“waveforms”) are a useful method for
assessing ventilatory status and determining response
to certain interventions.
BASIC WAVEFORMS
• Because patient effort can affect the waveforms, a
passive patient is a prerequisite for determining accu-
rate mechanical information.
• Effort can be recognized by transient drop in pressure
before a breath (signaling triggering), scooping of the
inspiratory pressure during constant flow, and vari-
ability in pressure waveforms.
PRESSURE-TIME WAVEFORMS
• Used for ventilator mode recognition, synchrony
between patient and ventilator, assessment of ade-
quacy of paralytic dose, among others (Fig. 32-1).
• By setting a brief end-inspiratory pause (e.g., 0.4 sec-
onds), the components of the airway opening pressure
can be subdivided into resistive and elastic compo-
nents (Fig. 32-2):
 The resistive pressure is related to flow and resist-
ance. This value is normally only 4–8 cmH2O when
flow is roughly 1 L/min.
 The elastic component is comprised of volume, com-
pliance, and positive end-expiratory pressure (PEEP)
or auto-PEEP. The elastic pressure is normally about
5 cmH2O when the tidal volume is 500 mL.
• These components can signal how the respiratory
system is deranged, serve to direct therapy, and reveal
changes related to treatment or time.
• Pressure on vertical axis, time on horizontal axis, pos-
itive pressure-upward deflection, negative pressure-
downward deflection.
VENTILATOR MODE RECOGNITION
• Volume-preset modes: assist-control (A/C), synchro-
nized intermittent mandatory ventilation (SIMV):
 Volume is selected by clinician, pressure determined
by respiratory system compliance and airway
resistance.
 A/C: volume, rate, inspiratory time, and sensitivity
(pressure that must be overcome during patient ini-
tiated breath to trigger delivery of breath by ventila-
tor; usually set at -2 cmH2O) selected:
 When patient initiates breath, ventilator delivers a
breath of set volume to patient.
 SIMV: volume, rate, inspiratory time, and sensitivity
selected for mandatory breaths:
 When patient initiates spontaneous breath
between mandatory breaths, he or she receives
only the self-generated volume (Fig. 32-3).
• Pressure-preset modes: pressure control (PC), pres-
sure support ventilation (PSV):
 Pressure is selected by clinician and is constant
throughout inspiration.
 PC: inspiratory pressure, rate, inspiratory time, and
sensitivity selected by clinician:
 When patient initiates breath, ventilator delivers
set pressure; volume delivered varies.
 PSV: inspiratory pressure and sensitivity selected by
clinician:
 Spontaneous breathing mode with constant pres-
sure delivered during inspiration until flow rate
decreases by some amount (Fig. 32-4).
SYNCHRONY BETWEEN PATIENT AND VENTILATOR
• Inspiration is normally shorter than expiration (normal
ratio 1:2 or 1:3).
• During volume-preset modes, inspiratory time
depends on inspiratory flow, set by clinician.
• When flow rate is too slow for the patient’s demand,
the inspiratory pressure waveform shows a “scooped”
appearance (Fig. 32-5). This may be corrected by
increasing the flow rate, raising the minute ventila-
tion, or sedating the patient.
• When inspiratory flow rate is too fast, the patient may
become uncomfortable and peak inspiratory pressures
(PIP) rise.
DETECTION OF AUTO-PEEP
• Auto-PEEP: end-expiratory alveolar pressure exceeds
pressure at the airway opening.
• Occurs secondary to insufficient expiratory time, high
minute ventilation, and expiratory airflow limitation.
• If auto-PEEP is present, baseline pressure on wave-
form will rise to auto-PEEP level following an end-
expiratory occlusion maneuver (Fig. 32-6).
ASSESSMENT OF ADEQUACY OF PARALYTIC DOSE
• Monitoring of adequacy of paralysis by peripheral nerve
stimulator may not be reliable in critically ill patients.
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FIG. 32-1 Pressure waveform of volume breath. In the passive
patient, the pressure rises smoothly and is convex upward.
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FIG. 32-2 Components of the pressure waveform. The top
figure shows the pressure waveform, while the three tracings
below reveal its components. The resistive pressure is found by
noting the difference between peak airway pressure and the
plateau pressure (at “x”) during a brief end-inspiratory pause.
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• Detection of “breakthrough breathing” (trigger
efforts, scooping of the inspiratory pressure) indicates
incomplete paralysis.
FLOW-TIME WAVEFORMS
• Used to assess auto-PEEP and response to therapy.
• Flow on vertical axis, time on horizontal, inspiration-
upward deflection, expiration-negative deflection.
• Different inspiratory waveforms for volume modes,
pressure modes, and spontaneous breaths:
 Volume modes: flow rate maintained throughout
breath (square flow waveform; Fig. 32-7).
 Pressure modes: flow at beginning of breath higher
than end of breath (decelerating flow waveform;
Fig. 32-7).
 Spontaneous breathing: flow is variable and gener-
ally decreases throughout the breath.
 Expiratory flow patterns are similar for all three.
DETECTION OF AUTO-PEEP
• Expiratory flow will not return to baseline (flow = 0)
prior to inspiration if auto-PEEP present (Fig. 32-8).
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FIG. 32-3 Pressure waveform of SIMV with mandatory and spontaneous breaths.
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FIG. 32-4 Pressure waveform of pressure breath.
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FIG. 32-5 Pressure waveform with inadequate flow and inspi-
ratory scoop. Notice the signs of effort (drop in pressure before
the breath, scooping of the pressure rise).
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FIG. 32-6 Pressure waveform with auto-PEEP. Note the rise in
pressure before the third breath, due to the end-expiratory pause
maneuver.
1.1
0
−1.1
I/s
FIG. 32-7 Square flow waveform of volume breath, decelerat-
ing waveform of pressure breath, and sinusoidal waveform of
spontaneous breath. Notice that volume-preset, constant-flow
breaths (left panel) have a square profile, while pressure-preset
breaths (right panel) typically show a decelerating flow profile.
BRONCHODILATOR RESPONSE
• Expiratory flow is impeded in bronchospasm.
• If bronchodilator therapy is effective, expiratory flow
may increase and return to baseline (flow = 0) more rap-
idly (Fig. 32-9), or the amount of auto-PEEP will fall.
PRESSURE-VOLUME LOOPS
• Used to assess changes in compliance and resistance.
• Orientation can vary, but most will have volume on
vertical axis and pressure on horizontal axis.
• Varies based on type of breath:
 Spontaneous breath: yields negative pressure as
breath is initiated and continues as inspiration pro-
gresses along with an increase in volume; with expi-
ration comes positive pressure and decrease in
volume as expiration ends.
 Mechanical ventilation breaths: yields positive pres-
sure as breath is delivered by ventilator along with
increase in volume; positive pressure diminishes
during expiration.
 Plotted counterclockwise (Fig. 32-10).
 If patient initiates breath, there will be a negative
pressure deflection that returns to positive deflec-
tion as breath is delivered by ventilator.
CHANGES IN COMPLIANCE
• Static compliance of the respiratory system can be
expressed by the following equation:
Static compliance = tidal volume/
(plateau pressure − PEEP)
• Normal compliance: 80–100 mL/cmH2O.
• Low compliance occurs with pulmonary edema, severe
pneumonia, ARDS, tension pneumothorax, pulmonary
fibrosis, kyphoscoliosis, and obesity.
• As compliance decreases, the pressure required to dis-
tend the lung increases.
 Results in shift in slope of pressure-volume curve to
the right.
• As compliance increases, the pressure required to dis-
tend the lung decreases.
 Results in shift in slope of pressure-volume curve to
the left.
CHANGES IN RESISTANCE
• Resistance in the pulmonary system results from fric-
tional resistance of the gas passing through narrow
tubes (airways, endotracheal tube), the secretions in
airways.
• As resistance increases, the inspiratory portion of the
pressure-volume loop will bow to the right.
FLOW-VOLUME LOOPS
• Used to detect response to therapy.
• Orientation can vary, but most will have flow on ver-
tical axis and volume on horizontal axis.
88 SECTION 3 • RESPIRATORY DISORDERS
70
0
I/m
in
Flow-time
FIG. 32-8 Volume breaths with impaired expiratory flow sec-
ondary to auto-PEEP. Flow persists at end-expiration, revealing
that the end-expiratory alveolar pressure is greater than the ven-
tilator expiratory pressure (i.e., auto-PEEP is present).
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FIG. 32-9 Square flow waveform with expiratory waveform
response to bronchodilator. Following successful bronchodila-
tion, expiratory flow may increase, as shown.
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FIG. 32-10 Pressure-volume loop: mechanical breath.
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RESPONSE TO BRONCHODILATORS
• Expiratory flow will improve with response to bron-
chodilator therapy.
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33 LIBERATION FROM
MECHANICAL VENTILATION
Mark C. Pohlman
KEY POINTS
• Liberation from mechanical ventilation is the process
by which patients are removed from the ventilator.
• This process has also been referred to as “weaning,”
but this implies a prolonged process of removal from
a benevolent device.
• Patients’ need for mechanical ventilation should be
assessed daily; most patients considered for “weaning”
don’t need any and can be promptly extubated.
• The SBT and calculation of the RSBI guide most assess-
ments about discontinuing mechanical ventilation.
• The following questions should be considered:
 What is the cause of the respiratory failure, and has
it been reversed?
 Is the patient capable of performing an SBT?
 How will the SBT be performed, and what is con-
sidered passing?
 How will the patient be managed after failing an SBT?
 What is the role of tracheostomy?
WHAT IS THE CAUSE OF 
RESPIRATORY FAILURE, 
AND HAS IT BEEN REVERSED?
• It is logical that unless the cause of respiratory failure
has been thoroughly addressed and reversed, liberation
of ventilation will not be possible. (Please see Chaps. 27
and 32 on respiratory failure and waveforms for more
discussion.)
• Causes that can slow the process of liberation can be
divided into two categories:
 Strength/drive
 Sedation
 Encephalopathy
 Malnutrition
 Muscle weakness
 Polyneuropathy of critical illness
 Electrolyte disturbance
 Circulatory adequacy
 Load
 Lung or chest wall compliance
 Airways resistance
 Minute ventilation requirements
WHICH PATIENTS ARE CAPABLE
OF PERFORMING AN SBT?
• Prior to assessing liberation parameters and perform-
ing a spontaneous breathing trial (SBT), the patient
should meet several requirements:
 Oxygenation (PaO2 > 60 on FiO2 ≤ 50%, and positive
end-expiratory pressure [PEEP] ≤ 8).
 pH ≥ 7.25 (metabolic acidosis increases respiratory
rate [RR] and places a “load” on the patient).
 Hemodynamic stability (i.e., no active malignant
arrhythmias, cardiac ischemia, or critical hypoper-
fusion).
 Patient is initiating spontaneous breaths.
 Presence of cough and gag reflexes (SBT/weaning
parameters can be obtained without this).
• The most useful liberation parameter is the rapid shal-
low breathing index (RSBI), also referred to as rate
volume ratio (RVR).
• The RSBI aims to quantitate the clinical observation
that, when removed from the ventilator, patients who
still have ventilatory failure will breath rapidly and
shallowly, whereas those who have recovered will
breath more slowly and deeply. Multiple trials have
shown this index to have better sensitivity, speci-
ficity, positive predictive value, and negative predic-
tive value than other means of assessing ventilatory
readiness.
• RSBI sensitivity in multiple trials is about 70–90% in
predicting successful liberation.
 Threshold value < 105 bpm is “positive” and indi-
cates a likelihood of weaning success.
 However, false positives are the concern and the
positive predictive value is about 80%, and speci-
ficity of 11–64% (i.e., those who pass but require
reintubation or fail their SBT).
• PI
max
/negative inspiratory force (NIF)/maximum
inspiratory pressure (MIP):
 Measures pressure generated by patient from func-
tional residual capacity (FRC), and requires patient
effort.
 Poor indicator of success or failure of extubation.
• Minute ventilation (VE):
 Values <10 L/min thought to be an indicator of lib-
eration success; however, several large trials found
this to be a poor predictor of outcome.
 Values >15–20 L/min helped identify those likely
to fail.
• Too much importance is likely placed on obtaining
weaning parameters: an SBT is always preferred.
HOW IS AN SBT PERFORMED? 
WHAT IS CONSIDERED “PASSING”?
• A typical SBT involves one of four methods: setting
the ventilator to continuous positive airway pressure
(CPAP; generally at 5 cmH2O); pressure support (PS)
of 5 cmH2O over PEEP; PS of 7 cmH2O over PEEP;
or removing the ventilator and using a T-piece.
• Disadvantage of the T-piece method is the lack of res-
piratory monitoring (ventilator waveforms, VT, alarms,
and so forth).
• Monitoring is most important during the initial few
minutes, as this is when most patients fail.
• If the patient does not fail (see below) within the
first few minutes, then a trial of 30–120 minutes is
attempted.
• If the patient passes an SBT, extubation is successful
≥80–90% of the time (assuming that the endotracheal
tube [ETT] is no longer needed for other problems).
• Objective criteria used to indicate “success” during
the SBT include:
 Oxygenation/ventilation
 SpO2 ≥ 85–90% or PaO2 ≥ 50–60
 pH ≥ 7.32, increase in PaCO2 ≤ 10
 Hemodynamic stability
 Not requiring significant vasopressors
 Heart rate (HR) < 120–140 bpm, change < 20%
 SBP < 180–200, but > 90, and no change > 20%
 Breathing pattern
 RR ≤ 30–35
 Not increased by >50%
• Subjective criteria used to indicate “success” during
the SBT include:
 No mental status changes (agitation, anxiety, lethargy,
or somnolence)
 No visible discomfort
 No diaphoresis
 No signs of dramatically increased work of breath-
ing (accessory muscles, abdominal paradox, respi-
ratory alternans)
HOW ARE PATIENTS MANAGED 
AFTER FAILING AN SBT?
• Two large randomized trials have evaluated the weaning
process. In both, the majority of patients considered
for weaning are already sufficiently recovered so as to
be ready for extubation. For the minority of patients
who fail an SBT, alternate modes for weaning were
compared (T-piece vs. PS vs. synchronized intermit-
tent mandatory ventilation [SIMV]).
 In one, T-piece was found to be best, while in the
other, PS was superior.  Both trials found SIMV to
delay weaning.
• Another trial found that identifying patients capable
of breathing spontaneously leads to a reduction in
duration of mechanical ventilation of 1.5 days, and
therefore appropriate patients should be screened and
SBTs should be conducted each day.
 This trial also found that weaning protocols (nurse-
or respiratory therapist-driven) lead to shorter dura-
tion of mechanical ventilation.
• Between SBTs, a stable, nonfatiguing mode of venti-
lation should be used (e.g., volume assist-control or
sufficient PS). There is no role for SIMV.
WHAT IS THE ROLE 
OF TRACHEOSTOMY?
• Many possible benefits of tracheostomy are theoreti-
cal and have not been demonstrated conclusively in
good clinical trials. Possible benefits include:
 Improved patient comfort
 Effective airway suctioning
 Decreased airway resistance
 More secure airway
 Ability for speech, eating
 Mobility
 Decreased incidence of ventilator-associated
pneumonia
 More rapid weaning from ventilator
• No data clearly support that tracheostomy reduces
risk of ventilator-associated pneumonia.
• It is not clear that early versus late tracheostomy
reduces duration of prolonged mechanical ventilation.
• Tracheostomy should be considered after the patient
has been stabilized on the ventilator and it appears pro-
longed (>2 weeks) ventilator support may be necessary.
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34 VENTILATOR-INDUCED
LUNG INJURY
Shashi Kiran Bellam
KEY POINTS
• Positive pressure ventilation can lead to functional
and structural changes in the lungs, especially in the
setting of underlying lung injury, and these changes
can be termed VILI.
• VILI encompasses macroscopic air leakage (baro-
trauma), microscopic changes in lung function and
structure, and the production of inflammatory media-
tors which may drive systemic inflammation and
organ-system dysfunction.
• VILI has been shown to be related to excessive pres-
sures as well as tidal volumes (volutrauma).
• VILI has been shown to be more common in younger
and smaller animals.
• The most impressive clinical study related to minimizing
VILI was the ARDS-NET “ARMA” trial which demon-
strated that using tidal volumes of 12 mL/kg ideal body
weight during mechanical ventilation of patients with
acute lung injury or ARDS leads to greater mortality than
using tidal volumes of 6 mL/kg ideal body weight.
• Ventilator management of patients with exudative-
phase ARDS should begin with a FiO2 of 1.0, tidal
volume of 6 mL/kg ideal body weight, and respiratory
rate 24–36 breaths/min. During initial stabilization on
the ventilator, heavy sedation is advisable to minimize
oxygen consumption.
• Goals of supportive therapy include achieving 88%
saturation of an adequate hemoglobin on a nontoxic
FiO2 (<60%).
VENTILATOR-INDUCED LUNG 
INJURY (VILI)
• Barotrauma—a macroscopic injury to the airways
leading to pneumothorax, pneumomediastinum, pneu-
moperitoneum, and subcutaneous emphysema.
 Early studies correlated barotrauma to peak airway
pressures, level of positive end-expiratory pressure
(PEEP), tidal volume, and minute ventilation, but
these correlations appear poor, at best.
 Other studies have only demonstrated a correlation
or worsening barotrauma in the setting of acute res-
piratory distress syndrome (ARDS).
 Gas-trapping (or auto-PEEP) has been shown to
relate to the development of barotrauma.
 Underlying lung diseases (such as asthma, chronic
obstructive pulmonary disease, and pneumonia) are
risk factors for the development of barotrauma.
 Barotrauma may often be occult with plain chest
x-rays unrevealing.
 Significant barotrauma may lead to hemodynamic
consequences (e.g., a tension pneumothorax).
• Microscopic lung injury—abnormalities of the alveolar
walls, surfactant dysfunction, and lung damage (consis-
tent histologically with ARDS) that signify functional
and anatomic changes that occur with mechanical
ventilation.
 Early animal studies have demonstrated micro-
scopic lung injury that correlated to the peak airway
pressures.
 Clinical human studies have failed to confirm the
importance of peak airway pressures as a predictor
of the development of microscopic lung injury;
more likely, plateau airway pressure (which more
closely represents lung stretch) predicts the devel-
opment of microscopic lung injury.
 Lung injury related to tidal volumes (volutrauma)
has been shown to correlate with some markers of
microscopic lung injury—even with negative pres-
sure ventilation, confirming that lung stretch, not
pressures per se, are responsible for injury.
 Heterogeneity of lung disease and injury may lead to
regional differences in volume and pressure which
may lead to regional microscopic lung injury without
obvious whole lung overdistention (volutrauma) or
elevated airway pressures.
 Low PEEP levels have been shown to lead to micro-
scopic lung injury in experimental animals, presum-
ably due to cyclic opening and closing of alveoli
(atelectrauma), which can be ameliorated by higher
levels of PEEP.
• Biotrauma—inflammatory mediators induced by
cyclic stress or shear.
 Various cells (epithelial, endothelial, fibroblasts,
and white blood cells) can be induced to produce
inflammatory mediators from lung stretching.
 Increased inflammatory mediators are not limited to
the lung and may drive systemic inflammation and
systemic organ-system dysfunction.
ACUTE RESPIRATORY DISTRESS
SYNDROME
• Definition:
 Diffuse pulmonary infiltrates in all four quadrants of
the lungs of acute onset.
 Hypoxemia with a ratio of partial pressure of arterial
oxygen (PaO2) to fraction of inspired oxygen (FiO2)
of <200.
 No evidence of elevated left atrial pressure.
• Greater than 50 causes have been identified, but the pri-
mary causes include: sepsis, aspiration of gastric con-
tents, pneumonia, trauma and burns, massive blood
transfusion, and drug reactions.
• Pathologic changes occur due to inflammatory injury
to alveoli leading to the histology of diffuse alveolar
damage.
• Clinical features include severe hypoxemia, decreased
respiratory system compliance, and elevated pulmonary
artery pressures.
• Common complications include barotrauma, commonly
manifested as pneumothorax.
• Mortality is estimated at 40%. Long-term survivors
may show relatively normal lung function and be
symptom-free.
• Treatment: ventilator strategies:
 Tidal volumes of 12 mL/kg ideal body weight are
clearly associated with higher mortality than lower
tidal volumes in the range of 6 mL/kg ideal body
weight. Since most patients weigh more than pre-
dicted based on height and gender, lung protective
tidal volumes may be closer to 4 mL/kg measured
weight, on average.
 Plateau pressures were maintained <30 cmH2O in
the low tidal volume group in the ARMA trial, but
the average for the group was only 26 cmH2O.
 Limiting tidal volumes may lead to hypercapnia, so
contraindications (such as increased intracranial
pressure) should be considered.
 In patients (as opposed to experimental animals)
levels of PEEP higher than necessary for oxygena-
tion have not been shown beneficial.
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35 ACUTE RESPIRATORY
DISTRESS SYNDROME
Nuala J. Meyer
KEY POINTS
• Patients with ALI or its most severe form, ARDS, present
with hypoxemic respiratory failure which is charac-
teristically resistant to oxygen therapy.
• Many primary insults can lead to ALI/ARDS, with
sepsis, pneumonia, and aspiration being the most
common.
• The clinician should seek to exclude other causes of
diffuse alveolar flooding and hypoxemia, including
pulmonary hemorrhage, atypical infection, or cardio-
genic pulmonary edema.
• Management of ALI/ARDS hinges on providing ade-
quate oxygenation, typically by intubation and
mechanical ventilation using PEEP.
• A ventilation strategy employing lung-protective
ventilation—tidal volumes of 6 mL/kg of ideal body
weight (IBW) and the maintenance of plateau airway
pressures below 30 cmH2O—reduces mortality in
ALI/ARDS.
DEFINITION
• The acute respiratory distress syndrome (ARDS) is a
clinical syndrome of severe lung injury which results
in damage to the alveolar-capillary membrane.
Numerous initial insults, either directly injurious to
the lung or indirectly injurious via systemic inflam-
mation, can result in a final pattern of lung inflamma-
tion, which in turn causes protein-rich fluid to leak
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into the alveolar space. ARDS is commonly referred
to as “low-pressure” or noncardiogenic edema.
• Acute lung injury (ALI) is defined as the acute onset
of respiratory distress with hypoxemia, bilateral pul-
monary infiltrates on frontal chest x-ray, and the
absence of any clinical evidence of left atrial hyper-
tension. The ratio of arterial partial pressure of oxygen
to the fraction of inspired oxygen (PaO2/FiO2 ratio) in
ALI is <300.
• ARDS describes those patients with the most severe
form of ALI. Like ALI, patients with ARDS have an
acute onset of respiratory distress, bilateral pulmonary
infiltrates on chest radiograph, and the absence of
evidence of left atrial hypertension, but hypoxemia is
more severe and characterized by a PaO2/FiO2 ratio
of <200.
• While historical definitions of ARDS often include “pul-
monary capillary wedge pressure (PCWP) < 18 mmHg”
as a criterion, pulmonary artery catheterization (PAC) is
not necessary to define ARDS.
EPIDEMIOLOGY
• Obtaining an accurate incidence for ARDS has been
notoriously difficult, but recent studies in the United
States and Australia cite an incidence of between 22
and 38 cases per 100,000 persons per year.
• Of patients entering European ICUs, approximately
7% met criteria for ARDS. ARDS accounted for 16%
of mechanically ventilated patients and 32% of
hypoxemic mechanically ventilated patients in the
same study.
• Mortality for ARDS remains high, at approximately
30% in the most recent trials. Mortality is as likely to
be from sepsis or multisystem organ failure as from
respiratory failure.
• As more patients survive, long-term outcomes such as
neuromuscular weakness, psychological difficulties, and
persistent dyspnea despite nearly normal pulmonary
function are becoming increasingly recognized.
ETIOLOGY
• Acute respiratory distress syndrome is a clinical syn-
drome incited by numerous initial events, both pul-
monary and extrapulmonary.
• Common pulmonary injuries include pneumonia,
aspiration, or pulmonary contusion.
• Sepsis, an extrapulmonary insult, is the most common
risk factor for ARDS. Other extrapulmonary etiolo-
gies include major trauma with multiple long bone or
pelvic fractures, hypertransfusion of blood products
(>10 units over a 12-hour period), disseminated intra-
vascular coagulopathy, or acute pancreatitis.
• The likelihood of developing ARDS increases with
the number of risk factors present.
• Several potentially treatable conditions can mimic
ARDS and should be actively considered and
excluded depending on patient history. They include:
 Acute eosinophilic pneumonia (AEP), characterized
by >20% eosinophils in bronchoalveolar lavage fluid.
 Acute hypersensitivity pneumonititis (HP), typically
with respiratory distress beginning within 6 hours of
organic exposure to birds or hay.
 Acute cryptogenic organizing pneumonia (COP),
best diagnosed by biopsy.
 Diffuse alveolar hemorrhage (DAH), which may be
present even when hemoptysis is absent. Unless
clinically obvious, the source of alveolar hemor-
rhage should always be sought with bronchoscopy.
Occasionally, angiography with embolization or sur-
gery is necessary for life-threatening hemorrhage.
 Pneumocystis pneumonia, or PCP, is pulmonary
infection with the fungus Pneumocystis jirovecii
(formerly Pneumocystis carinii) which is most often
encountered in patients with human immunodeficiency
virus or chronic corticosteroid therapy. Diagnosis is
made by staining sputum or bronchoalveolar lavage
fluid for P. jerovecii.
PATHOGENESIS
• Acute lung injury results from damage to the alveolar-
capillary membrane which allows proteinaceous fluid
to flood the alveolar space. Damage likely results from
damage to both the pulmonary capillary endothelium,
and to the alveolar epithelium.
• Type II respiratory epithelial cells, which typically com-
prise only 10% of normal respiratory epithelium, prolif-
erate in response to injury, yet become deficient in their
usual roles of fluid transport and surfactant production.
• The cascade of events causing such endothelial and
epithelial damage is not fully elucidated, but may
involve free radical damage from oxygen metabolites,
cytokine or leukotriene elaboration, complement fixa-
tion, or vasoactive substances.
• Both oxygen therapy, especially at FiO2 > 60%, and
ventilator stretch of the alveoli may also contribute to
lung injury.
CLINICAL FEATURES
• Acute respiratory distress syndrome is classically
described as passing through several distinct clinical,
radiographic, and pathologic stages.
• The initial or exudative phase involves an acute respi-
ratory decompensation, where the patient is often
extremely hypoxemic and relatively refractory to high
levels of inspired oxygen. As alveoli are flooded, the
patient’s alveolar dead space fraction rises, forcing the
patient to have a high minute ventilation to maintain
near-normal levels of arterial carbon dioxide.
 Patients are hypoxemic, extremely tachypneic, and
have a very low lung compliance (“stiff lungs”), man-
ifested by very high plateau airway pressures on the
ventilator when excessive tidal volumes are given.
 Chest radiographs at this phase show a rapid devel-
opment of bilateral infiltrates, often resembling car-
diogenic pulmonary edema.
 The pathologic description of this exudative phase is
“diffuse alveolar damage,” characterized by thicken-
ing and edema of the alveolar septae and spaces, with
hyaline membranes layering the alveolar epithelium.
• The subacute phase, often from days 5 to 7 onwards,
occurs in a subset of patients who fail to rapidly resolve.
These patients may have ongoing, oxygen-refractory
hypoxemia, low lung compliance, and persistent radio-
graphic infiltrates.
 Pathologically, the subacute phase is defined by
fibrosing alveolitis, whereby the alveolar ducts begin
to lay down collagen and fibroblasts in their septae.
• In a small proportion of patients, ARDS persists for
10 days or more, and pathologically enters a prolifer-
ative or fibrotic stage.
 Clinically, patients have persistent hypoxemia and
low lung compliance.
 Pathologically, extensive fibrosis is present, to the
extent that this stage may be difficult to distinguish
from any other form of pulmonary fibrosis.
 Radiographic studies, especially computed tomog-
raphy (CT), at this stage will often show cystic or
bullous formations in the lungs, predisposing the
patients to complications such as pneumothorax or
pneumomediastinum.
DIAGNOSTIC EVALUATION
• Bilateral pulmonary infiltrates on frontal chest x-ray
are necessary to meet criteria for ARDS (Fig. 35-1).
When patients with ARDS undergo CT, it often high-
lights striking inhomogeneity between areas of the
lung which are well ventilated and those which are
completely consolidated (Fig. 35-2). CT is not neces-
sary for the diagnosis.
• While ARDS may coexist with left ventricular failure,
ARDS is considered a low-pressure or noncardiogenic
form of edema. Appropriate approaches to distinguish
cardiogenic from noncardiogenic edema can be difficult.
 Echocardiogram to evaluate left ventricular func-
tion, combined with central venous catheterization
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FIG. 35-1 Chest radiograph of a patient with ARDS.
SOURCE: Adapted from Meyer NJ and Schmidt GA. Chapter 10C:
ARDS. In: Fein A, Kamholz S, Ost D, ed. Respiratory
Emergencies. London, England: Hodder Arnold, 2006;179–199.
FIG. 35-2 Chest CT image of the same patient with ARDS,
demonstrating heterogenous airspace flooding and consolidation.
SOURCE: Adapted from Meyer NJ and Schmidt GA. Chapter 10C:
ARDS. In: Fein A, Kamholz S, Ost D, ed. Respiratory
Emergencies. London, England: Hodder Arnold, 2006;179–199.
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to assess the right atrial filling pressure, can be help-
ful in confirming normal systolic function.
 PAC, with direct measurement of the PCWP, is also
possible, and historically a limit of 18 mmHg is con-
sidered the threshold below which ARDS is more
likely than left ventricular failure. However, PAC is not
necessary for the diagnosis of ARDS, and as PAC can
incur risk such as pulmonary embolism or arrhythmia,
we do not routinely advocate its use. A large multicen-
ter trial comparing PAC to central venous catheter in
this setting showed that the PAC conferred no benefit,
but was associated with more complications.
 Bronchoscopy with bronchoalveolar lavage can be
helpful to exclude treatable disease, such as AEP, DAH,
or an infectious agent. Lung biopsy can also be helpful
to exclude treatable conditions such as COP or HP.
 Edema fluid protein analysis, while not frequently
performed, can suggest low-pressure edema when
the initial edema-to-serum protein ratio is >0.6.
INTENSIVE CARE UNIT MANAGEMENT
• Most patients with ALI and ARDS will require intu-
bation with mechanical ventilation. All patients with
hemodynamic compromise in addition to ALI should
be intubated.
• Early use of noninvasive positive pressure ventilation
(NIPPV) can be considered, and has been proven to
decrease the rate of intubation and infection in immuno-
suppressed patients when compared to oxygen adminis-
tered by face mask. ARDS and sepsis are risk factors for
failure of NIPPV.
• Mechanical ventilation should achieve specific goals,
which have been validated in large multicenter trials:
 A lung-protective strategy, defined by tidal volumes
(Vt) ≤ 6 mL/kg of IBW, where IBW is calculated as =
50 + 0.91 (height in cm - 152.4) for males, and IBW =
45.5 + 0.91 (height in cm - 152.4) for females. For an
average male of 5'10'', IBW = 73 kg, and initial Vt
should be 438 mL. Similarly, an average woman of 5'4''
has an IBW = 55 kg, making the initial Vt 330 mL.
 Plateau pressure (PPLAT) should be ≤ 30 cm of water.
If PPLAT is >30 cm of water with a tidal volume of
6 mL/kg, tidal volume should be reduced further,
to as low as 4 mL/kg IBW.
 Permissive hypercapnia, whereby the PCO2 is
allowed to rise as tidal volumes are deliberately kept
low for lung protection, is generally a safe and
effective strategy without the use of sodium bicar-
bonate to offset the respiratory acidosis. In specific
patients—those with elevated intracranial pressure or
recently postmyocardial infarction—the PCO2 should
not be allowed to rise dramatically.
 PEEP—positive end-expiratory pressure—should be
employed in order to keep the fraction of inspired
oxygen (FiO2) in the presumed nontoxic range, below
0.6. PEEP is felt to decrease ventilator-induced lung
injury by lessening mechanical shear forces caused by
repetitive opening and closing of alveoli in atelectatic
regions of the lung, and reducing stretch between aer-
ated and collapsed lung regions. PEEP may also recruit
alveoli by preventing their collapse at end-expiration.
 Reducing the circulating volume of the patient with
diuresis or by withholding extra hydration may help
to decrease edemagenesis. A large clinical trial
showed that an aggressive diuretic regimen reduced
time on the ventilator for ALI/ARDS patients.
• Aside from diuresis, no pharmacologic therapy—
including corticosteroids, ketoconazole, inhaled nitric
oxide, surfactant, or prostaglandin therapy—has been
proven effective in reducing mortality or otherwise
changing outcomes in ARDS.
• With proper management, patients can survive to dis-
charge with resolution of symptoms and chest x-ray
findings (Fig. 35-3).
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36 EXTRACORPOREAL
MEMBRANE OXYGENATION
Anna N. Kamp
KEY POINTS
• Extracorporeal membrane oxygenation (ECMO)
improves outcome in neonates with severe respiratory
failure.
• Several trials in adults have failed to demonstrate any
advantage.
• ECMO should be considered a salvage strategy for
adults to buy time in the setting of potentially
reversible respiratory disease.
• Complications of ECMO include clotting, hemor-
rhage, accidental decannulation, air embolism, prob-
lems maintaining flow.
HISTORY
• Extracorporeal membrane oxygenation (ECMO) has
been used routinely since 1975; however, collection of
systemic data was not begun until 1985. Since 1989,
all neonatal, pediatric, and adult patients from partic-
ipating ECMO centers have been registered with the
Extracorporeal Life Support Organization (ELSO).
• The first successful use of ECMO support was in 1971.
An adult with acute posttraumatic respiratory failure
was maintained on ECMO for 3 days and survived.
• After this first adult survivor, about 150 additional
adults received ECMO for severe respiratory failure
with a survival rate of about 10–15%.
• A National Institutes of Health (NIH) sponsored mul-
ticenter prospective, randomized-controlled trial in
the late 70s of the use of ECMO for adults with acute
respiratory failure showed such a high mortality rate
that it was stopped early and for years, little research
was pursued in adults.
• It was not until 1974 that ECMO was first used in a
neonate. This sentinel case occurred at the Orange
County Medical Center in a neonate with severe meco-
nium aspiration whose PaO2 went as low as 12 mmHg
when a decision was made to try ECMO. After 3 days
on ECMO, the newborn recovered completely.
 After the initial success with a newborn, the physicians
involved continued to treat neonates with severe respi-
ratory failure with ECMO. While these infants had an
estimated 90% mortality rate, the infants supported on
ECMO were found to have a 75% survival rate.
However, this was not a randomized-controlled trial.
 The physicians reporting this success in neonates
in the late 1970s and early 1980s were met with
much skepticism because there was no randomized-
controlled trial.
• Because of the initial success with ECMO in neonatal
severe respiratory failure, several initial studies at the
University of Michigan and Boston Children’s
Hospital were organized using an adaptive design.
This adaptive design allowed for initial randomiza-
tion; however, the design was then adjusted so that
more patients would be randomized to the treatment
that seemed to be superior. These adaptive random-
ized studies showed a survival rate of 97% for ECMO
patients compared with a 60% survival rate for con-
ventional ventilator patients. However, there was still
much criticism of the adaptive design.
• In 1996, a true multicenter, randomized study was
conducted in the United Kingdom. This trial was
halted prematurely when early analysis showed a sta-
tistically significant survival rate of 70% for ECMO
infants compared with a 41% survival for the conven-
tional ventilator infants.
• There are about 120 centers worldwide that participate
in the ELSO registry. The ELSO originates from the
University of Michigan ECMO program. The registry
data are presented annually at the meeting of the
American Society of Artificial Internal Organs.
• Currently, there is an ongoing randomized trial in the
United Kingdom for ECMO in adults with severe res-
piratory failure.
INDICATIONS/CONTRAINDICATIONS
• It has been recommended, but not proven for all
instances, that ECMO be considered in acute severe
reversible respiratory or cardiac failure when the risk
of dying from the primary disease despite optimal
conventional treatment is 50–100%.
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• Because ECMO is a supportive measure, the main
requirement in considering ECMO is that the patient
has reversible disease.
• It is important to note that institutional experience
plays a large role in patient selection.
• Contraindications for the use of ECMO are based pre-
dominantly on the reversibility of the patient’s condi-
tion. ECMO is not a treatment; rather, it is a means by
which to sustain a patient while other treatments are
employed. Therefore, terminal disease, brain injury,
and cardiac arrest are some absolute contraindications.
Table 36-1 lists relative and absolute contraindications
to the use of ECMO.
• The oxygen index (OI) is a measurement that compares
the amount of ventilator support with the patient’s oxy-
genation. In neonates, ECMO is considered as the OI
increases toward 40.
OI =
MAP × FiO2 × 100
PaO2
where MAP is mean airway pressure in cmH2O and
FiO2 is expressed as a fraction of 1.
• In neonates, gestational age and birth weight are signif-
icant factors when considering a patient for ECMO.
Patients <34 weeks gestational age are at higher risk for
intracranial hemorrhage. Additionally, weight <2.0 kg
limits the use of ECMO due to the size of the catheters.
PHYSIOLOGY OF EXTRACORPOREAL
MEMBRANE OXYGENATION
• Extracorporeal membrane oxygenation may be deliv-
ered via venovenous (VV) or venoarterial (VA) cannu-
lation. VA cannulation is used commonly in pediatric
cardiac patients.
• VV cannulation drains the right atrium, usually
through the right internal jugular vein. Venous blood
drains from the right atrium by both venous flow and
aspiration by a siphon. Blood passes through a self-
regulating pump where it is pumped through a mem-
brane lung (referred to as the “oxygenator”); this is
where oxygen, water vapor, and carbon dioxide are
transferred. The oxygenated blood is then returned to
the patient.
 If the ECMO application is purely for respiratory
support, the oxygenated blood is returned to the
venous circulation, via cannulation of the femoral
vein or with a second catheter in the right internal
jugular vein. This is called VV cannulation. 
 However, if cardiac support is required, the oxy-
genated blood is returned to the arterial circulation,
usually through a catheter in the right common
carotid. This is called VA cannulation (Fig. 36-1).
• Once the ECMO circuit is attached and functioning,
circulation and gas exchange are supported mechani-
cally, and the native heart and lungs are “rested.” That
is, ventilator settings and inotropic support are
decreased to low, safe levels. ECMO support is con-
tinued until heart or lung function improves.
• The amount of blood flow through the circuit depends
on the degree of support required.
• While VA ECMO may seem to be conceptually iden-
tical to operating room cardiopulmonary bypass, it is
actually quite different in that it is partial bypass. The
patient is maintained at normothermia with normal
blood flow and normal hematocrit to maintain normal
systemic oxygen delivery (Table 36-2).
• An ECMO circuit has a semipermeable membrane of
silicone rubber between the blood and the gas, avoid-
ing a direct blood-gas interface, which is a significant
difference from an operating room (O.R.) cardiopul-
monary bypass machine.
• VA ECMO is run at about 80% of normal resting car-
diac output.
GAS EXCHANGE IN EXTRACORPOREAL
MEMBRANE OXYGENATION
• Oxygen delivery during ECMO is a combination of
blood oxygenation in the membrane, flow through the
circuit, cardiac output, and gas exchange through the
native lung.
 However, in planning the size of the ECMO circuit,
it is assumed there will be no gas exchange across
the native lung.
• Oxygenation in the membrane is described as the
“rated flow.” Rated flow is the amount of venous
blood that can be raised from a hemoglobin saturation
TABLE 36-1 Contraindications for the Use of ECMO
Relative
Ventilator 6–10 days
Immunosuppression
Systemic sepsis
Active bleeding
Absolute
Terminal disease
Brain injury
Ventilator >10 days
Septic shock
Cardiac arrest
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FIG. 36-1 A schematic of the venoarterial ECMO circuit.
SOURCE: Adapted from Wolfson PJ. The development and use of extracorporeal mem-
brane oxygenation in neonates. Ann Thorac Surg 2003;76:S2224–S2229.
of 75–95% in a specific time. The rated flow is used
to determine which type of membrane will be used for
ECMO and to evaluate how the membrane is func-
tioning during ECMO.
• If the extracorporeal blood flow is less than the rated
flow of the membrane, the blood leaving the mem-
brane will be fully saturated. Therefore, the oxygen
delivery is controlled by the blood flow of the circuit
and the oxygen uptake capacity of the patient.
• If the hemoglobin concentration is low, the amount of
oxygen that can be bound in the oxygenator is decreased.
• If the venous blood saturation is high, the amount of
oxygen that can be bound in the oxygenator is also
decreased.
• One can compensate for decreased oxygen uptake in
the oxygenator by increasing the flow of the circuit.
• In VV bypass, the arterial PO2 will be identical to the
mixed right atrial blood. The hemoglobin saturation
will usually be close to 80% with a PO2 of 40, and as
long as there is an increase in cardiac output to com-
pensate, oxygen delivery will be adequate.
 Improvement in native lung function will be identi-
fied as a step up from venous to arterial saturation.
• In VA bypass, however, the arterial blood gases may be
interpreted several ways, depending on the amount of
venous return going through the ECMO circuit and the
flow of the membrane. An increasing PO2 may be read as:
 Improving lung function at constant flows.
 Decreasing native cardiac output at constant extra-
corporeal flows.
 Increasing ECMO flow at constant native cardiac
output.
• The carbon dioxide removal in ECMO is determined
by the membrane lung surface area, the blood PCO2,
and membrane lung gas flow (called the sweep flow).
• The ventilating gas usually contains no CO2, so the
gradient for transfer of CO2 is the difference between
the blood CO2 and zero.
• As blood passes through the membrane lung, the
PCO2 drops; thus the gradient decreases and less CO2
is removed near the blood outlet end of the membrane
lung compared to the blood inlet end.
• Carbon dioxide transfer can be increased by increas-
ing both the sweep flow and the surface area of the
membrane lung.
• The ECMO circuit is extremely efficient at removing
CO2. For this reason, if the circuit is set to supply total
Membrane
lung
Bladder
Bridge
Fluids
Blood
drainage
Blood
return
Heat
exchanger
Heparin
Pump
TABLE 36-2 Venoarterial Mechanical Circulation
O.R. CARDIOPULMONARY
BYPASS ICU ECMO
Venous reservoir Yes No
Heparin (ACT) Large dose (>600) Titrated (120–180)
Autotransfusion Yes No
Hypothermia Yes No
Hemolysis Yes No
Anemia Yes No
Arterial filter Yes No
SOURCE: Adapted from Zwischenbeger JB, Bartlett RH, eds., ECMO:
Extracorporeal Cardiopulmonary Support in Critical Care. 3rd ed. Ann
Arbor, MI: Extracorporeal Life Support Organization; 2005:6.
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oxygen requirements, it will remove excessive CO2,
resulting in a respiratory alkalosis. Adding CO2 to the
sweep gas will decrease the gradient between the
blood PCO2 and the membrane lung, thus decreasing
the removal of CO2.
• If CO2 removal is the primary goal and the native lung
can supply oxygen absorption, CO2 removal can be
achieved with VV access and low blood flow. This is
termed extracorporeal carbon dioxide removal
(ECCO2R).
HEMODYNAMICS DURING
EXTRACORPOREAL MEMBRANE
OXYGENATION
• At initiation of ECMO, the exposure of blood prod-
ucts to artificial surfaces of the circuit and oxygenator
triggers an inflammatory response, leading to an
increase in capillary permeability. This capillary leak
lasts about 2–3 days as long as there is no associated
sepsis. The capillary leak itself resolves spontaneously;
however, the associated increase in total body water
may linger.
• Normal blood flow through the circuit to maintain
systemic perfusion is about 100 cc/kg/min.
• Blood flow through the extracorporeal circuit is lim-
ited by the size of the venous drainage catheter. The
shortest and largest diameter catheter that can be
placed in the right atrium will allow the highest rate of
blood flow.
• A catheter in the right internal jugular vein will usu-
ally allow venous drainage that approximates the
normal resting cardiac output of patients of all ages
and sizes.
• If total blood flow through the circuit is too low, the
result is inadequate oxygen delivery, shock, and aci-
dosis; this typically occurs at a flow <40 cc/kg/min.
• Resistance through the membrane lung and reinfusion
catheter causes the pressure on the oxygenated side of
the circuit to increase with increasing blood flow. These
postoxygenator pressures must be monitored because
higher pressures increase the chances of blood leaks or
circuit disruption.
• The redistribution of blood flow is significantly dif-
ferent between VV and VA ECMO.
 During VA ECMO, the blood is withdrawn from the
venous circulation and pumped through the circuit;
as a larger percentage of venous blood is directed
through the circuit, left ventricular preload decreases.
This results in normal mean arterial pressure but with
a reduced pulse pressure (since only the flow con-
tributed by the native circulation is pulsatile) and
dampened arterial waveform.
 During VV ECMO, blood is withdrawn and returned
to the venous circulation at exactly the same rate.
Therefore, there is no net effect on left ventricular
preload. The cardiac output is all native left ventri-
cular ejection.
• Hypertension on ECMO is a common complication.
 One etiology that has been investigated is the stim-
ulation of the renin-angiotensin-aldosterone axis by
the nonpulsatile flow to the kidney from the circuit.
This usually responds to vasodilator therapy with
angiotensin-converting enzyme (ACE) inhibitors,
nitroglycerine, and hydralazine.
 Other causes of hypertension include hypervolemia,
exogenous inotropes and pressors, and inadequate
sedation.
• The ECMO circuit is set up with a self-regulatory
system to avoid excessive negative pressure on the
venous circulation. There is a small collapsible bladder
in the venous line; when this bladder collapses, the pump
shuts off automatically. When the bladder refills, the
pump restarts.
 As ECMO is initiated and the circuit flow is increased,
the collapse of the bladder will identify the physical
limitations of the venous drainage. If this maximal
flow is not adequate to support the patient, additional
venous drainage may be necessary to increase flow.
 If the pump shuts off once ECMO has been ongoing,
it may signal other problems such as pneumothorax
or hypovolemia.
• The regulation of negative pressure on the venous cir-
culation is important to avoid serious problems with
the circuit.
 Negative pressure over 200 mm can cause hemolysis.
 The right atrium and superior vena cava can become
sucked into the catheter at high pressures and cause
endothelial damage.
 Negative pressure within the circuit can increase the
risk of air embolus.
• The University of Michigan group described a stan-
dard system for explaining the pressure flow in the
catheters called the “M number.” Using the M number
of a catheter, the pressure and flow of that catheter can
be determined using a nomogram.
• If ECMO is being used for cardiac support and the left
ventricle is not ejecting adequately, the left side of the
circulation can become overdistended. This can lead
to pulmonary edema or cardiac damage, and left-sided
decompression may be necessary.
 In neonatal VA ECMO, this is not a problem because
the left side can decompress via the patent ductus
arteriosus.
 In children and adults, however, just a few minutes
of left-sided overdistention can cause significant
pulmonary edema or cardiac damage.
 If cardiac failure is severe and the left ventricle is
not able to eject against the pressure of VA ECMO,
arterial resistance should be decreased by vasodila-
tory agents. If vasodilation is unsuccessful, left-sided
venting may be necessary. This can be achieved by
direct cannulation of the left atrium via thoracotomy
or by creating an atrial septal defect in the catheteri-
zation laboratory.
MANAGEMENT OF THE PATIENT 
ON EXTRACORPOREAL MEMBRANE
OXYGENATION
• Several monitors, in addition to patient vital signs,
blood gases, and ventilator settings, are used to main-
tain a patient on ECMO.
• Blood flow through the circuit is monitored continu-
ously. Blood flow is set at a level that will provide
appropriate oxygenation and CO2 exchange.
• Pressure is measured before and after the membrane
lung; an increasing pressure gradient across the
membrane lung may be a sign that thrombosis has
occurred.
• Mixed venous saturation is monitored continuously.
• Patient arterial blood gases are used to calibrate the
continuous monitors of the extracorporeal circuit.
• Systemic blood pressure is maintained by adjusting
the blood volume.
• Hemoglobin is maintained between 14 and 15 g/dL.
• Systemic anticoagulation is standard practice with an
extracorporeal circuit. Continuous heparin is given to
maintain the whole blood activated clotting time
(ACT) at about 180–200 seconds or less if the circuit
has a nonthrombogenic coating.
• Platelet transfusions are usually required to maintain
the platelet count >80,000 during ECMO.
• Ventilator settings while the patient is maintained on
ECMO are directed at recruiting alveoli while avoid-
ing ventilator-induced lung injury. Typically, the FiO2
is 20–30% and peak airway pressures are <40 cmH2O.
 Other methods of managing severe lung injury are
continued in an ECMO patient: lung-protective tidal
volumes; prone positioning (in neonates); postural
drainage; maintenance at dry weight; adequate
nutrition.
• Backup ventilator settings to provide full support are
posted near the patient in the event that ECMO is
abruptly discontinued.
• Measuring end-tidal CO2 in the airway is helpful in
assessing native lung recovery.
• Following the pulmonary and systemic mean blood
pressures during ECMO is a good indicator of the
likelihood of lung recovery.
COMPLICATIONS
PUMP COMPLICATIONS
• Clots in the circuit are the most common mechanical
complication. Major clots can lead to a consumptive
coagulopathy or oxygenator failure, as well as sys-
temic or pulmonary emboli.
• Cannulas can be a significant source of complications
while on ECMO.
 If the venous cannula is advanced too little or too
much, it can become obstructed, causing the pump
to shut down.
 The arterial cannula can be inserted too far into the
ascending aorta, causing increased afterload or aortic
insufficiency, or too far into the descending aorta,
compromising coronary and cerebral blood flow.
 Cannula placement should be confirmed using
echocardiography.
• Inadequate venous drainage can cause the pump to
“cut out” or quit pumping blood, and one must consider
all causes of decreased venous return in managing this
problem. Figure 36-2 outlines the management of low
venous drainage.
 If hypovolemia is the cause of low venous return,
correct it with fluid resuscitation or decrease the
flow rate of the pump.
 Any kinks in the tubing of the circuit can obstruct
venous return and should be assessed.
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Pump cutting out
↓
Give volume or decrease flow rate
↓
Increase height of bed
↓
Check venous catheter placement by chest x-ray and
echocardiogram
↓
Check for kinks in venous drainage lines
↓
Check bladder box function
↓
Change position of patient
↓
Ensure complete sedation/paralysis
↓
Consider additional venous catheter if necessary for adequate
venous return.
FIG. 36-2 Management of low venous drainage.
SOURCE: Adapted from Zwischenbeger JB, Bartlett RH, eds.,
ECMO: Extracorporeal Cardiopulmonary Support in
Critical Care. 3rd ed. Ann Arbor, MI: Extracorporeal Life
Support Organization; 2005:138.
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 An echocardiogram may be necessary to ensure that
cardiac tamponade is not the etiology of obstruction.
• If the circuit is squirting blood or pumping air, the
patient must be emergently removed from ECMO. To
emergently remove the patient from ECMO, the tech-
nician immediately clamps the Venous line, opens
the Bridge, and clamps the Arterial line (VBA)—a
common reminder for this management is that the
patient has had a Very Bad Accident. The patient must
then be hand-bagged or the ventilator settings adjusted
to pre-ECMO settings in an attempt to maintain respi-
ratory support.
• Massive air embolism, such as that which may develop
if a tear develops in the membrane lung, is the one
exception to the VBA rule. In this situation, the arterial
line is clamped first.
PATIENT COMPLICATIONS
• Bleeding complications are common because of sys-
temic heparinization.
• The neck cannulation site is most frequently the
source of moderate bleeding. Surgeons may vary in
their treatments to achieve hemostasis; however, if the
neck incision bleeds more than 10 cc/h for 2 hours
regardless of treatment strategies used, the neck
wound should be explored.
• Hemorrhages in the intrathoracic, abdominal, or
retroperitoneal cavities will need to be drained, as
allowing bleeding to tamponade in these sites is not
usually successful.
• A new intracranial hemorrhage is an indication to dis-
continue ECMO support. Most ECMO centers have
routine transfusion orders to maintain hemoglobin
levels, so routine pupil examination may be the only
indication of an intracranial hemorrhage.
• While a patient is on ECMO, it is unusual to have
severe hemodynamic instability. If this occurs, one
should immediately consider the venous catheter
placement, volume status, and circuit failure.
• A pericardial tamponade, tension pneumothorax, or
hemothorax may all present as decreased venous
return causing the pump to cut out. The ECMO circuit
does not affect the appearance of pneumothorax or
hemothorax on chest x-ray.
• Accidental decannulation is an emergent reason to
come off ECMO and is best avoided by adequate
sedation and paralytics.
• Hemolysis is a commonly recognized complication
and can often be attributed to the ECMO circuit, as
clots in the membrane can promote a coagulopathy.
However, disseminated intravascular coagulopathy
must be considered by checking ACT, platelet count,
fibrinogen, fibrin degradation products, prothrombin
time (PT), and partial thromboplastin time (PTT).
Then the circuit must be checked for clots, kinks, an
arterial catheter occlusion, and high temperatures and
pressures.
WEANING OFF EXTRACORPOREAL
MEMBRANE OXYGENATION
• Extracorporeal membrane oxygenation may be neces-
sary for anywhere from 1 day to 14 days or longer,
depending on the patient’s clinical situation.
• If the patient’s initial insult was severe respiratory
failure, one must look for evidence of native lung
recovery before attempting to wean off ECMO. This
includes: better breath sounds on physical examination
and improved chest x-ray, higher venous saturation
levels, increasing PaO2 or decreasing PaCO2 without
changing ventilator or ECMO settings, and improving
lung mechanics.
• For a patient with cardiogenic shock on VA ECMO,
evidence of cardiac recovery includes: increasing arte-
rial pulse contour, improving contractility by echocar-
diography, increasing mixed venous oxygenation with
no change in other parameters.
• As a patient improves and is approaching a weaning
trial, it is important to evaluate total body fluid and
maximize diuresis if possible, as most patients on
ECMO have a significant amount of third-spacing.
• Before beginning to wean, ensure the patient is prop-
erly sedated or paralyzed, as inadequate sedation con-
tributes to higher oxygen consumption and may result
in failure to wean from ECMO.
• Ventilator settings should be gradually increased
to recruit collapsed lung tissue prior to weaning
off EMCO.
OUTCOMES EVIDENCE IN ADULTS
• The National Heart, Lung, and Blood Institute of the
NIH conducted a randomized-controlled trial at nine
medical centers of severe acute respiratory failure in
1975–1979. Patients were randomized to either con-
ventional mechanical ventilation or mechanical venti-
lation with VA ECMO. The study was discontinued
after 90 patients because the mortality rate in each
group was about 90%. Once this study was published,
clinical research in adult ECMO was significantly
slowed.
• The University of Michigan has published the largest
series of extracorporeal life support to date. Between
1980 and 1998, 1000 patients were managed with
ECMO at U of M. ECMO use was initially limited to
neonates with respiratory failure; however, it was
expanded to the pediatric population in 1982 and to
adults in 1990.
 Of these patients, the survival to hospital discharge in
patients with respiratory failure was 88% in 586
neonates, 70% in 132 children, and 56% in 146 adults.
 Survival to hospital discharge in patients with car-
diac failure was 48% in 105 children and 33% in
31 adults.
• In a retrospective review of 36 adult patients with
severe respiratory failure managed with ECMO at the
University of Michigan, mortality was found to be
directly related to the duration of mechanical ventila-
tion prior to the initiation of ECMO. These 36 patients
were initially treated with conventional ventilation
and had a predicted mortality of 90% based on previ-
ously established NIH criteria published in 1974.
 18 of the 36 patients survived to hospital discharge.
 Of the 18 patients who died, ECMO was discontin-
ued in 11 patients due to irreversible lung disease.
 Patients who received conventional ventilation for
1–2 days and 3–4 days prior to management on ECMO
had a survival rate of 72% and 75%, respectively.
 Patients receiving conventional ventilation for 5–6 days
and ≥7 days had a survival rate of 25% and 20%,
respectively.
• A retrospective analysis of 219 adult patients in
Germany managed with ECMO for refractory postoper-
ative cardiogenic shock (after aortic valve replacement,
coronary artery bypass grafting, or both) found that 52 of
the 219 ECMO patients survived to hospital discharge.
• The CESAR Trial, a randomized-controlled trial com-
paring Conventional ventilation or ECMO for Severe
Adult Respiratory failure in adults is currently ongoing
in the United Kingdom.
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37 ACUTE-ON-CHRONIC
RESPIRATORY FAILURE
Timothy K. Baker, Steven Q. Davis
KEY POINTS
• Acute-on-chronic respiratory failure represents acute
decompensation of a chronically diseased respiratory
system.
• ACRF is most often caused by new respiratory system
loading, deterioration in neuromuscular competence,
or depressed drive.
• Auto-PEEP is a major contributor to the elastic load
during ACRF.
• Oxygen, bronchodilators, and corticosteroids are the
mainstays of treatment.
• Noninvasive positive pressure ventilation improves
outcomes in selected patients.
OVERVIEW
• Chronic respiratory failure (CRF) is a significant and
growing cause of morbidity and mortality in the
United States and across the world. The majority of
the clinical manifestations of CRF are related to the
102 SECTION 3 • RESPIRATORY DISORDERS
CHAPTER 37 • ACUTE-ON-CHRONIC RESPIRATORY FAILURE     103
spectrum of diseases related most significantly to cig-
arette smoking—that of emphysema and chronic
bronchitis, known as chronic obstructive pulmonary
disease (COPD).
• Acute-on-chronic respiratory failure (ACRF) occurs
when the chronically compromised respiratory system
suffers an incremental insult and becomes incapable
of adequately excreting carbon dioxide or maintaining
oxygenation.
PATHOPHYSIOLOGY
• Three components, respiratory drive, neuromuscular
competence, and respiratory load are essential to the
physiology and proper functioning of the respiratory
system.
• Respiratory drive is mediated by the central nervous
system (CNS), specifically in the medulla by the dorsal
and ventral respiratory groups and in the pons by the
pneumotaxic center. Given this, insults to the CNS can
lead to a depressed respiratory drive and ACRF.
• Possible etiologies include cerebrovascular events such
as hemorrhage or embolic phenomena. Additionally,
spinal cord compromise, especially in the upper cervical
area, can lead to loss of respiratory drive. Beyond pri-
mary neurologic events, other and often iatrogenic
causes also exist. These are most commonly due to
pharmacologic complications. Drugs, both illicit and
prescribed, such as sedatives and narcotics are often
implicated in the pathogenesis of ACRF. Additionally,
other metabolic causes such as hypothyroidism should
be excluded.
• The second component of the respiratory system is
neuromuscular function, primarily involving the mus-
cles of respiration, including the diaphragm and inter-
costal muscles and their innervation. The increased
load of the chronically disease respiratory system puts
at risk the neuromuscular component, such that only
modest loss of function may precipitate failure. As the
respiratory muscles are forced to work harder against
an increasing load, they may fail as force generators,
a condition called “fatigue.”
• Fatigue is related to a muscle’s work and its duration,
in concert with the amount of energy that is supplied
to the muscle by the circulation in the form of oxygen
and nutrients. Fatigue may also hinge on the concen-
tration of electrolytes such as phosphate.
• Several of the medicines that are commonly used to
treat ACRF can further contribute to metabolic derange-
ments, especially hypophosphatemia. Malnutrition and
other muscle disease play a role in some patients.
• To accomplish the work of the respiratory system, the
respiratory muscles must consistently sustain the
ventilatory load. In health the balance of neuromuscular
function and respiratory load is tipped greatly in favor of
function, clinically apparent as the “pulmonary reserve.”
Patients without preexisting chronic lung disease can
suffer a significant insult to their systems, resulting in a
large increase in respiratory load, without developing
respiratory failure.
• This is not the case for those with chronic lung disease;
these patients have a very low pulmonary reserve and
even slight insults, such as a mild viral respiratory ill-
ness, can tip the balance toward ventilatory failure.
The load on the respiratory system can be divided into
resistive and elastic components.
• Factors that contribute to the resistive load include
bronchoconstriction, compression of airways by pul-
monary edema (cardiac asthma), airway secretions,
and obstructive sleep apnea.
• The elastic load can be raised by pulmonary edema,
infiltrative processes such as pneumonia and tumors,
as well as inflammation, interstitial fibrosis, and
atelectasis. Chest wall elastic loads include obesity, rib
fracture with splinted breathing, pneumothorax, pleural
effusion, structural abnormalities, and abdominal dis-
tention from factors such as ascites and ileus.
• In most patients with ACRF, one of the most impor-
tant elastic loads is the inspiratory threshold load pre-
sented by auto-PEEP.
• Finally, all of these loads are amplified when minute
ventilation demands rise, such as during exercise,
acidemia, or elevated dead space.
CLINICAL MANIFESTATIONS
• Patients with ACRF can present with acute worsening
of pulmonary status over a very short period of time,
or with a more prolonged course that ultimately leads
them to seek medical attention. Patients typically
present with worsening of their baseline dyspnea,
with an increased and productive cough. Sputum may
be reported as becoming thicker and more purulent in
nature.
• As the patient’s pulmonary function continues to
worsen, the signs and symptoms become more omi-
nous and include those of acute respiratory distress
such as tachypnea, nostril flaring, accessory muscle
use, and pursed lip breathing. Examination usually
reveals prolonged expiration and wheezing that per-
sists to end-expiration.
• Other signs include rhonchi from worsened mucous
production and crackles from pulmonary edema, con-
solidation, or atelectasis.
• Pulse oximetry is an important bedside tool in assessing
the patient in ACRF and guiding oxygen therapy.
• Blood tests should include arterial blood gas analysis;
a complete blood count; and tests to exclude common
and treatable precipitants, such as hypophosphatemia
and hypothyroidism.
TREATMENT
• Initial choice of treatment for ACRF depends largely
on the severity of the symptoms, clinical signs, and
laboratory and radiographic data. In mild cases in
which the patient has not yet progressed to severe res-
piratory distress and failure, bronchodilators, sys-
temic corticosteroids, antibiotics, and supplemental
oxygen may be enough to avert a more severe exacer-
bation. However, in some cases, patients have already
progressed to overt respiratory failure and require
more intensive therapy.
OXYGEN
• There is a long-standing myth that administration of
oxygen to patients with COPD is contraindicated.
This is due to the belief that drive is depressed during
ACRF and that oxygen might undercut hypoxemic
respiratory drive, leading to worse ventilatory failure
and the need for intubation. While ACRF patients do
have a component of hypoxic drive, their overall drive
is supranormal. Raising PaO2 lowers drive modestly,
but leaves it supranormal. While patients with sleep
disordered breathing may critically hypoventilate fol-
lowing oxygen, in the majority of ACRF patients we
believe the benefit of assuring adequate tissue oxy-
genation far exceeds any risk of suppressing drive.
• Oxygen therapy can be guided with pulse oximetry,
seeking a saturation in excess of 88%; this can often
be accomplished with 3–5 L/min by nasal cannula or
by a face mask delivering an FiO2 of 30–35%.
BRONCHODILATORS
• Bronchodilators, such as beta2-agonists and anti-
cholinergic agents, are the mainstays of treatment of
ACRF, as they act on the reversible component of air-
flow obstruction, which is a significant contributor to
the load on the respiratory system.
• Beta2-agonists (albuterol, metaproterenol) act to relax
the smooth muscle of the airway. The most common
beta2-agonist in use is albuterol, which can be deliv-
ered by a metered-dose inhaler (MDI), 90 µg per puff,
or as a nebulized solution of 2.5 mg per treatment.
The two dosage forms appear to be equally efficacious
when equivalent doses are used, but the clinical situa-
tion may necessitate the use of a nebulizer as patients
with severe respiratory distress may become less able
to tolerate administration via MDI.
• Anticholinergic agents such as ipratropium are also
used to provide bronchodilation in patients experienc-
ing ACRF. Like albuterol, ipratropium can also be
administered in either an MDI or in a nebulized form.
The MDI delivers 18 µg per puff while the nebulized
form delivers 500 µg per treatment. Combined use of
ipratropium and albuterol in stable COPD has been
shown to be of benefit and is therefore often used in
this way during ACRF. The role for tiotropium during
acute exacerbations is uncertain.
CORTICOSTEROIDS
• There is often a significant amount of airway inflamma-
tion associated with an exacerbation of COPD and subse-
quent development of ACRF. Therefore, administration
of systemic corticosteroids is a useful component of
the treatment regimen. The agent chosen and the
dose administered are based on the severity of the
exacerbation.
 In mild exacerbations, it is often appropriate to start
with oral prednisone at a dose of 60 mg/day. This
can either be dosed as a rapid pulse of 60 mg daily
for 3 days, or tapered slowly over the course of
10–14 days.
 In more severe cases, the use of intravenous
methylprednisolone sodium succinate at a dose of
0.5–1.0 mg/kg every 6 hours is preferred. This is
then transitioned to an oral formulation, often pred-
nisone, as the patient’s clinical status improves.
ANTIBIOTICS
• This is an area of considerable debate in the treatment
of ACRF. In the situation where acute pulmonary
infection such as community acquired or nosocomial
pneumonia has lead to the development of ACRF,
appropriate antibiotic therapy is prudent.
• Less clear is what to do in the situation of a relatively
normal chest radiograph and the absence of fever or
leukocytosis, as is often seen in an acute exacerbation
of chronic bronchitis. The presence of purulent sputum
may aid in the decision to initiate antibiotic therapy.
Often, inexpensive, oral, broad-spectrum antibiotics
such as azithromycin, doxycycline, or trimethoprim-
sulfamethoxazole are given empirically for a course of
5–10 days.
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NONINVASIVE POSITIVE PRESSURE
VENTILATION
• For patients with severe ACRF, it is appropriate to con-
sider noninvasive positive pressure ventilation (NIPPV).
This technique has been shown to ameliorate symp-
toms, avert invasive mechanical ventilation in many
instances, and improve outcomes such as complications,
length of stay, and mortality.
• Patients must be carefully selected with regard to their
appropriateness for NIPPV. Criteria for selection include
the ability to maintain the airway, cardiovascular sta-
bility, spontaneous respiration, and tolerance of the
facial appliance. Recommended initial settings are an
inspiratory positive airway pressure (IPAP) of 10 cmH2O
and an expiratory positive airway pressure (EPAP) of
2–4 cmH2O. Both of these can be adjusted in the first
few minutes with a goal of IPAP 14–20 and EPAP 3–6.
• EPAP counterbalances auto-PEEP, in part, reducing the
inspiratory threshold load, and substantially reducing
the work of breathing. Even a CPAP mask (without a
ventilator) can improve symptoms, blood gases, and
the measured work of breathing.
• The key to the successful use of NIPPV is for the cli-
nician to be prepared to act early in instituting therapy
but also to recognize when it is failing.
• NIPPV generally improves subjective and blood gas
measures within 1 hour. Failure to improve should
lead to steps to adjust the ventilator settings, address
sources of patient-ventilator dyssynchrony, and seek
and correct leaks.
INVASIVE MECHANICAL VENTILATION
• While NIPPV is an appropriate initial therapy, it fails
approximately 25% of the time, at which time endotra-
cheal intubation and standard mechanical ventilation
are indicated. A key for successful transition to tradi-
tional ventilation is recognize the need for intubation
at a time when it can be performed in a controlled,
elective setting rather than in an emergency. Clinical
signs that may be useful are respiratory rate, menta-
tion, pattern of breathing, and the patient’s own assess-
ment of their respiratory status.
• Initial ventilator settings should employ low tidal
volume (5–7 cc/kg) and a respiratory rate of 20–24
breaths/min. Modest amounts of PEEP (5–10 cmH2O)
should be set to aid triggering. Any mode of ventilation
will work, as long as the work of ventilation is done by
the ventilator, allowing the patient to rest. We rest the
patient for at least 24–48 hours, during which time
attention is paid to treating the underlying condition
that led to ACRF.
• Following an initial period of rest and treatment, we
perform daily spontaneous breathing trials to identify
the earliest opportunity for extubation. Some studies
in subjects failing a spontaneous breathing trial have
shown that extubation to NIPPV (despite failing the
SBT) improves outcomes, but whether this is prudent
requires experienced bedside judgment.
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KEY POINTS
• Status asthmaticus is a life-threatening exacerbation
of asthma.
• Ventilatory failure is precipitated by excessive respi-
ratory mechanical load due largely to increased air-
ways resistance and auto-PEEP; oxygenation is only
modestly impaired.
• The mainstays of therapy include oxygen, beta-agonists,
ipratropium, and early intravenous corticosteroids.
• Parenteral magnesium, heliox, and noninvasive
positive pressure ventilation may be useful in severe
exacerbations.
• Circulatory depression due to pneumothorax or auto-
PEEP must be recognized.
• Minute ventilation should be limited in intubated
patients to prevent dangerous hyperinflation (DHI);
hypercapnia is well-tolerated in adequately sedated
patients.
EPIDEMIOLOGY AND DEFINITION
• Asthma is characterized by wheezing, dyspnea,
cough, airway hyperreactivity, and reversible airflow
obstruction. Status asthmaticus is a life-threatening
episode of asthma that is refractory to usual therapy.
• Severe attacks and death can occur regardless of the
asthma severity classification.
• More than 5000 people die from asthma each year in
the United States and this has increased significantly
during the last two decades.
PATHOPHYSIOLOGY
• One consequence of airway inflammation in asthma is
plugging of the large and small airways with tenacious
mucus that can be striking on postmortem analysis. Less
commonly, “sudden-onset asthma” results from a more
pure form of smooth muscle-mediated bronchospasm.
• Triggers of sudden attacks include nonsteroidal anti-
inflammatory agents, beta-blockers in susceptible
patients, allergen/irritant exposure, exercise, stress,
sulfites, and crack cocaine or heroine inhalation, and
medical noncompliance.
• Airway obstruction causes V/Q mismatch. Intra-
pulmonary shunt is trivial so modest amounts (1–3 L/min)
of supplemental oxygen generally correct hypoxemia.
Supplemental oxygen reverses hypoxic vasoconstric-
tion and bronchodilates the airways. Refractory hypox-
emia is rare and suggests additional pathology.
• Respiratory alkalosis is a feature of acute asthma and
may result in compensatory renal bicarbonate wasting
(nongap metabolic acidosis). As airflow obstruction
increases, PaCO2 rises due to poor alveolar ventilation
and a rise in CO2 production from increased work of
breathing.
• Lung mechanical abnormalities: hallmarks of expira-
tory airflow obstruction include incomplete alveolar
gas emptying and elevated positive end-expiratory
alveolar pressure. In the ventilated patients, the amount
of intrinsic or auto-PEEP can be measured by the end-
expiratory port occlusion technique as long as the patient
is relaxed at end-expiration.
• Circulatory abnormalities reflect a state of cardiac
tamponade resulting from dynamic hyperinflation
(DHI) and pleural pressure changes. During expira-
tion, high intrathoracic pressure decreases right-side
preload. Vigorous inspiration augments right ven-
tricular (RV) filling and shifts the interventricular
septum to cause incomplete left ventricular (LV) filling.
Lung hyperinflation increases RV afterload and may
cause transient pulmonary hypertension. The net
effect is to accentuate the normal inspiratory reduc-
tion in stroke volume, a phenomenon termed as pulsus
paradoxus.
• Ventilatory failure is the result of several mechanisms
including increased airway resistance, the inspiratory
threshold load presented by auto-PEEP, respiratory
muscle fatigue, systemic academia, and hypoperfusion
from circulatory abnormalities.
CLINICAL FEATURES
• No single clinical measurements reliably predicts
outcome.
• Characteristic of prior exacerbations that predict a
fatal or near-fatal outcome include intubation, hyper-
capnia, barotrauma, hospitalization despite corticos-
teroids, psychiatric illness, substance abuse, and
medical nonadherence.
• Severe exacerbations include several, but not neces-
sarily all, of the following features: dyspnea at rest,
upright positioning, inability to speak entire phrases,
respiratory rate (RR) > 30/min, use of accessory
muscle of respiration, heart rate (HR) > 120/min,
pulsus paradoxus > 25 mmHg, peak expiratory flow
rate < 50% predicted or personal best, hypoxemia and
eucapnia or hypercapnia.
• Imminent respiratory arrest is characterized by altered
mental status, paradoxical respirations, bradycardia,
quiet chest from insufficient airflow, and absence of
pulsus paradoxus. Bradycardia is an ominous sign as
the usual rhythm is sinus tachycardia. Presence of
subcutaneous emphysema suggests pneumomedi-
astinum or pneumothorax.
• A peak expiratory flow rate or forced expiratory
volume in one second (FEV1) < 50% of predicted or
personal best is an objective measure suggesting severe
exacerbation and may be used to assess progress in the
less critically ill patient.
• Hypercapnia on arterial blood gas suggests severe dis-
ease but is not always present. Patients who deterio-
rate clinically with impending respiratory failure
should be intubated regardless of PaCO2. Conversely,
improving patients should not be intubated despite
hypercapnia.
• Chest radiography is indicated when it is unclear if
asthma is the cause of respiratory distress; when there
are localizing signs or suspected barotraumas; and to
check endotracheal tube position in mechanically
ventilated patients.
THERAPY PRIOR TO INTUBATION
• Pharmacotherapy should start with inhaled albuterol
and data support the addition of ipratropium to albuterol
in any patient who is extremely ill on presentation or not
responding quickly to albuterol alone.
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• Systemic corticosteroids should be given early to treat
the inflammatory component of acute asthma and there
is evidence that this reduces the number of relapses in
the first week and the risk of death. There is little ben-
efit to the addition of inhaled corticosteroids.
• There is no benefit to adding aminophylline to inhaled
beta-agonist, however, it is recommended to continue
its use in those already taking it if attention is paid to
serum levels.
• Several trials have failed to justify the routine use of IV
magnesium sulfate but it is safe, inexpensive, and may
be beneficial in severe exacerbations. Administration
by inhalation is also being studied.
• Heliox (20% oxygen:80% helium) is less dense than air
and allows more laminar flow and possibly increased
distal delivery of albuterol. Concentrations of helium
< 60% are ineffective, precluding its use in patients with
significant hypoxemia.
• Noninvasive positive pressure ventilation is an option
for patients with hypercapneic respiratory failure who
do not require intubation as it helps overcome the
adverse effects of auto-PEEP and unloads the inspira-
tory muscles.
MANAGEMENT OF THE INTUBATED
ASTHMATIC
• The decision to intubate rests on the patient’s ability
to maintain spontaneous respiration.
• Goals of intubation/mechanical ventilation are to
maintain oxygenation and prevent respiratory
arrest.
• Hypotension is reported in 25–35% following intuba-
tion due to loss of vascular tone from sedation and
loss of sympathetic activity. Hypovolemia and DHI
may also contribute to the hypotension.
• DHI may be present if breaths sounds diminish, blood
pressure (BP) falls, and HR rises. A trial of hypopnea
(2–3 breaths/min) or apnea is both diagnostic and
therapeutic for DHI.
• To avoid dangerous levels of DHI, minute ventilation
should not exceed 115 mL/kg/min. RR is recommended
at 12–14 breaths/min and tidal volume (TV) between 6
and 8 mL/kg. High inspiratory flow rates (above 60
L/min) do not prolong expiratory time meaningfully.
Supplemental PEEP (at least 5 cmH2O) should always
be given, since auto-PEEP is universally present and
will frustrate the patient’s effort to trigger the ventilator.
In some patients, higher levels of PEEP are useful to
reduce the work of breathing. Externally applied PEEP
generally does not raise the end-expiratory alveolar
pressure, so there is little risk of worsening the hyperin-
flation or depressing the circulation.
• There is no consensus as to which ventilator mode to
use. Both pressure-preset and volume-preset modes
can be used successfully.
• Measurement of plateau pressure (Pplat) and auto-
PEEP requires patient-ventilator synchrony and
patient relaxation; however, neither measurement has
been validated as a predictor of complications. Despite
this, Pplat < 30 cmH2O is generally safe and auto-
PEEP < 15 cmH2O is acceptable.
• Sedation is indicated to improve comfort, safety, and
patient-ventilator synchrony. A continuous infusion of
narcotic in combination with propofol or benzodi-
azepine is recommended. Short-term muscle paralysis
is indicated if effective ventilation cannot be achieved
by sedation alone; however, these agents should be
minimized whenever possible to avoid the risk of
postparalytic myopathy.
• Often 24–48 hours of treatment is needed before
patients are ready for extubation. Readiness for extu-
bation can generally be judged based on improving
mechanical parameters. Prior to extubation, only a
brief spontaneous breathing trial is recommended
since a longer trial may provoke bronchospasm.
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39 HEMOPTYSIS AND
PULMONARY HEMORRHAGE
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KEY POINTS
• Massive hemoptysis is defined as more than 300–600 mL
in 12–24 hours.
• Massive lung hemorrhage can cause asphyxiation or
severe hypoxemia.
• Causes of lung hemorrhage may be anatomic or dif-
fuse and related to disordered coagulation or vascular
integrity.
• Some patients with life-threatening DAH will have no
hemoptysis.
• The plain chest radiograph usually discloses the side
of bleeding.
• Any coagulopathy should generally be corrected
aggressively, even when it is not the primary basis for
the lung hemorrhage.
• Specialized airway, bronchoscopic, and angiographic
techniques may be called for in protecting the lung,
diagnosing the source of bleeding, or achieving control.
• Multidisciplinary involvement of a pulmonary spe-
cialist, interventional radiologist, rheumatologist, and
thoracic surgeon is often helpful.
HEMOPTYSIS
• Most patients with hemoptysis do not require inten-
sive care unless they have such large rates of bleeding
that result in hemodynamic instability or they have
life-threatening hypoxemia from parenchymal hemor-
rhage or extensive aspiration of blood.
• Massive hemoptysis is defined as >300–600 mL of
blood in 12–24 hours although it is often clinically
difficult for the patient to estimate. Also, some
patients may have life-threatening hypoxemia due
to alveolar hemorrhage, along with diffuse
parenchymal infiltrates that satisfy criteria for
acute respiratory distress syndrome (ARDS), yet
have no hemoptysis.
• Many conditions may cause hemoptysis outlined in
Table 39-1. The more common causes include
bronchiectasis, mycetoma, tuberculosis, bronchogenic
carcinoma, lung abscess, and vascular-bronchial fistulas.
• The most common cause of death in patients with
hemoptysis is asphyxia from aspirated blood. If the site
of bleeding is known, lateral decubitus positioning
(bleeding lung down) may serve to protect the opposite
lung. Small doses of codeine or morphine may be help-
ful to blunt the cough reflex and slow the rate of bleed-
ing but at the risk of depressing the sensorium. Some
patients, especially those with diffuse parenchymal
hemorrhage, require intubation. In extreme circum-
stances, mainstem bronchus intubation of the non-
bleeding side may protect the uninvolved lung.
INITIAL EVALUATION
• Initial evaluation includes careful inspection of the nose
and mouth to exclude an upper airway source.
Coagulation screening should include platelet count,
prothrombin time (PT), partial thromboplastin time
(PTT), fibrinogen level, and, in appropriate patients,
antiphospholipid antibody assays. Blood should also be
sent for blood urea nitrogen (BUN), creatinine, urinalysis,
and serology screen (antinuclear antibodies [ANA],
Rheumatoid factor [RF], complement levels, cryoglob-
ulins, antineutrophil cytoplasmic antibodies [ANCA],
antiglomerular basement membrane antibody) when
excluding connective tissue disease and vasculitis.
• Chest x-ray will reveal the region of bleeding in 60%
of cases. Fiberoptic bronchoscopy can locate endo-
bronchial lesions or may at least locate the lobe or
segment form which the bleeding is coming. If bleed-
ing is brisk, visualization may be suboptimal and rigid
bronchoscopy may be more useful. Chest computed
tomography (CT) is similarly effective at determining
the site of bleeding and may be very useful in detect-
ing the source of bleeding as well. CT angiography is
the gold standard and has an 80% sensitivity, 84%
specificity, and 84% positive predictive value.
TREATMENT
• General treatment measures include maintaining
platelet count >50,000 in an actively bleeding patient.
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TABLE 39-1 Causes of Hemoptysis
LOCALIZED BLEEDING DIFFUSE BLEEDING
Infection Drug-induced
• Bronchiectasis • Anticoagulants
• Bronchitis • D-Penicillamine
• Bacterial pneumonia • Trimellitic anhydride (plastic,
• Fungal infections paint, epoxy manufacturing)
• Tuberculosis (especially • Cocaine
cavitary disease) • Propylthiouracil
• Lung abscess • Amiodarone
• Leprospirosis • Dilantin
Tumors Blood dyscrasias
• Bronchogenic carcinoma • Thrombotic thrombocytopenic
(squamous cell) purpura
• Necrotizing parenchymal cancer • Hemophilia
(usually adenocarcinoma) • Leukemia
• Bronchial adenoma • Thrombocytopenia
• Uremia
• Antiphospholipid antibody 
syndrome
Cardiovascular problems Pulmonary-renal syndromes
• Mitral stenosis • Goodpasture syndrome
• Wegener granulomatosis
• Pauci-immune vasculitis
Pulmonary vascular problems Vasculitis
• Pulmonary arteriovenous • Pulmonary capillaritis
malformations • Polyarteritis
• Pulmonary embolism • Churg-Strauss syndrome
with infarction • Henoch-Schönlein purpura
• Bechet syndrome • Necrotizing vasculitis
• Pulmonary artery catheterization • Connective tissue diseases
with rupture • Pulmonary veno-occlusive 
disease
Others Others
• Broncholithiasis • Hemosiderosis
• Sarcoidosis
• Ankylosing spondylitis
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Platelet transfusion is common and intravenous
immunoglobulin (IVIG) may be used if there is
platelet destruction from immune-mediated causes.
Dialysis, cryoprecipitate, or desmopressin (DDAVP)
may be used for platelet dysfunction due to uremia.
PT and PTT should be corrected to near normal with
fresh frozen plasma or vitamin K.
• Bronchial arterial embolization is the treatment of choice
for life-threatening hemoptysis from localized parenchy-
mal lesions. Endobronchial ablation is reserved for pal-
liative therapy in unresectable tumors affecting the larger
airway. External beam irradiation has been used for
mycetomas and occasionally for unresectable tumors.
• In the setting of diffuse disease, surgery is precluded.
Indications for surgery include recurrence of bleeding
after embolization, inability to embolize due to
anatomic problems, or multiple bleeding vessels on
angiography.
DIFFUSE ALVEOLAR HEMORRHAGE
• Up to 30% of patients with diffuse alveolar hemor-
rhage (DAH) will not have hemoptysis. Chest x-rays
often show diffuse disease but localized disease may
also be seen. DAH occurs in up to 33% of patients with
microscopic polyangiitis, 10% of patients with Wegener
granulomatosis, 10% of patients with Goodpasture syn-
drome, and 5% of patients with systemic lupus.
• Diagnosis is easily established when patients present
with hemoptysis, diffuse infiltrates, falling hemat-
ocrit, and other manifestations of systemic disease. In
those without hemoptysis or infiltrates, the diagnosis
is more difficult. Increasingly bloody serial aspira-
tions on bronchoalveolar lavage may be diagnostic. A
renal biopsy or thoracoscopic lung biopsy is fre-
quently recommended when DAH is diagnosed in
order to differentiate the various types of vasculitis
and to definitively diagnose or exclude Goodpasture
disease since its treatment differs markedly from that
of vasculitis.
• Despite treatment, >50% of patients with DAH from
vasculitis or collagen vascular disease require
mechanical ventilation. The mortality is 25% in
patients with Wegener granulomatosus and 50% in
patients with lupus.
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40 RESTRICTIVE DISEASES OF
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KEY POINTS
• Disorders of the chest wall that most profoundly
impact ventilatory function include kyphoscoliosis
(KS) and restrictive disease resulting from previous
thoracoplasty.
• Respiratory mechanics and gas exchange are also sig-
nificantly altered by the restrictive physiology of pul-
monary fibrosis.
• Diseases of the respiratory muscles can depress venti-
latory function.
• During mechanical ventilation, tidal volume should
generally be limited to prevent lung injury and circu-
latory depression.
KYPHOSCOLIOSIS
• KS is the prototypical severe thoracic deformity seen
in as many as 1 in 10,000 people in the United States.
• KS consists of anteroposterior angulation (kyphosis),
lateral displacement (scoliosis), and often some rota-
tion of the spine around its long axis.
• The most common form of KS is idiopathic (80%)
although secondary KS may be seen (polio, muscular
dystrophy).
• Clinical symptoms correlate with the degree of curva-
ture. Less than 70° rarely results in cardiopulmonary
sequelae. Angles >70° put patients at risk of develop-
ing respiratory failure, >100° are associated with dys-
pnea, and >120° may result in alveolar hypoventilation
and cor pulmonale. On examination, patients exhibit a
rapid shallow breathing pattern due to the reduction in
lung and chest wall compliance. Often crackles or
coarse wheezing are detected and reflect the atelectatic
and deformed lung.
• Pulmonary function alterations typically include
severe reduction in total lung capacity (TLC) and vital
capacity (VC) due to reduced IC (inspiratory capacity;
IC = TLC − FRC). Functional residual capacity (FRC)
is reduced, expiratory reserve volume (ERV) is also
low (ERV = FRC − RV), and residual volume (RV) is
relatively spared. In advanced KS and neuromuscular
disease associated with secondary KS, inspiratory
muscle function is severely reduced and contributes to
respiratory dysfunction.
• Gas exchange abnormalities include nocturnal hyper-
capnia and hypoxemia during rapid eye movement
(REM) sleep that may contribute to cardiovascular
complications. Significant arterial hypoxemia often
occurs late in the development of hypercapnia. A-a gra-
dients are usually no more than 25 mmHg and result pri-
marily from V/Q mismatch. Patients may have normal
or reduced ventilatory response to inspired CO2.
• As the spinal curvature increases, pulmonary hyper-
tension may occur. This is a consequence of increased
pulmonary vascular resistance from hypoxic vasocon-
striction or anatomic abnormalities and not from ele-
vated left atrial (LA) pressure. An increased gradient
between the pulmonary artery diastolic pressure and
the pulmonary wedge pressure usually exists. Early use
of O2 as well as correcting reversible causes of hyper-
capnia and sleep disordered breathing helps delay the
onset of right ventricular (RV) failure.
• Acute cardiopulmonary failure: Often precipitated by
pneumonia, upper respiratory tract infection, conges-
tive heart failure (CHF), and occasionally pulmonary
embolism (PE). Conservative management without
invasive mechanical ventilation is effective in the
majority of cases. One needs to look for potentially
reversible causes (reversible airflow obstruction,
aspiration). Arterial hypoxemia is aggravated by low
venous saturation; therefore, raising the cardiac
output or hemoglobin concentration or decreasing O2
consumption will help. If shock occurs, mechanical
ventilation is necessary. Patients in shock from sepsis
may not mount the usual hyperdynamic response
and if unresponsive to volume challenge, right heart
catheterization may be helpful. Shock from right
heart failure requires adequate circulating volume
and correction of hypoxemia to reduce pulmonary
vasoconstriction.
• Acute hypercapnic respiratory failure: Acute exacer-
bations are characterized by a dramatic decrease of
respiratory system compliance and increase in work
of breathing. Noninvasive positive-pressure ventilation
(NIPPV) is considered first-line therapy and has the
advantage of decreased incidence of nosocomial
pneumonia/otitis/sinusitis, need for sedation, as well
as improved patient comfort. Increased risk of aspira-
tion, facial pressure necrosis, and less control of
patient’s ventilation compared with invasive ventila-
tion are the disadvantages. Invasive ventilation is
required for cardiopulmonary arrest, refractory hypox-
emia, progressive ventilatory failure, and shock. Use
small tidal volumes (6–7 mL/kg) and high respiratory
rates (RR, 20–36/min) since large tidal volumes will
raise the pleural pressure far more than usual, risking
hemodynamic compromise. The addition of 5 cmH2O
positive end-expiratory pressure (PEEP) helps avoid
collapse of alveoli at low lung volumes. Hypercapnia
is generally well tolerated.
THORACOPLASTY
• A common surgical procedure used in the past to treat
tuberculous empyema and cavitary pulmonary tuber-
culosis. It is second to KS in producing severe restric-
tive physiology as a result of distortion of the chest
wall, pleural thickening, and secondary scoliosis.
• Other factors contributing to restriction in thora-
coplasty include reduced respiratory system compli-
ance, inspiratory muscle weakness, fibrothorax, lung
resection, and phrenic nerve injury.
• Pulmonary function abnormalities are similar to those
in KS. Unlike other restrictive diseases, however,
coincident airflow obstruction is common.
PULMONARY FIBROSIS
• With extensive fibrosis, gas exchange units are
deformed and dysfunctional and the lungs become
small and stiff. Traction bronchiectasis may result in
excess mucus production.
• As the fibrosis progresses, dyspnea occurs both at rest
and with exercise, leading to a sedentary lifestyle and
deconditioning. Dyspnea is often associated with a
persistent, nonproductive cough.
• Rapid shallow breathing with higher than normal
minute ventilation is common. Dry “Velcro” crackles
may be heard on auscultation. Loud P2, RV heave,jugular venous distention, and right-sided S3 suggest
pulmonary hypertension.
• Respiratory mechanics typically reveal reduced TLC,
VC, and IC. Less of a reduction is seen in FRC and
RV. Forced expired volume in one second (FEV1) and
forced vital capacity (FVC) are often reduced. Lung
stiffness requires large negative pleural pressures to
adequately breathe.
• Exercised-induced hypoxemia and low diffusing
capacity (DLCO) are hallmarks of early disease. Later,
resting hypoxemia and mild respiratory alkalosis are
common. Sleep-related desaturation is due to exagger-
ated effects of normal nocturnal hypoventilation and
V/Q variations or to respiratory muscle dysfunction
and obstructive sleep apnea.
• Pulmonary hypertension and cor pulmonale are
common in end-stage fibrosis (DLCO < 45% and VC
< 50% of predicted).
• Acute cardiopulmonary failure: Common causes
include pneumonia, bronchospasm, pulmonary embo-
lus, aspiration, heart failure, and pneumothorax. If
deterioration is seen over weeks to months, suspect
progressive fibrosis, bronchogenic carcinoma, steroid
myopathy, drug toxicity, cor pulmonale, or left ven-
tricular (LV) failure. First-line therapy is targeted at
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correcting hypoxemia with supplemental O2, NIPPV or
intubation, and mechanical ventilation if necessary to
minimize the adverse effects of hypoxic pulmonary
vasoconstriction. If intubated, the approach to mechanical
ventilation is similar to acute respiratory distress syn-
drome (ARDS; tidal volume 6 mL/kg, RR 20–36/min,
plateau pressure < 30 cmH2O, PEEP 5 cmH2O) to help
reduce ventilator-induced lung injury. Unfortunately,
there are several studies reporting the outcome of
patients referred to the ICU for acute respiratory failure
without a clearly identified reversible cause as very poor
and not improved by mechanical ventilation.
RESPIRATORY MUSCLE WEAKNESS
• Reduced inspiratory muscle function (diaphragm,
internal intercostals, and accessory muscles) produces
restrictive respiratory mechanics and results in hyper-
capnia and respiratory failure. Impaired clearance of
airway secretions is a common and potentially life-
threatening problem in these patients.
• Causes include but are not limited to myasthenia gravis,
postpoliomyelitis syndrome, amyotrophic lateral scle-
rosis, Guillain-Barré syndrome, Eaton-Lambert syn-
drome, muscular dystrophies, botulism, and critical
illness polyneuropathy.
• Severe hypoxemia, hypercapnia, and acidemia are
indications for respiratory support.
• Physical examination may reveal rapid, shallow
breathing and paradoxical abdominal movements.
Patients should be observed during sleep for nocturnal
hypoventilation and obstructive sleep apnea.
• PI
max
and PE
max
are the most sensitive ways to quantify
respiratory muscle weakness.
• Hypoxemic respiratory failure can often be treated
adequately with supplemental O2.
• With significant decline in lung volume and muscle
strength, NIPPV or intubation and mechanical venti-
lation are needed. No particular mode of mechanical
ventilation is superior; however, PEEP should be used
to prevent atelectasis.
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41 SLEEP-DISORDERED
BREATHING
D. Kyle Hogarth
KEY POINTS
• The incidence of sleep-disordered breathing (SDB) is
rising. Currently, SDB affects 2–4% of adults in the
United States. In patients with COPD, the incidence
can be as high as 20%.
• Untreated SDB leads to neurocognitive and cardio-
vascular end-organ effects.
• Untreated SDB can result in periods of profound
hypoxemia and hypercapnia.
• OHS can be an end-stage manifestation of SDB, usu-
ally requiring admission to the ICU. These patients
will usually require tracheostomy for definitive man-
agement of their disease.
SLEEP APNEA
• Sleep apnea is a disease state characterized by peri-
ods of absent breathing (apnea) or reduced tidal vol-
umes (hypopneas). The apnea-hypopnea index (AHI)
is the total number of apnea/hypopnea events per
hour of sleep.
• Sleep apnea is divided into two categories: obstructive
or central apnea. Obstructive apnea represents the
majority of patients, though mixed obstructive/central
apnea is not uncommon.
• Obstructive sleep apnea (OSA) is characterized by lim-
itation of airflow in the upper airways due to a variety
of factors, including anatomy, pharyngeal muscle tone,
and obesity.
• Central sleep apnea (CSA) is characterized by disor-
dered regulation of breathing and lack of appropriate
neural output for control of respiratory function.
RISK FACTORS FOR OBSTRUCTIVE SLEEP APNEA
• Obesity
• Increased neck circumference
• Craniofacial abnormalities
• Hypothyroidism
• Acromegaly
FACTORS THAT CAN WORSEN/AGGRAVATE
OBSTRUCTIVE SLEEP APNEA
• Upper airway injury
• Upper airway edema
• Alcohol or sedative use
• Hypothyroidism
• Hypoxia
RISK FACTORS FOR CENTRAL SLEEP APNEA
• Long-standing untreated OSA
• Poliomyelitis
• Encephalitis
• Brainstem neoplasm or infarction
• Spinal cord injury
DIAGNOSIS OF SLEEP APNEA
• Many patients with ICU admissions attributed to con-
gestive heart failure or chronic obstructive pulmonary
disease (COPD) actually suffer from profound OSA.
It is important to maintain a high index of suspicion in
patients with the risk factors mentioned above.
• Polysomnography remains the gold-standard study to
accurately diagnose OSA.
• Portable systems for home use are available, but are
not as proven as full polysomnography.
• Clinical scoring systems are useful, but are not reli-
able enough yet to accurately predict OSA.
COMPLICATIONS OF SLEEP APNEA
• Complications of sleep apnea are due to hypoventila-
tion and hypoxemia. These complications can include:
 Increased diurnal hypertension
 Pulmonary hypertension
 Left and right heart failure
 Increased somnolence
 Myocardial infarction
 Stroke
• Complications of OSA that can lead to needs for crit-
ical care management include:
 Postoperative respiratory failure:
 General anesthesia decreases upper airway pha-
ryngeal tone.
 Upper airway edema may increase the resistance
of the upper airway.
 Central drive may be reduced from anesthetics.
 Hypoxemia can be present from atelectasis and
splinting.
 Acute-on-chronic respiratory failure:
 Can be difficult to discern whether respiratory
failure is directly from an underlying illness
such as COPD or directly from poorly treated
OSA.
 However, patients with both COPD and OSA
have a higher risk for acute respiratory failure and
have higher daytime PaCO2 and lower daytime
PaO2.
• Long-term untreated OSA can progress to the obesity
hypoventilation syndrome (OHS), a disease state
characterized by:
 Hypercapnia while awake
 Hypersomnolence
 Stupor
 Right heart failure
 Left heart failure
• OHS can be the principal cause of admission for res-
piratory failure to the ICU and should be considered
in all patients with chronic hypercapnia.
• OHS can also aggravate other underlying conditions,
such as ischemic cardiomyopathy and COPD.
MANAGEMENT OF SLEEP APNEA
• Positive pressure ventilation (PPV) is the manage-
ment of choice for OSA. The application of external
positive pressure maintains potency of the narrowed
upper airway.
• Noninvasive ventilation may be helpful but, before
this is relied on solely, the likelihood of compliance
and follow-up, along with the potential for response
must be considered along with the life-threatening
nature of the patient critically ill from OSA.
• Oral appliances that move the mandible forward are
also available, and may help some patients.
• Surgical options to reduce upper airway obstruction
include uvulopalatopharyngoplasty, tonsillectomy,
tongue ablation, and tracheostomy.
• Adequate treatment in the ICU is generally signaled by
spontaneous diuresis, improved alertness, and (more
gradually) lower PaCO2.
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42 INHALATION INJURIES
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KEY POINTS
• Inhalation injury refers to the inhalation of toxic prod-
ucts of combustion.
• Early management focuses on maintaining airway
patency and determining the need for intubation.
Although obstruction is rarely present initially, serial
assessments are required as inflammation and edema
progress.
• Symptoms of bronchospasm and bronchorrhea may be
minimal initially, and peak after 24–48 hours. These
lead to increased work of breathing and decreased lung
compliance.
• Late airway complications are primarily infectious.
• Treatment is primarily supportive, involving intuba-
tion, removal of secretions, and the use of PEEP.
PATHOPHYSIOLOGY/MECHANISMS 
OF INJURY
• Thermal injuries: These injuries tend to be limited
to the upper airways, where mucosal damage results
in erythema and ulceration. Edema may take up to
24 hours to develop, and typically resolves within
5 days.
• Hypoxic gas inhalation: As fire burns, it utilizes
oxygen, decreasing the FiO2 of ambient air. Inhaling
hypoxic air not only decreases oxygen supply to vital
organs, but also increases the toxic effects of other
inhaled compounds, such as carbon monoxide.
• Bronchospasm: Several compounds found in smoke
are irritants to the bronchial mucosa and alveoli, which
trigger bronchospasm (Table 42-1).
• Mucosal edema: Inhaled toxins can damage tight
junctions between epithelial cells, increasing vascular
permeability, and causing mucosal edema. If severe,
this may lead to airway obstruction.
• Intrapulmonary shunting: The combination of pul-
monary edema and endobronchial debris contribute to
V/Q mismatch and shunting.
• Diminished compliance: Persistent bronchospasm,
bronchorrhea, and airway edema lead to decreased
lung compliance and increased airway resistance.
DIAGNOSIS
• Early diagnosis relies on high clinical suspicion and a
history of closed space exposure or aspiration of hot
liquid or steam.
• Physical examination may reveal facial burns, singed
nasal hairs, carbonaceous sputum, soot in the orophar-
ynx, wheezing, cough, or altered mental status.
• Laboratory data should include arterial blood gas, car-
boxyhemoglobin and cyanide levels, and plasma lac-
tate concentration.
• Initial chest radiographs are often normal. Serial studies
are nonspecific, but may show bronchial wall thicken-
ing, air trapping, or diffuse interstitial, alveolar, or mixed
infiltrates.
• Bronchoscopy is considered the gold standard for
diagnosis. Direct visualization of the airways reveals
endobronchial erythema and ulceration, providing
information about the extent and severity of injury
(Fig. 42-1).
• Radionuclide imaging using xenon-133 or techni-
cium-99 can support the diagnosis, but are not widely
used due to expense and logistic difficulty.
TABLE 42-1 Common Components of Housefire Smoke
GAS PROPERTY SOURCE
Ammonia Irritant Nylon
Hydrogen chloride Irritant Polyvinyl chloride, insulation
Nitrogen oxides Irritant Wall paper, acetylene torches, jet
engine fuel, diesel fumes
Phosgene Irritant Chlorinated hydrocarbons 
(paint stripping, welding)
Acrolein Irritant Wood, cotton, paper, acrylic,
polyethylene, polypropylene
Benzene Irritant Petroleum plastics
Carbon monoxide Asphyxiant Incomplete combustion of any
organic matter
Hydrogen cyanide Asphyxiant Wood, silk, nylon, polyurethane
SOURCE: Adapted from <<utdol.com>>—Smoke Inhalation.
RISK OF INFECTION
• In the setting of severe airway injury, there are several
factors that contribute to an increased likelihood of
tracheobronchitis or pneumonia:
 Necrotic epithelium sloughs off, leading to obstruc-
tion of distal airways and atelectasis.
 Neutrophils and alveolar macrophages function
abnormally.
 Mucociliary clearance is decreased.
• Classic radiographic findings of pneumonia may not
be present because of the diffuse nature of the infec-
tion and its location in central airways.
• Corticosteroids and prophylactic antibiotics have not
been shown to be effective.
MANAGEMENT
• Treatment is largely supportive, focusing on airway
protection/intubation, oxygen supplementation, and
antibiotics for documented infection.
• Pulse oximetry is affected by carboxyhemoglobin and
methemoglobin; arterial oxygen saturation should be
measured with co-oximetry instead.
• Criteria for intubation include: stridor, respiratory dis-
tress, deep burns to the face or neck, significant oropha-
ryngeal edema.
• Aerosolized bronchodilators can be helpful in the ini-
tial treatment of bronchospasm. However, after the
first 24 hours, airway resistance is more likely to be due
to airway edema, and bronchodilators may no longer be
effective.
• Intubation should be performed with a large endotra-
cheal tube (7.0 mm in internal diameter or larger) to
facilitate the clearance of secretions. The use of humid-
ified oxygen can also help mobilize secretions.
• Positive end-expiratory pressure (PEEP) should be
used to maintain small airway patency, recruit
atelectatic alveoli, and improve oxygenation.
• Extubation is appropriate after upper airway edema
has resolved. Although no test accurately predicts
airway patency, serial laryngoscopy and cuff-leak tests
may be helpful.
• Long-term sequelae of inhalation injury include
bronchiectasis, tracheal stenosis, interstitial fibrosis,
and bronchiolitis obliterans.
FUTURE THERAPIES
• Several studies in animal models may help shape future
treatment recommendations for inhalation injury.
 Exogenous surfactant has been shown to improve
lung compliance and oxygenation in a dog model.
 Leukotriene inhibitors decreased the severity of pul-
monary edema in a sheep model.
 Intravenous lisofylline decreases inflammatory
mediators and inhibits neutrophil recruitment. When
used with nebulized heparin, this reduces intrapul-
monary shunting and improves ventilation.
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FIG. 42-1 Upper airway damage from smoke inhalation. (A) Vocal cord edema; (B) carbonaceous debris, erythema, and ulceration.
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smoke_inhalation.html.
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43 SEPSIS, SEVERE SEPSIS, AND
SEPTIC SHOCK
Michael Moore
KEY POINTS
• Sepsis is defined as the combination of infection and
systemic inflammation.
• Mortality and morbidity is particularly high in the
subset of patients with sepsis and at least one organ
failure, termed “severe sepsis.”
• Complications of sepsis may involve the circulation,
lung, kidney, liver, hematologic system, gastrointestinal
tract, CNS, peripheral nerves, and the metabolic milieu.
• Treatment begins with source control, antimicrobial
therapy, and supportive measures.
• Most patients require large volumes of intravenous
fluids. If these fail to restore blood pressure, vasoac-
tive drugs (such as norepinephrine) should be infused
and adrenal insufficiency excluded.
• Initial antibiotics should cover any organism of
greater than trivial probability but the spectrum of
coverage should be narrowed as additional diagnostic
information is gained.
• For patients with severe sepsis and septic shock,
urgent resuscitation to a central venous oxyhemoglo-
bin saturation (ScvO2) >70% and infusion of
drotrecogin alpha may improve outcome.
• Patients requiring mechanical ventilation should gen-
erally be ventilated using a lung-protective strategy
including volume assist-control mode with 6 mL/kg
predicted body weight.
• The roles of intensive insulin therapy and low-dose
corticosteroids remain subject to study.
INTRODUCTION
• Sepsis is a complex syndrome that results from severe
infection that leads to systemic inflammation and
widespread tissue damage, often remote from the ini-
tial site of injury.
• It can produce a range of clinical conditions that can
rapidly result in hypotension, perfusion abnormalities,
global tissue hypoxia with single or multiple organ
dysfunction, and ultimately death.
• Rapid and timely intervention is critical to successful
treatment.
• Only recently have clinical trials suggested that spe-
cific strategies and new therapies may improve sur-
vival in severe sepsis.
• Effective interventions require rapid diagnosis and
prompt and appropriate treatment including car-
diopulmonary support, antibiotics, source control,
general supportive care, and, for those with severe
sepsis at high risk of death, drotrecogin alpha.
• Because sepsis and the clinical consequences of sepsis
have been historically difficult to define, diagnose, and
treat, the American College of Chest Physicians (ACCP)
and the Society of Critical Care Medicine (SCCM) spon-
sored a consensus conference to improve definitions and
set up a framework for research and patient care.
AMERICAN COLLEGE OF CHEST
PHYSICIANS/SOCIETY OF CRITICAL CARE
MEDICINE DEFINITION OF SEPSIS AND
RELATED DISORDERS
• Infection: Microbial phenomenon characterized by an
inflammatory response to the presence of microorgan-
isms or the invasion of normally sterile host tissue by
those organisms.
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• Bacteremia: The presence of viable bacteria in the
blood.
• Systemic inflammatory response syndrome (SIRS):
Generalized inflammatory response to a variety of
clinical insults. The syndrome is characterized by two
or more of the following:
 Temperature >38°C or <36°C
 Heart rate >90 beats/min
 Respiratory rate >20 breaths/min or PaCO2 <32 mmHg
 WBC >12,000 cells/mm3, <4000 cells/mm3, or
>10% immature (band) forms
• Sepsis: The systemic response to infection manifested by
two or more SIRS criteria resulting from an infection.
• Severe sepsis: Sepsis is defined as severe when it is
associated with hypotension, hypoperfusion, or organ
dysfunction.
• Septic shock: Sepsis associated with hypotension that
persists despite adequate fluid resuscitation and result-
ing in one or more organ failures. This includes olig-
uria, lactic acidosis, acute mental status changes,
respiratory failure, or the need for vasopressor support.
EPIDEMIOLOGY
• The incidence of sepsis is increasing and is expected
to increase approximately 1.5% per year until at least
2050 (Angus et al., 2001).
• The incidence of sepsis has increased 8.7% per year
from 1979 through 2000, now with almost 660,000
cases per year.
• The incidence is higher among men versus women
and among nonwhite persons versus white persons
(Martin et al., 2003).
• Angus et al. evaluated over 6.5 million discharge records
from seven large states in 1995:
 Estimated 750,000 cases of sepsis per year.
 Mortality rate was 28.6% with a national estimate of
215,000 deaths.
 Average cost per case was $22,100.
• Most common causative organisms in 2000 (Martin
et al., 2003):
 Gram-positive bacteria 52.1%
 Gram-negative bacteria 37.6%
 Polymicrobial infections 4.7%
 Fungi 4.6%
 Anaerobic bacteria 1.0%
 No specific organism is cultured in approximately
50% of cases (Martin et al., 2003)
• Most common sites of infection (Angus et al., 2001):
 Respiratory tract (44%)
 Bacteremia (17.3%)
 Genitourinary (9.1%)
 Abdominal (8.6%)
 Wound/soft tissue (6.6%)
 Device-related (2.2%)
 Central nervous system (CNS) (0.8%)
 Endocarditis (0.6%)
• Mortality:
 About 30% of patients die within the first month of
diagnosis and 50% die within 6 months.
 Up to 135,000 European and 215,000 American
deaths each year.
 Kills approximately 1400 people worldwide every day.
 Severe sepsis is the leading cause of death in the
noncoronary intensive care unit (ICU).
• Sepsis is increasingly recognized as a disease of the
elderly with an age-specific incidence of severe sepsis
of 26.2/1000 in persons >85 years old.
PATHOGENESIS
• The sepsis syndrome results from the host’s immune
response to infection: concepts related to its patho-
genesis are evolving.
• The normal host response to infection is the activation
of local and circulating phagocytic cells and genera-
tion of proinflammatory and anti-inflammatory medi-
ators designed to limit and control bacterial invasion
of host tissues.
• The prevailing theory has been that sepsis is the result of
an uncontrolled or hyperimmune response to infection.
• The balance of proinflammatory and anti-inflammatory
elements serves to facilitate tissue repair and healing.
• Remote tissue injury may ensue if the equilibrium
between these opposing forces is lost and new data
suggest that death may result from a prolonged sys-
temic hypoimmune response.
• Host factors that confer an increased risk of sepsis:
 Break in membrane integrity (surgery, toxic injury
to epithelium)
 Age (very young, elderly)
 Gender (men > women)
 Race (nonwhite > white)
 Genetic polymorphisms (e.g., tumor necrosis factor
[TNF] promoter gene and toll-like receptors)
 Comorbidities (e.g., diabetes mellitus and immuno-
suppression)
• Pathogenic microbial factors:
 Properties of capsule or envelope:
 Pili of Escherichia coli enable colonization of uri-
nary epithelium.
 Capsular polysaccharides of Streptococcus pneu-
moniae prevent phagocytosis.
 Cell wall components:
 Lipopolysaccharide of Gram-negative organisms
is known to trigger the septic response.
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 Exotoxins:
 Gram-positive organisms can secret exotoxins that
act as superantigens bypassing normal antigenic
specificity and costimulatory signals required for
T-cell activation.
 Hyaluronidase can promote bacterial spread along
tissue planes.
EXPANDED DEFINITIONS OF ACUTE
ORGAN DYSFUNCTION IN SEVERE
SEPSIS OR SEPTIC SHOCK
CARDIOVASCULAR SYSTEM
• Arterial systolic blood pressure ≤90 mmHg or the mean
arterial pressure (MAP) ≤70 mmHg for at least 1 hour
despite adequate fluid resuscitation or the use of vaso-
pressors in an attempt to maintain a systolic blood
pressure of ≥90 mmHg or a MAP of ≥65 mmHg (Levy
et al., 2003)
• Tachycardia
• Arrhythmias
• Cardiac arrest
RESPIRATORY SYSTEM
• The ratio of PaO2 to FiO2 ≤250 in the presence of other
dysfunctional organs or systems or ≤200 if the lung is
the only dysfunctional organ
• PaO2 <70 mmHg
• SaO2 <90%
• Tachypnea
• Mechanical ventilator dependence with or without
positive end-expiratory pressure (PEEP)
RENAL
• Urine output <0.5 mL/kg of body weight/h for 1 hour,
despite adequate fluid resuscitation
• Acute elevation of serum creatinine
• Oliguria
• Anuria
• Requirement for renal replacement therapy
HEMATOLOGIC
• Platelet count <80,000/mm3 or having decreased by
50% in the preceding 3 days
• Leukocytosis/leukopenia
• Increased prothrombin time
• Elevated partial thromboplastin time
• Decreased protein C
• Increased D-dimer
• Impaired leukocyte function
GASTROINTESTINAL
• Elevated pancreatic enzymes (amylase, lipase)
• Decreased gastric pHi
• Ileus
• GI bleeding or perforation
• Intestinal ischemia
• Acalculous cholecystitis
• Acute pancreatitis
• Intolerance of enteral nutrition
HEPATIC
• Hyperbilirubinemia
• Elevated aminotransferases
• Increased lactate dehydrogenase (LDH)
• Elevated alkaline phosphatase
• Hypoalbuminemia
• Elevated prothrombin time
• Jaundice
• Asterixis
NEUROLOGIC
• Delirium
• Altered consciousness
• Impaired mentation
• Confusion
• Psychosis
• Abnormal electroencephalogram (EEG)
METABOLIC/ENDOCRINE
• pH <7.30 or a base deficit ≥5.0 mmol/L in association
with a plasma lactate level >1.5 times the upper limit
of the normal value
• Hyperglycemia
• Hypertriglyceridemia
• Hypoalbuminemia
PROGNOSIS
• Prognosis in severe infections has multiple determi-
nants including host defense mechanisms, the envi-
ronment, and the specific microorganisms involved.
• Specific risk factors for death include comorbid con-
ditions, severity of acute illness and acute organ dys-
function, shock, nosocomial infection, and infection
caused by aerobic gram-negative bacilli, enterobacte-
ria, Staphylococcus aureus, and infection from a gas-
trointestinal or unknown source.
• The number and severity of organ failures are signifi-
cantly associated with outcome.
 Risk factors for hospital mortality were evaluated in
3608 ICU patients included in the European Sepsis
Study.
 Mortality was similar for patients with infection and
sepsis but increased in patients with sepsis and organ
dysfunction (i.e., severe sepsis or septic shock).
MANAGEMENT
INITIAL EVALUATION
• Severe sepsis is a medical emergency and immediate
attention to the “ABCs” or airway, breathing, and cir-
culation is appropriate.
• After initial stabilization, the source of infection
should be established, controlled, and broad-spectrum
antibiotics should be administered.
• Source control of infection includes identifying all
potential foci of infection and directly examining
material from these sites by Gram’s stain, culture, and
immunologic studies (where appropriate).
• After these initial steps, consider additional support for
dysfunctional or failing organs, disease-specific inter-
ventions, and other general supportive care measures.
• Consider early hemodynamic monitoring including
arterial line and central venous catheter for measure-
ment of central venous pressure (CVP) and the ScvO2.
• Eleven international organizations have published
Surviving Sepsis Campaign (SSC) guidelines for
managing severe sepsis and septic shock (Table 43-1).
INITIAL RESUSCITATION
• Initial intervention is administration of large amount
of intravenous fluids to reverse organ hypoperfusion
in the setting of relative hypovolemia.
• Fluid deficits may be in the range of 6–10 L of
crystalloids.
• Fluid choice has been controversial in the past but the
recent SAFE (Saline vs. Albumin Fluid Evaluation)
study has shown that there is no therapeutic advantage
to colloids versus crystalloids.
• Early (first 6 hours), goal-orientated resuscitation, aimed
at raising the ScvO2 to at least 70% in severe sepsis or
septic shock, improved outcome in a single study. Those
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TABLE 43-1 Synopsis of Major SSC Practice Guidelines
INTERVENTION GUIDELINES RECOMMENDATION
Initial resuscitation 1. Resuscitate within 60 min to achieve a MAP ≥ 65 mmHg, urine output ≥ 0.5 mL/kg/h, and a CVP of 8–12 mmHg
(12–15 mmHg in mechanically ventilated patients)
2. Packed red blood cells or dobutamine to achieve an ScvO2 of ≥70%
Fluids 1. Crystalloids or colloids
2. Packed red blood cells to achieve a target Hb of 7–9 g/dL
Source control and antibiotics 1. The site of infection should be rapidly identified and appropriate source control measures instituted
2. When the specific infecting organism is unknown, empiric antibiotics should be administered within the first hour
of treatment
Mechanical ventilation 1. 6 mL/kg tidal volume (IBW) for patients with ALI/ARDS
2. Avoid increased VT plus increased plateau pressure (PP)—maintain end-expiratory PP <30 cmH2O
3. PEEP should be employed to avoid oxygen toxicity in patients treated with high FiO2
4. Consider prone positioning in patients with dangerous FiO2 levels
Drotrecogin alfa (activated) 1. Indicated for all patients at high risk of death
2. No absolute contraindication
3. Administer as soon as possible after “high-risk of death” identified
Steroids 1. Indicated for patients with vasodepressor-dependent shock despite fluids
2. Administer 200–300 mg/day × 7 days by either continuous intravenous infusion or in divided doses at 6-h intervals.
3. The following steroid-related issues remain unresolved: adrenocorticotropic hormone (ACTH) stimulation test,
weaning, mineralocorticoid, need to discontinue after resolution of shock
Glycemia control 1. Maintain blood glucose <150 mg/dL with insulin and glucose∗
2. Monitor glucose concentrations at the bedside
Sedation 1. Intermittent as required, or;
2. Continuous with daily interruption
*The SSC group expressed concerns that an initial recommendation for strict glycemic management (80–110 mg/dL) might be so stringent that it might
not be adopted.
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randomized to goal-directed resuscitation received more
fluid, blood, and dobutamine in the early hours.
HEMODYNAMIC SUPPORT
• Vasopressor and inotropes are added if fluid resusci-
tation fails to restore adequate arterial pressure and
organ perfusion.
• Invasive monitoring of blood pressure is recommended.
• A number of different agents are available and the
choice of agents requires knowledge of the pharmaco-
dynamic properties as well as appropriate application
to the clinical situation.
• There have been no large scale, randomized, con-
trolled trials to determine which vasoactive drug strat-
egy is best, but norepinephrine is the most commonly
used initial vasoconstrictor.
• Vasopressin may be useful as a catecholamine-sparing
agent.
• Monitor for restoration of perfusion to vital organs
and peripheral tissues.
• Typical goals include MAP >65 mmHg, warm
extremities, normal capillary refill, increased urinary
output, and improved mentation.
• Careful monitoring for complications of vasoactive
drugs including impaired splanchnic blood flow and
oxygenation, impaired distal extremity perfusion, and
worsening acidemia.
RESPIRATORY SUPPORT
• Sepsis is a significant stressor on the respiratory system.
• Up to 85% of patients with severe sepsis require ven-
tilatory support.
• Supplemental oxygen should be given to maintain
SaO2 >87%.
• Recognition of the signs of impending respiratory
failure is critical.
• Endotracheal intubation and mechanical ventilation
may stabilize the septic patient and redirect cardiac
output from the respiratory muscles to vital organs.
• A lung-protective strategy (VT 6 mL/kg ideal body
weight [IBW]) for patients with evidence of acute lung
injury (ALI) or acute respiratory distress syndrome
(ARDS) should be considered the standard of care
(see Chaps. 34 and 35).
IMPORTANCE OF EARLY GOAL-DIRECTED THERAPY
• Rivers et al. (2001) recently showed that the early provi-
sion of therapy to maintain specific hemodynamic goals
significantly reduced in-hospital mortality in severe
sepsis and septic shock patients compared to standard
hemodynamic therapy (30.5% vs. 46.5%; P = .009).
• 28-day (33.3% vs. 49.2%; P = .01) and 60-day (44.3% vs.
56.9%; P = .03) mortality rates significantly decreased.
• This study indicates the importance of the early identi-
fication and resuscitation of patients with severe sepsis
to restore the balance between oxygen supply and
demand to avoid cardiovascular collapse and death.
INFECTION MANAGEMENT
• Includes source control and prompt administration of
anti-infective agents that cover the microbial organisms
suspected in the context of the patient’s presentation.
• Source control can be divided into three broad cate-
gories (Jimenez and Marshall, 2001):
 Drainage of an abscess
 Debridement of devitalized or infected tissue
 Removal of foreign bodies colonized by pathogens
and diversion, repair, or excision of an infected
focus in a hollow viscus
• The presentation of infected foci can be subtle and
requires a thoughtful search.
• Principles of anti-infective therapy in severe sepsis are:
 Obtain cultures of suspected sources of infection
 Promptly administer parenteral antibiotics
 Antibiotic choice is based on many factors:
 Most probable diagnosis and suspected pathogens
 Site of acquisition (i.e., community or nosocomial)
 Results of Gram’s stain
 History of prior antimicrobial treatment
 Known resistance patterns in the community or
institution
 The drug’s tissue penetration
 Comorbidities
 The patient’s hepatic and renal function
 History of allergy to antibiotics
 Potential toxicity
 Risk of influencing resistance
 Initial therapy should be broad spectrum and pro-
gressively narrowed as microbiologic data become
available
 Patients should be monitored closely:
 Evidence of a response
 Development of drug toxicity
 Selection of antibiotic-resistant strains
 Appearance of a superinfection
• Specific antibiotics are discussed elsewhere.
SEPSIS-SPECIFIC INTERVENTIONS
• Early goal-directed therapy aimed at raising the
ScvO2 to at least 70%.
• Drotrecogin alfa (activated):
 Drotrecogin alfa (activated) is a recombinant human
version of activated protein C that represents the
first therapy against sepsis to show efficacy in a
phase III clinical trial.
 The PROWESS (Recombinant Human Activated
Protein C Worldwide Evaluation in Severe Sepsis)
trial is discussed in detail in Chap. 45.
 In general, patients with severe sepsis and a high risk
of death without contraindications are candidates for
therapy.
• Replacement dose corticosteroids:
 Despite earlier negative trials, recent studies have
indicated that low-dose corticosteroids may reduce
morbidity and mortality in septic shock patients.
 Stress dose steroids are indicated in patients with
known adrenal insufficiency.
 A French multicenter placebo-controlled, random-
ized, double-blind, parallel group trial (n = 300)
demonstrated improved survival in patients with
septic shock treated with low-dose hydrocortisone
and fludrocortisone:
 28-day survival benefit was limited to patients with
relative adrenal insufficiency (change in cortisol
level <9 mg/dL after cosyntropin stimulation).
 No increase of adverse events in the treatment
group was found.
 A larger European trial to confirm these results is
underway.
GENERAL SUPPORTIVE MEASURES
• Adequate nutritional support is necessary as in any
other critically ill patient.
• Glycemic control:
 Critically ill patient commonly have hyperglycemia
associated with insulin resistance which can con-
tribute to severe infections, polyneuropathy, multi-
ple organ failure, and death.
 Intensive insulin therapy in a group of surgical
ICU patients reduced in-hospital mortality by
34%.
 A similar protocol in medical critical illness failed
to show any benefit to strict glycemic control.
 Other benefits in the surgical trial:
 Decreased incidence of acute renal failure
 Decreased incidence of episodes of septicemia
 Decreased incidence of bloodstream infections
 Reduced levels of inflammatory markers
 Less prolonged use of antibiotics
 Fewer red cell transfusions required
 Less risk of polyneuropathy
 Shorter length of stay in the ICU (16.8% of
patients in the intensive treatment group stayed for
over 5 days vs. 26.3% of control patients)
• Dialysis:
 The risk of mortality in sepsis patients with acute
renal failure is >50%.
 Renal replacement therapies in critically ill patients
are primarily limited to intermittent renal replace-
ment therapy (IRRT) and continuous renal replace-
ment therapy (CRRT).
 A recent meta-analysis suggested that CRRT was asso-
ciated with a significant mortality reduction (P < .01)
when adjustments were made for study quality and
severity of illness.
• Stress ulcer prophylaxis.
• Thromboembolism prophylaxis.
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44 EARLY GOAL-DIRECTED
THERAPY FOR SEPSIS
Jonathan D. Paul
KEY POINTS
• Severe sepsis and septic shock are associated with
severe morbidity and mortality, and rapid intervention
is critical.
• Patient-specific end points, as opposed to global end
points not accounting for the body’s metabolic status,
are necessary for successful resuscitation.
• For patients with severe sepsis and septic shock, cen-
tral venous oxyhemoglobin saturation should be mon-
itored and resuscitation in the first 6 hours should be
aimed at raising its value to at least 70%.
PRINCIPLES
• A landmark study of sepsis resuscitation was per-
formed to determine whether early goal-directed ther-
apy (EGDT) in the emergency department improves
outcomes in patients with severe sepsis and septic
shock.
• Resuscitation of septic patients to restore a normal cen-
tral venous oxyhemoglobin saturation was hypothesized
to ensure a balance between systemic oxygen delivery
and oxygen demand.
• Simple hemodynamic monitoring of the patient, as
assessed by vital signs, physical examination, central
venous pressure determination, and measurement of
urinary output are useful screening tools to identify
severe sepsis and septic shock.
• Resuscitation to mean arterial pressure (MAP) >65
mmHg, central venous pressure (CVP) 8–12 cmH2O,
and urine output (UO) of 0.5 mL/kg/h did not resusci-
tate effectively many subjects with sepsis. In contrast,
titration in the first 6 hours to raise the central venous
oxyhemoglobin saturation from a starting average
value of 49% to a value exceeding 70% significantly
reduced mortality.
METHODS
• The study was prospective, randomized, blinded, and
controlled.
• Inclusion criteria included fulfillment of two out of
four criteria for the systemic inflammatory response
syndrome (SIRS) and a systolic blood pressure <90
mmHg (after a small fluid challenge) or a serum lac-
tate concentration of at least 4 mmol/L.
• Criteria for SIRS are temperature ≥38°C or <36°C,
heart rate >90, respiratory rate >20 or partial pressure
of arterial CO2 <32 mmHg, and WBC count
>12,000/mm3 or <4000/mm3 or the presence of more
than 10% immature band forms.
• Exclusion criteria included age <18, pregnancy, or the
presence of an acute cerebral vascular event, acute
coronary syndrome, acute pulmonary edema, status
asthmaticus, cardiac dysrhythmias (as a primary diag-
nosis), contraindication to central venous catheteriza-
tion, active gastrointestinal hemorrhage, seizure, drug
overdose, burn injury, trauma, a requirement for
immediate surgery, uncured cancer, immunosuppres-
sion, do-not-resuscitate status, or advance directives
preventing implementation of the protocol.
• Standard therapy consisted of treatment at the clini-
cians’ discretion according to a protocol for hemody-
namic support (CVP ≥8–12 mmHg, MAP ≥65 mmHg,
and UO ≥0.5 mL/kg/h).
• EGDT patients were monitored in the emergency
department for at least 6 hours according to the same
end points, but additionally to a central venous oxygen
saturation (ScvO2) ≥70% (Fig. 44-1).
• ScvO2 ≥70% was raised by additional fluid infusion,
transfusion of RBCs until the hematocrit was ≥30%,
administration of inotropic agents, or intubation and
mechanical ventilation.
• Patients in both groups were subsequently transferred
to intensive care units (ICU) under the care of critical
care clinicians, and these physicians were blinded to
which protocol each patient was assigned.
RESULTS
• During the initial 6 hours in the emergency depart-
ment, the goal of ScvO2 ≥70% was met by 60.2% of
patients in the standard therapy group and 94.9% of
patients in the EGDT group. The goals for CVP, MAP,
and UO were achieved in 86.1% of patients in the
standard therapy group and 99.2% of patients in the
EGDT group.
• In the ICU, during 7–72 hours, patients in the standard
therapy group had significantly higher heart rates and
lower MAPs than patients in the EGDT group. Also,
patients in the EGDT group had significantly higher
ScvO2 values than those in the standard therapy
group. The two groups had similar CVP values.
• Common indices of organ dysfunction in the ICU
(acute physiologic and chronic health evaluation
[APACHE II] score, simplified acute physiology
score [SAPS II], and multiple organ dysfunction score
[MODS]) were significantly more deranged in
patients in the standard therapy group.
• Overall in-hospital mortality rates were significantly
higher in the standard therapy group than in the
EGDT group. Mortality at 28 and 60 days was also
higher in the standard therapy group (Table 44-1).
• Of the patients surviving until hospital discharge,
those in the standard therapy group had significantly
longer hospital stays.
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Supplemental oxygen ±
endotracheal intubation and
mechanical ventilation
Central venous and
arterial catheterization
Sedation, paralysis
(if intubated),
or both
Hospital admission
CVP
Crystalloid
Colloid
<8 mmHg
<65 mmHg
>90 mmHg Vasoactive agents
Transfusion of red cells
until hematocrit > 30%
>70%
<70%
Inotropic agents
Goals
achieved
Yes
No
>70%
ScvO2
<70%
MAP
>65 and <90 mmHg
8–12 mmHg
FIG. 44-1 Protocol for EGDT.
SOURCE: Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treat-
ment of severe sepsis and septic shock. N Engl J Med 2001;345:1368–1377.
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CONCLUSIONS
• Early trials studying resuscitation aimed at normaliz-
ing the venous oxyhemoglobin saturation may have
failed to show benefit because patient-specific therapy
was delayed until later in the clinical course (after the
first 6 hours).
• Rivers et al. demonstrated that EGDT, designed
to achieve specific hemodynamic end points (Table
44-2) in the emergency department, leads to increased
survival in patients with severe sepsis and septic
shock.
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45 DROTRECOGIN ALFA
(ACTIVATED)
Michael Moore
KEY POINTS
• Drotrecogin alpha (activated) is recombinant, human,
activated protein C.
• Drotrecogin possesses antithrombotic, profibrinolytic,
and anti-inflammatory properties that may explain its
benefit in sepsis.
• Drotrecogin lessens the duration of organ failures and
reduces mortality in patients with severe sepsis at high
risk of death. It is not effective in pediatric sepsis or in
patients with low risk of death. Because of its antico-
agulant properties, drotrecogin is contraindicated when
there is active bleeding or a high risk of bleeding.
• Drotrecogin is infused intravenously at a constant
dose (24 µg/kg/h) for 96 hours.
BACKGROUND
• Drotrecogin alfa (activated) was approved by the
Food and Drug Administration (FDA) in November
2001 for the reduction of mortality in severe sepsis in
adults at high risk of death.
• Observational data collected during studies of sepsis
and septic shock point to an association between
TABLE 44-1 Kaplan-Meier Estimates of Mortality and Causes of In-Hospital Death*
STANDARD THERAPY EARLY GOAL-DIRECTED
VARIABLE (N = 133) NO. (%) THERAPY (N = 130) RELATIVE RISK (95% CI) P VALUE
In-hospital mortality†
All patients 99 (46.5) 38 (30.5) 0.58 (0.38–0.87) .009
Patients with severe sepsis 19 (30.0) 9 (14.9) 0.46 (0.21–1.03) .06
Patients with septic shock 40 (56.8) 29 (42.3) 0.60 (0.36–0.98) .04
28-Day mortality† 61 (49.2) 40 (33.3) 0.58 (0.39–0.87) .01
60-Day mortality† 70 (56.9) 50 (44.3) 0.67 (0.46–0.96) .03
Causes of in-hospital death‡
Sudden cardiovascular collapse 25/119 (21.0) 12/117 (10.3) — .02
Multiorgan failure 26/119 (21.8) 19/117 (16.2) — .27
∗CI denotes confidence interval. Dashes indicate that the relative risk is not applicable.
†Percentages were calculated by the Kaplan-Meier product limit method.
‡The denominators indicate the number of patients in each group who completed the initial in-hour study period.
SOURCE: Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med
2001;345:1368–1377.
TABLE 44-2 Recommended Goals of Initial Resuscitation
of Sepsis-Induced Hypoperfusion Within 6 H of
Presentation to the Emergency Department
CVP 8–12 mmHg
MAP ≥65 mmHg
UO ≥0.5 mg/kg/h
ScvO2 ≥70%
coagulopathy (subclinical or clinical) or low protein C
levels and mortality.
• A phase II prospective, randomized, placebo-controlled
study of drotrecogin alfa (activated) in 131 patients
with severe sepsis was conducted to determine its
safety and effect on the coagulopathy of severe sepsis.
This study showed an acceptable safety profile with a
dose/dose-duration effect on the reduction of D-dimer
levels.
• Subsequently, the PROWESS trial was designed to
detect a difference in mortality in patients with severe
sepsis treated with drotrecogin alpha (activated).
MECHANISM OF ACTION
• The exact mechanism of action in terms of the reduc-
tion of mortality as seen in the PROWESS
(Recombinant Human Activated Protein C Worldwide
Evaluation in Severe Sepsis) trial is not certain.
However, the biologic activity of activated protein C is
well described.
• Protein C is a vitamin-K-dependent protein factor
synthesized by the liver. Protein C is converted to its
active state by complexing thrombin and thrombo-
modulin in the presence of endothelial cell protein C
receptor. After conversion, it has antithrombotic,
profibrinolytic, and anti-inflammatory effects medi-
ated through inactivation of factor Va and VIIIa, inac-
tivation of plasminogen activator inhibitor, and effects
on tumor necrosis actor (TNF), macrophage migra-
tion, thrombin-induced inflammation, and nuclear
factor kB (NF-kB).
• Experimental and animal data suggest multiple poten-
tial mechanisms, and it has been suggested that syn-
ergy among drotrecogin alpha’s antithrombotic,
profibrinolytic, and anti-inflammatory effects may be
responsible for its clinical effects.
• Finally, it is postulated that the restoration and preserva-
tion of microcirculatory blood flow prevents ischemia-
reperfusion injury while the anti-inflammatory effects
prevent organ dysfunction and failure.
PROWESS TRIAL
STUDY DESIGN
• Phase III randomized, double-blind, placebo-controlled,
multicenter trial.
• Primary end point was 28-day all-cause mortality
including prospectively defined stratification by age,
acute physiologic and chronic health evaluation
[APACHE II] score, and plasma protein C activity;
changes in baseline level of plasma D-dimer level and
serum interleukin (IL)-6 levels were also analyzed.
• Patients received drotrecogin alfa (activated) 24
µg/kg/h continuous infusion for 96 hours or placebo.
• Analysis was by intention-to-treat.
INCLUSION/EXCLUSION CRITERIA
• Patients with severe sepsis defined as having a known
or suspected source of infection with evidence of
SIRS (systemic inflammatory response syndrome)
and at lease one organ dysfunction
• Excluded patients (Table 45-1)
RESULTS
• 1728 patients were randomized and 1690 received the
study drug or placebo.
• Baseline characteristics were similar in the study
groups including demographics, severity of illness,
appropriateness of initial antibiotic therapy, and base-
line indicators of coagulopathy and inflammation.
• There was a statistically significant reduction in 28-day
all-cause mortality rate (24.7% vs. 30.8%; P = .005):
 The study was terminated after second planned
interim analysis
 Absolute risk reduction 6.1%
 Relative risk reduction 19.4%
• Thrombosis as determined by plasma D-dimer levels
was significantly lower in the drotrecogin group on
days 1–7 after the start of the infusion versus placebo.
• Inflammation measured by IL-6 levels was also sig-
nificantly decreased for the majority of days after start
of infusion of drotrecogin during the first 7 days.
• Serious bleeding was higher in the drotrecogin group:
 3.5% vs. 2.0% (P = .06) over 28 days
 2.4% vs. 1.0% (P = .044) during infusion period
 Rate of intracranial hemorrhage was 0.2% versus 0.1%
in the drotrecogin and placebo groups, respectively
 Number needed to harm = 66
CONCLUSIONS
• PROWESS demonstrated the safe and effective use of
drotrecogin alfa (activated) for the reduction of mor-
tality in patients with severe sepsis.
• An antithrombotic effect was demonstrated by a sig-
nificant reduction of D-dimer levels.
• An anti-inflammatory effect was demonstrated by a
significant reduction in IL-6 levels.
• An increase in serious bleeding events was seen in the
drotrecogin alfa (activated) group versus controls. The
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difference was primarily seen during drug infusion and
in patients with identifiable risk factors for bleeding.
CONTROVERSIES
• The PROWESS trial has generated a number of con-
troversies. These primarily relate to changes made to
the protocol midway through the trial, risk of serious
bleeding, FDA labeling restricting use based on
APACHE II scores, and cost-effectiveness.
PROTOCOL CHANGES
• Two main changes were made:
 The trial was amended to more effectively exclude
patients with a high risk of death from preexisting
illness.
 The master cell line used to manufacture drotreco-
gin was changed.
• The observed reduction in mortality was improved
after these changes were made.
• However, a subsequent analysis showed that the mortal-
ity benefit was greater in the subgroup of patient who
would have been excluded after the protocol changes.
The protocol changes made drotrecogin alpha (activated)
less effective than if the protocol were not amended.
• The manufacturer conducted extensive testing of the
new master cell line prior to its use in PROWESS. No
significant differences were seen. While it is not pos-
sible to rule out all potential changes in a complex
protein drug product, the new master cell line would
then be more effective, not less.
RISK OF SERIOUS BLEEDING
• More serious bleeding events were observed in the
drotrecogin alpha (activated) group: this was both pre-
dicted based on the known actions of drotrecogin, and
has been confirmed in studies subsequent to
PROWESS.
• Bleeding was seen primarily during the infusion
period and in patients with known risk factors for
bleeding (e.g., platelet count <30,000/mm3).
• Some authors have noted increased rates of fatal
intracranial hemorrhage in patients treated with
drotrecogin alpha (activated) in open-label use. In
published data to date, the rate of intracranial hemor-
rhage is 0.5% (open-label use).
USE OF APACHE II SCORES
• The APACHE II score was developed and validated as a
measure to predict mortality in critically ill ICU patients.
• The FDA approved drotrecogin alpha (activated) in
patients who are at high risk of death, such as those
who have an APACHE II score greater than the mean
value in PROWESS (APACHE II score = 25).
• Subsequent analysis has showed that the APACHE II
score can identify patients more likely to benefit from
drotrecogin alpha (activated).
TABLE 45-1 Trial Inclusion and Exclusion Criteria
Inclusion criteria
Known or suspected infection
Three of four SIRS criteria:
Temperature ≥38.0°C or ≤36.0°C
Heart rate ≥90 beats/min
Respiratory rate ≥20 breaths/min or PaCO2 of ≤32 mmHg
White cell count ≥12,000/mm3 or ≤4000/mm3
At least one dysfunctional organ or system:
Systolic BP ≤90 mmHg or MAP ≤70 mmHg despite adequate fluid
resuscitation, adequate volume status, or use of vasopressors
Urine output, 0.5 mL/kg/h despite adequate volume status
PaO2/FiO2 ratio ≤250 or ≤200 if lung was only dysfunctional organ
Platelet count <80,000/mm3 or 50% decrease during last 3 days
pH ≤7.30 or base deficit ≥5.0 mmol/L with plasma lactate >1.5 times
upper limit of normal
Exclusion criteria
Pregnancy or breast-feeding
Age >18 years or weight >135 kg
Conditions that increased risk of bleeding: surgery or anticipation of
need for surgery with general or spinal anesthesia, postoperative
bleeding; severe head trauma, intracranial surgery, or stroke within
3 months or any history of intracerebral AVM, cerebral aneurysm, or
CNS mass lesion; history of congenital bleeding diathesis;
gastrointestinal bleeding within 6 weeks without corrective surgery;
trauma considered to increase risk of bleeding
Known hypercoagulable condition or recently documented (within
3 months) or highly suspected DVT or PE
Advance directive to withhold life-sustaining treatment; physician, or
family, or both not in favor of aggressive treatment
Moribund state or patients not expected to survive 28 days because of
uncorrectable medical condition
HIV with CD4 <50/mm3
History of bone marrow, lung, liver, pancreas, or small-bowel
transplantation
Chronic renal failure requiring renal replacement therapy
Known or suspected portosystemic hypertension, chronic jaundice,
cirrhosis, or chronic ascites
Acute pancreatitis with no known source of infection
Use of banned medication including therapeutic anticoagulation,
ASA >650 mg/day within 3 days, systemic thrombolytic therapy
within 3 days, glycoprotein IIb/IIIa antagonists within 7 days,
antithrombin III, or protein C
ABBREVIATIONS: BP, blood pressure; MAP, mean arterial pressure; AVM,
arteriovenous malformation; CNS, central nervous system; DVT, deep
vein thrombosis; PE, pulmonary embolism; ASA, aspirin.
COST-EFFECTIVENESS
• Manns et al. used data from PROWESS and FDA analy-
ses to compare the cost-effectiveness of drotrecogin
alpha (activated) and standard therapy for severe sepsis:
 Cost per life-year gained was $27,936 for all patients
 Cost per life-year gained stratified by APACHE II
scores (FDA analysis)
 $24,484 for APACHE II scores >25
 $575,054 for APACHE II scores ≤24
 Cost per life-year gained increased with increasing
age and was higher in patients with lower expected
survival based on comorbid conditions
• Angus et al. conducted a prospective cost-effectiveness
analysis based on the PROWESS cohort:
 Drotrecogin alpha (activated) cost $160,000 per life
saved
 $48,000 per quality-adjusted life-year with an 82%
probability that the ratio is <$100,000 per quality-
adjusted life-year
 $27,000 per quality-adjusted life-year in patients
with APACHE II >25
 Drotrecogin alpha (activated) was cost-ineffective in
patient with APACHE II ≤24
 The cost-effectiveness profile was comparable to
other well-accepted therapeutic interventions
RECOMMENDED USE
• Drotrecogin alpha (activated) should be considered for
adult patients with recent onset of severe sepsis or septic
shock who are at a high risk of death, such as those with
APACHE II score >25 or with at least two organ failures.
• Careful evaluation of patients including assessment of
potential benefits and risks of adverse event is essen-
tial especially with regard to patients who were not
studied in the PROWESS trial (Table 45-2).
• APACHE II scores most effectively discriminated
among patients likely to benefit from therapy in the
PROWESS trial, but this single measure should not
replace clinical judgment regarding high risk of death.
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46 AN APPROACH TO SEPSIS
OF UNKNOWN ETIOLOGY
Nina M. Patel
KEY POINTS
• A thorough history and physical examination,
repeated at frequent intervals, are essential in primary
bacterial or nonbacterial sepsis to guide diagnostic
workup and empiric antimicrobial therapy.
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TABLE 45-2 Contraindications/Warnings/Precautions
Contraindications
Hypersensitivity to drotrecogin alpha (activated)
Active internal bleeding
Recent hemorrhagic stroke (within 3 months)
Sever head trauma (within 2 months)
Recent intracranial or intraspinal surgery (within 2 months)
Intracranial neoplasm or mass
Evidence of cerebral herniation
Presence of epidural catheter
Trauma with increased risk of life-threatening bleeding
Warnings/Precautions
Increased bleeding risk in patients with:
Concurrent therapeutic heparin
Oral anticoagulants
Glycoprotein IIb/IIIa antagonists
Platelet aggregation inhibitors
High dose aspirin (>650 mg/day within 7 days)
International normalized ratio (INR) >3.0
GI bleeding (within 6 weeks)
Platelet <30,000/mm3
Thrombolytic therapy (within 3 days)
Recent ischemic stroke (within 3 months)
Intracranial AVM or aneurysm
Known bleeding diathesis
Chronic severe liver disease
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• The detection of secondary sepsis in the ICU requires
extreme vigilance, a high clinical index of suspicion
on a daily basis, and focused attention to local and
systemic risk factors for infection.
• Broad-spectrum antibiotic therapy should be initiated
promptly in all septic patients, even amidst investiga-
tion for the primary source of infection. If a causative
infectious agent is identified, the spectrum of antibi-
otic therapy should be narrowed to offer coverage spe-
cific to that pathogen.
• Immunosuppressed patients require more exten-
sive empiric antimicrobial therapy than the normal
host.
• Sepsis has a high mortality rate, but vigilance toward
detecting infection early and instituting appropriate
therapy expediently improve morbidity and mortality.
EPIDEMIOLOGY
• 750,000 people per year acquire sepsis in the US.
• The mortality rate associated with sepsis is 35–45%.
DEFINITION
• Sepsis is defined as infection-provoked systemic
inflammatory response syndrome (SIRS; see
Chap. 43).
• If acute organ dysfunction or hypotension accompa-
nies SIRS, severe sepsis is present.
• Septic shock is severe sepsis accompanied by refrac-
tory hypotension.
• Primary sepsis is the sepsis syndrome or septic shock
in the absence of a clear source of infection.
• Secondary sepsis is the development of hemodynamic
instability and recurrent sepsis syndrome despite ade-
quate antimicrobial therapy for a known initial source
of infection.
DIFFERENTIAL DIAGNOSIS
• Primary and secondary sepsis may be bacterial or
nonbacterial in nature. In addition, a number of non-
infectious syndromes can mimic the clinical picture
observed in sepsis.
PRIMARY SEPSIS
• A thorough history and physical examination, with
attention to timing of onset of symptoms, localization
of symptoms and signs, travel and past medical history
(in particular, risk factors for immunosuppression),
are essential to guiding the diagnostic evaluation of
sepsis.
• Diagnostic evaluation begins with basic laboratory
tests: complete blood count (CBC) with differential,
comprehensive metabolic panel, blood cultures, urine
culture, and a chest radiograph.
• Fever, hypotension, tachycardia, tachypnea, decreased
urine output, and decreased mental status are seen fre-
quently in septic patients. Laboratory perturbations
suggestive of sepsis include leukocytosis or leukope-
nia; thrombocytopenia; hyper- or hypoglycemia;
anion gap metabolic acidosis (lactic acidosis, in par-
ticular); elevated transaminases or bilirubin (direct);
respiratory alkalosis; and hypoxemia.
• Clinical history and examination should guide further
testing:
 If mental obtundation or nuchal rigidity is present or
there is concern for central nervous system (CNS)
pathology, head computed tomography (CT) and
lumbar puncture should be performed to evaluate
for meningitis.
 If productive cough, shortness of breath, or other
respiratory symptoms are present, sputum should be
sent for Gram’s stain, culture, and susceptibility.
Thoracentesis should be performed to rule out an
empyema if there is a pleural effusion. If purulent
nasal drainage is present, CT of the sinuses should
be performed with a plan to aspirate the sinuses if
there is an air-fluid level.
 If indwelling vascular devices are present, one set
of blood cultures should be drawn through the
device. If the site looks infected or in the setting of
bacteremia, the catheter should be removed and
sent for culture. Also, transesophageal echocardio-
graphy should be considered to evaluate for
endocarditis.
 If ascites or indwelling drains are present, the peri-
toneal or drain fluid should be sampled and sent for
Gram’s stain and culture. Also, abdominal imaging
with CT or ultrasound should be considered.
 If there is a history of nephrolithiasis, pyelonephritis,
or other renal pathology, renal ultrasound should be
ordered to assess for a perinephric abscess and to
exclude urinary obstruction.
 If swollen, hot, tender joints are present, septic
arthritis should be ruled out with aspiration of the
affected joint. If persistent bacteremia and focal
bony pain are identified, plain films or bone scan
should be ordered to evaluate for osteomyelitis.
• If no obvious source of infection is present following
a detailed history and physical examination, one
should reconsider common sources of infection that
may be presenting in an uncommon fashion. A chest
radiograph should be repeated after hydration to
reassess for pneumonia if there are respiratory symp-
toms. Abdominal films and serial abdominal exami-
nations should be performed if there is even a mildly
abnormal abdominal examination.
• If no source is identified, sepsis is presumed due to
bacteremia or endocarditis. Staphylococcus aureus is
the most common cause of in-hospital bacteremia.
• Nonbacterial causes of sepsis include malaria
(Plasmodium falciparum), dengue fever, or other par-
asitic infections in the returned traveler, rickettsial
infection (Rocky Mountain spotted fever, ehrlichio-
sis), and viral hepatitis.
• Noninfectious sources of sepsis syndrome are drug
intoxication or withdrawal, anaphylaxis, vasculitis,
acute pancreatitis, massive tissue injury (e.g., rhab-
domyolysis), and heat stroke.
• Patients with diabetes mellitus, chronic renal disease,
chronic liver disease, asplenia, and immunodeficiency
or on immunosuppressive medical therapy should
be evaluated meticulously due to increased risk
for infection with encapsulated organisms, fungus,
gram-negative bacteria, S. aureus, or opportunistic
pathogens.
NOSOCOMIAL INFECTION
• Patients who redevelop fever or hemodynamic insta-
bility and sepsis syndrome despite what is deemed
adequate antibiotic therapy should be evaluated for
four major possibilities: (1) initial antibiotic cover-
age was not adequate, (2) secondary antimicrobial
resistance to the antibiotic has emerged, (3) the
antibiotic was unable to penetrate the site of infec-
tion (e.g., abscess), (4) a new primary infection has
developed.
• These patients should undergo resampling of the initial
site of infection. They also should have inspection of
all indwelling devices (e.g., lines) to assess for access
device-related infection. Workup for fungal and viral
infection should be completed in an immunosup-
pressed host with no other source of infection.
• Other occult or subtle infectious sources in the ICU
patient are ventilator-associated pneumonia, acalculous
cholecystitis, multidrug-resistant urinary tract infec-
tion, frontal or maxillary sinusitis, suppurative paroti-
tis, wound or decubitus ulcer infection, secondary
peritonitis, and pseudomembranous colitis.
• Several antibiotics, antiarrhythmics, and other med-
ications used in the ICU can lead to drug fever. The
possibility that drugs may be responsible for fever
should be considered in all ICU patients, particularly
if there is no obvious source of infection.
TREATMENT AND PREVENTION
• Appropriate antibiotic therapy decreases the mortality
rate of sepsis by 11%. However, delay in initiating
adequate therapy can lead to increased mortality and
morbidity from sepsis.
• Broad-spectrum antibiotic coverage with reasonable
gram-positive and gram-negative coverage is recom-
mended for initial therapy for primary sepsis if no
causative organism is identified. Particular attention
should be directed toward evaluating for the possibil-
ity of anaerobic infection, meningitis, methicillin-
resistant S. aureus (MRSA) infection, or pseudomonal
infection. These bacteria are not always covered by
standard broad-spectrum antibiotic coverage.
• Empiric broad-spectrum antibiotic therapy for sec-
ondary sepsis should always include coverage for
MRSA and Pseudomonas aeruginosa. Additional fac-
tors in antibiotic selection are local bacterial suscepti-
bility and resistance patterns as well as impaired host
immunity (e.g., neutropenia).
• Empiric antifungal therapy should be considered in
patients with neutropenia or severe immunosuppres-
sion who have not responded clinically to antibiotic
therapy.
• At 48–72 hours, all microbiologic data should be
reviewed and the antibiotic regimen tailored if possi-
ble. If a clear source of infection is identified, antibi-
otic coverage should be narrowed to prevent the
development of resistant organisms or bacterial
superinfection.
• An adequate response to therapy is marked by a nor-
malization of vital signs, resolution of leukocytosis or
leukopenia, and resolution of acidosis and other lab
abnormalities.
• Source control signifies: (a) drainage of abscesses or
fluid collections, (b) debridement of devitalized or
necrotic tissue, (c) removal of infected devices (e.g.,
catheter) or excision of an infected viscus. Aggressive
source control prevents extension of infection and
worsening of clinical status.
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47 EMPIRIC ANTIBIOTIC
SELECTION FOR SEVERE
INFECTIONS
Kevin Gregg
KEY POINTS
• Incorrect empiric antibiotic selection has been shown
to lead to increased mortality and longer hospital
stays in critically ill patients.
• Initial antibiotic coverage in a critically ill patient
should be broad, covering likely community-acquired
and nosocomial infectious organisms.
• Appropriate cultures should be drawn prior to the
administration of antibiotics whenever possible.
These should include samples from urine, peripheral
blood from multiple sites (including indwelling
catheters and arterial lines), and sputum.
• When selecting initial antibiotic coverage in the ICU, the
risk factors for infection should be carefully assessed in
each patient.
 Is the patient immunocompromised?
 Do they have instrumentation that could be a source
for infection?
 Are they mechanically ventilated?
 Have they been hospitalized or institutionalized recently?
 Have they recently been on antibiotics?
• Antimicrobial resistance patterns vary in different
hospitals and communities. These patterns may help
determine appropriate empiric therapy.
SEPSIS AND SEPTIC SHOCK IN THE
IMMUNOCOMPETENT PATIENT
• The most frequent sites of infection leading to sepsis
are the lungs, the blood, the abdomen, the urinary
tract, and the skin.
• Gram-positive organisms are most often responsible
for sepsis, followed by gram-negative organisms.
• Fungal infections account for only 5% of all cases of
sepsis.
• Initial antibiotic therapy should broadly cover gram-
positive, gram-negative, and anaerobic organisms if
the infecting organism is unknown.
• Ureidopenicillins + β-lactamase inhibitors, carbapen-
ems, and third- or fourth-generation cephalosporins
have very similar, broad antimicrobial spectra.
• Evidence shows that empiric monotherapy with a car-
bapenem or a third- or fourth-generation cephalosporin
is as efficacious as combination therapy with a β-lactam
and an aminoglycoside.
• Ureidopenicillins with β-lactamase inhibitors have
also been as effective as combination antibiotic ther-
apy in several small studies.
• If there is concern for methicillin-resistant Staphylococcus
aureus (MRSA), vancomycin or linezolid should be
included in the initial regimen.
• If there is concern for vancomycin-resistant Enterococcus
spp. (VRE), linezolid should be included in the initial
regimen.
• Combination antimicrobial therapy (“double cover-
age”) for Pseudomonas aeruginosa remains controver-
sial. The results of a meta-analysis suggest that routine
combination therapy in gram-negative bacteremia does
not decrease mortality. However, if P. aeruginosa or
multidrug-resistant (MDR) gram-negative bacilli are
suspected, combination therapy may still be war-
ranted. In that setting, increasing the likelihood of ade-
quate coverage by utilizing a second agent aids in
alleviating the increased morbidity and mortality asso-
ciated with inadequate coverage at the onset of sepsis.
• An algorithm for empiric selection of antibiotic ther-
apy is presented in Fig. 47-1.
SEPSIS AND SEPTIC SHOCK IN THE
IMMUNOCOMPROMISED PATIENT
• An infectious disease specialist should be consulted as
soon as possible; these patients are at risk for significant
morbidity and mortality if not managed appropriately.
• Immunocompromised patients are at risk for the same
infections that most often cause sepsis in immunocom-
petent patients, but are at higher risk for systemic fungal
and viral infections than an immunocompetent patient.
• Initial antimicrobial coverage should be the same as
in an immunocompetent host (carbapenem, third- or
fourth-generation cephalosporin, ureidopenicillin +
β-lactamase inhibitor) and should include vancomycin
or linezolid.
• In a neutropenic patient, combination therapy to treat
P. aeruginosa infection is recommended, although to
date there are not data to support improved patient
outcomes with this practice.
• If the immunocompromised patient is at high risk for
fungal infection, antifungal therapy with amphotericin B,
caspofungin, or voriconazole should be initiated.
• Empiric therapy with antiviral agents is generally not
warranted.
INTRAVENOUS CATHETER-RELATED
INFECTIONS
• There are little or no data to support the use of one
particular empiric antibiotic regimen for catheter-
related infections.
• In hospitals or communities with significant MRSA
prevalence, the recommended empiric therapy is
vancomycin.
• In immunocompromised or severely ill patients, addi-
tional coverage with an antipseudomonal agent is
recommended.
• If fungemia is suspected, amphotericin B or intra-
venous fluconazole may be initiated.
VENTILATOR-ASSOCIATED
PNEUMONIA, HOSPITAL-ACQUIRED
PNEUMONIA, AND HEALTH CARE-
ASSOCIATED PNEUMONIA
• Nosocomial pneumonia and ventilator-associated
pneumonia (VAP) cause significant morbidity and
mortality in critically ill patients including increased
organ dysfunction, length of stay, cost, and death.
• Patient risk factors requiring broad-spectrum antibi-
otics in suspected VAP, hospital-acquired pneumonia
(HAP), and health care-associated pneumonia (HCAP)
(American Thoracic Society [ATS] guidelines):
 Recent antibiotic therapy (within 3 months)
 Hospitalization for 2 or more days in the last
3 months
 Immunosuppression
 Chronic dialysis within the past 30 days
 Residence in a nursing home or other health care
institution
 Home infusion therapy
 Home wound care
 Family member with MDR organism
 High level of antibiotic resistance in hospital or
community
• If none of the risk factors requiring broad-spectrum
antibiotics are present, patients may be covered for typ-
ical pneumonia pathogens (Streptococcus pneumoniae,
Haemophilus influenzae, MSSA) and enteric gram-
negative bacilli (Escherichia coli, Klebsiella pneumo-
niae, Serratia marcesans). Coverage can often be a
single antibiotic covering these organisms: most fluo-
roquinolones, ampicillin/sulbactam, or ceftriaxone.
• Empiric broad-spectrum antibiotics should cover gram-
positive and gram-negative organisms, atypical organ-
isms (including Legionella pneumophila), MRSA,
P. aeruginosa, K. pneumoniae, and Acinetobacter spp.
• If P. aeruginosa is suspected, two antipseudomonal
antibiotics should be used (β-lactam + fluoro-
quinolone or aminoglycoside).
• A treatment selection algorithm is presented in
Fig. 47-2.
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FIG. 47-1 Empiric antibiotic therapy in sepsis and septic shock in the immunocompe-
tent patient.
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SEVERE COMMUNITY-ACQUIRED
PNEUMONIA
• Community-acquired pneumonia (CAP) necessitating
admission to the ICU should broadly cover typical
organisms (S. pneumoniae, H. influenzae, S. aureus),
atypical organisms (Mycoplasma pneumoniae,
Clamydia pneumoniae), and L. pneumophila.
• Empiric antibiotic selection for patients without risk
factors for P. aeruginosa infection should include an
intravenous third-generation cephalosporin and an intra-
venous macrolide or nonpseudomonal fluoroquinolone.
• For patients with risk factors for P. aeruginosa infec-
tion, empiric antibiotic selection should include: (1)
carbapenem or ureidopenicillin + β-lactamase inhibitor
or antipseudomonal cephalosporin and intravenous
antipseudomonal fluoroquinolone OR (2) carbapenem
or ureidopenicillin + β-lactamase inhibitor or
antipseudomonal cephalosporin and aminoglycoside
and fluoroquinolone.
FUNGAL INFECTIONS
• Fungal infections cause approximately 5% of all cases
of sepsis; therefore, the empiric use of antifungal ther-
apies should be based on patient risk factors.
• Patients at higher risk for fungal sepsis include:
patients on broad-spectrum antibiotics, patients who
are immunocompromised, and patients known to be
colonized with Candida spp.
FIG. 47-2 Empiric antibiotic therapy for VAP, HAP, and HCAP in patients at risk for MDR pathogens.
SOURCE: Adapted from ATS guidelines.
TABLE 47-1 Dosages of Antibiotics Commonly Used as
Empiric Therapy in the Critical Care Setting*
Ureidopenicillins + β-lactamase inhibitor
Piperacillin/tazobactam 3.375 g IV q 6 h†
Ticarcillin/clavulanate 3.1 g IV q 4–6 h†
Carbapenems
Meropenem 0.5–1.0 g IV q 8 h†
Imipenem/cilastatin 500 mg IV q 6 h†
Third-generation cephalosporins
Ceftriaxone 2.0 g IV q 24 h‡
Ceftizoxime 1.0–4.0 g IV q 8 h†
Cefotaxime 1.0–2.0 g IV q 4-12 h†
Ceftazidime 1.0–2.0 g IV q 8-12 h†
Fourth-generation cephalosporins
Cefepime 1.0–2.0 g IV q 12 h†
Aminoglycosides
Gentamicin 5.1 mg/kg IV q 24 h†,§
Amikacin 15 mg/kg IV q 24 h†,§
Tobramycin 5.1 mg/kg IV q 24 h†,§
Fluoroquinolones
Ciprofloxacin 200–400 mg IV q 24 h†
Gatifloxacin 200–400 mg IV q 24 h†
Moxifloxacin 400 mg IV q 24 h
Levofloxacin 250–750 mg IV q 24 h†
Glycopeptides
Vancomycin 15 mg/kg IV q 24 h†
Oxazolidinones
Linezolid 600 mg IV q 12 h†
*This list does not include all antibiotic options available.
†Antibiotic dose must be altered if renal function is impaired.
‡Dose for persons <65 years old. Dose 1.0 g IV q 24 h if >65 years old.
§Multiple daily dosing regimens available.
• Caspofungin is as effective as liposomal amphotericin
B and is associated with fewer side effects in neu-
tropenic patients with persistent fever.
• Amphotericin B, liposomal amphotericin B, caspo-
fungin, itraconazole, and voriconazole have different
antifungal spectra and associated toxicities which
should be considered on a patient-by-patient basis
when administering these drugs as empiric therapy.
DOSING REGIMENS
• Recommended dosing regimens by antibiotic option
are listed in Table 47-1.
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48 NEUTROPENIC PATIENTS
Nathan Sandbo
KEY POINTS
• The risk of infection rises when the ANC falls below
500/mm3 and is highest once the count is below 100/mm3.
• Fever is defined as an oral temperature of >38°C sus-
tained over 1 hour, or a single measurement of
>38.3°C in neutropenic patients.
• Evaluation of the febrile, neutropenic patient should
include a meticulous physical examination, seeking
even subtle evidence of infection, involving sites not
often involved in infection (periodontal, perianal), and
assessing any hardware, especially semipermanent
intravenous catheters.
• High-risk patients can be treated with intravenous antibi-
otics either in combination (extended spectrum β-lactam
combined with an aminoglycoside) or as monotherapy
(third- or fourth-generation cephalosporin, such as cef-
tazidime or cefepime, or carbapenems, such as
imipenem-cilastin). In selected patients at higher risk for
β-lactam-resistant gram-positive organisms, vancomycin
should be added.
• Fungal infections become more likely when fever
fails to respond to 3–5 days of broad-spectrum antibi-
otic therapy.
BACKGROUND
• The use of chemotherapies to treat malignancy has
evolved over the past two decades, and has resulted in
increasing doses with resultant increases in systemic
toxicity.
• Commonly used chemotherapeutic agents differen-
tially affect rapidly dividing cells, and myelosuppres-
sion is a frequent result, usually occurring around
days 10–14. Furthermore, there is a simultaneous
impairment of both cell-mediated and humoral host
immune responses, resulting in significant immuno-
suppression after treatment.
• Risk of opportunistic infections increases as the
absolute neutrophil count (ANC) drops below
500/mm3, with the highest risk occurring when ANC is
<100/mm3. Increased duration of neutropenia also is
associated with increasing risk of morbidity and
mortality.
• In addition, the basal epithelial cells lining the upper
and lower gastrointestinal (GI) tract, upper and lower
respiratory tract, and genitourinary tract are differen-
tially sensitive to the effects of chemotherapeutic
agents, resulting in disruption of the mucocutaneous
barrier, and further predisposition to infection. Severe
damage manifests clinically as mucositis and diffuse
GI ulcerations.
• The presence of other integumentary defects from
indwelling central venous lines, urinary catheters, or
other devices further increases the risk of opportunis-
tic infection.
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APPROACH TO FEVER IN
NEUTROPENIC PATIENTS
• Fever is most strictly defined in neutropenic patients
as an oral temperature of >38°C sustained over 1 hour,
or a single measurement of >38.3°C.
• The presence of fever in a neutropenic patient is
assumed to represent infection unless a clear alterna-
tive etiology is present. As a result, the workup of a
neutropenic patient is necessarily focused on the iden-
tification of a possible infectious focus, and subse-
quent risk stratification.
• History should focus on the timing and nature of recent
cytotoxic therapy, the administration of new drugs or
blood products, and the onset of new symptoms.
• Physical examination should be directed at identify-
ing a potential focus of infection, with attention to dis-
ruptions in the integument. Physical findings may be
extremely subtle or absent, especially with profound
neutropenia.
 Eyes: evidence of conjunctival abnormalities, scleral
hemorrhage, icterus, or retinal exudates
 Skin: appearance of new rashes, lesions, or purpura.
The presence of swelling or fluctuance. Examination
of indwelling lines and catheters for erythema, tender-
ness, or exudates
 Upper respiratory: examination of tympanic mem-
branes for erythema or pus; evidence of sinus ten-
derness or erythema
 Lower respiratory: presence of tachypnea, focal
crackles, or consolidation
 Upper GI:– presence of mucosal ulcers, focal pain,
or periodontal fluid collection
 Lower GI: presence of focal abdominal pain, peri-
anal tenderness, erythema, ulcerations, or fluid
collections
• Initial diagnostics may include laboratory inquiry of
cell counts, electrolytes, and hepatic enzymes. Chest
radiography should be obtained looking for infil-
trates. Relevant body fluid specimens (urine, cere-
brospinal fluid [CSF], sputum, stool) should be sent
for microbial cultures if clinical suspicion warrants.
It is recommended for all febrile neutropenic patients
that blood be sent from two independent sites for bac-
terial culture, with one from an indwelling central
venous catheter if present (including catheters with
port reservoirs).
• Empiric antimicrobial therapy should be initiated
immediately, and should target aerobic gram-negative
bacteria, as well as catheter-associated gram-positive
bacteria. The type of empiric regimen should be deter-
mined by patient risk (low vs. high).
 Low-risk patients (absence of pulmonary findings,
abdominal findings, or other evidence of focal infec-
tion, and lack of systemic toxicity or circulatory
compromise) can be treated with oral combination
therapy (ciprofloxacin and amoxicillin/clavulanate).
 High-risk patients can be treated with intravenous
antibiotics either in combination or as monotherapy.
Combination therapy usually consists of an
extended spectrum β-lactam combined with an
aminoglycoside. Monotherapy may consist of a
third- or fourth-generation cephalosporin, such as
ceftazidime or cefepime, or carbapenems, such as
imipenem-cilastin.
 The addition of coverage for β-lactam-resistant
gram-positive organisms with agents such as van-
comycin can be considered in selected patients at
higher risk for these infections (evidence of line
infection on examination, known colonization with
resistant organisms, positive blood cultures, and evi-
dence of circulatory compromise).
• Persistent fevers despite 3–5 days of broad-spectrum
antimicrobials should lead to the entertainment of
invasive fungal infections as possible etiologies, and a
further search for a focus of infection. An antifungal
agent is usually given at this time. Liposomal ampho-
tericin B or voriconazole has been shown to be
equally efficacious to standard formulations of
amphotericin B, with less systemic toxicity.
COMMON INFECTIOUS SYNDROMES
IN NEUTROPENIC PATIENTS
• Mucositis: This syndrome usually presents at days
10–14, and is often complicated by secondary superin-
fection with polymicrobial organisms, Candida
species, or reactivation of herpes simplex virus.
Management is targeted toward symptomatic relief
with topical anesthetics, topical or oral antifungals for
candida superinfection, and antiviral agents for herpes.
• Clostridium difficile enterocolitis: The risk of this
opportunistic infection increases with broad-spectrum
antimicrobial use, which frequently is present in neu-
tropenic patients. Diagnosis is obtained through the
identification of toxin in the stool, and therapy usually
consists of oral metronidazole and adequate hydration.
• Typhlitis: The range of clinical presentation can be
from mild mucosal inflammation to frank necrosis
and perforation. Symptoms are characterized by
abdominal pain (either diffuse or localized to the right
lower quadrant) and fever. Computed tomography
(CT) scan is usually needed to make the diagnosis,
most often showing thickening and edema of the cecal
wall, with or without inflammatory changes in the
surrounding tissues. Management consists of bowel
rest, nasogastric decompression, intravenous fluids,
and broad-spectrum antibiotics directed against
enteric bacteria. Surgical consultation is required, but
most patients can be managed medically. Mortality
can be as high as 50%.
• Perirectal infections: Most patients who develop
perirectal infections do not have a known predispos-
ing condition such as anal fissures or hemorrhoids, so
examination of the perirectal area for erythema, ten-
derness, or fluid collections is important in any neu-
tropenic patient. Medical therapy with appropriate
antibiotics is the most important therapeutic interven-
tion, with surgical drainage recommended for obvious
fluid collections.
• Disseminated candidiasis: The presence of indwelling
catheters, interruption of mucosal barriers, and broad-
spectrum antibiotics in neutropenic patients all pre-
dispose to the development of candidiasis, either focal
or disseminated. Hematogenous spread is common,
with consequent eye, skin, renal, hepatic, or splenic
lesions. Diagnosis is established through the isolation
of organisms from the blood or tissue biopsy.
Treatment is initiated with amphotericin B, flucona-
zole, or caspofungin.
• Aspergillosis: Aspergillosis is a common etiology of
persistent fever despite broad-spectrum antibiotics. The
clinical syndrome consists of multiple sites of tissue
infection, with a predilection for the lung. Diagnosis
requires identification of branching septate hyphae on
tissue biopsy, or growth in culture. Treatment is usually
initiated with liposomal amphotericin or voriconazole.
Complete resolution of infection usually requires
reconstitution of the neutrophil count.
• Catheter-related infections: Risk for the development
of catheter-related infection increases with degree of
neutropenia, duration of neutropenia, type of
indwelling line, and duration of use. Most etiologic
organisms are gram positives such as Staphylococcus
aureus or S. epidermiditis, and Corynebacterium.
Severely neutropenic patients are also at risk for more
unusual species, however, such as Enterobacteriaceae
and Acinetobacter anitratus. Removal of the line is
indicated when there is infection of the tunnel site,
evidence of hematogenous spread of infection, per-
sistent bacteremia, or infection with highly patho-
genic organisms such as S. aureus, Serratia species,
and fungus.
PROPHYLAXIS IN NEUTROPENIC
PATIENTS
• Trimethoprim/sulfamethoxazole is recommended for
prophylaxis for any neutropenic patient at higher risk
for pneumocystis pneumonia.
• Currently, no consensus exists for general bacterial
prophylaxis with oral quinolones, but they are widely
used.
• Use of vancomycin for prophylaxis for gram-positive
infections is discouraged.
• Oral fluconazole for prophylaxis of topical or sys-
temic fungal infections is still controversial, and not
currently recommended for all patients.
• Oral acyclovir for patients at high risk for herpes sim-
plex virus reactivation may be appropriate in high-risk
patients, but is not currently recommended for all
patients.
GROWTH FACTORS IN NEUTROPENIC
PATIENTS
• Granulocyte colony-stimulating factor (GCSF) can
shorten the duration of neutropenia, but has not been
shown to decrease infectious complications, length of
stay, or mortality.
BIBLIOGRAPHY
Bow EJ. Approach to infection in patients receiving cytotoxic
chemotherapy for malignancy. In: Hall JB, Schmidt GA, Wood
LDH, eds., Principles of Critical Care, 3rd ed. New York, NY:
McGraw-Hill; 2005:735–770.
Freifeld A, Marchigiani D, Walsh T, et al. A double-blind com-
parison of empirical oral and intravenous antibiotic therapy for
low-risk febrile patients with neutropenia during cancer
chemotherapy. N Engl J Med 1999;341:305–311.
Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for
the use of antimicrobial agents in neutropenic patients with
cancer. Clin Infect Dis 2002;34:730–751.
Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspo-
fungin and amphotericin B for invasive candidiasis. N Engl J
Med 2002;347:2020–2029.
Pizzo PA. Management of fever in patients with cancer and
treatment-induced neutropenia. N Engl J Med 1993;328:
1323–1332.
Vento S, Cainelli F. Infections in patients with cancer undergoing
chemotherapy: aetiology, prevention, and treatment. Lancet
Oncol 2003;4:595–604.
Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin
B for empirical therapy in patients with persistent fever and
neutropenia. National Institute of Allergy and Infectious
Diseases Mycoses Study Group. N Engl J Med 1999;340:
764–771.
Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared
with liposomal amphotericin B for empirical antifungal ther-
apy in patients with neutropenia and persistent fever. N Engl J
Med 2002;346:225–234.
136 SECTION 4 • INFECTIOUS DISORDERS
CHAPTER 49 • AIDS IN THE ICU     137
49 AIDS IN THE ICU
William Schweickert
KEY POINTS
• A large number of opportunistic infections may need
to be considered: knowledge of the CD4 count helps
limit the differential diagnosis.
• Some critical illness is a consequence not of infection,
but of antiretroviral treatment [lactic acidosis,
Immune-Reconstitution Syndrome (IRS), pancreatitis]
or organ-specific complications of HIV infection,
such as cardiomyopathy or renal failure.
• The antiretroviral regimen should generally be dis-
continued when a patient with AIDS is admitted to the
ICU, both to remove a potential confounding cause of
illness and to reduce the risk of provoking resistance.
• Infections should generally be diagnosed specifically,
even when invasive procedures are necessary, rather
than relying on empirical therapy.
OVERVIEW
• The acquired immunodeficiency syndrome (AIDS) is
caused by chronic infection with the human immun-
odeficiency virus (HIV), which replicates to progres-
sively deplete T-helper (CD4+) lymphocytes leading
to severe cellular immunodeficiency. Without treat-
ment, this immunodeficiency results in the develop-
ment of otherwise unusual opportunistic infections
and neoplasms characteristic of AIDS.
• The number of HIV-infected individuals continues to
increase, as does the potential for prolonged survival.
Therefore, critical care specialists can expect to care
for more HIV-infected patients admitted to the ICU
for complications related to their HIV infection or
their treatment. When presented with a patient with
AIDS or suspected to have HIV, a broad differential
diagnosis, including opportunistic diseases, should be
kept in mind to avoid delays in diagnosis.
KNOWN HIV PATIENT—UNDERSTAND THE
SEVERITY OF DISEASE
• The severity of a patient’s HIV disease burden will help
to navigate the differential diagnosis. Important histor-
ical clues include most recent CD4+ count and viral
load, known previous opportunistic infections or malig-
nancy, current medications, including prescribed pro-
phylactic medicines. Trimethoprim-sulfamethoxazole
(TMP-SMX) prophylaxis implicates a (recent) histori-
cal nadir CD4+ <200 cells/µL, while azithromycin may
implicate levels <100 cells/µL.
• Antiretroviral therapy may include nucleoside or
nucleotide reverse transcriptase inhibitors (NRTIs,
NtRTIs), nonnucleoside reverse transcriptase inhibitors
(NNRTIs), protease inhibitors (PIs), and fusion
inhibitors. Decisions to continue therapy must be care-
fully considered, but temporary interruption of the full
regimen is commonly performed during hospitaliza-
tions for severe HIV-related complications.
• Adverse effects, toxicities, and possible drug interac-
tions must be considered in respect to antiretroviral
medicines. Severe reported toxicities include pancre-
atitis and lactic acidosis.
SUSPICION FOR HIV/AIDS
• The history of opportunistic infections, wasting, oth-
erwise unexplained extensive herpes zoster, or persist-
ent generalized lymphadenopathy combined with a
history (or clinical evidence) of high-risk activities
will necessitate consideration of HIV infection and
related diseases.
• Common laboratory features found among HIV-infected
individuals may provide the initial consideration, includ-
ing: lymphopenia, anemia, thrombocytopenia, and
hypergammaglobulinemia.
• HIV infection should not be diagnosed without spe-
cific serologic tests—enzyme-linked immunosorbent
assay (ELISA) and Western blot.
NECESSARY DATA COLLECTION
• Lymphocyte subsets for CD4 count and viral load should
be sent immediately. All microbiologic tests should
include cultures for bacterial, fungal, viral, and
mycobacterial pathogens (especially sputum and blood).
Patients with respiratory distress should have a lactate
dehydrogenase level (LDH) drawn to help stratify risk
for Pneumocystis jiroveci infection (see “Pneumocystis
jiroveci (formerly P. carinii) Pneumonia,” below).
PULMONARY COMPLICATIONS
BACTERIAL PNEUMONIAS
• Pneumonias are the most common cause for hospital-
ization of the HIV-infected patient.
• Bacterial pneumonia should be suspected with acute
onset of fever, cough, and lobar consolidate on chest
x-ray (CXR).
• HIV engenders higher rates of usual bacterial infec-
tions (vs. the non-HIV population) including
Streptococcal pneumoniae (150-fold), Haemophilus
influenzae (100-fold), and Legionella (40-fold).
• Pseudomonas aeruginosa should be considered in late
stages of disease (CD4 <100 cells/µL) and in the pres-
ence of cavitary disease or a history of broad-spectrum
antibiotics.
PNEUMOCYSTIS JIROVECI (FORMERLY
P. CARINII) PNEUMONIA
• Although classified as a fungus (with properties of a
protozoan), this pathogen is given special attention as
effective diagnostic testing and therapy mediate
marked survival improvement.
• Presentation: dyspnea, nonproductive cough, and fever
usually progressing over several days to weeks; physi-
cal examination usually demonstrates acute respiratory
distress with scant findings on chest auscultation.
• Studies implicating possible P. jiroveci: (1) CXR—
diffuse bilateral interstitial pattern (most commonly);
although varying degrees of alveolar involvement can be
seen, including multiple atypical presentations such as
cystic changes, pneumothoraces, nodular disease, and
even a normal radiograph (up to 30%); (2) elevated LDH
levels—tends to correlate with disease severity and
changes tend to parallel the clinical course (N.B. this is a
nonspecific finding); and (3) CD4 count—P. jiroveci
rarely occurs when the CD4 count is >200 cells/µL.
• Diagnosis: visualization of organism in pulmonary
secretions or a lung biopsy. Most commonly, the
modality of choice is bronchoscopy with bronchoalve-
olar lavage (BAL)—the sensitivity of BAL for P. jiroveci
and other treatable pathogens commonly found in
AIDS patients exceeds 95%. In the few patients with
a nondiagnostic BAL, transbronchial or open lung
biopsy should be considered. Empiric therapy is not
recommended.
• TMP-SMX is first-line drug therapy, administered intra-
venously at a dose of 75 mg/kg daily in three divided
doses. Adverse drug reactions are common, including
rash, fever, liver, and renal dysfunction, thrombo- and
leukocytopenia, anemia, and hyponatremia.
• Adjunctive systemic corticosteroid therapy (pred-
nisone 40 mg twice daily) is recommended for mod-
erate and severe infection recognized by impaired gas
exchange, defined as PaO2 <70 mmHg on room air.
MYCOBACTERIAL INFECTIONS
• Mycobacterium tuberculosis (MTB). HIV infection is the
most significant predisposing factor for reactivation of
latent infection, and the radiographic presentation is
often similar to primary TB; apical infiltrates or cavities
are seen only in a minority. Extrapulmonary TB may
present as lymphadenitis and disseminated disease.
Purified protein derivative (PPD) testing is reasonable,
but of limited use—nearly 30% of AIDS patients are
anergic. Sputum, blood, or BAL stain and cultures are
the mainstays of diagnosis.
• Mycobacterium avium complex (MAC) is usually dis-
seminated (90%) and occurs later than MTB in the
course of HIV, typically when the CD4 lymphocyte
count is <50 cells/µL. Findings include fever, night
sweats, diarrhea, weight loss, anemia, and elevated
serum alkaline phosphatase levels. The diagnosis is
established by isolating the organism from blood
(mycobacterial blood culture) or less often from tissue
biopsy or other normally sterile body fluids. Recovery
of the organism from sputum, BAL, bowel, or stool
specimens may represent colonization or localized or
disseminated disease.
NEUROLOGIC COMPLICATIONS
BACTERIAL MENINGITIS
• The most common causes are S. pneumoniae, H.
influenzae, and less commonly, Listeria, M. tubercu-
losis, and endemic fungi (coccidioidomycosis and
histoplasmosis).
CRYPTOCOCCAL MENINGITIS
• The disease starts as a pulmonary infection and then
disseminates to the brain and other organs. Presenting
symptoms are often indolent and include headache,
fever, nausea, vomiting, and occasionally, skin lesions
or seizures.
• Serum cryptococcal antigen titer is a rapid and sensi-
tive screening test, and diagnosis is confirmed with
cerebrospinal fluid (CSF) analysis. Findings include
lymphocytic-predominant pleocytosis, elevated protein,
depressed glucose, and most importantly, cryptococcal
antigen testing, smear, and culture. Alternatively, organ-
ism isolation from blood, urine, sputum, or other skin
lesions is possible.
• Treatment of AIDS-related cryptococcal meningitis
should be initiated with amphotericin B, 0.7 mg/kg/day
plus flucytosine (100 mg/kg/day in four divided doses).
TOXOPLASMA ENCEPHALITIS
• The most common focal neurologic complication of
HIV infection.
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• Results from reactivation of latent infection and pres-
ents as a subacute headache with focal neurologic
findings (majority), and seizures (30%).
• Risk of toxoplasma is most pronounced in those with
CD4 counts <100 cells/µL without appropriate pro-
phylaxis (TMP-SMX).
• Diagnosis is made empirically with visualization of
multiple ring-enhancing lesions on contrast-enhanced
brain imaging (magnetic resonance imaging [MRI]
preferred over computed tomography [CT]) in a
patient with positive serology. CSF analysis is often
normal.
• Treatment is with pyrimethamine (100–200 mg load-
ing does and then 50–100 mg/day) plus folinic acid
(10 mg/day) plus sulfadiazine (4–8 g/day). Repeat
brain imaging after 2–3 weeks of treatment; absence
of improvement may require brain biopsy for defini-
tive diagnosis.
OTHER CAUSES OF FOCAL NEUROLOGIC
DISEASE
• Primary central nervous system lymphoma is the
second most common cause of focal brain disease in
this population. Brain imaging is necessary to implicate
the diagnosis, but it is radiographically indistinguish-
able from toxoplasmosis. If toxoplasma therapy yields
no improvement, lymphoma is quite possible, and a
brain biopsy is required for a definitive diagnosis.
• Progressive multifocal leukoencephalopathy is medi-
ated by the Jakob-Creutzfeldt virus, and can present
with seizures or focal neurologic symptoms. MRI
reveals single or multiple white matter lesions without
surrounding edema, and definitive diagnosis requires
brain biopsy.
IMMUNE RECONSTITUTION
SYNDROME
• Immune reconstitution syndrome (IRS) is the aug-
mentation of the immune response to preexisting clin-
ical or subclinical infection, and can mediate clinical
deterioration in almost any organ system.
• Most reports have been related to cytomegaloviral
(CMV) retinitis, TB, MAC, P. carinii pneumonia
(PCP), cryptococcosis, progressive multifocal leukoen-
cephalopathy, and herpes zoster. Its frequency is
increasing with the more pervasive use of highly active
antiretroviral therapy.
• A diagnosis of IRS begins with a suspicion of clinical
events occurring usually within weeks or months after
initiating or revising an antiretroviral regimen. The
differential diagnosis includes adverse drug effects
and unrecognized infections. The diagnosis of IRS is
one of exclusion, but requires convincing evidence of
a response to the antiretroviral regimen (reduction in
HIV RNA and usually a CD4 increase).
• The incidence of this complication may be reduced by
delaying the initiation of antiretroviral therapy until
after therapy directed at the opportunistic infection
has been completed, and case reports suggest a possi-
ble benefit from systemic corticosteroids.
OTHER ORGAN SYSTEM DISEASE
COMPLICATING AIDS
• Cardiovascular: Pericarditis (infectious and noninfec-
tious), valvular heart disease (infectious or marantic
endocarditis), and importantly, dilated cardiomyopa-
thy (characterized by myocarditis pathologically).
• Renal: HIV-associated nephropathy (nephritic syn-
drome or renal insufficiency), renal toxicity from
medications (either antibiotics or antiretrovirals).
Electrolytes, especially hyponatremia (syndrome of
inappropriate antidiuretic hormone [SIADH], hypov-
olemia, adrenal insufficiency), hypokalemia (GI
losses), and hyperkalemia (medications, renal insuffi-
ciency).
• Gastrointestinal: Diarrhea from infectious colitis
(bacterial, parasitic, viral) may lead to severe
hypovolemia.
• Endocrinology: Adrenal insufficiency (infectious—
TB, CMV, MAC).
• Pulmonary: Accelerated emphysema independent of
inhalational toxins.
• Hematology: Cytopenias from the disease itself,
marrow infiltration by infection or malignancy, or
most commonly, from medication effect.
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50 ENDOCARDITIS
D. Kyle Hogarth
KEY POINTS
• The possibility of an endocardial (or intravascular)
infection should be considered in all critically ill
patients with the following:
 Bacteremia or fungemia of uncertain origin
 Fever of unknown origin
 Hemodynamic instability of unclear etiology
• Blood cultures are the most important diagnostic test.
• Successful treatment requires prolonged duration of
antimicrobial agents and removal of indwelling devices.
• Classic organisms causing endocarditis are staphylo-
cocci, enterococci, aerobic gram-negative bacilli, and
yeasts.
• All patients with an indwelling intravascular device
are at risk for the development of endocarditis.
PATHOGENESIS
• Microbial invasion into the bloodstream, even if tran-
sient, can lead to adherence to a heart valve. The
organism replicates in a layer of fibrin and platelets,
allowing it to escape the normal immune defenses.
• The likelihood of endocarditis developing will depend on
the following factors: species of microbe, the inoculating
concentration of microorganisms, presence of antimicro-
bials, and the characteristics of the endocardium.
• Staphylococcus aureus, enterococci, and other strep-
tococci are the most adherent of organisms and are the
most likely to cause endocarditis, even in undamaged
valves. For example, S. aureus commonly causes skin
infections and can result in transient bacteremia. Also,
dental work on the teeth or gingiva may lead to tran-
sient bacteremia with viridans-type streptococci.
CLINICAL AND LABORATORY
FEATURES
• Common symptoms include fever, malaise, myalgias
and arthralgias, headache, and backache.
• Common signs include fever, cardiac murmur,
petechiae, Osler nodes, Janeway lesions, change in
mental status, stroke.
 Petechiae may be located on conjunctivae, the soft
palate, and distal portions of the legs and arms.
 Splinter hemorrhages may be located under the nail
beds (Fig. 50-1).
 Roth spots are hemorrhages in the fundus seen with
an ophthalmologic examination.
 Osler nodes are tender subcutaneous erythematous
papules that occur on the finger pads, while
Janeway lesions are nontender, larger, and occur on
the palms and soles (Figs. 50-2 and 50-3).
• Common lab findings include: anemia, thrombocy-
topenia, increased white blood cells, elevated sedi-
mentation rate, proteinuria, and hematuria.
• Systemic emboli from the endocarditis can lead to
stroke, splenic infarctions, mesenteric ischemia, and
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FIG. 50-1 Splinter hemorrhages in infective endocarditis.
FIG. 50-2 Osler nodes in infective endocarditis. Osler nodes
are tender, papulopustules located on the pulp of the finger in a
patient with bacterial endocarditis caused by S. aureus.
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renal infarcts. Right-sided endocarditis can lead to
septic pulmonary emboli.
• Many patients may have heart failure symptoms due
to valvular dysfunction from the infection.
DIAGNOSIS
• The most important lab test is the blood culture, and it
will be positive in 90% of cases of endocarditis.
• In approximately 5–10% of patients with presumed
endocarditis, no etiologic organism is initially
isolated.
• The causes of “culture-negative endocarditis” are the
following:
 Prior antibiotics given before blood cultures.
 Endocarditis due to fastidious organisms, such as
anaerobes, Coxiella burnetii, Legionella pneumophila,
Chlamydia psittaci, Chlamydia pneumoniae, various
fungi, and the HACEK organisms. (HACEK is an
acronym for Haemophilus species, Actinobacillus
actinomycetemcomitans, Cardiobacterium hominis,
Eikenella corrodens, and Kingella kingae.)
 Culture negative endocarditis can become “culture
positive” using longer incubation times and special
culture techniques to aid in isolation of fastidious
microorganisms. Serologic studies for Coxiella,
Bartonella, and Chlamydia can be used to help with
the diagnosis.
• Echocardiography is useful for detecting vegetations.
• Transthoracic echocardiography (TTE) has 60% sen-
sitivity for endocarditis.
• Transesophageal echocardiography (TEE) has a sensi-
tivity of 90–99% with a specificity of 90%.
MANAGEMENT
• In hospitals with low rates of methicillin-resistant
S. aureus (MRSA), initial therapy should be intravenous
(IV) nafcillin, 2 g every 4 hours plus ampicillin 2 g IV
every 4 hours and gentamicin, 1 mg/kg every 8 hours.
• Many centers have high rates of MRSA, and therefore
empiric therapy with vancomycin or linezolid should
be considered.
• Once the organism and its sensitivities are known,
then therapy directed to the specific organism should
be started.
• Parenteral antibiotics are always preferred over oral
drugs.
• Bacteriocidal agents are superior to bacteriostatic
drugs and are therefore preferred.
• Long-term antimicrobial therapy (6 weeks) is almost
always required for cure of endocarditis.
• Indications for urgent valve replacement include:
 Ineffective antimicrobial therapy
 Severe heart failure
 Valvular obstruction
 Fungal endocarditis
 The presence of an unstable prosthetic device (e.g.,
loose artificial mitral valve)
PROGNOSIS
• Outcomes are dependent on:
 Pathogenicity of the organism
 Location of infected valve (S. aureus is fatal in one-
third of patients with aortic or mitral valve disease.)
 Complications associated with the infection, espe-
cially congestive heart failure, shock, systemic
emboli, and myocardial abscess
 Size of the vegetation (>1 cm associated with an
increased morbidity and mortality
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FIG. 50-3 Janeway lesion in infective endocarditis.
51 INFECTIOUS
COMPLICATIONS OF
INTRAVENOUS DEVICES
Ajeet Vinayak
KEY POINTS
• Catheter-related infections are common, costly, and
associated with significant morbidity and mortality.
• CNS, S. aureus, enterococci, aerobic gram-negative
bacteria, and C. albicans are most often responsible
for catheter-related infection.
• The risk of catheter-related infection can be reduced by
preferring the subclavian site, using a chlorhexidine-
containing disinfectant, enforcing full barrier precau-
tions, and removing catheters at the earliest opportunity.
Antimicrobial impregnated catheters may be useful
especially when the incidence of catheter-related infec-
tions is high despite other precautions.
• Infected catheters must be removed when patients are
critically ill due to the catheter infection; the pocket or
tunnel of a long-term catheter is involved; infection
recurs following treatment; or certain resistant organ-
isms are involved.
• Empirical treatment of catheter-related infection
should cover staphylococcal species; vancomycin
should be used where methicillin-resistant strains are
prevalent. Antibiotics to cover gram-negative organ-
isms and fungi should be added in patients who are
critically ill or immunocompromised pending micro-
biologic confirmation of antimicrobial susceptibility.
EPIDEMIOLOGY
• It is estimated that 15 million patients days are spent
with a central catheter and over 5 million central venous
catheters (CVCs) are placed a year in the United States.
• The overwhelmingly largest complication associated
with the use of CVCs is the development of serious
catheter-related infections.
• The mortality rate associated with this complication is
estimated to be as high as 25% with costs related to its
treatment reaching half a billion dollars a year.
• CVCs account for over 90% of all cases of catheter-
related infection.
• The following risk factors are associated with a higher
risk of infection:
 Inappropriate barrier protection
 The internal jugular vein and femoral vein insertion
sites
 Distant site of infection
 Concurrent bacteremia
 Skin breakdown
 The use of multilumen catheters
• Infections are much more likely to occur from trans-
mission of skin flora to the tip of the catheter than
from an intraluminal origin of infection related
to tubing manipulation, or seeding from distant
sources.
• Intraluminal (vs. extraluminal) infections are more
likely with prolonged catheter duration (>2 weeks).
MICROBIOLOGY
• Common organisms include coagulase-negative
staphylococci (CNS), Staphylococcus aureus, and
enterococcal species. Other relatively common organ-
isms include aerobic gram-negative bacteria and
yeasts (e.g., Candida albicans).
• Cultures of Corynebacterium species, Bacillus cereus,
Trichophyton, Malassezia furfur, and Fusarium all
should raise suspicion for catheter-related infection.
• The majority of CNS, over 50% of S. aureus, and a
quarter of enterococci have broad resistance patterns.
PREVENTION
• Site of CVC placement influences risk of infection:
subclavian CVCs are superior to femorally placed
CVCs, and may be slightly safer than those inserted in
the internal jugular vein.
• The use of prophylactic vancomycin flushes has not
been shown to reduce the incidence of infection and
should be avoided given the risk of resistant organisms.
• Chlorhexidine-containing skin antiseptics appear to
reduce the risk of infection over traditional povidone-
iodine preparations.
• Full barrier protections (sterile gloves, gowns, mask,
cap, and large drapes) during insertion of CVCs
are clearly effective in prevention and should also
be considered when central catheters are inserted
peripherally.
• Gauze-based dressings have not been shown to be
clearly superior to transparent dressings.
• Triple antibiotic ointments may increase the risk of
candidal infections.
• Mupirocin may affect polyurethane catheter integrity
and should be avoided.
• Povidone-iodine ointment has been shown to be ben-
eficial with the insertion of hemodialysis catheters
and should be considered for use in other immuno-
compromised patient groups.
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• A variety of antibiotic-impregnated catheters are avail-
able. Benzalkonium chloride-coated pulmonary artery
catheters may prevent infections. Combined chlorhex-
idine and silver sulfadiazine-coated catheters reduce
infection and are cost-effective if these CVCs are used
for 14 days or less. While the combination of minocy-
cline and rifampin may be superior to the chlorhexi-
dine and silver sulfadiazine-coated CVCs, the
documentation of resistance to this combination has
been reported over longer dwell times. Therefore, this
catheter should also be employed for short-term use.
• The use of prophylactic doses of unfractionated and
low-molecular weight heparin has been shown to
reduce the incidence of catheter-related thrombosis.
Lower infection rates with the use of heparin may be
related to effects on thrombus formation or on pack-
aged antimicrobial preservatives.
• Appropriate nurse-to-patient ratios should be in place
in ICUs.
• Scheduled exchanges of catheters over a wire are not
indicated.
• Daily assessment for the continued need of intra-
venous access is imperative to minimize preventable
days with the catheter.
DIAGNOSIS
• No uniform consensus definition exists for intra-
venous catheter-related infections.
• Only 50% of line infections occur with local evidence
of exudation or inflammation at the insertion site.
• Suspected cases should be investigated with two sets
of blood cultures. Some experts recommend both sam-
ples be drawn from a peripheral site to avoid confusing
skin/hub contamination with clinical device infection.
Yet, the most recent consensus statement advises that
at least one sample be from a peripheral site.
• Semiquantitative (roll plate method) and quantitative
(sonification of flush) cultures are accepted as more
diagnostically accurate than qualitative cultures.
 While the former may be more accurate with
recently placed (<1 weeks) catheters, the latter
process may be superior to detect intraluminal infec-
tions associated with longer catheter placement.
 Accepted positive results include >15 colony form-
ing units (CFU) by the semiquantitative method and
>103 CFU by quantitative procedures.
• Time to culture positivity data may make two simul-
taneous qualitative cultures more accurate for
catheter-related infection if central samples are posi-
tive 2 or more hours earlier than peripheral samples.
• If metastatic seeding is considered possible, trans-
esophageal echocardiography is indicated.
MANAGEMENT
• Catheters should be removed in the following situations:
 Sepsis or septic shock with a clear diagnosis of
catheter-related bloodstream infection or those cases
without any other identifiable source of infection.
 Tunnel or pocket infection of long-term devices.
 Recurrent disease following treatment course
completion.
 Bacteremia with Corynebacteria, Bacillus sp., gram
negatives, or fungi.
 Subsequent tip positivity following replacement of a
catheter via changing the original catheter over a
wire. In this situation a new site should be used if
intravenous access is still needed.
• Initial parenteral antibiotic therapy should be directed at
treating staphylococcal species. The upfront choice of
vancomycin should be reserved in areas where
methicillin-resistant S. aureus is prevalent. Fungemia or
gram-negative organisms should be empirically treated
if patients are severely ill or immunocompromised.
• Once sensitivities are known and with clinical stability,
therapy can be tailored to less broad-coverage agents and
eventually to oral therapy including quinolones, linezolid,
or trimethoprim-sulfamethoxazole. Cases of corynebac-
terium and bacillus infections should be treated with
vancomycin.
• Antibiotic lock therapy consists of a mixture of antibi-
otic agent and heparin that is allowed to dwell within the
volume of the catheter between periods of catheter use.
• CVC infections should be treated for 5–7 days following
CVC removal. If the CVC is not removed, coagulase-
negative staphylococcal infections should be treated for
10–14 days with systemic antibiotics and concomitant
antibiotic lock therapy. Retained, tunneled devices with
coagulase-negative staphylococcal bloodstream infec-
tion should be treated with 7 days of systemic therapy
and a total of 14 days of antibiotic lock therapy.
• Given the metastatic potential of S. aureus bacteremia,
treatment should likely be no less than 2 weeks for
uncomplicated, quickly resolving cases, 4–6 weeks
for cases with endocarditis, and even longer when
there is osteomyelitis.
• Therapy directed at gram-negative organisms should
be adjusted from 10–14 days up to 4–6 weeks based
on suspicion of seeding, prolonged bacteremia, or the
presence of risk factors such as valvular heart disease.
• Amphotericin B should be preferred initially over
intravenous fluconazole in cases of candidemia asso-
ciated with organ dysfunction, prolonged prior expo-
sure to fluconazole, or prior known azole-resistant
candidal infection. Caspofungin may also be a useful
alternative drug in these situations, while reducing
drug complications associated with amphotericin.
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52 SEVERE COMMUNITY-
ACQUIRED PNEUMONIA
Shashi Kiran Bellam
KEY POINTS
• Community-acquired pneumonia is a common cause
of respiratory failure and ICU admission.
• CAP requiring ICU admission has a mortality rate
near or >50%.
• Prompt identification, assessment of sputum for cul-
ture, and empiric antibiotics are the principles of spe-
cific therapy.
• Most critically ill patients with CAP should be treated
with a third-generation cephalosporin plus either
azithromycin or a fluoroquinolone. As an increas-
ing incidence of MRSA is seen, VANCOMYCIN or
LINEZOLID may be needed as well.
• For those at risk of Pseudomonas, use an intravenous
antipseudomonal β-lactam plus an intravenous
antipseudomonal fluoroquinolone.
• General therapy primarily involves supportive care to
maintain hemodynamic stability and adequate
oxygenation.
GENERAL CLINICAL FEATURES
• Definition: “Community-acquired” is defined as patients
who present with pneumonia from outside the hospi-
tal. Common reasons for ICU admission include res-
piratory failure (both hypoxemic or hypercarbic) and
circulatory failure (ranging from volume-responsive
hypotension to septic shock).
• Pneumonias developing within 2 days of admission to
a hospital are still considered community-acquired,
since the infecting organism is likely to have been
acquired before the hospitalization.
• Community-acquired pneumonia (CAP) needs to be
distinguished from hospital-acquired pneumonia, as well
as the newly described entity “health care”-associated
pneumonia. The latter two are commonly caused by
organisms different from the community pneumonia
microbes (see Chap. 53).
• Microbiologic features: Common causes for CAP in gen-
eral include Streptococcus pneumoniae, Staphylococcus
aureus, and Haemophilus influenzae. Patients with
severe CAP requiring ICU care may be more prone to
have been infected with less common pathogens than
those listed above, such as Legionella pneumophila.
ROUTES OF ENTRY
ASPIRATION
• Small amounts of oral or gastric bacteria are aspirated
commonly and those organisms are cleared routinely
by the bronchial mucociliary clearance mechanisms
as well as normal immunologic responses in the alve-
oli. If the aspirate contains potentially virulent organ-
isms or the normal pulmonary clearance mechanisms
are dysfunctional, the organisms can proliferate and
lead to pneumonia.
• Aspiration of potentially virulent bacteria occurs
with large volumes of aspirated material (such as with
seizures, alcoholics with altered mental status, or with
oral disease) or if the normal clearance mechanisms
are ineffective (such as cases of foreign body aspira-
tion or malignancy with bronchial obstruction, or mus-
cular dysfunction in the oropharynx, or after a viral
respiratory infection which impairs ciliary function).
• Pneumonia can occur with small amounts of aspira-
tion and no dysfunction of normal clearance if a vir-
ulent organism is involved (including S. pneumonia,
S. aureus, and enteric gram-negative rods).
INHALATION
• As the number of organisms inhaled is usually small,
only highly virulent organisms lead to pneumonia by
this route, including respiratory viruses, Legionella spp.,
Mycoplasma pneumoniae, Chlamydia spp., Coxiella
burnetii, Mycobacterium tuberculosis, and fungi.
HEMATOGENOUS
• Organisms within the venous circulation can lodge in
the pulmonary vasculature and proliferate.
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• Infections by this route are more often diffuse or
multinodular and bilateral, and commonly include S.
aureus and Pseudomonas aeruginosa. Skin entry and
hematogenous dissemination can be seen in tularemia,
brucellosis, and melioidosis.
TYPICAL CLINICAL FEATURES
• Common symptoms include cough with sputum
(often purulent or bloody), shortness of breath, pleu-
ritic chest pain, all of an acute onset. Common signs
include fever, elevation in the white blood cell count
with a neutrophil predominance, arterial hypoxemia,
and possibly hypocarbia or hypercarbia (in respiratory
failure). Chest x-rays often disclose an infiltrate.
• Less common causes of pneumonia with specific clin-
ical features are:
 Legionnaire disease: Transmitted via infected water,
Legionnaire disease may be indistinguishable clini-
cally from pneumococcal pneumonia, but often
includes symptoms of dry cough, diarrhea or other
gastrointestinal upset, or encephalopathy not explained
by hypoxemia or shock.
 M. pneumoniae infection: Often in younger patients
(20s–30s) and frequently with an initial upper respi-
ratory tract infection followed by a dry cough with
low grade fevers and occasionally with symptoms
such as diarrhea, myalgia, arthralgia, skin rash, and
bullous myringitis. In severely ill patients, infiltrates
may be bilateral and accompanied by myocarditis or
encephalomyelitis.
 Chlamydia psittaci: Transmitted from birds, clinically
characterized by high fever and persistent dry cough
and occasionally with myalgia, headache, gastroin-
testinal symptoms, or a macular rash. Frequently,
hepatomegaly, splenomegaly, and pleural or pericar-
dial friction rubs are found on physical examination.
Severely ill patients can present with dyspnea, hypox-
emia, and encephalopathy (including coma).
 Viral pneumonia: Viral causes of critical illness usually
are due to influenza viruses, predominantly in winter
or early spring, and predominantly in nonimmunized
patients, more so in the elderly or in patients with other
comorbid conditions. Influenza is often complicated
by a bacterial pneumonia (often S. aureus).
MANAGEMENT
• Laboratory studies: White blood cell count, Gram’s
stain and culture of lower respiratory tract secretions
(defined as <10 epithelial cells per high-powered
field), and blood cultures should be obtained.
• L. pneumophila is not detectable on routine Gram’s stain
or cultures and requires specific cultures; direct fluores-
cent antibody testing of sputum (neither highly sensitive
nor specific) and urinary antigen testing (highly specific
but not highly sensitive for pneumonia) are also available.
• Antibiotics should be started within 4–8 hours of the
patient presenting for evaluation. Ideally, cultures will
be obtained prior to antibiotics being administered,
but antibiotics should not be delayed while waiting for
lab testing or cultures.
• An understanding of local resistance rates, as well as
characteristics of the patient, can help to guide initial
empiric antibiotic selection. Guidelines published by
the American Thoracic Society (ATS) and the
Infectious Disease Society of America provide man-
agement guidelines for CAP.
• Empiric therapy with an appropriate regimen should be
provided until culture data dictate more specific
therapy. For patients sufficiently ill from CAP to
require ICU admission, the ATS guidelines recommend:
 Third-generation cephalosporin (cefotaxime, ceftri-
axone) combined with either azithromycin or an
intravenous fluoroquinolone.
 If the patient is at risk for Pseudomonas infection
(structural lung disease, such as bronchiectasis; on
corticosteroids equivalent to >10 mg/day prednisone;
on broad-spectrum antibiotics more than 7 days of
the past month; or significantly malnourished), use an
intravenous antipseudomonal β-lactam (cefepime,
imipenem, meropenem, piperacillin/tazobactam) plus
an intravenous antipseudomonal fluoroquinolone (or
intravenous aminoglycoside plus azithromycin).
 Chlamydia infection should be treated with a tetracy-
cline (e.g., doxycycline 100 mg intravenously q 12 h).
 Legionella infection should be treated with
macrolides and rifampin.
• Pleural effusions: If an effusion is present, then thora-
centesis to assess pH, Gram’s stain and culture is indi-
cated. If empyema is present, then a chest tube should
be inserted.
• Supportive therapy:
 Mechanical ventilation as needed for respiratory
failure (via an endotracheal tube; current literature
does not support routine use of noninvasive
mechanical ventilation for severe CAP).
 Intravenous volume infusion will be required by
most patients with severe CAP to meet the criteria
for goal-directed management of early shock (see
Chap. 44).
 Intravenous medications to maintain systemic blood
pressure may be required, but should be instituted
once the intravascular volume has been resuscitated.
 Drotrecogin (as a therapy for sepsis) has been sug-
gested to be particularly useful in cases of severe
CAP from post hoc analysis of primary study data.
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53 VENTILATOR-ASSOCIATED
PNEUMONIA
D. Kyle Hogarth
KEY POINTS
• Ventilator-associated pneumonia is common in
mechanically ventilated patients and associated with
increased cost, duration of ventilation, and mortality.
• Prevention includes limiting time on the ventilator by
performing daily spontaneous breathing trials, elevat-
ing the head of the bed, and keeping ETT cuff pres-
sures >20 cmH2O.
• Organisms causing VAP differ from those causing
CAP (e.g., S. aureus and Pseudomonas aeruginosa)
and are often drug-resistant.
• Treatment should take into account the local microbi-
ologic susceptibility patterns, along with patient risk
factors, but should cover both gram-negative and
gram-positive organisms frequently identified to
cause VAP.
DEFINITION
• Ventilator-associated pneumonia (VAP) is pneumonia
developing in mechanically ventilated patients 48 hours
or more after intubation and mechanical ventilation.
• This definition is important to distinguish from
community-acquired pneumonia (CAP) requiring
mechanical ventilation at initial presentation. Severe
CAP has a different microbiologic epidemiology than
VAP.
• The new entity of Health Care Associated Pneumonia
(HCAP) has been developed to distinguish the patient
type that is never truly “in the community” but not in
the hospital (e.g., dialysis patients and nursing home
residents).
EPIDEMIOLOGY
• Ventilator-associated pneumonia is the most common
nosocomial infection in mechanically ventilated patients.
• VAP is associated with increased length of stay, time
on ventilator, cost, morbidity (acute renal failure
[ARF], shock, liver dysfunction), and mortality.
• Risks for drug-resistant organisms causing VAP
include:
 Antimicrobial therapy in preceding 90 days
 Current hospitalization of 5 days or more
 High frequency of antibiotic resistance in the com-
munity or in the specific hospital unit. This risk
factor stresses the importance of knowing the “local
flora” of your ICU or hospital
 Presence of risk factors for HCAP:
 Hospitalization for 2 days or more in the preced-
ing 90 days
 Residence in a nursing home or extended care
facility
 Home infusion therapy (including antibiotics)
 Chronic dialysis within 30 days
 Home wound care
 Family member with multidrug-resistant pathogen
 Immunosuppressive disease or therapy
RISKS FOR VENTILATOR-ASSOCIATED
PNEUMONIA
• Mechanical ventilation (consider noninvasive ventila-
tion for your patients)
• Length of time on ventilator
• Reintubation following unsuccessful extubation
• Aspiration of gastric contents
• Acid suppression
• Supine positioning of patient
INDEPENDENT RISKS FOR MORTALITY
FROM VENTILATOR-ASSOCIATED
PNEUMONIA
• Inadequate antibiotics
• Cancer
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• Immunosuppression
• Poor premorbid lifestyle score
• Advanced age
TYPICAL FLORA CAUSING
VENTILATOR-ASSOCIATED
PNEUMONIA
• Serratia species, Pseudomonas species, Staphylococcus
aureus, and Enterococcus species.
• A majority of these organisms will be resistant to var-
ious antibiotic agents available.
PREVENTION OF
VENTILATOR-ASSOCIATED
PNEUMONIA
• Minimizing time on the ventilator. This involves good
strategies of sedation, pain control, and daily sponta-
neous breathing trials (see Chaps. 5, 6, and 33)
• Semirecumbent positioning (30–45°)
• Oral, rather than nasal, intubation for endotracheal
tubes (ETT) and gastric tubes
• Aspiration of subglottic secretions with new ETT that
have a side port for subglottic aspiration
• Maintaining endotracheal cuff pressures at least
20 cmH2O
• Rotational bed therapy (for surgery patients only)
• Prevention of condensation collection in the tubing
from the ventilator to the ETT
• Antiseptic hand solution and strict infection control
• Maintaining adequate staffing in the ICU
• Postpyloric feeding
DIAGNOSIS OF
VENTILATOR-ASSOCIATED
PNEUMONIA
• Tracheal colonization and ETT colonization occur
within 24 hours of intubation. This can make the inter-
pretation of sputum Gram’s stains and cultures very
difficult.
• Mechanically ventilated patients should be examined
daily with an eye toward detecting VAP. Fevers,
increased sputum, increasing oxygen requirement, or
new infiltrates on chest radiograph should raise the
concern for VAP.
• If a patient develops a new or worsening infiltrate plus
two of the following three criteria, then the probability of
a VAP is high and empiric antibiotics should be begun:
 Fever >38°C
 Leukocytosis or leukopenia
 Purulent secretions
• The Clinical Pulmonary Infection Score (CPIS) can
be used to aid in diagnosis:
 CPIS is a score derived from the patient’s tempera-
ture, blood leukocytes, quantity of tracheal secre-
tions, cultures of tracheal aspirates, level of
oxygenation (PaO2/FiO2 ratio), and evaluation of the
radiograph for new infiltrates.
 The CPIS has been demonstrated to have 93% sen-
sitivity for VAP confirmed by bronchoscopy.
 Follow-up studies indicate that patients initially sus-
pected of having VAP who have low CPIS by day 3
of empiric therapy can have antibiotics discontinued
with improved outcomes.
• Some experts advocate the use of an “invasive” strat-
egy of deep pulmonary cultures using bronchoscopy
with lavage and protected brush specimen.
• Not all patients can have a bronchoscopy safely per-
formed in the ICU.
• While there is debate as to the best way to make the
diagnosis of VAP, what is agreed on is that initial
empiric antibiotic selection is very important. Equally
important is a policy of “de-escalation” when further
evidence shows that the patient does not have VAP and
then empiric antibiotics can be stopped. (See Fig. 53-1
for a treatment algorithm from the American Thoracic
Society (ATS)/Infectious Diseases Society of America
(IDSA) 2005 guidelines for VAP.)
VENTILATOR-ASSOCIATED
PNEUMONIA THERAPY
• Empiric therapy must begin by covering both gram
negatives and gram positives.
• Resistance is a major concern and knowing the resist-
ance patterns of the local flora of the ICU is extremely
important.
• Results of Gram’s stains of tracheal isolates or bron-
choscopy cultures can allow the therapy to be appro-
priately narrowed.
• Empiric broad-spectrum therapy should be narrowed
as soon as possible.
THE GRAM-NEGATIVE ORGANISMS
• Therapy for VAP must begin by empirically covering
for Pseudomonas and Serratia species. Thus, one of
the following agents should be employed.
• β-Lactams
 Piperacillin/tazobactam 3.375 g IV every 4–6 hours
 Imipenem/cilastatin 500 mg to 1 g IV every 6–8 hours
 Meropenem 1 g IV every 8 hours
 Cefepime 1 g IV every 8 hours or 2 g IV every
12 hours
 Ceftazidime 2 g IV every 8 hours
 Aztreonam 2 g IV every 6–8 hours (Note: not to be
used as monotherapy)
• Fluoroquinolones
 Ciprofloxacin 400 mg IV every 8–12 hours
• Aminoglycosides (Note: not to be used as monother-
apy)
 Amikacin 5–7.5 mg/kg IV every 8–12 hours
 Gentamicin 1.5–2.5 mg/kg IV every 8–24 hours or
5–7 mg/kg IV every 24 hours
 Tobramycin 1.5–2.5 mg/kg IV every 8–24 hours or
5–7 mg/kg IV every 24 hours
THE GRAM-POSITIVE ORGANISMS
• At least 50% of all isolates of S. aureus are methicillin
resistant (MRSA) in the United States. There are two
options for gram-positive coverage:
 Vancomycin 10–15 mg/kg IV every 8–24 hours
 Linezolid 600 mg IV every 12 hours
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HAP, VAP, or HCAP suspected
Obtain Lower Respiratory Tract (LRT) sample for culture
(quantitative or semiquantitative) & microscopy
Unless there is both a low clinical suspicion for pneumonia &
negative microscopy of LRT sample, begin empiric antimicrobial
therapy using algorithm in Figure 2 & local microbiologic data
Days 2 & 3: Check cultures & assess clinical responses:
(Temperature, WBC, chest x-ray, oxygenation, Purulent sputum,
hemodynamic changes, & organ function)
Clinical improvement at 48–72 hours
No Yes
Cultures − Cultures + Cultures +Cultures −
Search for other
pathogens,
complications, other
diagnoses or other
sites for infection
Adjust antibiotic therapy,
search for other
pathogens,
complications, other
diagnoses or other
sites of infection
Consider
stopping
antibiotics
De-escalate antibiotics,
if possible.
Treat selected patients
for 7–8 days
& reassess
FIG. 53-1 Treatment algorithm from the ATS/IDSA 2005 guidelines for VAP.
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54 FUNGAL INFECTIONS IN
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KEY POINTS
• Fungal infections most frequently affect immunocom-
promised patients. However, even patients with an
intact immune system are susceptible if they are either
severely ill or have a breach in their skin or mucous
membranes.
• Clinical presentation varies depending on the type of
fungus and severity of illness. In general, patients pres-
ent with fever, chills, and myalgias. Rash, meningitis,
and cough are symptoms that characterize certain
kinds of fungi. In progressive cases, disseminated dis-
ease involving infection of multiple organs is possible.
• Culturing sources of infection including blood, CSF,
and urine can sometimes make the diagnosis. Biopsies
of skin lesions, pulmonary nodules, or bone marrow
can also be helpful. In some cases, antigens can be
detected easily.
• Treatment usually involves antifungal medications
and, in certain cases, removal of the infected hardware.
In recent years, many species of fungi have emerged
that are resistant to what was considered standard
treatment. Fortunately, new antifungals are showing
promise for even the most resistant types of fungi.
OVERVIEW AND EPIDEMIOLOGY
• Although rare in the general population, fungal infec-
tions are increasingly becoming the cause for unex-
plained fevers in the intensive care unit (ICU).
• Fungi account for about 9% of all sepsis, severe
sepsis, and septic shock cases and the mortality rate
for fungemia is still extremely high at about 50%.
• There has been a threefold increase in fungemia
between 1979 and 2000.
• Fungal infections can be difficult to diagnose in many
cases. Empirical antifungal treatment is not appropri-
ate in all cases of severe sepsis or septic shock.
Clinical judgment is used in many instances in deter-
mining whether or not the patient should be treated.
THE HOST
• Identifying which patients are at high risk for fungal
infections helps in determining whether or not that
patient should be treated with antifungal medications.
• Patients with HIV/AIDS are very susceptible to
fungal infections. In one prospective study, 84% of
patients with AIDS were infected with Candida. The
CD4 count of these patients helps in determining the
type of fungus causing the infection. The most
common types are Candida albicans, Pneumocystis
jiroveci, and Cryptococcus neoformans. Dimorphic
fungi such as Histoplasma capsulatum and
Coccidioides immitis are found less frequently but
occur most often in this patient population. Molds
such as Aspergillus fumigatus and Fusarium spp. are
rarely, if ever, the cause for infection.
• Patients with neutropenia secondary to chemotherapy
or bone marrow transplant are also likely to be
infected with fungi. Almost any kind of fungus can
infect neutropenic patients. C. albicans and A. fumigatus
are the most common but mold such as Fusarium spp.
is occasionally the culprit.
• Any patient taking chronic corticosteroids or immune
modulators for solid organ transplants or rheumato-
logic conditions is subject to a wide variety of fungal
infections. Like with neutropenic patients, A. fumigatus
and C. albicans are frequent causes of infection.
Aspergillosis is found mostly in lung and heart trans-
plant recipients and candidiasis in liver, kidney, and
pancreas transplants.
• Patients with a relatively intact immune system can
also fall victim to fungal infections if their first-line of
defense against these diseases (i.e., skin or mucus
membranes) is somehow breached. Patients with
extensive burns often develop infections involving
highly resistant fungi such as Fusarium spp. In addi-
tion, patients with indwelling catheters such as central
lines, Foley catheters, peritoneal dialysis catheters,
and feeding tubes are also subject to fungal infections.
In fact, in one study, 95% of all patients with Foley
catheters were found to have candiduria.
• Severely ill patients such as those with uncontrolled
diabetes and frequent episodes of diabetic ketoaci-
dosis are sometimes infected with rhinocerebral
zygomycosis.
• Broad-spectrum antibiotics cause changes in normal
bacterial flora such that fungal infections can thrive.
TREATMENT
• Current recommendations for treating severe sepsis or
septic shock in the ICU state that empirical antifungal
therapy should not be used on a routine basis but may
be justified in selected subsets at high risk.
• Amphotericin B deoxycholate, one of the oldest anti-
fungal therapies, is a polyene antifungal medication
that is fungistatic in standard doses and fungicidal at
higher doses. It works by increasing membrane per-
meability, which leads to cell death. Used only in
intravenous form, amphotericin B successfully treats
a variety of fungal species. It is not used alone for
fungal meningitis because it does not cross the blood-
brain barrier. Side effects include chills, acute febrile
reactions, anemia, and nephrotoxicity. Anaphylaxis
occurs in 1% of all patients.
• Lipid-associated formulations of amphotericin B
include amphotericin B lipid complex (ABLC)
(Abelcet®; Enzon), amphotericin B colloidal dispersion
(ABCD) (Amphotec®; InterMune), and liposomal
amphotericin B (AmBisome®; Vestar). These antifun-
gals are less toxic and are used as second-line agents for
fungal diseases that are refractory to amphotericin B and
for patients with underlying renal dysfunction. They are
more expensive than amphotericin B.
• Flucytosine works by inhibiting fungal protein syn-
thesis. It can be given enterally or intravenously. It is
not recommended as monotherapy but can be used in
association with other antifungals especially for
meningitis, endocarditis, and endophthalmitis. Side
effects include nausea, vomiting, diarrhea, and
myelosuppression.
• Itraconazole is a triazole derivative that selectively
inhibits the fungal cytochrome P450 resulting in
decreased ergosterol synthesis and increased mem-
brane permeability. It is available in either enteral or
intravenous preparations. It works well against most
mucosal forms of candidiasis but has fallen out of
favor with the advent of newer triazoles. Its side
effects include nausea, vomiting, headache, and rash.
• Fluconazole is also a triazole derivative but has differ-
ent pharmacologic properties than itraconazole. This
antifungal is used as first-line treatment for many
types of fungal infections because, while it has simi-
lar efficacy to amphotericin B, it is far less toxic.
Recently, certain strains of Candida and other types of
fungi have developed resistance to this drug.
• Voriconazole is one of the newest triazoles that is sim-
ilar to fluconazole but has a higher potency and has
been effective against many fluconazole-resistant
fungi, invasive Aspergillus, and emerging fungi such
as Blastomyces dermatitidis, Fusarium spp., and
Penicillium marneffei. It is available in both oral and
parenteral formulations. Rare side effects include
visual disturbances, transaminitis, and rash but it is
relatively nontoxic.
• Caspofungin is in a new class of antifungal medica-
tions called echinocandins, which increases cell wall
permeability by inhibiting a certain component of its
synthesis. Caspofungin is only used in intravenous
form. It has shown to be successful against
fluconazole-resistant species of Candida but it
appears not to have significant activity against C. neo-
formans or filamentous fungi other than Aspergillus
(i.e., Fusarium spp. and P. boydii).
• For most fungal infections caused by an indwelling
catheter, it is recommended that the hardware be
removed and, if possible, the tip cultured.
PREVENTION
• Certain fungi such as Candida can be spread by the
hands of health care workers. Basic infection-control
measures such as hand-washing between patient con-
tact and sterile technique prior to insertion of any
device reduce risk of fungal infections.
• Antifungal prophylaxis has been successfully used for
patients with neutropenia and for patients with
advanced HIV or AIDS in decreasing the incidence of
invasive fungal infections.
• Preemptive therapy for nonneutropenic but critically
ill patients is controversial. Many physicians will treat
this patient population without a definitive diagnosis
if they are highly colonized with fungi or if they con-
tinue to remain febrile despite the use of broad-
spectrum antibiotics.
SPECIFIC FUNGAL INFECTIONS
CANDIDA ALBICANS
• No matter the patient, the most common type of
fungal infection in the ICU is Candida. In fact, 60%
of all fungal infections are caused by this yeast.
C. albicans is still the most frequent culprit but, in
recent years, a growing number of nonalbicans species
such as C. parapsilosis, C. glabrata, and C. krusei
have been implicated.
• Candida spp. is now the fourth most common cause of
nosocomial bloodstream infections in the United
States.
• Candida spp. are yeasts that can form pseudohyphae.
They are a normal part of the gut flora and can also be
found on the skin. They can cause infection by either
being translocated from the gut into the bloodstream,
or by translocation from the skin or urine into the
bloodstream.
• In the ICU, colonization with this yeast is frequent
and does not always lead to infection. However,
Candida found in the blood is never normal.
• The clinical manifestations vary since Candida spp.
can affect a multitude of organs. In the general popu-
lation, skin, nail, and vulvovaginal candidal infections
are common.
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• In the intensive care setting, oropharyngeal and
esophageal candidiasis are commonly seen especially
in patients with HIV/AIDS. This can present as a sore
throat, dysphagia, or as thrush (patches of thick, white,
creamy exudate on the tongue that is difficult to remove).
• Candida spp. can also infect the bloodstream causing
fevers, chills, and possibly septic shock. Once in the
bloodstream, Candida spp. can spread hematoge-
nously to many organs including the lungs, liver,
spleen, gallbladder, pancreas, peritoneum, heart,
meninges, skin, and eyes.
• Candida spp. are found in the urine in 20–30% of crit-
ically ill patients with Foley catheters. Candiduria can
potentially cause urosepsis but it is rare. Most patients
with candiduria are asymptomatic.
• Diagnosis is made by detecting pseudohyphae in the
blood. Only one positive culture is needed, but the
sensitivity of this test is so low, many patients with
disseminated candidiasis will have negative blood cul-
tures. The lysis-centrifugation method is best for
detecting this fungus in blood but it still takes 2–4 days
for a blood culture to turn positive.
• If a blood culture is positive, an ophthalmologic
examination should be performed in order to identify
white cotton wool exudates consistent with endoph-
thalmitis or chorioretinitis.
• A punch biopsy of skin lesions which consist of clus-
ters of painless pustules or macules on any part of the
body might be helpful in making the diagnosis.
• Culturing the tips of invasive catheters after removal
might be beneficial.
• Other tests such as antigen/antibody assays or poly-
merase chain reaction (PCR) have proved disappointing.
• For most cases of candidiasis, therapy consists of flu-
conazole instead of amphotericin B. The combination
of these two drugs has also been recommended for the
first 5–6 days of treatment.
• In cases of fluconazole-resistant Candida such as
C. glabrata, patients who are unstable with multiple
organs involved, and patients who received prophy-
laxis with fluconazole, amphotericin B is used instead
of fluconazole.
• Both voriconazole and caspofungin are quickly
becoming first-line agents for candidal disease. Both
antifungal drugs have excellent activity against all
Candida strains including triazole-resistant Candida
and they have less toxicity than amphotericin B.
• Although removal of the Foley catheter is recom-
mended for all, the use of antifungal treatment for
candiduria is usually reserved for the critically ill and
immunocompromised.
• In cases of candidal meningitis, endophthalmitis, and
endocarditis, flucytosine has been recommended in
combination with amphotericin B.
• For cases of candidemia, treatment should continue
for 2 weeks after the last negative blood culture. A
longer course of treatment might be required depend-
ing on which organs are involved.
CRYPTOCOCCUS NEOFORMANS
• C. neoformans is a polysaccharide-encapsulated yeast
which grew in prevalence during the 1980s with the
rapid growth of HIV.
• Almost 10% of all patients with HIV/AIDS have
C. neoformans but it can affect other immunocompro-
mised patients as well.
• The species exists in several varieties: the gatti variety
(serotype B) which has been associated with eucalyp-
tus trees, and neoformans (serotype D) and grubii
(serotype A) which have been associated with fruits,
trees, and bird excreta.
• C. neoformans is inhaled and usually causes an
asymptomatic pulmonary infection. It then travels
hematogenously to the cerebrospinal fluid (CSF)
where it can cause signs and symptoms of meningitis
including fever, headache, mental status changes, and
photophobia.
• Cryptococcosis can be detected in the CSF or blood
using the cryptococcal latex antigen test. India ink
stains are no longer used.
• The treatment is usually a combination of ampho-
tericin B and flucytosine followed by fluconazole.
Patients with HIV/AIDS should be treated for life
since recurrence is common.
• Although voriconazole shows good activity, caspo-
fungin has not been shown to be effective against
cryptococcosis.
ASPERGILLUS FUMIGATUS
• Aspergillus is a mold which produces hyaline or col-
orless, septate hyphae.
• The species A. fumigatus is the most common type
and is responsible for over 90% of invasive fungal
infections. Although uncommon in the United States,
A. flavus produces toxins called aflatoxins which can
cause liver cancer.
• A population-based study for San Francisco shows an
incidence of 1–2 cases per 100,000 a year.
• A. fumigatus is commonly found in patients with lung
and heart transplants but has also been described in
burn patients and those with alcoholic liver disease
and is increasing in patients with HIV/AIDS.
• Patients with lung cavitations from tuberculosis or
sarcoidosis can grow Aspergillus ‘fungal balls’
(aspergillomas).
• A. fumigatus is diagnosed by detecting the acute
angle branching septae in bronchoalveolar lavage or
biopsy.
• Amphotericin B was used as the primary weapon
against A. fumigatus but, since the advent of ampho-
tericin B-resistant species such as A. terreus,
voriconazole and caspofungin have been used with
much greater success.
HISTOPLASMA CAPSULATUM, COCCIDIOIDES
IMMITIS, BLASTOMYCES DERMATITIDIS
• All three fungi are dimorphic in that they grow as
mycelial forms, with spores, at 25°C on Sabouraud
agar and as yeast at 37°C on blood agar.
• These fungi commonly affect patients with HIV/AIDS
but have been found in other immunocompromised
patients.
• H. capsulatum is the most common of the three over-
all and B. dermatitidis, the least common but the inci-
dence for each fungus, is dependent on geographic
regions.
• H. capsulatum is found primarily in the Ohio and
Mississippi River valley states. It is isolated in the soil
where avian and bat excreta exist.
• C. immitis is endemic in the desert areas of the
Southwest United States and Northern Mexico. It, too,
is found in soil.
• B. dermatitidis is most commonly seen in the Ohio
and Mississippi River Valley states as well. It is iso-
lated from soil and rotten wood.
• All three fungi are transmitted by inhalation of spores
which can result in pneumonia and, possibly, dissem-
ination into the bloodstream.
• C. immitis commonly causes pneumonia with calci-
fied granulomas in HIV/AIDS patients. The clinical
presentation is typically fevers, chills, and cough.
Disseminated disease is rare but is seen more com-
monly in critically ill patients without HIV/AIDS.
• Unlike Coccidioides, H. capsulatum and B. dermati-
tidis more commonly cause disseminated disease in
patients with HIV/AIDS. In one study, 10–25% of
patients with AIDS developed disseminated histoplas-
mosis. Meningitis, bone lytic granulomas, skin granu-
lomas, and other organ lesions have been reported.
• Diagnostic tests for H. capsulatum include blood and
bone marrow cultures but detecting the polysaccha-
ride antigen in the serum or urine is faster and just as
sensitive. The specificity for the antigen assay is not
as good because false positive results are seen in
patients with blastomycosis, paracoccidioidomycosis,
and P. marneffei infection.
• C. immitis is commonly seen on the chest radiograph
as a diffuse reticulonodular pattern that is often con-
fused with Pneumocystis. Complement-fixation sero-
logic tests are also useful.
• B. dermatitidis can be detected by antigen assay.
• Amphotericin B followed by fluconazole has been the
recommended therapy for each fungus but voricona-
zole is gaining favor as first-line treatment.
PNEUMOCYSTIS JIROVECI (FORMERLY CARINII)
• P. jiroveci (still referred to as PCP) is an atypical
fungus that is neither yeast nor mold. In fact, it was
classified as a protozoan for many years but is more
recently considered a fungus.
• This fungus is considered the most common oppor-
tunistic infection in patients with HIV/AIDS. About
80% of patients with AIDS will be infected with PCP
at least once in their lifetime unless prophylactic
antibiotics are taken.
• PCP infects its host through respiratory transmission
and will commonly cause a clinical picture consisting
of dyspnea, hypoxemia, cough, and sometimes fever.
• The chest radiograph will typically show a diffuse
interstitial pattern: an elevated serum lactate dehydro-
genase (LDH) is a fairly sensitive, yet not specific,
marker.
• Diagnosis is made by direct fluorescent antibody
(DFA) of induced sputum or bronchoalveolar lavage.
Silver stains are no longer used.
• Unlike other fungi, PCP has been successfully treated
with trimethoprim/sulfamethoxazole and steroids
(prednisone, 40 mg twice daily, for 5 days, followed
by a tapering dose, to be used when the PaO2 is
<70 mmHg). Many patients with HIV/AIDS are
placed on prophylaxis.
PENICILLIUM MARNEFFEI
• Once rare in the Unites States, the incidence of the
dimorphic fungus, P. marneffei, is rising especially in
the HIV/AIDS population.
• This fungus is endemic in Southeast Asia, Hong
Kong, and Taiwan where penicilliosis is considered
the third most common opportunistic infection (fol-
lowing cryptococcus and tuberculosis) among HIV-
infected patients.
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• The transmission for this infection is thought to be
both from inhaled spores from the soil and direct inoc-
ulation of skin wounds.
• Patients with this infection present with fever, cough,
lymphadenopathy, and weight loss. Skin lesions are
characterized by umbilicated papules or nodules with
necrotic centers located mostly on the trunk and upper
extremities.
• The chest radiograph might show interstitial infiltrates
and anemia is commonly reported.
• Diagnosis of this fungus is currently made by cul-
ture of blood, stool, urine, CSF, and bone marrow.
P. marneffei produces a red soluble pigment on
Sabouraud agar. Biopsies of skin lesions or lymph nodes
are also helpful. PCR and antigen assays have been used
with some success but are not yet in clinical use.
• Treatment consists of amphotericin B, itraconazole,
or voriconazole. The fungus is resistant to flucona-
zole. The activity of caspofungin against this fungus
has yet to be studied. Lifelong secondary prophy-
laxis with itraconazole or voriconazole has been
recommended.
FUSARIUM SPP.
• Like Aspergillus, Fusarium is a saprophytic filamen-
tous mold that produces septate hyphae.
• F. solani is the most common type to produce infection
but F. oxysporum, F. moniliforme, and F. proliferatum
have also been recovered from humans.
• Fusarial infections were epidemic in Russia in the
early 1900s secondary to the ingestion of contami-
nated grains and is now becoming more common espe-
cially among patients with hematologic malignancies,
bone marrow transplants, and those with severe burns.
• Fusarium spp. usually cause disseminated disease by
direct inoculation or the ingestion of Fusarium toxins.
• Clinically, patients present with severe myalgias,
fevers, and skin lesions that are characterized as ini-
tially macular with central pallor and progress to
necrotic lesions with a surrounding rim of erythema.
These lesions can be seen on all extremities.
• Definitive diagnosis can be made by culturing blood
and skin biopsies. The fungus produces downy, cotton
colonies that are lavender to purple-red on Sabouraud
agar. Microscopically, they appear as sickle-shaped
and multicellular. The histopathology can be indistin-
guishable from Aspergillus.
• Fusarium is extremely resistant to many antifungal
medications. Only high-dose amphotericin B and
voriconazole have been effective in eradicating this
fungus.
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55 CENTRAL NERVOUS
SYSTEM INFECTIONS
John A. Schneider
KEY POINTS
• Imaging plays little role in the diagnosis of acute bac-
terial meningitis but CT should be performed before
lumbar puncture when an intracranial mass lesion is
suspected (antibiotics should not be delayed).
• Dexamethasone has been shown to reduce morbidity
in children with acute H. influenzae type B meningi-
tis and, when given before antibiotics, in adults with
pneumococcal meningitis.
• Rapid surgical decompression is indicated in patients
with spinal epidural abscess with worsening deficit.
• Herpes simplex encephalitis benefits from prompt
diagnosis and treatment with acyclovir.
EPIDEMIOLOGY AND ETIOLOGY
• Viruses are the major cause of aseptic meningitis—a
general term to describe a meningitis that is infectious
or noninfectious with a lymphocytic pleocytosis, for
which a cause is not apparent after initial evaluation and
routine stains and cultures of cerebrospinal fluid (CSF).
• A specific viral etiology is established in only up to
70% of aseptic meningitides. Enteroviruses are the
most likely causative pathogen in 85–95% where a
diagnosis is made. Arboviruses and herpes viruses are
also pathogens that cause aseptic meningitis, however,
they much more commonly cause encephalitis—
distinguished by the presence of decreased mentation
(i.e., confusion or stupor).
• Bacterial meningitis causes significant morbidity and
mortality with rates that remain unacceptably high
despite the availability of effective antimicrobial
therapy.
• Subdural empyema refers to a collection of pus in the
space between the dura and arachnoid. It accounts for
up to 20% of all localized intracranial infections.
• Epidural abscess refers to a localized collection of
pus between the dura mater and the overlying skull or
vertebral column. Because cranial epidural abscess
can cross the cranial dura, an accompanying subdural
empyema can be present. Spinal epidural abscess usu-
ally occurs secondary to hematogenous dissemination
from foci elsewhere in the body to the epidural space,
or by extension from vertebral osteomyelitis.
• Suppurative intracranial thrombophlebitis includes
both venous thrombosis and suppuration which usu-
ally begins in the paranasal sinuses, middle ear, mas-
toid, face, or oropharynx. Its development depends on
the close proximity of various structures to the dural
venous sinuses.
• The three most common meningeal pathogens
(accounting for 80% of cases) have remained the top
three for the last 25 years, however, their relative order
has reversed completely from Haemophilus influen-
zae, Neisseria meningitidis, Streptococcus pneumo-
niae in 1978 to Streptococcus pneumoniae, Neisseria
meningitidis, Haemophilus influenzae by 2005. Other
causative organisms include Streptococcus agalactiae
and Listeria monocytogenes.
• In infants (0–3 months), S. agalactiae and L. monocyto-
genes are more prominent than in adults (18–50 years)
where S. pneumoniae and N. meningitidis are dominant.
L. monocytogenes returns as an important pathogen in
those >50 years.
• Certain predisposing factors should raise awareness of
other pathogens: immunocompromised state—gram-
negative bacilli (Pseudomonas); basilar skull
fracture—group A β-hemolytic streptococci; head
trauma/postneurosurgery/CSF shunt—Staphylococcus
species, gram-negative bacilli (Pseudomonas).
• The organisms responsible for a brain abscess (case
fatality 30–60%) are highly variable and depend on the
predisposing condition: otitis media or mastoiditis—
streptococci, anaerobes, Enterobacteriaceae; sinusitis—
streptococci, anaerobes, S. aureus, Haemophilus spp.;
dental sepsis—Fusobacterium, other anaerobes, and
streptococci; penetrating trauma or postneurosurgical—
S. aureus, streptococci, Enterobacteriaceae, Clostridium
spp.; lung abscess, empyema, bronchiectasis—
Fusobacterium, Actinomyces, other anaerobes, strep-
tococci, Nocardia spp.; bacterial endocarditis—
S. aureus, streptococci; neutropenia—aerobic gram-
negative bacilli, Aspergillus spp., Mucorales, Candida
spp.; transplantation—Aspergillus spp., Candida spp.,
Mucorales, Enterobacteriaceae, Nocardia spp.,
Toxoplasma gondii; HIV infection—T. gondii,
Nocardia spp., Mycobacterium spp., L. monocyto-
genes, Cryptococcus neoformans.
PATHOGENESIS
• For bacterial meningitis, colonization is followed by
local invasion, bacteremia, meningeal invasion, and
finally bacterial replication in the subarachnoid space.
• Microorganisms can reach the brain and cause abscess
by three mechanisms in decreasing frequency: spread
from contiguous focus, hematogenous spread, and
traumatic spread.
• Specific virulence factors overcome host defense mech-
anisms to cause meningitis. The new arrival of an organ-
ism which colonizes the nasopharynx is the first step in
this process. Fimbria, polysaccharide capsule, and IgA
protease production are a few of the bacterial factors
that allow for colonization and subsequent invasion.
• Intravascular survival is facilitated as the most
common meningeal pathogens are encapsulated. The
mechanism for meningeal invasion is unknown. Once
meningeal pathogens enter the subarachnoid space,
host defense mechanisms are inadequate to control
the replication and infection that occurs.
• Marked inflammation occurs in the subarachnoid
space which manifests in the clinical symptoms and
signs of meningitis. Alterations in the blood-brain bar-
rier occur, which allows for increased permeability of
both pathogen and antimicrobials.
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• Vasogenic, cytotoxic, and interstitial mechanisms
contribute to cerebral edema which creates increased
intracranial pressure which may lead to subsequent
herniation. A vasculitis can occur which can lead to
narrowing or thrombosis of cerebral blood vessels and
subsequent ischemia and infarction. Direct neuronal
injury can also occur.
CLINICAL FEATURES
• Viral meningitis almost always has fever as one of its
presenting signs. Accompanying symptoms of vomit-
ing, anorexia, headache, and rash are common. Other
neurologic symptoms and signs are often reported.
• Bacterial meningitis classically presents with four
components: headache, fever, meningismus, and
altered mental status. At least one of these compo-
nents is present in all patients with acute bacterial
meningitis. Kernig or Brudzinski sign is present in
over 50% of patients. Emesis (35%), seizures (30%),
focal neurologic signs (10–20%), and papilledema
(<1%) may also be present.
• Rash present on the extremities occurs in 50% of
patients with meningococcemia. Rash is erythema-
tous and macular, and matures rapidly into petechial
and subsequent purpuric phases. This rash is more
commonly seen in younger patients with meningo-
coccal meningitis.
• Neonates may not have meningismus and may present
with temperature instability (hypo/hyperthermia), list-
lessness, irritability, refusal to eat, vomiting, diarrhea, or
respiratory distress. Likewise, elderly and neutropenic
patients may present with lethargy and obtundation.
• CSF shunt infections may not present with meningeal
signs. Frequent symptoms are headache, nausea,
lethargy, and change in mental status. Fever is vari-
able, and pain is often related to infection at the peri-
toneal or pleural endings of the shunt or may be
absent altogether.
• Brain abscess may be indolent or fulminant with some
clinical manifestations mimicking those for meningi-
tis. However, the clinical symptoms and signs may be
more due to the size and location of a space-occupying
lesion and the virulence of the infecting organism.
• Subdural empyema may be rapidly progressive, with
symptoms and signs secondary to the presence of
increased intracranial pressure, meningeal irritation,
or focal cortical inflammation. This acute presentation
of subdural empyema is seen most often in patients
with contiguous spread of infection. Headache, which
may be localized to the infected sinus or ear, is a
prominent complaint and becomes generalized as the
infection progresses.
• Spinal epidural abscess may develop within hours to
days, or the course may be more chronic, over weeks
to months. The presentation in most patients demon-
strates four clinical stages: (1) backache and focal ver-
tebral pain, with tenderness on examination; (2) nerve
root pain, manifested by radiculopathy or paresthe-
sias, or both; (3) spinal cord dysfunction, character-
ized by defects of motor, sensory, or sphincter
function; and (4) complete paralysis. Pain is the most
consistent symptom and is usually accompanied by
local tenderness at the affected level.
• Suppurative intracranial thrombophlebitis may
damage the nerves that traverse the cavernous sinuses.
The most common complaints in patients with septic
cavernous sinus thrombosis are periorbital swelling
and headache. Other symptoms include drowsiness,
diplopia, eye tearing, photophobia, and ptosis.
DIAGNOSIS
• For viral meningitis, CSF pleocytosis is almost always
present with the cell count ranging from 100 to 1000 mm3.
Early in infection neutrophils may dominate the CSF
profile; however, a lymphocytic predominance occurs
over the first 6–48 hours of infection. Protein and glu-
cose perturbations are minimal. A specific virologic
diagnosis depends on the isolation of virus from the
CSF in tissue culture. PCR for herpes simplex virus or
for varicella-zoster virus may also be diagnostic.
• Bacterial meningitis usually has the following typical
findings: opening pressure > 180 mmHg; WBC count
1000–5000/mm3; ≥80% neutrophils; protein 100–500
mg/dL; glucose ≤40 mg/dL. The Gram stain is posi-
tive in 60–90% and the culture 70–85% of cases. A
rapid streptococcal urinary antigen may help with the
diagnosis.
• Cranial computed tomography (CT) or magnetic res-
onance imaging (MRI) does not aid in the diagnosis of
acute meningitis. If the symptoms are prolonged or
there are neurologic deficits, it may be warranted.
Cranial imaging should be obtained prior to lumbar
puncture when there is evidence of papilledema or
focal neurologic deficits, however, it should not delay
the initiation of antibiotics and corticosteroids.
• Cranial CT or MRI is key to the diagnosis of brain
abscess or subdural empyema and MRI for spinal
epidural abscess and suppurative intracranial throm-
bophlebitis. For brain abscesses, CT characteristically
demonstrates a hypodense center with a peripheral
uniform ring enhancement following the injection of
contrast material; this is surrounded by a variable hypo-
dense area of brain edema. MRI is more sensitive than
CT and assists in early detection of cerebritis, cerebral
edema, inflammation into ventricles and subarachnoid
space, and earlier detection of satellite lesions.
• A lumbar puncture is contraindicated for the diagno-
sis of subdural empyema due to risk of herniation.
• Blood cultures should be obtained for all patients
presenting with stigmata of meningitis or brain
abscess.
MANAGEMENT AND TREATMENT
• Imaging should be performed to verify the suspicion
of brain abscess. If single or multiple ring-enhancing
lesions are found, the patient should be taken urgently
to surgery and all lesions >2.5 cm in diameter should
be excised or stereotactically aspirated and sent to
microbiology and pathology.
• Subdural empyema and epidural abscesses are medical
emergencies. Prompt surgical decompression through
a drainage procedure is necessary as antimicrobial
agents alone do not reliably sterilize the empyema.
Antibiotics for 3–6 weeks are recommended (longer if
bone is involved).
• Suppurative thrombophlebitis can usually be managed
with antibiotics. Ligation of the internal jugular vein
along with thrombectomy via a surgical procedure
may be needed with severe disease of cavernous sinus
thrombosis with sphenoid involvement. Anticoagulation
can be used in conjunction with antibiotics for severe
disease; however, risk of intracranial hemorrhage or
venous hemorrhagic infarcts does exist.
• For acute meningitis, the institution of antimicrobial
therapy should be based on the results of Gram stain
of the CSF. If a positive Gram stain is not obtained
from the CSF or the lumbar puncture is delayed longer
than 90–120 minutes, empirical antibiotic therapy should
be initiated after blood cultures are obtained.
• Dexamethasone (10 mg q6h × 2 days) should be initi-
ated 30 minutes prior to or concomitantly with antibi-
otics when a diagnosis of meningitis is made or if
empiric treatment is to begin.
• Specific antiviral chemotherapy is not available for
the enteroviruses.
• Early recognition and treatment improves outcome
in herpes simplex encephalitis. The treatment is
acyclovir at a dose of 10 mg/kg every 8 hours for
10–14 days.
• Empirical therapy for purulent meningitis depends on
the predisposing factors as outlined above. For infants
(0–3 months) ampicillin plus a third-generation
cephalosporin (ceftriaxone) should be administered.
For children and adults (3 months–50 years) a third-
generation cephalosporin should be administered and
for adults >50, ampicillin should be added to this reg-
imen. Vancomycin should be added to all the above
regimens in areas where there is S. pneumoniae resist-
ance to penicillin (PCN; United States). With penicillin
allergy, trimethoprim/sulfamethoxazole (TMP/SMX)
should replace ampicillin for treatment of L. monocy-
togenes and vancomycin + rifampin for treatment of
S. pneumoniae.
• For specific targets of antimicrobial therapy, the fol-
lowing should be administered: S. pneumoniae (ceftri-
axone or cefotaxime + vancomycin + dexamethasone);
N. meningitidis (Pen G); L. monocytogenes (ampicillin
+ gentamycin 2); H. influenzae, coliforms, and
Pseudomonas aeruginosa (ceftazidime 2 + gen-
tamycin).
• Duration of therapy is for 10–14 days.
• Empirical antimicrobial therapy for bacterial brain
abscess includes a third-generation cephalosporin (cef-
triaxone) and metronidazole.
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56 VIRAL ENCEPHALITIS
D. Kyle Hogarth
KEY POINTS
• A diagnosis of encephalitis should be considered in
any patient with unexplained headaches, fevers,
change in mental status, or seizures.
• The most common cause of fatal viral encephalitis is
HSV. Outcomes in patients with HSV encephalitis are
significantly improved by early recognition and
prompt institution of acyclovir therapy.
• 90% of cases of HSV encephalitis will have focal neu-
rologic abnormalities.
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• Early LP should be performed in all cases of sus-
pected encephalitis, but CT or MRI imaging should
first be performed in patients with focal neurologic
findings.
• The CSF is generally abnormal in encephalomyelitis:
usual findings include increased leukocytes, normal
glucose, mildly elevated or normal protein.
• PCR detection of HSV in CSF is the gold standard for
the diagnosis of HSV encephalitis. However, a negative
PCR result cannot always exclude HSV encephalitis
and acyclovir therapy should continue until culture
results are definitive or an alternative diagnosis is made.
• Worldwide, the arboviruses are the most common cause
of encephalitis. In North America, West Nile virus has
become an increasingly common cause of encephalitis.
• Viral encephalitis patients should receive full inten-
sive care support, as many can regain full neurologic
function, even after prolonged alteration of their
mental status.
APPROACH TO THE ENCEPHALITIS
PATIENT
• There are no specific clinical signs or symptoms that
can easily distinguish between causes of encephalitis.
Patients must be approached with a wide differential
diagnosis of etiologies.
• Patients will typically present with fever, headache,
and behavioral changes or altered mental status.
• The setting of the disease may provide helpful clues
as to the etiology. The likelihood of arbovirus
encephalitis depends on the season, location, degree
of insect exposure the patient has experienced, and
current prevalence of disease in a given community.
• Often, there are clues in the community as to the cur-
rent risk of viral encephalitis. For example, West Nile
virus infections are typically preceded by outbreaks
and deaths among birds.
• The rate of progression of the encephalitis may offer
suggestions as to the cause of disease. For example,
disease developing 1–2 weeks after a viral syndrome
or recent immunization is likely postinfectious,
whereas an acute fulminant course suggests herpes
simplex virus (HSV).
• Physical examination is usually only helpful if a char-
acteristic rash is present, such as the exanthems of
varicella, measles, Lyme disease, or Rocky Mountain
spotted fever.
• Urgent diagnostic imaging by CT or MRI should be
obtained. These tests are limited in diagnosing viral
encephalitis, but are useful in ruling out other causes
of the patient’s symptoms.
• Early lumbar puncture (LP) should be performed,
especially to rule out bacterial meningitis as the cause
of symptoms.
• Cerebrospinal fluid (CSF) should be sent for cell
count, chemistry, viral studies and cultures, and stains
and culture for fungi, bacteria, and mycobacteria.
• Completely normal findings on LP significantly
reduce the likelihood of encephalitis and raise the
possibility of toxic or metabolic encephalopathy.
HERPES SIMPLEX VIRUS
ENCEPHALITIS
• Herpes simplex virus encephalitis is the most
common fatal encephalitis.
• It is seen in all age groups, in both sexes, immuno-
competent and immunocompromised, in all seasons,
and accounts for 5% and 10% of all reported cases of
encephalitis.
• The early use of acyclovir therapy at a dose of
10 mg/kg every 8 hours for 10–14 days significantly
improves morbidity and mortality. The dosage of
acyclovir should be adjusted in patients with renal
failure.
• A temporal lobe syndrome in the setting of nonspe-
cific constitutional symptoms is the most common
clinical presentation for HSV, but parietal or frontal
lobes involvement is occasionally seen.
• Adult HSV encephalitis does not require mucocuta-
neous HSV lesions to be present.
• Examination of the CSF reveals an abnormality in
90–97% of cases. The white blood cell count is ele-
vated with a lymphocyte predominance, but early in
the course polymorphonuclear leukocytes will pre-
dominate. Red blood cells are present in 75–80% of
samples. Glucose is normal, and the protein content is
only moderately elevated.
• Viral cultures for HSV are almost always negative.
Polymerase chain reaction (PCR) analysis to detect
HSV DNA in CSF is the gold standard for the diag-
nosis of HSV, especially in the early phase of the dis-
ease. PCR has a demonstrated sensitivity of 96% and
a specificity of 99%.
• In 80–90% of cases, the initial electroencephalogram
(EEG) is abnormal, with predominantly spiked and
slow wave patterns localized to the area of the brain
involved.
• Long-term consequences include residual dysphasias,
paresis, paresthesias, behavioral changes, and amne-
sia. The mortality rate is 28% for HSV encephalitis,
even with acyclovir therapy. Only 38% of patients
recover with little residual deficit.
ARBOVIRUS ENCEPHALITIS
• Arboviruses are insect-transmitted viruses and are the
most common cause of encephalitis worldwide.
• The risk of arboviruses infection depends on many
factors that determine the predominance of the virus
in the environment. These include geography, season,
and local weather conditions.
• West Nile virus is an arboviral infection with increas-
ing frequency in the United States, causing significant
mortality and morbidity, including a polio-like illness
and seizures.
• Human beings are incidental hosts and most infec-
tions are asymptomatic and mild.
• Encephalitis from an arbovirus is typically an acute
fever with headaches, followed by neck pain and then
alteration in mental status.
• Examination of the CSF usually shows fewer than 500
leukocytes per microliter, with a lymphocyte predom-
inance, though polymorphonuclear leukocytes may
predominate early. The glucose is normal. The protein
content is normal or may be slightly elevated. Virus
isolation is rare, and enzyme immunoassays for IgM
antibodies in blood or CSF remain the best way to
detect West Nile or Japanese B viruses.
• There is no proven antiviral therapy that helps with
arboviral infections.
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57 LIFE-THREATENING
INFECTIONS OF THE HEAD
AND NECK
Nuala J. Meyer
KEY POINTS
• Serious infections of the head and neck can pose life-
threatening situations due to their potential for
encroachment on either the airway or CNS.
• As deep neck or facial infections tend to spread along
fascial planes, a thorough understanding of the
anatomic spaces in the neck is essential to proper
management of such infections.
• Deep infections of the head and neck are classically
polymicrobial, reflecting the normal mouth flora.
Anaerobes tend to greatly outnumber aerobic bacteria.
Accordingly, empiric antibiotic therapy should consist
of broad gram-positive and anaerobic coverage.
 Penicillin with clindamycin or metronidazole remains
an excellent choice in immunocompetent patients.
 Clindamycin alone may be considered in penicillin-
allergic patients.
• Immunocompromised patients may lack the classic
manifestations of life-threatening infections—such as
edema, fluctuance, or systemic toxicity—and are at
much greater risk for unusual organisms causing viru-
lent disease. Antimicrobial coverage in such patients is
by necessity broad-spectrum, and frequently requires
consideration of mold-fighting antifungal agents.
SUBMANDIBULAR SPACE INFECTIONS
• Classically described “Ludwig angina,” this pyoder-
mic induration of the tissue of the neck extends into
the muscles between the larynx and over the floor of
the mouth.
• Aggressive, rapidly spreading cellulitis of the sub-
mandibular space, often described as “woody.”
• Etiology is typically infection of the 2nd or 3rd molar
teeth.
• Clinically, patient is febrile with mouth pain, drool-
ing, and dysphagia, often sitting up and leaning for-
ward to maximize the airway size.
 Respiratory distress is common.
 Stridor and cyanosis are ominous signs.
 Potential for direct extension of infection into the
lateral pharyngeal space, retropharyngeal space, or
mediastinum. Any asymmetry of the submandibular
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area should be viewed with great concern for lateral
extension.
• Treatment: First priority is the maintenance of an ade-
quate airway.
 Urgent tracheostomy may be necessary, and should
be performed before the development of stridor or
cyanosis.
 If intubation is attempted, it should be done fiberop-
tically with a flexible scope and with a surgeon pres-
ent to perform immediate tracheostomy should the
intubation fail.
 Infected teeth should be extracted.
 If cellulitis fails to respond to antibiotics alone or if
fluctuance is present, needle aspiration or surgical
incision and drainage is indicated.
• Prognosis: Mortality has declined dramatically with
aggressive management, but may still be as high as 4%.
LATERAL PHARYNGEAL SPACE
INFECTIONS
• Anatomically, this space is defined as an inverted cone
with its base at the skull, its apex at the hyoid bone,
bounded medially by the carotid sheath, and laterally
by the parotid. The space is divided into anterior and
posterior compartments.
 The posterior compartment of the lateral pharyngeal
space contains the 9th through 12th cranial nerves, the
carotid sheath, and the cervical sympathetic trunk.
 Symptoms from infection in this space often relate
to the structures located within this posterior
compartment.
 Postanginal sepsis involves lymphatic spread of
infection into the carotid sheath, often 1–3 weeks
following clinical pharyngitis. The carotid artery
itself can be involved, leading to arteritis and even
rupture. This rare but potentially fatal complica-
tion is often signaled by several minor bleeds prior
to major hemorrhage, and must be treated with
urgent surgical intervention.
 Lemierre syndrome, or suppurative jugular throm-
bophlebitis, is the most common vascular compli-
cation of lateral pharyngeal space infections.
 Vocal cord paralysis may result from suppurative
compression of lower cranial nerves.
• Dental infections are the most common source of
infection, followed by peritonsillar abscess. More
rarely, parotitis, otitis, or mastoiditis can occur.
• Infection of the anterior compartment often causes
trismus—inability to open the mouth—as well as
induration below the mandible. Suppurative infections
can lead to systemic toxicity with fever and rigors and
medial bulging of the pharyngeal wall.
• Treatment of these infections depends on the presence
of local suppuration; if pus is present—as determined
by computed tomography (CT) or direct visualization—
needle aspiration or surgical incision and drainage is
indicated. With the absence of abscess formation, many
such infections can be managed by a prolonged course
of antibiotics, usually on the order of 3–6 weeks.
 Penicillin plus clindamycin or metronidazole is
often required, as mouth anaerobes such as
Fusobacterium and Bacteroides species are fre-
quently recognized as penicillin-resistant.
 Surgical ligation is required for an infected carotid
artery with potential for rupture, whereas involve-
ment of the internal jugular vein can frequently be
treated by antibiotics alone. The role of anticoagula-
tion in vascular infections is unclear, and has not
been proven to be helpful.
• Prognosis of lateral pharyngeal space infections
depends on the extent of the infection, but both
morbidity—often stroke—and mortality remain high
(20–40%).
RETROPHARYNGEAL INFECTIONS
• Also known as the “danger” space, the retropharyngeal
space extends between the fascia from the esophagus
and pharynx back to the vertebral spine. Infections
here can spread from the base of the skull through the
entire posterior mediastinum down to the diaphragm.
• In children, these infections arise typically via lym-
phatic drainage following suppurative adenitis. In
adults, infection may follow penetrating trauma—
often trauma to the esophagus, or choking injuries—
or may result from tooth or peritonsillar abscess.
• Symptoms include fever, drooling, trismus, and possi-
ble nuchal rigidity, with the neck held tilted to the
unaffected side. On examination, there may be
bulging of the posterior pharyngeal wall but occasion-
ally direct examination is compromised by the
patient’s pain and trismus.
 CT and x-ray of the lateral neck may show cervical
lordosis with swelling.
 Occasionally, gas collections are seen in the
retropharyngeal space.
• The main dangers are laryngeal edema with airway
obstruction, or abscess rupture with aspiration.
• Acute necrotizing mediastinitis can also follow infec-
tions in the danger space, with potential necrotic
extension into the retroperitoneum, pleural space,
pericardial space, or rupture into the airways. In
adults, this diagnosis carries a 25% mortality rate
despite prompt antibiotic therapy, and surgical
debridement is the rule.
CLINICAL SYNDROMES
PERITONSILLAR ABSCESS
• Also known as quinsy, peritonsillar abscess is a com-
plication of acute tonsillitis and typically strikes
young adults.
• Classically, patients are febrile with unilateral sore
throat, dysphagia, trismus, drooling, and muffled voice.
• Drainage may be attempted by experienced physicians,
with the patient in the Trendelenburg position, and with
recognition of potentially life-threatening hazards:
 Airway obstruction
 Aspiration of purulent material
 Lateral extension to deep lateral pharyngeal space
DIPHTHERIA
• Pharyngeal infections caused by toxigenic strains of
Corynebacterium diphtheriae, still sporadically
occurs despite widespread immunization against the
bacterium.
• Inflammation may occur at any site in the upper
airway, with tonsillitis being the most common
presentation.
• Diphtheria classically forms a tenacious membrane on
the airway mucosa, which frequently discolors and
becomes necrotic.
 Airway obstruction may follow either membrane
formation or mucosal swelling.
 Membranes tend to bleed extensively, especially
with attempts at removal.
 Urgent tracheostomy may be required, as well as
bronchoscopy to identify and remove any mem-
brane in the lower airways.
 Distant complications of diphtheria include myocardi-
tis and peripheral neuropathy, usually within 2 weeks
after the initial infection. These occur secondary to
circulating toxin, and can progress to shock, heart fail-
ure, and dysrhythmia.
 Treatment for all suspected cases of diphtheria should
include administration of equine diphtheria antitoxin
immediately—to reduce the risk of myocarditis—in
addition to antibiotic therapy with penicillin or a
macrolide.
EPIGLOTTITIS
• Involves typically nonsuppurative inflammation of the
supraglottic structures and epiglottis (also called
“supraglottitis”).
• Can affect young children and adults.
• Haemophilus influenzae was once the most common
bacterial cause of epiglottitis, but with vaccination
efforts it has been replaced by other oral flora, such as
Streptococcus pneumoniae and Staphylococcus aureus.
• Triad of fever, stridor, and drooling; adults may com-
plain of sore throat and exquisite odynophagia. Patients
are classically found sitting up, leaning forward, with
noticeably slow inspirations. Inspiration draws the
epiglottis down, which can further obstruct the airway,
so slowing inspiration can minimize obstruction.
• Cyanosis, pallor, or bradycardia reflect severe airway
obstruction and signal the need for urgent tra-
cheostomy or intubation.
• Treatment involves ICU monitoring, antimicrobial
therapy, and, not infrequently, an artificial airway.
 Children require artificial airway management more
often than adults.
 Intubation, if indicated, should be done under direct
visualization and in the operating room, with imme-
diately available equipment and personnel for a sur-
gical airway if necessary.
LARYNGOTRACHEOBRONCHITIS
• Also known as croup; primarily affects young children.
• Follows typically a viral upper respiratory infection.
• Causes swelling of the conus elasticus, which narrows
the infraglottic structures and produces the classic
“barking” or “brassy” cough.
• May involve inspiratory stridor, hoarseness, and res-
piratory distress.
• Lateral neck x-ray may show infraglottic narrowing,
or “steeple sign.”
• Treatment includes humidified oxygen, hydration,
and antibiotics if a secondary bacterial infection is
suspected.
 Artificial airway—either surgical or via intubation—
may be necessary and is fraught with potential com-
plication and loss of airway.
 Airway manipulation should be performed only by
experienced personnel.
SINUSITIS AND OTITIS
• Although typically quite treatable with antibiotic ther-
apy alone, can have devastating complications due to
their vascularity and proximity to the central nervous
system (CNS).
• Sinus infection is especially common in the ICU set-
ting as a nosocomial infection, particularly in patients
with nasotracheal, nasogastric, or (less commonly)
orotracheal or orogastric tubes.
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• Malignant otitis externa is a necrotizing infection of
the ear caused by Pseudomonas aeruginosa, which
tends to occur in diabetic or otherwise immunocom-
promised patients.
• Immunocompromised patients are also at risk for
fungal disease of the sinus or ear, which can be inva-
sive and aggressively necrotizing. Common molds
implicated in disease derive from the Aspergillus,
Rhizopus, and Mucor families.
• Both sinus and ear disease can extend directly or via
the hematogenous route into the skull itself or to
intracranial structures. The myriad CNS effects of
such extension are beyond the scope of this chapter,
but include:
 Periorbital cellulitis
 Cranial osteomyelitis
 Septic intracranial thrombophlebitis involving the
cavernous venous sinus or superior sagittal vein
 Brain abscess
 Cranial epidural abscess
 Subdural empyema
• Early consultation with otolaryngologists, potential
imaging either by direct endoscopy or by CT, and
quick surgical intervention can be lifesaving in such
cases.
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KEY POINTS
• Serious soft-tissue infections causing necrosis of sub-
cutaneous tissue, fascia, and muscle are rare but can
be rapidly fatal without prompt diagnosis and early
definitive therapy.
• The characteristic presentation of extensive subcuta-
neous involvement and systemic toxicity in the
absence of significant superficial signs can hamper
diagnosis in early stages.
• Severe pain and loss of functionality (when involving
an extremity) with signs of systemic toxicity should
trigger urgent surgical exploration and debridement.
• Delaying definitive surgical therapy while obtaining
confirmative radiographic testing may significantly
increase morbidity and mortality.
MAJOR SOFT-TISSUE INFECTIONS
SUPERFICIAL PYODERMAS
• Characterized by superficial infections limited to the
dermis, including erysipelas, impetigo, furunculosis,
and carbunculosis.
• While they may require treatment, they rarely cause
systemic involvement and are not life-threatening
infections.
CELLULITIS
PATHOGENESIS
• Most cases occur with inoculation from minor trauma,
underlying skin lesions, or surgical wounds, or spread
from other soft tissue or bone. However, they can
occur without predisposing event, particularly with
group A streptococcus.
• Other risk factors include mild immunosuppression
(e.g., diabetes or steroid use), impaired lymphatic
drainage (e.g., saphenous vein harvest, mastectomy,
heart failure, or previous infection in same lymphatic
system), or specific recreational or occupational expo-
sure (e.g., swimming, butcher, or fish handler).
• Streptococcus pyogenes and Staphylococcus aureus
are the most common causative organisms. S. pneu-
moniae and other streptococci are less common.
Gram-negative bacilli can be seen in immunosup-
pressed states and with chronic illness and nursing
home exposure predisposing to colonization.
• Rare but fulminant forms of cellulitis are caused by
Aeromonas hydrophila (fresh-) and vibrio species
(salt-) water exposure.
PRESENTATION
• Pain, local tenderness, erythema, and edema with ill-
defined borders are the hallmark signs. Fever may be
absent or low-grade with limited infections.
• Lymphangitis and regional lymphadenopathy are omi-
nous signs of progression to systemic involvement.
MANAGEMENT
• Cultures of wound drainage or skin biopsy are recom-
mended, but the yield is low (25%). Aspiration after
injection of 0.5 mL of nonbacteriostatic saline in the
leading edge of erythema may also be attempted.
Superficial swabs of uninterrupted skin are not useful
and blood cultures are rarely positive but should be
taken nevertheless in patients showing systemic signs.
• In the absence of specific culture data, antibiotic
choices are empirically based on site and predisposing
risk factors. Penicillinase-resistant penicillins (naf-
cillin, dicloxacillin) or first-generation cephalosporins
are the most common first-line agents. Vancomycin
may be appropriate in settings with a high prevalence
of methicillin-resistant S. aureus (MRSA). Diabetic
wounds also should prompt coverage for gram nega-
tives and anaerobes. Infections related to bites need
specific coverage based on the offending animal.
Aminoglycosides (gentamicin, tobramycin) should be
added if there is a history of water injury.
• Borders of erythema should be marked with a pen at
the time of initial evaluation to aid subsequent judg-
ment of progression. Areas of fluctuance, suppuration,
or crepitus should be sought carefully.
• Analgesia is an important part of therapy.
• Failure to defervesce on appropriate antibiotics after
48–72 hours should prompt reinspection for an
undrained source.
ANAEROBIC CELLULITIS
• Also referred to as gangrenous cellulitis, this subclass
of cellulitis results from inoculation of nonviable
tissue in inadequately debrided wounds or areas of
disrupted vascular supply (e.g., diabetic ulcers).
• Presentation is characterized by suppurative drainage
and gas formation in discolored tissue with little pain
or systemic signs.
• Organisms most commonly include clostridial species
or polymicrobial infections with gram-negative rods,
gram-positive cocci, and facultative anaerobes.
• Once fluid or tissue is cultured, therapy consists of
appropriate antibiotics and adequate surgical debride-
ment. While its limitation to nonviable tissue and thus
lack of symptoms distinguishes it from more serious
soft-tissue infections, systemic spread is inevitable if
inadequately treated.
NECROTIZING FASCIITIS
PATHOGENESIS
• While inciting events are similar to those of cellulitis,
necrotizing fasciitis is characterized by inoculation of
subcutaneous tissue and spread along deep fascial
planes with relative sparing of the overlying skin.
• Any site may be involved but the perineum and
extremities are seen most commonly. Most cases are
related to minor trauma (80%), surgical wounds, and
decubitus ulcers.
• Chronic illness (diabetes, renal disease, arteriosclerosis)
or poor nutrition is usually present, but group A strepto-
coccal infections can occur without precipitating event.
• Histology of deep tissues shows nonspecific inflam-
mation with fibrinoid necrosis and thrombosis of ves-
sels, highlighting the need for surgical intervention as
antibiotics and host immunity are inadequate in the
ischemic tissue where infection progresses.
• Group A streptococcus species, usually S. pyogenes,
produce toxins with the ability to act as superantigens,
inducing a nonspecific inflammatory cascade and a
toxic shock syndrome (TSS).
• In polymicrobial infections, virulent organisms such
as streptococci, gram-negative rods (Escherichia coli,
Klebsiella, Proteus), or S. aureus create a necrotic
milieu that supports growth of anaerobes.
PRESENTATION
• Symptoms usually occur several hours to several days
after a history of minor trauma, although with group
A streptococcal infections, the onset may be sooner.
Presentation is characterized by severe pain that is out
of proportion to the superficial appearance of the
involved area.
• Swelling and erythema can progress rapidly to pallor,
bluish discoloration, appearance of superficial vesicles,
and frank gangrene. Crepitus is a rare and late finding.
• Pain progressing to numbness is an ominous sign of
compression and destruction of superficial nerves.
• Systemic toxicity, disorientation, and shock are not
uncommon as the condition progresses.
• Computed tomography (CT) scan and magnetic reso-
nance imaging (MRI) are useful in determining the
extent of deep fascial involvement when clinical sus-
picion exists but signs and symptoms are lacking.
However, time-consuming studies should never be
used as confirmatory tests prior to definitive surgical
exploration once signs and symptoms are present.
MANAGEMENT
• Early surgical exploration and wide debridement is the
mainstay of effective therapy. Failure to adequately
debride all involved tissue adversely affects survival.
• Blood and fluid drainage should be cultured immedi-
ately. Debrided tissue is especially likely to provide
useful microbiologic information (more than intraop-
erative wound swabs).
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• Aminoglycosides and clindamycin are considered
first-line therapy in most cases. Clindamycin targets
ribosomes and has the potential added benefit of
reducing toxin-mediated inflammation out of propor-
tion to bacterial killing. Alternatively, extended spec-
trum fourth-generation penicillins may be used as
monotherapy. If a group A streptococcal infection is
suspected, penicillin G with clindamycin is the treat-
ment of choice.
• Drotrecogin may be indicated in many of these very
sick patients, but a careful working relationship with
the surgeon is important to time therapy appropriately
and reduce the risk of wound hemorrhage.
• In streptococcal Toxic Shock Syndrome (TSS), intra-
venous immunoglobulin may reduce toxin-mediated
inflammation and improve host immunity, however,
clinical trials demonstrating its effectiveness are
lacking.
• Mortality rates have been reported from 4 to 74%.
Higher APACHE (Acute Physiology and Chronic
Health Evaluation) scores at presentation, age >50,
diabetes, truncal location, and inadequate initial
debridement are associated with worse outcomes.
MYONECROSIS
PATHOGENESIS
• Myonecrosis, also known as gas gangrene, can be
divided into clostridial and nonclostridial causes.
• Historically, clostridial myonecrosis was seen with
penetrating war wounds but now more commonly
results from penetrating trauma or open fractures
(particularly motor vehicle or agricultural accidents),
surgical or burn wounds, malignancy (particularly
colorectal), arterial insufficiency, septic abortions, or
intramuscular injections.
• Necrosis is exotoxin-mediated and can progress to
shock, disseminated intravascular coagulation, and
multisystem organ failure while bacteremia only
occurs in 10–15% of cases.
• Nonclostridial organisms and pathogenesis are similar
to that of necrotizing fasciitis.
PRESENTATION
• Symptoms usually present 2–3 days after initial injury.
In clostridial etiologies, severe pain and tense edema are
hallmark signs. With disease progression, woody edema
spreads and the skin takes on a characteristic bronze
appearance. Gas bubbles may be present in wound
drainage. Muscle may herniate through open wounds.
• With nonclostridial organisms, pain is constant but
erythema is more prominent than edema.
MANAGEMENT
• As in necrotizing fasciitis, early debridement and fas-
ciotomy are critical. Surgical exploration reveals dusky
“cooked” appearing muscle that is noncontractile.
• Penicillin G is therapy of choice for clostridial organ-
isms with chloramphenicol or metronidazole first-line
in penicillin-allergic patients. Polymicrobial infections
are treated with aminoglycosides and clindamycin.
• Hyperbaric oxygen may be a useful adjuvant therapy
in clostridial infections but clinical data are lacking
and its use controversial. The main utility may be in
limiting debridement of extensive infections when
wide excisions may be life threatening or require sac-
rifice of a limb.
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KEY POINTS
• The urinary tract is the most common site of nosoco-
mial infection.
• 80% of nosocomial genitourinary infections follow
urinary catheterization.
• These infections prolong hospital stay and increase
costs.
• Bacteremia complicates 1–3% with an attributable
mortality of 13%.
• UTIs are a common cause of ICU admission and a
common consequence of ICU care and urinary
catheterization.
• Urinary catheters act as a reservoir of multidrug-
resistant hospital pathogens.
DEFINITIONS
• Bacteriuria—presence of bacteria in the urine
• Significant bacteriuria—105 organisms/mL by quantita-
tive method or 102 aerobic gram-negative organisms/mL
in symptomatic patients with pyuria
• Pyuria—presence of ≥5 WBCs per high-powered field
in urine
• Complicated urinary tract infections (UTIs)
 A UTI in a healthy, young, nonpregnant woman is
considered uncomplicated
 All others are considered complicated
 Complicated UTIs are associated with an underlying
condition which increases the risk of treatment failure
 Obstruction
 Diverticulae
 Fistulae
 Surgical urinary diversions
 Neurogenic bladder
 Vesicoureteral reflux
 Indwelling catheter
 Ureteral stent
 Nephrostomy tube
 Pregnancy
 Diabetes
 Renal failure
 Renal transplantation
 Immunosuppression
 Multidrug-resistant pathogens
 Hospital-acquired infection
REVIEW OF SPECIFIC
GENITOURINARY SYNDROMES
ACUTE PYELONEPHRITIS
MICROBIOLOGY
• Nosocomial urinary tract pathogens:
 Escherichia coli (47%)
 Enterococcus spp. (13%)
 Klebsiella (11.0%)
 Pseudomonas aeruginosa (8%)
 Proteus mirabilis (5.0%)
• ICU urinary tract pathogens:
 Enterococcus spp. (24%)
 Candida albicans (21%)
 E. coli (15%)
• Resistant Enterococcus spp. are of increasing concern
in nosocomial UTI and bacteremia in ICU patients.
• Vancomycin-resistant enterococci may serve as a
reservoir of resistant genes for Staphylococcus aureus.
• Persistent or relapsing bacteriuria caused by P. mirabilis
should prompt a search for a staghorn calculus.
• Chronic bacteriuria due to Corynebacterium urealyticum
can be associated with alkaline urine and renal stones.
PATHOGENESIS
• Women with recurrent UTIs often have vaginal and
periurethral cells to which E. coli adhere more readily
compared to controls.
• Most E. coli implicated in UTIs have several viru-
lence factors including adhesins, siderophores, toxins,
polysaccharide coatings, and other properties that
assist the bacteria in avoiding or subverting host
defenses, injuring or invading host cells and tissues,
and stimulating a noxious inflammatory response.
• These various factors allow adhesion to periurethral
cells, multiplication in the bladder, ascent via the
ureters, and invasion of renal tissue in patients with
anatomically normal urinary tracts.
• Regular bladder voiding is the most important host
defense.
DIAGNOSIS AND ASSESSMENT
• Acute pyelonephritis is a syndrome of fever with renal
inflammation suggested by costovertebral angle ten-
derness or flank pain, often with signs of systemic
toxicity and bacteremia.
• Silent pyelonephritis is present in up to a third of
patients with cystitis.
• Spinal cord injury patients are prone to silent, compli-
cated, life-threatening pyelonephritis which presents
with fever and nonspecific abdominal discomfort,
increased spasms, and autonomic dysreflexia.
• Pyelonephritis requiring ICU admission should prompt
a search for urinary tract obstruction, renal abscess or
perinephric abscess, and resistant pathogens.
• Features suggestive of obstruction: classic renal colic,
severe costovertebral angle tenderness, and palpable
kidney (hydronephrosis).
• At presentation, Gram’s stain of a drop of unspun
urine can provide rapid, specific information and can
be valuable for distinguishing less common etiologies
including S. aureus, Enterococcus spp., Candida spp.,
and polymicrobial-anaerobic organisms.
• Urine culture identifies the organism except in the
case of prior antibiotic therapy, complete obstruction,
or perinephric abscess.
• Obtain blood cultures to rule out concomitant
bacteremia.
ANTIMICROBIAL THERAPY
• Many antimicrobial regimens have been shown to be
effective empiric therapy as most antibiotics are
excreted through the kidney. Treatment includes a
β-lactam plus aminoglycoside, cephalosporins, carbapen-
ems, trimethoprim-sulfamethoxazole monobactams,
and quinolones.
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• An initial combination of two agents effective against
aerobic gram-negative bacilli and Enterococcus spp. is
appropriate in septic patients with UTI.
• For patients with a high risk of aminoglycoside toxic-
ity consider a nonaminoglycoside regimen or limit to
a single dose to cover the first 24 hours.
• Resistance:
 β-Lactamase inhibitors usually eliminate ampicillin
resistance in E. coli and other Enterobacteriaceae.
 Resistance rates in uropathogens to trimethoprim-
sulfamethoxazole are growing.
 A quinolone plus aminoglycoside double covers
aerobic gram-negative bacilli but will not reliably
kill enterococci.
 Piperacillin-tazobactam or ticarcillin-clavulanic
acid will cover most aerobic gram-negative bacilli
and Enterococcal spp.
• Adjust empiric therapy based on culture and sensitiv-
ity to the least toxic, cost-effective single agent.
• Start oral therapy once tolerated and after fever has
resolved; continue for a total of 10–14 days.
• Cell wall synthesis inhibitors may have a higher
relapse rate following completion of therapy;
trimethoprim alone, trimethoprim-sulfamethoxazole,
or a quinolone is preferred.
• Optimal treatment for vancomycin-resistant Enterococcus
is not known and should be chosen in consultation
with an Infectious Diseases physician.
IMAGING
• Contrast-enhanced computerized tomography (CT)
 Initial study of choice for patients with urosepsis
 Accurately defines renal parenchyma and surround-
ing anatomy
 Improved ability to distinguish complications of
upper UTI
 Assists in placement of percutaneous drains
 Noncontrast images help identify renal calculi
• Ultrasound (US)
 Can be technically inadequate because of obesity,
overlying bowel gas, subcutaneous emphysema,
wounds, or dressings
 Portable but results depend on the skill of the operator
 Reliably diagnoses most causes of obstruction and
perinephric collections
 May be initial investigation in severe urosepsis
when unsafe to transport patient or if at high risk for
contrast-induced nephrotoxicity
• Intravenous urography (IVU)
 Little or no role
 Helical CT scan superior at demonstrating the col-
lecting system, early papillary necrosis, tuberculo-
sis, and renal scarring due to childhood reflux
nephropathy
• Retrograde urography with cystoscopy
 Can demonstrate collecting system in a nonexcret-
ing kidney
 Rare complications include hemorrhage, perfora-
tion, or septicemia
 May permit relief of obstruction by passage of a
stent or manipulation of a calculus
ACUTE FOCAL BACTERIAL NEPHRITIS
• Analogous to lobar pneumonia and represents infec-
tion limited to one or more lobes of the kidney.
DIAGNOSIS
• Clinical features similar to acute pyelonephritis but
patients do not defervesce within 48 hours.
• E. coli is the most common organism isolated from
patients with acute focal bacterial nephritis (AFBN).
• Differential diagnosis includes neoplasm, evolving
renal infarct, and abscess.
IMAGING
• Ultrasound may be normal or may reveal a solid,
hypoechoic, poorly defined mass without evidence of
liquefaction.
• Noncontrast CT scanning is frequently normal.
• Contrast CT invariably reveals one or more wedge-
shaped areas of decreased density: this is seen in a sig-
nificant proportion of patients with acute pyelonephritis.
• Demonstration of enhancing tissue within the mass on
delayed CT images excludes cancer and abscess.
TREATMENT
• Acute focal bacterial nephritis usually resolves on
antimicrobial therapy.
• Increased risk of scarring and atrophy.
• Needle aspiration or percutaneous drainage not
indicated.
RENAL ABSCESS
• Acute focal bacterial nephritis may progress to renal
cortical abscess especially when associated with
obstruction.
• Abscesses may drain spontaneously into the calyxes
or rupture through the renal capsule to form a per-
inephric abscess.
• Usual pathogens are Enterobacteriaceae (E. coli,
Klebsiella pneumoniae, and Proteus spp.).
PATHOGENESIS
• Organisms commonly arise via the ascending route
versus hematogenous spread.
• Staphylococcal septicemia can present with renal cor-
tical abscess with or without other features of invasive
staphylococcal infection.
DIAGNOSIS
• Clinical features can be subtle initially.
• Symptoms include chills, fever, back or abdominal pain.
• Diagnostic clues include costovertebral angle tender-
ness, a flank mass, or involuntary guarding of the upper
lumbar and paraspinal muscles.
• Prominent abdominal features such as nausea, vomiting,
and abdominal guarding may suggest another intra-
abdominal cause.
IMAGING
• Ultrasound usually demonstrates an ovoid mass of
decreased attenuation within the parenchyma and may
initially mimic AFBN, a cyst, or a tumor.
• Gas can be present within the abscess.
• Debris within a cyst or abscess strongly indicates
infection.
• CT scanning shows a distinctly marginated, low-
attenuation, nonenhancing mass.
• CT ring sign: surrounding rim of increased
enhancement.
• CT scan has higher sensitivity for small lesions (<2 cm
diameter) and gas.
• Hemorrhagic cysts and necrotic tumors can mimic an
abscess. Diagnosis can be confirmed by aspiration,
nuclear medicine scanning, or serial scanning that
shows resolution with antimicrobial therapy.
TREATMENT
• Classic therapy is incision and drainage or nephrec-
tomy for larger abscesses.
• IV antimicrobial therapy usually successful after
microbial diagnosis by urine, blood, or aspirate culture.
• Closely monitor response by fever, leukocytosis, and
diminution of size by US or CT.
• Larger abscesses often require guided percutaneous
drainage.
EMPHYSEMATOUS PYELONEPHRITIS
• Emphysematous pyelonephritis is a fulminant disor-
der with a historically high mortality.
• Patients present acutely with features of pyelonephritis
and severe sepsis with or without multiorgan failure.
• Gas forms in the renal parenchyma and surrounding
tissues due to mixed acid fermentation of glucose by
Enterobacteriaceae.
• Risk factors include uncontrolled diabetes mellitus
and urinary tract obstruction.
• E. coli and Klebsiella spp. predominate.
• Pathology reveals extensive necrotizing pyelonephri-
tis with abscess formation and papillary necrosis.
• Poor perfusion is present in most cases due to infarc-
tion, vascular thrombosis, arteriosclerosis, or
glomerulosclerosis.
IMAGING
• Plain radiographs
 Early, reveals mottling of parenchyma
 Later, one sees extensive bubbles in the parenchyma
and a gas crescent surrounding the kidney within the
perinephric space
• US
 More sensitive than plain films at detecting gas
• CT
 Identifies the gas clearly and unambiguously
THERAPY
• IV antibiotics and other supportive therapies for sepsis
• ICU support including tight control of hyperglycemia
• Guided percutaneous drainage
• Nephrectomy may be required in minority of cases
• 18% mortality in one series
PERINEPHRIC ABSCESS
• Older descriptions of perinephric abscess emphasized
its insidious nature, delayed diagnosis, and high mor-
tality (50%).
• Risk factors include renal obstruction and diabetes
mellitus.
• Usually confined within the renal fascia but can
spread to adjacent structures and spaces.
ETIOLOGY
• Majority occur secondary to pyelonephritis caused by
Enterobacteriaceae (E. coli, K. pneumoniae, Proteus
spp.).
• Minority are bacteremic in origin due to S. aureus or
pyogenic streptococci.
• Occasional polymicrobial infection with Candida and
Aspergillus spp.
DIAGNOSIS
• Early diagnosis commonly confirmed by US or CT.
• Most patients have fever and chills.
• Other features may include weight loss, nausea, vom-
iting, dysuria, flank pain, abdominal pain, pleuritic
chest pain, and pain in the thigh or groin.
• Symptoms usually present for weeks to months.
• Flank mass or renal tenderness present in majority of
cases.
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• May present with initial diagnosis of acute pyelonephritis
or as fever of unknown origin.
IMAGING
• Ultrasound demonstrates fluid that may contain debris
or gas.
• CT shows loculated collections with decreased atten-
uation; abscess wall may enhance with IV contrast.
• May see thickened renal fascia and unilateral kidney
or psoas muscle enlargement.
• Diagnosis confirmed by guided aspiration of pus.
TREATMENT
• Antimicrobial agents and percutaneous drainage.
• Multiple loculations may complicate percutaneous
drainage.
• Empiric antimicrobials should cover mixed anaerobes
and S. aureus.
PYONEPHROSIS
• Pus in collecting system with infection proximal to an
obstructed hydronephrotic kidney.
• Unilateral loss of renal function is present with infec-
tion of the renal parenchyma.
• Clinical presentation similar to perinephric abscess
and may be insidious.
• Initial investigations should include a plain abdominal
radiograph to look for calculi.
• US will reveal a distended upper urinary tract.
Sedimented echoes or dispersed internal echoes
within the dilated collecting system allows distinction
from simple hydronephrosis.
• Direct aspiration is indicated in septic patients with
hydronephrosis.
• CT is more sensitive for detecting radiolucent calculi
and will also establish perinephric infection.
• Treatment should include nephrostomy tube placement.
PYOCYSTIS
• Pus in the urinary bladder with or without gas-forming
organisms.
• Can present with sepsis, lower urinary tract signs, and
pneumaturia.
• Risk factors include end-stage renal disease (ESRD)
and urinary diversion procedures.
• Treatment with antimicrobial therapy and bladder irri-
gations may be sufficient.
• Surgical resection is required in cases with bladder
wall necrosis seen by CT.
INFECTED CYSTS
• Dependent debris demonstrated by CT or US suggests
infection.
• Diagnosis established by aspiration of cyst fluid for
Gram’s stain and culture.
• Pyocysts may arise from ascending infection or by
hematogenous seeding.
• Systemic responses to infection such as fever and leuko-
cytosis are often blunted in the presence of uremia.
• May present as persistent sepsis unresponsive to IV
antibiotics.
• Diagnosis complicated by polycystic renal disease:
 US or CT frequently fails to distinguish an infected
cyst from the rest of a polycystic kidney.
 Diagnostic options include white blood cell scan-
ning, MRI, and positron emission tomography
(PET) scanning followed by percutaneous drainage
of a particular cyst.
TREATMENT
• Stable patients should receive a trial of lipophilic
antimicrobial therapy such as trimethoprim-
sulfamethoxazole, ciprofloxacin, or ofloxacin.
• Percutaneous drainage may suffice, or unilateral
nephrectomy can be done, preserving the uninfected
kidney.
• Lipophobic agents such as β-lactams and aminogly-
cosides penetrate cysts poorly.
URINARY TRACT INFECTION
DUE TO CANDIDA
• Diagnosis of cystitis (and possibly upper tract infec-
tion) should be suspected when ≥104 colony-forming
units/mL are present and especially when associated
with pyuria.
DISSEMINATED INVASIVE CANDIDIASIS
• May originate in the urinary tract or secondarily seed it.
• Kidneys are almost universally involved.
• Renal failure may develop from bilateral renal infection.
• Risk factors include neutropenia, loss of mucous
membrane integrity due to chemotherapy, burns,
steroid use, diabetes mellitus, total parenteral nutri-
tion, and upper gastrointestinal tract surgery.
• Invasion is often preceded by overgrowth on superfi-
cial tissues and often associated with prolonged broad-
spectrum antibacterial therapy.
• Direct proof of deep candidal infection is frequently
lacking and blood cultures are positive in only half the
cases.
PRIMARY INFECTION OF THE KIDNEYS
• Generally associated with indwelling urinary
catheters, an obstructed urinary tract, and broad-
spectrum antibacterial agents.
• Candiduria is usually present for a variable period
prior to renal infection.
• Persistent candiduria can be assumed to reflect renal
infection if the patient has a predisposition, is receiv-
ing broad-spectrum antibiotics, and has otherwise
unexplained fever or leukocytosis.
• Search for specific features of disseminated candidia-
sis such as white “cotton wool” exudates in the retina
and nodular skin lesions.
• Unilateral or bilateral hydronephrosis should raise
suspicion of a fungus ball.
• Microscopic examination of the urinary sediment may
reveal Candida casts.
• Careful evaluation of the clinical and laboratory data
should allow selection of those patients who require
early empiric antifungal therapy.
TREATMENT
• Renal or disseminated infection requires systemic
amphotericin B therapy or fluconazole.
• Amphotericin B carries a significant risk of
nephrotoxicity.
• Fluconazole is not active against many nonalbicans
species but its high urinary levels may overcome such
resistance.
• Outcome is superior if IV catheters are removed on or
before the first day of therapy.
• To date, there are no clinical trials validating the effi-
cacy of other agents, such as the less nephrotoxic lipid
formulations of amphotericin B, 5-flucytosine,
voriconazole, and caspofungin in the treatment of
ascending Candida pyelonephritis or renal candidiasis.
• Hydronephrosis due to a fungus ball:
 Requires percutaneous nephrostomy tube.
 Irrigation of the ureter with an amphotericin B solu-
tion may be effective.
 Lack of radiologic response should prompt surgical
excision.
PERSISTENT CANDIDURIA IN THE STABLE
INTENSIVE CARE UNIT PATIENT
• Common clinical situation that is often benign and
resolves spontaneously or with withdrawal of the uri-
nary catheter.
• Treat symptomatic candiduric patients if they have
had a transplant, are neutropenic, or are preparing to
undergo an invasive urologic procedure.
• Amphotericin B washouts are no longer recommended.
PROSTATIC INFECTIONS
ACUTE BACTERIAL PROSTATITIS
• Rare cause of severe sepsis or septic shock.
• Symptoms include high fever, urgency, frequency,
dysuria, difficulty voiding or acute retention of urine,
and suprapubic or perineal pain.
• Rectal examination reveals a tender and swollen
prostate.
• Gram-negative bacilli are the most frequent pathogens.
TREATMENT
• Intense inflammation helps assure adequate antimi-
crobial levels at active site.
• Treat for a total of 6 weeks with an oral antimicrobial
agent with good prostatic penetration to attempt to
eradicate the organisms and prevent chronic infection.
• Choices include trimethoprim, trimethoprim-
sulfamethoxazole, ciprofloxacin, and ofloxacin.
PROSTATIC ABSCESS
• Confirmed by transrectal ultrasonography or CT scan.
• Drain by transurethral resection of the prostate with
unroofing, or guided perineal aspiration.
CATHETER-ASSOCIATED
BACTERIURIA
GENERAL CONSIDERATIONS
• Incidence 10–20% in patients with indwelling catheters.
• One percent of patients will acquire bacteriuria from
single “in-out” catheterizations.
• The per-day risk is 1–5% with higher prevalence of
resistant pathogens seen in the ICU.
• Risk factors include time, age, female sex, and dis-
connection of the collecting tube-catheter junction.
• Systemic antimicrobials are initially protective but are
associated with an increased prevalence of multidrug-
resistant enterococci, coagulase-negative staphylo-
cocci, Candida spp., and Pseudomonas spp.
• Samples should always be taken by aspiration of urine
through the distal catheter or collection port and after
local disinfection.
PATHOPHYSIOLOGY
• Ascent of bacteria to the bladder occurs outside the
lumen.
• The space between the catheter and the urethral
mucous membrane is filled by a static and variable
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amount of fluid, mucus, and inflammatory exudate that
lacks inhibitory factors against bacterial proliferation.
• Progressive multiplication of organisms originating
from the meatus accounts for the time-dependence
and association with the female urethra.
• A minority of organisms originate from the collecting
bag and ascend intraluminally.
• Contamination of the collecting bag can occur from
one source patient to the collecting bags of others via
health care personnel and is associated with most epi-
demics of catheter-associated bacteriuria.
PREVENTATIVE STRATEGIES
• While bladder catheterization is unavoidable in most
ICU patients it should not be routinely used to avoid
incontinence and contamination of the perineal skin.
• Early withdrawal of catheters in selected patients:
 Alert, stable, and continent
 Anuric renal failure managed with once-a-day
catheterization
 Male patients with intact voiding mechanism man-
aged with condom drainage
• Use intermittent catheterization in stable patients with
neurogenic bladders or in some patients with dis-
turbed consciousness.
• Frequently question catheter necessity and attempt
removal when feasible.
• Avoid regularly scheduled replacement.
• Studies of antimicrobial impregnated catheters have
shown equivocal results.
TREATMENT
• Treat catheterized patients prior to instrumentation of
the urinary tract to avoid bacteremia.
• Catheter-associated bacteriuria is generally asympto-
matic but treatment can be justified to relieve symp-
toms of cystitis especially if the catheter removal is
imminent.
• Short course treatments work well once the catheter
has been removed.
BIBLIOGRAPHY
Baumgarten DA, Baumgartner BR. Imaging and radiologic man-
agement of upper urinary tract infections. Urol Clin North Am
1997;24:545–569.
Eggimann P, Garbino J, Pittet D. Epidemiology of Candida
species infections in critically ill non-immunosuppressed
patients. Lancet Infect Dis 2003;3:685–702.
Gordon KA, Jones RN, SENTRY Participant Groups (Europe,
Latin America, North America). Susceptibility patterns of
orally administered antimicrobials among urinary tract infec-
tion pathogens from hospitalized patients in North America:
comparison report to Europe and Latin America. Results from
the SENTRY Antimicrobial Surveillance Program (2000).
Diagn Microbiol Infect Dis 2003;45:295–301.
Hall JB, Schmidt, GA, Wood LDH. Principles of Critical Care,
3rd ed. New York, NY: McGraw-Hill; 2005:1123–1136.
Huang JJ, Tseng CC. Emphysematous pyelonephritis: clinicora-
diological classification, management, prognosis, and patho-
genesis. Arch Intern Med 2000;160:797–805.
Laupland KB, Zygun DA, Davies HD, et al. Incidence and risk
factors for acquiring nosocomial urinary tract infection in the
critically ill. J Crit Care 2002;17:50–58.
Lundstrom T, Sobel J. Nosocomial candiduria: a review. Clin
Infect Dis 2001;32:1602–1607.
Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the
treatment of candidiasis. Clin Infect Dis 2000;30:662–678.
Wong AH, Wenzel RP, Edmond MB. Epidemiology of bacteriuria
caused by vancomycin-resistant enterococci, a retrospective
study. Am J Infect Control 2000;28:277–281.
60 GASTROINTESTINAL
INFECTIONS
Nina M. Patel
KEY POINTS
• Gastrointestinal infections rarely proceed to a level of
severity that requires ICU admission.
• More frequently, noninfectious or infectious diarrhea
complicates the ICU course and leads to increased
morbidity in ICU patients.
• C. difficile-induced infectious diarrhea remains the
most common cause of infectious nosocomial diarrhea.
• A possible association between gastric stress ulcera-
tion and H. pylori infection is postulated.
• Immunosuppressed patients are subject to infectious
esophagitis and, if myelosuppressed, typhlitis.
PATHOGENESIS
• Normal gastrointestinal (GI) host defenses are often
deranged in the ICU patient.
 Motility is often slowed by narcotics and sedatives in
endotracheally intubated or postoperative patients.
 Gastric acidity, which constitutes a barrier to the
survival of pathogens, is compromised by acid sup-
pression therapy for stress ulcer prophylaxis.
 Antibiotics disrupt normal intestinal flora, and lead
to increased susceptibility to colonization and infec-
tion by normal flora and foreign pathogens.
• Diarrhea is defined as >200 g stool output per day.
Diarrhea can be classified into secretory, osmotic, and
inflammatory/hemorrhagic categories, based on the
pathophysiologic disturbances induced within the
intestinal mucosa and intraluminally.
 Secretory diarrheas (e.g., Vibrio cholerae) impair
normal sodium reabsorption or promote electrolyte
secretion into the lumen. Enterotoxigenic
Escherichia coli and V. cholerae infections are
potential causes of secretory diarrhea in the returned
traveler.
 Osmotic diarrheas result from the presence of
poorly absorbed osmoles (e.g., lactate and bile) in
the intestinal lumen. These osmoles introduce a gra-
dient for movement of water into the lumen to
achieve osmotic equilibrium. Osmotic diarrhea in
the ICU often results from iatrogenic sources (e.g.,
hyperosmotic enteral feeds).
 Inflammatory diarrheas incur significant damage
within the intestinal mucosa that leads to bloody and
mucus-laden stools. Hemorrhagic diarrheas mani-
fest with frank blood in the stool and can be associ-
ated with the hemolytic-uremic syndrome (e.g., E. coli
O157:H7).
 Nosocomial diarrheas are frequently noninfectious
(e.g., medication-induced changes in intestinal flora)
or related to hospital-acquired Clostridium difficile
colitis. C. difficile is a gram-positive anaerobic bacil-
lus that has been noted to infect up to 10% of ICU
patients following treatment with most antibiotics as
well as some chemotherapeutic agents. Increasing
use of third-generation cephalosporins in the past
two decades may account for increasing rates of
C. difficile infection. C. difficile infection can occur as
early as 48 hours following the start of antibiotic
therapy and up to months after treatment. The spec-
trum of C. difficile infection can range from asymp-
tomatic colonization to inflammatory colitis. A most
feared complication of C. difficile colitis is progres-
sion to toxic megacolon, which can progress to
colonic perforation if not addressed early.
• Immunosuppressed patients may be afflicted by
opportunistic infections of the esophagus or the intes-
tine. Candidal species, herpes simplex virus (HSV;
HSV1 > HSV2), and cytomegalovirus (CMV) are the
most commonly isolated organisms in patients with
esophagitis. Cryptosporidium, Microsporidium,
Cyclospora, and Isospora are additional pathogens
which cause diarrhea in the HIV-infected patient.
• Neutropenic patients are subject to increased risk of
typhlitis (necrotizing enterocolitis). This condition is
characterized by intramural infection, hemorrhage,
and necrosis of the bowel wall, primarily involving
the terminal ileum and cecum. A number of factors,
including impaired host defenses and neutropenia,
contribute to increased risk of bacterial infection
within the cecal wall.
CLINICAL EVALUATION, DIAGNOSIS,
AND TREATMENT
DIARRHEA
• History, when available, is an essential component in
the evaluation of diarrhea. The onset, frequency, and
character (bloody or nonbloody) of bowel movements
as well as the presence of fever are valuable in deter-
mining the etiology and guiding the diagnostic
workup. Other key features are: travel history, history
of recent changes in medications or antibiotic use,
food ingestion preceding illness, and illness amongst
close contacts.
• Fecal leukocytes indicate the presence of an inflam-
matory diarrhea. In addition to history, this test is
useful in guiding an initial workup. Systemic leuko-
cytosis is also frequently seen in the setting of infec-
tious diarrhea.
• Additional tests include the stool osmotic gap, stool
culture, and C. difficile toxin assay. In the absence of
immunosuppression or a suggestive travel history,
examining stool for ova and parasites (O&P) is
rarely indicated. The stool osmotic gap [2(Na + K)]
facilitates differentiation between secretory and
osmotic diarrheas. A gap (osmotic gap >50) will be
present in patients with osmotic diarrhea (due to the
presence of unmeasured osmoles) and will be absent
in patients with secretory diarrhea, because their pri-
mary derangement leads to increased stool elec-
trolyte content. Stool culture is used with variable
frequency—in nontoxic patients culture results
rarely change management. However, in a critically
ill patient, cultures may provide valuable suscepti-
bility data and epidemiologic data in the case of
foodborne illness.
• In patients with HIV or in the returned traveler, stool
should be sent for O&P to evaluate for parasitic infec-
tion, including Cryptosporidium, Giardia, and
Entamoeba histolytica.
• Endoscopy has limited utility in the diagnosis of diar-
rhea, though it may help to distinguish infectious,
inflammatory diarrhea from inflammatory bowel dis-
ease. If seen, pseudomembranes are confirmatory in
addition to a suggestive clinical history of C. difficile
colitis.
• Treatment of the ICU patient with diarrhea centers
around supportive care with fluid and electrolyte
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repletion; antibiotics as indicated; and in some situa-
tions antimotility agents or probiotics.
 In vitro fertilization (IVF) replacement can be
achieved with normal saline and supplemental elec-
trolytes or lactated Ringer solution.
 Empiric antibiotic therapy should not be instituted
routinely as it infrequently improves clinical course
and may lead to increased resistance or a prolonged
carrier state of the intestinal pathogen. Exceptions
include severely immunocompromised patients
(e.g., HIV with CD4 <200) or toxic-appearing
patients (prolonged fever, diarrhea, and/or signifi-
cant bloody diarrhea).
 C. difficile colitis is treated by discontinuation of the
offending agent whenever possible and metronida-
zole (500 mg PO q 8 h preferred or 500 mg IV q 6 h).
Oral vancomycin (125–500 mg PO qid) is the first-
line alternative. If the presumed responsible agent
cannot be discontinued (e.g., septic patient), treat-
ment for C. difficile should be added to the existing
antibiotic regimen.
 High rates of recurrence (20–40%) of C. difficile
infection have been reported. In these situations,
patients should either be treated with a new agent or
have a full repeat course of therapy if clinically sig-
nificant diarrhea is occurring.
ESOPHAGITIS AND GASTRITIS
• The clinical evaluation for esophagitis is often limited
in the ICU due to the presence of endotracheal tubes,
nasogastric tubes, and sedation. If alert and able,
patients may complain of dysphagia, odynophagia, or
retrosternal chest burning.
• Physical examination should focus on assessment for
oral thrush and oral, labial, or genital lesions consis-
tent with HSV infection.
• Upper endoscopy with biopsy, brushing, and tissue
culture facilitates achievement of a microbiologic
diagnosis. Esophageal plaques or ulcers may be seen
in candidal or HSV and CMV infections, respectively.
• Treatment:
 Candida albicans esophagitis is treated with flu-
conazole (100–200 mg qd × 14–21 days). Other
candidal species may be resistant to fluconazole
therapy and may require the use of other antifungal
agents (e.g., caspofungin or amphotericin).
 Acyclovir (5 mg/kg IV tid × 7–14 days) is the treat-
ment for HSV-induced esophagitis.
 Ganciclovir (5 mg/kg IV bid) is the treatment for
CMV esophagitis.
• A small, prospective evaluation of ICU patients found
that Helicobacter pylori infection (confirmed by urea
breath testing) was associated with major gastric
mucosal injury on esophagogastroduodenoscopy
(EGD). These findings suggest a role for H. pylori in the
pathogenesis of stress-induced gastritis in ICU patients,
but need to be confirmed in a larger population.
TYPHLITIS
• Fever and abdominal pain in the setting of neutrope-
nia warrant attention to the possibility of typhlitis.
• Abdominal plain films often demonstrate ileus or
other nonspecific findings (Fig. 60-1).
• If clinical suspicion is high, abdominal computed
tomography (CT) scanning should be pursued. CT
findings include cecal wall thickening; intramural air,
hemorrhage, or edema; and abscess formation. CT is
helpful in differentiating typhlitis from appendicitis,
pseudomembranous or ischemic colitis, and colonic
pseudo-obstruction.
• Medical management with bowel rest, broad-spectrum
antibiotic therapy (possibly the addition of antifungal
therapy), IVFs, and nasogastric decompression is the
treatment of choice in nontoxic patients.
• However, in the setting of intestinal perforation, peri-
tonitis, or severe GI bleeding, emergent surgical inter-
vention is imperative.
• An algorithm for diagnosis and management of
typhlitis is shown in Fig. 60-2.
FIG. 60-1 Typhlitis. Supine film of the abdomen showing
pneumatosis intestinalis of the right ascending colon (arrows)
with slightly distended small bowel loops from typhlitis.
SOURCE: Reproduced with permission from Katz JA, Wagner ML,
Gresik MV, et al. Typhlitis: an 18-year experience and post-
mortem review. Cancer 1990;65:1041–1047.
PREVENTION
• Some investigators speculate that the use of probi-
otics may decrease rates of diarrhea and C. diffi-
cile infection in the ICU by reconstituting normal
flora.
• Adequate hand-washing and contact precautions are
essential in avoiding transmission of all infectious
diarrheas. C. difficile spores may exist in the hospital
environment for several months; therefore, aggressive
infection control plays an integral role in preventing
C. difficile transmission within the hospital.
CONCLUSIONS
• Gastrointestinal infections infrequently precipitate
ICU admission but may result in significant morbidity
during the ICU course.
• Since patients frequently cannot verbalize abdominal
symptoms in the ICU, the intensivist must maintain a
high level of vigilance to detect GI infections.
• C. difficile colitis is the most commonly encountered
hospital-acquired infectious diarrhea.
• Electrolyte and fluid repletion is integral to the manage-
ment of all infectious diarrheas. The role of antibiotic
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FIG. 60-2 Recommended approach to the patient with suspected typhlitis. G-CSF, granulocyte
colony-stimulating factor.
SOURCE: Reproduced with permission from Canadian Medical Association. Can J Surg
1999;42(6):415.
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therapy in community-acquired infectious diarrheas is
variable.
• Esophagitis occurs most frequently in immunocom-
promised patients.
• Typhlitis is a medical emergency that will often
progress through conservative therapy, requiring oper-
ative intervention.
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KEY POINTS
• Consider malaria in any critically ill, febrile patient
who has traveled recently to a malarious area.
• Begin antimalarial treatment when the diagnosis is
clinically suspected or confirmed.
• Be prepared to prevent or treat complications such as
hypoglycemia, seizures, pulmonary edema, renal fail-
ure, or hyperpyrexia.
• Restrict fluids when possible to reduce the risk of pul-
monary edema.
EPIDEMIOLOGY
• Malaria is a leading cause of morbidity and death
worldwide, with over 1 million deaths per year.
• Severe mosquito-borne protozoal infection caused by
four species of Plasmodium: P. falciparum, P. vivax,
P. malariae, or P. ovale. P. falciparum causes most
life-threatening infections.
• Endemic throughout tropical countries. P. falciparum
is the most common cause of malaria in Africa, Haiti,
some parts of South America and Southeast Asia.
P. vivax is dominant in India.
• Children from endemic areas eventually acquire
immunity to severe malaria. However, immunity will
lapse once recurrent exposures are discontinued.
• Malaria can be transmitted by transfusion of blood prod-
ucts, bone marrow, infected needles, or transplacentally.
• Eighteen human genetic polymorphisms are associated
with resistance to malaria including: α and β tha-
lassemias, hemoglobins S, E, and C, glucose-6-phosphate
dehydrogenase (G6PD) deficiency, and Duffy blood
group.
PATHOPHYSIOLOGY
• Sporozoites are carried in the gut of Anopheles mos-
quitoes. Transmission to humans occurs during a
blood meal. After transmittal, sporozoites invade
hepatocytes and mature into schizonts. After 6–16 days,
merozoites are released into the bloodstream.
• In the case of P. vivax and P. ovale, sporozoites may
remain dormant in the liver for months or years in the
form of hypnozoites and cause relapsing infection.
• Erythrocytic cycle consists of invasion, develop-
ment from rings to mature pigmented multinucle-
ated schizonts, and rupture with the release of 4–32
merozoites, depending on species. These can rein-
fect erythrocytes or develop into gametocytes,
which can then be taken up by a mosquito where
they can complete a sexual cycle and produce more
sporozoites.
• Most symptoms are related to the asexual erythrocytic
cycle and the body’s immune response. This response
is mediated by the presence of a malarial toxin release
at schizont rupture.
• Organ dysfunction is partially secondary to adherence
of parasitized erythrocytes to the wall of venules, with
resultant hypoxia and lactic acidosis from diminished
blood flow. This most commonly occurs in brain,
kidney, gut, placenta, skeletal muscle, liver, bone
marrow, and retina. These effects may not become
manifest until days after initiating antimicrobial ther-
apy due to delayed increases in parasitemia.
CLINICAL FEATURES: P. FALCIPARUM
MALARIA
• Shortest interval between mosquito bite and symp-
toms is 7 days, with 80% of patients developing
symptoms within 1 month of leaving an endemic area.
• Presenting symptoms include headache, fever, chills,
malaise, or lethargy. Myalgias, orthostasis, vomiting,
and diarrhea are common.
• Signs include stigmata of anemia, jaundice, and tender
hepatosplenomegaly.
• Classical tertian or subtertian fever (every 36–48 hours)
is rarely seen as is the classic “paroxysm” (chill, hot
phase, and diaphoresis).
• Life-threatening falciparum malaria is defined by the
presence of any one of the following: cerebral malaria
(impaired consciousness), severe normocytic anemia,
renal failure, jaundice, pulmonary edema, hypo-
glycemia, circulatory collapse, spontaneous bleeding
or disseminated intravascular coagulation (DIC),
repeated generalized seizures, acidemia or acidosis,
macroscopic hemoglobinuria.
• Defining characteristics of severe malaria may not be
present at initial presentation. Likewise, severity of
clinical syndrome at time of presentation is not a reli-
able indicator of development of life-threatening
malaria.
• Cerebral malaria is defined as the presence of
unarousable coma, P. falciparum parasitemia, and
exclusion of other causes of coma. This syndrome
should be considered in any febrile patient, possibly
exposed to P. falciparum, with an impaired level of
consciousness, coma, or seizures. Empiric antimalar-
ial therapy should be initiated for patients with a high
clinical suspicion of cerebral malaria, even if para-
sitemia is not present on blood smear. Other clinical
features may include dysconjugate gaze, bruxism,
symmetrical upper motor neuron lesion, and abnormal
extensor or flexor posturing. Remarkably, survivors
often are free of neurologic sequelae.
• Renal impairment occurs in one-third of patients.
• Acute pulmonary edema is common and is often fatal.
Development is associated with hyperparasitemia,
renal failure, lactic acidosis, excessive fluid replace-
ment, and parturition.
• Hematologic abnormalities include anemia secondary
to hemolysis of parasitized erythrocytes; thrombocy-
topenia from splenic sequestration or immune-
mediated destruction; and DIC, which is present in
about 15% of severe cases.
• Endocrine abnormalities include hypoglycemia from
either quinine-induced hyperinsulinemia or inhibition
of gluconeogenesis by tumor necrosis factor-alpha
(TNF-α).
DIAGNOSIS
• Include malaria in the differential diagnosis of acute
febrile illnesses, especially in the presence of recent
travel to endemic areas, recent blood transfusion, or
needlestick.
• Other travel-related febrile illnesses can present simi-
larly, such as yellow fever, viral hemorrhagic fever,
influenza, severe acute respiratory syndrome (SARS),
hepatitis A and B, brucellosis, and leptospirosis.
• Diagnosis is established by microscopic examination
of thin smears and thick films of patients’ blood,
preferably made without addition of anticoagulant,
with identification and quantification of intraerythro-
cytic parasites. Parasitemia should be quantitated by
microscopic examination, but this may not be an accu-
rate measure of total body parasite load, due to
sequestration of parasites in end organs.
• If available, antigen capture assay utilizing antibodies
to P. falciparum PfHRP-2 antigen may be used, as it
has similar sensitivity and specificity to microscopic
detection.
TREATMENT
• Given complexity of clinical syndromes and propensity
for multiorgan involvement, management is preferably
administered in an intensive care environment.
• Maintain oxygenation, airway, and circulation.
• Initiate treatment with intravenous antimalarial agents
based on weight of patient.
 Quinine and quinidine are the first-line agents for
treatment of severe malaria. In the United States,
quinidine is usually used because of its widespread
availability.
 Quinidine is initiated via continuous infusion at
10 mg/kg over 1 hour followed by a continuous drip
at 0.02 mg/kg/min.
 Continuous ECG monitoring is required to assess
for increased QT interval from quinine-based
therapy.
 Artemisinin derivatives (artesunate, artemether,
arteether) are second-line agents useful only when
quinine resistance may be a problem.
• Monitor for and aggressively treat hypoglycemia
(especially after initiation of quinine-based therapy).
• Utilize antipyretics and external cooling if needed.
• Carefully administer IV fluids, and consider invasive
hemodynamic monitoring to optimize therapy, as
under-resuscitated patients are susceptible to circula-
tory collapse and shock, and over-resuscitated
patients are prone to developing severe pulmonary
edema.
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• Perform lumbar puncture to rule out meningitis, and
consider EEG to exclude subclinical seizures.
Prophylactic phenobarbital may be considered, but its
benefit is not fully established.
• Look for and treat concurrent bacterial infections that
may complicate the clinical picture.
• Exchange transfusion should be considered in patients
with substantial hyperparasitemia (>10%) or progres-
sion of disease on optimal antimicrobial therapy.
• Provide appropriate supportive care for end-organ
complications such as pulmonary edema, renal fail-
ure, anemia, acidosis, and splenic rupture.
• Aggressive antimalarial and supportive therapy may
reduce mortality to 10–15% in severe malaria.
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62 TETANUS
William Schweickert
KEY POINTS
• Tetanus is a toxin-mediated disease caused by
C. tetani, characterized by severe muscle spasm, which
can progress to respiratory failure and cardiovascular
instability.
• The diagnosis is made clinically.
• hTIG should be given as soon as possible.
• The site of entry should be debrided surgically and
further toxin production limited by intravenous
metronidazole.
• Benzodiazepines, narcotics, and intravenous magne-
sium may all play roles in reducing spasms and circu-
latory instability.
• Patients who survive should be immunized since clin-
ical tetanus does not confer immunity.
EPIDEMIOLOGY
• Adoption of tetanus toxoid vaccination programs of
children in the United States and other developed
countries has resulted in dramatic decreases in the
incidence of tetanus. Between 1998 and 2000, there
were approximately 43 cases on average per year in
the United States; similar rates have been reported in
European countries.
• Although primarily a disease of the nonimmunized
(underdeveloped countries) or inadequately immu-
nized patients, tetanus can (rarely) develop in patients
who had received their primary series, as well as
proper “booster” doses of toxoid.
• Groups at highest risk include those aged >60 years,
the impoverished, and intravenous drug abusers.
PATHOGENESIS
• The disease is caused by Clostridium tetani, an anaer-
obic bacterium normally present in mammalian gut
and frequently isolated from soil.
• Once inoculated into injured tissue, spores transform
into vegetative, pathogenic gram-negative rods which
produce two toxins, tetanospasmin and tetanolysin.
Tetanospasmin, a neurotoxin, is responsible for the
clinical disease. Tetanolysin has hemolytic properties
and is speculated to propagate local tissue damage.
• Toxin formed in a skin wound spreads to adjacent
muscle, accumulates in motor fiber nerve endings,
and utilizes retrograde axonal transport to track to the
ventral horn of the spinal cord and brainstem.
• Tetanospasmin selectively binds inhibitory interneurons’
membrane proteins, blocking neurotransmission. This
irreversible blockade results in the loss of modulation of
excitatory impulses from the motor cortex, translating
into increased muscle tone and painful muscle spasm.
Simple sensory stimuli may prompt severe spasm.
• Autonomic neurons experience disinhibition as well,
and later in the course, patients may experience auto-
nomic dysfunction.
• Tetanospasmin’s irreversible binding creates effects
on anterior horn cells, brainstem, and autonomic neu-
rons that remain indefinitely. Recovery requires the
growth of new axonal nerve terminals, hence the usual
4- to 6-week duration of clinical tetanus.
CLASSIFICATION
• Generalized tetanus (the most common, most severe
form) is characterized by diffuse muscle rigidity.
• Localized tetanus describes rigidity of a group of
muscles in close proximity to the site of injury.
• Cephalic tetanus includes trismus (lockjaw) plus
paralysis of one or more cranial nerves.
• Both local and cephalic tetanus may progress to gen-
eralized tetanus, the latter occurring in approximately
65% of cases.
CLINICAL MANIFESTATIONS
• C. tetani most commonly enters the host through skin
disruption, primarily via lacerations (especially in the
setting of associated tissue necrosis or a foreign
body). Other clinical settings include: neonates with
an infected umbilical stump or patients with burns,
animal bites, septic abortions, and rarely abdominal
surgery involving necrotic infections.
• The incubation period ranges widely—days to
months. The interval between injury and onset of clin-
ical symptoms may be dictated by the proximity of the
wound to the central nervous system.
• Clinical manifestations include muscular rigidity (the
most prominent early symptom), specifically trismus,
risus sardonicus (sardonic smile), opisthotonos, and
nuchal rigidity. Rarely, cranial nerve palsy can occur
(most commonly, facial nerve).
• Patients with generalized tetanus experience tonic
contraction of skeletal muscles with intermittent
intense muscular spasms—both are exquisitely
painful. Commonly, a patient will clench fists, arch
the back, and flex and abduct the arms, extend the
legs, and may become apneic. Spasms may be initi-
ated by the slightest of sensory stimuli, including
touch, noise, lights, and swallowing.
• Autonomic nervous system dysfunction in severe
tetanus usually occurs 1–2 weeks after the onset of the
disease. Impaired sympathetic inhibition symptoms
include tachycardia, labile hypertension alternating
with hypotension, peripheral vasoconstriction, fever,
and profuse sweating. Overactivity of the parasympa-
thetic nervous system causes increased bronchial and
salivary gland secretions, bradycardia, and sinus
arrest.
LABORATORY RESULTS
• Tissue cultures are positive in fewer than 50% of
patients. The organism is noninvasive, so blood cul-
tures serve little value except in diagnosing secondary
infection.
• Labs are otherwise nonspecific, including leukocyto-
sis with lymphocyte predominance, elevated transam-
inases, and creatinine kinase (after the development of
muscle spasm).
DIAGNOSIS
• The diagnosis of tetanus is made on clinical grounds
alone, suspected when there is a history of tetanus
prone injury in the setting of inadequate tetanus
immunization.
• The differential diagnosis includes: neuroleptic
malignant syndrome, strychnine poisoning, Stiff-man
syndrome, drug-induced dystonia, meningitis,
hypocalcemic tetany, or the differential of isolated
trismus.
TREATMENT
• The principles of initial treatment of tetanus consist of
airway management, sedation, treatment of the portal
of entry, antitoxin therapy, administration of appropri-
ate antibiotics, and general supportive measures.
• The period of onset of the disease ranges from <1 to
12 days; therefore, even patients with mild tetanus
(trismus, dysphagia, and localized rigidity) should be
observed in an ICU for at least 1 week.
• In severe cases, the first priority is airway manage-
ment to ensure airway protection and adequate venti-
lation, combined with correction of hypotension
related to hypovolemia or autonomic instability.
• Antibiotics are universally recommended—first-line
therapy is metronidazole (15 mg/kg IVP followed by
20–30 mg/kg/day IV for 7–14 days); however, they are
only effective against vegetative forms of C. tetani.
• The use of passive immunization to neutralize
unbound toxin is associated with improved survival.
Antitoxin therapy with human tetanus immune globu-
lin (hTIG) is given intramuscularly (500 IU) as early
as possible. The use of intrathecal hTIG to neutralize
toxin that has entered but is not yet fixed to nervous
tissue has not been fully validated (see single study
outcome) and is not routinely recommended.2
• The source of toxin should be removed by wound
debridement and removal of foreign bodies.
• Muscle rigidity and spasms are treated with high-dose
benzodiazepines and narcotics. However, cases of
refractory spasms should undergo consideration for
intravenous magnesium therapy, intrathecal baclofen,
or epidural blockade.
PROGNOSIS
• With modern intensive care management, mortality
ranges from 10 to 15% overall. In areas without such
advances, mortality rates from 25 to 50% are usual.
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• Clinical tetanus does not induce immunity against fur-
ther attacks of the disease and all patients should begin
their primary immunization series prior to leaving the
hospital. Passive immunization with hTIG does not
interfere with successful active immunization.
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63 VIRAL HEMORRHAGIC
FEVERS
D. Kyle Hogarth
KEY POINTS
• Clinical presentations may sometimes be a flu-like
syndrome, but can also be abrupt: fever associated
with generalized myalgias and headache is common.
Severe cases progress to pulmonary edema, shock,
and bleeding from mucosal surfaces.
• Clinical diagnosis is dependent on a history of potential
exposure within the preceding few days up to a maxi-
mum of 4 weeks. The exposure may be to rodents, ticks,
or fresh animal or human blood, or patients. Typically,
the patient has been to an endemic area recently.
• Management is mainly supportive. Respiratory assis-
tance, replacement of blood components, and support
of the circulation are the mainstays of therapy. Certain
infections can be treated with ribavirin.
• Prevention of transmission of infection is extremely
important. Routine respiratory isolation of suspect
cases in a single room, standard universal precautions
for exposure to contact with blood or body fluids, and
careful disinfection of exposed surfaces. With appro-
priate precautions the risk of nosocomial transmission
is minimal.
• With prompt supportive therapy, many patients can
make a rapid and complete recovery without signifi-
cant long-term sequelae.
OVERVIEW OF THE VIRAL
HEMORRHAGIC FEVERS
• The diseases are caused by many different enveloped
RNA zoonotic viruses.
• Viral hemorrhagic fevers (VHFs) are characterized by
an acute onset with high fever and the potential for
high rates of mortality. These infections are endemic
on every continent except Australia.
• Bleeding is a complication of severe disease, and is a
manifestation of the underlying pathology of wide-
spread capillary leak.
• Death usually results from hypovolemic shock with or
without acute respiratory distress syndrome (ARDS).
In survivors, recovery is rapid and usually complete.
HISTORY AND CLINICAL DIAGNOSIS
• A thorough history is essential in making the diagno-
sis. The zoonotic character of these infections means
that they are primarily rural diseases in developing
communities. An exposure and travel history must
cover the maximum 4-week incubation period before
the onset of fevers.
• Questions must include a thorough travel history:
information on any possible contact with ticks, fresh
animal blood, rodent urine or blood, wild animals, and
mosquitoes and other insects, recent camping in
exotic areas, possible entry into bat caves, and atten-
dance at ceremonial funerals should be sought.
• The fever is often high and has an abrupt onset. Severe
body pains and headache are prominent and may be
excruciating. Other features seen can include nausea
and vomiting, severe sore throat, petechiae, oozing
from the gums, and bradycardia. As the disease pro-
gresses, respiratory distress secondary to pulmonary
edema and hypovolemic shock from diffuse bleeding
become hallmarks of the disease.
LABORATORY DIAGNOSIS
• Total peripheral white counts usually show lymphope-
nia and elevated neutrophil counts. Thrombocytopenia
and platelet dysfunction are common. Disseminated
intravascular coagulation (DIC) is not a feature of
VHF except as a complication of the terminal phase.
• Serum glutamic-oxaloacetic transaminase (SGOT) is
usually raised. In VHFs, the SGOT is disproportion-
ately high compared with the serum glutamic-pyruvic
transaminase (SGPT). Ratios of SGOT:SGPT may be
as high as 11:1! The level of the SGOT reflects prog-
nosis, with higher SGOT levels increasing the risk of
death. The bilirubin is usually normal, the exception
being yellow fever which is associated with jaundice.
• Care must be taken in collection, handling, and trans-
port of specimens. Sera may be safely handled for
immunologic tests by inactivation by heating to 60°C
for 30 minutes.
• The most rapid and accurate method of diagnosis is
by reverse transcriptase-polymerase chain reaction
(RT-PCR).
• Virus isolation from serum requires a high level of lab-
oratory biocontainment, and can require at least 1 week.
• Detection of high-titer IgG antibody with virus-
specific IgM antibody can be diagnostic. However, the
more rapid VHFs, particularly Ebola, evolve so
quickly that patients may die before enough time has
passed to develop antibodies.
MANAGEMENT
• Viral hemorrhagic fevers are self-limiting diseases and
the majority of medical management is supportive.
• Early initiation of ribavirin therapy is useful for the
following infections: Lassa, South American hemor-
rhagic fevers, Crimean-Congo hemorrhagic fever
(CCHF), and Hantavirus pulmonary syndrome.
Ribavirin does not work for Ebola, Marburg, yellow
fever, Rift Valley fever, and dengue.
• Therapy with immune plasma may help in Argentine
hemorrhagic fever, but has not been demonstrated to
be effective in other VHFs.
• Fluid balance and volume status are the main chal-
lenges in managing patients. They will often present
with a paradoxical high hematocrit due to capillary
leakage aggravated by dehydration. Development of
low-pressure pulmonary edema (ARDS) is common.
Ventilatory support should follow low-tidal volume
strategies (e.g., 6 cc/kg ideal weight).
• Pregnant patients often present with absent fetal
movements. Maternal survival in Lassa fever has been
shown to depend on aggressive obstetric intervention
to evacuate the uterus.
PREVENTION OF SPREAD
• The key to prevention of transmission is good hospi-
tal and laboratory practice with strict isolation of
febrile patients with VHF and rigorous use of gloves
and disinfection. Attempts should be made to mini-
mize the number of personnel caring for and interact-
ing with these patients.
• Aerosol spread in hospitals has not been documented.
The risk to personnel caring for a VHF patient is about
equal to that of HIV transmission, if full barrier pre-
cautions are fully implemented.
• High risk of infection is associated with direct per-
cutaneous or mucosal contact with blood or body
fluids. Postexposure prophylaxis with ribavirin
should be offered to contacts with high-risk expo-
sures. People with medium- or low-risk contact his-
tories may be safely observed for development of
persistent high fever for 3 weeks from the last date
of contact.
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64 ANTHRAX AND SMALLPOX
Ajeet Vinayak
KEY POINTS
• The CDC classify both anthrax and smallpox among
the category A agents in terms of bioterrorism poten-
tial. Category A agents include those that carry the
greatest risk to public health, have the potential for
widespread effect, and need extensive planning to
address prevention, recognition, and treatment.
• Due to nonspecific prodromal states in these diseases,
attention should be on clinical manifestations aware-
ness, a high degree of suspicion, and preparedness
(which includes resource allocation, triaging, case-
reporting, and isolation/containment).
• Following a bioterrorism exposure, anthrax would
probably present as an influenza-like respiratory ill-
ness, progressing to critical illness, possibly charac-
terized by hemorrhagic mediastinitis.
• The World Health Organization (WHO) estimates
mortality for 50 kg of anthrax released over a popula-
tion of 5 million would approach 100,000 people.
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• Smallpox is spread easily by droplets and fomites,
while with anthrax human-to-human transmission
probably does not occur.
• Smallpox is characterized by its rash—no effective
antiviral treatment is available.
ANTHRAX
EPIDEMIOLOGY AND MICROBIOLOGY
• The causative bacteria, Bacillus anthracis, is a large,
gram-positive, aerobic, spore-forming bacillus respon-
sible for zoonotic infections among grazing herbivores.
In nature, these animals are infected by ingestion of the
hardy, resistant spores found in the soil with a minor
contribution of spread due to biting insects.
• Three types of infection are possible: cutaneous, gas-
trointestinal, and inhalational anthrax.
• While exceedingly rare, naturally occurring human
infection most commonly occurs as cutaneous anthrax
resulting from contact with animal hides. Naturally
occurring inhalational anthrax was reported as an
occupational hazard in slaughterhouses and the textile
industry (woolsorters disease).
• As a weapon, anthrax would be spread as an aerosol
of spores leading to inhalational anthrax on germina-
tion in lymph nodes or cutaneous disease from direct
contact.
• Two binary toxins, edema toxin and lethal toxin,
along with a phagocytosis-resistant capsule are the
responsible virulence factors leading to the clinical
manifestations of anthrax (edema, hemorrhage, necro-
sis, and death).
HISTORY AND POTENTIAL
• 1876: First disease to fulfill Koch postulates (cri-
teria used to link specific bacteria with specific
disease).
• 1881: First vaccination for bacterial disease was
developed for anthrax by Louis Pasteur (for sheep).
• 1940s: Only known wartime use of anthrax by the
Japanese army in Manchuria.
• 1950s: Both the former Soviet Union and Iraq admit
to the possession of weapon-grade anthrax.
• 1979: Release of anthrax spores in a Soviet military
factory in Sverdlovsk resulted in the death of at least
66 people.
• 2001: 22 suspected bioterrorism cases (11 inhala-
tional, 11 cutaneous) in 5 U.S. states with 5 reported
deaths.
CLINICAL MANIFESTATION AND DIAGNOSIS
CUTANEOUS ANTHRAX
• This form results from direct contact of spores on an
area of abraded skin. Commonly exposed areas of
skin are affected.
• Disease develops usually within 2–5 days of exposure.
• The primary lesion is pruritic and maculopapular
leading to a rounded ulcer, with subsequent satellite
vesicles. Eventually, a large, dark eschar forms over
the course of a week.
• The incidence of bacteremia and mortality are low
but, without antibiotics, mortality rates can be from
5 to 15%. Cure is the usual rule with therapy.
GASTROINTESTINAL ANTHRAX
• This form occurs from ingestion of contaminated meat
and is the rarest form of anthrax disease. Symptoms
appear 2–5 days after ingestion.
• Germination of the spores leads to nausea, vomiting,
fever, and acute abdomen. Hematemesis or hema-
tochezia can occur.
• An oropharyngeal variant can occur if spores germinate
in the upper gastrointestinal or oropharyngeal area and
lead to fever, sore throat, dysphagia, and lymphadenitis.
• Mortality is very high in this form and this is likely
due to late detection and frequent advancement to sys-
temic disease with frank sepsis.
INHALATIONAL ANTHRAX
• Spores inhaled into the alveoli are ingested by
macrophages and transported to mediastinal lymph
nodes where germination can occur up to 60 days
later. On germination in the lymph nodes, edema,
hemorrhage, and necrosis can lead to hemorrhagic
mediastinitis and systemic spread.
• Symptoms usually begin 1–6 days after exposure. The
first phase consists of myalgia, low-grade fever, nonpro-
ductive cough, and chest pain. Rhinitis is uncommon.
The chest radiograph can show a widened mediastinum.
• Usually 2–3 days following the initial phase, rapidly
progressive symptoms may herald a fatal course.
These symptoms include fevers, diaphoresis, dyspnea,
and shock. Stridor can occur if affected lymph nodes
cause tracheal obstruction. Anthrax meningitis is a
rare complication after bacteremia and is character-
ized by hemorrhagic cerebrospinal fluid (CSF).
• Detection of bioterrorism-related inhalational anthrax
will rely on recognition of clustered cases of a rapidly
fulminant flu-like illness.
• Chest radiographs can show a widened mediastinum.
Pneumonic processes (which were once thought to be
rare) seemed to occur frequently based on the recent
experience with contaminated pieces of mail in 2001.
• Presumptive diagnosis can be made on Gram’s
stained blood, CSF, or vesicular fluid (from a skin
lesion) showing gram-positive bacilli. If anthrax is
suspected, the appropriate selective media should be
requested to isolate the organism. Polymerase chain
reaction (PCR), enzyme-linked immunosorbent assay
(ELISA), and serologic testing can be done at appro-
priate laboratories.
PREVENTION AND TREATMENT
• Cultures should be collected prior to initiation of
antimicrobial therapy.
• Treatment for anthrax includes ciprofloxacin (400 mg
IV q12) or doxycycline (100 mg IV q12). For sus-
pected bioterrorism, the Centers for Disease Control
and Prevention (CDC) has recommended adding one
or two additional agents with in vitro activity against
B. anthracis. These agents include: rifampin, van-
comycin, imipenem, chloramphenicol, penicillin,
ampicillin, clindamycin, and clarithromycin. The use
of penicillin G or ampicillin alone is not recommended
because of isolation of inducible β-lactamases in iso-
lates recovered in 2001. (Doses of ciprofloxacin and
doxycycline should be adjusted for children.)
• Routine universal precautions should be used during
the care of patients with anthrax. Human-to-human
transmission is not thought to occur.
• Postexposure prophylaxis with oral ciprofloxacin or
doxycycline is recommended for 60 days. This dura-
tion of therapy is based on the potential of delayed
germination of resistant spores based on human expe-
rience and investigation involving monkeys.
• Vaccination with a noncell vaccine is used among mil-
itary personnel. The use of this vaccine in a regimen
for postexposure prophylaxis is investigational only.
SMALLPOX
HISTORY AND POTENTIAL
• Spread of contaminated items to native Americans
during the French and Indian Wars led to high mortality.
• A worldwide campaign that successfully eradicated
smallpox by 1977 led to cessation of vaccination in
1980.
• A projection made in 1999 suggested exposure to a
crowd of 1000 people in a major urban center could
lead to 15,000 cases with 2000 mortalities within
2 months. Furthermore, within a year 14 countries would
have re-established endemic smallpox.
EPIDEMIOLOGY AND MICROBIOLOGY
• Smallpox is an orthopoxvirus with a characteristic
brick shape.
• Two clinical diseases are possible: variola major and
variola minor (milder form).
• High person-to-person transmission occurs via droplet
nuclei and direct contact. Spread of the disease on
fomites (blankets, clothing, and so forth) can also occur.
• High infectivity occurs at the onset of the rash which
predictably follows onset of constitutional symptoms
by 2–3 days. The eventual scabs are considered to
have a low infectious potential.
CLINIICAL MANIFESTATION AND DIAGNOSIS
• There are four types of variola major: classical (also
called ordinary and accounting for 90% of cases),
modified, flat (also referred to as malignant), and
hemorrhagic. The characteristic manifestation of the
classical type is described below.
• A 12–14 (range 7–17) day incubation period precedes
the onset of constitutional symptoms which consist of
malaise, high fever, nausea, abdominal pain, back ache,
and headache.
• The rash follows after another 2–3 days beginning in
the mouth and oropharynx then spreading to the arms,
trunks, and legs.
• Initially maculopapular, the rash homogeneously
becomes vesicular (with a characteristic central depres-
sion) before turning pustular. During the second week
of the rash, these tense pustules become flattened and
confluent.
• See Fig. 64-1 for an algorithm for evaluation by the CDC.
• Mortality of classical variola major occurs most com-
monly during the second week and appears to be related
to the degree of confluence that develops. Overall mor-
tality of this commonest form approaches 30%.
• Management of fluid balance, renal failure, and electrolyte
abnormalities are the focus of critical care. Pulmonary
edema and pulmonary hemorrhage may occur.
• Contagion risk does not stop until all scabs have fallen
off.
• Modified variola major is a milder form of this dis-
ease that occurs in persons with partial protection
from prior vaccination.
• The hemorrhagic variant is more severe with nearly
uniform mortality. While either gender can be
affected, pregnant women appear to be at higher risk.
This form is characterized by a more severe, earlier
prodromal phase and then skin lesions marked by
petechiae and hemorrhage. Prior vaccination does not
affect severity of disease.
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• Flat variola major is characterized by flat rubbery
lesions rather than the tense pustules. This variant is
also more severe than the ordinary disease and also
seems to have a milder subtype among vaccinated
individuals.
• Variola minor has fewer constitutional symptoms and
a sparser rash.
• Initial cases should have laboratory confirmation. Scabs
can be picked off with forceps or vesicular fluid can be
sampled on cotton swabs. Samples should be appropri-
ately packaged and sent to local or state authorities for
analysis by light and electron microscopy as well as
PCR methods.
PREVENTION AND TREATMENT
• Small outbreaks can be treated in isolation wards of
individual hospitals. Strict airborne and contact isola-
tion must be maintained.
• In large-scale outbreaks, entire hospitals would likely
turn into treatment centers for severely ill patients with
many affected people quarantined to their residences.
• No effective antiviral therapy is available.
• Antibiotic use has a role in secondary infection
management.
• Postexposure vaccination within 4 days has been
shown to attenuate disease course and may offer some
protection.
• Groups with contraindication to vaccination include
patients with HIV infection, exfoliative skin disor-
ders, immunodeficient patients, and pregnant women.
• In these special populations vaccinia immune globulin
may be used or if this is unavailable, postexposure
vaccination reconsidered.
• Adverse reactions to vaccination include self-limited
rashes (eczema vaccinatum and generalized vaccinia)
as well as serious complications: vaccinia gangrenosa
(especially in the immune compromised) and postvac-
cinal encephalitis (1 in 300,000).
Patient with acute,
generalized vesicular or
pustular rash illness
Institute airborne and contact
precautions alert infection
control on admission
High risk of smallpox
(see accompanying table)
Testing at CDC
Response team advises
on management and
specimen collection
Moderate risk of smallpox
(see accompanying table)
Low risk of smallpox
(see accompanying table)
Infectious disease and/or
dermatology consultation
alert local and state health
departments immediately
Infectious disease and/or
dermatology consultation
varicella ± other lab testing
as indicated
History and exam
highly suggestive
or varicella
Diagnosis
uncertain
Varicella testing
optional
Test for varicella and 
other conditions as
indicated
Non-smallpox
diagnosis confirmed
report results to
infection control
No diagnosis made
Ensure adequacy of
specimen infectious disease
and/or dermatology consultation
to re-evaluate patient
Smallpox Not smallpoxFurther testing
Cannot rule out
smallpox
Classify as high risk
FIG. 64-1 CDC evaluation of patients for smallpox.
SOURCE: Adapted from http://www.bt.cdc.gov/agent/smallpox/diagnosis/evalposter.asp.
• In addition, caution is advised in patients with a known
cardiac condition or more than two cardiac risk factors.
• All cases should be reported to local, state, and
national health care authorities.
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65 SARS
Shefali Shah
KEY POINTS
• Severe acute respiratory syndrome is caused by an
infectious process and involves a febrile respiratory ill-
ness progressing, in some patients, into severe pneumo-
nia and acute respiratory distress syndrome (ARDS).
• SARS is caused by a novel coronavirus that likely
originated from an animal reservoir. The virus evolved
into a human pathogen, with the first human case in
November 2002, and is now capable of human-to-
human transmission.
• It is responsible for the first major outbreak of the
twenty-first century, and due to its rapid transmission,
illustrates the need for a coordinated global effort in
response to an infectious pandemic.
• Diagnosis is heavily dependent on history of exposure
and clinical symptoms.
• Clinical features include high fevers, malaise, chills
and rigors, cough, diarrhea and in some cases pro-
gression to ARDS and death.
• Treatment is primarily supportive. The major goals of
therapy are respiratory support, circulatory support,
and treatment of comorbid conditions.
• Prevention of transmission of infection is extremely
important. Respiratory isolation, adherence to contact
precautions, and careful disinfection of surfaces min-
imize the risk of transmission.
ETIOLOGY AND EPIDEMIOLOGY
• Severe acute respiratory syndrome (SARS) emerged
as a human pathogen in November 2002 and can be
traced to an index patient in Guangdong Province in
southern China.
• The causative agent is a novel coronavirus (SARS-
CoV). Coronaviruses are a family of enveloped,
single-stranded RNA viruses. Coronaviruses are also
the etiologic agents for the common cold.
• Precursor SARS-CoV-like viruses have been found in
animals among the wild-game markets in Guangdong
Province in China. The initial SARS-affected individ-
ual had contact with these animals. Human strains iso-
lated later in the outbreak evolved from strains found
early in the outbreak. This epidemiologic evidence
supports the hypothesis that SARS likely originated in
animals and interspecies transmission with viral evo-
lution led to the human pathogen that caused the
outbreak.
• The first major outbreak occurred in Guangzhou,
China between January and March 2003, and then
spread to Hong Kong, Vietnam, Singapore, Canada,
and elsewhere. The subsequent outbreaks can be
traced to those who had contact with the index patient.
• SARS is the first pandemic of the twenty-first century.
The exceeding global economy in which we live
where international air travel is commonplace com-
bined with the highly infectious nature of the virus
led to the widespread transmission of SARS. It
illustrates the potential of an infectious disease to dis-
seminate globally and cause serious health problems
worldwide.
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• The end of the outbreak occurred in July 2003. From
December to January 2004, a small number of new
cases of SARS emerged that were relatively mild and
did not result in significant transmission. In these
cases, the animal precursor virus was probably not
adapted for efficient human-to-human transmission.
However, this incident illustrates the possibility of re-
emergence and a future outbreak.
• The most recent cases of SARS were found in China
in April 2004 originating from a lab worker.
• To date, SARS has affected more than 8000 patients
and has caused 774 deaths in 29 countries.
TRANSMISSION
• The primary mode of transmission is through respira-
tory droplets and aerosolized infectious particles.
• The use of aerosol-generating procedures such as
endotracheal intubation and bronchoscopy amplify
transmission of SARS-CoV.
• SARS-CoV survives for many days when dried on
surfaces and in feces. The role of fecal-oral transmis-
sion is unknown, but may be important considering
the watery diarrhea that is a common clinical feature.
• Transmission is rare during the first 5 days of infection.
• Characteristic of the 2003 SARS outbreak was its
“superspreading” phenomenon where a few individu-
als greatly augmented transmission of the virus. The
reason for this phenomenon is still unclear.
Researchers are currently investigating the possibility
of coinfection of another entity in the role in infection
and transmission of SARS-CoV.
• There have been no reports of vertical or perinatal
transmission, though there is anecdotal evidence of
increased pregnancy-related complications in those
infected with SARS.
HISTORY AND CLINICAL
CHARACTERISTICS
• A thorough travel and exposure history is essential for
diagnosis.
• The incubation period lasts from 2 to 8 days and most
patients develop symptoms within the first 10 days
after exposure.
• The earliest symptom is high fever, usually of sudden
onset. Affected individuals also initially present with
myalgias, malaise, chills, and rigors. Upper respiratory
complaints of rhinorrhea and sore throat are rare
(Table 65-1).
• Initially, there are no obvious respiratory symptoms or
chest x-ray changes.
• Within about 3–7 days, the patient usually deterio-
rates rapidly, with exacerbations in shortness of breath
and an increase in lung infiltrates on imaging consis-
tent with a viral pneumonitis.
• About a quarter of patients experience watery diarrhea.
• Elderly patients may be afebrile, and present with
malaise, decreased appetite, or even a fall.
CLINICAL COURSE
• One-third of patients improve, with defervescence
and resolution of radiographic changes.
• Two-thirds of patients have persistent fever, increas-
ing dyspnea, tachypnea, hypoxemia, and worsening of
the pulmonary physical examination. Serial chest
radiographs or computed tomography (CT) scans
reveal progression to unilateral or bilateral multifocal
airspace consolidations in these patients.
• 20–30% require admission to an ICU, most of whom
need mechanical ventilation.
• Viral load peaks at around the 10th day of illness and
subsequently decreases, but some patients deteriorate
during the second week of the illness despite the
decreasing viral load. This observation suggests that
some of the lung damage is immunopathogenic in
nature.
• Diffuse alveolar damage can lead to fibrosis and for-
mation of cysts. The rupture of these cysts can cause
pneumomediastinum, an unusual complication.
• Overall mortality rate is about 15%. Terminal events
include severe respiratory failure, multiple organ fail-
ure, sepsis, or intercurrent illness.
• Residual ground-glass opacifications have been noted
on follow-up chest x-ray and CT scans in a majority
of patients 1 month after admission.
• 6–20% of surviving patients have had some degree of
residual respiratory impairment likely secondary to
TABLE 65-1 Initial Clinical Symptoms in Adults with
SARS∗
1. Fever (99.9%)
2. Cough (65.5%)
3. Malaise (58.8%)
4. Chills/rigor (51.5%)
5. Myalgia (48.5%)
6. Shortness of breath (45.9%)
7. Headache (38.8%)
8. Dizziness (27.3%)
9. Chest pain (22.4%)
10. Diarrhea (20.1%)
∗Among cases in China, Hong Kong, Canada, and Singapore, 2003.
pulmonary fibrosis, muscle weakness, or residual
effects of the virus.
LABORATORY FINDINGS
• The most frequent initial chest radiographic finding is
patchy consolidation.
• Chest radiograph and CT usually demonstrate bilat-
eral ground-glass opacifications or consolidations.
These findings can be unilateral.
• Often there is progression to bilateral bronchopneu-
monia over 5–10 days.
• T-cell lymphopenia and less often thrombocytopenia
may be found.
• The levels of alanine aminotransferase and creatine
kinase may be elevated.
• Lactate dehydrogenase is often elevated.
• Bacterial cultures of sputum yield no significant
pathogens. Serum antibodies for common viruses such
as adenovirus, coxsackievirus, respiratory syncytical
virus (RSV), cytomegalovirus (CMV), influenza A
and B are negative.
• The most rapid test for diagnosis is reverse transcriptase-
polymerase chain reaction (RT-PCR) of specimens
from the lower respiratory tract. In those with a pro-
ductive cough, nasopharyngeal aspirates or throat
swabs can be used for specimen collection. Viral RNA
is also detectable in plasma, serum, leucocytes, feces,
and urine.
• Identification of seroconversion remains the gold stan-
dard for diagnosis, but antibody is detectable only weeks
after the illness. IgM does not aid in early diagnosis.
• Due to delayed seroconversion, the serum should be
tested at least 21 days and preferably 28 days after
onset of symptoms to confirm SARS.
• Mainstay of diagnosis remains history of exposure
and clinical findings (Table 65-2).
PROGNOSTIC FACTORS
• Age
 Mortality exceeds 50% in those >65 years old.
 Those younger than 12 years of age usually have an
uneventful course and a good outcome.
• Coexisting illness, especially diabetes mellitus,
chronic hepatitis B, and heart disease increase the risk
of intensive care unit admission and mortality.
• High viral load in nasopharyngeal aspirates, feces,
and serum during days 10–15 of the illness is predic-
tive of poor clinical outcomes.
• Elevated lactate dehydrogenase is also correlated to a
poorer outcome.
MANAGEMENT/TREATMENT
• Treatment is largely supportive.
• There is no response to antibiotics. However, early
treatment with broad-spectrum antibiotics that are
effective against common pathogens found in typical
and atypical pneumonias can rule out the diagnosis of
community-acquired pneumonia and may even serve
a protective effect.
• Early nasal CPAP (continuous positive airway pres-
sure) may be useful.
• Controversy surrounds the use of high-dose steroids,
but these have been thought beneficial in some cases.
Steroids should be administered with a proton pump
inhibitor to prevent gastrointestinal (GI) distress and
bleeding.
• At present, there is no clinical evidence for the effi-
cacy of antiviral therapies.
• If the patient progresses to respiratory failure, then
supportive care with mechanical ventilation with low
tidal volume strategy is employed. Tidal volumes of
6 mL/kg of ideal body weight with target plateau
pressures of <30 cm of water are generally used.
• There are a number of potential targets for antiviral
drugs in the replication cycle of SARS-CoV, includ-
ing fusion inhibitors and protease inhibitors. The dis-
covery of the full genome sequence provides a basis
for development of future drugs. Vaccine development
and monoclonal antibodies for prophylaxis are other
options that show promise for prevention and are cur-
rently under investigation.
HISTOLOGY
• Lung biopsies have shown
 Diffuse alveolar damage
 Inflammatory infiltration in interstitial tissue of the lung
 Congestion with dilation, bleeding, and deformation
of capillaries
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TABLE 65-2 Diagnosis of SARS
1. History
a. Recent (<20 days) close contact with an infected patient, or
b. History of travel to an area with recent SARS within 10 days of
symptom onset, or
c. High-risk profession (e.g., laboratory worker or hospital employee
during an outbreak)
2. Clinical symptoms
a. Acute onset fever (≥38.0°C)
b. Headache, arthralgia, myalgia, fatigue, or chest pain
c. Cough
d. Clinical evidence for pulmonary infection
e. Dyspnea
f. ARDS
3. Lymphopenia
4. Chest radiograph or CT consistent with patchy or speckled
pneumonia
5. No response to antibiotic treatment for typical or atypical pneumonias
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 Exfoliation of the pulmonary alveolar epithelia
 Hyaline changes in some pulmonary alveoli with
proliferation and fibrosis of connective tissue
• Viral RNA has also been detected at high viral loads
in the lung, bowel, and lymph nodes, and also found
in the spleen, liver, and kidney.
PREVENTION
• Early triage, early case detection, and isolation of
affected patients are essential to prevent spread.
• Nosocomial transmission has been one of the major
features of the outbreak, so rigid adherence to precau-
tions is an essential control measure. Particularly strict
adherence should be employed when an infected
patient undergoes a procedure that can increase aerosol
droplets in the environment, for example, endotracheal
intubation or bronchoscopy.
• Protection against respiratory droplets and contact
precautions can prevent the bulk of transmission.
Strict hand-washing, gowning, gloving, and respira-
tory masks should be employed during any outbreak.
• Community containment during an outbreak is another
mainstay for prevention of further transmission.
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66 INFLUENZA
Gordon E. Carr
KEY POINTS
• Influenza is caused by an RNA virus that displays
remarkable genetic instability.
• Point mutations in the viral genome cause small anti-
genic changes (antigenic drift), allowing the virus to
evade existing immunity in the population, producing
annual epidemics which kill roughly 50,000 in the
United States annually.
• Reassortment of the viral genome produces novel
viral subtypes (antigenic shift), potentially changing
both the ability to spread in the population and the
pathogenicity, and leading sporadically to pandemics.
• Fever, cough, myalgias, and headache in the proper epi-
demiologic context should raise suspicion for influenza.
• Influenzal respiratory infection may be complicated
by bacterial pneumonia, myocarditis, encephalitis,
and rhabdomyolysis.
• Antiviral therapy is minimally effective in established
infection, treatment is largely supportive.
VIROLOGY
• Two clinically important types exist: influenza A and B.
• Different nucleoprotein (NP) and matrix protein (M)
antigens distinguish the viral types.
• Both types have a segmented genome consisting of
single-stranded negative-sense RNA in eight fragments.
• Influenza A viruses are further characterized according
to the immunologic reactivity of hemagglutinin (HA)
and neuraminidase (NA) glycoproteins displayed by
different subtypes, for example, H1N1, H3N2.
• 15 HA and 9 NA variants have been identified.
• Intracellular replication of the viral genome depends
on a viral RNA-dependent RNA polymerase.
• Influenza A RNA polymerase is susceptible to fre-
quent errors, with a replication error rate of 1/104
bases as compared to an error rate of 1/109 bases for
most DNA polymerases.
• Due to its segmented genome, and the high error rate
of its RNA polymerase, influenza undergoes constant
genetic change.
• This constant genetic change translates into antigenic
instability, contributing to a cyclical pattern of out-
breaks as new viral subtypes are able to evade estab-
lished immunity.
• The virus’ genetic instability may also underlie changes
in pathogenicity. For example, genetic mutations under-
lie changes in both tissue tropism and virulence in birds.
However, the molecular basis of pathogenicity in human
influenza infection remains to be fully elucidated.
EPIDEMIOLOGY
• Influenza persists in an animal reservoir, mainly
aquatic birds, and is capable of causing infection in
many species.
• In humans, two patterns of disease are described: epi-
demics and pandemics.
EPIDEMICS
• Both influenza A and B can cause annual epidemics,
which result when the virus can evade preexisting
immunity in the population.
• This ability to evade immunity results from point
mutations in the viral genome (antigenic drift).
Antigenic drift causes small changes to viral antigens.
• Other factors also determine the extent of viral epi-
demics: the virus’ ability to spread among humans,
the ability to replicate in the human host, and the pres-
ence or absence of immunity in the population.
• Influenza epidemics contribute to more than
200,000 hospital admissions each year in the United
States, and probably contribute to more than 50,000
deaths.
• The morbidity and mortality of influenza A epidemics
stem from primary viral infection as well as from the
role of host factors, such as cardiovascular and respi-
ratory disease and the patient’s immune status.
• In one prospective study, epidemic or sporadic
influenza A and B accounted for about 10% of cases
of community-acquired pneumonia (CAP).
• However, among patients with heart disease, this
study found that influenza accounted for 25% of the
cases of CAP. This finding demonstrates the crucial
influence of host factors in determining outcome from
infection.
• The highest rates of hospitalization occur among the
elderly and young children.
PANDEMICS
• Only influenza A causes pandemics.
• Pandemics can claim tens of millions of lives world-
wide, and occur at unpredictable intervals.
• Pandemics may disproportionately affect younger and
healthier people.
• Pandemics result from the emergence of novel viral
subtypes. These novel subtypes emerge from the reas-
sortment of genome segments (antigenic shift).
• Antigenic shift creates viral subtypes with potentially
drastic immunologic novelty. Whether antigenic shift
also leads to changes in viral pathogenicity requires
further study.
• Currently, there is concern that the H5N1 subtype,
currently circulating among birds in Asia, may lead to
a pandemic. This subtype appears to be particularly
novel, both in terms of pathogenicity and antigenicity.
• Furthermore, both animal-to-human and human-
to-human transmission have been documented. The
World Health Organization (WHO) and other agen-
cies are actively monitoring H5N1.
PATHOPHYSIOLOGY
• Transmission occurs by three routes: inhalation of res-
piratory droplets, contact with fomites, and contact
with infected animals such as pigs and birds.
• In humans, the viral attachment seems to be limited to
the epithelial cells of the respiratory tract.
• The molecular basis of pathogenicity in humans is
poorly understood, although several viral proteins
have been implicated. Nonstructural protein 1, PB2,
NA, and HA are important contributors.
• The virus probably does not disseminate systemically.
• Systemic illness results from the interplay between
viral and host factors. The host immune response to
infection and the viral ability to resist it are important
determinants of the extent of disease.
• Primary infection of the respiratory tract may be cata-
strophic in patients with respiratory, cardiovascular,
metabolic, or immunologic diseases. Likewise, the
systemic consequences of infection may lead to the
deterioration of other underlying comorbidities.
• Cytokines and interferons are important mediators of
systemic disease. One study found a correlation
between systemic cytokine levels and the extent of
symptoms and viral replication.
PRESENTATION
• Signs and symptoms can be highly variable, and often
include the acute onset of fever, malaise, respiratory
symptoms, myalgias, and headache.
• The combination of fever and cough for <36 hours,
with or without the other symptoms listed above, and
in the right epidemiologic context, should prompt
consideration of influenza infection.
• Infection with different subtypes can present with
variable signs and symptoms. For example, in the
recently reported cases of H5N1 infection in humans,
there has been prominent lymphopenia and diarrhea.
DIAGNOSIS
• No symptom or set of symptoms reliably indicates
influenza infection.
• The role of laboratory studies is still evolving.
Physicians must rely on clinical and epidemiologic
clues until well-validated and clinically practical tests
for influenza are widely available.
• A two-step approach to clinical diagnosis has been
proposed. First, the physician must identify an
influenza-like illness (ILI): acute onset of fever and
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respiratory symptoms with or without myalgias,
malaise, fatigue, or other symptoms.
• Once an ILI has been identified, one should consider
the epidemiologic context. During times of high preva-
lence and in communities with more viral presence, the
likelihood of influenza infection is much more likely.
• The Centers for Disease Control and Prevention
(CDC) maintains a Web site: http://www.cdc.gov/
flu/weekly/fluactivity.htm. This Web site provides
important information about regional and temporal
patterns of influenza activity, which should assist in
appropriate diagnosis of an ILI.
COMPLICATIONS
• Many complications stem from the exacerbation of
chronic conditions, notably cardiovascular, pul-
monary, and immunologic diseases
• Bacterial pneumonia develops in about 75% of
patients with influenza who develop pneumonia
• Myocarditis, pericarditis
• Encephalitis
• Rhabdomyolysis
TREATMENT
• Two classes or drugs are available to treat influenza,
but they are of limited utility: the M2 inhibitors
(amantidine and rimantadine) and the NA inhibitors
(oseltamivir and zanamivir). These drugs target
enzymes involved in the viral life cycle.
• Anti-influenza drugs are minimally effective at treat-
ing established infection. Currently available drugs
seem to shorten the length of fever or other symptoms
by about a day, and may reduce the need for antibi-
otics if given within the first 48 hours of infection.
• There are limited settings where these drugs may be
of more benefit.
 During pandemics.
 In the case of the high-risk patient who is not
immune or has not been vaccinated, if treatment can
be initiated within 48 hours of the onset of illness
(zanamivir and oseltamivir).
 In the case of infected, unvaccinated household con-
tacts of high-risk patients.
• For the most part, care of the patient with influenza is
supportive. For those progressing to acute respiratory
distress syndrome (ARDS), a lung-protective ventila-
tion strategy should be used.
• Adequate care of the patient with influenza demands
close attention to the patient’s cardiopulmonary and
immunologic state, and the presence of other comorbidi-
ties. Patients with pneumonia should be risk-stratified
based on a validated scale such as the PORT
(Pneumonia Patient Outcomes Research Team) score.
PREVENTION
• Vaccines: live attenuated and inactivated vaccines are
available.
 In one meta-analysis, vaccination lead to a 50%
reduction in all-cause mortality, a 47% reduction in
hospital admissions for influenza and pneumonia,
and 35% reduction in cases of ILI.
 Annually revised vaccination recommendations are
available on the CDC Web site: http://www.cdc.gov/
flu/professionals/vaccination/#recs.
 Some recommendations for use of inactivated vac-
cine (from the CDC Web site).
 Persons aged >65 years
 Residents of nursing homes and other chronic-
care facilities that house persons of any age who
have chronic medical conditions
 Adults and children who have chronic disorders of
the pulmonary or cardiovascular systems, includ-
ing asthma (hypertension is not considered a high-
risk condition)
 Adults and children who have required regular
medical follow-up or hospitalization during the
preceding year because of chronic metabolic dis-
eases (including diabetes mellitus), renal dysfunc-
tion, hemoglobinopathies, or immunosuppression
(including immunosuppression caused by medica-
tions or by human immunodeficiency virus [HIV])
 Adults and children who have any condition (e.g.,
cognitive dysfunction, spinal cord injuries, seizure
disorders, or other neuromuscular disorders) that
can compromise respiratory function or the han-
dling of respiratory secretions or that can increase
the risk for aspiration
 Children and adolescents (aged 6 months to
18 years) who are receiving long-term aspirin
therapy and, therefore, might be at risk for experi-
encing Reye syndrome after influenza infection
 Women who will be pregnant during the influenza
season
 Children aged 6–23 months
 More comprehensive and detailed recommendations
are available from the CDC.
• Drugs: anti-influenza drugs may be useful for the pre-
vention of infection in selected groups.
 For postexposure prophylaxis of high-risk patients
older than 13 years and residents of residential facil-
ities who can begin treatment within 48 hours of
exposure (oseltamivir).
 For wider use during pandemics.
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67 PLAGUE: THE BLACK
DEATH
Samip Vasaiwala
KEY POINTS
• Plague is caused by a gram-negative bacterium,
Y ersinia pestis, spread by fleas from a rodent reservoir.
• The bubonic form of plague is characterized by fever,
chills, and tender, erythematous lymphadenopathy
(buboes).
• Septicemic plague is defined by positive blood cul-
tures and sepsis, without lymphadenopathy.
• Pneumonic plague is acquired through droplet infection
(primary pneumonic plague) or through spread to the
lungs from another infected part of the body (secondary
pneumonic plague) and resembles bacterial pneumonia
of other causes. Strict droplet precautions are manda-
tory for suspected or established cases of plague.
• A high index of suspicion is required to make the diag-
nosis. Since antimicrobials typically used to treat severe
pneumonia and sepsis do not treat plague adequately,
establishing a diagnosis is especially important.
• The treatment of choice is streptomycin.
HISTORY
• The first documented mention of the plague is possi-
bly given in the Bible in the book of Samuel in which
an outbreak of a disease with buboes is described
(I. Samuel V9-12).
• The first pandemic originated in northern Africa
(Ethiopia or Egypt) around the year 532 and spread to
the Mediterranean via the Nile. The pandemic started
as the plague reached Constantinople (now Istanbul,
Turkey) and Greece in the year 541. The most impor-
tant political impact of this pandemic was the eradica-
tion of one-half of the inhabitants of the Byzantine
Empire by the year 565. The prominent medical
thought in this was offered by Hippocrates and
Galen, who both believed in the theory of a vaporous
eruption of substances into the air from swamps as the
cause of these epidemics.
• The term “Black Death” was coined in England during
the second pandemic because of the black spots
(buboes) it produced on the skin. The devastation
caused by this disease during this period is evident by
a 33% drop in the population of Europe from the year
1347 to 1352. The understanding of the etiology of this
disease was not more advanced than the original views
of Galen and Hippocrates, with others suggesting pos-
sible unfavorable constellation of stars and comets and
the wrath of God. Cities like Marseille introduced
quarantine measurements to avoid these epidemics. In
fact, the word “quarantine” is derived from the 40-day
restriction placed on travel in Marseille in the year
1384. It was not until the year 1546 that Girolamo
Fracastoro (1478–1553) and later in 1658, Athanasius
Kircher implicated plague as a potential infection.
• It was not until the third pandemic that the discovery of
the bacterium Y. pestis as the etiologic agent of the
plague was made. This pandemic likely started in the
Chinese province of Yunnan around 1855, spreading to
Japan, Taiwan, and Mumbai, India by the year 1896 and
eventually to South America, South Africa, and parts of
western North America. Alexandre Yersin (1863–1943)
accurately described the bacterium as a gram-negative
organism in the year 1894. Based on epidemiologic
data, Paul-Louis Simond (1858–1947) proposed the role
of the flea in plague transmission. Ricardo Jorge was the
first to implicate living rodents as a reservoir of infec-
tion as an explanation of endemic plague.
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EPIDEMIOLOGY: THE LIFE CYCLE
OF YERSINIA PESTIS
• The pathogen that causes plague belongs to the genus
Yersinia, a member of the family Enterobacteriaceae.
Y. pestis, a facultative anaerobe and an obligate para-
site, is a gram-negative, nonmotile, nonspore-forming
coccobacillus (0.5–0.8 µm in diameter and 1–3 µm long).
It exhibits bipolar staining with Giemsa, Wright, or
Wayson staining. The organism grows at temperatures
from 4 to 40°C, with the optimum pH for growth ranges
from 7.2 to 7.6.
• Plague is a zoonotic disease with no role of human
infection as a part of its life cycle. Transmission
between rodents happens via their associated fleas.
Also, direct contact and ingestion do not play a sig-
nificant role in the life cycle of Y. pestis, although
infection is definitely possible via these routes. The main
vector for transmission of the plague is the oriental rat
flea (Xenopsylla cheopis). With each bite, this flea
will ingest approximately 0.3–0.5 µL of blood from an
infected rodent, with an estimated 300 Y. pestis organ-
isms. The organisms multiply in the stomach of the flea
and within 2–3 days they develop a dark brown mass
containing bacilli, a fibrinoid material, and hemin
within the flea stomach. This mass eventually obstructs
the gastrointestinal tract of the flea by days 3–9. Now,
as the hungry flea attempts to repeatedly feed, the
blood sucked from the rodents gets mixed with the
organisms and is regurgitated back into the mam-
malian host, with an estimated inoculation of
11,000–24,000 organisms. The infection of the
mammal with subsequent bacteremia and another flea
bite completes the life cycle (Fig. 67-1).
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FIG. 67-1 Natural cycle of plague
• In the United States, the most common source of the
human plague is through the bite of Odontotermes
montanus, which is carried by squirrels. Cat and dog
fleas (Chlamydophila felis and Ctenocephalides canis)
do bite humans but are not associated with significant
human disease. However, human disease associated
with contact with infected cats is rising. Most of the
human cases of plague in the United States are
reported in the southwest and Pacific west coast.
CLINICAL MANIFESTATIONS
• Human plague usually presents in three common
forms: bubonic, septicemic, and pneumonic. The less
common forms of presentation like meningitis,
pharyngitis, tonsillitis, and skin infections are not dis-
cussed in this chapter. The incubation period of
plague is usually 2–8 days.
BUBONIC PLAGUE
• This is the most common form and presents with sudden
onset of fever, chills, headache, and weakness. Also,
gastrointestinal complaints such as nausea, vomiting,
and diarrhea are common. The classic finding is that of
a bubo, tender lymphadenopathy of usually either the
inguinal or axillary lymph nodes with associated ery-
thema and overlying skin edema but lacking fluctuance.
SEPTICEMIC PLAGUE
• This is a very difficult diagnosis to make since there
may be no characteristic physical findings. The defi-
nition is positive blood cultures in a patient with no
palpable lymphadenopathy. The signs and symptoms
are not very different from other gram-negative sepsis
syndromes. The mortality from septicemic plague is
high, ranging from 30 to 50% because the antibiotics
normally used to broadly cover septic patients are not
very effective against Y. pestis.
PNEUMONIC PLAGUE
• The last case of pneumonic plague recorded in the
United States that was due to a person-to-person
spread was during the 1924–1925 Los Angeles plague
epidemic. Primary pneumonic plague is acquired by
inhalation of respiratory droplets from an infected
individual, animal, or from laboratory specimens. It
is more commonly seen in patients with bubonic
or septicemic plague who then acquire secondary
pneumonic plague. Infected cats with pneumonic
plague are the most common source of primary pneu-
monic plague in humans. There are no obvious clini-
cal or radiographic findings that readily differentiate
plague pneumonia from other types of bacterial pneu-
monia. Sputum may be clear, purulent, or hemor-
rhagic and may contain few gram-negative rods.
DIAGNOSIS
• A high index of suspicion is needed to make a diag-
nosis of plague. Key questions include those that
address travel to endemic areas, exposure to potential
animal or rodent vectors, and classic clinical signs.
Routine laboratory evaluation may reveal an elevated
white blood cell count.
CULTURE
• Y. pestis grows well on the routine laboratory culture
media and blood culture is positive in 27–96% of
cases. Aspirates from buboes can also be sent for
culture.
STAINING
• Gram’s stain reveals small gram-negative coccobacilli.
Wright-Giemsa stain of peripheral blood reveals rod-
shaped organisms in 40% of cases. Wayson stain or a
fluorescent antibody stain shows bipolar staining
resembling a “closed safety pin.”
SEROLOGY
• A fourfold rise in antibody titers to the F-1 antigen of
Y. pestis or a single titer of >1:16 using a passive
hemagglutination test is suggestive of the diagnosis.
RAPID DIAGNOSTIC TESTS
• A new test to detect the F-1 antigen of Y. pestis has
been developed and has a sensitivity and specificity of
100% against laboratory isolates of Y. pestis. This test
has also proved to be more sensitive than the enzyme-
linked immunosorbent assay (ELISA) and culture. A
polymerase chain reaction test aimed at the plasmino-
gen activator gene of Y. pestis has been developed but
is not yet routinely available for clinical use.
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TREATMENT
• Streptomycin, which has been used against plague for
the last 45 years, continues to be the treatment of
choice. It is administered as an IM dose of 30 mg/kg/
day (up to a total dose of 2 g/day) in two divided doses
for 10 days. However, due to its toxicity, patients are
usually not maintained on a full 10-day regimen and
are generally switched over to tetracycline (2–4 g/day
in four divided doses orally).
• Other therapies include doxycycline (100 mg bid PO or
IV), chloramphenicol (25 mg/kg IV as a loading dose
followed by 60 mg/kg/day in four divided doses; drug of
choice for plague meningitis), and trimethoprim-
sulfamethoxazole (160/800 mg bid; for bubonic plague).
• Although some outbreaks of drug-resistant plague
have been reported, antibiotic-resistant strains are rare
and not increasing in frequency.
• All patients diagnosed with plague are placed under
strict respiratory droplet isolation until it is clear that
they don’t have pneumonic plague, their sputum cul-
ture is negative, and they have been treated at least for
48 hours with effective antibacterial therapy.
• Trimethoprim-sulfamethoxazole (15–30 mg/kg/day
PO for 5–7 days) is also used for chemoprophylaxis
for close contacts of patients suspected of having or
diagnosed with pneumonic plague.
VACCINE
• Vaccination is recommended for individuals at high
risk: military personnel serving in endemic areas and
laboratory personnel working with fully virulent strains.
A killed whole vaccine, which is no longer commer-
cially available in the United States, is administered as a
series of injections 1–3 months apart followed by a
booster every 6 months until the exposure terminates.
CONCLUSION
• The recent epidemics in India remind us that plague
should not be thought of as a disease of the past.
Attempts have been made by the United States and the
former Soviet Union at eradicating plague from cer-
tain locales; these attempts were expensive and
mostly unsuccessful. Plague is here to stay.
• The diagnosis of this illness requires a very high level
of suspicion.
• Recent research in the basic science and epidemiol-
ogy of plague has dramatically advanced our knowl-
edge of this infectious disease. Further arenas of
research will focus on the development of a vaccine
that provides long-lived immunity against plague and
the modulation of virulence and drug resistance.
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68 BOTULISM
David Brush
KEY POINTS
• Botulism is a clinical diagnosis that should be sus-
pected in any adult with an acute onset of cranial nerve,
gastrointestinal and autonomic dysfunction, and a his-
tory compatible with botulism exposure. Treatment
should be initiated immediately, with cultures and toxin
assays used to later confirm the diagnosis.
• Proper management of patients with botulism involves
early diagnosis, timely antitoxin administration, careful
monitoring for respiratory compromise, and supportive
care including mechanical ventilation if necessary.
• Respiratory failure is the primary cause of death in
patients with botulism. Serial examination of oropha-
ryngeal tone and frequent monitoring of spirometry
can identify patients in need of mechanical ventilation
before respiratory collapse is imminent.
• Patients with wound botulism need early and defini-
tive surgical intervention.
• All suspected cases of botulism should be reported to
public health authorities immediately. Prompt epidemi-
ologic investigation helps prevent additional cases and
can identify new risk factors for intoxication.
OVERVIEW
• Botulism results from intoxication with the protein
neurotoxin formed by Clostridium bacteria, usually
Clostridium botulinum.
• Toxins are subclassified by antigenic differences into
types A through G. Types A, B, E, and F are responsi-
ble for most cases of human disease.
• Botulism neurotoxin permanently blocks alpha motor
neurons from releasing acetylcholine, producing motor
system paralysis and autonomic dysfunction (Fig. 68-1).
• Patients with the classic manifestations of botulism
demonstrate acute, bilateral cranial neuropathies with
symmetric descending weakness that may progress to
respiratory failure.
• After treatment and toxin elimination, recovery of
function occurs over the course of weeks to months as
new neural synapses form.
EPIDEMIOLOGY
• Between 2001 and 2003, 425 cases of botulism were
reported to the Centers for Disease Control (CDC). Of
these cases, approximately 15% were foodborne bot-
ulism, 66% were infant botulism, 18% were cases of
wound botulism, and 1% of cases were adult colo-
nization botulism. Sources of botulism are listed in
Table 68-1.
FOODBORNE BOTULISM
• Onset of symptoms usually occurs 12–36 hours after
ingestion.
• Noncommercial food is most often implicated as the
source in reported events (91%), frequently from home-
canned vegetables (44%).
• In the United States, the consumption of Alaskan native
foods such as fermented or smoked meats and fish are
the most frequent cause of multicase outbreaks.
• Commercial food products and improper food han-
dling at restaurants are an occasional cause of botu-
lism, often resulting in multicase outbreaks.
WOUND BOTULISM
• Onset of symptoms varies, with reported incubations
ranging from 4 to 14 days.
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TABLE 68-1 Sources for Botulism
Home-canned vegetables, fruits, or fish
Noncommercial, noncanned fermented fish or meat
Home fermented beans
Commercial food improperly handled
Peyote consumption
Injection drug use
Wound infection
Sinusitis caused by cocaine inhalation
Colonization of the gastrointestinal tract with C. botulinum
Bioterrorism
SOURCE: Adapted from Ref. 1.
FIG. 68-1 Action of botulinum toxin.
SOURCE: Adapted from http://www.agen.ufl.edu/~chyn/age2062/
lect/lect_25/FG19_011.GIF.
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• The increased incidence of epidemics among injec-
tion drug users, especially those who use black tar
heroin, has increased the occurrence of wound botu-
lism in the United States.
• While most common among injection drug users,
wound botulism can occur in any deep wound and can
be a postsurgical complication.
• Sinusitis as a result of intranasal cocaine use has also
been a reported cause of botulism.
ADULT COLONIZATION BOTULISM
• Rare case reports exist of adult onset “infant” botu-
lism due to colonization of the gastrointestinal tract by
C. botulinum.
• Factors which are thought to predispose patients to
colonization include Crohns disease, achlorhydria,
antimicrobial therapy, gastrectomy, intestinal surgery,
and bone marrow transplantation.
BIOTERRORISM
• On at least three occasions between 1990 and 1995,
botulinum toxin has been used as an aerosolized
bioweapon in terrorist attacks. Other potential terror-
ist use of botulinum toxin includes deliberate contam-
ination of food.
PHYSICAL SIGNS AND SYMPTOMS
• The hallmark of botulism intoxication is the acute
presence of bilateral cranial neuropathies associated
with symmetrical descending weakness that often
progresses to involve the upper extremities and
diaphragm (Table 68-2).
• Patients may experience a prodrome of gastrointestinal
symptoms including nausea, vomiting, and diarrhea.
• In the absence of hypotension, the patient with botu-
lism usually has a normal to slow heart rate. Other
signs of autonomic dysfunction may include orthosta-
sis, hypothermia, and urinary retention.
• With the exception of blurred vision, botulism does
not cause sensory deficits.
• Patients with botulism remain responsive and do not
usually manifest mental status changes.
• Normal pupillary function does not rule out botulism
intoxication. Pupils are dilated or unresponsive in
fewer than 50% of cases.
• Signs of upper airway obstruction from loss of pha-
ryngeal tone or signs of diaphragmatic weakness
require urgent intubation and mechanical ventilation.
• Botulism does not cause pyrexia. A febrile patient in
whom botulism is suspected should have further
workup for a concomitant infectious process. Wound
infections containing C. botulinum are often polymi-
crobial with other bacterial agents responsible for
pyrexia.
• Wounds infected with C. botulinum may appear to be
healing well without evidence of infection.
LABORATORY FINDINGS AND
DIAGNOSTIC STUDIES
• Botulism is a clinical and epidemiologic diagnosis
that can be confirmed with laboratory or electrophys-
iologic testing. Treatment should not be delayed pend-
ing these test results.
TABLE 68-2 Signs and Symptoms in Patients with
Botulism Intoxication
Common signs and symptoms (signs are usually symmetrical)
Diplopia
Blurred vision
Xerostomia
Dysphagia
Dyspnea
Dysarthria
Dizziness
Fatigue
Nausea*
Vomiting*
Diarrhea*
Sore throat
Opthalmoparesis
Pupils fixed or dilated
Facial paresis
Tongue weakness 
Diminished gag reflex
Respiratory insufficiency
Upper extremity weakness
Diaphragmatic weakness
Lower extremity weakness
Uncommon signs and symptoms
Paresthesias
Ataxia
Nystagmus
Rare signs and symptoms
Lethargy or obtundation at presentation
Deep tendon hyperreflexia
∗Uncommon in cases of wound botulism.
• Routine laboratory tests including serum electrolytes,
complete blood count, liver function profiles, cere-
brospinal fluid (CSF) studies, urinalysis, and electrocar-
diograms are normal unless secondary complications
occur.
• Botulism is confirmed by the presence of botulism
toxin in blood, stool, gastric contents, or wound
tissue. These samples as well as implicated food items
(if available) should be sent for culture and toxin iden-
tification to the appropriate state and national
officials.
• Toxin typing confirming botulism is obtained in
approximately 75% of cases.
• The most sensitive test for botulinum toxin is the
mouse bioassay, in which serum or feces from the
patient are injected into mice which are observed for
signs of botulism. Toxin may also be identified through
enzyme-linked immunosorbent assay (ELISA) or gel
hydrolysis.
• Cultures demonstrating C. botulinum in serum stool
or wound tissue provides good evidence for botulism
infection.
• Electrophysiologic testing of clinically affected mus-
cles shows reduced amplitude in compound muscle
action potentials and a normal conduction velocity in
85% of cases.
DIFFERENTIAL DIAGNOSIS
• Classic acute inflammatory polyneuropathy (Guillain-
Barré syndrome) presents with sensory deficits, rapid
areflexia, and rarely begins with bulbar neuropathies.
Elevated CSF protein is common.
• Miller-Fischer variant acute inflammatory polyneu-
ropathy often produces oculomotor weakness and
may involve other cranial nerves but has a character-
istic ataxia lacking in patients with botulism.
• Myasthenia gravis lacks autonomic symptoms and is
rarely a fulminant disease. Tensilon testing must be
interpreted with caution, as some patients with botu-
lism demonstrate increased strength after edropho-
nium administration.
• Eaton Lambert myasthenic syndrome can be excluded
by electromyography and antibody study.
• Normal radiologic studies can help rule out stroke.
• Tick paralysis can be excluded by careful physical
examination demonstrating the absence of an attached
Dermacentor tick.
• Patients with polio are febrile and usually have asym-
metric neurologic deficits.
• Magnesium intoxication can be ruled out by the
absence of high serum magnesium levels.
MANAGEMENT
TOXIN NEUTRALIZATION
• Trivalent equine antitoxin (obtained from state health
departments or the CDC) neutralizes only toxin mole-
cules yet unbound to nerve endings, making early
administration critical to the prevention of progression.
• Before administration of antitoxin, skin testing
should be performed to test for sensitivity to serum or
antitoxin.
RESPIRATORY SUPPORT
• Significant respiratory compromise can exist in the
absence of symptoms. Objective measurements are
needed to identify patients in need of mechanical
support.
• Hypercapnia is a late finding signaling impending and
rapid respiratory collapse. Most patients show signs
of respiratory insufficiency requiring ventilatory sup-
port before developing hypercapnia.
• Proper assessment of oropharyngeal function for
airway obstruction is critical. Loss of glossal and pha-
ryngeal tone as well or gag impairment necessitates
mechanical ventilation.
• Maximal inspiratory and maximal expiratory pres-
sures (MEP) are the most sensitive indicators of res-
piratory insufficiency in neuromuscular weakness.
Effective cough cannot be accomplished if the MEP is
<40 cmH2O.
• Normal vital capacity (VC) in adults is usually 50 mL/kg.
Patients with serial measurements demonstrating a
decline in the VC by 15–20 mL/kg will need ventila-
tory support. Patients with a VC at or below 12 mL/kg
should be immediately intubated. Noninvasive venti-
lation is rarely appropriate given the oropharyngeal
dysfunction and expected duration of respiratory
muscle weakness.
• Patients with botulism usually require extended peri-
ods of mechanical ventilation usually from 2–8 weeks.
Tracheostomy should be considered early on in the
patient’s course to reduce the complications of long-
term mechanical ventilation.
SOURCE ELIMINATION
• Unless an ileus is present, purgatives may be used in
patients when there is a concern for contaminated
food in the gastrointestinal tract.
• Patients with wound botulism should undergo aggres-
sive wound debridement.
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• Antibiotics against C. botulinum such as penicillin G
(3 million units IV q4) or metronidazole (500 mg IV q8)
are frequently used but are unproven in clinical trials.
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69 CEREBROVASCULAR
ACCIDENT
Nina M. Patel
KEY POINTS
• Initial history, physical examination, and noncontrast
head CT are crucial elements in the diagnosis and
classification of stroke.
• Diverse illnesses (e.g., hypoglycemia, intracerebral
tumor, seizure, metabolic encephalopathy, and menin-
gitis) can masquerade as stroke.
• Maintenance of adequate CPP is crucial in the man-
agement of all stroke subtypes. This often requires
greater than baseline systemic blood pressure.
• t-PA should be administered to select patients who
present within 3 hours of onset of ischemic CVA.
• Vigilance in providing supportive medical care to
avert worsening neurologic injury and compromised
cerebral perfusion is essential to management.
• Early neurosurgical consultation and evaluation is an
essential component to management of SAH and
ICH.
EPIDEMIOLOGY
• Cerebrovascular accident (CVA) or stroke is a leading
cause of death and occurs in 200/100,000 persons/year.
• It occurs at equal rates in men and women, and the
mean age of onset is 72.
PATHOPHYSIOLOGY
• Cerebrovascular accidents are caused by a decrease
in cerebral perfusion and can be classified by cause
into three major categories: (1) ischemia or infarction,
(2) intracranial hemorrhage (ICH), and (3) subarachnoid
hemorrhage (SAH). Ischemic strokes are due to
atherothrombotic disease, embolic disease, or systemic
hypoperfusion.
• The incidence of CVA by etiology is shown below.
Ischemic etiologies account for roughly 80% of all
CVAs, while hemorrhagic etiologies lead to 20%.
 Atherothrombotic: 40–50%
 Embolic: 30%
 ICH: 12%
 SAH: 8%
• Atheromatous plaques in the large vessels (e.g., ascend-
ing aorta and aortic arch) lead to 65–70% of ischemic
CVAs. Embolic CVAs arise in the setting of atrial fibril-
lation, endocarditis (infective or noninfective), and left
ventricular mural thrombus. Thrombophilic states can
lead to cerebral venous thrombosis or paradoxical
embolus in the setting of deep venous thrombosis with
a patent foramen ovale.
• ICH occurs in patients with chronic hypertension (basal
ganglia and cerebellar hemorrhage), amyloid angiopa-
thy, coagulopathy, trauma, intracranial aneurysm, or
arteriovenous malformation (AVM).
• SAH is most frequently due to the rupture of a saccu-
lar berry aneurysm or an AVM, though cocaine abuse,
trauma, and pituitary apoplexy can also lead to SAH.
CLINICAL PRESENTATION
ATHEROTHROMBOTIC CEREBROVASCULAR
ACCIDENT
• 10–20% of patients with atherothrombotic CVA expe-
rience a transient ischemic attack (TIA) prior to CVA.
• The majority of patients, however, do not have pre-
ceding symptoms and present with the sudden onset
of a focal neurologic deficit (e.g., hemiparesis, apha-
sia, agnosia, and neglect). If multiple, small infarcts
occur, patients may develop a global impairment, with
decreased level of consciousness, as opposed to a
Section 5
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focal deficit. If embolic in nature, the maximal extent
of neurologic deficit usually occurs at initial onset.
INTRACRANIAL HEMORRHAGE
• Intracranial hemorrhage presents as focal neurologic
impairment.
• If these patients develop increased intracranial pres-
sure (ICP), decreased mental status, vomiting, and
headache may be seen.
SUBARACHNOID HEMORRHAGE
• Patients with SAH will often state that they are having
“the worst headache of my life.” Decreased level of
consciousness and lethargy also occur frequently in
the setting of severe SAH.
DIFFERENTIAL DIAGNOSIS
• Hypoglycemia, intracerebral tumor, seizures, Bell
palsy, metabolic encephalopathy, meningitis, subdural
hematoma, and brain abscess are other diagnostic
considerations in the evaluation of a patient with focal
or diffuse neurologic injury.
• History and physical examination are essential in deter-
mining the nature and distribution of the insult and time
of onset.
• A complete blood count (CBC) with differential,
chemistry panel, and coagulation studies are useful to
evaluate for infection, metabolic encephalopathy, or
coagulopathy. If the history is suggestive, urine toxi-
cology or thrombophilia workup should also be sent.
• If ischemic CVA is a possibility, ECG should be per-
formed to assess for atrial fibrillation, ischemia, or
infarction. Echocardiography should be performed to
evaluate for valvular lesions, left ventricular dysfunc-
tion, ventricular mural thrombus, atherosclerotic
lesions in the aortic arch, and patent foramen ovale if
the clinical history and examination are suggestive.
• Noncontrast brain computed tomography (CT) is the
imaging study of choice for suspected stroke. It is a
rapid and sensitive means to evaluate for ICH. If the
study is negative for ICH, ischemic CVA is most
likely.
• Carotid Doppler and transcranial Doppler ultrasound
evaluations of extra- and intracranial vasculature are
not helpful in acute management of a CVA.
• MRI is more sensitive than noncontrast CT in detect-
ing cerebral infarction within the first 24–48 hours
after onset; however, it does not improve ability to
diagnose acute SAH.
• Lumbar puncture demonstrating CSF fluid with xan-
thochromia is highly supportive of a diagnosis of
SAH. Increased ICP must be ruled out by history,
examination, or CT prior to a lumbar puncture.
• Cerebral arteriography is valuable in identifying the
presence and location of an aneurysm in patients with
SAH.
TREATMENT AND PROGNOSIS
• Immediate goals of therapy in all patients with a CVA
are to stabilize airway, breathing, and circulation.
Mechanical ventilation may be necessary in patients
with impaired consciousness or Glasgow Coma Scale
scores <8. Supplemental oxygen should be adminis-
tered if hypoxemia is present. Maintenance of an ade-
quate mean arterial pressure (MAP) is crucial to
sustaining CPP and minimizing secondary brain
injury. If volume resuscitation is necessary to main-
tain blood pressure, normal saline or other isotonic
fluid should be utilized. Hypo-osmotic fluid may
exacerbate cerebral edema.
• Hyperglycemia is often observed in the setting of
CVA and may contribute to neurologic injury or
impaired recovery. Insulin therapy should be titrated
to achieve tight glycemic control.
• Fever may exacerbate neurologic injury and should be
managed aggressively.
• Thromboembolic prophylaxis with intermittent com-
pression devices and early mobilization (as feasible)
is imperative. Subcutaneous heparin may be used in
patients with ischemic CVA.
ATHEROTHROMBOTIC/EMBOLIC DISEASE
• Patients with ischemic CVA often develop systemic
hypertension. Lowering of systemic blood pressure in
the setting of acute CVA may compromise cerebral
perfusion. As such, hypertension is tolerated, unless
there is evidence of resultant organ damage (e.g., con-
gestive heart failure). In these situations, blood pres-
sure is lowered cautiously with vigilant monitoring of
neurologic status for signs of deterioration.
• The NINDS (National Institute of Neurological
Disorders and Stroke) study established a role for
thrombolytic therapy with alteplase (t-PA) in patients
with acute ischemic CVA who present within 3 hours
of onset of symptoms. CT to rule out ICH must be
performed in all patients prior to administration of t-PA.
t-PA was given at a dose of 0.9 mg/kg (10% in a bolus
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over 1 minute, followed by a 1 hour infusion).
Blood pressure was maintained at ≤185/110 and all
other anticoagulant or antiplatelet therapy was held
for 24 hours. t-PA improved neurologic recovery at
3 months, though it did not impact the mortality rate
from ischemic CVA. t-PA increased the incidence of
ICH. The inclusion and exclusion criteria for t-PA are
extensive and should be reviewed closely prior to
administering this therapy.
• Initiation of aspirin therapy (160–300 mg/day) within
48 hours of onset of ischemic CVA reduces the in-
hospital risk of recurrent CVA and death.
• Anticoagulation with heparin in atherothrombotic
CVA has not been shown to improve outcomes.
Anticoagulation is indicated in the setting of acute
myocardial infarction, ventricular mural thrombus, rheu-
matic heart disease, and cerebral venous thrombosis.
• The short-term mortality rate is 10–15% in patients
with ischemic CVA due to the development of cere-
bral edema. Hypothermia or decompressive hemi-
craniectomy may be attempted to alleviate persistent
cerebral edema, though neither of these techniques has
proven efficacy. Twenty percent of patients require
long-term care and 33–50% are left with major neuro-
logic deficit.
INTRACEREBRAL HEMORRHAGE
• General supportive care measures as delineated above
apply to patients with ICH.
• Blood pressure management in patients with ICH is a
difficult issue. Up to one-third of patients will have
recurrent bleeding within 24 hours. This phenome-
non, however, has not been clearly associated with
elevated blood pressure. As such, the goals of blood
pressure management are first and foremost, to main-
tain adequate CPP.
• Increased ICP presents significant difficulty. This prob-
lem does not respond appreciably to corticosteroid
therapy or ventriculostomy. Mannitol and hyperventila-
tion are used acutely to lower ICP. Decompressive sur-
gical evacuation of hematoma can be considered if
conservative management fails.
• The mortality rate associated with ICH is 30–40%.
Twenty percent of survivors require long-term care.
SUBARACHNOID HEMORRHAGE
• The goals of management of SAH are centered around
the prevention of known life-threatening secondary com-
plications: rebleeding, hydrocephalus, and vasospasm.
• After initial stabilization, patients are examined and
graded using the Hunt-Hess scale, the Fisher grade,
or other neurologic grading systems. These scales
predict the risk of death and vasospasm based on
the size of the lesion and the patient’s neurologic
status.
• Seizure and thromboembolic prophylaxis are standard
therapy in the management of SAH. Corticosteroids
are also used routinely, though it is unclear if they
confer any benefit.
• Management of blood pressure control in SAH pres-
ents a quandary. Avoidance of significant hyperten-
sion is desired to decrease the risk of rebleeding.
However, decreasing systemic pressure lowers MAP
and hence, CPP. Labetalol, hydralazine, and enalapril
are short-acting agents that do not increase ICP and
therefore, are frequently used for blood pressure man-
agement in the setting of increased ICP. Invasive mon-
itoring to accurately titrate therapy is recommended
for the management of these patients.
• Rebleeding commonly occurs within 24 hours of ini-
tial onset. Twenty percent of patients will rebleed
within 1 week. Hypertension, coughing, and Valsalva
maneuvers are actively avoided to decrease the risk of
increasing ICP and subsequent rebleed.
• Early surgical clipping of aneurysms is increasingly
performed in patients with a Hunt-Hess score of 1–3.
Timing of surgery in patients with scores of 4 and 5 is
not well established.
• Ventriculostomy is performed in patients with
decreased level of consciousness and evidence of
acute hydrocephalus on CT scan.
• Vasospasm is a known complication of SAH that
manifests as a global decline in neurologic status or a
focal neurologic deficit and occurs with greatest fre-
quency at days 5–10. Nimodipine (60 mg q 4 h × 21
days) decreases the incidence of ischemia, perhaps by
affecting vasospasm. If vasospasm does occur, initial
therapy consists of aggressive fluid resuscitation with
a goal MAP >15–20% above the initial MAP. If there
is no resolution of neurologic impairment, MAP is
gradually increased with the continued use of intra-
venous fluids as well as vasoactive agents.
• Cardiopulmonary complications of SAH are frequent
and include arrhythmias, ventricular dysfunction,
neurogenic pulmonary edema, aspiration pneumonia,
and pulmonary embolism.
• Cerebral salt wasting occurs in 30–50% of patients
with SAH and should be treated with free water
restriction.
• The prognosis for patients with SAH is grim. The
mortality rate within the first 24 hours is 25% and at
1 year is 50–60%. More than one-half of survivors
suffer residual neurologic deficit.
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70 CNS HEMORRHAGE
Steven Q. Davis, Alex Ulitsky
KEY POINTS
• Intracranial hemorrhage is marked by high mortality
and long-term neurologic morbidity.
• ICH is most often due to hypertension, but some patients
have AVMs, amyloid angiopathy, or cocaine abuse.
• Supportive management includes assessment of the
need for intubation; correction of hypovolemia; mainte-
nance of modest hypertension (MAP 100–120 mmHg);
reversal of coagulopathy; prevention of throm-
boembolism; and prompt recognition and treatment of
complications.
• SAH may be complicated by rebleeding; hydro-
cephalus; vasospasm; or hyponatremia.
• The radiologist and neurosurgeon play key roles in diag-
nosis, monitoring, and management of these patients.
INTRODUCTION
• Bleeding in the central nervous system (CNS) is often
a devastating neurologic event with high morbidity
and mortality. Blood can extravasate anywhere within
the cranial vault and spinal cord, and hemorrhages are
thus classified by their location within the CNS and
the vascular pathology underlying them. This chapter
will focus on intracerebral (ICH) and subarachnoid
(SAH) types of bleeding commonly encountered in
neuro- and medical ICUs.
INTRACEREBRAL HEMORRHAGE
• Intracerebral hemorrhage is one of the most common
types of CNS bleeding, accounting for 10% of all
strokes and associated with a 30–40% 30-day mortality.
It is defined as bleeding directly into the brain
parenchyma, usually due to rupture of a penetrating
vessel. This event occurs most commonly in middle
aged (average age 61) people with long-standing hyper-
tension, although other underlying processes, such as
arteriovenous malformations (AVMs) and cocaine use
in younger patients and amyloid angiopathy in the eld-
erly, are often responsible. The incidence is markedly
increased in African Americans, Hispanics, and
Japanese, and there is a slight male predominance.
• ICH is subclassified into spontaneous, due to trauma or
surgery, primary (unrelated to congenital or acquired
conditions), and secondary (related to congenital or
acquired conditions such as anticoagulation, neoplasia,
or conversion of a thrombotic CVA; Table 70-1).
PATHOPHYSIOLOGY
• The precise mechanism of vessel rupture is unknown,
but is likely related to increased vessel fragility and
segmental constriction associated with long-standing
hypertension. Other processes may be responsible in
non-hypertension-related bleeds.
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TABLE 70-1 Causes of Intracranial Hemorrhage
PRIMARY∗ SECONDARY
Hypertension Vascular malformations
Cerebral amyloid angiopathy Arteriovenous malformations
Anticoagulant/fibrinolytic use Dural arteriovenous fistulas
Antiplatelet use Cavernous malformations
Drug use Aneurysms
Amphetamines Saccular
Cocaine Mycotic
Phenylpropanolamine Fusiform
Other illicit drugs Tumors
Other bleeding diathesis Primary brain tumors
Secondary metastasis
Hemorrhagic transformation of a
cerebral infraction
Venous infarction with hemorrhage
secondary to cerebral venous
thrombosis
Moyamoya disease
∗Primary hemorrhage unrelated to underlying congenital or acquired
brain lesions or abnormalities. See text for details.
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• Most of the neurologic damage is thought to be due to
edema that develops 3–7 days after the initial event, as
well as hematoma expansion, which mostly occurs in
the first 24 hours (Fig. 70-1).
• The size of the hematoma also appears to be the best
predictor of outcome, with patients whose hematoma
volume is >60 cm3 having a 30-day mortality of
over 90%.
CLINICAL PRESENTATION
• Most common sites of hypertensive ICH are the basal
ganglia, deep cerebellum, and pons. Since the internal
capsule lies adjacent to the basal ganglia, it is invari-
ably damaged, and thus contralateral hemiparesis is
often the sentinel focal neurologic sign (Fig. 70-2).
• Numerous other possible manifestations may occur,
depending on the site of damage and ranging from
nausea, vomiting, and ataxia with cerebellar bleeds to
deep coma and death with pontine hemorrhage.
• Interestingly, patients are almost always awake during
the event, and maybe under emotional or physical
stress before the bleed happens.
DIAGNOSIS
• After a thorough history and physical examination have
been performed, noncontrast computed tomography (CT)
is the study of choice in diagnosing cerebral hemor-
rhage. Location of the blood may also provide a clue as
to the etiology. For example, bleeding into the basal
ganglia, pons, or cerebellum in a patient with a history
of hypertension usually results from a rupture of deep
perforating arteries, whereas single or multiple hemor-
rhages extending to the cortical surface in an elderly
person point to amyloid angiopathy as the culprit.
• MRI and angiography may be useful if the cause of
hemorrhage is uncertain or a structural abnormality
such as an AVM or a tumor is suspected.
• Lumbar puncture (LP) should be avoided in these
patients since they often have increased intracranial
pressure (ICP) and are at risk for herniation.
• A complete laboratory evaluation, particularly look-
ing for coagulopathy, infection, and electrolyte distur-
bances should also be performed on every patient.
TREATMENT: MEDICAL
• The initial evaluation should include global assess-
ment of neurologic function, such as the Glasgow
Coma Scale (GCS). Patients with a GCS score of <8
are at risk for airway compromise and should be elec-
tively intubated. Intubation should be performed by
well-trained personnel and induction agents such as
etomidate or propofol, known not to increase ICP,
should be used for induction. Once mechanical venti-
lation is established, rate and tidal volume should be
set to keep PaCO2 between 30 and 35 mmHg (Table
70-2, Fig. 70-3).
• Intravenous (IV) fluids should be initiated in order to
achieve euvolemia and maintain adequate intravascular
volume to optimize cerebral perfusion. Hypervolemia,
which can worsen cerebral edema, should be avoided.
• Any underlying coagulopathy driving the hemorrhage
should be corrected as quickly as possible. This is best
done with fresh frozen plasma and parenteral vitamin
K (in warfarin or liver failure-associated bleeds) or
protamine sulfate for heparin-induced bleeding.
Activated factor VII (NovoSeven) presents an attrac-
tive alternative because of rapid onset of action and
small fluid volume that needs to be delivered, but is
currently limited by lack of availability and price.
• Seizure activity is frequent in intracerebral bleeding, at
the time of the event or shortly after, and can increase
ICP and cause further neuronal damage. Patients need
to be carefully monitored for signs of seizure and
FIG. 70-1 Hematoma expansion in ICH after 3 hours.
FIG. 70-2 Location and CT images of common sites of ICH
with hypertension.
seizures should be controlled immediately with IV
lorazepam, followed by IV phenytoin, although anti-
convulsive prophylaxis is not generally recommended.
• Blood pressure management in ICH is controversial.
Hypertension, sometimes severe, is common after a
parenchymal bleed, but is often self-limited. The mean
arterial pressure (MAP) should be kept between 100 and
120 mmHg, to maintain brain perfusion without
increasing the edema surrounding the hematoma.
Agents such as beta-blockers, calcium channel blockers,
and angiotensin-converting enzyme (ACE) inhibitors
are generally considered safe, since they do not increase
ICP, while nitrates and sodium nitroprusside are gener-
ally avoided since they can suddenly increase ICP.
• ICP monitoring and management are important in
taking care of ICH patients. Monitoring is accom-
plished by using ICP bolts or ventriculostomies. The
advantage of the latter is in that they can be used to
draw off cerebrospinal fluid (CSF) and decrease ICP
rapidly. Several other methods for controlling ICP
exist. Hyperventilation can rapidly lower ICP by
inducing vasoconstriction, but its effects are short-
lived, and thus it is used only to establish early and
quick control of ICP. Mannitol, a hexose sugar, is
commonly used to treat increased ICP. It is believed to
draw interstitial fluid into the vasculature and thus
decrease brain volume. It is usually administered as
IV boluses whenever ICP becomes elevated—
continuous infusion is generally avoided because of
fear of actually increasing brain edema through leak-
age of mannitol into the hematoma.
• Finally, prevention and treatment of medical complica-
tions, such as gastric ulcers and infection, is essential.
Fever in particular should be aggressively evaluated
and treated, since hyperthermia is deleterious to neu-
ronal function.
TREATMENT: SURGICAL
• The role of surgery in ICH is uncertain, due to lack of
large randomized-controlled studies and negative
results in studies that have been performed. Despite
this fact, surgery is often performed, particularly in
patients with large hematomas and rapid neurologic
deterioration. It is generally accepted that urgent sur-
gical removal of a hematoma is indicated for infraten-
torial lesions >3 cm or smaller lesions that are causing
brain stem compression. However, most of the avail-
able evidence (including a recently completed STICH
[Surgical Treatment of Ischemic Heart Failure] trial)
tends to show that surgery is likely of little or no ben-
efit in most ICH patients.
SUBARACHNOID HEMORRHAGE
• Spontaneous SAH is defined as bleeding into the sub-
arachnoid space, usually due to a ruptured intracranial
aneurysm, although it can also occur with a rupture of
an AVM or be secondary to trauma. Its incidence is
about 25,000–30,000 cases/year and the event carries
a 50% 30-day mortality, with many survivors left with
devastating neurologic deficits and disability.
PATHOPHYSIOLOGY
• 3–4% of the American population carries aneurysms,
for a prevalence of 8–10 million people.
• Aneurysms are most commonly located at the bifur-
cation of arteries in the circle of Willis, usually in the
anterior circulation.
• Most ruptured aneurysms are >7 mm in diameter,
although it is still difficult to predict which asympto-
matic aneurysms will rupture.
• As the aneurysm forms and grows, a neck and a dome
are created. In the neck, internal elastic lamina disap-
pears, media thins, and connective tissue replaces
smooth muscle cells, thinning the arterial wall. The
dome is the most common site of rupture, with the
actual tear usually being no more than 0.5 mm in length.
CLINICAL PRESENTATION
• The classic presentation of SAH is the abrupt onset of
excruciating headache, often described by patients as
the worst headache of their lives. In about 50% of
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TABLE 70-2 Acute Management of ICH
TYPE TREATMENT
Airway Intubation and mechanical ventilation if patient
has aspiration, neurogenic pulmonary edema.
GCS motor score of withdrawal, or worse
Fluid 2–3 L of 0.9% NaCl per 24 h
Fludrocortisone acetate, 0.3 mg/day if patient
has hyponatremia
Blood Accept MAP of ≤130 mmHg. If MAP is
>130 mmHg, esmolol bolus, 500 µg/kg in
1 min; or labetalol, 20 mg IV in 2 min; or
enalaprilat, 0.625 mg IV in 5 min
Nutrition Enteric nutrition with continuous infusion on
day 2
Additional measures Nimodipine, 60 mg 6 times a day for 21 days
Stool softener
Pneumatic compression devices
Acetaminophen with codeine or morphine,
1–2 mg, or tramadol (if no seizures), 50–100 mg,
orally every 4 h for pain management
Phenytoin, 20 mg/kg if seizures have occurred
SOURCE: Adapted from Wijdicks EF, Kallmes DF, Manno EM, et al.
Subarachnoid hemorrhage: neurointensive care and aneurysm repair.
Mayo Clin Proc 2005;80:550–559.
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patients, sudden and transient loss of consciousness fol-
lows the headache. The pain is generalized and vomit-
ing is common.
• Although less frequent than with ICH, focal neuro-
logic signs can occur with SAH. They range from 3rd
and 6th nerve palsies (most common) to hemiparesis,
nuchal rigidity, and aphasia. The cranial nerve palsies,
when seen before the rupture, may cause prodromal
symptoms of an enlarging aneurysm and should alert
the clinician to that possibility.
• Occasionally, small leaks of blood escape from an
aneurysm, causing sudden headache that is transient.
These so-called sentinel bleeds often signal imminent
rupture and should be immediately diagnosed and
addressed.
COMPLICATIONS OF SAH
• There are four major complications that occur in
patients after SAH and which cause the majority of
morbidity and mortality in those who survive the ini-
tial event. Their management will be further discussed
in the Treatment section of this chapter.
 Rerupture: The incidence of rerupture of an
untreated aneurysm is about 30%, mostly occurring
in the first 48 hours after the initial event and having
a 60% mortality.
 Hydrocephalus: This can occur suddenly and usually
presents as stupor or coma. Alternatively, hydro-
cephalus can develop over several days and present
as progressive drowsiness, incontinence, and slowed
mentation.
Medical management
Obtain patient history; perform baseline laboratory
evaluation, emergent head CT, neurologic assessment
GCS score ≤8, or progressive
neurologic deterioration,
or respiratory insufficiency
Coagulopathy is present Seizures occur or
cortical hemorrhage MAP > 130 mmHg
Intubate patient; set
ventilator to initially maintain
PCO2 at 30–35 mmHg
Correct with fresh frozen
plasma, 15 mL/kg of body
weight, and vitamin K, 2 mg IV
Consider phenytoin load of
10–15 mg/kg of body weight
Consider treatment to decrease
by 15% with use of labetalol,
10–20 mg IV daily over 15 min,
or hydralazine, 10–20 mg IV
every 15 min as needed, or
nicardipine infusion, 5–15 mg/h
Supportive care for stabilized patient
 Neurologic assessments every 1–2 h 
 IV fluids-normal saline with electrolyte replacement at maintenance rates
 Acetaminophen, cooling blankets to maintain temperature below 37.5°C
 Sequential compression devices
 Prophylaxis for gastric ulcers
Patient has GCS score ≤8 or neurologic deterioration
Place ICP monitor
Treat ICP >20 mmHg
 Hyperventilation
 Mannitol, 0.25–1.0 g/kg of body weight as needed
FIG. 70-3 Medical management of ICH.
 Vasospasm: This narrowing of the arteries at the base
of the brain is a common occurrence, peaking at
7 days after initial bleed and causing infarction, with
its adherent morbidity and mortality. This entity pres-
ents with sudden focal neurologic signs that vary
depending on the artery involved and can usually be
diagnosed with transcranial Doppler ultrasound
(TCD). In general, increasing amount of blood sur-
rounding an artery is predictive of an increasing prob-
ability of vasospasm.
 Hyponatremia: This can be severe and is the result
of inappropriate antidiuretic hormone (ADH) secre-
tion, developing in the first 2 weeks after the hem-
orrhage. The phenomenon, also known as “cerebral
salt-wasting syndrome” usually clears in 1–2 weeks
and occasionally requires water restriction.
DIAGNOSIS
• The hallmark of diagnosing SAH is the noncontrast
CT scan, which can detect blood in CSF in 95% of
cases within 72 hours of the event (Fig. 70-4).
• If CT is nondiagnostic and no mass lesions or hydro-
cephalus is present, an LP should be performed. The
diagnostic finding in the CSF is xanthochromia, or
yellow tinge of the fluid which appears within 6 hours
of the hemorrhage and has a 99% sensitivity.
• Once the diagnosis of SAH is established, a conven-
tional or CT/MR angiography is usually performed
to localize the aneurysm and help in planning
treatment.
TREATMENT: MEDICAL
• Medical management centers on optimizing the
patient’s status and minimizing neuronal damage
prior to surgical intervention. In general, patients with
a SAH and a GCS < 8 should be intubated for airway
protection, with ventilator settings that produce mild
hyperventilation (PaCO2 30–35 mmHg).
• Rebleeding is most common in the first 24 hours after
the initial hemorrhage. Prevention measures include
avoidance of straining, excessive stimulation, and
hypertension, and thus patients should be kept in a
quiet, darkened room.
• Precise blood pressure and intravascular volume con-
trol are important in maintaining brain perfusion and
preventing rebleeding and vasospasm. The target
MAP is between 100 and 120 mmHg, with euvolemia
or slight hypervolemia preferable. Hypertension often
occurs with SAH, precipitated by headache, increased
ICP, and an increased catecholamine drive and must
be aggressively managed with IV medications to keep
MAP at goal.
• Patients must be carefully monitored for signs of
hydrocephalus such as stupor or sudden change in men-
tation, which in the presence of enlarged ventricles on
CT are an indication for urgent ventriculostomy and
CSF drainage. Nonresolving hydrocephalus necessi-
tates permanent shunting.
• Vasospasm is a major complication of SAH and leads
to substantial morbidity and mortality. Daily monitor-
ing of intracranial vessels with Doppler ultrasound can
sometimes predict impending vasospasm, but is not
entirely reliable. The key to prevention and treatment of
vasospasm is to maintain slight hypervolemia and
hypertension. Once vasospasm occurs, aggressive
volume expansion and inducement of hypertension
(with vasoactive drugs) should be started and invasive
hemodynamic monitoring is recommended to optimize
volume and pressure management. Oral nimodipine, a
calcium channel antagonist, has been shown to improve
neurologic outcomes after vasospasm, but can also
cause hypotension. In refractory cases, balloon angio-
plasty of narrowed vessels may be considered, which
can produce good results in experienced hands. Once
begun, treatments for vasospasm should be continued
for several days, and then weaned gradually while
closely monitoring the patient. Vasoactive drugs should
be weaned first, and then the aggressive fluid therapy
may be gradually withdrawn.
• Anticonvulsants such as phenytoin decrease the fre-
quency of seizures in the perioperative period and are
often used prophylactically.
• Up to half of patients with SAH develop cerebral salt
wasting, with resulting hyponatremia that can be
severe. Free water should be restricted while assuring
that the patient does not become hypovolemic.
Occasionally, hypertonic saline is used to treat severe
hyponatremia.
• Deep vein thrombosis (DVT) prophylaxis should be
maintained in all patients with pneumatic compression
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FIG. 70-4 SAH with visible giant aneurysms in anterior cere-
bral artery (ACA; left) and middle cerebral artery (MCA; right).
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devices throughout the hospitalization, and laxatives
and stool softeners should be administered to prevent
constipation and straining.
TREATMENT: SURGICAL
• After initial medical optimization and delineation of
cerebral vascular anatomy, definitive surgical treat-
ment of the aneurysm should be undertaken as soon as
possible. Currently, two options for treatment exist—
endovascular coiling or surgical clipping. The choice
of technique depends on many factors, such as the
location of the aneurysm, the size of the dome relative
to that of the neck, clinical status of the patient, and
the center’s experience with the procedure. Data com-
paring the two approaches are scant and contradictory,
therefore, necessitating patient-by-patient decision
making (Fig. 70-5).
PREDICTORS OF OUTCOME
• The most important clinical factor predicting outcome
is the presenting level of consciousness, graded on a
World Federation of Neurosurgical Societies (WFNS)
grading scale, with grades IV or V (out of five) predict-
ing a >90% mortality, although with aggressive care up
to 50% of grade IV and 20% of grade V patients can
survive with favorable outcomes (Table 70-3).
• The size of the aneurysm and comorbid conditions
do not seem to influence the outcomes very much,
Hydrocephalus is present on CT or
secondary neurologic deterioration
due to intraventricular blood
Cerebellar hemorrhage >3 cm in
diameter or hemorrhage of any size
with neurologic deterioration
Large accessible cortical hematoma
or secondary neurologic deterioration
in young patient
Place external ventricular drain Surgical evacuation Consider surgical evacuation
Supportive care for stabilized patient
 Neurologic assessments every 1–2 h
 IV fluids-normal saline with electrolyte replacement
 at maintenance rates
 Acetaminophen, cooling blankets to maintain
 temperature below 37.5°C
 Sequential compression devices
 Prophylaxis for gastric ulcers
Place ICP monitor
Treat ICP >20 mmHg∗
 Hyperventilation
 Mannitol, 0.25–1.0 g/kg of body weight as needed
Patient has GCS score ≤8 or neurologic deterioration
Surgical management
Obtain patient history; perform baseline laboratory
evaluation, emergent head CT, neurologic assessment
FIG. 70-5 SAH management.
while factors such as the age, development of
vasospasm, and intracerebral extension do play a
significant role.
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71 ANOXIC ENCEPHALOPATHY
Maria Dowell
KEY POINTS
• Anoxic encephalopathy is the most common cause of
coma in most critical care units.
• Cardiac arrest is the most common cause of global
brain ischemia. Amongst early postarrest survivors,
roughly 30% leave the hospital but 90% are unable to
resume their former full activities due to persistent
neurologic deficits.
• Other potential causes of brain ischemia or anoxia
include severe hypotension, cardiac failure, strangula-
tion, cardiopulmonary bypass, status epilepticus, dif-
fuse cerebral atherosclerosis, increased intracranial
pressure (ICP), cerebral artery spasm, closed head
trauma, fat embolism, multivascular in situ clotting
(disseminated intravascular coagulation [DIC]), vas-
culitides affecting the cerebral vessels, and hypervis-
cosity states.
• The degree of neuronal injury depends on the degree
of mismatch between metabolic demand and delivery
of oxygen and glucose to the brain.
PATHOPHYSIOLOGY
• Cerebral blood flow and metabolism during and after
cardiopulmonary resuscitation (CPR) is complex.
Twenty seconds after cessation of cerebral blood flow,
neuronal oxygen stores are depleted and unconscious-
ness results. Within 5 minutes of cerebral anoxia, brain
glucose and adenosine triphosphate (ATP) stores are
depleted. Biochemical changes that may be involved
include increased intracellular calcium, release of neu-
rotoxic excitatory amino acids, superoxide production,
and brain lactic acidosis. After cerebral anoxia, transient
reactive global hyperemia resulting from vasoparalysis
persists for 15–30 minutes. Thereafter, postischemic
cerebral hypoperfusion is present for 2–12 hours.
• There is some evidence that if cerebral blood flow can
be maintained during hyperemia, brain recovery may
be enhanced. The mechanisms responsible for injury
are poorly understood but may relate to diffuse arterial
spasm, calcium influx, vasoconstrictor prostaglandins,
and intravascular coagulation.
• Distinct regions of the brain exhibit special vulnerabil-
ity to ischemia (hippocampus, neocortex, cerebellum).
DIAGNOSTIC APPROACH
TO ANOXIC COMA
• Level of consciousness: This should initially be
assessed by verbal stimulation, then if no response, a
shout and gentle shake. Noxious stimuli can be applied
by digital supraorbital pressure. Painful stimuli should
be avoided.
• Motor response: The finding of flaccidity and areflexia
indicate severe brainstem depression. Extensor postur-
ing responses correlate with deep lesions of the mid-
brain and upper pons. Flexor posturing responses
occur after damage to the hemispheres. Withdrawal
and localizing responses imply voluntary behavior and
obeying commands marks the return of consciousness.
• Neurophthalmologic function: This is assessed by pupil-
lary size and response to light, spontaneous eye move-
ments, oculocephalic and oculovestibular responses.
Papilledema is not a reliable indicator of ICP in the post-
cardiac arrest period. Absence of elicited eye move-
ments is a grave sign. Spontaneous, roving, horizontal
eye movements indicate only that midbrain and pontine
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TABLE 70-3 WFNS Grading System
WFNS GRADE GCS SCORE MOTOR DEFICIT
I 15 Absent
II 14–13 Absent
III 14–13 Present
IV 12–7 Present or absent
V 6–3 Present or absent
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areas are intact but do not imply an intact frontal or
occipital cerebral cortex.
• Diagnostic imaging: Imaging by computed tomogra-
phy (CT) scan often fails to show abnormalities in early
stages. One may see focal infarcts, edema, and atrophy
days after the injury. Magnetic resonance imaging
(MRI) may provide more useful detail at an earlier
stage. Electroencephalogram (EEG) is a sensitive indi-
cator in assessing the degree of cortical dysfunction and
the presence of epileptic activity.
MANAGEMENT
• Clinical management involves the restoration of ade-
quate cardiopulmonary function to prevent further
cerebral injury. Neuropathologic abnormalities can
continue for hours to days and no simple therapy
exists that can reverse anoxic damage.
• States of reduced cerebral energy requirements such
as hypothermia may prevent or reduce the extent of
cerebral injury. Hyperglycemia, cerebral lactic acido-
sis, dysregulation of calcium homeostasis, elevated
ICP, and excessive release of excitatory neurotrans-
mitters can increase ischemic cerebral damage.
• Several clinical trials have demonstrated significant
benefit in survival and neurologic outcome by the use
of cooling to 32–34°C following cardiac arrest.
Postarrest cooling was induced by applying cooling
blankets or ice packing in a subset of patients having
return of spontaneous circulation but remaining unre-
sponsive. Cooling should be achieved as rapidly as
possible and temperature should be measured every
15–30 minutes during cooling via bladder probe, pul-
monary artery catheter, or tympanic probe if invasive
monitoring is not available. Patients uniformly require
neuromuscular blockade and sedation to minimize
shivering and discomfort. Passive rewarming is then
started 24 hours after the initiation of cooling. The
optimal method, depth, and duration of cooling as
well as the therapeutic window will likely require fur-
ther investigation before this approach is widely
accepted in the guidelines for resuscitation. Initiation
of hypothermia induces diuresis and careful attention
to intravascular volume and electrolytes during cool-
ing and rewarming is required.
• It has been postulated that hyperglycemia contributes to
cerebral damage, therefore, limiting glucose solutions
in the immediate postarrest period seems prudent.
• Elevated ICP after cardiac arrest indicates a severe
degree of anoxic damage and therapy to reduce ICP in
this setting is controversial. 
• Corticosteroids and barbiturates have no role in
postarrest management.
NEUROLOGIC OUTCOMES AFTER
CARDIAC ARREST
• Patients in a coma less than 12 hours after resuscita-
tion usually make a favorable recovery. Comas lasting
more than 12 hours often have neurologic deficits due
to focal or multifocal infarcts of the cerebral cortex.
• Somatosensory evoked potentials (SEPs) have the
highest prognostic reliability and are the most fre-
quently applied method in clinical and experimental
studies evaluating outcome after CPR. Bilateral
absence of median nerve-stimulated SEPs is associated
with a <1% chance of awakening from coma since it
implies that widespread cortical necrosis has occurred.
Importantly, the presence of cortical responses is not a
guarantee for awakening from coma.
• Serum levels of molecular markers for brain injury are
under study to detect the extent of cerebral damage and
neurologic outcome after CPR. Increased levels of
neuron-specific enolase (NSE) and the astroglial pro-
tein S100 are associated with hypoxic-ischemic brain
injury and poor neurologic outcome. Interestingly,
decreased levels of NSE, but not S100, was found in
the majority of patients with therapeutic hypothermia
and was associated with better neurologic outcome.
• Early in the course of hypoxic-ischemic encephalopa-
thy, several neurologic signs can predict outcome with
some reliability.
• Absence of pupillary responses on the first day or
absence of corneal reflexes after the first day follow-
ing CPR predicts poor outcome. If there are no pur-
poseful motor responses after 3 days, there is a high
risk of persistent vegetative state or severe disability.
• Verbal responses, purposeful eye movements or motor
responses, normal ocular reflexes, and response to
verbal commands at 1 day following CPR predict at
least a 50% chance of regaining independent function.
Patient age, gender, or presence of postanoxic seizure
failed to correlate with outcome.
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72 THERAPEUTIC
HYPOTHERMIA
John E.A. Blair, Raina M. Merchant
KEY POINTS
• Hypothermia is thought to blunt the effects of neuro-
logic damage from ischemia-reperfusion injury.
• Several methods of cooling exist, with external cool-
ing being inexpensive but slow, cumbersome, and dif-
ficult to control. Several invasive methods exist such
as extracorporeal cooling and cold intravenous fluids,
each with their characteristic features.
• Hypothermia places patients at increased risk for
arrhythmias, coagulopathies, infection, and metabolic
derangements. The incidence and severity of these
complications increases when core temperature is
<30°C, but careful monitoring is necessary for any
degree of hypothermia.
• Hypothermia may improve mortality and neurologic
outcomes after cardiac arrest. Clinical trials are con-
flicting regarding its use in traumatic brain injury,
with some suggestion that benefits may derive from
maintaining the hypothermic state for longer than
48 hours. Its use in stroke and neurologic fever still
requires further investigation.
• There are other clinical situations where therapeutic
hypothermia may prove beneficial such as subarach-
noid hemorrhage, neuroprotection during invasive sur-
geries, myocardial infarction, and acute liver failure.
It is important for staff in intensive care units to be
aware of the complications of this potentially useful
intervention.
HISTORY
• The use of hypothermia for clinical purposes origi-
nates in ancient times, with use by Egyptians, Greeks,
and Romans. Hippocrates advocated packing
wounded patients in snow to reduce hemorrhage. In
the nineteenth century, Napoleon’s Surgeon General
Baron Larrey found that injured soldiers who became
hypothermic were more likely to die if they were
placed close to the fire than those with more gradual
rewarming.
• Case reports of successful resuscitation of hypothermic
drowning victims despite long periods of asphyxia in
the 1930s and 1940s led to animal experiments in the
1950s demonstrating benefit from hypothermia during
or after focal brain ischemia and traumatic brain injury.
• Several small trials were conducted in the 1960s using
hypothermia for various brain injuries, but were dis-
continued due to side effects, uncertain benefit, and
management problems.
• Research in therapeutic hypothermia was rekindled in
the 1980s when animal studies showed benefits from
mild (defined as core body temperature of 32–35°C in
most studies) hypothermia with fewer side effects
than deeper hypothermia used earlier. In addition,
larger clinical trials became more feasible as the capa-
bilities of intensive care units grew.
RATIONALE
• Therapeutic hypothermia is thought to preserve neu-
ronal function in several types of brain injury. Much
of what is known about the neuroprotective mecha-
nisms is based on animal models.
• Hypothermia has been clearly shown to be neuropro-
tective if applied early enough in many animal exper-
iments involving both global ischemia (simulating the
clinical circumstance of cardiac arrest or near drown-
ing), and focal ischemia models (simulating the clini-
cal circumstance of stroke).
• Favorable neurologic outcome after brain injury
depends on rapid restoration of circulation followed
by blunting or prevention of the reperfusion response.
• Hypothermia is thought to suppress the reperfusion
response by suppressing many of the chemical reac-
tions associated with reperfusion injury, including
destructive enzymatic reactions, free radical produc-
tion, inflammatory cell invasion, excitatory amino
acid release, and mitochondrial damage that may sub-
sequently cause primary necrosis and/or trigger apop-
tosis (programmed cell death). Hypothermia may also
reduce cerebral edema and enhance cellular mem-
brane integrity.
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COOLING METHODS
• Two general methods of cooling are available: exter-
nal surface cooling and invasive cooling. The optimal
method has yet to be determined, as neither method
combines ease of use with efficacy.
• External cooling methods include cooling blankets,
cooling helmets, specially designed cooling beds, wet
towels, sprays, ice packs, fans, and immersion. These
methods are easily applied, but slow in reducing core
temperature.
• Invasive cooling methods range from the very com-
plex and expensive extracorporeal cooling to the
simple large-volume cold intravenous fluid infusions.
These methods are not as well studied as the external
cooling methods (Table 72-1).
SIDE EFFECTS
• There are several potential side effects of therapeutic
hypothermia that if encountered may counteract any
benefit from the intervention itself. Awareness of poten-
tial complications is essential. Generally, hypothermia
has effects in almost every organ system, but special
attention must be paid to the cardiovascular, hemato-
logic, immunologic, and metabolic systems.
• Cardiovascular: Initially, hypothermic patients
develop sinus tachycardia followed by bradycardia.
Most malignant arrhythmias develop after the tempera-
ture drops below 30°C, when atrial fibrillation may soon
lead to ventricular arrhythmias. To complicate matters,
arrhythmias become more difficult to treat at lower
temperatures. In addition to arrhythmias, hypother-
mia reduces cardiac output by approximately 25%.
Below 30°C, contractility decreases, causing both
systolic and diastolic dysfunction.
• Hematologic: Hypothermia increases bleeding time
due to a reduction in platelet count and function and
alteration of coagulation enzyme kinetics. Coagulation
tests such as prothrombin time and partial thrombo-
plastin time will remain normal unless performed at the
patient’s actual core temperature. Despite these abnor-
malities, none of the clinical trials studying patients
with traumatic brain injury (TBI), subarachnoid hem-
orrhage, or cardiac arrest experienced intracranial
bleeding with cooling.
• Immunologic: Hypothermia inhibits release of several
inflammatory cytokines and suppresses leukocyte
migration and phagocytosis. Clinically, this may pres-
ent as delayed wound healing and respiratory tract
infections.
• Other effects: Hypothermia seems to cause a reduction
in circulating volume through diuresis, which is often
profound. Low levels of the electrolytes magnesium,
potassium, inorganic phosphate, and calcium have also
been observed. Hypothermia can also impair insulin
sensitivity and secretion, often inducing hyperglycemia.
MONITORING
• Younger patients have a higher capacity to counteract
changes in temperature and are therefore more diffi-
cult to cool and require higher doses of sedatives than
older patients, who have a lower basal metabolic rate,
lower body mass index, and less effective vasocon-
striction. Obese patients are more difficult to cool
through external cooling methods due to the insulating
properties of fat.
TABLE 72-1 Cooling Methods
ADVANTAGE DISADVANTAGE
External cooling
Cooling blanket Special equipment needed, cumbersome
Cooling helmet Fast cooling times Special equipment needed
Specially designed cooling beds Special equipment needed
Wet towels, ice packs, alcohol or water sprays Simple, no special equipment needed Slow, difficult to titrate, cumbersome
Fans Associated with increased infection rates
Immersion Cumbersome
Invasive cooling
Extracorporeal venovenous cooling, Very invasive, cumbersome, requires specialist
peritoneal lavage to initiate and administer
Cooling catheter Temperature easily titrated and maintained Special equipment needed
Ice water nasal lavage Difficult to titrate
Large-volume ice-cold IV fluids Simple Short duration of effect
Antipyretic drugs May not induce hypothermia
• All patients receiving therapeutic hypothermia should
be comatose, intubated, and sedated, as these patients
are most likely to benefit from a therapy that improves
neurologic outcome.
• Shivering during cooling can generate heat and lead to
increases in oxygen consumption by 40–100%, both of
which are prevented by administration of neuromuscu-
lar blocking agents, sedatives, anesthetics, and opiates.
• Paralysis and sedation may make it difficult to assess
neurologic status and presence of seizures, so careful
monitoring for any new neurologic signs is warranted.
• Diligent monitoring for complications of hypothermia
along with early aggressive therapy against these
complications is necessary. For example, early elec-
trolyte supplementation and intensive insulin adminis-
tration may prevent arrhythmias and infections,
respectively.
• Hospitals should develop specific protocols and strict
guidelines for the initiation and monitoring of thera-
peutic hypothermia, with extensive education for all
members of the medical staff involved.
CLINICAL APPLICATIONS
OF HYPOTHERMIA
CARDIAC ARREST
• Two recent randomized, controlled trials have demon-
strated favorable neurologic outcomes after induction
of mild hypothermia in comatose patients surviving
out-of-hospital ventricular fibrillation (VF) arrest.
• The hypothermia after cardiac arrest (HACA) group
randomly assigned the use of a cooling blanket to cool
137 of 235 comatose survivors in out-of-hospital VF
in 9 European centers to a target temperature of
32–34°C for 24 hours. Primary and secondary out-
comes were favorable 6-month neurologic function
and mortality, respectively, which were significantly
improved in the hypothermia group.
• An Australian group randomly cooled 43 of 77 car-
diac arrest victims in 4 centers to a goal temperature
of 33°C for 12 hours by applying cold packs to the
head, neck, torso, and limbs. The primary outcome of
favorable neurologic function at discharge was signif-
icantly improved in the patient undergoing therapeu-
tic hypothermia.
• A recent meta-analysis of these studies found that
patients in the hypothermia group were more likely to
have no or minimal neurologic damage at discharge
(relative risk [RR] 1.68, 95% confidence interval [CI]
1.29–2.07, number needed to treat [NNT] 6). There
was a trend toward improved survival at discharge in
the hypothermia group.
• The HACA trial reported 6-month outcomes. Being
alive at 6 months with favorable functional neurologic
recovery was more likely in the hypothermia group
(RR 1.40, 95% CI 1.08–1.81, NNT 6). There was also
improved survival at 6 months in the hypothermia
group (RR 0.74, 95% CI 0.58–0.95, NNT 7).
• Current recommendations from the International
Liaison Committee on Resuscitation (ILCOR) and
American Heart Association (AHA) state that uncon-
scious adult patients with spontaneous circulation
after out-of-hospital cardiac arrest should be cooled
to 32–34°C for 12–24 hours when the initial rhythm
was VF.
• Such cooling may also be beneficial for other rhythms
or for in-hospital cardiac arrest. Studies regarding
these types of arrests are ongoing.
TRAUMATIC BRAIN INJURY
• Traumatic brain injury (TBI) is any brain injury sus-
tained from externally inflicted trauma. Common
causes include motor vehicle crashes, falls, acts of
violence, and sports injuries. In the United States, TBI
accounts for approximately 270,000 hospitalizations,
52,000 deaths, and 80,000 patients with permanent
neurologic deficits.
• In treating TBI, the majority of neurologic damage
occurs not at the initial impact, but at later stages
during the hospitalization. Most interventions for TBIs
are focused on prevention of this secondary neurologic
injury.
• The secondary injury from TBI often stems from cere-
bral edema and increased intracranial pressures (ICP)
which damage injured areas of the brain, as well as
the release of substances such as glutamate, nitric
oxide, and free radicals, both thought to be mitigated
by hypothermia.
• There have been several clinical studies using
hypothermia for TBI reliably demonstrating a reduc-
tion in ICP. However, the studies were conflicting as
to whether this reduction translates to improvement in
mortality and neurologic outcome.
• A thorough meta-analysis of the literature demon-
strated a small but statistically significant mortality
(RR for death 0.81; 95% CI 0.69–0.96) and neuro-
logic (RR for a poor neurologic outcome 0.81; 95%
CI 0.69–0.96) benefit in TBI survivors who were
cooled to a target temperature of 32–35°C. These ben-
efits seemed to be even greater in patients cooled for
>48 hours.
• Since the meta-analysis, two large single-center trials
reported favorable mortality and neurologic outcomes
when mild hypothermia was applied for >48 hours,
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and the rate of rewarming was slower compared to
previous studies. In contrast, the only multicenter trial
studying hypothermia for TBI patients showed no
mortality or neurologic benefits.
• The differences in outcomes between studies seem to
be multifactorial, related to the length of time spent
cooled, rate of rewarming, expertise in specific cen-
ters, and procedural variations between studies.
• Therapeutic hypothermia for TBI is a complex under-
taking and should be performed with caution in tertiary
care centers with expertise in the area. Since mortality
and survival benefit seem to appear after cooling for
48 hours, careful monitoring and management of com-
plications from hypothermia should be performed.
STROKE
• There is strong evidence in animal models that thera-
peutic hypothermia is an effective strategy in control-
ling stroke. Despite these data, very few clinical trials
have been conducted using hypothermia for human
stroke patients.
• A focal ischemic event causes necrosis in a central
core region nearest the occluded vessel. Surrounding
that core is an area of hypoperfused but functional
neurons at risk of necrosis called the penumbra. The
penumbra will become necrotic unless perfusion is
restored or other interventions initiated.
• Hypothermia is thought to reduce the damage caused
by hypoperfusion and therefore the size of the
ischemic penumbra through mechanisms previously
described. It also may reduce resultant cerebral edema
caused by the stroke.
• To date, there are no published randomized, con-
trolled trials using hypothermia as part of therapy for
stroke. There have been several uncontrolled feasibil-
ity trials with varying protocols for patients with
middle cerebral artery (MCA) infarction, confirming
the safety of hypothermia in this setting. Outcomes
after cooling are yet to be determined.
• Although a promising strategy for neuroprotection,
hypothermia for stroke remains experimental.
Randomized, controlled trials need to be performed in
order to define the role of hypothermia for stroke in
the future.
NEUROLOGIC FEVER
• Fever is a very common phenomenon among neuro-
logic patients in the intensive care unit, affecting many
patients with ischemic stroke, head injury, intracranial
hemorrhage, and subarachnoid hemorrhage.
• Several studies have found a significant association
between fever and outcomes after TBI, intracerebral
hemorrhage, subarachnoid hemorrhage, and stroke
independent of other factors such as extent of neuro-
logic injury and comorbidities.
• Animal studies have demonstrated that elevated brain
temperatures may lead to greater release of excitatory
amino acids and free radicals, breakdown of the
blood-brain barrier, inhibition of protein kinases, and
cytoskeletal proteolysis leading to more profound
neuronal death in global and focal brain ischemia
models.
• Theoretically, keeping core body temperature and
therefore brain temperature normothermic in patients
with neurologic injury slows the destructive processes
associated with brain hyperthermia.
• Administration of antipyretics such as acetaminophen
or cooling blankets for fever in neurologic patients
has not proven efficacious in lowering temperature,
indicating a role for more intense forms of cooling in
these settings.
• Randomized, controlled trials have not been con-
ducted to assess outcomes after cooling for fever in
neurologic patients, but a trial is underway by the
Copenhagen Stroke Study.
• Cooling neurologic patients with fever remains of the-
oretical benefit. In managing these patients, it is
important to rigorously search for foci of infection.
OTHER POTENTIAL USES OF HYPOTHERMIA
• Subarachnoid hemorrhage: Data are limited to animal
studies which show a reduction of cerebral vasospasm
and decrease in ICP.
• Intraoperative hypothermia: Small clinical studies
have shown neurologic protection using hypothermia
in patients undergoing cerebral aneurysm clipping,
cardiac surgery, and spinal cord protection in thora-
coabdominal aortic aneurysm repair.
• Myocardial infarction: A pilot study demonstrated that
hypothermia is feasible in the setting of percutaneous
coronary intervention after myocardial infarction.
• Acute liver failure: Animal models demonstrate that
hypothermia may be beneficial in lowering ICP in
hepatic encephalopathy.
CONCLUSIONS
• Therapeutic hypothermia is a promising strategy for
controlling the neurologic damage that follows many
injuries to the brain.
• Intensivists should be aware of the side effects of
hypothermia and take great care to prevent and treat
them.
• Future research will help determine the clinical sce-
narios in which therapeutic hypothermia should be
used, as well as the specifics of effective cooling
protocols.
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73 STATUS EPILEPTICUS
D. Kyle Hogarth
KEY POINTS
• Status epilepticus (SE) is defined as a protracted
seizure episode or multiple frequent seizures lasting
30 minutes or longer. There is no interictal return to
baseline mental status.
• Single seizures that persist longer than 5–7 minutes
should be treated to prevent progression to SE.
• Recommended treatment is lorazepam 0.1 mg/kg
intravenously.
• Delay in recognition and treatment of seizures is asso-
ciated with increased mortality, and prolonged seizure
duration is a negative prognostic factor.
EPIDEMIOLOGY
• The incidence of generalized convulsive status epilep-
ticus (GCSE) in the United States is estimated to be
up to 195,000 episodes per year.
• In adults, cerebrovascular disease and noncompliance of
anticonvulsive medications are the most common causes
of SE. Central nervous system (CNS) infection, neo-
plasm, and metabolic disturbances can also cause SE.
• Three major factors determine the outcome of patients
with SE: the type of SE, the etiology, and the duration
of seizure.
• Causes associated with increased mortality included
anoxia, intracranial hemorrhage, tumor, infection, and
trauma.
• SE in the setting of acute ischemic stroke has a very
high mortality, approaching 35%.
CLASSIFICATION
• The simplest classification scheme divides SE into
GCSE and nonconvulsive SE (NCSE), depending on
whether convulsive movements are present.
• Inadequately treated GCSE can become NCSE. After
prolonged generalized convulsions, visible motor
activity may stop, but the electrochemical seizure con-
tinues. The patient is still seizing!
• Patients who do not start to awaken after 20 minutes
of GCSE should be assumed to have entered NCSE.
• Management of NCSE should be guided by the elec-
troencephalogram (EEG).
• A high suspicion for NCSE should be maintained in
patients with unexplained alteration in level of
consciousness.
PATHOPHYSIOLOGY
• The systemic manifestations of early phase GCSE result
from an adrenergic surge and excessive muscle activity.
The adrenergic surge causes tachycardia, hypertension,
and hyperglycemia.
• The systemic manifestations of late phase GCSE relates
to complications of extreme muscle activity; hyperther-
mia, acidosis, rhabdomyolysis, and secondary acute
renal failure.
CLINICAL MANIFESTATIONS
• Seizure recognition in the ICU can be difficult to
diagnose for the following reasons:
 Nonconvulsive seizures in the setting of depressed
consciousness
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 Masking of seizures by pharmacologically induced
paralysis or sedation
 Misinterpretation of other abnormal patient move-
ments as seizures
• Tachycardia, tachypnea, and hypertension are often
signs of seizure that can be misinterpreted as evidence
of inadequate sedation.
• Patients with metabolic disturbances, anoxia, and other
types of nervous system injury may demonstrate abnor-
mal movements that can be confused with seizure.
Myoclonus in postanoxic coma can occur in the pres-
ence and absence of epileptiform discharges.
INITIAL MANAGEMENT
• The initial approach to seizure management involves the
ABCs: airway, breathing, and circulation. Medication to
treat tachycardia and hypertension before the seizure
activity stops is not warranted.
• The conventional agents used for first-line treatment
of SE are the benzodiazepines, phenytoin, and pheno-
barbital. Lorazepam is more efficacious than pheny-
toin, and easier to use than phenobarbital for GCSE.
• A single intravenous dose of 0.1 mg/kg of lorazepam
is recommended therapy.
• If lorazepam is not available, a single intravenous dose
of 0.15 mg/kg diazepam can be given, but phenytoin or
phenobarbital should also be started as the duration of
action of diazepam against SE is only about 20 minutes.
• If there is no intravenous access, 0.2 mg/kg of mida-
zolam administered intramuscular will be rapidly and
reliably absorbed.
• Phenytoin is useful in SE, but the prolonged loading time
limits its usefulness acutely. However, a 20 mg/kg dose
of phenytoin produces an adequate serum level for the
next 24 hours and should be begun for the patient in SE.
• Phenobarbital in the management of acute SE is not
routinely recommended.
OTHER MANAGEMENT ISSUES
• Seizures in ICU patients have many potential causes
that must be investigated. Medications are a major
cause of seizures in critically ill patients, especially in
the setting of renal or hepatic dysfunction.
• Recreational drugs are frequently overlooked but can
cause seizures. Acute cocaine or methamphetamine
intoxication is characterized by a state of hypersympa-
thetic activity followed by seizures. Ethanol withdrawal
can obviously cause seizures and narcotic withdrawal
may produce seizures in the critically ill.
• Serum glucose, electrolyte concentrations, and serum
osmolality should be measured. Dextrose and thiamine
should be administered if hypoglycemia is present.
• New-onset seizures warrant brain imaging. Computed
tomography (CT) scanning is rapid and can detect
acute blood, swelling, large tumors or abscesses, and
subacute or remote ischemic strokes.
• When CNS infection is suspected, empiric antibiotic
treatment should be started while imaging studies are
being obtained.
REFRACTORY STATUS EPILEPTICUS
• In refractory SE (RSE), cessation of EEG seizure
activity is the goal.
• High-dose barbiturates, most commonly pentobarbi-
tal, are extremely useful in RSE, but side effects of
hypotension can be severe and may limit use.
• If successful in stopping RSE, barbiturate anesthesia
should not be rapidly discontinued. Therapy should be
continued for at least 48 hours after cessation of EEG
seizure activity. Then, a gradual taper of the dose
should occur with the administration of phenobarbital
during the drug taper.
• Pentobarbital is loaded at 5–12 mg/kg followed by an
infusion of 1–10 mg/kg/h. Thiopental sodium may be
given in 75–125 mg IV boluses followed by infusion
rates of 1–5 mg/kg/h as an alternative agent.
• Midazolam can be loaded at 0.2 mg/kg followed by
continuous infusion of 0.05–2.0 mg/kg/h for RSE.
• There are only case report data supporting propofol
use in SE.
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74 ACUTE SPINAL CORD
COMPRESSION
Nuala J. Meyer
KEY POINTS
• Acute and subacute spinal disorders are frequently the
result of extramedullary compression of the spinal cord.
• Compression may result from trauma, tumor, infec-
tion, or spondylosis.
• In the multiple injured trauma patient, a spinal injury
should be assumed present and unstable until ade-
quately assessed. A stable injury is one in which only
one of the columns (anterior, middle, or posterior) is
involved, and no further neural structures are in danger.
• The hallmark of spinal cord disease is the presence of a
level below which sensory, motor, or autonomic nerv-
ous function is impaired, and the determination of this
level may be invaluable in localizing the site of injury.
• Outcome of spinal injury is extremely dependent on
the extent of injury at the time of diagnosis; complete
cord injuries have no potential for functional recovery,
whereas incomplete injuries have recovery potential.
Evolving spinal injuries must be recognized early in
order to maximize the potential for recovery. After
48 hours, fixed paralysis is unlikely to be reversed.
PATHOPHYSIOLOGY
• Anatomically, the spinal column is surrounded by a
ring of bones made up of vertebral bodies anteriorly
and spinous processes and pedicles posteriorly.
Within the ring lies the epidural space, the dura, and
the thecal sac. Compression of the thecal sac may be
asymptomatic, or may progress to complete paraple-
gia, strangulating the spinal cord.
• The pattern of cord compression determines the pat-
tern of injury.
 Anterior cord syndrome results in loss of all spinal
cord function—motor, sensory, and autonomic—
below the level of the lesion, with only positional
and vibratory sense preserved. This occurs most fre-
quently from clot, compression, or ischemia of the
anterior spinal artery or from anterior compression
of the cord.
 Central cord syndrome, caused by hemorrhage within
the cord, classically incites arm weakness worse than
leg weakness, with variable sensory deficits.
 Brown-Séquard syndrome is the result of complete
or partial transaction of the cord, typically from
blunt trauma or penetrating injury. It involves the
loss of motor function below the level on the ipsilat-
eral side, with loss of contralateral pain and temper-
ature function.
LOCALIZING SIGNS
• High cervical cord injuries are frequently life threat-
ening due to weakness of respiratory muscles and
diaphragm (C3-C5).
 When injury is extensive and involves the junction
of the cervical cord with the medulla, the outcome
is usually fatal from medullary cardiopulmonary
collapse.
 C4-C5 lesions lead to quadriplegia, but usually with
preserved breathing function due to a functional C3
lesion.
 Midcervical (C5-C6) lesions will cause loss of
biceps and brachioradialis reflexes.
 C7 injuries spare the biceps but weaken the hand and
wrist, whereas C8 lesions cause loss of wrist and
digit flexion.
• Thoracic cord lesions are mapped by their sensory
dermatomes. Landmarks include the nipple (T4) and
umbilicus (T10).
 Thoracic injuries may causes weakness of the lower
extremities, along with bowel, bladder, and sexual
dysfunction. Midline back pain is common.
 Upper and lower abdominal wall musculature is
paralyzed by lesions above T9, whereas below this
level only the lower muscles are affected.
• Lumbar cord injuries paralyze thigh flexion and
adduction at L2-L4, and cause loss of foot and ankle
motor function at L5-S1. The cremasteric reflex
reflects intact function at L1-L2.
• Sacral cord injuries or conus syndrome tend to spare
lower extremity motor function but cause saddle anes-
thesia with bowel, bladder, and sexual dysfunction.
NEOPLASTIC CORD COMPRESSION
• Most neoplasms affecting the spinal column in adults
are extramedullary, arising from metastases to the ver-
tebrae with epidural compression, as opposed to neo-
plasms of neural origin.
• Almost any malignancy has the potential to metasta-
size to vertebrae, but the most common to do so
include breast, lung, prostate, and renal cell cancer,
along with lymphoma and myeloma.
• Approximately 20% of patients with malignant spinal
cord compression are presenting with their initial
manifestation of cancer.
• Metastatic cord compression is most common in the
thoracic spine, followed by lumbosacral vertebrae.
• Bone destruction by tumor may cause vertebral col-
lapse, which in turn may compress the cord, cauda
equine, or individual nerve roots.
• Intradural tumors—mainly meningiomas and
neurofibromas—tend to be slow growing and benign.
• Primary tumors of the spinal cord are uncommon and
typically present as hemicord or central cord
symptoms.
214 SECTION 5 • NEUROLOGIC DISORDERS
CHAPTER 75 • DELIRIUM IN THE INTENSIVE CARE UNIT     215
CLINICAL PRESENTATION
• Pain is the common initial symptom in the vast major-
ity of patients.
 It may be nerve root pain or localized back pain.
 Most patients rate their pain as severe and progres-
sive, and worse with movement.
 In one study, patients had pain on average 3 months
prior to being diagnosed with cord compression.
• Motor weakness is present in more than 60% of patients
at diagnosis, and is classically symmetric lower extrem-
ity weakness.
• Sensory complaints are common and often begin 1–2
weeks before the diagnosis of cord compression.
• Bowel and bladder dysfunction are late findings in
cord compression, and while common at the time of
diagnosis, point to advanced compression.
• Ataxia or inability to walk is frequently present at
diagnosis, either due to weakness or spinocerebellar
dysfunction. One study found that only 18% of patients
were able to walk at the time of diagnosis.
DIAGNOSIS
• Plain radiographs or bone scan are inadequate studies
to diagnose compression of the thecal sac, as they are
insensitive—missing approximately 20% of cases—
and delay the definitive diagnostic study, the MRI or
myelogram.
• While MRI is less invasive and spares the patient a
lumbar puncture, myelogram may be especially help-
ful for a patient with intractable pain who is unable to
lie still. The two tests performed equivalently well in
studies of sensitivity and specificity.
TREATMENT
• Corticosteroids improved the percentage of patients
ambulatory at 3 and 6 months in one trial, and are gen-
erally used in high doses (Decadron 30 mg daily in
divided doses). Slightly lower doses may be used for
less severe symptoms, for example, when no weak-
ness is present.
• Radiation therapy is the definitive therapy for most
patients with malignant cord compression.
• Surgery—decompression or vertebral resection—
should be considered if compressive symptoms are
worsening despite radiotherapy, if the patient has
received his or her maximal allowable dose of radia-
tion already, or if a vertebral compression contributes
to the cord compression.
• Pain control with both opioids and nonopioid anal-
gesics is a mainstay of therapy.
EPIDURAL ABSCESS
• The classic triad for an infected fluid collection in the
epidural space is fever, back pain, and progressive
weakness.
 Back pain is almost invariably present, and may be
subacute or chronic.
 As the abscess expands, it induces edema and
thrombosis, compressing the spinal cord and poten-
tially leading to irreversible spinal injury.
• Risk factors for epidural abscess are immunocompro-
mised states, IV drug abuse, or skin infections. Infection
may arise from hematogenous spread (approximately
two-thirds of cases) or by direct extension from ver-
tebral osteomyelitis or decubitus ulcers (one-third).
• Staphylococcus aureus and other gram-positive
organisms are the most common to cause epidural
abscess, but tuberculosis remains an important cause
in the developing world.
• MRI is the diagnostic study of choice.
• Treatment is emergency decompressive laminectomy
and long-term antibiotic therapy.
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75 DELIRIUM IN THE
INTENSIVE CARE UNIT
Joseph Levitt
KEY POINTS
• Delirium is present when there is an acute change or
fluctuation in mental status, inattention, and either dis-
organized thinking or altered level of consciousness.
• Delirium is extremely common in the ICU but often
goes unrecognized.
• Development of delirium is associated with increased
mortality, prolonged hospital stay, and discharge to
long-term care facilities.
• Screening for delirium is simple and reliable and
should be a routine part of daily patient care.
• Many known risk factors exist but it is unclear if alter-
ing these factors can prevent delirium or its long-term
sequelae.
• Psychoactive drugs are major risk factors for develop-
ing delirium in the ICU. However, clinical data are
lacking to support detailed recommendations, other
than close monitoring for adverse effects and avoiding
oversedation.
PATHOPHYSIOLOGY
• Delirium should be considered a form of unrecog-
nized organ dysfunction.
• Delirium results from an imbalance of neurotransmit-
ters controlling cognitive function. Dopamine increases
excitability of neurons while gamma aminobutyric acid
(GABA) and acetylcholine suppress neuronal activity.
Excesses in dopamine and depletion of acetylcholine
are felt to be important in the development of delir-
ium. Other neurotransmitters, such as serotonin, endor-
phins, and noradrenalin, also play a role.
• Factors leading to neurotransmitter imbalance include
reduction in cerebral metabolism, primary intracranial
disease, systemic illness, secondary infection of the
brain, exogenous toxic agents, withdrawal from sub-
stances of abuse such as alcohol or sedative-hypnotics,
hypoxemia, metabolic disturbances, and the adminis-
tration of psychoactive medications such as benzodi-
azepines and narcotics.
• Hyperactive delirium is more frequently recognized
by care providers but is much less common than
hypoactive or mixed forms.
• Delirium encompasses and should replace other terms
describing recognized entities such as “ICU psychosis”
and “toxic confusional state.”
PREVALENCE AND IMPACT
• Delirium is exceedingly common, occurring in from
20 to 80% of ICU patients depending on risk factors
and screening modality; however, it may go unrecog-
nized by clinicians in up to 66–84% of cases.
• Delirium is not a normal “transitional state” between
coma and normal consciousness and has been found
to occur as often in patients without prior coma and
frequently persists beyond hospital discharge.
• The occurrence of delirium has been found to be an inde-
pendent risk factor for increased mortality, prolonged
hospitalization, and discharge to skilled nursing facility
in both ICU and non-ICU hospitalized patients. In
mechanically ventilated patients, it is associated with
increased aspiration, nosocomial pneumonia, self-
extubation, and reintubation.
• Overall, a three times greater mortality has been
found in ICU patients who develop delirium com-
pared with those who don’t, even when controlling for
other independent risk factors.
• Health care costs directly attributable to delirium have
been estimated in the billions of dollars.
MONITORING AND RISK FACTORS
• Delirium may be the presenting sign of a serious
underlying disorder including evolving sepsis,
impending respiratory failure, alcohol withdrawal, or
hypoglycemia; recognition of delirium necessitates an
evaluation for underlying etiology.
• Recently, the Society of Critical Care Medicine’s
guidelines recommended routine daily monitoring for
delirium, as well as sedation levels in all critically ill
patients.
• Many validated sedation scales exist in clinical prac-
tice, but less attention has been paid to monitoring for
delirium. The Confusion Assessment for the ICU
(CAM-ICU) can be performed at the bedside in about
a minute, has good interoperator reliability, is
designed to include mechanically ventilated patients,
and has a sensitivity and specificity of 95% of detect-
ing delirium.
• Risk factors for developing delirium can be divided
into host (older age, prior mild cognitive impairment,
smoking, hypertension), underlying illness (sepsis,
organ dysfunction, metabolic derangements, mechani-
cal ventilation), and iatrogenic (psychoactive medica-
tions, notably benzodiazepines and opiates) categories.
MANAGEMENT
• Initial management should focus on correcting reversible
organic etiologies and risk factor modification.
• While many risk factors have been identified, it is
unclear whether altering these risk factors can prevent
occurrence of delirium in the ICU.
• A study of general medicine patients showed a 40%
reduction (15–9.9%) in incidence of delirium through
a protocol of
 Repeated reorientation
 Cognitively stimulating activity three times daily
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 Imposing a sleep protocol preserving day and night
rituals
 Early mobilization exercises
 Early removal of catheters
 Avoiding restraints
 Use of regular eyewear and hearing aides
• While some risk factors are unavoidable and clinical data
are lacking for detailed guidelines in the ICU, attention
should be paid to minimizing iatrogenic causes.
• Psychoactive medications are exceedingly common
and to some degree necessary in the ICU. However,
frequent monitoring of sedation levels is critical in
avoiding excessive use and oversedation.
• Benzodiazepines and their metabolites are particu-
larly implicated in provoking delirium. Substituting
haloperidol for benzodiazepines in the treatment of
agitation, particularly in nonmechanically ventilated
patients, may decrease rates of delirium.
 A study of postcardiac surgery patients showed that
dexmedetomidine for agitation led to better outcomes
compared to benzodiazepines or propofol, but more
experience is needed before it can be recommended.
• While no drugs have Food and Drug Administration
(FDA) approval for the treatment of delirium, haloperi-
dol has the most clinical experience in the ICU.
 Haloperidol is a dopamine (D2) antagonist and should
be particularly effective in hyperactive delirium.
 While non-ICU doses start at 0.5–1 mg, ICU doses
should start at 5 mg (IV or PO) every 12 hours with
maximal effective dose usually 20 mg/day.
 Potential adverse effects are rare but significant and
include torsades de pointes (should be avoided in
patients with long QT intervals on ECG), dystonia, and
extrapyramidal side effects, hyperthermia (associated
with malignant hyperthermia), laryngeal spasm, and
anticholinergic effects.
 Newer atypical neuroleptics (e.g., risperidone and
olanzapine) may be effective and have fewer adverse
effects, but more experience is needed.
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WEAKNESS IN THE ICU
Michael Moore
KEY POINTS
• Neuromuscular disorders (NMDs) both precipitate
and complicate critical illness.
• Maximal inspiratory and expiratory pressures and the
VC are readily available measures assisting the clini-
cian in assessing the impact of NMDs on the ade-
quacy of ventilation.
• Critical illness myopathy and neuromyopathy compli-
cates many patients with protracted critical illness,
regardless of cause.
NEUROMUSCULAR DISORDERS
IN CRITICAL CARE
• Neuromuscular weakness can be attributed to disor-
ders involving the peripheral nerves, neuromuscular
transmission, or skeletal muscles.
• Weakness can be divided into disorders that result in
ICU admission and disorders acquired during treat-
ment of critical illness.
• Common disorders that lead to ICU admission
include Guillain-Barré syndrome (GBS), myasthenia
gravis (MG), dermatomyositis/polymyositis (DM/PM),
and metabolic myopathies related to mitochondrial
disease.
• Common clinical scenarios that result in weakness
after admission to the ICU include persistent blockade
of the neuromuscular junction from neuromuscular
blocking agents (NMBA), sensorimotor axonal
polyneuropathy, and acute myopathies.
REVIEW OF RESPIRATORY MUSCLE
IMPAIRMENT
• Requires objective testing as symptoms can be subtle.
SYMPTOMS
• Orthopnea
• Sleep disturbance
• Tachypnea
• Exercise intolerance
OBJECTIVE TESTING
• Most important respiratory muscle parameters:
 Maximal inspiratory pressure (MIP)
 Maximum expiratory pressure (MEP)
 Vital capacity (VC)
 Assessment of oropharyngeal function
• Frequent assessment and attention to serial changes is
required in patients with an evolving neuromuscular
disorder (NMD).
• MIP and MEP:
 Most sensitive measure of respiratory muscle strength
 Measurement requires a bedside manometer fitted
with a mouthpiece
 MIP
 Maximal inspiratory effort at residual volume
 Normal values
• −70 cmH2O in women
• −100 cmH2O in men
 Hypercapnia more likely when MIP less negative
than −20 cmH2O
 MEP
 Maximal expiratory effort at total lung capacity
 Normal values
• 100 cmH2O in women
• 150 cmH2O in men
 Effective cough unlikely when MEP <40 cmH2O
• VC:
 Normal VC is approximately 50 mL/kg
 Clearance of secretions with coughing is impaired
when VC <30 mL/kg
 Risk of respiratory failure increased with serial
decline in VC <15–20 mL/kg
• Arterial blood gases and VC are commonly normal in
the early stages of respiratory muscle weakness.
• Sleep-related deterioration in ventilation and oxy-
genation is common.
BULBAR MUSCLE IMPAIRMENT
• Increased risk of aspiration-related respiratory failure.
• Symptoms:
 Nasal speech
 Protruding tongue
 Difficulty swallowing
• Intact musculature involving the mouth, pharynx,
palate, tongue, and larynx are necessary for effective
oropharyngeal function.
• Assessment is primarily based on clinical observation
(i.e., swallow study).
• Early consultation with an experienced speech pathol-
ogist is recommended.
NEUROMUSCULAR DISORDERS
LEADING TO INTENSIVE CARE
UNIT ADMISSION
• Respiratory failure is the most common reason
patients with a primary NMD are admitted to the ICU.
• Most will have a previously defined NMD but the
recent onset of acute or subacute bilateral muscle
weakness should elicit a broad differential diagnosis
(Table 76-1).
• The differential diagnosis is initially based on the
patient’s history and a careful neurologic examination
(Table 76-2).
• Additional diagnostic tests such as nerve conduction
studies and electromyogram (EMG) are often required
(Table 76-2).
• Upper and lower motor neuron disease may occasion-
ally be responsible for new-onset weakness that neces-
sitates ICU admission.
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TABLE 76-1 Causes of Acute and Subacute Bilateral
Weakness
SYNDROME/LEVEL
OF ABNORMALITY REPRESENTATIVE DISORDER
Basilar artery occlusion Embolic
Thrombotic
Vasculitic
Myelopathy Cord compression (e.g., abscess,
neoplasm, disc herniation, and
trauma)
Transverse myelitis
Central nervous system infections Poliomyelitis
West Nile virus
Central nervous system toxins Neurotoxic fish poisoning
Peripheral nerve disorders GBS
Diphtheria
Heavy metal toxicity
Vasculitic neuropathy
Disorders of neuromuscular MG
transmission
Eaton-Lambert syndrome
Botulism
Tick paralysis
Organophosphate poisoning
Penicillamine toxicity
Myopathic disorders DM/PM
Metabolic myopathy
(e.g., mitochondrial disease)
Toxic myopathy
(e.g., corticosteroid injury and
rhabdomyolysis)
Electrolyte disorders Periodic paralysis
Hypophosphatemia
Hypokalemia
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GUILLAIN-BARRÉ SYNDROME
• Acute inflammatory demyelinating polyneuropathy
that most often presents with ascending symmetrical
weakness and depressed or absent reflexes.
• Typically evolves over days to weeks but a subset of
patients have a rapid decline in function over hours.
• Sensory involvement is common and paresthesias
may be the initial complaint.
• Other early symptoms include an aching discomfort
in the lower back and legs.
• Autonomic dysfunction is common and results in
brady- or tachyarrhythmias, orthostatic hypotension,
hypertension, or abnormal sweating.
• Bowel and bladder function are usually preserved.
• The Miller-Fischer variant presents with ataxia, oph-
thalmoparesis, and areflexia.
EPIDEMIOLOGY
• More common in young adults and elderly patients.
• Approximately two-thirds of patients have a preceding
gastrointestinal (GI) or respiratory infectious syndrome.
• Most common triggers are infections with Campylobacter
jejuni and cytomegalovirus.
DIAGNOSIS
• Based on clinical presentation and electrodiagnostic
studies compatible with a demyelinating polyneuropathy
• Cerebrospinal fluid
 Elevated protein levels after the first week of symptoms
 Limited mononuclear pleocytosis (<10 cells/cm3)
• Signs or symptoms that suggest alternative diagnoses
 Intact reflexes despite generalized weakness
 Asymmetric weakness
 Fever during the initial presentation
 Electrodiagnostic features inconsistent with an
acquired demyelinating polyneuropathy
• Important to rule out a rapidly progressive spinal lesion
CLINICAL COURSE
• Monophasic illness with a fairly predictable natural
history
• 90% reach nadir of neuromuscular impairment by
4 weeks
TABLE 76-2 Differential Diagnosis of NMDs Leading of ICU Admission
LEVEL OF REPRESENTATIVE NERVE
ABNORMALITY PRESENTATION DISORDER CONDUCTION EMG
Upper motor neuron Weakness Cortical Normal Normal
Spasticity Subcortical
Hyporeflexia Brainstem
Sensory/autonomic changes Spinal cord lesions
Lower motor neuron Weakness Poliomyelitis Normal Denervation
Flaccidity Postpolio syndrome
Hyporeflexia Amyotrophic lateral sclerosis
Fasciculations
Bulbar changes
No sensor changes
Peripheral nerve Weakness GBS Reduced Denervation
Flaccidity Diphtheria
Hyporeflexia Heavy metal toxicity
Bulbar changes Vasculitic neuropathy
Sensory/autonomic changes
Neuromuscular junction Fluctuating weakness MG Normal Abnormal repetitive stimulation
Fatigability Eaton-Lambert botulism
Normal reflexes Tick paralysis
No sensor changes Organophosphate
+/- Autonomic changes Penicillamine
Muscle Weakness DM/PM Normal Small motor units
Normal reflexes Metabolic myopathies
No sensory/autonomic changes Muscular dystrophy
+/- Pain
SOURCE: Modified from Luce J. Neuromuscular diseases care. In: Hall JB, Schmidt GA, Wood LDH, eds. Principles of Critical Care 2nd ed. New York,
NY: McGraw-Hill; 1998: 995–1004.
• Respiratory failure
 10% of patients present with and up to 43% will
eventually develop respiratory failure
 Predictors of respiratory failure
 “20/30/40 rule”
• VC <20 mL/kg
• MIP less negative than −30 cmH2O
• MEP <40 cmH2O
 Inability to cough
 Time from onset to admission <7 days
 Inability to stand or lift head or elbows
 Autonomic dysfunction
• Morbidity and mortality
 Strongly associated with the need for and duration
of mechanical ventilation
 Two-thirds experience mild residual deficits
 10–20% have complete recovery
 Mortality reported to be between 3 and 8%
 Causes of mortality
• Pneumonia
• Acute respiratory distress syndrome (ARDS)
• Sepsis
• Pulmonary emboli
• Cardiac arrest
TREATMENT
• Plasma exchange:
 Improved strength and reduced the incidence of res-
piratory failure in three multicenter trials conducted
in the 1980s.
 Two to four exchanges may be needed depending on
severity.
• Intravenous immune globulin:
 Also effective.
 Mechanism is unclear but may be related to neutral-
izing neuromuscular blocking antibodies.
 May be superior to plasmapheresis in patients with
C. jejuni infections and antibodies to peripheral
nerve gangliosides.
• A randomized, multicenter, international trial that com-
pared plasma exchange, IVIg, and plasma exchange
followed by IVIg concluded that IVIg and plasma-
pheresis are equally effective without additional ben-
efit with combined therapy.
• IVIg may be preferred because of ease of administra-
tion and acceptable side effect profile.
• Corticosteroids have not been shown to be beneficial.
MYASTHENIA GRAVIS
• Acquired autoimmune disorder of neuromuscular
junction transmission characterized by muscle weak-
ness, progressive muscle fatigue with repetitive use,
and improvement in strength after rest.
• Clinical presentation:
 85% have generalized weakness with fatigability
involving the trunk and extremities.
 Ocular muscle involvement including ptosis and
diplopia are common.
 Bulbar muscle impairment results in dysphonia and
dysphagia.
• Incidence highest in younger women and older men.
• Neuromuscular weakness results from autoantibodies
to acetylcholine receptors that impair neuromuscular
transmission.
• Respiratory muscle function:
 Isolated respiratory muscle impairment can occur
but typically presents along with generalized muscle
weakness.
 VC, MIP, and MEP are significantly reduced.
• Upper airway obstruction with abnormal vocal cord
adduction during inspiration has been described.
DIAGNOSIS
• Relies on a compatible clinical presentation and three
principal studies:
 Positive anticholinesterase test
 Presence of serum acetylcholine receptor antibodies
 Electrophysiologic (EP) studies indicative of a neu-
romuscular junction disorder that show decrement
in response to repetitive nerve stimulation
• Acetylcholine receptor-binding antibodies are identi-
fied in approximately 71–93% of patients.
• Single fiber EMG may be useful if the diagnosis remains
undefined.
ASSOCIATED CONDITIONS
• Thymic hyperplasia or thymoma.
• Autoimmune conditions including rheumatoid arthri-
tis, lupus, thyroiditis, and Graves’ disease.
• Thyroid function testing should be obtained in all
patients with MG.
• Thymic abnormalities are common and chest com-
puted tomographic (CT) or magnetic resonance imag-
ing (MRI) has been used as a screening tool in MG.
MYASTHENIC CRISIS
• 15–27% of patients experience myasthenic crisis.
• Defined as a rapid and severe decline in respiratory
muscle function.
• Associated with a mortality of 4–13%.
• Cardiac dysrhythmias are a common cause of death.
• 73 episodes of myasthenic crises and respiratory fail-
ure were described in a retrospective study.
 50% of patients were extubated within 2 weeks.
 Median ICU and hospital stays were 14 and 35 days,
respectively.
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 Independent predictors of prolonged intubation:
 Preintubation serum bicarbonate >30 mg/dL
 Peak VC <25 mL/kg on day 1–6 postintubation
 Age >50 years
TREATMENT
• First line of therapy
 Anticholinesterase agents, most commonly
pyridostigmine
 Respiratory muscle function improves in approxi-
mately 50% of patients
 Side effects of therapy
 Muscarinic effects include abdominal cramping
with frequent defecation, increased urinary fre-
quency, bronchospasm, bradycardia, fascicula-
tions, and increased oral secretions
 Cholinergic crisis
• Usually occurs during initiation of therapy
• Can be difficult to differentiate from myasthenic
crisis
• Treatment for both usually requires withholding
anticholinesterase medications for 4–10 days
• Second line of therapy
 Majority of patients require additional immunosup-
pressive therapy
 Response to anticholinesterase therapy is usually
incomplete and relapse is common
 Dose escalation often leads to significant side effects
 Corticosteroids
 Most commonly used agents
 Result in remission or marked improvement in
approximately 75% of patients
 Azathioprine
 Delayed onset of action
 Usually requires at least 3 months of therapy
 Cyclosporine
 Reduces acetylcholine receptor antibody production
 Toxicity limits use
 Cyclophosphamide
 Beneficial in refractory patients
 Also limited by toxicity
• Third line of therapy
 Plasma exchange and IVIg commonly used for
intensive short-term therapy
 Plasma exchange
 Rapidly removes acetylcholine receptor antibodies
 Usually improves strength within several days
 Typical treatment is with 2- to 4-L exchanges two
to three times per week over a 10- to 14-day period
 First-line therapy for myasthenic crisis
 Intravenous immune globulin
 Results in a rapid improvement in most patients
 Usually reserved for use after a course of plasma
exchange
• Thymectomy
 Has been associated with clinical improvement and
remission
 Generally recommended for patients <60 years
 Preoperative plasma exchange is recommended in
patients with significant ventilatory impairment
DIFFERENTIAL DIAGNOSIS
• Disorders of neuromuscular transmission that mimic
MG
 Eaton-Lambert syndrome
 Botulism
 Tick paralysis
 Organophosphate toxicity
 Myasthenic-like syndrome induced by penicillamine
• Botulism
 Toxin-mediated irreversible inhibition of neuromus-
cular transmission
 Causes an acute symmetric descending paralysis
that begins with bulbar impairment
 Early bulbar involvement of botulism may initially
be confused with the Miller-Fischer variant of
GBS which predominantly involves the bulbar
musculature
 Most commonly associated with food-borne and
intestinal sources
• Tick paralysis
 Tick-borne neurotoxin that causes an ascending
paresis or paralysis
 Typically affects children
 Diagnosis requires a high index of clinical suspicion
 Treatment
 Careful physical examination to identify and
remove all ticks and their body parts
 Close observation and supportive care
 Significant improvement in neuromuscular strength
usually occurs within several hours of tick identifi-
cation and removal
DERMATOMYOSITIS AND POLYMYOSITIS
• Idiopathic inflammatory disorders which usually
present with progressive symmetrical muscle weak-
ness over several months.
• An acute presentation with rapidly evolving muscle
weakness is less common.
• Shoulder and pelvic girdle muscles are most often
affected.
• Neck flexion muscles are weakened in up to 50% of
patients with sparing of facial muscles.
• Pharyngeal muscle involvement may present with
dysphonia or dysphagia.
• Myalgias and muscle tenderness occur in up to 50%
of patients.
• Etiology is likely related to an immune-mediated
mechanism.
• Clinical predictors of poor outcome:
 Symptom duration >6 months before diagnosis
 Severe symptoms
 Presence of dysphagia
DIAGNOSIS
• Diagnostic criteria include
 Presence of symmetrical proximal muscle weakness
 Elevated skeletal muscle enzymes
 Compatible findings on electromyography and
skeletal muscle biopsy
 Characteristic dermatologic findings in DM
 Heliotropic changes of the eyelids
 Gottron sign
• Muscle enzymes
 Creatine phosphokinase is most consistent indicator
of muscle inflammation
 Others include aldolase, aspartate aminotransferase,
alanine aminotransferase, and lactate dehydrogenase
• Electromyography
 Typically reveals features of a generalized myo-
pathic disorder
 May be normal in 10–15% of patients
• Muscle biopsy is most definitive and demonstrates
variable degrees of type I and II fiber necrosis and
inflammation
IMPORTANT COMPLICATIONS
• Respiratory and cardiovascular complications are
main concern in the ICU
• Respiratory complications
 Infectious pneumonia from immunosuppression
 Aspiration pneumonia
 Dysphagia suggests pharyngeal muscle dysfunc-
tion and increased risk of aspiration
 Most common pulmonary complication
 Respiratory muscle weakness
 Both inspiratory and expiratory muscles are
involved
 Reported in up to one-third of patients
 Interstitial lung disease
 Identified in nearly one-third of patients
 Nonspecific interstitial pneumonitis is most
common underlying histopathologic lesion
• Cardiac complications
 Tachyarrhythmias and other conduction abnormalities
 Myocarditis
 Dilated cardiomyopathy
 Chronic pulmonary hypertension
TREATMENT
• Corticosteroids
 Most patients respond over weeks to months
 Requires high-dose therapy (0.5–1.5 mg/kg prednisone)
that can be gradually tapered after patient response
• Alternative immunosuppressive agents
 Considered in patients with poor prognostic markers
or limited response to corticosteroids
 Options include methotrexate, azathioprine, and
cyclophosphamide
 Methotrexate or azathioprine may be particularly
useful for corticosteroid intolerance and long-term
maintenance therapy
• Alternative therapies
 Refractory patients have been treated with IVIg,
cyclosporine, tacrolimus, alkylating agents, and tumor
necrosis factor inhibitors
 IVIg
 71% of patients refractory to combination
immunosuppressive therapy showed significant
improvement in strength after treatment with IVIg
 IVIg also reported to be beneficial for life-
threatening esophageal involvement
 Surgical division of the cricopharyngeal muscle has
been used for severe refractory cricopharyngeal
achalasia
 A pacemaker-defibrillator should be considered for
serious conduction abnormalities or ventricular
dysrhythmias
MITOCHONDRIAL DISEASE
• Metabolic myopathies result from acquired mutations
in genes coding for critical proteins in glycolysis,
fatty acid oxidation, or oxidative phosphorylation.
• Increasingly recognized disorders that may present
with diverse manifestations in the critical care setting
including respiratory muscle dysfunction.
• Possible indicators of an underlying mitochondrial
disorder:
 Unexplained dyspnea progressing to respiratory failure
 Sedative-related respiratory failure out of proportion
to sedative dose
 Respiratory failure with persistent unexplained lactic
acidosis
 Prolonged paralysis following neuromuscular blockade
 Unexplained difficulty weaning from mechanical
ventilation
DIAGNOSIS
• Glycolytic disorders suggested by lactate-to-pyruvate
ratio >20.
222 SECTION 5 • NEUROLOGIC DISORDERS
CHAPTER 76 • NEUROMUSCULAR WEAKNESS IN THE ICU     223
• Disorders of fatty acid oxidation suggested by low
carnitine levels.
• Muscle biopsies are usually diagnostic and have char-
acteristic findings on light and electron microscopy.
TREATMENT
• Primarily supportive.
• Includes treatment of precipitating infections and
withholding sedatives and neuromuscular blockers.
• High carbohydrate diet may be beneficial in fatty acid
oxidation disorders.
NEUROMUSCULAR DISORDERS
ACQUIRED IN THE INTENSIVE
CARE UNIT
• Acquired NMDs are the most common cause of
severe generalized weakness in the ICU.
• While the neuromuscular dysfunction is generally
reversible, respiratory muscle involvement can lead to
prolonged mechanical ventilation and delayed weaning.
• After successful extubation patients often require pro-
longed physical rehabilitation and may be unable to per-
form basic activities of daily living for weeks to months.
• Recent studies have documented significant weakness
up to several years after hospital discharge suggesting
the possibility of permanent disability.
• Increased awareness over the past two decades has
brought into focus the major medical, economic, and
psychosocial costs of ICU-acquired neuromuscular
dysfunction.
CAUSES OF INTENSIVE CARE UNIT-ACQUIRED
WEAKNESS
• Three basic causes of ICU-acquired neuromuscular
weakness:
 Persistent blockade of the neuromuscular junction
after NMBA
 Sensorimotor axonal polyneuropathy
 Acute myopathy
• Diagnosis is usually made by EP studies and muscle
and nerve biopsy.
• Elucidation of the underlying cause of weakness can
be difficult and combined disorders of muscle and
nerve may occur.
PERSISTENT NEUROMUSCULAR JUNCTION
BLOCKADE
• Paralysis with NMBAs can result in residual blockade
of the neuromuscular junction after discontinuation.
• Rare cause of persistent neuromuscular weakness.
• The use of vecuronium in patients with renal failure
may result in accumulation of the active metabolite
3-desacetylvecuronium and prolonged paralysis.
• Diagnosis can be made by EP studies with repetitive
nerve stimulation protocol.
CRITICAL ILLNESS POLYNEUROPATHY
• First described in the 1980s by Bolton and colleagues
who reported a group of critically ill patients who
developed generalized weakness after several weeks
in the ICU.
• Most patients had underlying sepsis and underwent
neurologic evaluation for diffuse limb weakness or
because of difficulty weaning from mechanical
ventilation.
• Neurologic examination findings:
 Distal muscles affected most prominently
 Sparing of the cranial nerves
 Reduced or absent deep tendon reflexes
• Electroneurography (ENG) and EMG suggested an
axonal sensorimotor polyneuropathy.
• Survivors had parallel improvement in EP studies and
clinical examination over several months.
• Pathogenesis:
 Mechanism is not understood.
 The peripheral nervous system may be a target for
tissue damage in the setting of sepsis.
 Sepsis-induced loss of effective vascular autoregula-
tion, increased microvascular permeability, and
cytokine-mediated neuronal injury may be involved.
INTENSIVE CARE UNIT-ACQUIRED MYOPATHY
(CRITICAL ILLNESS MYOPATHY)
• A severe ICU-acquired myopathy was first reported
25 years ago, with numerous individual case reports
and case series having been published subsequently.
• Myopathy was most often described in the setting of
ventilated status asthmaticus patients who were
treated with corticosteroids and NMBAs.
• However, myopathy has also been documented in
patients treated with corticosteroids without paralysis
and in critically ill septic patients who received nei-
ther corticosteroids nor NMBAs.
• Some authors have attempted to subdivide ICU-
acquired myopathies but it is not clear that distinct
subtypes exist.
• A recent editorial suggested the term critical illness
myopathy be used as the sole descriptor for all
instances of ICU-acquired myopathy.
SYMPTOMS
• Typically not recognized until withdrawal of sedation
allows neuromuscular assessment.
• Generalized muscle weakness with variable manifes-
tations based on severity:
 Less severe—predominantly distal weakness with
foot and wrist drop.
 More severe—quadriplegic paresis that may resem-
ble a “locked in” state or even coma.
 Reflexes may be depressed or absent.
• Sensation is intact.
• Respiratory muscle function is relatively preserved
even in setting of near-quadriplegic limb weakness.
DIAGNOSIS
• Serum creatine kinase (CK) levels
 Elevated or normal
 Neither establish nor exclude an underlying myopathy
• EMG
 Normal or decreased compound muscle action
potential (CMAP) amplitudes depending on severity
 Spontaneous fibrillations and positive sharp waves
in resting muscle similar to critical illness
polyneuropathy
 Voluntary contractions elicit a characteristic myo-
pathic pattern of abundant low amplitude, short
duration polyphasic units with early recruitment
• Muscle biopsy
 Pathologic findings are variable
 Most common finding is fiber atrophy and vac-
uolization without inflammation
 Electron microscopy
 Selective loss of myosin with relative sparing of
actin and Z bands
 Highly characteristic of ICU-acquired myopathy
PATHOGENESIS
• Pathophysiology is uncertain.
• Myosin loss may interfere with normal contractility.
• May also be related to temporary muscle inexcitabil-
ity detected by direct muscle stimulation.
 Documented in patients with severe ICU-acquired
myopathy related to corticosteroids and NMBAs.
 Also found in a heterogenous group of patients with
ICU weakness who had not received either corticos-
teroids or NMBAs.
POLYNEUROPATHY, MYOPATHY,
OR “POLYNEUROMYOPATHY”
DIAGNOSTIC DILEMMA
• ICU-acquired neuromuscular weakness often presents a
diagnostic dilemma: polyneuropathy, myopathy, or both.
• Studies using standard ENG/EMG and muscle
histopathology have failed to differentiate a primary
neuropathy from a myopathy.
• EMG differentiation between an axonal motor
polyneuropathy and severe myopathy requires patient
cooperation and the inability to cooperate may pre-
clude reliable diagnosis.
• Sensory ENG studies might be limited by tissue edema.
• Routine histopathologic findings in muscle biopsy
specimens may be similar.
• Recent evidence suggests that both polyneuropathy
and myopathy may coexist.
CLINICAL IMPLICATIONS
• A purely clinical approach that defines the presence of a
“critical illness weakness syndrome” may be adequate.
• Since there is no specific therapy, clarification of the
underlying mechanisms of ICU-acquired weakness
may only be important from a research perspective.
• However, EP studies may detect rare cases of GBS
triggered by acute nonneurologic critical illness.
• In addition, the prognosis for recovery may be differ-
ent with a pure myopathy and severe axonal polyneu-
ropathy (see below).
INTENSIVE CARE UNIT-ACQUIRED
WEAKNESS: INCIDENCE AND RISK
FACTORS
• Studies have generally focused on two types of patient
cohorts:
 Status asthmaticus
 Heterogeneous ICU population in which sepsis, sys-
temic inflammatory response syndrome (SIRS), and
multiorgan failure were dominant
STATUS ASTHMATICUS
• In studies of asthma patients who acquire a myopathy
in the ICU systemic corticosteroid use has been uni-
versal and most received NMBAs.
• Ventilated and paralyzed asthmatic patients have a
30% incidence of myopathy.
• The risk increases with duration of paralysis and the
incidence is similar with steroidal and nonsteroidal
NMBAs.
• Myopathy has also been reported in mechanically ven-
tilated patients with airflow obstruction who received
corticosteroids and deep sedation without paralysis.
• This suggests that prolonged paralysis increases the
risk of myopathy in status asthmaticus but avoidance
of NMBAs does not eliminate the risk of neuromus-
cular weakness.
224 SECTION 5 • NEUROLOGIC DISORDERS
CHAPTER 76 • NEUROMUSCULAR WEAKNESS IN THE ICU     225
SEPSIS, SIRS, AND OTHER CAUSES
OF CRITICAL ILLNESS
INCIDENCE OF INTENSIVE CARE UNIT-ACQUIRED
PARESIS
• The reported incidence has varied widely due to dif-
ferences in diagnostic criteria and case mix.
• In studies of patients with sepsis and multiorgan fail-
ure, the reported incidence has been 70–82%.
RISK FACTORS FOR INTENSIVE CARE
UNIT-ACQUIRED PARESIS
• Most studies involving mixed ICU populations (pri-
marily sepsis, SIRS, and multiorgan dysfunction)
have not found a relationship between corticosteroid
and/or NMBA use and persistent muscle weakness.
• Multiple risk factors have been identified in this
population:
 Sepsis
 Higher APACHE (Acute Physiology, Age, Chronic
Health Evaluation) III score and presence of SIRS
 Duration of mechanical ventilation
 Presence of multiorgan dysfunction
• One multicenter prospective study, however, found
corticosteroid therapy to be a significant risk factor
for ICU-acquired paresis.
OUTCOMES
• Recovery rates from ICU-acquired weakness have
varied greatly.
• Resolution of severe quadriparesis in the setting of
severe asthma treated with corticosteroids and NMBAs
has occurred within 10–14 days but may require several
weeks.
• In studies in mixed ICU populations significantly longer
recovery times have been reported.
• Two prospective studies found that all survivors
recovered by 2–3 months with a median recovery time
of 21 days.
• Recent evidence suggests that ICU-acquired weak-
ness may be prolonged and potentially permanent.
 A study in 109 ARDS survivors found significant
functional limitation at 1 year largely attributed to
muscle wasting and weakness.
 Another study found that one-third of patients with
ICU stays >1 month had persistent weakness 1–5 years
after discharge.
 An evaluation of 19 rehabilitation patients with
severe ICU-acquired weakness found that 33% had
persistent quadriparesis 2 years after discharge.
 Finally, 85% patients in one study had incomplete
recovery 1–2 years after ICU discharge.
• The data combined suggest that patients with ICU-
acquired weakness may never fully recover with
potentially profound effects on functional capacity and
quality of life.
TREATMENT AND PREVENTION
• There is no specific treatment other than physical
rehabilitation.
• The risk of neuromuscular weakness may be largely
determined by the severity and duration of the under-
lying illness and may not be easily preventable.
• Unproved but potentially beneficial preventative
strategies:
 Maintaining as much muscle activity as is safely
possible during critical illness
 Avoidance of oversedation and decreased duration
of ventilatory support by daily period of sedation
withdrawal
 Tight glycemic control in ICU
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77 HEAD TRAUMA
Nina M. Patel
KEY POINTS
• Injury from head trauma can be potentiated by subse-
quent hypoxia and ischemia, which should be avoided
if at all possible.
• Invasive monitoring of ICP should be considered in
carefully selected patients with head trauma.
• Prophylaxis of and further aggressive treatment of
seizures after head trauma should be instituted.
• Systemic sepsis is often a late complication of head
trauma and early empiric antibiotics coupled to source
control should be pursued.
INTRODUCTION
• Traumatic brain injury (TBI) occurs in 3/1000 people
per year in the United States.
• Motor vehicle accidents (MVA) are the most common
cause of TBI, followed by falls, assault, and penetrat-
ing trauma.
• Alcohol intoxication is a causal or contributory factor
in 10–50% of head trauma occurrences.
NORMAL CEREBRAL PHYSIOLOGY
• Cerebral blood flow (CBF) is determined by the equation:
CBF = Cerebral perfusion pressure (CPP)
Cerebral vascular resistance
(normal = 50 mL/100 g brain tissue/min)
• CPP is determined by the equation:
 CPP = mean arterial pressure (MAP) − intracranial
pressure (ICP)
(normal CPP = 70–100 mmHg, ICP = 0–10 mmHg)
 In a range of CPP of 50–150 mmHg, autoregulation
of cerebrovascular resistance occurs to maintain
CBF.
 Significant decreases in MAP or increases in ICP
can lead to a CPP that is too low to be corrected by
autoregulation.
PATHOPHYSIOLOGY
• Primary brain injury results from direct mechanical
injury to the brain parenchyma. Injury may be focal or
diffuse. Leading etiologies of primary brain injury
include:
 Skull fracture—depressed or nondepressed, linear or
stellate
 Epidural hematoma—between skull and dura
mater, often temporal or temporoparietal, results
from middle meningeal artery tear, often lenticular
in shape
 Subdural hematoma—between dura mater and
brain, results from tear of bridging vein, often
crescent-shaped, occurs in up to 30% of severe head
injuries
 Intracranial hemorrhage—intraparenchymal hema-
toma, frontal or temporal lobes, may not appear
until >24 hours following injury
 Diffuse axonal injury—acceleration-deceleration
(most often with a MVA) leads to shearing forces
with resultant axonal injury
• Secondary brain injury is the consequence of altered
physiologic responses in reaction to primary brain injury.
 Two major contributing factors to secondary brain
injury are hypotension and hypoxia. 
 Intracranial hypertension (ICH), dysregulation of
total body sodium and water content, infection and
coagulopathy are potential manifestations of sec-
ondary brain injury.
 Many aspects in the management of primary brain
injury are directed toward preventing or controlling
secondary brain injury.
DIAGNOSIS
• Evaluation of the patient with head trauma begins with
a thorough history (when available), physical exami-
nation assessing sites of injury, and a neurologic exam-
ination (including appraisal of brainstem reflexes).
• The gross neurologic examination focuses on identi-
fying the presence or absence of a focal deficit and the
level of consciousness.
• Level of consciousness is assessed with the Glasgow
Coma Scale (GCS; see Table 77-1):
 13–15 = mild head injury
 9–12 = moderate head injury
 ≤8 = severe head injury
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• If there is concern for cervical spine injury, cervical
spine films should be performed prior to manipulating
the cervical spine.
• Head computed tomography (CT) should be per-
formed in all patients with a depressed GCS score to
evaluate for intracranial hematoma, cerebral edema,
intracerebral hemorrhage, or cerebral infarction.
MANAGEMENT
• The goals of acute and continued management of TBI
center upon: (a) preservation of cerebral oxygenation,
(b) maintenance of cerebral perfusion, (c) avoidance
of secondary brain injury, and (d) prompt neurosurgi-
cal evaluation.
INITIAL
• Airway stabilization with either orotracheal or naso-
tracheal intubation is essential in all patients with
GCS ≤8 (coma).
• Short-term modest hyperventilation (PCO2 to 30–35
mmHg) to acutely decrease ICP is indicated, though
continuous and aggressive hyperventilation (PCO2
<25 mmHg) may increase risk of cerebral vasocon-
striction and decrease CBF.
• Volume resuscitation with normal saline should be
instituted to achieve a stable circulation with a target
CPP >70 mmHg. Hypotonic solutions should be
avoided. Hypertonic saline may effectively increase
intravascular volume while decreasing cerebral edema.
• Timely neurosurgical consultation to determine if
lesion is amenable to surgical therapy.
MEDICAL MANAGEMENT IN INTENSIVE
CARE UNIT
• Intracranial hypertension is defined as an ICP
>20 mmHg for >5–10 minutes. The presence of ele-
vated ICP implies decreased CBF and is associated
with poorer outcomes in patients with TBI. ICP mon-
itoring is often used to indirectly measure CBF, as
there is no direct means to measure CBF.
 Aggressive monitoring of ICP with an intraventric-
ular or subdural pressure monitor is recommended
in patients with GCS scores of <10. Alternative
methods of monitoring CBF include evoked poten-
tials, electroencephalography, and jugular venous
oximetry.
 Aggressive control of fever, titrated mechanical ven-
tilation with goals of PO2 >70 mmHg and mild
hypocapnia (PCO2 30–35 mmHg) at minimal levels
of positive end-expiratory pressure, elevation of the
head of the bed to 30° to maximize jugular venous
drainage, and sedation to minimize acute increases
in ICP are all integral components in the medical
management of ICH.
 Mild hypothermia (32–34°C) has not been consis-
tently shown to confer significant neuroprotective
benefit in randomized, controlled trials.
 Paralysis, osmotic diuresis with mannitol (0.5–1.0 g/kg
of 20% solution q 2-6 h, m goal serum osmolality
310–320 mOsm/kg H2O), and/or drainage of CSF
with an intraventricular catheter is pursued if ele-
vated ICP persists despite conservative measures.
Overdiuresis without volume repletion in patients
receiving mannitol will lead to hypovolemia and may
compromise CPP.
 If all of the above measures fail to control ICP, a
pentobarbital (10 mg/kg bolus over 10 minutes,
1–3 mg/kg/h with invasive blood pressure monitoring)
coma may be utilized as a last resort.
• Adjunctive aspects of management of patients with
TBI include: seizure prophylaxis (phenytoin),
nutritional support (enteral feeding), stress ulcer
prophylaxis, deep vein thrombosis (DVT) prophy-
laxis, and rehabilitation.
• Abnormal free water regulation in TBI may give rise to
syndrome of inappropriate antidiuretic hormone
(SIADH) or diabetes insipidus, thus complicating
management of fluid and electrolyte status. Serum and
urine osmolarity and sodium measurements are useful
TABLE 77-1 The GCS Score
FINDING SCORE
Eye opening
Spontaneous 4
To voice 3
To pain 2
None 1
Verbal response
Oriented 5
Confused speech 4
Inappropriate words 3
None 2
Inappropriate words 1
Motor response
Obeys commands 6
Localizes pain 5
Withdraws 4
Abnormal flexion 3
Extension 2
None 1
in determining which disorder is present. If SIADH is
present, free water restriction should be implemented.
Diabetes insipidus is treated with desmopressin.
PROGNOSIS AND CONCLUSIONS
• There is a 30–50% mortality rate associated with TBI.
• Factors associated with a poor outcome include: older
age, initial low GCS, significant intracranial bleed,
hypotension, hypoxia, elevated ICP, and/or significant
associated systemic injury.
• Meticulous initial evaluation, early neurosurgical con-
sultation, aggressive vigilance in managing secondary
brain injury, and maintaining adequate CBF are essen-
tial to improve outcomes in TBI.
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78 COMA AND PERSISTENT
VEGETATIVE STATE
Nathan Sandbo
KEY POINTS
• An essential aspect of management of the comatose
patient is to assure a stable circulation and oxygena-
tion while evaluation is conducted to avoid secondary
damage to the central nervous system.
• Therapeutic hypothermia should be considered in
carefully selected patients following anoxic or other
brain injuries.
• A focused history, neurologic examination, and brain
imaging coupled to laboratory examinations create
the essential database for diagnosis of causes of coma.
• The vegetative state is a chronic condition of pre-
served sleep-wake cycles but with an absence of
cognitive function and no awareness of self or
environment.
• The longer a vegetative state persists, the less likely
significant recovery of brain function becomes.
COMA
EPIDEMIOLOGY
• In the intensive care unit, the presence of coma is
associated with poor outcome. Up to 61% of patients
are dead within 2 weeks.
• The ability to successfully resuscitate cardiac arrest
patients has increased the prevalence of nontraumatic
coma in the intensive care unit.
DEFINITION AND PHYSIOLOGY
• Defined as a state of unarousable, psychological unre-
sponsiveness, implicating a disorder in the two primary
components of consciousness, arousal, and awareness.
• Coma should be distinguished from other similar
disorders:
 Hypersomnia—characterized by excess drowsiness
 Akinetic mutism—defined by a silent, alert, and
awake appearance, with no response to environmental
stimuli
 Locked-in syndrome—a state of paralysis of all
somatic musculature, but with preserved conscious-
ness. Occurs mainly with pontine infarction or may
be mimicked by neuromuscular paralysis from phar-
macologic agents
• Most sensory stimuli pass through the ascending retic-
ular activating system (ARAS), which lies in the center
of the brain stem. Damage to this system from
ischemia, infection, or compression can result in coma.
EVALUATION
• Coma of both traumatic and nontraumatic etiologies
can be graded using the Glasgow Coma Scale (GCS).
A patient’s score can be from 3 to 15, and is deter-
mined by the sum of three components: motor
response, verbal response, and eye opening. Although
this scoring system provides prognostic information,
it is not as reliable as a thorough assessment of indi-
vidual components of brain stem reflexes.
• Neurologic examination should focus on:
 Assessment of response to different degrees of
external stimuli: verbal command, touch (such as
light shaking), and finally noxious stimulation such
as nail bed pressure or supraorbital pressure.
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 All responses should be recorded:
 Purposeful attempts to remove the stimuli implies
preservation of brain stem function and connec-
tion to the cerebral hemisphere.
 Decorticate (flexor) posturing indicates cerebral
damage or toxic depression.
 Decerebrate (extensor) posturing indicates destruc-
tive lesion of the midbrain and upper pons or severe
metabolic insults.
 Absence of motor function as shown by flaccid
paralysis indicates severe brain stem damage.
 Eye opening to varying degrees of stimuli (sponta-
neous, speech, pain, or none):
 Any eye opening indicates preserved function of
the ARAS.
 Size and reactivity of pupils:
 Small reactive pupils may indicate metabolic brain
disease. Pinpoint pupils suggest narcotic overdose.
 Bilateral fixed and dilated pupils are due to sympa-
thetic overactivity from endogenous catecholamines
(seizure, anoxic ischemia), exogenous catechols
(norepinephrine, dopamine), or atropine like drugs.
 Midposition and fixed pupils imply both sympa-
thetic and parasympathetic failure at the level of
the midbrain and is found in brain death.
 Unilateral dilated pupil suggests third nerve compres-
sion due to a space-filling defect (mass, herniation).
 Assessment of eye movements:
 Deep coma usually has no spontaneous eye
movement.
 Roving pupils suggest brain stem function without
cortical input.
 When cortical input is depressed, but brain stem
function remains, passive head motion will result
in conjugate deviation to the side opposite the
direction of motion (doll’s eye reflex). Absence of
this reflex is suggestive of brain stem injury.
 Confirmation can be made by the cold coloric test,
in which ice-cold water is infused into the exter-
nal auditory canal. Comatose patients have tonic
deviation toward the side of infusion, normal
patients have deviation toward the side of infu-
sion and additionally have nystagmus away from
that side. Brain death results in the absence of any
response.
 Pattern of breathing:
 Cheyne-Stokes breathing: a crescendo-decrescendo
pattern of rate and depth of respiration.
 Central neurogenic hyperventilation is sustained
hyperpnea found in patients with upper brain stem
damage.
 Assess for presence of focal neurologic deficits,
such as unilateral muscle weakness. Note presence
of myoclonus, or evidence of seizure activity.
• As well as assessing for focal neurologic syndromes,
a thorough assessment of systemic disorders which
can cause coma is warranted. Common syndromes
that cause coma should be sought such as hypother-
mia, drug ingestion, metabolic derangements present
on the laboratory panel, evidence of sepsis syndrome
in the circulatory examination.
• Laboratory assays of serum looking for infection, elec-
trolyte abnormalities, and toxic ingestion should be sent.
• Imaging of the brain is most quickly and reliably
achieved by computed tomography (CT) looking for
structural lesions or hemorrhage.
• Acquisition of cerebrospinal fluid (CSF) for cell
count and electroencephalogram (EEG) looking for
subclinical seizures or diffuse slowing suggestive of a
metabolic encephalopathy are also indicated in almost
all cases, although exclusion of a mass lesion or other
cause of intracranial hypertension must precede
lumbar puncture.
DIFFERENTIAL DIAGNOSIS
• Metabolic and toxic etiologies are the most common
causes of depressed consciousness. Metabolic coma
usually results in preservation of the pupillary response,
as opposed to structural etiologies. Metabolic coma
may be accompanied by asterixis, myoclonus, tremor,
or seizures.
• Head trauma and cerebrovascular disease are also
common causes of coma.
• Hypoxic-ischemic encephalopathy is a devastating
cause of coma in the intensive care unit. Cardiac arrest
is the most common cause. Other causes include severe
hypotension, status epilepticus, increased intracranial
pressure, head trauma, and hyperviscosity syndromes.
• Supratentorial mass lesions usually are accompanied
by focal neurologic signs.
TREATMENT
• Maintenance of adequate cerebral perfusion and oxy-
genation is the mainstay of therapy in coma.
• Identification and, if possible, correction of the under-
lying etiology, such as metabolic derangements.
• Airway protection is paramount as coma patients lack
protective reflexes.
• Empiric initial treatment with intravenous glucose,
usually accompanied by thiamine.
• Identification and treatment of seizures.
• Identification and treatment of intracranial hyperten-
sion, especially in traumatic head injury and hemor-
rhagic or ischemic cerebrovascular accident (CVA).
• Identification and prompt treatment of systemic
infections.
• Treatment of hyperthermia with antipyretics.
• Consideration for therapeutic hypothermia in selected
patients (closed head trauma, anoxic-ischemic injury
secondary to cardiac arrest).
PERSISTENT VEGETATIVE STATE
• Chronic condition characterized by preserved sleep
wake cycles, with an absence of evidence of cognitive
function, and lack of awareness of self and environ-
ment. Usually results from severe, diffuse brain injury
secondary to anoxic damage. Brain stem functions
remain intact.
• The presence of this state for more than a few weeks
is termed a “persistent” vegetative state; whereas the
term “permanent” vegetative state is a clinical diagno-
sis made when the likelihood of recovery is exceed-
ingly small.
• May develop in 1–14% of patients with coma.
• Most pathologic patterns consist of either diffuse lam-
inar cortical necrosis or diffuse axonal injury.
• Prognosis depends on cause:
 In acute traumatic and nontraumatic brain injuries
up to 33% of patients in persistent vegetative state
(PVS) at 1 month regained some level of conscious-
ness by 3 months, and 52% at 12 months. Lack of
recovery at 12 months portended a bleak prognosis,
with <5% regaining consciousness.
 Nontraumatic causes of coma have a significantly
worse prognosis, with <15% of patients regaining
consciousness at 1 year.
 In degenerative and metabolic brain disorders
recovery after several months is unlikely.
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79 BRAIN DEATH
Nathan Sandbo
KEY POINTS
• The Uniform Determination of Death Act states that
an individual who has sustained either irreversible
cessation of circulatory and respiratory functions, or
irreversible cessation of all function of the entire
brain, including the brain stem is dead.
• The determination of death by brain criteria is based on
clinical examination; importantly, the cause of coma
must be known, and the cause must be sufficient to
explain irreversible cessation of whole brain function.
INTRODUCTION
• The advent of mechanical ventilation and improved
ability to support the circulation has led to patients
with complete cessation of all brain function and cere-
bral blood flow, but with preserved cardiopulmonary
function.
• Importantly, observational series from the 1950s detailed
the eventual circulatory deterioration of these patients.
• Making the diagnosis of brain death is important not
only for the patient and his/her family, but now entails
the opportunity for organ donation for transplantation.
• As a result, it is of critical importance to distinguish
between the severely brain injured patient and brain
death.
• Currently, the primary etiologies leading to brain death
in adults are traumatic head injury and subarachnoid
hemorrhage.
DECLARATION OF DEATH USING
NEUROLOGIC CRITERIA
• Guidelines have been established by the President’s
Commission in 1981 and are accepted by the
American Medical Association, American Academy
of Neurology, and the American Bar Association.
• The Uniform Determination of Death Act states that
an individual who has sustained either irreversible
cessation of circulatory and respiratory functions, or
irreversible cessation of all function of the entire
brain, including the brain stem is dead.
• The determination of brain death is a clinical diagno-
sis, and the clinical examination is the primary tool to
gather the relevant data. The practitioner performing
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the examination must be competent to perform the
requisite tests to exacting standards. He/she must also
be free of any conflict of interest.
• The core feature in establishing the diagnosis is
demonstrating unresponsiveness, brain stem areflexia,
and apnea.
• Prior to making the diagnosis, two preconditions must
be met: (1) the etiology of the coma must be known and
(2) the etiology must be adequate to explain the coma.
Conversely, reversible metabolic, toxic, endocrine, or
pharmacologic derangements must not be present at
the time of evaluation.
• Imaging of the brain by either computed tomography
(CT), magnetic resonance imaging (MRI), or both is
required in the vast majority of patients as part of the
workup to determine the etiology of coma.
• Confirmatory tests include electroencephalogram
(EEG) and cerebral perfusion studies; however, these
should be used only when the underlying etiology or
the reversibility of coma is uncertain.
CRITERIA FOR BRAIN DEATH
• An individual with irreversible cessation of all function
of the entire brain, including the brain stem, is dead.
• The patient must be in deep coma and unresponsive to
all external stimuli, including pain, bright light, or
loud noises.
• Brain stem reflexes must be absent:
 Pupils must be unreactive to light. The size of the
pupils is most often midposition (4–6 mm) although
this is not required.
 Ocular movement must be absent to passive head
turning (i.e., absent oculocephalic reflex) and to irri-
gation of ear canals with 30 mL of iced water at
head elevation of 30°.
 Corneal reflexes must be absent.
 Oropharyngeal reflexes (gag, cough) must be absent
(if testable).
 Apnea testing is a critical part of brain stem assess-
ment. Patient must have a normal blood pressure
and be ventilated with 100% oxygen prior to test-
ing. A maximum stimulus for breathing is attained
when PCO2 is >60 mmHg. This usually occurs by
10–15 minutes of apnea. Arterial blood gas (ABG)
should be sent to confirm the appropriate level of
PCO2 stimulus.
 Decerebrate or decorticate posturing require intact
brain stem structures at and below the level of the
vestibular nuclei, and are inconsistent with brain
death.
 Spontaneous reflex movements have been well
described in patients and can confuse the diagnosis of
brain death. The Lazarus sign, gooseflesh followed
by upper extremity extensor movements and flexion
of arms and hands to the sternum; undulating toe
flexion, and hip flexion have all been described. If
present, a careful reassessment of the neurologic
examination and confirmatory tests may be used to
reassure caregivers and family of the certainty of the
diagnosis.
• The cause of coma must be known and irreversible.
 If not immediately ascertainable by clinical data and
neuroimaging, confirmatory studies, such as EEG,
and cerebral perfusion studies (Doppler ultrasound,
cerebral angiography, or technetium scintigraphy)
should be performed.
 If present, hypothermia, hypotension, and metabolic
derangements should be corrected. If a toxic inges-
tion is suspected, identification of the agent should
be made, if possible. An observation period of four
times the elimination half-life should be used prior
to making the diagnosis of brain death. If an
unknown agent is suspected, an observation period
of 48 hours may be used.
 After determination of brain death, family and/or
legal surrogate decision-maker should be notified.
Appropriate organ-procurement agencies should be
contacted to facilitate approaching the legal surro-
gate for organ donation (Table 79-1).
TABLE 79-1 Criteria for Determination of Brain Death
1. Coma, unresponsive to stimuli above the foramen magnum.
2. Apnea off ventilator (with oxygenation) for a duration sufficient to
produce hypercarbic respiratory drive (usually 10–20 min to achieve
PCO2 50–60 mmHg).
3. Absence of cephalic reflexes, including papillary, oculocephalic,
oculovestibular (caloric), corneal, gag, sucking, swallowing, and
extensor posturing. Purely spinal reflexes may be present, including
tendon reflexes, plantar reflexes, and limb flexion to noxious stimuli.
4. Body temperature above 34°C.
5. Systemic circulation may be intact.
6. Diagnosis known to be structural cause or irreversible metabolic
disturbance; absence of drug intoxication, including ethanol,
sedatives, potentially anesthetizing agents, or paralyzing drugs.
7. In adults with known structural cause and without involvement of
drugs or ethanol, at least 6 h of absent brain stem function; for
others, including those with anoxic-ischemic brain damage, at least
24 h observation plus negative drug screen.
8. Diagnosis of brain death inappropriate in infants younger than 7 days
of age. Observation of at least 48 h for infants aged 7 days to 2 months,
at least 24 h of observation for those aged 2 months to 1 year, and at
least 12 h for those aged 1–5 years (24 h if anoxic-ischemic brain
damage). For other children, adult criteria apply.
9. Optional confirmatory studies include:
a. EEG isoelectric for 30 min at maximal gain
b. Absent brain stem evoked responses
c. Absent cerebral circulation demonstrated by radiographic,
radioisotope, or magnetic resonance angiography
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80 ANEMIA, TRANFUSION,
MASSIVE TRANFUSION
Maria Dowell
KEY POINTS
• Anemia developing in the ICU often has a contribu-
tion from phlebotomy, but other causes of red cell
loss, as well as red cell destruction or underproduction
should be explored.
• For patients without active blood loss or cardiac dis-
ease, a transfusion target of 7–9 g/dL of hemoglobin
appears safe.
• Massively transfused patients may develop hypother-
mia or coagulopathy, each of which may accelerate
their further blood loss.
ANEMIA
• Common in critically ill patients and often multifactorial.
• Oxygen delivery to tissues depends on hemoglobin
concentration, hemoglobin saturation, and cardiac
output. Compensatory mechanisms for anemia include
increasing cardiac output (overall blood flow), periph-
eral vascular changes (individual organ perfusion),
and increased oxygen extraction.
• Evaluation of the anemic patient should determine
whether or not there is active bleeding and any need
for urgent transfusion. Consideration should then be
given to the pathophysiologic process responsible for
the anemia. Besides a careful history and examina-
tion, examination of the blood smear and evaluation
of the red cell indices and reticulocyte count may pro-
vide clues to the possible pathophysiology involved.
• The differential diagnosis includes blood loss, hemol-
ysis, sequestration, and underproduction.
 Blood loss: Generally through hemorrhage or phle-
botomy. Gastrointestinal bleeding is the most common
site of blood loss, but retroperitoneal, intrapleural,
intramuscular, or mediastinal hemorrhage may result
from invasive procedures. Compensation for the daily
phlebotomy that tends to occur in the ICU roughly
requires a twofold increase in erythropoiesis.
 Hemolysis: May be diagnosed by anemia, increased
erythroid production (reticulocytosis, polychroma-
sia, basophilic stippling, nucleated red blood cells
[RBCs]), and increased RBC turnover (hemoglo-
binemia/uria, hyperbilirubinemia, increased lactate
dehydrogenase [LDH], decreased haptoglobin).
Intravascular destruction causes hemoglobinemia
and may be due to glucose-6-phosphate dehydroge-
nase (G6PD) deficiency (Heinz bodies), microan-
giopathic hemolytic anemia, transfusion reaction, or
erythrocytic infection. Extravascular destruction
may arise from sickle cell disease and immunohe-
molytic anemia. Patients in the ICU may also expe-
rience microangiopathic hemolytic anemia with
schistocytes (disseminated intravascular coagula-
tion [DIC], thrombotic thrombocytopenic purpura
[TTP], hemolytic uremic syndrome [HUS], valve
prosthesis) or iatrogenic hemolysis from intra-aortic
balloon pumps, left ventricular assist devices, and
extracorporeal membrane oxygenation.
 Sequestration: Splenic sequestration may arise from
any causes of spleen enlargement. Anemia and mild
thrombocytopenia are common and blood smears
may reveal spherocytes, giant platelets, and reticu-
locytosis. Splenectomy may be performed if under-
lying disorder cannot be completely corrected.
 Underproduction: An absolute reticulocyte count is a
simple way to evaluate bone marrow function and an
anemic patient with a low or normal reticulocyte
count has at least some degree of underproduction.
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Underproduction may manifest as megaloblastic
anemia (folate or B12 deficiency), hypochromic
anemia (iron deficiency), marrow infiltration (tumor,
fibrosis, granulomata, miliary tuberculosis), or pri-
mary reduction in erythroid activity (chronic renal
failure).
• Critically ill patients may be at increased risk for the
immunosuppressive and microcirculatory complica-
tions of RBC transfusion; therefore, erythropoietin was
evaluated in several studies and has been shown to
reduce the number of RBC transfusions during hospi-
talization. As the dosing regimens varied considerably
among these studies, defining the optimal dosing regi-
men and route of administration remains the subject of
ongoing investigation. There is general agreement,
however, that iron should be administered concurrently.
TRANSFUSION
• Indications/contraindications: In the face of increased
awareness of infectious diseases transmitted by blood
transfusion, in general there is no justification for
transfusing anemic patients with adequate cardiovas-
cular compensation and whose anemia will respond to
medical therapy. Many critically ill patients, however,
have severely limited oxygen delivery in the face of
increased oxygen demand and transfusion may
improve oxygenation to critical organs. Other indica-
tions include major trauma with bleeding, shock due
to blood loss, intraoperative blood loss, and anemia.
The Transfusion Requirements in Critical Care trial
determined that a restrictive strategy of RBC transfusion
(hemoglobin <7 g/dL to preserve a level of 7–9 g/dL)
was at least as effective and likely superior to liberal
transfusion (hemoglobin <10 g/dL to preserve level of
10–12 g/dL). The possible exception to this was the
setting of acute myocardial infarction (MI) and unsta-
ble angina.
• Blood components: One unit (approximately 200–250 mL)
of packed RBCs will increase the hemoglobin by 1 g/dL
and hematocrit by 3% in an average-sized adult.
• Adverse effects/immunologic considerations: The
most common adverse effect, but associated with few
clinical consequences, is allergic, nonhemolytic,
febrile transfusion reaction. Also commonly seen are
RBC alloimmunization and leukocyte/thrombocyte
alloimmunization. RBC transfusions are associated with
higher rates of infectious complications probably
related to exogenous iron availability to the bacteria and
immunosuppressive effects related to leukocyte expo-
sure and sensitization. Hepatitis A/B/C, human immun-
odeficiency virus (HIV), human T-cell lymphotropic
viruses (HTLV), and parvovirus B19 infections occur
rarely. In several hematologic conditions (aplastic
anemia, acute leukemia, myelodysplasia), transfusion
should be avoided if possible to reduce the risk of
alloimmunization in bone marrow transplant candi-
dates or those requiring long-term blood product
support.
• Iron overload: It is generally advisable to avoid trans-
fusions in stable patients with chronic anemia to avoid
the complications of iron overload (cardiac failure,
arrhythmias, cirrhosis). Diagnosis of iron overload
requires elevated serum iron content, transferrin satu-
ration, ferritin, and evidence for increased hepatic iron
stores.
• Transfusion therapy: Workup for transfusion requires
RBC typing and an antibody screen and crossmatch
(30–45 minutes). If the situation requires extremely
urgent transfusion, a blood sample must be delivered
to the blood bank before blood is administered after
which group O, Rh-negative packed RBC may be
given. If time permits in emergent situations or mas-
sive transfusions, an abbreviated immediate spin
crossmatch (5 minutes) can be done and involves
reaction of the recipient’s serum with donor red cells
to look for IgM to ABO blood groups.
MASSIVE TRANSFUSION
• Generally refers to volume transfused within a 24-hour
period that approximates the patient’s normal blood
volume.
• Clinical results depend on the effects of shelf storage
and the dilutional effects on platelet number and coag-
ulation factors. Theoretically, aged RBC packs expe-
rience seepage of K+ into the plasma, reduced plasma
bicarbonate levels, rise in lactate concentration, and
deterioration of some of the coagulation factors. With
the rise in serum K+ during storage, massive transfu-
sion could lead to hyperkalemia, however, this rarely
occurs except in patients with shock, acidosis, and
reduced renal perfusion. Hypokalemia may actually be
more common as a result of the hypokalemic RBCs
uptake of K+ after transfusion.
• Due to the rise in lactic acid content of stored RBCs,
massive transfusion may result in a temporary shift of
the oxygen dissociation curve of hemoglobin with
tighter binding of O2 to hemoglobin and impaired
tissue oxygenation. The temporary increase in O2
affinity can be compensated for by increases in car-
diac output and regeneration of 2,3-bisphosphoglycer-
ate (2,3-DPG) by RBCs.
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• Normal functioning platelets are virtually absent in
stored blood. Useful tests in guiding management of
coagulopathy during massive transfusion are platelet
count, fibrinogen level. Prothrombin time (PT), partial
thromboplastin time (PTT), and bleeding time may
also be useful.
• Hypocalcemia may result from the binding of calcium
by the citrate anticoagulant in stored blood. However,
citrate is rapidly metabolized by the liver and clini-
cally significant hypocalcemia does not usually
develop. Nevertheless, the serum ionized calcium
level and an ECG to assess QT interval should be
monitored during massive transfusion.
• Massive transfusions may result in lowering of the
patients’ core body temperature as the rapidly admin-
istered products may not have been fully warmed to
body temperature. Hypothermia can cause a coagu-
lopathy (see Chap. 72).
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81 SICKLE CELL DISEASE
D. Kyle Hogarth
KEY POINTS
• Sickle cell disease is a disease of chronic hemolytic
anemia.
• The acute manifestation of the disease is the VOC.
• Sickle cell patients will require ICU management for
the ACS, very severe anemia, sepsis, stroke, priapism,
and splenic sequestration.
• Red cell transfusion is an important treatment for
most sickle cell patients requiring ICU management.
Aggressive initiation of rapid exchange transfusion is
indicated for CNS events, serious respiratory disease,
or multiorgan failure in sickle cell patients.
• Patients requiring surgery should undergo preopera-
tive red cell transfusion and attentive supportive care
postoperatively.
• Secondary pulmonary hypertension is an underrecog-
nized complication of the disease and occurs in 30%
of patients.
INTRODUCTION
• Sickle cell anemia affects 1 in 500 African American
births in the United States. It is an autosomal recessive
disease.
• Sickle hemoglobin will form rod-like polymers in
deoxygenated red cells. This occurs in areas with low
oxygen tension, acidosis, or hyperosmolarity (see
Fig. 81-1).
• The consequence of the polymerization of the hemo-
globin is impaired blood flow and tissue damage. The
subsequent ischemia and reperfusion of the tissue
leads to generalized inflammation, organ dysfunction,
and the potential for organ infarction.
• Fever and leukocytosis are common consequences of
the tissue ischemia.
• The tissue ischemia and infarction produce severe pain.
These episodes are referred to as “acute pain crisis” but
are better referred to as vaso-occlusive crisis (VOC).
Depending on the organ location and syndrome, the
vaso-occlusive crisis sometimes has other names, for
example, acute chest syndrome (ACS).
FIG. 81-1 Sickle cells. Homozygous sickle cell disease.
SOURCE: Lichtman MA, Beutler E, Kipps TJ, eds., Williams
Hematology, 7th ed. New York, NY: McGraw Hill.
• The microcirculation can be acutely or chronically
impaired in virtually any organ in the body. Typically,
chronic dysfunction of organs follows after damage
done from a lifetime of acute attacks.
• Sickle cell disease is essentially a severe hemolytic
anemia. The hemolysis is mostly extravascular and is
due to mechanical injury and destruction of erythro-
cytes that are no longer pliable or flexible due to intra-
cellular hemoglobin S polymerization.
• Labs at baseline typically demonstrate a normocytic,
normochromic anemia with reticulocytosis.
• Hydroxyurea reduces disease severity and mortality rate.
PHYSIOLOGY
• As a consequence of the chronic anemia and dimin-
ished oxygen-carrying capacity, the cardiac output is
increased.
• Most adult patients are functionally asplenic due to
subclinical infarctions of the spleen.
• The baseline glomerular filtration rate is elevated,
leading to hyperfiltration. Thus, a low baseline serum
creatinine range is normal and typically ranges from
0.5 to 0.6 mg/dL. This is due to the increased cardiac
output and higher plasma content. Therefore, a serum
creatinine level >0.6 mg/dL raises the concern about
renal insufficiency.
• Sickle cell patients have a baseline hyperdynamic car-
diovascular examination. They have relatively low
blood pressure, low systemic and pulmonary vascular
resistance, and high cardiac output. Baseline sickle cell
patient examinations are very similar to septic patients.
• Leukocytosis is commonly present, but reticulocytes
are often miscounted as white blood cells (WBCs) in
the complete blood count and may give an artificially
elevated WBC count.
VASO-OCCLUSIVE PAIN CRISIS
• The VOC is the most common manifestation of sickle
cell anemia.
• The attacks are severely painful and result from impaired
microvascular flow, and affect the bones most commonly
(Fig. 81-2).
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FIG. 81-2 Proposed mechanisms of vascular occlusion in sickle cell disease.
Panel A (on left) illustrates adhesion of sickle cells to the vascular endothelium
in postcapillary venules and venules. Panel B (on right) illustrates the subsequent
trapping of dense red cells in the partially obstructed postcapillary venules, fol-
lowed by retrograde obstruction.
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• Management involves analgesics, including non-
steroidal anti-inflammatory medications and/or opioids.
Hydration should be maintained with isotonic saline.
• Hypoxemia should be corrected immediately.
• All patients should be evaluated for and monitored for
development of the ACS.
ACUTE CHEST SYNDROME
• A dreaded complication of sickle cell disease is the
ACS. This VOC of the lung leads to an acute lung
injury syndrome, and in extreme states is similar to
the acute respiratory distress syndrome.
• ACS should be considered present in patients with a
new pulmonary infiltrate, fever, and chest pain.
• Laboratory findings often include an acute drop in the
hemoglobin level and elevated WBC count.
• 25% of patients with ACS will require mechanical
ventilation.
• Mortality for adults with this syndrome is 9%.
• Management is pain control, IV hydration, mechanical
ventilation if necessary, and antibiotics covering for both
typical and atypical community-acquired organisms.
• Simple transfusion of 2–4 units of packed red blood
cells (RBCs) should be initiated once ACS is diagnosed.
Simple transfusion is as effective as a complete RBC
exchange. However, during ACS the hemoglobin should
be kept below 10 g/dL during the transfusion. As the
hemoglobin tends to decline during ACS, this is usually
easy to do.
SEPSIS
• Sickle cell patients are at increased risk of sepsis and
meningitis from encapsulated organisms, such as
Haemophilus influenzae and Streptococcus pneumoniae.
• This increased risk is due to the progressive loss of the
spleen due to microinfarctions in the splenic circulation.
STROKE
• Stoke will occur in about 7% of sickle cell patients
over a lifetime, with a peak incidence in adults over
50 years old.
• The strokes commonly affect large vessels.
• Management of stroke in sickle cell patients is emer-
gency exchange transfusion.
PRIAPISM
• Prolonged erection of the penis is extremely painful
and is a potential complication of sickle cell disease.
• Therapy has only been evaluated in case reports and
case controls. Exchange transfusion is considered the
accepted management, though it has not been rigor-
ously tested.
• Others have tried adrenergic agonists, nitrates, percu-
taneous drainage and irrigation of the corpus caver-
nosum, and a urologic procedure called a Winter shunt.
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82 BLEEDING DISORDERS
IN THE ICU
Michael Moore
KEY POINTS
• Bleeding disorders can be subdivided into vascular dis-
orders, platelet disorders, fibrin generation disorders,
fibrinolytic disorders, and complex coagulopathies.
• Brisk bleeding is rarely from spontaneous bleeding
due to coagulopathy: look for another cause.
• Vascular and platelet disorders usually lead to imme-
diate bleeding that is prolonged.
• Fibrin generation disorders usually lead to delayed
bleeding after initial hemostasis.
• TTP is a serious disorder suggested by the classic
pentad of fever, mental status changes, microangio-
pathic hemolytic anemia, low platelets, and renal
dysfunction.
• Consultation with hematology is suggested for com-
plex bleeding issues in the critically ill patient.
• General guidelines for invasive procedures in coagu-
lopathic patients include: perform invasive procedures
only when necessary, limit planned intervention as
much as possible, perform under direct vision by most
experienced operator available, coordinate the proce-
dure with appropriate support staff (i.e., blood bank
and pharmacy), and carefully monitor for immediate
and delayed bleeding complications.
INTRODUCTION
• Generalizations to help direct workup and treatment:
 Exclude uncomplicated vascular injury amenable to
surgical hemostasis.
 Brisk bleeding is almost never secondary to sponta-
neous bleeding from a coagulopathy alone.
 Clinically significant bleeding is most often seen in
the setting of a potential or known bleeding site.
 Use initial and follow-up laboratory screening to
predict and prevent bleeding complications in criti-
cally ill patients prior to procedures.
• Diagnosis of bleeding disorders in the ICU:
 Determine history of congenital and acquired bleeding
diathesis, recent surgery, pregnancy/abortion, transfu-
sion, medications, and/or current organ dysfunction.
 Determine by physical examination if bleeding is con-
sistent with a known vascular injury or trauma or sug-
gestive of a systemic disorder.
 Mechanism of bleeding disorder and clinical
presentation:
 Vascular and platelet disorders are characterized
by immediate bleeding that is prolonged after
onset with petechial and mucosal abnormalities.
 Fibrin generation disorders (coagulation cascade
defects) and fibrinolysis are characterized by
delayed bleeding after initial hemostasis with
prominent ecchymoses or deep muscle and joint
hemorrhage.
 Complex coagulopathies may have features of
both vascular/platelet disorders and coagulation
cascade defects.
• Screening labs:
 Complete blood count (CBC)
 Peripheral smear
 Platelet function screen and bleeding time
 Prothrombin time (PT)/partial thromboplastin time
(PTT)
 Thrombin time
 Functional fibrinogen level
 Fibrin-degradation products (FDP)/D-dimer assay
VASCULAR DISORDERS
• Vascular disorders consist of vasculitides, vascular
malformations, and microcirculatory obstructions.
 Vasculitis of any cause results in increased bleeding
risk secondary to vascular fragility.
 Vascular malformations may bleed when trauma-
tized or unintentionally biopsied.
 Diagnosis of vasculitides is suspected by palpable
purpura and absence of systemic coagulopathies.
PLATELET DISORDERS
• Platelet disorders are divided into thrombocy-
topenias, thrombocytosis/thrombocythemias, and
thrombocytopathies.
THROMBOCYTOPENIA
• The platelet count reflects the balance between platelet
production and the rate of platelet removal from the
circulation and thrombocytopenia can be secondary to
underproduction states, shortened platelet survival, or
sequestration.
UNDERPRODUCTION THROMBOCYTOPENIAS
• Etiology—generalized decrease in marrow mass or a
selective decrease in megakaryocyte number second-
ary to infectious states, drugs/toxins, immune mecha-
nisms, prior radiation injury, and occasionally idiopathic
hypoplastic or aplastic marrow.
• Diagnosis—history and bone marrow biopsy.
• Ineffective marrow states as a subgroup of underpro-
duction are characterized by normal or increased blood
cellularity with abnormal release of precursors into the
circulation. These states are found in megaloblastic
anemia with thrombocytopenia, marrow replacement
by tumor or granulomas, and in metabolic states such
as hypothyroidism and azotemia.
SHORTENED PLATELET SURVIVAL
• Common in critically ill patients.
• Etiology—fever, consumption of platelets secondary
to bleeding, sepsis, and specific disease states.
• Specific disease states leading to shortened platelet
survival include immune thrombocytopenic purpura
(ITP), posttransfusion purpura (PTP), thrombotic
thrombocytopenic purpura (TTP), disseminated
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intravascular coagulation (DIC), and heparin-induced
thrombocytopenia (HIT).
SEQUESTRATION
• Hypersplenism may result in thrombocytopenia alone
or in thrombocytopenia with anemia and neutropenia.
• Can be acute or chronic; secondary to chronic liver dis-
ease, splenic venous occlusion, or leukemia/lymphoma
involving the spleen.
• Diagnose an enlarged spleen by physical examination
or ultrasonography.
• Treatment is splenectomy in some cases.
SPECIFIC DISEASES
Immune thrombocytopenic purpura
• Associated with exposure to specific drugs, connec-
tive tissue diseases, lymphomas, and viral infections.
• Diagnosis confirmed by finding antiplatelet antibod-
ies in serum or on platelets.
• Therapy consists of general measures such as discon-
tinuing offending agents and avoidance of drugs that
interfere with platelet function.
• Directed therapy may involve corticosteroids, IVIG,
splenectomy, or IV human anti-Rh
o
(D) IgG.
• Platelet transfusion is often limited by the short sur-
vival of transfused platelets.
Posttransfusion purpura
• Diagnosis suggested by an otherwise unexplained,
abrupt onset of severe thrombocytopenia following
transfusion.
• Treatment—IVIG.
Thrombotic thrombocytopenic purpura
• Typical triggers—infections, drugs (especially ticlopi-
dine and clopidogrel), chemotherapy, and malignancies.
• Intravascular clumping of platelets results in throm-
bocytopenia and vascular occlusion of arterial beds.
• Diagnosis—suggested by classic pentad of fever,
mental status changes, microangiopathic hemolytic
anemia, low platelets, and renal dysfunction.
• Important diagnostic considerations—schistocytes on
a peripheral smear, negative direct Coombs’ test in the
setting of hemolysis.
• Standard therapy—corticosteroids and plasma exchange.
• Platelet transfusion has been shown to worsen the
vaso-occlusive state.
Heparin-induced thrombocytopenia
• Heparin-induced thrombocytopenia can occur with
any heparin product including low molecular weight
heparin (LMWH) given or exposed by any route
including heparin-coated catheters.
• Small, reversible decrease in platelet number 1–2 days
after initiation of unfractionated heparin is common.
• Immune-mediated HIT is uncommon (<1% of patients)
but a potentially serious complication of heparin
exposure.
• After initial exposure, platelet numbers usually drop
5–7 days later with a more rapid drop over 1–2 days
on re-exposure.
• Clinical consequences range from asymptomatic to
life-threatening venous or arterial thrombosis.
• Clinical diagnostic criteria include otherwise unex-
plained thrombocytopenia <150,000/µL or a 50%
decrease 2–7 days after heparin exposure.
• Treatment—discontinue all heparin products.
• Normalization of platelet count after stopping heparin
confirms the presence of HIT.
• All patients with HIT are hypercoagulable and require
immediate alternative anticoagulation.
Mechanical surface-related thrombocytopenia
• Platelets passing over or through mechanical surfaces
can result in a decrease in platelet number.
• Common examples include cardiopulmonary bypass
(CPB) and intra-aortic balloon pumps.
THROMBOCYTOSIS
• An elevated platelet count >350,000/µL is common is
the ICU.
• Can be complicated by thrombosis or bleeding.
• Can be reactive or secondary to myeloproliferative
states.
• Reactive thrombocytosis:
 Most common in ICU.
 Associated with common clinical states including
inflammation, bleeding, surgery, hemolysis, severe
injury, and cancer.
 Usually uncomplicated and does not require treatment.
• Myeloproliferative states:
 Thrombocytosis secondary to myeloproliferative
states can be associated with either bleeding or
thrombosis especially when the platelet count is
>1 × 106/µL.
 Diagnosis is usually known prior to presentation.
 Suspected by an abnormal peripheral smear or after
bone marrow biopsy.
 No definitive test is available to predict complica-
tions but a prolonged bleeding time may indicate
risk. Risk is greatest in older patients with fixed vas-
cular disease.
 Treatment for symptomatic patients:
 Plateletpheresis
 Avoid splenectomy
 Anagrelide or hydroxyurea
THROMBOCYTOPATHY
• Qualitative platelet abnormalities are common in the
ICU.
• Frequent contributor to other bleeding abnormalities
and can be independently associated with increased
bleeding risk.
• Thrombocytopathy can result from a number of clini-
cal states including uremia, drugs, myeloproliferative
disorders, dysproteinemias, cardiopulmonary disor-
ders, and active DIC.
UREMIA
• Common in ICU patients.
• Interferes with platelet function and prolongs the
bleeding time.
• Hemodialysis is the most effective treatment.
• Other therapies include corticosteroids, cryoprecipi-
tate, platelet transfusions, and intravenous estrogens.
• DDAVP will correct bleeding time but its usefulness
decreases over 1–2 days.
DRUGS
• Aspirin (ASA), nonsteroidal anti-inflammatory drugs
(NSAIDs), ethanol, and glycoprotein (GP) IIb/IIIa
platelet inhibitors are common offenders.
• ASA is a classic platelet inhibitor and irreversibly
inhibits cyclooxygenase resulting in net decrease in
thromboxane A2 and prolongation of the bleeding
time. After discontinuation of ASA therapy, newly
formed platelets function normally and the significant
effects on bleeding time usually resolve after 3 days.
DDAVP or platelet transfusion will rapidly reverse
significant platelet abnormalities in cases of acute
bleeding.
• NSAIDs reversibly inhibit cyclooxygenase and result
in shorter periods of platelet dysfunction after
discontinuation.
• GP IIb/IIIa platelet inhibitors affect the bleeding time
in a less predictable fashion.
• Treatment:
 Discontinue offending agent.
 Avoid surgery or invasive procedures for several
days after the offending agent has been discontinued
and new unaffected platelets are released into the
circulation.
 Platelet transfusion or DDAVP for acute bleeding or
emergent procedures.
DYSPROTEINEMIAS
• Abnormally increased immunoglobulins can interfere
with platelet function and prolong bleeding time.
CARDIOPULMONARY BYPASS
• Platelet contact with membranes used in CPB causes
an acquired thrombocytopathy.
• Can contribute to significant bleeding in post bypass.
• Rule out hypofibrinogenemia and inadequate heparin
neutralization.
FIBRIN GENERATION DISORDERS
• The coagulation cascade involves a series of events that
ultimately lead to the generation of a stable fibrin clot.
• Assess the coagulation cascade by PT and activated
partial thromboplastin time (aPTT).
• Bleeding can result from specific factor deficiencies,
inhibitors to factors, and combined deficiency states.
FACTOR DEFICIENCIES
HYPOFIBRINOGENEMIA
• Low functional fibrinogen levels are most commonly
from decreased hepatic synthesis or increased con-
sumption during DIC in ICU patients.
• Risk of spontaneous bleeding:
 Increases when levels fall below 100 mg/dL.
 Significantly increases when levels fall below
50 mg/dL.
 Bleeding risk is increased by high titers of fibrin
split products.
• Treatment:
 Fresh frozen plasma (FFP) or cryoprecipitate (less
volume).
 One cryopack will increase fibrinogen level
4–10 mg/dL.
 Measuring serial fibrinogen levels every 6–12 hours.
HEMOPHILIA A
• Sex-linked recessive deficiency of factor VIII.
• Most common hereditary disorder of coagulation
occurring in 1:10,000 live births.
• Laboratory features:
 Elevated aPTT
 Normal PT
 Normal von Willebrand factor (VWF)
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• Critically ill patients with hemophilia A require care-
ful correction of factor VIII levels.
• Treatment:
 Concentrated factor VIII.
 Dose and frequency is dependent on degree of
bleeding or need for invasive procedures.
 Rule out a factor VIII inhibitor prior to major surgery.
• Monitor levels before invasive procedures or surgery
and after replacement.
HEMOPHILIA B
• Sex-linked recessive deficiency of factor IX.
• Clinical and laboratory features are similar to hemo-
philia A.
• Treatment considerations are the same except replace
factor IX with FFP, factor IX concentrates, prothrom-
bin complex, or recombinant factor IX.
FACTOR VII DEFICIENCY
• Non-X-linked disorder of variable severity.
• Can present with a severe hemophilia-like condition.
• Laboratory feature—prolonged PT.
• The half-life of factor VII is short and replacement
therapy may require frequent dosing.
VON WILLEBRAND FACTOR
• Inherited abnormality of factor VIII-related antigen
that results in abnormal platelet function.
• Clinical features—bleeding disorder similar to other
quantitative or qualitative platelet disorders.
• Classification:
 Type I—most common; characterized by abnormal
secretion of normal VWF from vascular endothelial
cells.
 Type II—abnormal structure and function of VWF.
 Type III—severely decreased synthesis of normal
VWF.
• Diagnosis:
 Prolonged bleeding time, moderately prolonged PTT,
and depression of factor VIII coagulant (VIII:C) level.
 Low ristocetin cofactor and von Willebrand antigen.
 In vitro platelet function analyzer allows rapid
diagnosis.
• Treatment:
 Normalize VWF levels during active bleeding and
prior to surgery or invasive procedures.
 Type I patients may respond to DDAVP infusion.
 Tachyphylaxis develops after 1–2 days and is not
indicated for long-term use or as monotherapy for
major surgical procedures.
 Factor VIII concentrate can be used for tachyphy-
laxis because of its high VWF content.
 Factor VIII-related antigen level (VIII:C) can be used
to assess bleeding tendency and effect of treatment.
INHIBITORS
• Factor inhibitors can result in a life-threatening bleed-
ing diathesis during critical illness.
• Diagnosis is made when normal plasma mixed with
patient’s plasma fails to correct the PT or PTT.
• Inhibitor potency can be determined by titration studies.
FACTOR VIII INHIBITORS
• Most common inhibitor.
• Patient groups at risk: hemophilia, advanced age,
postpartum, lymphoma, or autoimmune disease.
• Treatment:
 Potency of inhibitors is measured in Bethesda units
 Potent inhibitors (>10 Bethesda units):
 Prothrombin complex concentrate (PCC)
 Combination immunosuppressive regimes including
steroids, cytotoxic agents, IVIG, and plasmapheresis
 Nonhemophiliacs:
 Require less intense immunosuppressive therapy
 Treat underlying malignancy or autoimmune
disease
 Treat for 10 days after major invasive procedures
LUPUS ANTICOAGULANTS
• Phospholipid inhibitor associated with prolonged
aPTT but indicates an underlying thrombophilia in
about 25% of patients.
• First described in systemic lupus erythematosus
(SLE) patients who clinically present with a throm-
bophilia in the setting of a prolonged aPTT.
• Also seen in drug-induced lupus, other autoimmune
diseases, and de novo in otherwise normal patients.
• Diagnosis:
 Prolonged PTT
 Prolonged Russell viper venom time with evidence
of an inhibitor
 Tissue thromboplastin inhibition (TTI) test with
steep rise in PT
• Treatment:
 Long-term anticoagulation in patients with deep vein
thrombosis (DVT) or pulmonary embolism (PE)
 Inhibitor potency may decrease with immunosup-
pressive therapy or after discontinuation of offend-
ing drug
COMBINED FACTOR DEFICINECY STATES
VITAMIN K DEFICIENCY
• Common in ICU patients.
• Risk factors include poor nutritional status, antibiotics,
and biliary obstruction.
• Diagnosis:
 Suggested by clinical setting
 Prolonged PT with low factor VII level
 Absence of liver disease or warfarin effects
• Treatment:
 Vitamin K supplementation
 Oral or SQ route preferred
• Complications:
 Hematoma (IM)
 Anaphylaxis (IM, IV)
FIBRINOLYTIC DISORDERS
PRIMARY FIBRINOLYSIS
• Abnormal breakdown of fibrinogen induced from a
circulating activator of plasminogen in plasma.
• This is pathologic when secondary to states of tissue
injury or therapeutic when induced by exogenous acti-
vators of plasminogen (e.g., urokinase or streptokinase).
• Euglobulin lysis time:
 Measures plasmin generated by circulating activators
 Abnormal in primary fibrinolysis
SECONDARY FIBRINOLYSIS
• Normal mechanism of clot degradation.
• Plasminogen activators present in formed clots gener-
ate plasmin.
• Euglobulin lysis time is normal.
• D-dimer levels:
 Unique to the breakdown of cross-linked fibrin
 Elevated in states of increased clot formation
 Helps differentiate fibrinogenolysis (primary fib-
rinogenolysis) from fibrinolysis (secondary fib-
rinogenolysis)
COMPLEX COAGULOPATHIES
ACUTE DISSEMINATED INTRAVASCULAR
COAGULATION
• Most important complex coagulopathy in the ICU.
• Clinical features/pathophysiology:
 Generally a state of increased propensity for clot
formation.
 May present with clinical and laboratory evidence
of hypercoagulability.
 Acutely can present with a consumptive coagulopathy
and bleeding.
 Laboratory findings include thrombocytopenia, pro-
longed clotting times, low levels of cascade factors
(especially factor VIII), and increased fibrinolysis
(high FDP, D-dimer. and hypofibrinogenemia).
 Microangiopathic hemolysis is common.
 Hemorrhagic or vaso-occlusive complications can
cause multiple organ dysfunction.
• Triggers include sepsis, tissue injury, neoplasm, burns,
giant hemangioma, retained products of conception.
• Diagnosis is made by presence of a complex coagu-
lopathy in the appropriate clinical setting.
• Treatment:
 Correct the underlying cause.
 Supportive care with transfusion of RBCs, platelets,
and FFP.
 Cryoprecipitate to correct hypofibrinogenemia.
 Monitor therapy by following clotting times, platelet
count, fibrinogen level, and FDPs.
• Heparin therapy:
 May be beneficial in severe purpura fulminans, mas-
sive thromboembolism, and acute promyelocytic
leukemias.
 Gage success of therapy based on evidence of less
bleeding with rising platelet counts and increased
fibrinogen levels.
 Contraindicated if evidence of bleeding in critical
sites (e.g., intracranial hemorrhage).
MASSIVE TRANSFUSION
• Transfusion of 1–2 blood volumes of stored RBCs in a
24-hour period increases risk of a complex coagulopathy.
• Pathophysiology:
 Dilutional and consumptive thrombocytopenia
 Thrombocytopathy
 Low factor V and VIII levels
 Cold-induced coagulopathy
 Citrate-induced hypocalcemia
• Diagnose secondary or recurrent bleeding in appro-
priate clinical setting.
• Treatment:
 Transfuse adequate amounts of platelets and FFP
 Blood warmers may be useful
 Replete calcium
ANTIBIOTIC THERAPY
• Multiple or broad-spectrum antibiotics may predis-
pose to a complex coagulopathy.
• Mechanisms:
 Vitamin K deficiency
 Penicillin-induced platelet dysfunction
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LIVER DISEASE
• Hepatic function is vital for most clotting factor and
thrombopoietin synthesis and predisposes to a com-
plex coagulopathy.
• Pathophysiology:
 Multifactorial thrombocytopenia ± thrombocytopathy.
 Hepatocyte injury can trigger primary fibrinolysis
(mimics DIC).
 DIC superimposed on liver failure results in a severe
complex coagulopathy.
• Treatment:
 Replete clotting factors, platelets, and correct vita-
min K deficiency.
 FFP is first-line therapy.
 Other options include prothrombin complex (vitamin-
K-dependent factors), fibrinolysis inhibitors, and rVIIa.
RENAL DISEASE
• Prolongs bleeding time from uremia-induced
thrombocytopathy.
• Nephrotic syndrome increases risk of acquired factor
deficiencies.
• Treatment:
 Hemodialysis
 Platelet transfusion
 FFP
DYSPROTEINEMIAS
• Multiple myeloma and Waldenström macroglobulinemia
can result in significant coagulopathies.
• Pathophysiology:
 Thrombocytopenia (disease or therapy related)
 Thrombocytopathy
 Impaired conversion of fibrinogen to fibrin
• Laboratory manifestations:
 Low platelet count
 Increased bleeding time
 Prolonged thrombin time
• Treatment—decease paraprotein levels via chemotherapy
or plasmapheresis.
INVASIVE PROCEDURE GUIDELINES
FOR COAGULOPATHIC PATIENTS
GENERAL GUIDELINES
• Perform invasive procedures only when necessary.
• Limit planned intervention as much as possible and per-
form under direct vision by most experienced operator
available.
• Carefully define the coagulopathy to gauge risk and
plan therapy.
• Evaluate success of preprocedure therapy prior to
procedure.
• Coordinate procedure with appropriate support staff,
that is, blood bank and pharmacy.
• Carefully monitor for immediate and delayed bleeding
complications.
SPECIFIC COAGULOPATHIES
VASCULITIS
• Avoid skin incisions over sites of vasculitic rashes.
• Platelet transfusion is not indicated without concomi-
tant thrombocytopenia or thrombocytopathy.
THROMBOCYTOPENIA
• Platelet counts of 50,000–80,000/µL are generally
adequate for procedures performed under direct
vision.
• Platelet counts of 80,000–100,000/µL are preferred
for major surgical procedures, insertion of central
lines, or closed-space needle biopsies.
• Lumbar punctures generally safe with platelet count
of 50,000/µL.
THROMBOCYTOPATHY
• An attempt to normalize the bleeding time is gener-
ally warranted despite the poor predictive value of an
elevated bleeding time.
• Discontinue thrombocytopathy-inducing drugs and
wait.
 Acutely transfused normal platelets will correct a
prolonged bleeding time in this setting.
 DDAVP infusions may temporarily override the
thrombocytopathic effects of aspirin and ticlopidine
in urgent situations.
THROMBOCYTHEMIA
• Platelet counts in excess of 1 × 106/µL in myelo-
proliferative disorders predispose to excessive
bleeding.
• Avoid or minimize invasive procedures.
• Normalize platelet count.
FIBRIN GENERATION DEFECTS
• A normal PT and PTT is mandatory, when achievable,
for procedures in critical sites (e.g., neurosurgery).
• Correct known factor deficiency states.
• Clotting times should not exceed 1.2–1.3 times the
baseline for procedures done under direct vision or
line placements.
• Evaluate for delayed onset bleeding.
FIBRINOLYTIC STATES
• Avoid any invasive procedures.
• Hyperfibrinolytic states with short clot survival,
hypofibrinogenemia, and elevated levels of FDPs may
result in serious bleeding during and after procedures.
• Intracranial bleeding, thrombotic events, and recent
major surgical procedures are contraindications to the
initiation of fibrinolytic therapy.
• If bleeding occurs during therapeutic fibrinolysis, dis-
continue and provide blood product support including
cryoprecipitate as source of fibrinogen.
ANTICOAGULANT DRUG EFFECTS
UNFRACTIONATED HEPARIN
• Discontinue heparin approximately 6 hours before
invasive procedures.
• Protamine sulfate is antidote for emergencies.
LOW MOLECULAR WEIGHT HEPARIN
• Relatively long half-life.
• No predictably effective antagonist.
• Can measure LMWH levels prior to procedure.
WARFARIN
• Prothrombin time normalizes in 2 or more days after
discontinuation.
• FFP or prothrombin complex (less volume) will
immediately correct the PT for emergent situations.
• Oral or intravenous vitamin K (1–5 mg):
 Onset of effect approximately 8–12 hours after
administration.
 High-dose vitamin K may lead to warfarin resistance.
• Temporary heparinization for flexible planning of
interventions after stopping warfarin therapy.
DIRECT THROMBIN INHIBITORS
• Discontinue
• Follow PTT until normal prior to invasive procedures
• No effective antagonist
DROTRECOGIN ALFA (XIGRIS)
• Recombinant activated protein C product with
antithrombotic and profibrinolytic properties used in
the management of patients with severe sepsis.
• Major side effect is bleeding.
• Most serious bleeding events are seen in patients with
coexisting thrombocytopenia ≤30,000/µL.
• Discontinue 2 hours prior to procedure and maintain
platelet count above 30,000/µL.
• Wait 12 hours after major invasive procedures before
cautiously restarting the infusion.
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83 THROMBOLYTIC THERAPY
Amit Pursnani
KEY POINTS
• Thrombolytic therapies may be employed in the man-
agement of selected patients with pulmonary embo-
lus, acute stroke, and MI.
• Stringent inclusion and exclusion criteria must be
applied to properly select patients who may benefit.
• Early treatment is important and for each clinical entity
the window of opportunity for benefit may close, leav-
ing the patient with only risk of treatment.
THROMBOLYTIC AGENTS
• Thrombolytic agents are proteins or other substances
that activate a blood proenzyme, plasminogen, to its
active enzyme form plasmin. Plasmin then solubilizes
fibrin and degrades a number of other plasma pro-
teins, including fibrinogen.
• Applications for thrombolytic therapy include acute
myocardial infarction (AMI), acute pulmonary
embolism (PE), and acute ischemic stroke.
• A number of thrombolytic agents are available and
described below.
STREPTOKINASE
• Streptokinase (SK) is derived from group C, β-hemolytic
streptococci. This agent activates adjacent plasminogen
by forming a noncovalent SK-plasminogen activator
complex. Its half-life in plasma is 30 minutes.
UROKINASE
• Urokinase (UK) is derived from cultured human cells.
It activates plasminogen directly by enzymatic action.
Its half-life in plasma is 20 minutes.
TISSUE PLASMINOGEN ACTIVATOR
• Tissue plasminogen activator (t-PA) is derived by
recombinant genetic technology from human DNA. It
is fibrin-specific unlike the agents above. It works by
activating plasminogen associated with fibrin directly
by enzymatic action. It has a very short half-life. The
following are preparations of tPA that are available:
 Alteplase (t-PA) is the glycosylated protein of 527
amino acids produced by recombinant DNA tech-
nology. There are two derivatives of tPA:
 Reteplase (sometimes called rPA) is a 39,571
molecular weight deletion mutant of tPA. It con-
tains 355 of the 527 amino acids of native tPA.
 Tenecteplase is a 527 amino acid protein produced
by recombinant technology. It differs from
alteplase (tPA) by only 6 amino acids.
PRECAUTIONS WITH USE OF THROMBOLYTICS
• Bleeding is the major complication of thrombolytic
therapy. Consequently, absolute contraindications
include dissecting aortic aneurysm, pericarditis, hem-
orrhagic stroke, or neurosurgical procedures within
6 months or known intracranial neoplasm. Relative
contraindications include major surgery or bleeding
within 6 weeks, known bleeding diathesis, and severe
uncontrolled hypertension.
• Allergic reactions: SK and the related agent anistre-
plase are potentially allergenic. Patients are usually
pretreated with intravenous hydrocortisone 100 mg
and antihistamines.
• Antibody production: SK and anistreplase induce anti-
body production, which makes re-treatment with
either of these agents less effective.
THERAPY FOR PULMONARY
EMBOLISM
BACKGROUND AND INDICATIONS
• Traditionally, thrombolysis has been reserved for
massive PE resulting in cardiogenic shock. However,
recent evidence suggests a role for thrombolysis in
stable patients (normal systemic arterial pressure) with
submassive PE and subsequent right ventricular
dysfunction.
• One study has shown that the combination of heparin
and t-PA decreased the need for escalation of treat-
ment due to clinical deterioration of patients with
submassive PE more often than patients on heparin
and placebo. Escalation of treatment included the use
of pressors, mechanical ventilation, or use of open-
label t-PA. Results of this study are summarized in
Table 83-1.
• The goal of thrombolytic therapy is rapid clot lysis,
which hastens reperfusion of lung tissue and prevents
chronic complications of PE such as pulmonary
hypertension and the more acute complication of right
ventricular infarction. A secondary goal is decreasing
the risk of subsequent pulmonary emboli by dimin-
ishing the source of embolization.
• Prior to thrombolytic administration, objective evi-
dence of pulmonary embolization must be obtained by
some imaging modality—most typically computed
tomography (CT) angiography or ventilation-perfusion
scanning, and on rare occasion pulmonary angiography.
For unstable patients, a bedside echocardiogram may
give inferential information in the form of right heart
strain and pressure overload, but it must be considered
as less compelling diagnostic information than visuali-
zation of the pulmonary circulation by some modality.
EXCLUSION CRITERIA
• Cerebrovascular accident, intracranial trauma, or sur-
gery within past 2 months
• Active intracranial disease (neoplasm, aneurysm, vas-
cular malformations)
• Major internal bleeding within past 6 months
• Uncontrolled hypertension (systolic blood pressure
[SBP] >200 mmHg, diastolic blood pressure [DBP]
>110 mmHg)
• Bleeding diathesis/coagulopathies
• Recent major surgery, organ biopsy, or obstetric delivery
(within 10 days)
• Recent trauma
• Infective endocarditis/pericarditis
• Pregnancy
• Aortic aneurysm
• Hemorrhagic retinopathy
DOSING AND USE OF THROMBOLYTICS
• Agents that have been used include SK, UK, and
alteplase (t-PA). t-PA is infused at 100 mg over 2
hours. Postinfusion partial thromboplastin time (PTT)
monitoring is necessary to ensure value 2.5 times con-
trol. If <2.5, heparin infusion should be adjusted to
maintain goal PTT. Patients should preferably be in a
closely monitored setting (i.e., intensive care unit).
Patients should be anticoagulated with heparin (and
eventually warfarin) immediately after thrombolytic
agent is completely infused. One should not adminis-
ter heparin concomitantly; check PTT every 6 hours
until therapeutic (1.5–2 times value of upper limit of
normal). Blood for laboratory tests should not be
drawn during thrombolytic infusion. If bleeding
occurs, thrombolytic infusion should be immediately
stopped and blood products should be given as
needed.
• There is a larger time window of opportunity for
thrombolysis for PE compared to stroke or MI. That
is, there is a persistent but attenuated benefit from
using thrombolytics up to 14 days after the diagnosis
of PE is made. But clearly, most benefit is derived if
these agents are used early.
THROMBOLYTIC THERAPY FOR
ACUTE ISCHEMIC STROKE
BACKGROUND AND INDICATIONS
• Acute ischemic stroke is the result of a sudden inter-
ruption of cerebral blood flow. The goal of reperfu-
sion therapy is to reperfuse potentially salvageable
tissue around the core of infarcted brain tissue.
Thrombolytic therapy is typically used after imaging
(usually CT) to rule out hemorrhagic infarct.
• Indications and exclusions for thrombolytic therapy
for stroke:
 Age ≥18 years
 Diagnosis of ischemic stroke causing clinical neuro-
logic deficits
 Symptom onset <3 hours prior to treatment initiation
 No history of stroke in last 14 days
 No history of intracerebral hemorrhage (ICH)
 SBP <185 mmHg
 DBP <110 mmHg
 No rapidly resolving symptoms
 No subarachnoid hemorrhage or suggestive symp-
toms thereof
 No gastrointestinal (GI) or urinary tract hemorrhage
in last 14 days
 No arterial puncture at noncompressible site within
last 7 days
 No seizure at onset of stroke
 Prothrombin time (PT) <15 or international normal-
ized ratio (INR) <1.7 without use of anticoagulation
 PTT in normal range (if previous use of heparin)
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TABLE 83-1 Comparison of t-PA to Placebo in the
Treatment of Pulmonary Embolus with Right Heart Strain
ESCALATION
THERAPY MORTALITY∗ OF TREATMENT∗
Placebo and heparin 3.4% 24.6%
t-PA and heparin 2.2% 10.2%
∗The P-value for mortality difference was .71 and P-value for escalation
of treatment difference was significant at .006.
SOURCE: Adapted from Goldhaber SZ. Perspective: thrombolysis for
pulmonary embolism. N Engl J Med 2002;347:1131–1132.
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 Platelet count >100,000/mm3
 Blood glucose >50 mg/dL
 No aggressive measure to decrease blood pressure
in limits above
INTRAVENOUS THROMBOLYTIC THERAPY
• tPA is given at a dose of 0.9 mg/kg (max 90 mg) over
60-minute period with the first 10% of dose given
over 1 minute as bolus.
• Neurologic examinations should be performed every
15 minutes during infusion of t-PA, followed by
assessments q 30 min for next 6 hours, and q 60 min
for next 16 hours.
• Blood pressure checks should be performed q 15 min
for 2 hours, then q 30 min for 6 hours, then q 60 min
for 16 hours. If SBP >180 or DBP >105, antihyper-
tensive drugs should be administered to maintain
blood pressure below those levels.
• In the NINDS (National Institute of Neurological
Disorders and Stroke) t-PA study, 31–50 % of patients
receiving t-PA had complete or near-complete recovery
at 3 months versus 20–38% of patients receiving
placebo. The incidence of symptomatic brain hemor-
rhage was 6.4% of t-PA group and 0.6% of placebo
group. Mortality rates similar in both groups at 3 months
and 1 year.
INTRA-ARTERIAL THROMBOLYTIC THERAPY
• Local arterial thrombolysis can be performed with a
catheter placed at the site of arterial occlusion.
• It has not yet been compared head-to-head with intra-
venous thrombolytic therapy. There is a high rate of
arterial canalization—approximately 40% with full
arterial canalization and 35% with partial canalization.
• The PROACT (Prourokinase for Acute Ischemic
Stroke) trial showed benefit of intra-arterial thrombol-
ysis in stroke caused by occlusion of middle cerebral
artery (MCA)—identified either on brain CT or CT
angiography.
THERAPY FOR ACUTE MYOCARDIAL
INFARCTION
• Thrombolytics prevent recurrent thrombus formation
and rapidly restore hemodynamic stability in selected
patients with MI. These agents can dissolve pathologic
intraluminal thrombus or embolus not yet dissolved by
the endogenous fibrinolytic system. When given within
12 hours of symptom onset, they restore patency of
occluded arteries, salvage myocardium, and reduce
morbidity and mortality of AMI.
• Thrombolytic agents studied for MI include SK and
alteplase (recombinant tPA). Alteplase is more expen-
sive but has shown a greater benefit in the GUSTO-1
(Global Utilization of Streptokinase and Tissue
Plasminogen Activator for Occluded Coronary
Arteries) trial with a 15% relative risk reduction (1%
absolute risk reduction) compared to SK. Newer agents
like tenecteplase and reteplase are as effective as
alteplase.
• Benefit from thrombolytic therapy is largely correlated
with time to therapy. Early therapy has the greatest
impact on infarct size and left ventricular ejection frac-
tion. Thrombolytic treatment should be started within
30 minutes of arrival (door-drug time). Maximum ben-
efit occurs when administered within 1–3 hours of
symptom onset.
• American College of Cardiology/American Heart
Association (ACC/AHA, 2004) guidelines recom-
mend thrombolytic therapy for patients without con-
traindications within 12 hours of symptom onset. It is
reasonable to give thrombolytic therapy within 12–24
hours after symptom onset if persistent ST elevations
or continuing symptoms are present.
• Achievement of TIMI-3 (Thrombosis in Myocardial
Infarction Trial 3) flow (normal flow which fills
distal coronary bed completely) after thrombolytic
therapy occurs in only 50–60% of patients—much
less than that achieved with percutaneous coronary
intervention (PCI) which is almost 90%. TIMI-3 flow
postintervention is highly correlated with long-term
survival.
• Risks of thrombolytic therapy for MI include bleeding—
with the most worrisome complication being hemor-
rhagic stroke. In this light, the absolute and relative
contraindications for thrombolytic therapy in MI are
summarized below:
 Absolute contraindications include prior ICH, cere-
bral vascular lesion, malignant intracranial neoplasms,
ischemic stroke in last 3 months, significant head or
facial trauma in last 3 months, suspected aortic dis-
section, and active bleeding.
 Relative contraindications are hypertension (SBP
>180), ischemic stroke more than 3 months old,
dementia, major surgery in last 3 weeks, prolonged
cardiopulmonary resuscitation (CPR, >10 minutes),
internal bleeding in last 2–4 weeks, noncompress-
ible vascular puncture, pregnancy, active peptic
ulcer, current anticoagulant use, and prior exposure
or allergic reaction to SK/alteplase (if these are the
drugs being considered).
PERCUTANEOUS CORONARY
INTERVENTION VERSUS
THROMBOLYTICS FOR MYOCARDIAL
INFARCTION
• Trials that have compared thrombolytic therapy to
angioplasty suggest an advantage of PCI or angioplasty
in terms of mortality, especially if performed early—
within 90 minutes of symptom onset. Primary PCI is
also preferable if transfering to neighboring institution
with cardiac catheterization lab within 30–60 minutes.
• PCI does not have the risk of ICH that is inherent to
thrombolytic therapy.
• Table 83-2 summarizes the results of thrombolytic
therapy versus PCI for mortality and nonfatal rein-
farction rate. There is both a clear mortality benefit
and a benefit with respect to nonfatal reinfarction
when comparing PCI to thrombolytic therapy.
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84 THROMBOTIC
THROMBOCYTOPENIC
PURPURA-HEMOLYTIC
UREMIC SYNDROME
Shashi Kiran Bellam, Joyce Tang
KEY POINTS
• Demographically, peak incidence of TTP-HUS is in
the third decade. Certain stereotyped populations that
develop TTP-HUS include HIV-infected individuals,
postchemotherapy patients, and patients receiving
cyclosporine postorgan transplantation.
• TTP is characterized by the following classic pentad:
fever, microangiopathic hemolytic anemia, thrombocy-
topenia, neurologic symptoms, and renal impairment.
• Diagnosis of TTP, however, requires only two of these
five findings: microangiopathic hemolytic anemia and
thrombocytopenia that are both otherwise unexplained.
• To diagnose TTP, it is essential to rule out other condi-
tions that may result in hemolytic anemia and thrombo-
cytopenia, including DIC and malignant hypertension.
• Treatment should include early plasmapheresis.
CLARIFICATION OF TERMINOLOGY
• Thrombotic thrombocytopenic purpura (TTP) and
hemolytic uremic syndrome (HUS) share a common
pathologic basis, overlap in terms of the organ sys-
tems they affect, and are treated in a similar fashion.
Classically, the term TTP is used in states where neu-
rologic symptoms predominate the clinical picture,
whereas HUS refers to conditions in which renal dys-
function predominates. The term TTP-HUS, however,
can be used more generally to encompass the full
spectrum of conditions.
PATHOPHYSIOLOGY
• Etiologies of TTP-HUS include the following:
 Drugs (platelet inhibitors, quinine, bleomycin, mit-
omycin, gemcitabine, cisplatin, cyclosporine, vala-
cyclovir, others reported)
 Autoimmune diseases (antiphospholipid antibody
syndrome, systemic lupus erythematosus [SLE],
scleroderma)
 Pregnancy and postpartum state
 HIV/AIDS
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TABLE 83-2 Thrombolytic Therapy Vs. PCI
ENDPOINT
(AT 30 DAYS) ANGIOPLASTY FIBRINOLYSIS
Mortality 8.5% 14.2%
Nonfatal 1.6% 6.3%
reinfarction
SOURCE: Adapted from Andersen HR, Nielsen TT, Rasmussen K, et al.,
for the DANAMI-2 Investigators. A comparison of coronary angioplasty
with fibrinolytic therapy in acute myocardial infarction. N Engl J Med
2003;349:733–742.
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 Enterohemorrhagic Escherichia coli with bloody
diarrhea
 Idiopathic
• TTP-HUS has numerous etiologies, but a single
common pathologic endpoint:
Inciting event → platelet aggregation → thrombi
formation
• Vessels in the kidneys and brain are disproportionately
affected.
CLINICAL PRESENTATION
• Thrombotic thrombocytopenic purpura is character-
ized by pentad of fever, microangiopathic hemolytic
anemia, thrombocytopenia, neurologic symptoms, and
renal impairment. 
• Symptoms of TTP vary with the extent and severity of
the thrombotic lesions. Neurologic findings can be
nonspecific and mild (such as a headache) or severe
(such as seizures or coma). Renal dysfunction may
range from mild insufficiency to acute renal failure.
• Even in the absence of characteristic physical findings,
however, the existence of characteristic laboratory find-
ings of hemolytic anemia and thrombocytopenia should
be sufficient to arouse suspicion and workup for TTP.
DIAGNOSIS
• Differential diagnosis includes disseminated intravas-
cular coagulation (DIC), malignant hypertension,
preeclampsia, and vasculitis.
• Key lab findings for diagnosis of TTP include the
following:
 Evidence for a hemolytic anemia
 Schistocytes on smear (usually >1%)
 Elevated indirect bilirubin, lactate dehydrogenase
(LDH), severely reduced haptoglobin
 Thrombocytopenia (often <50,000/µL, but the range
is wide)
 Absence of coagulation abnormalities
 Normal prothrombin time (PT)/partial thrombo-
plastin time (PTT)
 Normal fibrinogen level
 Normal level of fibrin-degradation products
 Negative direct Coombs’ test
• DIC may be distinguished from TTP-HUS by the
following:
 Different precipitating factors: DIC is more common
in the setting of sepsis or peripartum situations, while
TTP-HUS will evolve without evidence of infection
and often earlier in pregnancy when it is pregnancy
related
• Patients with malignant hypertension and preeclamp-
sia may have supporting pertinent histories and phys-
ical findings suggesting these as diagnoses. TTP is
rare in pregnant patients.
• Patients with vasculitis may have other signs/symptoms
of systemic involvement including rash and arthralgias.
TREATMENT AND OUTCOMES
• Therapy for TTP should be approached as a hemato-
logic emergency.
• Plasma exchange (plasmapheresis) is the therapy of
choice for TTP.
• Plasma exchange should occur daily until evidence that
disease is in remission (platelet count >150,000/µL,
afebrile, normal mental status, normal renal function,
and normal urinary sediment).
• The usual length of plasma exchange treatment is
5–10 days.
• In patients not improving with plasma exchange,
splenectomy should be considered.
• Steroids and vincristine are used but there is no proven
role for them.
• The mortality rate is 20–30%.
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85 DISSEMINATED
INTRAVASCULAR
COAGULATION
Steven Q. Davis, Sandy Nasrallah
KEY POINTS
• Disseminated intravascular coagulation is a syndrome
resulting in both thrombosis and hemorrhage.
• DIC is the most important coagulopathy in critical ill-
ness, as it complicates several disease states com-
monly seen in the intensive care unit setting.
• It is an acquired disorder, resulting from an underly-
ing condition.
• Multisystem organ failure can occur.
• Diagnosis is based on clinical presentation in con-
junction with a panel of blood tests.
• The complete picture of DIC is characterized by
thrombocytopenia, prolonged clotting times, low
levels of clotting factors and fibrinogen, and increased
fibrin degradation products and D-dimer.
• Treatment of DIC is aimed at treating the primary
disorder.
• Transfusion of blood products may be required to
counteract the hemorrhagic complications while the
primary disorder is being treated.
PATHOPHYSIOLOGY
• Widespread activation of the clotting cascade is initi-
ated by the increased presence of tissue factor, which
can result from (Fig. 85-1):
 Enhanced expression by inflammatory cells
 Vascular epithelial injury
 Release of thromboplastins into the systemic
circulation
• Inflammatory cytokines can initiate clotting, which,
in turn, can stimulate inflammation, resulting in a
self-perpetuating cycle.
• Counteracting, homeostatic systems are disrupted in
disseminated intravascular coagulation (DIC), leading
to an imbalance favoring clot formation:
 Dysregulation and excessive production of thrombin
and subsequent fibrin deposition causes widespread
activation of the clotting cascade.
 The normal anticoagulant mechanisms are perturbed,
resulting from decreased concentrations and activa-
tion of antithrombin III and protein C, as well as
insufficient levels of tissue factor pathway inhibitor to
prevent coagulation.
 Impaired fibrinolysis occurs via enhanced pro-
duction of plasminogen-activator inhibitor (PAI)
type 1.
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FIG. 85-1 Pathogenic pathways involved in disseminated intravascular coagulation. In patients with dissemi-
nated intravascular coagulation, fibrin is formed as a result of the generation of thrombin mediated by tissue factor.
Tissue factor, expressed on the surface of activated mononuclear cells and endothelial cells, binds and activates
factor VII. The complex of tissue factor and factor VIIa can activate factor X directly (black arrows) or indirectly
(white arrows) by means of activated factor IX and factor VII. Activated factor X, in combination with factor V, can
convert prothrombin (factor II) to thrombin (factor IIa). Simultaneously, all three physiologic means of
anticoagulation—antithrombin III, protein C, and tissue factor pathway inhibitor (TFPI)—are impaired. The result-
ing intravascular formation of fibrin is not balanced by adequate removal of fibrin because endogenous fibrinoly-
sis is suppressed by high plasma levels of PAI-1. The high levels of PAI-1inhibit plasminogen-activator activity and
consequently reduce the rate of formation of plasmin. The combination of increased formation of fibrin and inad-
equate removal of fibrin results in disseminated intravascular thrombosis. FDPs denote fibrin-degradation products.
SOURCE: Adapted from Levi M, ten Cate H. Current concepts: disseminated intravascular coagulation. N Engl J
Med 1999;341:586–592.
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• Systemic clotting occurs within the microvasculature,
which can then lead to multisystem organ failure.
• Overconsumption of clotting factors and platelets
exhausts the coagulation system, therefore, leading to
widespread bleeding.
COMMON UNDERLYING
CONDITIONS
• Sepsis-induced DIC can occur with any type of microor-
ganism infection. The pathogen promotes a generalized
inflammatory response by the host immune system,
resulting in a widespread release of cytokines. These
cytokines may then stimulate circulating granulo-
cytes and macrophages to produce and release more
tissue factor.
• Trauma can lead to DIC by hemolysis, endothelial
damage, and the release of fats and phospholipids
from damaged tissues.
• The mechanism by which malignancy causes DIC is
unclear, but is possibly related to expression of tissue
factor on tumor cell surfaces.
• During obstetrical emergencies, thromboplastin-like
products can seep into the maternal circulation, acti-
vating widespread clot formation. This can occur with
several obstetrical conditions, including amniotic
fluid embolism and abruptio placentae.
• Vascular disorders, including giant hemangiomas and
large aortic aneurysms, may mediate DIC by the local
activation of coagulation with systemic depletion of
clotting factors.
CLINICAL PRESENTATION
• DIC can be acute or chronic.
 Acute DIC develops when a large amount of tissue
factor is released within the circulation in a short
amount of time, overcoming the natural anticoagu-
lant and fibrinolytic mechanisms.
 Chronic DIC occurs when there is a continuous,
slow release of tissue factor within the circulation.
When this process is gradual enough, the body is
able to compensate by adequately repleting clotting
factors and platelets, which results in more throm-
bosis than bleeding.
• Bleeding is the most common clinical manifestation
of acute DIC, occurring in about 60% of patients.
 Ecchymoses, petechiae, and diffuse oozing of blood
from line sites, surgical wounds, and mucosal sur-
faces may occur. If widespread, this bleeding can be
life-threatening.
 Bleeding within the central nervous system (CNS)
can present with mental status changes, coma, or
focal neurologic deficits.
 Pulmonary hemorrhage occurs in approximately 15%
of patients with DIC, resulting from pulmonary vas-
cular endothelial damage. This can lead to tachypnea
and dyspnea and, if severe enough, may cause the
acute respiratory distress syndrome (ARDS).
 Gastrointestinal (GI) bleeding may lead to signifi-
cant blood loss secondary to the large amount of GI
mucosal endothelium subject to injury.
• Acute renal failure (ARF) is also commonly seen with
DIC.
 ARF is likely directly caused by DIC via clotting of
the renal microvasculature, leading to ischemia of
the renal parenchyma.
 Indirectly, severe hypotension, as may occur with
sepsis or trauma, can also lead to acute tubular
necrosis concomitant with DIC.
• Jaundice is frequently present in patients with DIC.
 This is caused by an unconjugated hyperbilirubinemia,
resulting from hemolysis. Deposits of intravascular
fibrin cause lysis of red blood cells by shear stress
forces.
 Hepatic dysfunction from an underlying disorder, such
as sepsis, may also contribute to this presentation.
DIAGNOSIS
• There is no single test that can diagnose DIC.
• One of the clinical conditions known to trigger DIC
must be present to make this diagnosis.
• There are several blood tests that can be used in con-
junction with the clinical presentation to identify the
presence of DIC:
 Low platelets, defined as <100,000, or an abrupt
drop in the platelet count
 Prolongation of prothrombin time (PT) and activated
partial thromboplastin time (aPTT), representing the
overconsumption of coagulation factors
 Elevated concentration of fibrin degradation prod-
ucts, indicative of increased fibrinolysis
 Elevated D-dimer, resulting from cross-linked fibrin
degradation
 Decreased circulating fibrinogen concentration,
reflecting its massive deposition within the blood
vessels
 Decreased levels of specific coagulation factors,
including factors V, VII, and VIII
 Decreased levels of anticoagulant factors, such as
antithrombin, protein C, and protein S
 Schistocytes seen on peripheral blood smear, signi-
fying the presence of hemolysis
TREATMENT
• The paramount therapy for DIC is treatment of the
underlying, driving condition.
• Supportive (replacement) therapy may positively
impact morbidity and mortality when the patient is
significantly bleeding or at risk for bleeding.
 When active bleeding occurs, platelets, fresh frozen
plasma (FFP), and cryoprecipitate can be given to
replace the exhausted platelets and coagulation
factors.
 These blood products should also be given in situa-
tions where an invasive procedure must be
performed.
• In theory, the use of anticoagulants could disrupt the
massive clotting that occurs during DIC, but there
has been little clinical evidence to support this pre-
sumption. In specific clinical situations, however,
the use of anticoagulants, such as heparin, may be
appropriate.
 For catastrophic thromboembolism or purpura ful-
minans, heparin therapy is appropriate together with
the aforementioned blood product support.
 In chronic, low-grade DIC, subcutaneous heparin
may help to prevent thrombotic complications.
 Heparin dosing is variable, depending on the clot
burden generated by the coagulopathy. In general, the
dose is lower than that given for anticoagulation for
more routine purposes (i.e., venous thromboembolism).
• Replacement of anticoagulant factors, such as
antithrombin and protein C, has been used with vari-
able success and is not routinely recommended.
• Clotting times, platelet count, and fibrinogen level are
all used to follow the progress of therapy. Fibrinogen-
degradation product (FDP) levels lag behind clinical
improvement.
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86 THROMBOCYTOPENIA IN
CRITICALLY ILL PATIENTS
Daniel A. Pollyea
KEY POINTS
• Thrombocytopenia is a common occurrence in the
ICU and increases risk for bleeding complications.
• Common skin findings from low platelets include
petechiae, purpura, or ecchymosis, particularly in
dependent areas.
• Causes of thrombocytopenia can be classified into one
of four broad categories, including: pseudothrombo-
cytopenia, dilution, increased platelet destruction, and
decreased platelet production.
• Sepsis is the most common cause of thrombocytope-
nia in ICU patients.
• Drug-induced thrombocytopenia is not uncommon in
the ICU. Heparin is the most common ICU medication
responsible for thrombocytopenia, but others include
thiazide diuretics, valproic acid, and trimethoprim/
sulfamethoxazole.
DEFINITION
• Thrombocytopenia is defined as a platelet count
<150,000/mm3.
• The risk of bleeding complications increases as platelet
counts decrease (Table 86-1).
INCIDENCE AND PROGNOSIS
• Thrombocytopenia is common in intensive care unit
(ICU) patients.
• Twenty-three percent reach a nadir platelet count
<100,000/mm3.
252 SECTION 6 • HEMATOLOGY AND ONCOLOGY
TABLE 86-1 Bleeding Risk Stratification According to
Platelet Count∗
PLATELET COUNT
(CELLS/MM3) BLEEDING RISK
>100,000 No increase in risk
50,000–100,000 Increased risk with major trauma
10,000–50,000 Increased risk with minor trauma
<10,000 Risk of spontaneous bleeding
*As platelet counts decrease the risk of bleeding increases.
SOURCE: Adapted from Reed ed, Steven EW. Thrombocytopenic disorders
in critically ill patients. Am J Respir Crit Care Med 2000; 162:347–351.
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• Ten percent have a nadir platelet count <50,000/mm3.
• Patients with thrombocytopenia were found to have
increased length of ICU stays and increased mortality.
• Mortality increases as platelet counts decrease.
PATHOPHYSIOLOGY
• Platelets are small, anucleated blood elements that are
derived from megakaryocytes in the bone marrow.
• The average adult has 250 billion platelets per liter of
blood, for a total body platelet count of over 1 trillion.
• Platelets survive in the circulation for 8 days, requiring
the production of roughly 250 billion platelets each
day.
• Injury results in a disruption of the vascular endothe-
lium. Platelets that are subsequently exposed to the
subendothelium release the contents of their cyto-
plasmic granules, which cause platelet aggregation
and activation of the coagulation cascade, allowing a
thrombus to form.
• For these reasons, low platelet counts can result in
uncontrolled bleeding.
CLINICAL PRESENTATION
AND EVALUATION
• A thorough history and physical, in concert with a
measured low platelet count, is essential for the diag-
nosis of thrombocytopenia.
• Patients with symptomatic thrombocytopenia most
commonly present with bleeding, typically from cuta-
neous and mucosal sources.
• Skin findings can include petechiae, purpura, or
ecchymoses, particularly in dependent areas.
• An ocular fundoscopic examination should be
employed if a central nervous system bleed is suspected.
• Stool samples should be tested for evidence of occult
gastrointestinal bleeding.
• Metrorrhagia or menorrhagia are occasionally pre-
senting complaints.
• Splenomegaly may be present (see “Dilutional Causes
of Thrombocytopenia,” below).
DIFFERENTIAL DIAGNOSIS
AND MANAGEMENT
• It is often difficult to identify one discrete etiology for
thrombocytopenia in ICU patients, as multiple causes
often exist.
• However, thrombocytopenia can be classified into one
of four broad categories.
• These include pseudothrombocytopenia, dilutional
causes, increased platelet destruction, and decreased
platelet production (Table 86-2).
PSEUDOTHROMBOCYTOPENIA
• If the blood sample has been inadequately anticoagu-
lated, clumps of platelets can be improperly counted
by automated cell counters.
• If thrombocytopenia seems inappropriate given the
clinical context, a repeat sample should always be
evaluated.
DILUTIONAL CAUSES
TRANSFUSION RELATED
• Often ICU patients require massive donor blood
transfusions.
• Platelets are only viable in donor blood for 24 hours.
• Therefore, the transfusion of large amounts of platelet-
free blood can result in a dilutional thrombocytopenia.
SPLENOMEGALY
• Up to one-third of all circulating platelets can be
found in the spleen.
• Patients with splenomegaly can sequester up to 90%
of the total platelet volume in the spleen, resulting in
peripheral platelet counts that appear low.
• No intervention is necessary for splenomegaly-
associated thrombocytopenia.
TABLE 86-2 Differential Diagnosis of Thrombocytopenia
Pseudothrombocytopenia Laboratory error
Dilutional causes Aggressive transfusion of blood products
Increased destruction Sepsis/DIC
Drug-induced
Thrombotic microangiopathies
(TTP/HUS)
HELLP
ITP
Decreased production • Bone marrow failure
 Bone marrow replacement
 Leukemia
 Lymphoma
 Chemotherapy
 Radiation
• Bone marrow infection
PLATELET DESTRUCTION
DISSEMINATED INTRAVASCULAR
COAGULATION-RELATED SEPSIS
• Sepsis is the most common cause of thrombocytope-
nia in ICU patients.
• It is estimated that 50% of septic patients experience
thrombocytopenia.
• The mechanism by which this occurs is not entirely
known, but it often involves disseminated intravascu-
lar coagulation (DIC).
• DIC results from an activation of the coagulation path-
ways, leading to excessive thrombin formation. This is
thought to be partially due to endothelial damage asso-
ciated with widespread infection.
• The resultant consumption of coagulation factors can
cause a combination of bleeding and clotting compli-
cations, as well as thrombocytopenia from the platelet
consumption involved in thrombosis.
• Prolonged prothrombin time (PT) and activated par-
tial thromboplastin time (aPTT), as well as decreased
fibrinogen and coagulation factors are also seen.
• Management requires identification and treatment of
the underlying disorder, which in ICU patients is often
gram-negative sepsis, meningococcemia, or viremia.
DRUG-INDUCED
• Common culprits include quinine, thiazide diuretics,
valproic acid, trimethoprim/sulfamethoxazole, and
heparin.
• Heparin is by far the most common ICU medication
responsible for thrombocytopenia.
• An antibody against platelet factor 4 in 1–3% of the
population leads to a consumptive thrombocytopenia
in the presence of heparin.
• Patients can experience venous as well as arterial
thromboses as a result of the platelet aggregation.
• Thrombocytopenia is usually apparent within 14 days of
administration of heparin, but it can occur more quickly.
• Even minimal exposure to heparin, such as from line
flushes or placement of heparin-coated catheters, can
cause thrombocytopenia in susceptible patients.
• Diagnosis of heparin-associated thrombocytopenia
is possible with an assay for heparin-induced IgG
antibodies.
• Management includes immediate discontinuation of
heparin and heparin products.
• If anticoagulation remains necessary, substitution with
lepirudin, argatroban, or Coumadin is possible.
THROMBOTIC MICROANGIOPATHIES (THROMBOTIC
THROMBOCYTOPENIC PURPURA/HEMOLYTIC
UREMIC SYNDROME)
• These are multisystem diseases characterized by throm-
bocytopenia, fevers, and microangiopathic hemolytic
anemia.
• Those who have predominant neurologic symptoms
are classified as having thrombotic thrombocytopenic
purpura (TTP), while those with predominant symp-
toms of renal failure are considered to have hemolytic
uremic syndrome (HUS). These microangiopathies
are characterized by fevers, acute renal failure, throm-
bocytopenia, anemia, and neurologic symptoms.
• TTP and HUS often overlap.
• A prognosis for these conditions can be made based
on the extent of symptoms and the severity of labora-
tory values (Table 86-3).
• The pathophysiology involved is still largely unclear,
but platelet activation from endothelial injury,
Escherichia coli Shiga toxins, and autoimmunity have
all been suggested.
• In TTP, deficiency of a protease that cleaves von
Willebrand factor (VWF) results in deposition of
VWF in the vessels, causing platelet aggregation and
shearing of red blood cells.
• Schistocytes should be visualized on the peripheral
blood smear.
• Without treatment, mortality approaches 90%.
• Plasma exchange with fresh frozen plasma until the
platelet counts recover is required for management of
TTP/HUS.
• Platelet transfusion has been considered contraindi-
cated due to concerns that it could worsen the con-
sumptive process. However, in practice, if platelet
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TABLE 86-3 Severity Score for HUS/TTP*
SCORE NEUROLOGIC SYMPTOM RENAL INVOLVEMENT PLATELET COUNT (mm3) HEMOGLOBIN (g/dL)
0 None None >100,000 >12
1 Confusion Creatinine 120–150 mmol/L 20,000–100,000 9–12
Proteinuria
Hematuria
2 Seizures Creatinine >250 mmol/L <20,000 <9
Coma Requires dialysis
Focal deficits
*Poor outcome if score >6 at presentation.
SOURCE: Adapted from Michal R, Amiram E. High incidence of relapses in thrombotic thrombocytopenic purpura. Am J Med 1987;83:437–444.
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transfusions are necessary for management of an acute
bleed or in preparation for an invasive procedure, they
may be administered with caution.
HELLP SYNDROME
• HELLP is an uncommon obstetric complication char-
acterized by hemolysis, elevated liver enzymes and
low platelets.
• It ordinarily presents in the third trimester, but can
also be seen within a week after delivery.
• HELLP is often associated with severe preeclampsia
or eclampsia.
• Besides the noted laboratory abnormalities, patients
also have schistocytes on peripheral blood smears.
• Management requires immediate delivery of the fetus
and platelet transfusions as needed.
IDIOPATHIC THROMBOCYTOPENIC PURPURA
• Patients with idiopathic thrombocytopenic purpura (ITP)
have isolated thrombocytopenia with normal red blood
and white blood cell counts, and an unremarkable
peripheral blood smear.
• ITP is a diagnosis of exclusion, thought to be the result
of an autoantibody-mediated platelet destruction.
• Prednisone, intravenous immunoglobulins (IVIG),
immunosuppressive agents, splenectomy, and platelet
transfusions can be used to manage ITP.
DECREASED PLATELET PRODUCTION
BONE MARROW FAILURE
• This condition results from decreased or absent
hematopoietic precursors in the bone marrow.
• In addition to thrombocytopenia, these patients can
have anemia or neutropenia, depending on the cell
lines affected.
• A variety of etiologies can account for bone marrow
failure (Table 86-4).
• Relevant causes in ICU patients include:
 Leukemia and lymphoma, which can invade the bone
marrow and reduce or extinguish megakary- ocytes.
 Some forms of chemotherapy or radiation which
can poison the bone marrow and prevent platelet
production.
 Viral infections, including varicella, parvovirus,
hepatitis C, Epstein-Barr, and HIV, which can infect
and damage the bone marrow.
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87 PLASMAPHERESIS IN THE
ICU
Nuala J. Meyer
KEY POINTS
• “Therapeutic apheresis” refers to a blood processing
technique designed to remove large molecular weight
substances from the circulation.
• Apheresis techniques employed in the ICU include
therapeutic plasma exchange and therapeutic cytore-
duction. Both techniques require high-flow venous
access, typically a central catheter with two lumens
for blood removal and return. Cytapheresis is the
selective removal of a specific cell type—such as
defective red cells or excess platelets or leukocytes.
Plasmapheresis employs a highly permeable filter and
dialysis equipment to remove a specific protein or to
exchange the plasma volume.
• Apheresis is most helpful when the substance to be
removed has a relatively large molecular weight, a
TABLE 86-4 Causes of Bone Marrow Failure in the ICU
Bone marrow replacement
Leukemia
Lymphoma
Myelodysplastic syndrome
Chemotherapy
Radiation
Bone marrow infection
Varicella
Parvovirus
Hepatitis C
Epstein-Barr virus
HIV
long half-life, and is toxic yet resistant to conventional
therapy.
• The most common disorders for which apheresis is
performed are hematopoietic, immunologic, or neuro-
logic disorders.
• The American Society for Apheresis (ASFA) and
American Association of Blood Banks (AABB) have
issued guidelines for therapeutic apheresis which clas-
sify the use of apheresis as category I—first-line therapy
with efficacy based on published trials or extensive
clinical experience or category II—therapeutic aphere-
sis is generally accepted in a supportive role. We will
not discuss the many disorders for which apheresis has
been attempted but without good supporting evidence
for its role (categories III and IV). The more commonly
encountered ICU situations are discussed below.
HEMATOLOGIC DISORDERS
EMPLOYING PLASMA EXCHANGE
THROMBOTIC THROMBOCYTOPENIC PURPURA
• Thrombotic thrombocytopenic purpura (TTP) is a
syndrome characterized by the pentad of microangio-
pathic hemolytic anemia, thrombocytopenia, renal
failure, neurologic changes, and fever. All five fea-
tures are rarely present, but the diagnosis relies on the
presence of an intravascular hemolytic anemia.
• Once considered universally fatal, more than 90% of
patients now survive when plasmapheresis is instituted
early.
• Plasmapheresis has a category I indication for TTP.
• Hemolytic uremic syndrome (HUS) shares many
pathologic similarities with TTP, but is considered a
category II indication for plasmapheresis, as data for
it have been less conclusive.
HYPERVISCOSITY SYNDROME
• Hyperviscosity syndrome results from circulating
paraproteins in high titers which are capable of raising
the serum viscosity, and typically stems from multiple
myeloma (IgG, IgA, or light chain disease) or
Waldenström macroglobulinemia (IgM).
• Clinical findings include headache, visual impair-
ment, mental status changes, and epistaxis, thought to
represent compromised cerebral microcirculation as
well as platelet dysfunction.
• The diagnosis is made by measuring serum viscosity.
Normal values are between 1.4 and 1.8; symptoms are
rarely present until viscosity is measured above 5.
• Plasma exchange has a category II indication for
neurologic impairment due to paraprotein-driven
hyperviscosity, and a category II indication for acute
myeloma renal failure.
COAGULATION FACTOR INHIBITORS
• Circulating anticoagulants, or inhibitors, are antibodies
which interfere with and inactivate coagulation factors,
and can often cause severe, life-threatening hemorrhage.
• Patients with a circulating inhibitor will fail to correct
their coagulopathy in a mixing study.
• Acquired factor VIII inhibitor is the most frequent
abnormality described, although any factor can be a
target of antibody production.
• Plasma exchange is given a category II indication for
the treatment of severe coagulation inhibitors.
CATASTROPHIC ANTIPHOSPHOLIPID
SYNDROME
• “Catastrophic” antiphospholipid syndrome (APS) is
the term used to describe an accelerated form of APS
resulting in multiorgan failure from occlusion of mul-
tiple small vessels in the presence of antiphospholipid
antibodies.
• Catastrophic APS is rare but life threatening, with a
mortality rate approaching 50%.
• Optimal treatment remains empiric in the absence of
large clinical trials, but a recent international consen-
sus statement recommends plasma exchange along
with anticoagulation and high-dose steroids for cata-
strophic APS whenever the patient’s condition is
deemed life threatening.
NEUROLOGIC DISORDERS
EMPLOYING PLASMA EXCHANGE
• Neurologic conditions are among the most common
indications for plasma exchange in the United States.
• Guillain-Barré syndrome and chronic inflammatory
demyelinating polyradiculoneuropathy (CIDP)—the
acquired demyelinating neuropathies—are thought to be
immune-mediated although their precise immunopatho-
genesis is not known. Both are considered category
I indications for plasmapheresis.
• Myasthenia gravis (MG) is a neuromuscular disorder
of skeletal muscle weakness, caused by autoantibod-
ies to the acetylcholine receptor (AChR). In an acute
myasthenic crisis, when the patient may have ventila-
tory failure due to profound muscle weakness,
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plasmapheresis may induce dramatic reductions in
anti-AChR antibodies and in symptomatology. MG is
a category I indication for plasma exchange.
• Lambert-Eaton myasthenic syndrome, a presynaptic
disorder of the neuromuscular junction which pres-
ents with symptoms similar to MG, is also believed to
be immune-mediated and can respond to plasma-
pheresis. It is given a category II status.
RENAL DISORDERS EMPLOYING
PLASMA EXCHANGE
• As mentioned above, multiple myeloma with acute renal
failure is a category II indication for plasmapheresis.
• Goodpasture disease, or antiglomerular basement
membrane (anti-GBM) antibody disease, is a category I
indication for plasmapheresis, whereby anti-GBM
antibody is removed from the circulation.
HEMATOLOGIC DISEASES EMPLOYING
CYTAPHERESIS
LEUKOSTASIS
• Leukostasis arises when excess white blood cells
aggregate and cause microvascular infarcts, resulting
in end-organ ischemia, hemorrhage, or infarction.
• Patients may present with acute dyspnea, mental status
changes, or visual changes, and on examination may
demonstrate pulmonary infiltrates, renal or hepatic
insufficiency, priapism, or even cerebral infarct.
• Patients at highest risk for leukostasis are those with
acute leukemia, especially acute myelogenous
leukemia, or the blast phase of chronic myelogenous
leukemia (CML) with blast counts >50,000. Despite
blast counts of >500,000, patients with chronic lympho-
cytic leukemias have a much lower risk for leukostasis.
• Acute leukemia is considered a medical emergency,
and if a patient is exhibiting symptoms consistent with
leukostasis, primary consideration should be given to
emergent reduction in the white cell count by leuka-
pheresis, chemotherapy, or a combination of the two.
• Leukapheresis has a category I indication for acute
leukemia in blast crisis.
THROMBOCYTOSIS
• In myeloproliferative disorders such as essential
thrombocytosis, the platelet count can occasionally
exceed 1 million. These abnormal platelets contribute
to a bleeding diathesis characterized by both hemor-
rhage and thrombosis.
• Symptoms of excess platelets mimic those of hyper-
viscosity, with headache, visual changes, and epistaxis.
• Cytapheresis to selectively decrease the platelet count
to below 1 million has a category I indication in
myeloproliferative syndromes.
• In contrast, cytapheresis is not indicated for reactive
thrombocytosis, such as may accompany an infectious
or rheumatologic process.
RED BLOOD CELL EXCHANGE
• In severe sickle cell crises, the abnormal red cells can
aggregate and contribute to microvascular or macrovas-
cular thrombosis, ischemia, or infarct.
• Clinically, vaso-occlusive crises can present as severe
pain crises, acute chest syndrome, cerebrovascular
accident or transient ischemic attack (TIA), or seques-
tration crisis.
• Exchanging the patient’s sickled red blood cells
(RBCs) for normal morphology cells can greatly
reduce morbidity, and should be undertaken emergently
in these circumstances. It may be helpful to follow the
patient’s fraction of sickled cells as a marker for
improvement.
• RBC exchange has a category I indication in severe
sickle cell crisis.
COMPLICATIONS OF APHERESIS
• Therapeutic apheresis procedures are generally safe
and well tolerated, with approximately a 5% incidence
of adverse events. The majority of adverse events are
reversible.
• Possible reactions include transfusion reaction,
nausea, pallor, rigors, fever, and rarely seizure.
• Complications may also arise from the placement of
central venous catheters.
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88 ACUTE LEUKEMIA
Shashi Kiran Bellam
KEY POINTS
• Acute leukemia is uniformly fatal if untreated, but
many patients can be cured with the combination of
chemotherapy and aggressive supportive care.
• Critical care is often required for either the complica-
tions of the disease or of the treatment.
• Blood transfusions should be used to maintain a hemo-
globin of 10 g/dL and a platelet count >10,000/µL.
• Extreme leukocytosis may lead to leukostasis, which
is a medical emergency and requires immediate
leukopheresis and chemotherapy.
• Many complications occur from the infiltration of
leukemic cells into various organs.
• Infection and bleeding are predisposed by the severe
pancytopenia and resolve with supportive care and
restoration of normal bone marrow production.
• Rapid cellular turnover, often precipitated by chemother-
apy, can lead to hyperuricemia and renal failure.
GENERAL CLINICAL FEATURES
• Etiology: Leukemia occurs when a genetic alteration
occurs in a hematopoietic stem cell leading to the pro-
liferation of a clone of cells in the bone marrow; ulti-
mately, the normal bone marrow elements are replaced
by neoplastic cells.
• Diagnosis: White blood cell (WBC) counts are fre-
quently elevated with abnormal cell types (especially
blasts), but some patients have normal or low WBC
counts. Anemia and thrombocytopenia are common.
More precise diagnosis and classification depends on
bone marrow aspirate and biopsy, with subsequent cyto-
chemical tests (e.g., presence of myeloperoxidase),
immunochemical tests (e.g., flow cytometry), and
cytogenetic analyses allowing for a more precise classifi-
cation. Arterial blood gases may reveal low oxygen con-
tent due to consumption of oxygen by blast cells after
sampling. This “pseudohypoxemia” may be minimized
by transport on ice and prompt laboratory measurements.
THERAPY
• Primarily chemotherapy; the successfulness of
chemotherapy depends on the individual response to
therapy and the ability of the patient to survive the com-
plications that occur with treatment. Chemotherapy can
be split into several stages (remission, consolidation,
and maintenance).
• The goal of remission therapy is to induce a complete
remission (defined as absence of leukemic cells in the
bone marrow and blood, return of normal bone marrow
cells, and return of normal peripheral blood counts).
• For induction chemotherapy, anything less than com-
plete remission does not improve survival. After
induction chemotherapy and complete remission,
most patients would relapse within 2–4 months with-
out further therapy.
• Consolidation chemotherapy aims to destroy any
residual leukemic cells (undetected) after induction
chemotherapy, and usually consists of 1–4 monthly
cycles. Patients who relapse after acute leukemia can
undergo a repeat of the induction chemotherapy regi-
men to attempt to achieve a second remission, though
the likelihood of a second remission is lower than a
first remission, and patients who relapse usually do
not have a long survival. Bone marrow or peripheral
stem cell transplantation can be an option for some
patients who suffer a relapse of their leukemia.
• Patients with evidence of peripheral organ hypoperfu-
sion may benefit from red blood cell (RBC) transfusions
to maintain a hemoglobin concentration >10 g/dL. The
significance of potential additional immunosuppres-
sion due to RBC transfusion on patients who have
leukemia and/or are neutropenic is unknown.
• All transfusions should be leukocyte depleted to
decrease the rate of alloimmunization.
• Platelets should be transfused to maintain a platelet
count of >10,000/µL. All transfusions should be single-
donor platelets collected by apheresis to decrease the
rate of alloimmunization.
• Severely neutropenic patients who remain bacteremic
despite antibiotics may benefit from granulocyte
transfusions, though complications such as rapid
alloimmunization, worsening respiratory status due to
granulocyte agglutination or infiltration into the lung,
and transmission of cytomegalovirus (CMV) infection
are potential complications.
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COMMON COMPLICATIONS
OF LEUKEMIA
HYPERVISCOSITY SYNDROME
• Etiology: Hyperviscosity syndrome is a condition of
decreased blood movement through small capillaries
leading to physical occlusion and hypoxemia (leukosta-
sis). RBC transfusions can precipitate leukostasis by
increasing blood viscosity.
• Clinical features: Include respiratory distress, cardiac
arrhythmias, and altered mental status, including coma.
• Diagnosis: Hyperviscosity occurs in the setting of
hyperleukocytosis, is defined as >100,000 blast
cells/µL. However, risks of hyperviscosity can occur
at levels between 50,000 and 100,000 blast cells/µL.
Immature myelocytes are much larger than immature
lymphocytes; thus, the incidence of leukostasis is
more common in chronic myeloid leukemia (CML) in
blast phase or acute myeloid leukemia (AML) than
acute lymphocytic leukemia (ALL). Chronic lympho-
cytic leukemia (CLL) rarely leads to leukostasis.
• Treatment: Hydration, leukopheresis to directly
remove blast cells from the circulating blood volume,
and prompt use of chemotherapeutic agents such as
hydroxyurea to decrease the blast count. Central nerv-
ous system (CNS) abnormalities can be treated with
cranial irradiation (200–400 cGy). Pulmonary abnor-
malities may respond to thoracic radiation.
MYELOID SARCOMA
• Etiology: Myeloid blast cells may form a solid tumor,
most commonly in CML with blast phase. These solid
tumors (aka myeloid sarcoma) may occur in the bone,
lymph nodes, skin, soft tissues, and gastrointestinal
(GI) tract.
• Clinical features: Common symptoms include pain,
neuropathy, and intestinal obstruction.
• Treatment: Local radiation (1000–2000 cGy) in addi-
tion to chemotherapy (which often treats these masses
quickly).
CENTRAL NERVOUS SYSTEM LEUKEMIA
• Definition: Penetration of leukemic cells into the
CNS, more commonly in children, in ALL, and with
elevated circulating blast counts.
• Clinical features: Presentations include cranial or
spinal nerve defects (neuropathy or radiculopathy).
The most common symptoms occur due to increased
intracranial pressure and include headache, nausea,
papilledema, and lethargy. Facial nerve palsies,
diplopia, spinal radiculopathy, and the cauda equina
syndrome can also occur. Mass lesions, seizures, and
meningismus are uncommon.
• Diagnosis: Finding of leukemia cells in the cere-
brospinal fluid (CSF). In that setting, usually the open-
ing pressure is elevated, the glucose concentration is
low, and the protein level is elevated. Thrombocytopenia
should be treated with platelet transfusion prior to
attempting lumbar puncture.
• Treatment: Radiation (2400 cGy to the whole brain in
12 fractions) and intrathecal chemotherapy (methotrex-
ate 12 mg/m2 to a maximum dose of 15 mg every 3
days intrathecal for at least 6 doses along with hydro-
cortisone 50 mg to prevent an inflammatory arach-
noiditis). Spinal column radiation is appropriate for
patients with symptomatic radiculopathy, but risks
damage to underlying bone marrow. Dexamethasone
(4 mg qid) can be an adjunctive treatment to lower
intracranial pressure. Chronic chemotherapy once the
CSF is clear of malignant cells should occur monthly.
An Ommaya reservoir is often used to allow for repet-
itive intraventricular administration of chemotherapy.
HEPATOSPLENOMEGALY
• Etiology/clinical features: Leukemic infiltration with
blast cells (usually in ALL or CLL) into the liver and
spleen can cause symptoms of acute hepatitis (jaun-
dice, hepatomegaly, transaminitis). Splenic infiltra-
tion may lead to vascular infarction, clinically
presenting as a painful subcapsular hematoma; rarely,
spleen rupture may occur leading to shock with
intraperitoneal hemorrhage.
• Diagnosis: Biliary ultrasound to rule out bile duct
obstruction should be performed, auscultation of the
left upper quadrant (LUQ) demonstrating a rub with
respiratory variation can be seen in splenic subcapsu-
lar hematoma, and diagnostic peritoneal lavage may
reveal intraperitoneal hemorrhage.
• Therapy: Liver infiltration usually responds to
chemotherapy; however, initial drug options may be
limited as many chemotherapeutics are metabolized
in the liver. Spleen rupture may require surgical repair.
KIDNEY INFILTRATION AND URETERAL
OBSTRUCTION
• Etiology/clinical features: Leukemic infiltration into
the kidney is more common in ALL and presents as
oliguric acute renal failure; enlarged retroperitoneal
lymph nodes may cause ureteral obstruction.
• Diagnosis: Renal ultrasound reveals kidney enlarge-
ment but no ureteral obstruction.
• Therapy: Kidney infiltration resolves with chemother-
apy, but decreased urinary function may not allow ade-
quate excretion of products of tumor lysis. Radiation
(200–400 cGy) to the kidneys or ureters can re-
establish renal excretory function prior to chemother-
apy in the case of obstructing lymphadenopathy.
TYPHLITIS (NECROTIZING ENTEROCOLITIS)
• Etiology: Typhlitis usually affects the terminal ileum,
appendix, cecum, and right colon in granulocytopenic
patients.
• Clinical features: Mimics inflammatory bowel disease,
with nausea, vomiting, abdominal pain, and tenderness,
watery or bloody diarrhea, and fever. Intestinal mucosal
ulceration allows for the loss of proteins and elec-
trolytes as well as the translocation of enteric organ-
isms into and through the bowel wall, potentially
leading to ileus, bowel perforation, and peritonitis.
Bacterial seeding of the portal vein can lead to jaundice
and hepatitis.
• Therapy: Includes antibiotics, transfusion of blood
products as needed, repletion of serum electrolytes,
and bowel rest. Agents that decrease bowel peristalsis
(e.g., narcotics) should be avoided. Granulocyte trans-
fusions can be lifesaving. Bowel perforation requires
surgical evaluation.
LYSOZYMURIA AND RENAL TUBULAR
DYSFUNCTION
• Lysozyme is a protein in granulocytes that is capable
of lysis of bacterial cells walls. It is excreted in the
urine, but is toxic to renal tubule cells and can lead to
marked hypokalemia. Treatment of the underlying
leukemia is usually adequate.
DISSEMINATED INTRAVASCULAR COAGULATION
• Etiology/clinical features: Disseminated intravascular
coagulation (DIC) universally occurs in acute
promyelocytic leukemia and can occur with any type
of leukemia. Clinical presentations include diffuse
bleeding or oozing from venipuncture sites, thrombo-
sis within the renal vasculature leading to mild renal
insufficiency (potentially exacerbated by aminoglyco-
side antibiotics, leading to acute renal failure at
normal antibiotic serum concentrations).
• Therapy: Chemotherapy to reduce the tumor burden
leads to improvement in the DIC. Blood product or
factor repletion and/or heparin administration is not
well validated and usage is institution and/or physi-
cian dependent.
• All-trans retinoic acid (ATRA) is an effective agent for
acute promyelocytic leukemia, but can lead to hyper-
leukocytosis and the retinoic acid syndrome. ATRA
induces differentiation of leukemic blasts in the bone
marrow leading to leukocytosis in the peripheral
blood. Concomitant chemotherapy and/or leukophere-
sis may be useful in reducing the WBC count. The
retinoic acid syndrome occurs in 25% of patients
receiving ATRA and presents as fever, progressive res-
piratory distress with diffuse infiltrates on chest x-ray
(CXR), pleural effusions, and weight gain anytime
from 2 days to 4 weeks after ATRA treatment.
Untreated, retinoic acid syndrome can lead to death.
Prompt treatment with steroids (dexamethasone 10 mg
bid for 3 days) is effective in most patients.
LACTIC ACIDOSIS
• Elevated blood lactate or pyruvate concentrations are
common in patients with leukemia due to a variety of
causes. Occasionally, hemodialysis or peritoneal dial-
ysis to remove lactic acid may be useful.
COMMON COMPLICATIONS
OF THERAPY
INFECTION AND SEPSIS
• Etiology/clinical features: Severe immunosuppression
may occur due to both the effect of leukemia and the
effect of therapy. Chemotherapy leads to cellular
death of mucosal barriers, leading to invasion of
endogenous organisms, such as gram-negative enteric
bacteria, gram-positive cocci, and fungi (such as
Candida and Aspergillus). Patients with ALL also
have specific susceptibility to Pneumocystis pneumo-
nia, mycobacterial, and viral infections due to lym-
phocyte dysfunction. Clinical features include fever
(temperature >101.5°F) and neutropenia.
• Therapy: Cultures of blood, urine, and sputum, and
empiric therapy with either ceftazidime or imipenem
(either as a single agent therapy) or a combination of
antipseudomonal penicillin with an aminoglycoside.
Antibiotic regimen depends on renal function, allergy
history, and individual physician preference. Empiric
vancomycin can be indicated depending on preva-
lence of methicillin-resistant gram-positive bacteria.
Transfusions of blood products as described above
should be used. Granulocyte-stimulating factors
(granulocyte colony-stimulating factor [G-CSF] or
granulocyte-macrophage colony-stimulating factor
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[GM-CSF]) can reduce the risk of febrile neutropenia
when used prophylactically.
TUMOR LYSIS SYNDROME
• Etiology/clinical features: Uric acid, a product of cell
turnover, is excreted by the kidneys and elevated
levels may cause nephropathy, either due to the high
cell turnover of the underlying leukemia, or as a
response to therapy. Urate crystals precipitate in the
collecting system due to dehydration and aciduria.
Phosphate levels may be elevated due to cellular death
leading to calcium phosphate precipitation in the
calyces and tubes.
• Therapy: Hydration to maintain urine flow, correction of
acidosis, including usage of sodium bicarbonate and
acetazolamide to alkalinize the urine to a pH of 7.0–7.5.
Allopurinol (300 mg/day) will inhibit the conversion of
cellular byproducts to uric acid. The combination of
allopurinol, hydration, and alkalinization of the urine is
usually adequate to prevent uric acid nephropathy.
Rasburicase (0.20 mg/kg) rapidly metabolizes serum
uric acid and can be given intravenously for 1–5 days.
Allopurinol should be held during that time and can be
restarted after the hyperuricemia resolves.
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89 SUPERIOR VENA CAVA
SYNDROME
Nuala J. Meyer
KEY POINTS
• Superior vena cava syndrome occurs when blood flow
through the SVC is obstructed by direct compression
or thrombus.
• SVC obstruction is most frequently caused by malig-
nancy or thrombosis. Infections are an infrequent cause.
• Patients typically present with edema of the face,
neck, and upper extremities, but may demonstrate
airway obstruction, esophageal obstruction, dyspnea,
dysphonia, or even cardiovascular compromise.
• Treatment of SVCS depends on the severity of the
patient’s symptoms as well as the underlying cause.
DEFINITION
• Superior vena cava syndrome (SVCS) is the name
given to the symptoms and signs of obstruction to
blood flow through the SVC.
• SVC obstruction occurs as a consequence of external
compression or invasion of the vessel—most commonly
by tumors of the lung or mediastinum—or of throm-
bosis within the SVC.
ETIOLOGY
• Malignancy is the most common cause of SVC obstruc-
tion, accounting for approximately 85% of cases.
 Lung cancer is the most common malignant cause
of SVCS, and among primary lung neoplasms,
small cell carcinoma is an especially frequent cause.
 Lymphoma is the second leading malignant cause of
SVCS, and may occur in 2–4% of cases of non-
Hodgkin lymphoma (Figs. 89-1, 89-2, and 89-3).
 Other malignancies rarely implicated in SVC obstruc-
tion include the tumors of anterior mediastinum
(teratoma or germ cell tumors and thymoma) or
metastatic disease to the mediastinal lymph nodes.
 SVCS may be the presenting symptom of cancer.
FIG. 89-1 Demonstrate SVCS on the CT scan of a patient with
an anterior mediastinal mass. The arrow points to the SVC, which
is moderately narrowed from Fig. 89-1.
• Thrombosis is a rapidly expanding cause of SVCS,
especially given the advent of indwelling catheters
and pacemaker leads. Thrombosis may also occur de
novo in patients with hypercoagulable states.
• Infectious complications—especially syphilitic aortitis or
fibrosing mediastinitis associated with histoplasmosis—
were historically important causes of SVCS. These
complications are relatively rare in the industrialized
world.
PATHOPHYSIOLOGY
• Tumors tend to involve the SVC by extrinsic com-
pression or by direct invasion. Enlarged mediastinal
lymph nodes or tumors arising from the central air-
ways are classically at fault.
• Rare intravascular lymphomas may arise within the
SVC itself.
• Thrombosis results from the typical risk factors of
stasis, vascular injury, or hypercoagulability, but most
often forms around a nidus for clot such as indwelling
lines.
• The more rapid the SVC obstruction, the more acute
the symptoms due to the lack of time to form collat-
eral venous channels.
CLINICAL FEATURES
• Obstruction of the SVC raises the central venous pres-
sure and impedes venous outflow from the head and
neck, reducing venous return to the right atrium.
• Depending on the extent of mediastinal compression,
airway or esophageal obstruction may also be present,
causing dyspnea or dysphagia.
• Laryngeal edema, airway obstruction, and stridor are
the most ominous complications of SVCS and represent
true medical emergencies requiring rapid treatment.
• In patients with chronic or indolent obstruction of the
SVC, venous collaterals form and may cause impres-
sive distention of the azygos, internal mammary,
intercostal, and long thoracic veins.
• Patients report dyspnea as the most frequent symp-
tom; facial swelling and fullness, arm edema, and
cough are also common. Symptoms may worsen with
lying supine or bending forward.
• On examination, one typically finds facial plethora
with obvious venous distention of the neck and chest.
• Especially when the cause is thrombotic, SVCS may
coexist with pulmonary embolism.
DIAGNOSTIC EVALUATION
• Early recognition and diagnosis is critical to appropri-
ately manage patients with obstruction of the SVC.
Malignant compression must be distinguished from
thrombotic occlusion, as these represent distinct ther-
apeutic categories.
• As malignancy is the leading cause of SVCS, the most
helpful initial test is typically a chest radiograph.
Abnormalities may include mediastinal mass or
widening, pleural effusion, or lung mass.
• Infused chest computed tomography (CT) is helpful
to confirm the diagnosis of SVCS, to define the extent
of venous blockage, and to evaluate collateral
drainage. CT is also helpful in elucidating the ultimate
cause of SVC obstruction.
• Venography or ultrasonography of upper extremity
veins may also permit diagnosis of SVCS, but fre-
quently do not reveal the etiology of obstruction.
• When malignancy is suspected without a known pri-
mary cancer, tissue biopsy should be obtained.
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FIG. 89-2 The SVC is further narrowed.
FIG. 89-3 Here the SCV, surrounded and compressed is barely
recognized.
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 Depending on the clinical presentation, minimally
invasive procedures such as sputum cytology, pleu-
ral fluid analysis, or excisional lymph node biopsy
may yield a diagnosis in a majority of cases.
 If lymphoma is suspected, bone marrow biopsy may
prove diagnostic.
 Bronchoscopy with transbronchial needle aspiration
from paratracheal lymph nodes may prove diagnostic.
 When less invasive measures fail to make a histo-
logic diagnosis, consideration should be given to
mediastinoscopy, thoracoscopy, or thoracotomy.
• Symptomatic obstruction occurs over weeks, and the
delay of therapy until a diagnosis has been obtained is
both safe and appropriate for most patients with malig-
nant SVCS. Radiation therapy without first obtaining
a diagnosis is NOT recommended as it may preclude
definitive diagnosis.
INTENSIVE CARE UNIT
MANAGEMENT
• Treatment of an occluded SVC is directed at the
underlying pathologic process.
• In the case of iatrogenic or thrombotic SVCS result-
ing from indwelling vascular hardware, treatment is
generally a combination of anticoagulation, percuta-
neous transluminal angioplasty, and/or metallic wall
stents.
 Some authors advocate the use of thrombolytic ther-
apy with or without angioplasty if the clot has been
symptomatic for fewer than 5 days.
 Subsequent oral anticoagulant therapy is generally
indicated for at least the short term.
• Malignant SVCS is treated based on the severity of
symptoms and the knowledge of the underlying
histology.
 In emergent cases, such as stridor, hypotension, or
cardiopulmonary collapse, the patient should
receive either emergent endovascular wall stenting
or emergent radiotherapy. Wall stenting may be
superior in this instance, both for its faster resolu-
tion (72 hours vs. 1–3 weeks for radiotherapy) and
for its preservation of diagnostic ability.
 For less emergent symptoms, treatment is based on
the knowledge of the specific tumors response to
treatment.
 Treatment-responsive tumors with relatively good
prognoses, such as non-Hodgkin lymphoma, germ
cell tumors, or early small cell lung cancer, respond
well to chemotherapy with or without the addition
of radiotherapy.
 Less responsive tumors—nonsmall cell lung cancer
or primary mediastinal B-cell lymphoma—may
respond as well to endovascular stents or radiotherapy/
chemotherapy at presentation.
• Benign SVCS, as may occur following fibrosing
mediastinitis related to prior infection with histoplas-
mosis, tuberculosis, or other indolent infections, often
occurs over many years with ample time for the for-
mation of extensive collateral venous drainage. Such
patients rarely require any intervention. If the syn-
drome develops rapidly, consideration should be given
to endovascular stenting or even SVC bypass surgery.
• No trial has demonstrated a benefit of corticosteroids
in SVCS.
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90 BONE MARROW
TRANSPLANTATION
Joseph Levitt
KEY POINTS
• Stem cell transplantation is the reconstitution of a
patient’s hematopoietic stem cells after myeloablative
chemotherapy with previously harvested stem cells.
• During the period prior to engraftment of the stem cells,
the patient is functionally without an immune system.
• Reintroduction of the patient’s native stem cells is an
autologous bone marrow transplant (BMT). Introduction
of another person’s stem cells is an allogeneic BMT.
• Allogeneic BMT carries the risk of GVHD.
• The various disease syndromes associated with BMT
will be discussed below, and include GVHD, HVOD,
infections, and bronchiolitis.
• Allogeneic BMT requires immune suppression of the
patient, predisposing them to serious infectious com-
plications even after successful transplant.
BACKGROUND
• Hematopoietic stem cell transplantation (SCT) con-
sists of infusing previously harvested patient bone
marrow or peripheral stem cells (autologous or auto-
SCT) or a donor’s cells (allogeneic or allo-SCT) fol-
lowing myeloablative chemoradiation therapy.
• Donors are matched by their human leukocyte antigen
(HLA) pattern. Identically matched siblings (25%
chance per sibling) have the best results. When no
matched sibling exists, donors can be selected from a
registry. Many antigen interactions other than HLA
exist but are not screened for. Unrelated donors are
likely to have more mismatches in unmeasured anti-
gens and thus more graft-versus-host disease (GVHD).
• Auto-SCT patients suffer many of the same complica-
tions as allo-SCT but do not develop GVHD. However,
they also don’t benefit from the beneficial graft-versus-
malignancy effect and show higher relapse rates.
• Understanding the time course of recovery of immune
function is essential in diagnosing various clinical
syndromes following SCT.
 Engraftment of stem cells and return of granulo-
cytes usually occurs 3 weeks following chemoradi-
ation therapy.
 Lymphocyte numbers may normalize at 1 month but
antibody levels are reduced for >3 months and
secretory IgA may be permanently suppressed.
 Abnormal T-cell antigen production (important for
vaccine-mediated immunity) may persist for a year.
• The incidence of many opportunistic infections has
been dramatically altered by effective prophylactic
regimens.
• Morbidity and mortality following SCT result from
rejection, relapse of underlying condition, infection,
toxicity (hepatic, gastrointestinal [GI], cardiac, lung,
and central nervous system [CNS]) of chemothera-
peutic conditioning regimens, and GVHD.
RELAPSE AND REJECTION
• Rejection is rare (<1%) in HLA identical recipients
conditioned with total body irradiation (TBI), but
risks rise with increasing HLA mismatching and prior
history of receiving multiple transfusions.
• Relapse of hematologic malignancies occurs in about
20% of cases transplanted after first relapse or in
chronic phases but increases to 50–70% of transplants
after relapse or in blast crisis.
• Less experience exists for relapse rates in solid tumor
malignancy.
INFECTIONS
• Serious bacterial infections occur in up to 50% of
patients; most during the 30 days of neutropenia fol-
lowing transplant. Most common sources are indwelling
central catheters, lung, and translocation from the
GI tract.
• Sepsis syndromes in the posttransplant period may
have many etiologies but treatment should include
efforts to identify a source (careful examination
including skin and catheter sites, blood and urine cul-
tures, chest x-ray, and computed tomography [CT]
scan) and early empiric broad-spectrum antibiotics
(including Pseudomonas and methicillin-resistant
Staph aureus coverage).
• Invasive hemodynamic monitoring and vasoactive
drugs, including inotropes are often necessary for
management due to the tendency for transplant
patients to become whole body volume overloaded
and many have occult cardiac dysfunction secondary
to cardiotoxic therapies.
• Fungal infections are also common during neutropenia.
Aspergillus is the most common in lung and sinuses
with Candida frequently invading the GI tract and blood
stream via indwelling catheters. The development of
new antifungal therapies with improved side effect pro-
files (voriconazole and caspofungin) has increased the
prevalence of empiric treatment in unexplained fever.
• Viral infections are most common between 30 and
100 days posttransplant. Cytomegalovirus (CMV) is
the most common, particularly in seropositive patients
or seronegative recipients with a seropositive donor.
Routine ganciclovir prophylaxis is practiced by many
centers for these high-risk patients. Use of seronega-
tive or leukocyte-filtered blood products in seronega-
tive patients reduces rates of CMV transmission.
Routine screening for CMV viremia and treatment
with ganciclovir at first sign of positivity is also rec-
ommended even in absence of symptoms.
• Incidence of herpes simplex virus (HSV) and varicella
(VZV) infections are markedly reduced with the rou-
tine use of acyclovir prophylaxis.
• Respiratory syncytial virus (RSV) and parainfluenza
virus are common causes of diffuse pulmonary infil-
trates and may occur in the early posttransplant phase,
especially during endemic months.
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• Pneumocystis (PCP) infections are rare when
trimethoprim-sulfamethoxazole prophylaxis is com-
plied with.
GRAFT-VERSUS-HOST DISEASE
ACUTE
• Acute GVHD occurs in the first 3 months following
allo-SCT and consists of lymphatic infiltration of
skin, liver, and GI tract.
• Incidence of at least mild GVHD is 20–50% in HLA
identical patients and 80% with nonidentical or unre-
lated donors despite the routine use of prophylactic
immunosuppressive regimens of methotrexate and
cyclosporine. T-cell depleted donor stem cells are also
used to reduce GVHD rates in some protocols.
• Presentation may include fever, macular dermatitis,
cramping abdominal pain, watery or bloody diarrhea,
jaundice, cholestasis, and hepatocellular necrosis.
• Associated mortality depends on severity and site of
organ involvement. Hepatitis is the most serious com-
plication but desquamative dermatitis and severe
mucositis predisposing to GI bleeding (in setting of
low platelets and liver dysfunction) and malnutrition
can cause significant morbidity.
• Clinical diagnosis can be difficult because of the many
other conditions (veno-occlusive disease, viral- and
drug-induced hepatitis) that may mimic the presenta-
tion in this population. Biopsy, particularly of skin, is
recommended when it can be performed safely.
Endoscopic biopsy of the GI tract and even transjugu-
lar liver biopsy (percutaneous procedures are too high
risk) may be necessary, even with positive skin biopsy,
to rule out other etiologies.
• Hepatitis due to GVHD is characterized by extremely
high alkaline phosphatase levels.
• Acute GVHD has variable response to increased immuno-
suppression. Treatment consists of corticosteroids
(methylprednisolone 2 mg/kg/day) and antithymocyte
globulins. Steroid refractory disease is often fatal.
CHRONIC
• Chronic GVHD may involve the lung as well as skin,
liver, and GI tract.
• It usually occurs following a history of acute GVHD
but 20–30% of cases can develop de novo.
• It usually follows an indolent course but adversely
affects long-term survival.
• Chronic GVHD suppresses host immunity inde-
pendent of the immunosuppressive therapy used to
treat it and infection is the most common cause of
death.
HEPATIC VENO-OCCLUSIVE DISEASE
• Hepatic veno-occlusive disease (HVOD) results from
occlusion of hepatic venules by thrombosis and cellular
debris that is likely due to endothelial injury related to
the chemoradiation-conditioning regimen.
• Incidence is as high as 20–60% in transplantation fol-
lowing TBI.
• Onset occurs 14 days posttransplant and is character-
ized by the triad of weight gain, painful hepatomegaly,
and jaundice. Ascites, elevated transaminases, and pro-
gression to hepatorenal syndrome may occur.
• Diagnosis is clinical and criteria are based on degree
of hyperbilirubinemia and weight gain plus or minus
the presence of ascites.
• No definitive diagnostic test exists but CT and ultra-
sound can confirm the hepatomegaly and ascites and
may help rule out other diagnoses (i.e., Budd-Chiari).
Doppler ultrasound criteria for pulsatile hepatic vein
flow and reversal of portal flow exist but are not spe-
cific for HVOD. Wedge hepatic venous pressure gradi-
ent during transvenous liver biopsy may be diagnostic
but is not generally indicated.
• Overall mortality is 30% but is >90% in severe (graded
by degree of hyperbilirubinemia and weight gain) cases.
• No effective treatment exists, although experimental
therapies with anticoagulants and thrombolytics are
being tried.
PULMONARY COMPLICATIONS
• Pneumonia syndromes develop in 40–60% of patients
with the etiology heavily dependent on the time course
posttransplant.
INFECTIOUS ETIOLOGIES
• Bacterial or fungal infections are the most common eti-
ologies of focal opacities particularly during neutropenia.
Typical appearing nodules with cavitation or enhancing
rings (halo sign) on CT scan are highly suggestive of
fungal infection, (although septic emboli from indwelling
catheters may also appear nodular and cavitate).
• Aspergillus is the most common fungal infection of
the lung, although mucormycosis, Fusarium, histo-
plasmosis, and other endemic fungi are seen.
• Candida is often found on airway sampling (sputum
or lavage) but is thought to only cause invasive infec-
tion in the lung through hematogenous spread.
Isolating Candida from other sites (blood, urine, GI
tract) is recommended before initiating therapy.
• As previously mentioned, CMV, HSV, and VZV are
more common between 30 and 100 days posttrans-
plant and usually cause a diffuse infiltrate.
• RSV and parainfluenza virus are the most common
infectious causes of diffuse infiltrates in the first 30 days.
NONINFECTIOUS ETIOLOGIES
• Pulmonary hemorrhage, high-pressure pulmonary
edema, acute respiratory distress syndrome (ARDS),
and drug toxicity are all frequent causes of diffuse
infiltrates in first 30 days.
• The idiopathic pneumonia syndrome (IPS) is a
common clinical entity of nonspecific lung injury likely
related to drug toxicity but may be multifactorial.
 Diagnostic criteria are (1) signs and symptoms of
pneumonia, (2) hypoxemia or restrictive defect of
pulmonary function testing, (3) bilateral infiltrates,
and (4) a nondiagnostic bronchoscopy with bron-
choalveolar lavage (BAL).
 Onset is a mean of 45 days posttransplant.
 Overall mortality is 60% but when it progresses to
respiratory failure, mortality approaches 100%.
• Pulmonary GVHD presents >100 days posttransplant
and is highly associated with CMV infection and
bronchiolitis obliterans.
• Bronchiolitis obliterans occurs in 10% of patients but,
depending on diagnostic criteria, incidence may be
>30% in chronic GVHD. Onset is >100 days post-
transplant and is characterized by breathlessness due
to progressive airflow obstruction.
 Definitive diagnosis is made by surgical biopsy
which shows cellular infiltration compressing small
airways. However, diagnosis can be made on clinical
grounds and spirometry showing airflow obstruction
that doesn’t respond to bronchodilators.
 Chest x-ray may show hyperinflation or be normal.
High-resolution CT scans show mosaic attenuation on
expiratory views highlighting air-trapping in terminal
airways.
• Airflow obstruction may be progressive and rapidly
fatal or may stabilize but rarely resolves. Treatment con-
sists of increasing immunosuppression but is of unclear
benefit.
DIAGNOSIS AND MANAGEMENT
• Bronchoscopy with BAL is the diagnostic procedure
of choice and can be performed safely even with pro-
found thrombocytopenia.
• Diagnostic yield is high for bacterial, PCP, and viral
infections and pulmonary hemorrhage but less so for
fungal infections and other noninfectious etiologies.
BAL fluid should be processed for:
 Bacterial, viral, and fungal cultures and stain
 Rapid detection for viral pathogens including poly-
merase chain reaction (PCR), direct fluorescent
antibodies, or shell viral culture for CMV
 Cell count and cytologic review
• Transbronchial biopsy adds little to diagnostic yield
and can often not be performed due to thrombocy-
topenia. CT-guided percutaneous biopsy of peripheral
nodules may be possible.
• Surgical lung biopsy is necessary for diagnosis of most
noninfectious etiologies including IPS. However,
experience shows that even this can be nonspecific and
often does not alter therapy or outcomes and should
only be performed in highly selected patients who can
safely tolerate the procedure and have a high probabil-
ity of clinical benefit.
• Treatment is often empiric with broad-spectrum
antibiotics, antifungal and antiviral therapies, and
immunosuppression.
• Early use of noninvasive positive pressure ventilation
may improve mortality in neutropenic patients with
respiratory failure.
• Transplant patients who progress to respiratory failure
often do so despite maximal therapy to prevent it.
Mechanical ventilation in the setting of multisystem
organ failure is universally fatal. Standard of care is to
restrict protracted intensive care in such cases.
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91 TOXICITIES OF
CHEMOTHERAPY
Michael Moore
KEY POINTS
• Complications of chemotherapy should be in the differ-
ential diagnosis of all cancer patients admitted to the ICU.
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• Fever, hypersensitivity reactions, mucositis, gastritis,
and myelosuppression are the most common toxicities.
• Not all toxicities of chemotherapy agents are known,
especially with newer agents.
• Certain agents have known toxicity syndromes (e.g.,
bleomycin pulmonary toxicity).
INTRODUCTION
• As more intensive anticancer regimens are being used
to achieve cure, an increasing number of oncology
patients are admitted to intensive care units (ICUs) for
complications of treatment.
• A thorough oncologic and chemotherapy history is an
integral component of managing the cancer patient
admitted to the ICU.
PRINCIPLES OF DRUG-INDUCED
TOXICITY
• Drug toxicity is often a diagnosis of exclusion:
 Antineoplastic drug toxicity is frequently clinically
and pathologically nonspecific.
 Always consider other causes like infection, tumor
effects, and other drug toxicities.
• Dose, schedule, and combination make a difference:
 Antineoplastic drugs are often given in combination
and combined with radiation.
 Toxicities of combination therapy may be more
severe than individual drugs.
 Different drug schedules may have a different spec-
trum of side effects for the same agent.
 Very high-dose chemotherapy with colony-
stimulating factor or stem cell support has exposed
new toxicities.
• Not all toxicities are known:
 New drugs and drug combinations are often tried
before all toxicities are known.
 Diagnosis of sporadic versus dose-related drug tox-
icity is often difficult.
• Treatment is supportive:
 Treatment-related toxicity is important to diagnose
to avoid additional exposure.
 Specific therapy is rarely indicated or available.
COMMON REACTIONS: FEVER AND
HYPERSENSITIVITY REACTIONS
• Acute hypersensitivity reactions:
 Most common with L-asparaginase, taxanes (pacli-
taxel and docetaxel), and platinum agents.
 Antianaphylaxis medications should be readily
available.
 Paclitaxel is routinely administered with corticos-
teroids and antihistamines.
• Hypersensitivity from platinum agents often occurs
during second or third exposure.
• Hypersensitivity reactions associated with rituximab
and trastuzumab can be managed with a slower infu-
sion rate and premedication.
• Febrile reactions are common with bleomycin and
cytarabine.
COMMON REACTIONS:
MYELOSUPPRESSION
• Complications of myelosuppression account for most
therapy-related ICU admissions.
• Cell lines are variably suppressed:
 Granulocytes (half-life 6 hours) affected early and
most severely.
 Platelets (half-life 5–7 days) affected next.
 RBCs (half-life 120 days) relatively spared.
• Nitrosoureas and mitomycin C typically produce a
late, severe thrombocytopenia.
• Rule out bleeding and other causes of anemia before
very low hemoglobin levels are attributed to
chemotherapy alone.
• For most agents, granulocyte counts nadir at 7–14 days
and recover by 21–28 days after administration of a
single dose.
• Pelvic or spinal irradiation and multicourse
chemotherapy may be associated with severe and pro-
longed myelosuppression.
• Bone marrow biopsy helps characterize cytopenias in
critically ill patients.
• Hematopoietic growth factors (i.e., granulocyte colony-
stimulating factor) may be useful to ameliorate bone
marrow suppression.
• Empiric institution of broad-spectrum antibiotic ther-
apy has been shown to improve mortality in febrile
neutropenic patients in some clinical situations.
COMMON REACTIONS: MUCOSITIS
AND DIARRHEA
GENERAL CONSIDERATIONS
• Gastrointestinal tract epithelial cells proliferate rap-
idly and are particularly susceptible.
• Toxicity ranges from mild mouth sores to ulcerative
stomatitis and severe bloody diarrhea.
• Loss of the protective mucosal barrier contributes to
patient morbidity and mortality especially in neutropenic
hosts.
• Table 91-1 lists agents that commonly cause stomati-
tis or diarrhea at standard doses.
• High-dose chemotherapy regimens prior to bone
marrow transplantation frequently cause severe
mucositis.
TREATMENT
• Candida and herpes viruses commonly cause or
worsen stomatitis and esophagitis.
• Always consider Clostridium difficile infections in
hospitalized patients with diarrhea.
• Aggressive mouth care with soft swabs and saline or
peroxide rinses is imperative.
• Stomatitis pain can be severe and should be treated
with topical anesthetics and/or systemic narcotics.
• Consider early use of intravenous alimentation when
enteral feeding is compromised.
SPECIFIC AGENT: IRINOTECAN (CPT-11)
• Causes severe diarrhea in the absence of mucositis.
• Two distinct types of diarrhea have been described:
 Early-onset:
 Occurs during or within 30 minutes of infusion
 Acute cholinergic response
 Controlled with IV atropine, 0.5–1.0 mg
 Late-onset:
 Appears 6–10 days after administration
 May be linked to a secretory process in the small
intestine
 Can be massive (10 L/day)
 Treatment:
 Early recognition
 Aggressive treatment with loperamide and
octreotide
COMMON REACTIONS: PULMONARY
TOXICITY
OVERVIEW
• A large number of antineoplastic drugs can cause pul-
monary toxicity (Table 91-2).
• Pulmonary toxicity syndromes include:
 Acute pleuritic chest pain
 Hypersensitivity lung disease
 Noncardiogenic pulmonary edema
 Pneumonitis/fibrosis: This is classically associated
with the “three B’s”: busulfan, bleomycin, and car-
mustine (BCNU)
CLINICAL PRESENTATIONS
• Onset of pneumonitis/fibrosis:
 Usually subacute over several weeks but acute pre-
sentations occur.
 Busulfan: after prolonged, continuous treatment.
 Bleomycin: after a few cycles of therapy.
 BCNU: can occur many years after therapy.
• Signs and symptoms:
 Frequently nonspecific but dyspnea is invariably
present.
 Dry cough, fatigue, fever, and end-expiratory crackles
are common.
 Hemoptysis is atypical and suggests an alternative
diagnosis.
• Differential diagnosis includes infection, irradiation,
cardiogenic edema, pulmonary embolus, hemorrhage,
leukoagglutinin reaction, and progressive tumor.
• May be reversible or can progress in the absence of
additional exposures.
DIAGNOSTIC TESTING
• Chest x-ray can be normal or reveal a basilar or dif-
fuse reticulonodular pattern:
 Bleomycin occasionally produces a nodular appear-
ance that can mimic recurrent tumor.
 Methotrexate can be associated with a pleural effu-
sion or hilar adenopathy.
• Pulmonary function tests reveal restriction and reduced
DLCO (diffusing capacity of the lung for carbon
monoxide).
• Lung biopsy:
 Histologic findings are not specific.
 May not definitively establish the diagnosis.
 Patient selection and timing of biopsy is controversial.
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TABLE 91-1 Antineoplastic Drugs That Cause Stomatitis
or Diarrhea
DRUG EFFECT
Anthracyclines Stomatitis
Bleomycin Stomatitis
5-FU Stomatitis, anal sores, diarrhea
Capecitabine Stomatitis, diarrhea
Cytarabine Stomatitis, diarrhea
Cyclophosphamide Stomatitis
Dactinomycin Stomatitis, diarrhea
Taxanes Stomatitis
Vinca alkaloids Stomatitis
Methotrexate Stomatitis
Irinotecan (CPT-11) Diarrhea
Gefitinib Diarrhea
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TREATMENT
• Generally supportive
• Discontinue precipitating agent
• Empiric trial of corticosteroid therapy is supported by
anecdotal reports
SPECIFIC AGENTS
BLEOMYCIN
• Believed to directly injure the pulmonary capillary
endothelium and type I pneumocytes stimulating an
inflammatory cascade.
• Sporadic rather than dose related below a threshold
cumulative total dose of 450–500 mg.
• Incidence dramatically increases above threshold dose.
MONITORING THERAPY
• Serial DLCO measurements have been used to predict
and prevent pulmonary toxicity.
• Stopping therapy when a significant decrease in
DLCO is shown is recommended but has not been
shown to alter the incidence of fatal toxicity.
• Patients may present with an acute decline in pulmonary
function weeks to months after a normal DLCO.
RISK FACTORS
• Age over 70
• Prior or concurrent pulmonary radiation therapy
• Concurrent treatment with cyclophosphamide or
methotrexate
• Oxygen therapy:
 Small studies have reported a high incidence of severe
postoperative respiratory distress in bleomycin-
treated patients attributed to a high intraoperative con-
centration of inspired oxygen.
 Limiting intra- and perioperative FiO2 to the lowest
safe concentrations is recommended.
TRETINOIN (ALL-TRANS-RETINOIC ACID, ATRA)
• Derivative of vitamin A used for acute promyelocytic
leukemia (APL).
• Retinoic acid syndrome:
 Unique pulmonary toxicity
 Symptoms include high fever, fluid retention, pul-
monary infiltrates, and respiratory distress.
TABLE 91-2 Antineoplastic Drugs That Have Pulmonary Toxicity
AGENT TYPE OF TOXICITY INCIDENCE (%) COMMENT
Bleomycin Pneumonitis/fibrosis 2–40 Chest x-ray may be atypical
Hypersensitivity pneumonitis Rare Eosinophilia may be seen on lung biopsy;
steroids felt to be useful
Acute chest pain Rare Substernal pressure or pleuritic pain; self-limited
over 4–72 h
Busulfan Pneumonitis/fibrosis 4 Insidious onset after prolonged therapy; poor prognosis
Carmustine (BCNU) Pneumonitis/fibrosis 20–30 Toxicity is dose related; common in pretransplantation
regimens; effects may appear years after therapy
has ended
Cyclophosphamide Pneumonitis/fibrosis <1 May potentiate toxicity of bleomycin, BCNU
High-dose cytarabine Noncardiogenic pulmonary edema 4–20 Care is supportive, but corticosteroids are occasionally
helpful; prognosis is variable
Gemcitabine Noncardiogenic pulmonary edema 1–5 Care is supportive, but corticosteroids are occasionally
helpful: prognosis is variable
Methotrexate Hypersensitivity pneumonitis 8 Prognosis is good; dramatic response to corticosteroids
reported
Acute pleuritic pain Rare May be associated with pleural effusion or friction rub;
subsides over 3–5 days
Noncardiogenic Rare Few reports, most with intrathecal injection
Pulmonary edema
Mitomycin C Pneumonitis/fibrosis 3–12 High mortality reported
Procarbazine Acute hypersensitivity Onset within hours after drug dose; recovery rapid
Tretinoin (ATRA) Retinoic acid syndrome 10–20 Corticosteroids suggested
Vinorelbine Acute dyspnea 5 Readily reversible chest pain
Gefitinib Interstitial lung disease 1–3 One-third of the cases can be fatal
Trastuzumab Organizing pneumonia Rare Case reports only
 Incidence as high as 25%.
 Occurs as soon as 2 days after therapy.
 Treatment with dexamethasone may be helpful.
GAITANIS
• Oral inhibitor of epidermal growth factor receptor
(EGFR) tyrosine kinase approved for treatment of
refractory lung cancer.
• Results in interstitial lung disease in about 1% of the
patients worldwide.
• Approximately one-third of reported cases have been
fatal.
• Patients present with acute dyspnea, with or without
cough, and low-grade fevers.
• Prompt discontinuation of the agent with adequate
supportive care is recommended.
CARDIOVASCULAR TOXICITY
OVERVIEW
• The majority of cardiac events in cancer patients are
related to preexisting heart disease or secondary to tumor
effects as opposed to anticancer drugs (Table 91-3).
• Anthracyclines are an exception to this rule:
 Doxorubicin and daunorubicin have very similar
effects on the heart.
 Doxorubicin is more commonly used and its cardiac
effects better studied.
 Trastuzumab also reported to cause a cardiomyopa-
thy similar to the effects anthracycline therapy.
• Immunomodulatory agents such as interferon and
interleukin (IL)-2 also have cardiotoxic effects.
ECG CHANGES AND ARRHYTHMIA
• Cisplatin and others may produce secondary effects
through alterations in plasma potassium, calcium, and
magnesium levels.
• Direct effects appear limited to the anthracyclines and
paclitaxel and can occur up to 40% during infusions.
• Acute anthracycline-induced fatal arrhythmia has
been reported and is very rare:
 Cardiac monitoring during drug infusion not
warranted.
 ECG changes usually transient and do not necessi-
tate stopping therapy.
 No association with cardiomyopathy.
• Doxorubicin:
 Incidence up to 40% during infusion.
 Most common effects are nonspecific ST-T-wave
changes.
 Premature atrial and ventricular contractions, sinus
tachycardia, and decreased QRS voltage are also
common.
• Paclitaxel:
 Causes asymptomatic, reversible sinus bradycardia:
 Heart rates ranging from 30–50 beats per minute
(BPM)
 Incidence 29% during a 24-hour infusion
 Third-degree heart block is rare.
 Myocardial infarction and tachyarrhythmias have
been reported.
MYOCARDIAL ISCHEMIA AND INFARCTION
• Rarely caused by antineoplastic agents.
• Radiation therapy to the heart may result in acceler-
ated atherogenesis.
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TABLE 91-3 Antineoplastic Drugs That Have Cardiac Toxicity
DRUG EFFECT INCIDENCE (%) COMMENT
Anthracyclines Acute ECG changes Common Almost always benign and reversible
Acute myocarditis/pericarditis syndrome Rare
Chronic cardiomyopathy 1–2 May appear years after treatment
Cyclophosphamide Acute hemorrhagic cardiac necrosis Unusual Only in very high doses
5-FU Angina/myocardial infarction Rare Usually within hours of drug dose; asymptomatic
(Capecitabine—oral ECG changes more common
prodrug of 5-FU)
Mitoxantrone Cardiomyopathy 1–2 Drug is structurally related to anthracyclines,
but incidence of cardiomyopathy is probably
somewhat less; risk is <1% if cumulative dose
<120 mg/m2
Paclitaxel Arrhythmias 10–20 Most common is asymptomatic bradycardia
Vinca alkaloids Angina/myocardial infarction Rare Scattered case reports
Trastuzumab Cardiomyopathy More common Often managed medically
when combined
with chemotherapy
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• Vinca alkaloids:
 Reported to precipitate myocardial infarction in a
few instances.
 Concomitant use of bleomycin may be a risk factor.
• 5-Fluorouracil (5-FU):
 Up to 4% of patients have reported anginal symptoms.
 Transient asymptomatic ECG changes suggestive of
ischemia are more common.
 Nitrates and calcium channel blockers may reverse
vasospasm.
• Capecitabine:
 Orally administered prodrug of 5-FU
 Similar toxicities associated with prolonged infu-
sion of 5-FU
CARDIOMYOPATHY AND PERICARDITIS
ANTHRACYCLINES
• Can cause a myocarditis-pericarditis syndrome:
 An acute drop in ejection fraction seen in the hours
to weeks after drug administration
 Associated with pericardial effusion
 May result in sudden death
 Exceedingly rare
• Cardiomyopathy:
 Classically, the presentation is subacute (doxorubicin)
 Develops in 1–10% of patients receiving 550 mg/m2
 Increased incidence with cumulative doses >600 mg/m2
 Total dose most important risk factor
 No cutoff dose below which treatment is conven-
tional heart failure therapy
• Late presentation of cardiomyopathy:
 Clinical course:
 Symptoms appear around 30–60 days after
administration.
 Symptoms include tachycardia, dyspnea, car-
diomegaly, peripheral and pulmonary edema.
 Treatment is conventional congestive heart failure
(CHF) therapy.
• Late presentation:
 57% of anthracycline-treated survivors of childhood
cancers have abnormalities of left ventricular after-
load or contractility:
 Trastuzumab is associated with moderate car-
diomyopathy
 No specific therapy after onset
 Care is supportive
 Seems to be worse with the coadministration of
anthracyclines
TRASTUZUMAB
• Cardiotoxicity greatest with combination chemother-
apy (especially anthracyclines).
• Clinical symptoms are well controlled with CHF therapy.
CYCLOPHOSPHAMIDE
• Minimal cardiac toxicity at standard doses.
• Higher doses can cause severe myopericarditis and
arrhythmias:
 Hemorrhagic myopericarditis is the major non-
hematologic dose-limiting toxicity.
 Usually seen at doses higher than 1.5 g/m2.
 Virulent form:
 Symptoms appear within 48 hours after last dose.
 Cardiogenic shock usually results in rapid death.
 Typical presentation:
 Toxicity develops 7–10 days after therapy.
 Usually preceded by a decrease in QRS amplitude.
 Symptoms include edema, tachycardia, and
tachypnea.
 Hemorrhagic or serosanguineous pericardial effu-
sion is common:
 Tamponade may be present.
 Pericardiocentesis usually does not result in clini-
cal improvement.
• Treatment is supportive.
• Prognosis is good if patients survive the acute phase.
• Ifosfamide at higher doses can cause severe myoperi-
carditis and arrhythmias:
 Toxicity associated with total doses in excess of
1000 mg/m2.
 Symptoms generally develop within 2 weeks of
receiving the drug.
NEUROTOXICITY
GENERAL CONSIDERATIONS
• Rare primary reason for ICU admission.
• Neurologic problems are common and most are pro-
duced by local tumor effects.
• Rule out neurologic changes from commonly used
medications including high-dose corticosteroids, nar-
cotics, and benzodiazepines (Table 91-4).
PERIPHERAL NEUROPATHY
• Common side effect of some widely used anticancer
drugs
• Paclitaxel and docetaxel:
 Glove-stocking paresthesias
 Rarely, motor
CISPLATIN
• Primarily sensory but may progress to disabling ataxia.
• Symptoms may worsen after treatment is completed
and persist for years.
• Other toxicities include tinnitus, deafness, Lhermitte
sign, autonomic neuropathy, seizures, transient corti-
cal blindness, and retinal injury.
OXALIPLATIN
• New platinum agent.
• Can cause dose-limiting acute and chronic neuropathy.
• Acute and reversible sensory neuropathy in up to 95%
of patients.
• Chronic neuropathy:
 Develops in 15–20% of patients treated with cumu-
lative doses >780 mg/m2.
 Doses >1000 mg/m2 may cause Lhermitte sign and
urinary retention.
 Usually reversible.
• Pharyngolaryngeal dysesthesias:
 Acute and reversible syndrome.
 Reported in 1–2% of patients.
 Causes a distressing and overwhelming sensation of
difficulty with breathing and swallowing.
 Symptoms frequently triggered or exaggerated by
cold exposure.
272 SECTION 6 • HEMATOLOGY AND ONCOLOGY
TABLE 91-4 Antineoplastic Drugs That Have Neurologic Toxicity
DRUG INCIDENCE (%) COMMENT
Encephalopathy
L-Asparaginase 25–50 Ranges from drowsiness to stupor; onset usually on the day after start of therapy; generally
resolves rapidly when therapy is over
High-dose busulfan 15 Acute obtundation, seizures; prophylactic anticonvulsants often used
High-dose carmustine 10 Severe acute or chronic encephalomyelopathy; time of onset variable; usually not reversible
(BCNU)
High-dose cytarabine 10–20 Ranges from disorientation to coma; onset usually 5–7 days after start of therapy;
prognosis variable
Fludarabine Rare at conventional Optic neuritis, altered mental status, paralysis. May appear weeks after treatment
doses
Hexamethylmelamine Variable Toxicity ranges from depression to hallucinations; usually reversible when drug is withdrawn
Ifosfamide 5–30 Frequency greater with higher doses; ranges from mild somnolence to coma; onset hours
after infusion, recovery usually within days; use of methylene blue might reverse or
shorten the duration of toxicity
High-dose methotrexate 2–15 Onset usually 1 week after administration; most common presentation is a stroke-like
syndrome; usually reversible
Mitotane 40 Lethargy, somnolence, dizziness, vertigo
Pentostatin Rare at conventional Lethargy, seizures, coma
doses
Procarbazine 10 Usually mild drowsiness or depression, rarely stupor or manic psychosis
High-dose thio-TEPA Dose-dependent Somnolence, seizures, coma; dose-limiting extramedullary toxicity
Vincristine/vinblastine Rare SIADH
Acute cerebellar syndrome
High-dose cytarabine 10–20 Ranges from mild dysarthria to disabling ataxia; onset is 5–7 days after start of therapy;
prognosis is variable
5-FU <1 Usually seen with large bolus doses; reversible in 1–6 weeks
Acute paraplegia
Intrathecal administration of Rare These are the only drugs normally given intrathecally; all cause acute reversible arachnoiditis
cytarabine, methotrexate, fairly often, paralysis exceedingly rarely; paralysis may or may not be reversible
thio-TEPA
Peripheral neuropathies
Cisplatin Dose-dependent Ototoxicity; distal sensory neuropathy
Oxiliplatin Common Acute and chronic sensory neuropathy; reversible pharyngolaryngeal dysesthesias;
cold exposure may exacerbate symptoms
Hexamethylmelamine Variable Peripheral paresthesias and weakness
Procarbazine 10–20 Decreased tendon reflexes, mild distal paresthesias
Paclitaxel, docetaxel Common Distal sensory neuropathy
Vinca alkaloids See text Symmetrical areflexia and distal paresthesias; symmetrical motor weakness starting with
dorsiflexors; jaw pain; cranial nerve palsies; paralytic ileus
Thalidomide Peripheral neuropathy
ABBREVIATIONS: thio-TEPA, N,N′N′-triethylenethiophosphoramide; SIADH, syndrome of inappropriate antidiuretic hormone.
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 Education is required to avoid panic and unneces-
sary medical interventions.
VINCA ALKALOIDS
• Tubulin poisons that disrupt microtubule function in
neuronal axons.
• Vincristine most neurotoxic.
• Symmetric mixed sensorimotor neuropathy:
 Most common toxicity.
 Can progress to quadriparesis in severe cases.
 Symptoms are dose related and gradual in onset.
 Deep tendon reflexes are lost.
 Peripheral nerve conduction velocities are charac-
teristically normal despite severe clinical deficits.
 Paresthesias and motor weakness may or may not
gradually improve.
• No known treatment for vinca-related neuropathies.
• Vincristine has accidentally been administered
intrathecally and is invariably fatal.
THALIDOMIDE
• Causes reversible and irreversible sensory neu-
ropathies with chronic use in 60% of patients.
• Symptoms range from mild reversible paresthesias to
severe irreversible sensory neuropathies.
• Central nervous system (CNS) manifestations are
common and include sedation, dizziness, muscle inco-
ordination, fatigue, unsteady gait, tremulousness, mood
changes, confusion, and weakness.
CRANIAL NERVE PALSIES
• Cranial nerve palsies include vocal cord paralysis,
dysphagia, optic atrophy (rare), ptosis, ophthalmople-
gias, and facial nerve paralysis.
• Occur in up to 10% of vincristine-treated patients.
• Cranial neuropathies may be abrupt in onset and
mimic a brain stem stroke.
• Symptoms are usually bilateral and reversible with
discontinuation of the drug.
AUTONOMIC NEUROPATHY
• Symptoms include ileus, bladder atony, impotence,
and orthostatic hypotension.
• May occur in patients without signs of peripheral
nerve toxicity.
• Severe paralytic ileus:
 Can presents as an acute abdomen.
 Occurs acutely or following long-term administra-
tion of vincristine, vinblastine, or vinorelbine.
 Usually reversible over the course of several days.
 Treatment:
 Nasogastric tube drainage is standard therapy.
 Metoclopramide in patients without suspicion of
mechanical obstruction.
SPECIFIC AGENTS
L-ASPARAGINASE
• Twenty-five to 50% incidence of cerebral dysfunction.
• Toxicity ranges from mild depression and drowsiness
to confusion, stupor, and coma.
• Encephalopathy:
 Often occurs on the first day after administration
and usually clears rapidly after the end of therapy.
 Resembles hepatic encephalopathy and may be
associated with high ammonia levels.
 Electroencephalogram (EEG) shows diffuse slow-
ing with resolution after drug therapy.
• Clotting abnormalities:
 Thrombotic and hemorrhagic cerebrovascular accidents
 Severe decrease in fibrinogen levels associated with
elevated prothrombin time
CYTARABINE (ARA-C)
• Neurotoxic at high doses (2–3 g/m2 twice daily).
• 10–20% incidence of cerebellar and cerebral toxicity.
• Risk factors:
 Large cumulative doses
 Age over 55
• Cerebellar toxicity:
 Most common and severe.
 Onset usually 5–7 days after the start of therapy.
 Symptoms include intention tremor, dysarthria, hor-
izontal nystagmus, limb and truncal ataxia.
• Cerebral toxicity:
 Symptoms range from mild somnolence to disorien-
tation, memory loss, seizure, and coma.
 EEGs show diffuse slowing.
 Lumbar puncture and computed tomography (CT)
are normal.
 Symptoms last days to weeks and may be irreversible.
 Rarely fatal.
 Treatment is supportive care.
METHOTREXATE
• Systemic administration:
 Neurotoxic at high doses (1–7 g/m2).
 2–15% incidence of various transient CNS syndromes.
 Onset is abrupt after several hours to several weeks
of treatment.
 Clinical syndromes:
 Stroke-like syndrome with hemiplegia and speech
disorder.
 Findings may fluctuate.
 Focal or generalized seizures are common.
 Recovery occurs completely over several days.
 May or may not recur with subsequent courses.
 Diagnostic studies:
 Electrolyte levels and radiologic studies are normal.
 EEG shows a variety of abnormalities.
 CSF may reveal elevated protein levels.
 Treatment is generally supportive.
• Intrathecal methotrexate:
 Clinical syndromes:
 Acute arachnoiditis:
• Most common.
• Resolves over 12–72 hours without sequelae.
• May mimic bacterial meningitis if severe.
 Acute reactions:
• Rare.
• Symptoms include paralysis, cranial nerve palsies,
and seizure.
 Necrotizing leukoencephalopathy:
• Occasionally seen with concomitant cranial
irradiation.
• Delayed effect with insidious onset months after
treatment.
 Cerebrospinal fluid (CSF) may show increased
pressure, high protein concentrations, and a reactive
pleocytosis.
 Recovery is often complete.
IFOSFAMIDE
• Can cause an encephalopathy.
• Associated with high-dose therapy.
• Symptoms range from subtle sensorimotor deficits to
severe mental status changes and death.
• Treatment:
 Early recognition with discontinuation
 Intravenous methylene blue
 Symptoms usually resolve over 24–48 hours
RENAL AND URINARY TOXICITY
• Common renal abnormalities are listed in Table 91-5.
CISPLATIN
• Renal injury is a dose-limiting toxicity
• Renal dysfunction:
 Mild to acute renal failure
 Creatinine levels rise over days, peak at 3–14 days;
then decline toward pretreatment levels
• Risk factors
 Coexisting aminoglycoside therapy
 Preexisting renal dysfunction
 Dehydration
• Vigorous pretreatment hydration minimizes renal
dysfunction:
• Electrolyte disorders are a common consequence of
toxicity, including magnesium, calcium, potassium,
and sodium:
 May be refractory to treatment if serum magnesium
levels are not first corrected
 Use aminoglycosides with extreme caution
 Replete magnesium via IV or IM route
• Sodium:
 Hyponatremia from renal salt wasting
 Symptomatic orthostatic hypotension
METHOTREXATE
• Associated with high-dose methotrexate (>50 mg/kg).
• Renal failure usually reversible over 2–3 weeks fol-
lowing drug withdrawal.
• Preventions/treatment:
 Careful hydration.
 Urinary alkalinization promotes drug excretion.
 Follow levels and give leucovorin rescue:
 Leucovorin is continued until the drug concentra-
tion has fallen to a safe level.
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TABLE 91-5 Antineoplastic Drugs Producing Renal and Electrolyte Abnormalities
AGENT TOXICITY COMMENT
Cisplatin Magnesium, calcium, potassium,
sodium wasting; renal insufficiency
Cyclophosphamide Impaired free water excretion Transient; seen with doses >50 mg/kg
Ifosfamide Proximal tubular defect —
High-dose methotrexate Acute renal failure Usually reversible
Mitomycin C Renal failure with microangiopathic Common with cumulative dose >60 mg
hemolytic anemia (HUS/TTP)
Nitrosoureas (BCNU, Progressive renal failure appearing
CCNU, methyl-CCNU) After large cumulative doses Decrease in renal size may be noted;
effect may occur years after therapy
Streptozotocin Renal failure, proximal renal tubular Transient proteinuria is earliest manifestation
acidosis, nephrotic syndrome
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 Goal methotrexate level is <5 × 10−8 M.
 Will not completely prevent toxicity.
 Hemodialysis with high-flux membranes.
 Carboxypeptidase-G2 on compassionate emergent
use basis.
• Toxic levels persist in the setting of acute renal
failure.
• Renal dysfunction contributes to other morbidities
including cytopenias and mucositis.
• Toxic methotrexate may also persist in patients with
large third-space fluid reservoirs (e.g., pleural effu-
sions or ascites).
CYCLOPHOSPHAMIDE AND IFOSFAMIDE
• Urologic complications include bladder fibrosis, blad-
der cancer, and hemorrhagic cystitis.
• Can be difficult to manage.
• See “Hemorrhagic Cystitis,” below.
THROMBOTIC AND HEMORRHAGIC
TOXICITY
GENERAL CONSIDERATIONS
• All myelosuppressive agents potentially cause throm-
bocytopenia and bleeding.
• Thrombotic microangiopathies occur with various
chemotherapeutic agents.
HEMORRHAGIC CYSTITIS
• Well-described complication of cyclophosphamide and
ifosfamide.
• Can be idiosyncratic but increased incidence with pro-
longed or high-dose therapy.
• Acrolein, a metabolite of cyclophosphamide, is believed
to cause local bladder irritation.
• Clinical presentation:
 Acute form appears within days after treatment.
 Symptoms range from minimal hematuria with mild
dysuria, urgency, and frequency to massive hemor-
rhage requiring transfusion.
 Thrombocytopenia with high-dose cyclophos-
phamide increases morbidity.
 Bleeding usually self-limited with a median dura-
tion of 1 month.
• Prevention:
 Sodium 2-mercaptoethane sulfonate (mesna):
 Provides free sulfhydryl groups to neutralize
acrolein in urine.
 Required with ifosfamide therapy.
 Not useful in treating established cystitis.
 Adequate prehydration with frequent voiding:
 Decreases contact time of acrolein in bladder.
 Avoid hypotonic solutions for hydration.
• Treatment:
 Stop therapy. No other treatment for mild episodes.
 Severe cases:
 Vigorous hydration to promote urine flow
and maintenance of adequate platelet counts
(50,000/mL).
 Continuous bladder irrigation:
• Use large-bore catheter.
• Avoid obstructing clots.
 Other therapies:
• Intravesical instillation of formalin
• Urinary diversion
• Hypogastric artery embolization and cystectomy
with urinary diversion
MICROANGIOPATHIC HEMOLYTIC ANEMIA
• Can be effect of cancer or cancer therapy.
• Most closely associated with mitomycin C.
• Other agents include bleomycin, cisplatin, interferon,
and gemcitabine.
• Thrombotic thrombocytopenic purpura/hemolytic-
uremic syndrome (TTP/HUS) is a late complication of
allogeneic and autologous bone marrow transplantation.
• The severity of the presentation and the prognosis in
transplant patients is variable.
• The prognosis in mitomycin C-associated HUS may
be poor.
• Treatment:
 Staphylococcal protein A immunoadsorption may
be useful for mitomycin C-associated HUS.
 Other therapies including plasma exchange with
cryosupernatant, IVIg, and glucocorticoids are of
uncertain benefit.
THROMBOEMBOLISM
• Thalidomide is associated with significant risk of
thromboembolic complications.
• Increased risk when administered with other chemother-
apeutic agents.
HEPATOTOXICITY
• Many cytotoxic agents can result in hepatotoxicity but
few do so regularly or severely (see Tables 91-6 and
91-7).
• Veno-occlusive disease (VOD) of the liver is a major tox-
icity of high-dose regimens given before transplantation.
VENO-OCCLUSIVE DISEASE OF THE LIVER
• Rare and sporadic with cytotoxic drugs at conven-
tional doses.
• High-dose chemotherapy or chemoradiotherapy for
bone marrow transplant:
 Most common cause
 Incidence up to 20%
 Common cause of death
• Clinical picture:
 Resembles Budd-Chiari syndrome
 Symptoms begin at mean of 10 days after marrow
reinfusion
 Death or recovery occurs by day 35 after transplantation
 Late-onset VOD occurs with some regimens
• Diagnosis:
 Largely clinical
 Presence of at least two of the triad of jaundice,
hepatomegaly, or right upper quadrant pain, and
ascites or unexplained weight gain
 Hyperbilirubinemia is usually out of proportion to
transaminase concentrations
 Major differential diagnosis:
 Graph-versus-host disease
 Abdominal catastrophe:
• Suggested by acute, severe abdominal pain
• Includes pancreatitis, bowel infarction, biliary
obstruction, peritonitis, and pyogenic liver
abscess
 Cyclosporine-induced hepatotoxicity
 Sepsis
 Liver biopsy:
 Percutaneous approach usually contraindicated
 Transvenous can still result in fatal hemorrhage
 Histopathology:
• Early disease characterized by subintimal
edema, hemorrhage within small central venules,
and centrilobular congestion
• Late disease characterized by fibrous oblitera-
tion of central venule lumina and centrilobular
sinusoidal fibrosis
 Ultrasound studies may show increased mean
hepatic artery resistive index or reversal of portal
venous flow.
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TABLE 91-6 Cytotoxic Agents That Have Hepatic Toxicity
FREQUENCY
DRUG OF TOXICITY COMMENT
L-Asparaginase Common Fatty metamorphosis; decreased synthetic function; reversible
Azathioprine Uncommon Cholestasis/necrosis; hyperbilirubinemia; variable prognosis
High-dose cytarabine Common Elevated bilirubin and transaminases; reversible
Floxuridine (FUDR) Common Biliary sclerosis with hepatic intra-arterial infusion; chemical hepatitis
Methotrexate Common Cirrhosis, fibrosis, fatty metamorphosis; laboratory data may be normal; seen with prolonged
daily therapy; variable prognosis
High-dose methotrexate Common Elevated transaminase levels, usually reversible in weeks
6-Mercaptopurine Common Cholestasis or necrosis; usually reversible
Mithramycin Common Necrosis; rarely seen with lower doses used for hypercalcemia
Nitrosoureas Occasional Generally mild and reversible
(BCNU, CCNU)
Vincristine Rare May produce severe damage when combined with radiation to the liver
TABLE 91-7 Toxicities of IL-2
TOXICITY COMMENT
Febrile reaction complex Dose-dependent fever and chills are
ameliorated with antipyretics and
meperidine
Cardiovascular toxicity Capillary leak syndrome; see text. Rare
cases of eosinophilic myocarditis 
Toxicity CNS Dose-dependent reversible somnolence
Disorientation, cognitive deterioration
Appears several days after beginning of
a treatment course
Hematopoietic toxicity Frequent anemia, occasional
thrombocytopenia, rare neutropenia;
lymphopenia with rebound
lymphocytosis, dramatic eosinophilia
Gastrointestinal toxicity Mild nausea, vomiting, diarrhea.
Mucositis is unusual, but may be
severe. Profound, reversible
cholestasis with hyperbilirubinemia
and elevated alkaline phosphatase but
normal transaminases
Infectious complications Increase in staphylococcal bacteremia,
often catheter related
Renal toxicity Oliguria and prerenal azotemia reversible
when infusion discontinued
Cutaneous toxicity Rash ranging from discrete nonpruritic
maculopapular lesions to diffuse
erythroderma with flaky exfoliation
after resolution of redness
Other Hypo- and hyperthyroidism, decrease in
vitamin-K-dependent coagulation
factors, severe myalgias
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• Treatment is supportive:
 No prospective randomized studies
 Supportive
BIOLOGIC AGENTS
• A variety of cytokines are available for widespread use.
• Each has a unique toxicity profile dependent on dose,
schedule, and combination therapy.
• “Cytokine cascade” is a shared feature:
 Typical features include fever and myalgia.
 Capillary leak syndrome:
 Can lead to hypotension and cardiovascular collapse.
 Fluid resuscitation may lead to pulmonary edema.
 Vasopressors often required.
 Resolves rapidly after discontinuation of therapy.
• Arrhythmias and myocardial infarction have been
reported.
• CNS toxicity is frequent:
 Usually reversible
 May persist for days after cessation of treatment
• Side effects of IL-2 treatment seen at recommended
dose for renal cancer (600,000 U/kg every 8 hours for
14 doses) listed in Table 91-7 as an example.
TOXICITIES OF “TARGETED” AGENTS
• “Targeted therapies” include agents that inhibit specific
targets such as surface receptors or intra- and extracel-
lular proteins that play role in tumor progression.
• Many are monoclonal antibodies and small molecule
kinase inhibitors.
• Increasing use has resulted in new clinical toxicities
being recognized and reported.
• Clinical experience with the newer targeted agents is
still limited.
MONOCLONAL ANTIBODIES
• Toxicities such as acute infusion reactions are
common to the drug class.
• Specific toxicities likely related to the modulation of
the targeted pathway by each specific antibody.
• Rituximab (Rituxan):
 Chimeric anti-CD20 antibody routinely used in var-
ious lymphoid malignancies.
 Case reports support role in various dermatologic
and systemic toxicities.
 Toxicity ranges from mild cutaneous reactions to
Stevens-Johnson syndrome and serum sickness.
 Generally resolve with discontinuation of therapy,
corticosteroids, and supportive care.
• Radioisotope-labeled antibodies are frequently asso-
ciated with prolonged myelosuppression.
ANTIANGIOGENIC AGENTS
• Thalidomide and bevacizumab (Avastin) are the only
agents currently approved for cancer therapy.
• Toxicities include bleeding, thromboses, hypertension,
and proteinuria.
• Treatment:
 Discontinue treatment
 Appropriate medical therapy
• Thalidomide is associated with high rates of throm-
boembolic complications in several trials:
 Combination with other chemotherapeutic agents
appears to be greatest risk factor.
 Management approaches are evolving.
SMALL MOLECULE TYROSINE KINASE
INHIBITORS
• Predominant toxicities dictated by the pathways inhib-
ited by each agent.
• Imatinib mesylate:
 Inhibits the Bcr-Abl protein-tyrosine kinase.
 Approved for chronic myeloid leukemia (CML) and
active against gastrointestinal stromal tumors.
 Common toxicities include mild nausea, emesis,
edema, and rash.
 2–4% of patients develop pleural and pericardial
effusions and severe cutaneous reactions.
 Severe events more common with high-dose therapy
(>600 mg/day).
• Gefitinib:
 EGFR tyrosine-kinase inhibitor approved for the
treatment of lung cancer.
 Mild to moderately severe skin rash and diarrhea in
most patients
 Mild toxicity managed with dose reduction or sup-
portive care.
 Severe symptoms (5–10% of patients) require discon-
tinuation of therapy and aggressive supportive care.
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92 RADIATION PNEUMONITIS
Peter H. O’Donnell
KEY POINTS
• Radiation pneumonitis can occur in any patient
receiving radiation to the thorax, though certain fac-
tors predispose patients to develop this syndrome.
• The clinical syndrome is varied, but usually includes
symptoms of dyspnea and cough.
• Radiographic changes can include opacification or
fibrotic changes. Often these changes will not follow
anatomic lines but instead the radiation field.
• The diagnosis is usually made clinically.
• Steroids are typically used to manage the disease, but
there are no prospective trials demonstrating their
effectiveness.
OVERVIEW OF RADIATION
PNEUMONITIS
• Radiation pneumonitis is an acute, inflammatory, injury-
response of the lung, occurring usually 1–3 months
following thoracic irradiation, which may produce a
clinical syndrome of pulmonary symptoms primarily
characterized by dyspnea and cough (Table 92-1).
• The clinical symptoms are often accompanied by
chest radiographic changes, most often manifested as
a hazy opacification of areas of lung which have been
irradiated. Virtually pathognomonic for radiation
pneumonitis on chest x-ray is the appearance of sharp
boundary lines for the haziness, which do not corre-
spond to anatomic lung lobes but rather to the prior
radiation field.
• Diagnosis can often be made by history plus chest
radiography. Historical cues which suggest the
diagnosis—besides (1) a recent history of thoracic
irradiation—include: (2) lack of symptoms of infec-
tion; (3) recent withdrawal of steroids; (4) multiple
courses of lung or thoracic irradiation; (5) recent con-
comitant chemotherapy; and (5) a history of previous
radiation pneumonitis.
• The incidence of symptomatic radiation pneumonitis
among patients receiving thoracic irradiation is
approximately 7–8%, whereas the total number with
radiation-induced chest radiograph changes, whether
symptomatic or not, is much higher at about 40%.
• Factors associated with increased incidence of radia-
tion pneumonitis include: (1) larger volumes of irradi-
ated lung; (2) higher total dose of radiation; (3) higher
daily fraction doses; (4) concomitant chemotherapy;
and (5) recent withdrawal of steroids.
• The clinical severity of radiation pneumonitis can be
scored according to several proposed scales, where, in
general, 0 = no radiation pneumonitis; 1 = mild; 2 =
steroid therapy may be indicated; 3 = patient requires
supplemental oxygen; 4 = life threatening; and 5 =
death from radiation pneumonitis.
• Radiation pneumonitis, therefore, can present a vari-
able clinical spectrum. In addition, it should be real-
ized that radiation pneumonitis represents an acute
manifestation of pulmonary radiation injury; the
related chronic form, radiation fibrosis, also exists as
an important but distinct clinical syndrome.
CLINICAL PRESENTATION
• The primary symptoms are dyspnea (frequency ~ 90%)
and cough (~60%), the latter more commonly
nonproductive.
• Some patients demonstrate low-grade fever, but most
will be without fever.
• Patients sometimes also describe a feeling of chest
fullness.
• Physical examination is often without specific abnor-
mality. Radiation changes of the skin, in the area of
the thorax, might be a helpful clue in patients who are
unable to provide a verbal history.
• Laboratory tests, such as the complete blood count
and arterial blood gas, usually add little toward
making the diagnosis, since abnormalities, if present,
are usually nonspecific.
• The chest radiograph remains as one of the corner-
stones, along with the history, in making the diagno-
sis. Radiation pneumonitis on chest x-ray is most
often manifested as a hazy opacification of areas of
lung which have been irradiated. The appearance of
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TABLE 92-1 Overview of Radiation Pneumonitis
History Thoracic radiation 1–3 months prior
Clinical symptoms Dyspnea, cough
Confirmatory studies Chest radiograph with haziness having sharp
boundary lines, which do not correspond to
anatomic lung lobes
Differential diagnosis Tumor recurrence or progression, lymphangitic
spread of cancer, infection, aspiration
Predisposing factors Large total or fraction radiation doses; large
volume of lung irradiated; concurrent
chemotherapy; recent withdrawal of steroids
Severity Can range from mild symptoms to fatal
syndrome; may progress to pulmonary
fibrosis
Treatment Supportive, oxygen, bronchodilators, prednisone
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sharp boundary lines for the haziness, which do not
correspond to anatomic lung lobes but rather to the
prior radiation field, is virtually pathognomonic. Less
common findings also include fuzziness of the pul-
monary vasculature in affected areas, and sometimes,
the presence of air bronchograms. However, symp-
toms can precede radiographic changes. While usu-
ally not necessary for diagnosis, chest computed
tomography (CT) will also demonstrate radiation-
induced lung changes.
• In considering the differential diagnosis, possibly the
most important distinction is to determine whether the
symptoms and radiographic changes could represent
tumor recurrence or progression, rather than radiation-
induced injury. Specifically, lymphangitic spread of
tumor may present similarly.
• The differential diagnosis of these patients also
includes infection, especially given the particular sus-
ceptibility of cancer patients—and even more specifi-
cally those with thoracic disease—for pulmonary
infectious diseases. In addition to the usual bacterial,
viral, and fungal pathogens, Pneumocystis carinii
(PCP) should be considered.
• An aspiration event, with either chemical pneumonitis
or aspiration pneumonia, is possible.
• Finally, the differential diagnosis should also contain
the possibility of chemotherapy-induced pneumonitis.
MECHANISMS OF RADIATION-INDUCED
LUNG INJURY
• Radiation can cause both direct cellular injury and
DNA damage to dividing cells.
• Direct cellular damage by ionizing radiation involves
initiation of apoptotic signal transduction pathways,
including breakdown of cellular membrane sphin-
gomyelin with resultant generation of the apoptotic
second-messenger ceramide.
• Additionally, irradiated cells cause cellular activation
of “stress response” cytokines, including transforming
growth factor-beta (TGF-beta) and basic fibroblast
growth factor.
• These inflammatory cellular activations, whether
apoptotic or directed at tissue repair, explain how such
pneumonitis at the alveolar-capillary interface could
cause clinical manifestations.
• Similarly, from the standpoint of radiation-induced
DNA damage, type II pneumocytes and capillary
endothelial cells—which share comparatively high
mitotic indices compared to other cells in the lung—are
thus particularly subject to radiation-induced injury and
are the fundamental cellular locations of DNA damage
in radiation pneumonitis. Radiation-induced DNA
injury likely involves generation of DNA-damaging
reactive oxygen species.
• The turnover rate of these mitotic cells (e.g., 20–35 days
for type II pneumocytes based on studies in mice)
might partially explain the delay between the admin-
istration of radiation and the occurrence of clinical
symptoms in radiation pneumonitis.
FACTORS WHICH INCREASE THE RISK
OF RADIATION PNEUMONITIS
• Several well-studied factors have been shown to be
associated with a higher incidence of developing radia-
tion pneumonitis. Chiefly, the development of radiation
pneumonitis seems to obey a “threshold phenomenon,”
where both the percentage of irradiated lung and the
total radiation dose can determine a threshold at which
radiation pneumonitis is more likely to occur.
• Though very high doses in small lung fields can cause
symptoms, larger irradiated lung volumes (especially
at or above 50%), especially when both lungs are irra-
diated, correlate with a higher incidence of sympto-
matic radiation pneumonitis.
• Similarly, larger total radiation doses correlate with a
higher incidence, but the relationship does not appear
to be linear. Risk increases at partial-lung total
doses above 25–30 Gy. For comparison, 64–70 Gy are
typically used to treat stage III nonsmall cell lung
cancer (NSCLC).
• While total radiation dose matters, evidence suggests
that fraction dose is equally important in conferring
risk. Daily fraction doses above 2.67 Gy have been
associated with increased incidence of pneumonitis,
and some suggest the daily fraction threshold is at or
below 2 Gy.
• Chemotherapy alone can cause clinical pneumonitis,
but concurrent chemoradiation has been shown to be
associated with an even greater incidence of pneu-
monitis, particularly with certain drugs. While many
chemotherapeutic agents have been implicated, the
best known include dactinomycin, doxorubicin,
cyclophosphamide, and bleomycin, the latter most
commonly associated with pulmonary fibrosis.
• One study in breast cancer patients receiving radiation
demonstrated the synergistic effect of concomitant
chemoradiation on the incidence of pneumonitis as
opposed to sequential treatment. In that study, the
incidence of radiation pneumonitis was 8.8% when
chemoradiation was concurrent, compared to 1.3%
when sequential.
• Of note, some chemotherapeutic agents have been
associated with radiation “recall” pneumonitis. In
these situations, patients who have had prior thoracic
irradiation will develop pneumonitis on administra-
tion of the chemotherapeutic agent. This phenomenon
has been best characterized with doxorubicin and
dactinomycin.
• Even more well-described is the phenomenon of radi-
ation recall pneumonitis on withdrawal of steroids, a
clinical scenario which can arise in patients who
receive corticosteroids as part of chemotherapeutic
regimens, or who receive steroid treatment for other
clinical indications. In these patients, symptomatic
radiation pneumonitis can develop shortly after with-
drawal of the steroid. Given the inflammatory under-
lying mechanism of radiation pneumonitis (see
above), it follows that steroid withdrawal could
unmask and precipitate an acute pneumonitis initiated
by prior radiation damage.
TREATMENT
• Given the inflammatory nature postulated for radiation-
induced lung injury, it is not surprising that corticos-
teroids comprise the mainstay of therapy for radiation
pneumonitis.
• Interestingly, no prospective clinical trials have demon-
strated the utility of steroids in humans, but a wealth of
clinical experience has shown their effectiveness.
• Prednisone, given at 1 mg/kg daily, is the standard
therapy for symptomatic radiation pneumonitis if the
clinical scenario warrants treatment. This dose is con-
tinued, usually for weeks, and then gradually reduced
in a protracted taper, with clinical alertness for
rebound of symptoms.
• Prophylactic steroids have not been shown to decrease
the incidence of radiation pneumonitis.
• Of note, many cases of radiation pneumonitis will be
clinically mild, and can be managed supportively
(oxygen, bed rest) and with bronchodilators.
FUTURE DIRECTIONS
• Several novel prophylactic and therapeutic strategies
have been proposed which attempt to target the reac-
tive oxygen and cytokine cascades which underlie the
mechanisms of radiation lung injury.
• One promising intravenous agent, amifostine, a reac-
tive oxygen species scavenger, has been shown in two
phase III trials to decrease the incidence of radiation
pneumonitis in patients undergoing radiation for
NSCLC.
• In the first study, 146 patients with advanced stage
NSCLC were randomized to receive either radiation
alone or radiation plus amifostine (given just prior to
each radiation treatment). At 2 months follow-up, the
group receiving amifostine had an incidence of pneu-
monitis of 9% compared to 43% in those receiving
radiation alone (P < .001). There was no difference
between the groups in the number of patients showing
complete or partial response to the radiation treatment.
• In the second study, 60 patients with NSCLC were
randomized to receive a regimen of etoposide plus
cisplatin plus radiation with or without concurrent
amifostine. Again, the incidence of pneumonitis was
lower in the amifostine group (3.7%) compared to the
standard-treatment group (23%) (P = .037), and
median survival was not significantly changed for the
two groups, though the amifostine group did experi-
ence a significantly higher incidence of hypotension.
• Other novel strategies under preclinical investigation
include whether inhibitors of tumor necrosis factor-
alpha (TNF-alpha) or TGF-beta, molecules implicated
in the lung injury cytokine pathway, could be clini-
cally useful.
• Finally, continued improvements in the ability to pref-
erentially deliver radiation energy to tumor with spar-
ing of normal surrounding tissue, via advances in
radiation physics and radiation-delivery techniques,
should only decrease the incidence of radiation lung
injury while preserving or increasing the therapeutic
effect of ionizing radiation.
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93 ACUTE RENAL FAILURE
Nina M. Patel
KEY POINTS
• Acute renal failure is common in the ICU and associ-
ated with substantial mortality.
• Dividing the causes among pre-renal azotemia, intrin-
sic renal failure, and post-renal failure is useful.
Intravascular volume and renal perfusion should be
judged and obstruction excluded, generally by assess-
ing patency of a urinary catheter and performing renal
ultrasound.
• Critical electrolyte disorders should be anticipated,
sought, and corrected.
• No specific therapy has been shown to reduce the sever-
ity or duration of acute tubular necrosis. In particular,
dopamine is clearly ineffective and should not be used
for this purpose.
• Indications for renal replacement therapy include
hyperkalemia, severe acidemia, fluid overload, and
uremia.
• It is uncertain whether continuous renal replacement
therapy is superior to intermittent dialysis.
• More than 50% of survivors will recover sufficient renal
function to avoid long-term dialysis.
EPIDEMIOLOGY
• Acute renal failure (ARF) occurs in up to 20% of ICU
patients.
• Mortality rates associated with ARF in the ICU are
50–70%.
• Survivors of ARF will recover renal function (no
longer require dialysis) in 50–75% of cases.
• Approximately 30% of survivors will require lifelong
hemodialysis.
• Acute tubular necrosis (ATN) and prerenal azotemia
are the two most common causes of hospital-acquired
ARF.
• Sepsis accounts for >50% of cases of ARF in the ICU.
PATHOPHYSIOLOGY
• Acute renal failure constitutes a sudden loss in renal
function (decrease in glomerular filtration rate
[GFR]) with consequent derangement of elec-
trolytes, acid-base regulation, and extracellular fluid
balance.
• ARF may also manifest with increasing blood urea
nitrogen (BUN) and decreasing urine output (UO).
• The classification of ARF is stratified into prerenal,
intrinsic renal, and postrenal azotemia.
• Prerenal azotemia results from decreased renal perfusion.
Hospital-acquired prerenal azotemia is most often
caused by systemic hypotension due to volume loss
(hemorrhage, gastrointestinal [GI] bleed, or GI loss)
or effective hypoperfusion (congestive heart failure
[CHF], cirrhosis, sepsis).
• Nonsteroidal anti-inflammatory drugs (NSAIDs),
angiotensin-converting enzyme (ACE) inhibitors, cal-
cineurin inhibitors (tacrolimus, cyclosporine), ampho-
tericin B, and radiocontrast media (RCM) can induce
a decrease in glomerular perfusion and/or renal
vasoconstriction.
• Intrinsic renal azotemia is subclassified into vascular,
interstitial, glomerular, or tubular causes of disease.
 Atheroemboli (recent intravascular procedure),
malignant hypertension (HTN), vasculitis, hemolytic
uremic syndrome/thrombotic thrombocytopenic pur-
pura (TTP), and scleroderma are vascular etiologies
of ARF.
 A number of commonly administered medications
precipitate acute interstitial nephritis (NSAIDs, peni-
cillin, cephalosporins, sulfonamides, ciprofloxacin,
furosemide, thiazides, phenytoin, allopurinol,
rifampin, cimetidine).
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 Glomerular diseases (nephrotic and nephritic syn-
dromes) are often associated with systemic disease
(connective tissue disease, vasculitis) and character-
istically display an active urine sediment.
 Prolonged systemic hypotension, medications (e.g.,
aminoglycosides, RCM, and amphotericin), cast
nephropathy due to myeloma light chains, uric acid
nephropathy in tumor lysis syndrome, and myoglo-
binuria in rhabdomyolysis frequently cause ATN.
• Postrenal azotemia occurs when there is obstruction in
urinary flow at any level between the renal pelvis and
the urethra. Nephrolithiasis, prostate disease, retroperi-
toneal obstruction (e.g., lymph nodes or mass), and
medication-induced crystalluria (protease inhibitors,
methotrexate, acyclovir, sulfonamides) commonly
lead to obstructive uropathy.
CLINICAL FEATURES
• Clinical history focuses on identification of volume
loss, changes in color or quantity of urine, intake of
nephrotoxic medications or illicit substances, pres-
ence of concurrent illnesses (e.g., HTN, diabetes mel-
litus [DM], CHF, and cirrhosis), and symptoms or
signs of obstructive uropathy.
• Assessing intravascular volume status is valuable in dis-
tinguishing prerenal azotemia from other causes of
ARF. Dry oral mucous membranes, tachycardia, and
orthostatic hypotension are consistent with intravascular
volume depletion. Inpatients should have daily weights
checked to monitor for changes in volume status.
• Skin examination should center on presence of rash,
purpura, livedo reticularis or stigmata of endocarditis
or other systemic conditions associated with intrinsic
renal disease.
• Nephrolithiasis may manifest as flank pain and cos-
tovertebral angle tenderness.
• UO is variable, but can be useful in determining etiol-
ogy and prognosis in ARF.
• A severe vascular insult (bilateral renal artery or vein
occlusion), complete urinary tract obstruction, bilat-
eral cortical necrosis, severe ATN, or rapidly progres-
sive glomerulonephritis may produce anuria (UO
<50–100 mL/day).
• Nonoliguric ATN (UO >500 mL/day) often, but not
always, has a lower rate of progression to dialysis than
oliguric ATN (UO <500 mL/day).
DIFFERENTIAL AND DIAGNOSIS
• There are no standard criteria for the diagnosis of
ARF, though it is often defined as a 50% decrease in
GFR, a 0.5 mg/dL increase in plasma creatinine
(Pcre), or a 25% decrease in creatinine clearance.
• Creatinine clearance is used as an estimate of GFR
and is calculated based on a 24-hour urine collection
(CREcl mL/min = [Ucre × (volume/Pcre)] ×
1000/1440). Normal values: men = 120 ± 25 mL/min;
women = 95 ± 20 mL/min.
• Limitations in use of CREcl are that tubular secretion
of CRE increases with decreasing GFR, resulting in
an overestimation of GFR and renal function. Also,
some drugs [e.g., trimenthoprim (TMP) and cimeti-
dine] compete with creatinine for secretion.
• When available, current Pcre should be compared to a
baseline value to determine the acuity of presentation.
• An electrolyte panel, calcium, magnesium, phospho-
rus, uric acid level, creatine kinase (CK), and liver
function panel should be checked in the initial
assessment.
• Urinalysis (UA) may reveal muddy brown casts, gran-
ular casts, and epithelial cell casts in ATN. RBC casts
and proteinuria occur in glomerular disease.
• A number of urine and serum examinations help dif-
ferentiate ATN and prerenal azotemia:
PRERENAL AZOTEMIA ATN
Plasma BUN/Cre >20:1 <10–15:1
Una <20 meq/L >40 meq/L
Uosm >500 mOsm/kg <400 mOsm/kg
FEna <1% >1%
(FEna; fractional excretion of Na = [Una × Pcre/Pna × Ucre] × 100)
• Patients with chronic renal failure or patients on
diuretic therapy will have altered excretion of water
and sodium. If prerenal azotemia is highly suspected,
patients should undergo a trial of volume repletion for
at least 24 hours. If unsuccessful, ATN is likely.
• Renal ultrasound (US) should be obtained and may
reveal hydronephrosis in significant urinary obstruc-
tion. Doppler US may demonstrate renal vein throm-
bosis or renal artery stenosis.
• Plain films of the abdomen reveal radiopaque calculi
(calcium, struvite, cystine).
• Non-contrast-enhanced computed tomography (CT)
is the gold standard for suspected nephrolithiasis and
can diagnose radiolucent as well as radiopaque stones.
With IV contrast, CT can also diagnose renal cell
cancer and renal vein thrombosis.
• Intravenous pyelogram (IVP), MRI, and radionuclide
studies can be utilized for specific indications.
• Renal biopsy is indicated for suspected glomeru-
lonephritis or vasculitis, or when noninvasive meas-
ures have failed to yield a diagnosis.
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TREATMENT
• Initial management includes identifying the etiology
and either discontinuing the nephrotoxic agent, reliev-
ing the obstruction, or treating the insult, and always,
assuring adequate renal perfusion.
• Severe electrolyte derangements (e.g., hyperkalemia
and hyperphosphatemia) should be corrected and
enteral (when possible) nutritional support provided.
• Subsequent management of ARF is divided into non-
dialytic and dialytic therapy.
• Crystalloid infusion is an effective means of expanding
intravascular volume. Indiscriminate use of crystal-
loids can lead to pulmonary edema. Fluid management
should be titrated to markers of volume status and per-
fusion (fluid balance, daily weight, central venous
pressure, central venous O2%).
• Vasoactive agents are utilized to augment systemic
blood pressure (BP), if intravenous fluids (IVFs)
alone fail. Dobutamine, vasopressin, and norepineph-
rine have variable effects on UO and CREcl, and do
not appear to compromise renal perfusion.
• “Renal dose” dopamine (0.5–2 µg/kg/min) does not
improve outcomes (Pcre, mortality, length of stay,
dialysis) and should not be used in patients with ARF.
• Fenoldopam (selective dopamine1-receptor agonist) and
N-acetylcysteine, in concert with hydration, have been
shown to decrease rates of radiocontrast-mediated
nephropathy. Sodium-bicarbonate therapy pre- and
postradiocontrast exposure has also been shown to
decrease the development of radiocontrast nephropathy.
• Indications for dialysis are hyperkalemia, severe
metabolic acidosis, fluid overload, and uremia.
• Preliminary studies suggest that increased doses of
dialysis (Kt/Vurea) and use of biocompatible mem-
branes are improving survival in ARF and ATN.
• ICU patients who received daily hemodialysis versus
intermittent hemodialysis were observed to have
lower mortality rates.
• Data regarding continuous renal replacement therapy
(CRRT) versus intermittent hemodialysis is controver-
sial. At present, CRRT does not confer a survival benefit.
CONCLUSIONS
• Acute renal failure occurs frequently in the ICU, and
is a major cause of ICU morbidity and mortality.
• Diagnosing the etiology of ARF can be challenging.
Urine studies, renal US, rigorous attention to iatro-
genic sources of renal failure (e.g., medications and
contrast) and at times, renal biopsy are useful to dis-
cern the etiology of decreased renal function.
• Medical therapies for the prevention and treatment of
ARF are targeted at the inciting insults. If metabolic
derangements, fluid overload, or uremia ensue, renal
replacement therapy is indicated.
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94 RENAL REPLACEMENT
THERAPY IN THE ICU
Ignatius Y. Tang
KEY POINTS
• Primary indications for RRT include uremia, hyper-
kalemia, acidemia, volume overload, and drug
intoxication.
• Continuous dialytic modalities are better tolerated in
the setting of hemodynamic instability or hypoperfused
states.
• Some form of anticoagulation is almost always required
during dialytic therapy.
INDICATIONS
• Uremia
• Hyperkalemia refractory to medical therapy
• Volume overload refractory to diuretics
• Severe metabolic acidosis
• Some drug intoxications (e.g., lithium, ethylene glycol,
methanol, salicylates, theophylline, and phenobarbital.
Digoxin and tricyclic antidepressants are insignificantly
removed by dialysis because of their large volumes of
distribution. Phenytoin and warfarin are not signifi-
cantly removed because of their high protein binding.)
TIMING OF INITIATION OF RENAL
REPLACEMENT THERAPY
• There is no evidence that initiating renal replacement
therapy (RRT) prophylactically would alter the out-
comes of acute renal failure (ARF). However, one
should not delay therapy until the patient has com-
plete renal shutdown.
MODALITIES OF RENAL
REPLACEMENT THERAPY
• Intermittent hemodialysis (IHD)
• Continuous venovenous hemofiltration (CVVH)
• Continuous venovenous hemodialysis (CVVHD)
• Continuous venovenous hemodiafiltration (CVVHDF)
• Continuous arteriovenous hemofiltration (CAVH)
• Continuous arteriovenous hemodialysis (CAVHD)
• Continuous arteriovenous hemodiafiltration (CAVHDF)
• Slow continuous ultrafiltration (SCUF)
• Slow low efficiency dialysis (SLED)
• Peritoneal dialysis (PD)
NOTES ON RENAL REPLACEMENT
THERAPY MODALITIES
• All the modalities above except PD require a vascular
access and an artificial membrane (dialyzer or filter).
Biocompatible membranes which minimally activate
complement are usually used.
• In PD, a catheter is placed in the peritoneal cavity.
Dialysis solution is infused via the catheter into the
peritoneal cavity. This is not commonly done for ARF.
• The continuous modalities are done continuously,
24 hours a day while the intermittent modalities are
done 4–6 hours (IHD) or 8–16 hours (SLED) per ses-
sion daily or every other day, depending on the patient’s
needs.
• PD is rarely used because of its inferior solute clear-
ance compared to hemodialysis and hemofiltration.
• CVVH was shown to be more effective and improve
survival in a population with infection and sepsis who
developed ARF.
• Continuous arteriovenous renal replacement therapies
are also rarely used because of the bleeding complica-
tions that occur with arterial cannulation.
• SCUF is used only for fluid removal; it does not pro-
vide significant solute clearance.
PRINCIPLES OF SOLUTE CLEARANCE
DURING RENAL REPLACEMENT
THERAPY
• Diffusion: solute removal based on concentration gra-
dient; effective for small molecule removal.
• Convection: solute removal based on ultrafiltration;
more effective for large molecule removal.
• Hemodialysis: diffusive clearance. Blood and dialysis
solution flow in countercurrent directions while diffu-
sion occurs across the membrane.
• Hemofiltration: convective clearance. No dialysis
solution is used. Instead, replacement fluid is used to
replete the solutes that are cleared.
• Hemodiafiltration: diffusive and convective clearance,
that is, combination of hemodialysis and hemofiltration.
Both replacement fluid and dialysis solution are used.
• PD: diffusive and convective clearance. PD solution is
placed in the peritoneal cavity. Diffusion across the
peritoneal membrane occurs during the dwell period.
• In hemodialysis, increasing either the blood or the
dialysate flow rates, or both would increase solute clear-
ance. In contrast to IHD in which blood flow rates of
300–450 mL/min and dialysate flow rates of 600–800
mL/min are employed, lower blood and dialysate flow
rates for a prolonged period of time are used in SLED.
In continuous hemodialysis or hemodiafiltration, typical
blood and dialysate flow rates are 150–200 mL/min and
16–32 mL/min, respectively. Using a dialyzer with a
large surface area also results in increased clearance.
• In hemofiltration, increasing the ultrafiltration (or
effluent) flow rates would increase solute clearance.
The blood flow rates are 150–200 mL/min.
PRINCIPLES OF FLUID REMOVAL
DURING RENAL REPLACEMENT
THERAPY
• Fluid removal is effected by ultrafiltration.
• In hemodialysis, hemofiltration, and hemodiafiltration,
the driving force for ultrafiltration is the hydraulic
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pressure gradient across the membrane. High ultrafil-
tration rates can be achieved with high flux mem-
branes that have a high ultrafiltration coefficient.
• In PD, the driving force for ultrafiltration is the
osmotic gradient generated by the high glucose con-
tents of the peritoneal dialysate solutions.
ANTICOAGULATION
• Anticoagulation is usually required during RRT to
prevent clotting of the dialyzer/filter and the RRT cir-
cuit because clotting of the dialyzer/filter would com-
promise the efficiency of solute clearance of RRT.
Frequent clotting of the RRT circuit also results in
increased blood loss.
• Heparin is the usual anticoagulant. Citrate, lepirudin,
and argatroban are alternative choices in patients who
cannot tolerate heparin, for example, those with
heparin-induced thrombocytopenia.
• Lepirudin is rarely used because it is renally excreted
and accumulates in renal failure. Citrate and argatroban
may not be used in patients with severe liver dysfunc-
tion because both are hepatically metabolized.
• PD does not require anticoagulation.
COMPLICATIONS OF RENAL
REPLACEMENT THERAPY
• Hypotension (excessive ultrafiltration)
• Bleeding (excessive anticoagulation)
• Clotting (inadequate anticoagulation)
• Infection (catheter-associated)
• Pneumothorax and hemothorax (catheter-associated)
• Increased intracranial pressure (rapid osmotic shifts
in IHD)
• Anaphylactoid reaction with certain membranes (e.g.,
AN69 with angiotensin-converting enzyme [ACE]
inhibitors)
• Citrate toxicity (arrhythmia, metabolic alkalosis, and
hypocalcemia)
• Electrolyte imbalance (errors in replacement fluid or
dialysate, parenteral nutrition, and other intravenous
fluids)
DOSE ADJUSTMENT IN RENAL
FAILURE AND DURING RENAL
REPLACEMENT THERAPY
• The doses for all drugs and those with active metabo-
lites that are mainly renally eliminated should be
adjusted. Drugs may be removed by RRT.
• Rules of thumb: drugs with small molecular weights,
small volumes of distribution, or low protein/tissue
binding can be removed during RRT and may need
supplementation. Lipophilic drugs are less likely to be
removed. High flux membranes can remove large
molecules such as vancomycin and vitamin B12.
IMPACT OF RENAL REPLACEMENT
THERAPY ON SURVIVAL
• There appears an association of improved outcome
with increased dose of RRT.
• Daily IHD was associated with a lower mortality rate
and a shorter duration of ARF when compared to
alternate-day IHD.
• CVVH has been shown in a prospective randomized-
controlled study to improve outcomes if the ultrafil-
tration rate is 35 mL/kg/h.
• RRT does not hasten renal recovery. It only supports
the patient during ARF.
INTERMITTENT VERSUS CONTINUOUS
TREATMENTS
• No difference in survival benefits is proven. Continuous
RRT (CVVH, CVVHD, and CVVHDF) is usually indi-
cated for hemodynamically unstable patients.
• Continuous RRT is useful in critically ill patients with
multiorgan failure, requiring significant nutritional and
fluid support.
• It may also be useful in liver failure patients with hepatic
encephalopathy or stroke patients to avoid increase in
intracranial pressure.
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95 SEVERE ELECTROLYTE
DISORDERS
William Schweickert
KEY POINTS
• Disorders of sodium concentration are nearly always
caused by excess free water (hyponatremia) or free
water loss (hypernatremia).
• Severe or symptomatic acute hypernatremia should be
corrected rapidly (2 mEq/L/h) but only partially, gener-
ally using hypertonic saline.
• Severe hypernatremia should be corrected only
slowly, since rapid correction risks cerebral swelling.
• Mild hypokalemia (>2.5 mEq/L) is generally asymp-
tomatic and does not benefit from urgent correction.
• Severe hyperkalemia risks life-threatening arrhythmias:
treatment may include dialysis, diuretics, kayexalate,
insulin with glucose, sodium bicarbonate, and cal-
cium gluconate.
• Hypocalcemia is common in critical illness and gen-
erally does not benefit from treatment.
HYPONATREMIA
• Hyponatremia should be envisioned as a problem of
free water excretion. In the event of a large free
water intake, two processes prevent its occurrence:
(1) kidney formation of a dilute filtrate in the Loop
of Henle and (2) antidimone (ADH) is turned off.
When these two steps are impaired, hyponatremia
results.
• Symptoms are due to cerebral edema as the extra water
enters the brain, causing headache, nausea, or lethargy;
severe disease may culminate in seizures or coma.
• First step is to determine tonicity (to exclude pseudo-
hyponatremia)—generally unnecessary, but can be
proven by checking serum osmolality.
 Isotonic hyponatremia: rare lab artifact due to
hyperlipidemia or hyperproteinemia.
 Hypertonic hyponatremia (high serum osmolality):
presence of another effective osmole (glucose, man-
nitol) that moves free water into the extracellular
volume. Recall that each 100 mg/dL increase in
glucose >100 mg/dL, plasma Na will decrease by
1.6 meq/L.
 Hypotonic hyponatremia: true excess of water rela-
tive to sodium. Almost entirely due to increased
ADH secretion, but will need to determine if this is
appropriate (decreased effective circulating volume)
or inappropriate. Note: primary polydipsia is an
exception.
 Hypovolemic (primary Na loss with secondary
water gain):
• Urinary Na levels to determine source of loss.
• Renal losses will have a UNa >20 meq/L and
FENa >1%. Etiologies include diuretics, hypoal-
dosteronism, and salt-wasting nephropathy.
• Extrarenal losses produce a UNa <10 meq/L, FENa
<1%, frequently mediated by gastrointestinal
(GI) losses, third spacing, and insensible losses.
 Euvolemic (primary water gain): utilize U
osm
to
determine cause:
• Syndrome of inappropriate antidiuretic hormone
(SIADH): patients are euvolemic or mildly hyper-
volemic with an inappropriately high U
osm
(>100).
Seek etiology: endocrinopathies (hypothyroidism,
adrenal insufficiency), pulmonary or intracranial
pathology, malignancy, pain, nausea, drugs (neu-
roleptics).
• Psychogenic polydipsia: usually requires intake
of >12–20 L/day, U
osm
<100, low uric acid.
• Reset osmostat (ADH regulation reset to regu-
late a lower Na)—variable U
osm
.
 Hypervolemic (low effective circulating volume):
• Etiologies include congestive heart failure
(CHF), cirrhosis, nephrotic syndrome—all
lead to decreased effective arterial volume =
UNa <10 meq/L, FENa <1%.
• Advanced renal failure (UNa >20 meq/L).
• Treatment:
 Rate of correction:
 Chronic hyponatremia, brain cells excrete
osmoles to minimize intracellular swelling.
Correcting too rapidly can increase serum osmo-
lality relative to brain, create water shift from
brain with resultant brain dehydration: cerebral
pontine myelinolysis. Therefore, rate of increase
of Na should not exceed 0.5 meq/L/h.
 Patients with serious neurologic symptoms or a
sodium concentration <100 meq/L need an initial
rapid correction until symptoms resolve or a safer
level is reached. The goal is to correct the serum
Na at a rate of 1.5–2 meq/L/h. Consider the use of
hypertonic saline.
 Hypovolemic hyponatremia: calculate sodium
deficit and replace with 0.9 normal saline:
 (0.6 × ideal body weight × (140 − measured Na) ×
0.85 (in women only)
 Hypervolemic hyponatremia: sodium and water
restriction (<1 L/day).
 SIADH—free water restriction usually suffices. If
chronic can use demeclocycline.
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HYPERNATREMIA
• Hypernatremia is simply a deficit of water relative to
sodium; this is almost always due to loss of hypotonic
fluid and impaired access to free water. The body usu-
ally defends against this with the potent mechanism of
thirst, but critically ill patients are often unable to drink.
• Symptoms are due to osmotic shrinkage of brain cells
and include lethargy, seizures, and coma.
• First, check volume status and determine why the
patient is not drinking.
 If hypovolemic, determine source of loss (renal vs.
nonrenal) via UNa levels:
 Renal losses (UNa >20 meq/L, ↑ urine volume,
U
osm
= 300–600): diuretics, osmotic diuresis
 Extrarenal losses (UNa <10 meq/L, ↓ urine
volume, U
osm
>600): GI or insensible losses
 If euvolemic, determine whether there is a lack of
ADH activity:
 Diabetes insipidus (DI): ADH is absent (central)
or has no effect (nephrogenic):
• Central: central nervous system (CNS) trauma,
surgery, hemorrhage, tumor, idiopathic
• Nephrogenic: drugs (lithium, amphotericin),
metabolic (hypercalcemia, hypokalemia), sickle
cell, sarcoid, amyloid
• Tests: U
osm
<300 in complete, 300–600 in partial
OR water deprivation test
 Reset osmostat
 If hypervolemic, usual causes are exogenous NaCl infu-
sion (high U
osm
>600), or mineralocorticoid excess.
• Treatment:
 Rate of correction: in chronic hypernatremia, brain
cells generate osmoles to minimize intracellular
dehydration. Too rapid correction prompts decrease
serum osmolality relative to high brain osmolality,
water passes into the brain with resultant swelling.
Therefore, rate of increase of sodium should not
exceed 0.5 meq/L/h
 Hypovolemic hypernatremia: replace volume until
clinically judged euvolemic and initiate free water
replacement. Utilize free water deficit equation:
 [Ideal body weight × 0.6 × (measured Na/140 − 1)
(0.85 in women)]
 Hypervolemic hypernatremia: loop diuretics + D5W
 Central DI: desmopressin (dDAVP)
 Nephrogenic DI: treat underlying cause; salt restric-
tion + thiazide diuretic
HYPOKALEMIA
• Potassium enters the body via oral intake or IV infusion
and is largely stored in cells, and excreted in urine.
Hypokalemia can ensue in the setting of decreased
intake, increased translocation into cells, or (most com-
monly) increased losses in urine or the GI tract or sweat.
• Symptoms: Severe hypokalemia (<2.5 meq/L) can be
accompanied by diffuse muscle weakness, mental
status changes. Milder forms of hypokalemia are gen-
erally asymptomatic.
• ECG manifestations:
 Mild hypokalemia: flat or inverted T waves, ST
depression, prolonged QT interval
 Severe hypokalemia: prominent U waves, ventricu-
lar tachycardia, or fibrillation
• Workup:
 Evaluate for possible causes of transcellular shifts:
 Insulin, albuterol, refeeding, periodic paralysis
 Determine whether potassium depletion is due to GI
or renal losses via UK:
 GI losses: UK <25 meq/L; renal losses: UK >30 meq/L
 GI loss: vomiting, nasogastric (NG) drainage; diar-
rhea, villous adenoma
 Renal loss: determine blood pressure and acid-base
status:
 Hypo- or normotensive:
• Acidosis: diabetic ketoacidosis (DKA), renal
tubular acidosis (RTA, types 1 and 2)
• Alkalosis: diuretics, Bartter, or Gitelman syn-
drome, loss of gastric fluid
• Either: magnesium deficiency
 Hypertensive:
• Hyperaldosteronism: primary or secondary
• Pseudohyperaldosteronism: Cushing syndrome,
licorice
• Treatment: Enteral or intravenous replacement of
potassium combined with chloride or other anions.
 Severe hypokalemia requires rapid intravenous infu-
sion. If K is <2 meq/L, maximum 40 meq/h is nec-
essary. Recheck values frequently.
 When K is >2 meq/L and there are no ECG
changed, 10 meq/h suffices.
 Remember to treat any coexisting hypomagnesemia
(avoid lethal arrhythmia)!
HYPERKALEMIA
• Urinary excretion is stimulated by a rise in plasma
potassium, plasma aldosterone, or enhanced distal
delivery of sodium and water. Hyperkalemia rarely
occurs with isolated intake and release of intracellular
potassium can cause a transient plasma elevation.
Persistent hyperkalemia requires an impairment in
urinary potassium excretion.
• Symptoms include weakness, irritability, paresthesias,
and paralysis.
• ECG manifestations:
 Mild hyperkalemia: peaked T waves, premature
ventricular contractions (PVCs)
 Severe hyperkalemia: widening of QRS, depressed
ST, prolonged PR, sinus arrest, ventricular arrhyth-
mia (tachycardia, fibrillation, or arrest)
• Workup:
 Exclude pseudohyperkalemia (hemolyzed speci-
men, severe thrombocytosis/leukocytosis)
 Evaluate for transcellular shifts:
 Beta-blocker, insulin deficiency, digoxin intoxica-
tion, massive cellular necrosis, hyperkalemic peri-
odic paralysis
 Determine whether severely decreased or normal
glomerular filtration rate (GFR):
 Normal GFR: determine why there is decreased
aldosterone function
• Hyporeninemic: type 4 RTA (diabetic nephropa-
thy, angiotensin-converting enzyme inhibitor
[ACEI], nonsteroidal anti-inflammatory drugs
[NSAIDs])
• Primary adrenal: Addison disease, congenital
adrenal hyperplasia, heparin
• Renal tubular disorder: K-sparing diuretics,
cyclosporine, systemic lupus erythematosus
(SLE), multiple myeloma
 Decreased GFR: any cause of acute oligo- or anuric
renal failure or chronic disease
• Treatment:
 Correct underlying disorder
 Effectively decrease total body potassium
 Kayexalate (oral or rectal), diuretics (furosemide),
hemodialysis (definitive)
 Transient effect: insulin (usually accompanied by
glucose), consider bicarbonate
 Stabilize membranes to avoid arrhythmia (with any
ECG changes): calcium gluconate
HYPOCALCEMIA
• The free or ionized calcium is physiologically rele-
vant. Total calcium levels must be interpreted relative
to the plasma albumin concentration
 Recall the approximation: for every 1.0 mg/dL that
the albumin is below 4.0, the calcium is lowered by
about 0.6 mg/dL. Alkalemia causes more calcium to
bind to albumin and will drop ionized calcium further
• Symptoms, when severe: tetany, including laryn-
gospasm, mental status changes, and seizures
• ECG changes: QT prolongation
• Causes:
 Vitamin D deficiency
 Malnutrition, poor sunlight exposure, malabsorp-
tion, drugs (e.g., phenytoin and phenobarbital),
renal failure
 Hypoparathyroidism (postsurgical or idiopathic)
 Hypomagnesemia impairs parathyroid hormone
(PTH) release
 Uptake by necrotic tissue (severe pancreatitis, rhab-
domyolysis)
 Impaired action of PTH occurs in severe sepsis
• Diagnosis: measure PTH levels as well as concurrent
phosphate level
• Treatment: correct underlying cause. Replace ONLY
if the patient is symptomatic
 Evidence that calcium administration in the criti-
cally ill may cause hypoxic cell damage
 Remember to correct magnesium (to avoid
arrhythmia)!
HYPERCALCEMIA
• Most common cause of severe disease is malignancy
(bone involvement or ectopic PTH-like hormone).
Others: hyperparathyroidism, vitamin D toxicity, or
sarcoidosis.
• Manifestations: lethargy and mental status changes,
vomiting, reversible nephrogenic DI, renal insuffi-
ciency, and ectopic calcifications.
• ECG changes: QT interval shortening, potentiation of
digoxin toxicity.
• Treatment: increasing urine output with saline, fol-
lowed by loop diuretics once euvolemic:
 Slow effectors—pamidronate (or equivalent), calcitonin
HYPOPHOSPHATEMIA
• Causes include depleted stores, refeeding syndrome,
malabsorption, phosphate-binding antacids, renal losses
(RTA type 2, acute tubular necrosis [ATN], hyper-
parathyroidism), or transcellular shifts (insulin, DKA
recovery, catecholamine infusion, alcohol withdrawal).
• Symptoms/adverse effects: muscular and diaphrag-
matic weakness, heart failure, arrhythmias, confusion,
and rhabdomyolysis when severe.
• Treatment: oral supplementation, unless severe (below
1.0 mg/dL).
HYPERPHOSPHATEMIA
• Four main causes include excessive administration
(laxatives), decreased renal excretion, transcellular
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shift out of cells (respiratory acidosis, rhabdomyoly-
sis, chemotherapy), and artifact from hemolysis.
• Usually requires some degree of renal failure, although
it may result from severe tissue necrosis in normal renal
function.
• Severe acute toxicity can result in ectopic calcifica-
tion and hypocalcemia.
• Treatment: dietary restriction, phosphate binders when
mild, dialysis if severe. Saline hydration or acetazo-
lamide may help in those without renal failure.
HYPOMAGNESEMIA
• Results from malnutrition and chronically decreased
body stores (alcoholism), diarrhea, or urinary wasting
(diuretics, cisplatin, or amphotericin).
• Manifestations: tetany, laryngospasm, cardiac arrhyth-
mias, hypocalcemia (and its effects).
• Correction may require large doses, critically ill
patients require intravenous replacement (oral poorly
tolerated).
HYPERMAGNESEMIA
• Causes: decreased renal excretion (renal failure, salt
depletion), excessive intake (laxative or antacids),
endocrinopathies, and tissue breakdown (rhabdomyolysis).
• Results in lethargy, weakness, and hyporeflexia.
When severe, bradycardia, heart block, and hypoten-
sion may ensue.
• Treatment: hydration with loop or thiazide diuretic if
patient urinates. Dialysis if anuric.
 Intracardiac conduction abnormalities can be reme-
died with IV calcium gluconate.
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96 ACID-BASE BALANCE
Meredith McCormack
KEY POINTS
• Acid-base homeostasis is important to maintain tissue
and organ performance. Both acidosis and alkalosis
can have harmful effects and when severe, can be life
threatening.
• It is the nature of the condition responsible for the
acid-base disturbance that largely determines the
patient’s prognosis.
• It is appropriate to focus on diagnosing and treating the
underlying disorder, as most acid-base derangements
do not benefit from specific correction of the abnor-
mal pH.
INTRODUCTION
• The Henderson-Hasselbalch equation demonstrates
the relationship between key components of the blood
that determine acid-base balance. Here, the relation-
ship among pH, HCO3−, and PaCO2 can be readily
seen.
pH = pK
a
+ log([HCO3−]/(PCO2 × 0.03))
• The Henderson-Hasselbalch equation predicts that
acidemia results from conditions that increase the
PCO2 or decrease the HCO3−. Conversely, alkalemia
results from decreased PCO2 or increased HCO3.
• Compensatory responses tend to return the pH to
normal.
• There are four primary acid-base disorders.
 Metabolic acidosis
 Characterized by a decrease in plasma [HCO3−]
through loss of HCO3− or accumulation of H+
 Accompanied by compensatory fall in [PCO2]
through hyperventilation
 Respiratory acidosis
 Characterized by an increase in [PCO2] (hypoven-
tilation)
 Compensatory increase in [HCO3−] via renal
excretion of H+ occurs slowly over days
 Metabolic alkalosis
 Characterized by increase in plasma [HCO3−]
through H+ loss or HCO3− gain
 Accompanied by compensatory rise in [PCO2]
through hypoventilation
 Respiratory alkalosis
 Characterized by decrease in [PCO2] (hyperventi-
lation)
 Compensatory decrease in [HCO3−] via renal
excretion of NH4+
METABOLIC ACIDOSIS
• Diagnostic evaluation
 The presence of a low pH and a low [HCO3−] are the
cardinal features of a metabolic acidosis.
 Determination of the presence of an anion gap (AG)
will aid in determining the underlying cause.
 The formula is:
 AG = [Na+] − ([Cl−] + [HCO3−]) and the expected
value is between 8 and 10.
 The AG is comprised largely of albumin and to a
lesser extent, phosphate. Chronically, low albumin
or phosphate will affect the value.
 To correct for this, the expected value can be cal-
culated as corrected AG = 2(albumin [g/dL]) + 0.5
(phosphate [mg/dL]).
 Determination of the presence of an osmolar gap
may also be helpful in determining the etiology of
the metabolic acidosis.
 Calculated serum osmolality = 2[Na+] + glucose/
18 + blood urea nitrogen (BUN)/2.8.
 Osmolal gap = measured serum osmolality −
calculated serum osmolality.
 The presence of an elevated osmolal gap suggests
the presence of an additional solute in the plasma.
 To determine if there is appropriate respiratory com-
pensation, one can use Winter formula.
 PCO2 = 1.5[HCO3−] + 8 ± 2.
 If this equation is not balanced by inserting the PCO2
from the patient’s arterial blood gas and the [HCO3−]
from a blood chemistry drawn simultaneously, this
suggests the presence of a secondary process.
 Investigate the presence of a secondary process
using the delta formula.
 Here, the change in the AG is calculated (com-
pared to predicted) and the change in [HCO3−] is
calculated compared to the normal value of 24.
 ∆AG > ∆[HCO3−] → concomitant metabolic
alkalosis.
 ∆AG = ∆[HCO3−] → no secondary metabolic
disorder.
 ∆AG < ∆[HCO3−] → concomitant nongap met
acidosis.
• AG metabolic acidosis
 Lactic acidosis
 Lactic acidosis is the most important cause of
metabolic acidosis in critical illness.
 Lactic acid has been shown to correlate with out-
come in hemorrhagic and septic shock.
 Inadequate tissue oxygenation underlies the lactic
acidosis in many patients.
 Therapy should focus on restoring circulation and
tissue oxygenation while diagnosing and treating
the underling etiology (i.e., sepsis, hemorrhage,
and bowel infarction).
 Administration of sodium bicarbonate has not
been shown to improve outcomes in patients with
lactic acidosis.
 Renal failure
 Renal failure is often associated with a hyper-
chloremic metabolic acidosis that is partially asso-
ciated with an elevated AG.
 The AG reflects retained sulfates, phosphate, and
other organic ions.
 Hemodialysis will permit removal of these ions
and will restore Na+ and Cl− balance.
 Diabetic ketoacidosis
 Poisoning/ingestion
 Ethanol: alcoholic ketoacidosis is associated with
both an elevated AG and an elevated osmolar gap.
 Methanol and ethylene glycol are both associated
with elevated anion and osmolal gaps.
 Salicylate ingestion usually results in a mixed dis-
turbance, a metabolic acidosis and a respiratory
alkalosis.
• Respiratory alkalosis is caused by the direct
stimulation of the respiratory center by the sali-
cylate and the metabolic acidosis is caused by
lactate accumulation.
• Non-AG metabolic acidosis
 Renal tubular acidosis (RTA)
 The defect in all types of RTA is the inability to
excrete Cl− in proportion to Na+.
 Type I (classic distal) RTA can present with pro-
found hypobicarbonatemia and hypokalemia and
replacement with sodium bicarbonate and potas-
sium infusion is usually required.
 Type IV RTA is associated with aldosterone defi-
ciency or resistance. Clinical features include high
serum potassium and low urine pH (<5.5).
Treatment is directed at the underlying cause.
 Diarrhea
 Loss of bicarbonate through the digestive tract is
typically accompanied by losses of Na+ that are
out of proportion to the losses of Cl−.
 This results in a non-AG hyperchloremic meta-
bolic acidosis.
 Pancreatic diversion can have a similar effect.
 Hyperalimentation
 Parenteral nutrition with excess Cl− can cause
hyperchloremic acidosis.
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 Weak anions such as acetate are often used in
addition to Cl− to allow adjustment for a patient’s
acid-base status.
RESPIRATORY ACIDOSIS
• Diagnostic evaluation
 Diagnosis of respiratory acidosis involves recognizing
the decrease in pH accompanied by an elevated PCO2.
 Assessment of the clinical situation and reviewing
the serum bicarbonate concentration in relation to
the PCO2 can help determine the chronicity.
 In an acute respiratory acidosis, [HCO3−] should
increase about 1 meq/L for every 10 mmHg rise in
PCO2.
 In chronic respiratory acidosis, the [HCO3−] should
increase about 3–5 meq/L for every 10 mmHg rise
in PCO2.
• Differential diagnosis
 Central nervous system (CNS) suppression
 CNS disease
 Drugs
 Neuromuscular disease
 Myasthenia gravis
 Guillain-Barré syndrome
 Hypophosphatemia
 Hypokalemia
 Pulmonary disease
 Chronic obstructive pulmonary disease (COPD)
 Obesity-hypoventilation
 Mechanical derangement of the chest wall
METABOLIC ALKALOSIS
• Metabolic alkalosis occurs as either a loss of anions
(Cl− from the stomach) or an increase in cations,
which is rare.
• Chloride responsive metabolic alkalosis
 This is a consequence of temporary chloride loss.
 Urine chloride is typically below 20 mmol/L.
 Most common causes are vomiting, gastric drainage,
volume contraction. Diuretic use is also chloride
responsive but urine chloride may be >20 mmol/L.
 Treatment is replacement of chloride and volume loss.
Saline with potassium supplementation is often given.
• Chloride-resistant metabolic alkalosis
 This is typically a consequence of a hormonal
mechanism and is less easily corrected by the
administration of chloride.
 Urine chloride is typically elevated (>20 mmol/L).
 Most common causes are processes involving excess
mineralocorticoid activity. Examples include hyper-
cortisolism, hyperaldosteronism, sodium bicarbon-
ate therapy, and severe renal artery stenosis.
 Treatment is directed at the underlying cause.
• Other causes
 Rarely, metabolic alkalosis is a consequence of
cation administration rather than anion depletion.
 Examples include the milk-alkali syndrome and
massive blood transfusions or plasma exchange.
The latter occurs because Na+ is paired with citrate
(a weak anion) instead of Cl−.
RESPIRATORY ALKALOSIS
• Respiratory alkalosis is the most common acid-base
disorder. It occurs during normal pregnancy and at
high altitudes. In critically ill patients, it often indi-
cates poor prognosis.
• Diagnostic evaluation
 Requires recognition of elevated pH and decreased
PCO2.
 In an acute process, the compensatory response is an
approximate decrease in [HCO3−] of about 1–2 meq/L
for every 10 mmHg decrease in PCO2.
 In a chronic process, the compensatory response is
an approximate decrease in [HCO3−] of about 5 meq/L
for every 10 mmHg decrease in PCO2.
• Differential diagnosis
 Hypoxemia
 High altitude
 Pulmonary disease
 Heart failure
 Anemia
 Respiratory center stimulation
 Pregnancy
 CNS disease
 Liver disease
 Sepsis
 Drugs
 Pulmonary disease
 Pneumonia
 Interstitial lung disease
 Pulmonary emboli
• Treatment is directed at the underlying cause.
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97 DIABETIC KETOACIDOSIS
IN ADULTS
Steve Skjei
KEY POINTS
• Ketoacidosis is a common complication of DM and
produces a host of metabolic disturbances.
• Common triggers include noncompliance, infection,
or acute medical disorders.
• Dehydration with a requirement for large volume
resuscitation is the rule.
• Management requires volume and electrolyte correc-
tion, insulin to clear acidemia, and a simultaneous
search and treatment of precipitating disorders.
• Continuous insulin administration is essential in DKA.
DEFINITION
• Reduced circulating insulin action (due to insulin defi-
ciency and/or resistance) and consequent elevation in
hormones yielding hyperglycemia, hyperosmolality,
and lipolysis leading to fatty acid oxidation and subse-
quent ketoacidosis. Serious and potentially lethal com-
plication of type 1 or, less commonly, type 2 diabetes.
COMMON CAUSES OF DIABETIC
KETOACIDOSIS
• Infection (pneumonia, urinary tract infection [UTI],
gastroenteritis)
• New-onset type 1 diabetes mellitus (DM)
• Discontinuation of insulin therapy or inadequate
insulin therapy in type 1
• Drugs (e.g., corticosteroids)
• Acute illness such as myocardial infarction (MI), pan-
creatitis, and cerebral vascular accident (CVA)
• Trauma
COMMON SYMPTOMS OF DIABETIC
KETOACIDOSIS
• Usually begins with polyuria, polydipsia, polyphagia,
and weight loss
• Dehydration
• Altered mental status
• Abdominal pain, nausea, and vomiting (can also be
caused by pancreatitis or intra-abdominal infection,
both potential causes of diabetic ketoacidosis [DKA])
FREQUENT PHYSICAL EXAMINATION
FINDINGS IN DIABETIC KETOACIDOSIS
• Kussmaul (deep, rapid) respirations and a “fruity”
odor to breath (from ketones)
• Tachycardia and/or hypotension (from volume depletion)
• Dry mucous membranes
• Altered mental status
FREQUENT METABOLIC
DERANGEMENTS IN DIABETIC
KETOACIDOSIS
• Hyperglycemia (blood sugar usually but not always
>250 mg/dL)
• Hyperosmolality
• Ketonemia and secondary anion gap acidosis
• Volume depletion due to osmotic diuresis (due to
glycosuria)
• Hyperkalemia or hypokalemia (due to potassium losses
from osmotic diuresis leading to total body potassium
depletion)
• Hyponatremia (due to volume depletion, hyper-
glycemia, or hypertriglyceridemia)
• Hypophosphatemia, hypomagnesemia
INITIAL MANAGEMENT
• After the initial basic assessment of the patients’
airway, breathing, and cardiovascular status and vital
signs, the following information is gathered:
 Directed history including history of DM, treatment
history, and any recent changes in treatment of DM,
prior episodes of DKA, and evidence of infection or
other precipitating cause.
 Arterial blood gas (ABG), serum electrolytes, com-
plete blood count (CBC), blood and urine cultures and
possibly throat cultures, chest x-ray (CXR), ECG.
 Urine and serum ketones. Beta-hydroxybutyrate
(not detected by ketone assay) is converted to ace-
toacetate in the process of treating DKA. If ketones
are frequently monitored, this may give the impres-
sion that ketonemia is worsening.
 Head computed tomography (CT) and/or lumbar
puncture (LP) if clinical suspicion warrants.
 Evaluation for other causes of anion gap metabolic
acidosis, if discovered on evaluation.
DIAGNOSIS
• Mild DKA: pH 7.25–7.30, urine/serum ketones (+),
glucose >250, bicarb 15–18, anion gap >10, patient alert
292 SECTION 7 • RENAL AND METABOLIC DISORDERS
CHAPTER 98 • INTENSIVE INSULIN THERAPY IN THE CRITICALLY ILL     293
• Moderate DKA: pH 7.00 to <7.24, urine/serum
ketones (+), glucose >250, bicarb 10 to <15, anion
gap >12, altered sensorium
• Severe DKA: pH <7.00, urine/serum ketones (+), glucose
>250, bicarb <10, anion gap >12, stupor/coma
DIFFERENTIAL DIAGNOSIS
• Starvation ketosis (bicarb usually ≥ 18, pH usually
normal)
• Alcoholic ketoacidosis (decreased caloric intake in
alcoholic patients in whom alcohol has stimulated
liver’s ketogenic response; often normal blood sugar
or hypoglycemic)
• Other causes of anion gap metabolic acidosis
(MUDPALES—methanol, uremia, diabetic ketoacido-
sis, paraldehyde, alcoholic ketoacidosis, lactic acidosis,
ethylene glycol, salicylates)
TREATMENT PRINCIPLES
• ICU monitoring
• ABCs
• Volume resuscitation, initially with isotonic fluids
• Correction of hyperglycemia, acidosis, and electrolyte
imbalance
• Search for and treat underlying precipitant
• Uninterrupted insulin therapy
TREATMENT SPECIFICS
• Intravenous fluids (IVFs): Choice and rate guided by
volume status to maintain adequate circulating
volume. Also guided by corrected serum sodium
(= measured sodium + (0.016 × [glucose − 100])) and
osmolality to avoid overly rapid correction of
hyperosmolality/ hyponatremia. Add 5% dextrose
to infusion when glucose <250 to keep glucose
150–200.
• Insulin therapy: Often in adults treat initially with reg-
ular insulin 0.15 units/kg IV, followed by 0.1 units/kg/h
gtt with infusion rate adjusted to decrease glucose by
50–70 mg/dL/h. Continue insulin gtt until acidosis
resolved. Must treat with subcutaneous insulin
before discontinuation of gtt to prevent redevelopment
of DKA.
• Potassium: When potassium normalizes add potas-
sium to IVFs to prevent development of hypokalemia
and potentially severe arrhythmias, as long as the
patient is not oliguric. Potassium management must
be undertaken with patient’s renal function in mind.
• Bicarbonate: Controversial due to lack of efficacy and
concern for harm, especially in children. Complications
may include intracellular acidosis, impaired tissue
oxygen extraction, and hypokalemia.
• Phosphate and magnesium deficiencies should be
repleted.
MONITORING
• Frequent vital signs
• ECG monitoring (for QRS duration, T-wave morphology)
• Monitor glucose q 1 h
• Monitor basic metabolic profile (BMP), magnesium,
phosphorus q 2 h
• Beta-hydroxybutyrate (not detected by ketone assay)
is converted to acetoacetate in the process of treating
DKA. If ketones are frequently monitored, this may
give the impression that ketonemia is worsening.
Therefore, the anion gap is a better means of monitor-
ing improvement in acid-base status
• Cerebral edema may be a serious, even fatal conse-
quence of treatment of DKA. The best means of pre-
vention is ensuring that osmolality is not corrected too
rapidly and that sodium bicarbonate is not used.
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98 INTENSIVE INSULIN
THERAPY IN THE
CRITICALLY ILL
Steve Skjei
KEY POINTS
• Hyperglycemia is common in acute illness in both
diabetic and nondiabetic patients.
• Hyperglycemia in this setting is a risk factor for poor
outcome that is potentially modifiable.
• Studies evaluating restoration of normoglycemia or
near-normoglycemia have shown improvement in out-
come in patients treated with IV insulin infusion with
the goal of decreasing hyperglycemia and normalizing
blood glucose concentrations.
• Hypoglycemic episodes are an almost inevitable con-
sequence of protocols used to achieve “tight” glycemic
controls and efforts must be expended to minimize this
complication.
MECHANISMS OF HYPERGLYCEMIA
IN THE CRITICALLY ILL
• Increased levels of “stress” hormones such as cortisol,
epinephrine, and glucagon inhibit glycogen produc-
tion and stimulate gluconeogenesis.
• Cytokine production in response to stress increases
insulin resistance.
• Medications frequently used in critical illness such as
corticosteroids and vasopressors may exacerbate
insulin resistance.
INTENSIVE INSULIN THERAPY
IN CRITICALLY ILL PATIENTS
• Patients in a surgical intensive care unit (ICU) were
prospectively randomized to “conventional” or inten-
sive insulin therapy.
 Conventional treatment was an IV insulin drip if
glucose exceeded 215 mg/dL, with target levels of
180–200 mg/dL.
 Intensive treatment was an IV insulin drip if
glucose exceeded 100 mg/dL, with target levels of
80–110 mg/dL.
 Hypoglycemia (glucose <40 mg/dL) occurred
more frequently in the intensive treatment group
(5.2% vs. 0.8%) but did not cause hemodynamic
disturbance.
 Overall, mortality was significantly lowered in the
intensively treated group (4.6% vs. 8.0%) with the
greatest effect demonstrated in those patients with
ICU stays >5 days and in those with multiorgan fail-
ure secondary to a septic focus. The study was
stopped early due to this difference (Fig. 98-1).
 Benefit was noted across the range of APACHE II
scores.
 Several markers of morbidity were improved, such
as markers of inflammation (white blood cell count
[WBC], C-reactive protein [CRP], fever).
• Additional studies in patients undergoing coronary
artery bypass graft (CABG) and in patients with
myocardial infarction (MI) have shown improvements
in outcome with intravenous insulin infusion.
• A study of medical ICU patients treated with a simi-
lar goal of euglycemia did not reveal a difference in
survival related to this intervention although post hoc
subset analysis revealed that longer-term admissions
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FIG. 98-1 Survival curves comparing intensive insulin therapy to conventional treatment in crit-
ically ill patients in a surgical ICU.
SOURCE: Adapted from Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in
critically ill patients. N Engl J Med 2001;345:1359–1367.
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to the ICU did exhibit a difference in outcome associ-
ated with tight glycemic control.
• Questions have arisen regarding the mechanism of
benefit observed in these studies
 Avoidance of hyperglycemia
 Degree of hyperglycemia has been associated with
increased risk of in-hospital mortality post-MI.
 Osmotic diuresis from hyperglycemia may decrease
cardiac output.
 Hyperglycemia may decrease complement activation.
 Insulin drug effect
 Insulin may improve immune function.
 Insulin may have anti-inflammatory properties.
 Insulin inhibits lipolysis, thus reducing free fatty
acids which may contribute to cardiac arrhythmias.
 Insulin may have anabolic effects in critical
illness.
• Whether antihyperglycemic strategies other than
insulin may be effective in improving ICU outcome
remains to be determined.
• At present, there is no consensus on a target glucose
level or specific insulin infusion protocol.
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99 THYROID DISEASE
Stephen Skjei, Shashi Kiran Bellam
KEY POINTS
• Most patients admitted to the ICU have low levels of T3
and T4 with normal to low levels of serum thyrotropin,
a condition termed “euthyroid sick syndrome”; TFTs
need to be interpreted on this background.
• T3 is the logical replacement therapy for those patients
who do need treatment of severe hypothyroidism.
• Management of myxedema coma (MC) should
include glucocorticoids while the adrenal status is
being assessed.
• Thyroid storm is often signaled by hyperthermia and
altered mental status.
• Thyroid hormone secretion can be blocked by addi-
tion of iodine to an antithyroid drug; iopanoic acid is
useful in life-threatening thyrotoxicosis.
• Beta-blockers are useful to ameliorate some cardiac
effects of thyrotoxicosis and to offer perioperative
protection, but need to be used with caution in the eld-
erly and those with cardiomyopathy and airway
disease.
THYROID BASICS
• Thyroid hormone production by the thyroid occurs
under the control of thyroid-stimulating hormone (TSH),
produced in the pituitary gland.
• Thyroid releases thyroid hormone 80% in form of T4,
20% in form of T3.
• T3 is the primary active hormone.
• T4 is metabolized to T3 at the tissue level by tissue
deiodinases, including type 1 deiodinase.
• Type 2 deiodinase is found primarily in brain/pituitary,
metabolizes T4 → T3.
• Type 3 deiodinase metabolizes T4 → reverse T3 (rT3)
which is hormonally inactive.
• Thyroid hormone participates in a negative feedback
loop, inhibiting release of TSH by pituitary.
• Laboratory measurements of T4 or T3 usually measure
total hormone, which is mixture of “free” and protein
“bound” hormone. The free fraction is hormonally
active. This is approximated by free thyroxine index
(FTI) measurements or by nondialysis “free T4” meas-
urements. It can be directly measured by free T4 by
dialysis.
THYROID HORMONE AND THYROID
FUNCTION TESTS IN ILLNESS
• Nonthyroidal illness (NTI) syndrome or euthyroid sick
syndrome (ESS) frequently seen in acutely/chronically
ill patients or in states of starvation.
 Type 1 deiodinase inhibition with increase in type 3
deiodinase activity may produce low levels of T3
with elevated levels of reverse T3.
 May also produce state of low T4 and low T3 with
normal or slightly low TSH—these patients are
often very sick and T4 levels may correlate inversely
with mortality.
 Recovery from NTI syndrome frequently leads to
elevated TSH.
 Whether or not treatment is beneficial is still
controversial—thyroid hormone may increase car-
diac oxygen demand and/or precipitate arrhythmias;
many studies evaluating T4 or T3 therapy in these
patients with conflicting results.
• Other factors common in critical illness may lead to
abnormal thyroid function tests (TFTs).
 Hemodialysis
 Corticosteroid treatment
 Vasopressor treatment
 Altered levels of binding proteins—thus, FTI or free
T4 are more informative tests
 Total T4 measurements
• Interpretation of TFTs in critical illness is often com-
plicated and may require endocrine consultation.
HYPOTHYROIDISM IN THE INTENSIVE CARE UNIT
• Hypothyroidism is defined as an inadequate tissue
delivery of thyroid hormone.
• Most cases of hypothyroidism in the United States are
due to autoimmune thyroid (Hashimoto) disease. The
second most common cause is postsurgical; medica-
tions such as amiodarone and lithium may cause
hypothyroidism as well. Iodine deficiency is still
common in parts of the world. History of thyroid dis-
ease, neck surgery, medication use and compliance,
and pregnancy should be sought.
• Hypothyroidism must be differentiated from NTI syn-
drome mentioned as above.
• Symptoms/signs of hypothyroidism include cold
intolerance, fatigue, dry skin, constipation, bradycar-
dia, anemia.
• Consideration should always be given for pituitary
cause of hypothyroidism.
• In the ICU, clinically significant hypothyroidism may
develop in patients with primary hypothyroidism
when challenged by an intercurrent illness.
MYXEDEMA COMA
• Myxedema coma (MC) typically occurs in a patient
with long-standing hypothyroidism suffering some
event (e.g., illness/infection, surgery, stroke, trauma,
cold weather, and drug overdose such as tranquilizers,
narcotics, and sedatives) that leads to decompensation.
• MC is characterized by hypothermia, hypoventilation,
altered mental status, bradycardia, and hyponatremia.
It carries a high risk of morbidity and mortality;
endocrine consult should be obtained.
• Physical signs of severe hypothyroidism are present and
include dry skin, thinning of eyebrows, delayed relax-
ation phase of deep tendon reflexes, and macroglossia.
• Laboratory evaluation reveals a markedly decreased
serum T4 level and elevation of TSH (except in the set-
ting of central hypothyroidism).
• Pulmonary complications of MC include hypoventila-
tion, aspiration pneumonia, and laryngeal obstruction.
• Cardiac complications of MC include pericardial effu-
sion (common but rarely causing tamponade).
• Treatment includes supportive care and thyroid hor-
mone replacement. One regimen would be to give an
intravenous load of 400 µg T4 followed by 50–100 µg
T4 IV qd until improvement occurs, then transition to
a maintenance dose. Doses are given intravenously at
first due to impaired absorption seen in hypothy-
roidism. Some thyroidologists recommend T3 therapy
instead, and others use a combination of T4 and T3.
Doses may need to be decreased in the elderly and
those with heart disease.
• There is a 5–10% incidence of concurrent hypoadren-
alism, so a cosyntropin stimulation test should be
administered if possible, and then empiric glucocorti-
coids should be given until adrenal status is known
(routine doses of 50–100 mg hydrocortisone q 6 h).
Glucocorticoids should be given prior to levothyrox-
ine because of the risk of precipitating adrenal crisis if
T4 is given to a patient with hypoadrenalism, so a full
stimulation test may not be always be possible.
• Supportive care may include intubation and mechanical
ventilation. An underlying precipitant such as infection
or ischemia should be sought and treated. Hyponatremia,
if present, may be due to impaired free water clearance
and may be managed with free water restriction.
HYPERTHYROIDISM IN THE INTENSIVE CARE UNIT
• Hyperthyroidism (thyrotoxicosis) is most commonly
due to hypersecretion of thyroid hormone by an
abnormal thyroid gland such as multinodular goiter,
solitary adenoma, or Graves’ disease. Occasionally,
patients will develop a transient hyperthyroidism due
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to thyroid inflammation (thyroiditis) following an
upper respiratory infection (URI). Hyperthyroxinemia
due to exogenous overdose may also occur.
• Patients with preexisting multinodular goiter who are
euthyroid or slightly hyperthyroid may develop
hyperthyroidism if large doses of exogenous iodine
are given, such as commonly occurs with IV contrast
radiologic studies and amiodarone administration.
• Symptoms/signs of thyrotoxicosis include tremulous-
ness, weight loss, irritability, palpitations, irregular
menstrual periods, diarrhea, heat intolerance, and
atrial fibrillation. Occasionally, patients present with
cardiomyopathy and congestive heart failure (CHF).
Symptoms may be muted in the elderly.
• Important elements of the history include prior history
of thyroid disease and treatment, duration of symp-
toms, recent history of URI, history of ocular symp-
toms or pretibial myxedema to suggest Graves’ disease,
recent history of IV contrast or amiodarone administra-
tion, history of goiter, and any possibility of pregnancy.
• Physical examination and historical features should
be used to attempt to differentiate the cause of hyper-
thyroidism, as treatment differs between causes.
Endocrine consultation should usually be sought.
• The two principal antithyroid drugs used are propylth-
iouracil (PTU) and methimazole. Side effects of these
medications include rash, agranulocytosis, hepatitis,
cholestatic jaundice, and arthritis. Agranulocytosis and
hepatotoxicity may be life threatening.
• Patients with hyperthyroidism may develop an
extreme form of the condition if an intercurrent illness
develops. This syndrome is called thyroid storm.
THYROID STORM
• Thyroid storm usually occurs in patients with poorly
controlled thyrotoxicosis who develop a precipitating
factor, such as surgery, infection, pulmonary embolism,
or myocardial infarction.
• Symptoms and signs include fever, altered mental
status, arrhythmias, tachycardia, CHF, and a widened
pulse pressure.
• Consideration of this condition should prompt
endocrine consultation.
• Treatment should be focused on four modalities: (1)
decrease thyroid hormone levels, (2) decrease action
of thyroid hormones on peripheral tissues, (3) prevent
cardiovascular collapse, and (4) treat precipitating
factors.
1. PTU or methimazole prevents further synthesis of
thyroid hormone. PTU has theoretical advantage of
blocking T4 → T3 conversion in periphery. One reg-
imen of PTU would be 250 mg PO q6.
Once further synthesis is blocked, iodine (such
as SSKI) may be administered to inhibit thyroid
hormone release from the gland. Glucocorticoids
may also be administered to further diminish T4 →
T3 conversion. Other treatments are available, but
are beyond the scope of this discussion.
Hyperthyroidism may be especially difficult to
treat in those patients treated with amiodarone.
2. Beta-blockers decrease the action of thyroid hor-
mones on peripheral tissues. Beta-blockade should be
used cautiously and perhaps not in elderly patients,
asthmatics, or patients with cardiomyopathies.
Short-acting intravenous beta-blockade (esmolol)
allows for rapid termination of therapy in the event
of serious adverse effects.
3. External cooling and sedation can decrease heat gen-
eration and systemic oxygen consumption. Atrial
fibrillation is commonly seen; ventricular response
rate should be controlled with beta-blockers.
4. Precipitating factors should be sought and treated.
PREGNANCY AND THYROID DISEASE
• Cases of thyroid disease in pregnant women should
prompt endocrine consultation as any potential diag-
nostic or therapeutic modalities will have implications
for mother and fetus.
• In general, PTU is the favored thionamide in preg-
nancy. If hyperthyroid patients are unable to tolerate
PTU, they may require thyroidectomy for treatment of
hyperthyroidism.
• TFTs may be difficult to interpret in pregnancy due to
estrogen-related changes in thyroid-binding globulin
levels. Additionally, human chorionic gonadotropin
(hCG) is a weak TSH receptor agonist. hCG peaks at
the end of the first trimester, and thus these patients
may have TFTs that seem to reflect hyperthyroidism
(low TSH, elevated T4). In this case, patients fre-
quently do not require treatment as the effect is tran-
sient. However, patients with Graves’ disease may
present similarly. Endocrine consultation should be
sought to distinguish between the two and to deter-
mine if treatment is necessary.
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100 ADRENAL INSUFFICIENCY
Shashi Kiran Bellam
KEY POINTS
• Traditional criteria for diagnosing adrenal insufficiency
are based on the response of normal, nonstressed,
healthy controls. These criteria are not appropriate for
evaluating adrenal function in critically ill patients.
• Hypotensive ICU patients should have a random
serum cortisol level assessed. If >25 µg/dL, they have
sufficient adrenal function. If not, they may have rel-
ative adrenal insufficiency and should be considered
for replacement corticosteroids.
• Nonhypotensive ICU patients should undergo a low-
dose (1 µg) cosyntropin stimulation test. If any cortisol
level is >25 µg/dL, they likely have sufficient adrenal
function. If not, they have relative adrenal insufficiency
and should receive replacement corticosteroids.
• The recommended replacement corticosteroid dose is
either hydrocortisone 50 mg IV q 6 h or hydrocorti-
sone 100 mg IV q 8 h.
PHYSIOLOGY OF ADRENAL FUNCTION
• Cortisol is the primary glucocorticoid hormone,
secreted by the adrenal glands.
• In healthy, unstressed persons, cortisol is secreted in a
diurnal pattern under the influence of corticotropin
(adrenocorticotrophic hormone [ACTH]), which is
released from the pituitary gland.
• Aldosterone is the primary mineralocorticoid hor-
mone in the body. It is secreted by the adrenal gland.
• Aldosterone secretion is regulated primarily by the
renin-angiotensin system and potassium levels.
• Cortisol binds to the glucocorticoid receptor (GR)
present on all cells.
ACUTE STRESS RESPONSE
• Acute stress (including infection, surgery, trauma,
burns, or illness) causes an increase in production of
corticotropin-releasing hormone (CRH) and ACTH,
which leads to increased cortisol production propor-
tional to the severity of illness.
• Diurnal variation in cortisol secretion is lost.
• There is decreased production of the other adrenal
hormones (aldosterone and androgens).
• GRs are increased in number in acute stress, thereby
increasing the cellular response to secreted cortisol.
• The sum total of response to acute stress is a dramatic
increase in cellular glucocorticoid activity which con-
tributes to the maintenance of cellular and organ
homeostasis.
PHYSIOLOGIC ACTIONS OF
GLUCOCORTICOIDS IN ACUTE STRESS
• Glucocorticoids increase blood glucose levels by
increasing hepatic gluconeogenesis and inhibiting
adipose tissue glucose uptake.
• Glucocorticoids stimulate free fatty acid release from
adipose tissue and amino acid release from body proteins.
• These responses facilitate delivery of energy and sub-
strate to cells and organs to respond to stress and
repair from injury.
• Glucocorticoids are required for the normal heart
response to angiotensin II, epinephrine, and norepi-
nephrine, contributing to the maintenance of cardiac
contractility, vascular tone, and blood pressure.
• Glucocorticoids decrease the production of vasorelax-
ants such as nitric oxide and vasodilatory prostaglandins.
• Glucocorticoids attenuate both the accumulation at
inflammatory sites and function of most cells involved
in immune and inflammatory responses.
ASSESSMENT OF ADRENAL FUNCTION
IN THE CRITICALLY ILL
• The diagnosis of adrenal insufficiency is based on the
measurement of serum cortisol levels.
• The traditional criteria for diagnosing adrenal insuffi-
ciency are based on the response of normal, nonstressed,
healthy controls. These criteria are not appropriate for
evaluating adrenal function in critically ill patients.
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• In addition, the high-dose cosyntropin stimulation test
is probably not appropriate for critically ill patients.
• For hypotensive critically ill patients with an appro-
priate adrenal response to illness, the baseline cortisol
level (at any time of the day) should be >25 µg/dL.
• For nonhypotensive critically ill patients, the normal
adrenal response to a low-dose cosyntropin stimula-
tion test (which consists of administering 1–2 µg of
synthetic corticotropin and measuring cortisol levels
at baseline, 30 minutes, and 60 minutes after that
dose) should be a cortisol level >25 µg/dL.
ADRENAL INSUFFICIENCY
IN THE CRITICALLY ILL
• The reported incidence is approximately 30% and can
be as high as 60% for patients in septic shock.
• Acute adrenal insufficiency can present with hypoten-
sion, mild eosinophilia, unexplained fever, hypona-
tremia, and hyperkalemia.
• Chronic adrenal insufficiency presents with weakness,
weight loss, anorexia, lethargy, slowed mentation, and
general failure to thrive.
• Causes of acute adrenal insufficiency include hypo-
thalamic and pituitary disorders (secondary adrenal
insufficiency), and destruction of the adrenal glands
(primary adrenal insufficiency).
• Synthetic glucocorticoids (orally or intravenously) may
cause adrenal suppression if used for more than 5 days.
• Primary adrenal insufficiency in immunocompro-
mised patients (e.g., HIV) is commonly due to adrenal
gland infection with cytomegalovirus, tuberculosis,
cryptococcus, and other organisms.
• Certain drugs (e.g., ketoconazole, megestrol acetate,
and etomidate) can impair adrenal function.
• In sepsis, circulating suppressive factors released during
systemic inflammation may cause adrenal insufficiency.
• Once the septic episode has resolved, adrenal function
commonly returns to normal.
• Treatment with cortisol has been shown to improve
shock reversal, decrease days on vasopressors, shorten
ventilator time, and shorten ICU stay.
• The dosage of replacement corticosteroid is 100 mg
hydrocortisone IV q 8 h or 50 mg IV q 6 h.
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101 RHABDOMYOLYSIS
Steven Q. Davis, Suneel M. Udani
KEY POINTS
• Rhabdomyolysis is caused by damage to skeletal
muscle resulting in the release of myoglobin. It should
be suspected in all patients with crush or burn injuries
as well as renal failure of unclear etiology.
• Intravascular volume depletion as well as severe elec-
trolyte and metabolic derangements can be profound
requiring aggressive fluid resuscitation as well as fre-
quent monitoring of electrolytes and volume status.
• Refractory electrolyte and metabolic derangement
may necessitate renal replacement therapy to prevent
life-threatening arrhythmias, seizures, or multisystem
organ failure.
PATHOPHYSIOLOGY
• The final common pathway resulting in rhabdomyol-
ysis is adenosine triphosphate (ATP) supply-demand
mismatch. Therefore, any process causing inadequate
ATP generation or inadequate ATP delivery to mus-
cles may result in muscle injury and rhabdomyolysis.
 Specifically, ATP is responsible for maintaining
normal balance of intracellular and extracellular
sodium and calcium. Increased metabolic activity or
direct muscle injury (from burns, trauma, or direct
toxin) causes influx of sodium and calcium into the
cell. Massive influx overwhelms the ATP-dependent
electrolyte balance resulting in pathologic concen-
trations of calcium inside the cell.
 The high intracellular calcium concentrations trigger
persistent muscle contraction depleting already
diminished energy stores. Free intracellular calcium
may also activate a variety of proteases and catalytic
enzymes further causing cellular destruction.
Finally, the resulting activation of the inflammatory
cascade intensifies the destructive process ultimately
leading to an active myolysis on top of cell necrosis.
• Once muscle death has occurred, myoglobin is
released into the bloodstream and filtered into the renal
tubules. Myoglobin accumulates in the renal tubules
(exacerbated by the usual concomitant intravascular
volume depletion) eventually precipitating and causing
tubular obstruction, damage, and necrosis.
• Metabolic and electrolyte derangements result from
initial cell death and are complicated further by renal
insufficiency.
 Cell death causes the release of organic and inorganic
acids as well as electrolytes which are normally
maintained at a low extracellular concentration but
have high intracellular concentration (e.g., potassium
and phosphate).
 Hypocalcemia may occur in the early stages of rhab-
domyolysis from accumulation in necrotic muscle as
well as from the precipitation of calcium-phosphate
complexes caused by increased extracellular phos-
phate concentration. Once perfusion is restored to
muscle and the active lysis process completes, the
sequestered calcium may be released into the blood-
stream resulting in a late-stage hypercalcemia.
 The accumulation of organic and inorganic acids
into the bloodstream causes a metabolic acidosis.
The acidosis and acidemia may lower urinary and
intratubular pH, facilitating further myoglobin pre-
cipitation, tubular obstruction, and renal insuffi-
ciency. Worsening renal insufficiency can further
exacerbate the ongoing metabolic acidosis.
ETIOLOGY
• Causes of rhabdomyolysis may be classified into four,
broad categories: direct trauma or muscle injury,
excessive muscle activity, inherited defects of enzyme
muscle, and “other” medical causes.
 Direct muscle injury causes rhabdomyolysis by
injury to myocytes. The direct injury disrupts
normal cellular membranes, initiating the cascade
described above resulting in increased intracellular
calcium. This etiology was the first recognized
cause of rhabdomyolysis. While crush injury is the
most apparent cause, direct muscle injury can also
result from burns or electrical shock injuries.
 Excessive muscle activity remains an important cause
of rhabdomyolysis in the appropriate clinical setting.
Many of these instances may initially go unrecog-
nized, at least as regards the potential for skeletal
muscle injury. However, in the setting of concomitant
intravascular volume depletion and/or previous renal
insufficiency, rhabdomyolysis, with its subsequent
clinical sequelae can occur. Injury to muscle is
directly related to the duration and intensity of muscle
activity. Therefore, situations such as marathons or
intensive military training in previously sedentary
individuals have been identified as common clinical
scenarios. Prolonged seizures with excessive muscle
activity can also precipitate muscle injury.
 Inherited diseases that result in decreased synthesis
of ATP such as McArdle’s can also lead to rhab-
domyolysis. As outlined above, ATP supply-demand
mismatch leads to muscle injury. When the degree
of mismatch and resulting injury is severe, rhab-
domyolysis may ensue. In individuals with unex-
plained muscle damage, a family history of
rhabdomyolysis or multiple episodes, an inherited
muscle enzyme defect should be suspected.
• The range of “other” medical causes of rhabdomyolysis
is extensive. While the first three categories of etiology
may be readily apparent, the “other” causes are more
subtle and require a broad differential to identify. The
medical causes of rhabdomyolysis may, themselves, be
classified into four categories: drugs or toxins, infection,
alterations in temperature, and metabolic derangements.
 Drugs or toxins may be the most common etiology
of rhabdomyolysis in the adult, Western world
where crush and burn injuries are not routinely seen.
 Alcohol remains the toxin most frequently
encountered, likely, because of its widespread
abuse and the multiple pathways by which it can
cause muscle injury. Primarily, ethanol is directly
myotoxic by inhibiting calcium accumulation by
the sarcoplasmic reticulum, disturbing intra-
extracellular electrolyte balance by inhibition of
the Na-K-ATPase and disruption of cellular mem-
branes. Asymptomatic elevations in creatinine
kinase (CK) and histologic evidence of muscle
injury have been seen in otherwise healthy indi-
viduals ingesting large amounts of alcohol.
Alcohol may also indirectly lead to muscle injury
by the concomitant electrolyte imbalance seen in
individuals ingesting large amounts of alcohol.
The malnutrition (as well as the vomiting and/or
diarrhea) associated with chronic alcohol abuse
leads to depleted potassium and phosphate stores.
Potassium and phosphate stores are critically
important in maintaining adequate energy supply
for active muscles. Specifically, hypokalemia
results in impaired glycogen metabolism and
hypophosphatemia results in impaired ATP syn-
thesis. Once again if muscle demand of ATP
exceeds supply, muscle injury may ensue.
 Drugs of abuse other than alcohol may also lead to
rhabdomyolysis. Cocaine, phencyclidine (PCP),
methylenedioxymethamphetamine (MDMA), and
other sympathomimetic drugs or drug combina-
tions lead to rhabdomyolysis primarily by the
combination of excessive muscle activity and
intravascular volume depletion.
 Prescription medications, especially lipid-lowering
agents, are an increasingly important etiology of
rhabdomyolysis. Fibrates may be directly myotoxic,
although the mechanism has not been elucidated.
A large and ever-growing population of people is
currently taking lipid-lowering agents in the
“statin” class or hydroxymethylglutaryl coenzyme
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A (HMG-CoA) reductase inhibitors. While the
exact mechanism leading to muscle injury has not
been determined, two theories predominate. The
first is that statins inhibit not only cholesterol syn-
thesis but also inhibit the formation of coenzyme
Q, an important coenzyme in ATP synthesis. If
ATP synthesis is significantly impaired and
demand exceeds supply, muscle injury ensues.
The second theory relates to the inhibition of cho-
lesterol synthesis. Decreased cholesterol synthesis
results in decreased lipid availability for cellular
membrane synthesis. Membranes may lose their
integrity predisposing them to injury and death.
While the use of statins in most patients is very
safe, the risk of adverse effects may be increased
when medications affecting CYP 450 and, thereby,
statin metabolism, such as antifungals and
macrolide antibiotics, are used at the same time.
 Infections, both viral and bacterial may lead to rhab-
domyolysis by either direct muscle invasion or
toxin-mediated myocyte death. Viral infection lead-
ing to muscle injury is more common, the predomi-
nant viruses being influenza A and B and slightly
less commonly coxsackie and HIV. While muscle
biopsy has not been able to provide direct evidence,
muscle invasion is the presumed mechanism of
injury. A review of bacteria responsible for causing
rhabdomyolysis identified Legionella species as the
most common. Other infectious diseases associated
with rhabdomyolysis include tularemia, pneumo-
coccal pneumonia, salmonellosis, and staphylococ-
cal sepsis (especially toxic shock syndrome). Both
toxin-mediated and direct muscle invasion are
thought to be responsible and histologic evidence of
invasion by Streptococcus, Salmonella, and
Staphylococcus species has been found.
 Extreme alterations in temperature may trigger
muscle injury and rhabdomyolysis. While hyperther-
mia is a more common cause, muscle injury has also
been seen with severe hypothermia. Hyperthermia
resulting from neuroleptic malignant syndrome
(NMS), heat stroke, and malignant hyperthermia are
the most common pathways of injury. In NMS, the
triad of excessive muscle rigidity, fever, and mental
status changes after the administration of haloperidol
or phenothiazines (sometime in combination with
anti-Parkinsonian agents or tricyclic antidepressants)
leads to muscle injury by a combination of excessive
muscle activity and intravascular volume depletion.
Malignant hyperthermia, an inherited (most com-
monly autosomal dominant) disorder of the calcium
channel in the sarcoplasmic reticulum and heat
stroke may lead to muscle injury and rhabdomyoly-
sis by the same combination of effects.
 Electrolyte and metabolic derangements may be, as
in the case of alcohol abuse, a secondary cause of
muscle injury. However, they may also be the pri-
mary precipitant. Specifically, muscle hypoxia from
generalized suffocation or inadequate local blood
flow will precipitate muscle injury. Severe
hypokalemia or hypophosphatemia, as previously
outlined, can lead to rhabdomyolysis. Their role as
a primary precipitant may be difficult to detect,
however, because of the release of potassium and
phosphate into the bloodstream after myocyte death.
Therefore, after clinical presentation potassium and
phosphate levels may be elevated, while they were
initially extremely low.
 The above represent the common identified causes of
rhabdomyolysis. More causes clearly exist and in one
large review of causes of rhabdomyolysis a single eti-
ology could not be identified in 3% of cases.
CLINICAL PRESENTATION,
DIAGNOSTIC EVALUATION, AND
CLINICAL CONSEQUENCES
• Rhabdomyolysis, clearly, does not always present
“classically” with the triad of muscle pain, weakness,
and “tea-colored” urine. While the symptoms may be
elicited once the diagnosis is suspected, often rhab-
domyolysis is asymptomatic until it is more advanced
and metabolic derangements manifest. Ultimately,
laboratory evaluation is necessary to make a diagnosis
of rhabdomyolysis. Specifically, serum CK levels are
useful to detect muscle injury. While the concentra-
tion of myoglobin in the blood and myoglobinuria is
more important in the actual process of injury, hepatic
metabolism and myoglobin’s relatively small molecu-
lar weight allows its rapid clearance from the blood-
stream into the urine. Therefore, serum myoglobin
assays are unreliable for predicting clinical conse-
quences. While no established value of CK is diagnos-
tic of rhabdomyolysis, levels in the 10,000–100,000s
are not uncommon. Myocardial injury as a cause of
elevated CK level must always be excluded and a CK
level less than five times the upper limit of normal in
the setting of renal failure must make one suspect other
potential etiologies of renal failure. Urine myoglobin
assay may be helpful to confirm myoglobinuria and
clinical suspicion.
• Once rhabdomyolysis has occurred, the metabolic and
electrolyte abnormalities previously outlined may man-
ifest. The clinician should specifically monitor for:
 Hyperkalemia
 Hyperphosphatemia
 Hypocalcemia early, hypercalcemia late
 Anion gap metabolic acidosis
 Acute renal failure (incidence varies but may compli-
cate approximately 30% of cases of rhabdomyolysis)
• The most devastating consequences of rhabdomyoly-
sis are usually a result of these metabolic derange-
ments and the subsequent renal failure. These include,
but are not limited to, seizures and tetany from severe
hypocalcemia, life-threatening cardiac arrhythmias
from hyperkalemia, and severe acidosis and, in
extreme cases, multisystem organ failure. Respiratory
failure from fluid overload and/or direct lung injury
may be a late-stage manifestation. Disseminated
intravascular coagulation (DIC) may occur as a result
of activation of the coagulation cascade by muscle
breakdown products. When it does occur, DIC has its
peak incidence on days 3–5. In these instances sup-
portive care remains the treatment.
• In the absence of obvious causes from history and
physical examination, any of the above medical
causes may be responsible. Toxicology assays and the
previously mentioned viral and bacterial serologies
should be sent as part of the diagnostic evaluation.
TREATMENT
• If any reversible cause or ongoing muscle injury is
present, it must be treated aggressively and as quickly
as possible.
• Once muscle injury has occurred, the mainstay of
treatment for rhabdomyolysis is aggressive volume
resuscitation to prevent renal failure and correction of
electrolyte imbalances. In patients whose muscles are
compressed as a result of trauma, initiating fluid
resuscitation prior to extrication of the injured limb
may prevent exacerbation of ongoing intravascular
volume depletion from sequestration of blood flow to
the injured limb as part of the reperfusion process.
• While the type of fluid to be used for resuscitation is
debated, the amount of fluid needed and goals of
diuresis is not. To restore adequate intravascular
volume, intravenous fluids in the 10 L range may be
necessary and goal diuresis should be approximately
200 cc/h to continuously flush the renal tubules of
myoglobin in an attempt to prevent precipitation and
tubular obstruction.
• The type of fluid administered has been debated and,
while no absolute recommendation exists, the general
recommendation is large amounts of iso- or slightly
hypertonic crystalloid. Sodium bicarbonate (in the
form of 0.45 normal saline [NS] with 2 amps of
NaHCO3) may be preferable to NS in attempt to
alkalinize the urine and help prevent further myoglo-
bin precipitation. No randomized trial, however, has
confirmed its benefit. The administration of mannitol
has been used as a standard in traumatic causes of
rhabdomyolysis and some nontraumatic cases. In
theory, mannitol, as an osmotic diuretic, helps to flush
myoglobin out of the renal tubules. Randomized trials
of adequate methodology have not been carried out to
confirm its benefit and a recent retrospective review in
a series of trauma patients did not find a benefit to
administering mannitol to posttrauma patients with
rhabdomyolysis.
• Once aggressive fluid resuscitation has been initiated,
frequent monitoring is of the utmost importance, with
attention to electrolytes, acid-base balance, and
intravascular volume.
• The indications for dialysis in rhabdomyolysis
patients remain the same as general indications for
dialysis—profound acidosis, pulmonary edema lead-
ing to impending respiratory failure, electrolyte
imbalances refractory to conservative measures, that
is, hyperkalemia causing electrocardiographic changes
that are not responsive to intestinal potassium binders
(sodium polystyrene sulfate or Kayexalate).
• Hypocalcemia, while often seen in the early stages of
rhabdomyolysis, rarely needs treatment as the deficit
does not represent a total body deficit and the initial
calcium sequestered in injured muscle may redistrib-
ute into the bloodstream.
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GASTROINTESTINAL
HEMORRHAGE
Maria Dowell
KEY POINTS
• The majority of GI bleeding encountered in the ICU is
from an UGI source.
• Large-bore intravenous access and proactive resuscita-
tion with crystalloids and blood products are essential.
• Massive bleeding typically engenders a coagulopathy
that requires factor and platelet replacement.
• Early intervention with endoscopy, angiography, or
surgery may be needed, and critical care management
of these patients should coordinate these various sub-
specialties as resuscitation is ongoing.
EPIDEMIOLOGY
• Upper gastrointestinal (UGI) bleeding is defined as
bleeding located proximal to the ligament of Treitz.
• Approximately 75% of all GI bleeding comes from an
UGI source. The mortality from UGI bleeding requir-
ing intensive care unit (ICU) admission may be as
high as 10%.
PRESENTATION AND EVALUATION
• Upper gastrointestinal bleeding commonly presents
with hematemesis and/or melena. A nasogastric lavage
often, but not always, yields blood or coffee-ground
material.
• Initial management is directed at maintaining hemody-
namic stability. Intravenous access with two large-bore
catheters should be maintained at all times. Evidence
of hypotension or shock requires prompt resuscitation
with crystalloid and packed red blood cells. Pay close
attention to end-organ perfusion and in particular,
coronary and renal perfusion. If variceal hemorrhage
is suspected, central venous pressure (CVP) monitor-
ing may be useful.
• Hematocrit should be maintained >30% in order to
ensure adequate oxygen-carrying capacity and to
prevent end-organ ischemia. The initial hematocrit with
an acute bleed may be misleading as both loss of ery-
throcytes and plasma are equivalent. Platelets should
be maintained >50,000/mm3 and any coagulopathy
should be corrected with fresh frozen plasma.
• With active hematemesis, a nasogastric tube should be
placed to reduce the risk of aspiration. Endotracheal
intubation is indicated with hematemesis and
decreased mental status, prior to endoscopy for active
hematemesis, prior to insertion of esophageal tam-
ponade tube, and in the setting of shock.
• Radiology and surgery should be consulted early in
the course of management. When endoscopic evalua-
tion is unable to identify the etiology of bleeding,
angiography and radionuclide studies may be of help.
Angiography can visualize acute arterial hemorrhage
in 75% of UGI bleed patients but it must be bleeding
at a brisk rate of 0.5–1 mL/min. Radionuclide using
99mTc-pertechnetate-labeled red blood cells can detect
bleeding <0.5 mL/min using intermittent scan over
1–2 days. This scan, however, can only localize the
bleeding to an area and cannot precisely determine the
mucosal location.
• Continuous hemodynamic monitoring should be per-
formed as rebleeding is a definite risk.
VARICEAL HEMORRHAGE
• Presents as symptom of decompensated cirrhosis in
up to 50% of patients and accounts for 30% of all
deaths related to cirrhosis. Overall mortality is 50%.
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The first phase of bleeding is the initial episode of
hemorrhage in which 50% stop spontaneously. The
initial bleed is followed by the second phase lasting
about 6 weeks and is defined by a high risk of recur-
rent bleeding especially within 48–72 hours.
INITIAL MANAGEMENT
• Cardiopulmonary management includes intubation
for airway protection, especially in the setting of
encephalopathy, active hematemesis, or emergent
endoscopy. Hypotension refractory to fluid resuscita-
tion should be treated with the vasoconstrictor; norep-
inephrine is a reasonable first choice agent (avoid
dopamine as it can cause splanchnic vasodilatation
and worsen the bleeding).
• Respiratory, ascitic fluid, and urinary tract infections
are common and prophylactic antibiotics have been
shown to reduce these and improve short-term mortality.
In addition to fresh frozen plasma, recombinant factor
VIIa is emerging as a procoagulant that can rapidly cor-
rect severe coagulopathy associated with decompen-
sated liver disease and promote hemostasis. If decreased
mental status is present, hepatic encephalopathy should
be considered as a potential cause and empiric lactulose
therapy should be initiated.
PHARMACOTHERAPY
• Selective splanchnic vasoconstrictors have the added
advantage of diverting blood flow from the splanchnic
circulation to the systemic circulation, thereby
improving blood pressure and renal perfusion. The
agent of choice is octreotide at a recommended dose
of 50 µg IV bolus followed by an infusion of 50 µg/h
for 5 days. Terlipressin, a long-acting vasopressin
analogue, has recently been shown to reduce mortal-
ity but is awaiting larger prospective trials for confir-
mation of this early observation.
ENDOSCOPIC THERAPY
• Endoscopy may be performed under stable conditions
within the first 24 hours. Emergent endoscopy with
therapeutic hemostatic intent is recommended for
patients with GI hemorrhage who have been initially
stabilized with fluid and blood product resuscitation
and continue to bleed. Determining the source of bleed-
ing is important since esophageal varices are amenable
to endoscopic therapy, whereas gastric varices may
require more aggressive salvage measures.
• Endoscopy for esophageal varices is based on inter-
rupting blood flow using either endoscopic sclerother-
apy (EST) or endoscopic variceal band ligation (EVL).
EVL has been shown to be superior to EST as the
initial therapy unless the endoscopic field of view is
too poor.
• Absolute contraindication to endoscopy includes sus-
pected GI perforation, uncontrolled unstable angina,
severe coagulopathy, untreated respiratory decompensa-
tion, and severe agitation. Complications include ulcer-
ation, dysmotility and stricture formation, esophageal
perforation, mediastinitis, and portal hypertensive gas-
tropathy. With massive exsanguinations, emergent sur-
gical intervention should be considered instead of
endoscopy.
• Gastric varices may initially be controlled with EVL;
however, this is not always effective. Other interven-
tions include nonendoscopic esophageal tamponade
tubes (e.g., Sengstaken Blakemore tube) once an
endotracheal tube is secured. This should be done by
skilled personnel as esophageal ulceration and perfo-
ration may occur. Following temporary stabilization,
creation of an artificial vascular shunt between the
systemic and portal circulation to decompress the
varices can be performed. This may be accomplished
by a transjugular intrahepatic portosystemic shunt
(TIPS) with a radiologically guided metallic stent.
Since the advent of TIPS, there has been a reduction
in surgical decompression.
• Once hemodynamically stable, nonspecific beta-
blockade should be initiated (nadolol 20–40 mg daily)
to decrease portal hypertension.
NONVARICEAL HEMORRHAGE
• These lesions have a more favorable prognosis com-
pared to variceal bleeding. Peptic ulcer disease (PUD)
accounts for the majority of nonvariceal bleeds.
PEPTIC ULCER DISEASE
• Thermal therapy and injection therapy with epineph-
rine are the most commonly used hemostatic endo-
scopic methods. Thermal therapy produces coagulation
and dehydration at the ulcer base resulting in constric-
tion and destruction of the submucosal feeding vessels.
Injection therapy causes vasoconstriction and necrosis
of the bleeding vessel and surrounding tissue.
Combination therapy with injection and thermal coag-
ulation is superior to either monotherapy in active
bleeding although thermal therapy may be used alone
with nonbleeding ulcers.
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• Acid suppression with proton pump inhibitors is used
as an adjunct to endoscopic hemostasis. Octreotide
may be considered as a pharmacologic adjunct as well.
• In a minority of patients, endoscopy may not visualize
the lesion and angiography may be required.
Angiography with the option of hemostatic therapy
using the vasoconstrictor, epinephrine, or emboliza-
tion is reserved for poor surgical candidates or unsta-
ble patients awaiting surgery.
• Surgical therapy should be considered for life-
threatening hemorrhage that is refractory to medical
and endoscopic intervention and for the patient in
whom medical management has failed to heal or pre-
vent recurrence of the ulcer.
• Once hemodynamically stable, long-term acid sup-
pressive therapy with either oral H2-receptor blockers
or proton pump inhibitors should be started. If evalu-
ation for Helicobacter pylori is positive, treatment
should be initiated.
MALLORY-WEISS TEAR
• Generally a self-limiting cause of bleeding and rarely
requires more than supportive measures. Patients with
portal hypertension, however, are at increased risk of
massive bleeding and EVL or EST should be per-
formed. In the rare instance, a Mallory-Weiss tears
continues to bleed in patients without portal hyperten-
sion; endoscopic therapy with either thermal or injec-
tion therapy should be attempted prior to surgical
oversewing. Acid suppression therapy is given as
adjunctive therapy to accelerate healing.
DIEULAFOY LESION
• This lesion results from a dilated submucosal vessel
which erodes the overlying epithelium in the absence
of a primary ulcer. Massive bleeding can occur if the
eroding vessel is an artery. The endoscopic treatment
of choice is combination epinephrine injection and
thermal coagulation. EVL has also reportedly been
successful; however, the risk of bleeding after any
endoscopic therapy is up to 40%. If rebleeding occurs,
surgical wedge resection should be performed.
STRESS-RELATED MUCOSAL DAMAGE
• This is the result of multiorgan system failure in criti-
cally ill patients. Mortality is >30% when bleeding is
substantial, likely a reflection of the underlying dis-
ease(s). Two major risk factors are coagulopathy and
mechanical ventilation >48 hours. Other suggested
risk factors include sepsis, shock, acidosis, peritonitis,
extensive burns, hepatic failure, and renal failure.
• Endoscopically, stress-related mucosal damage
(SRMD) appears as multiple shallow erosions or sub-
mucosal hemorrhage that progress to deeper ulcera-
tions which may erode into the submucosa.
• Therapy is supportive with an attempt to correct pre-
cipitating factors. Acid suppression is used as an
adjunct to endoscopic or angiographic interventions.
Surgery should be avoided, since near-total gastrec-
tomy is required, and mortality exceeds 50%.
• Prophylactically, acid suppression and adequate nutri-
tional support, preferably enteral, have been shown to
decrease the incidence of SRMD.
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103 LOWER
GASTROINTESTINAL
HEMORRHAGE
Maria Dowell
KEY POINTS
• Massive bleeding from the upper GI tract (UGIH)
may mimic bleeding from the lower GI tract (LGIH)
and must be considered in the patient passing frank
blood per rectum.
• The two most common causes of LGIH are diverticu-
losis and angiodysplasia.
• When the rate of bleeding precludes direct visualization
by colonoscopy, imaging by tagged red cell scanning or
angiography should be considered.
EPIDEMIOLOGY
• Lower gastrointestinal (LGI) bleeding is defined as
bleeding from a source distal to the ligament of Treitz.
• 10% of patients thought to have LGI bleed are found
to have an upper source.
PRESENTATION AND EVALUATION
• Hematochezia is the most common presenting sign. In
patients with hematochezia and hemodynamic com-
promise, however, a brisk upper GI (UGI) bleed
should be included on the differential diagnosis.
• The two most frequent LGI bleeding sources are
diverticulosis and angiodysplasia.
• Initially, concentrate evaluation on resuscitation and
correction of coagulopathy. Nasogastric tube aspira-
tion is then performed and if positive, an urgent
esophagogastroduodenoscopy (EGD) is warranted. If
the aspiration is negative or patient has low risk for
upper bleed, an urgent colonoscopy should be done
after rapid oral purge.
COLONOSCOPY
• Emergent colonoscopy after rapid oral purge (4 L of
Golytely orally or via nasogastric tube over 2 hours)
is the initial approach. Metoclopramide (10 mg) is
given at the start of the cleansing to facilitate intestinal
transit time and minimize emesis.
• Following colonic cleansing, colonoscopy has higher
diagnostic yield and lower complication rate com-
pared to angiography.
• Overall diagnostic yield of emergent colonoscopy is
69–80%.
• Aside from diverticular bleeding and angiodysplasia,
the most common findings are colitis, neoplasia, and
anorectal disease.
• If the source is not determined on colonoscopy and an
upper endoscopy is negative, a small bowel etiology
should be considered. Small bowel evaluation with
push enteroscopy, capsule endoscopy, or enteroclysis
may be done once hemostasis is achieved.
ENDOSCOPIC THERAPY
• As with UGI bleeding, both thermal coagulation and
injection therapy with epinephrine have been used to
obtain hemostasis in acute LGI bleeding.
• Thermal coagulation and injection therapy with epi-
nephrine can achieve hemostasis and may prevent
recurrent diverticular bleeding and the need for hemi-
colectomy. Unfortunately, massive diverticular bleed
may not be amenable to endoscopic therapy due to
poor visualization thereby necessitating angiographic
or surgical therapy.
• Angiodysplastic lesions are often located in the
cecum and right colon and are frequently responsive
to endoscopic therapy. Additional lesions responsive
to endoscopic therapy include postpolypectomy sites,
radiation colitis, and anorectal sources. Argon-plasma
coagulation has been used effectively in radiation
colitis and postpolypectomy bleeding. Band ligation
similar to esophageal variceal band ligation can also
be used to treat bleeding from internal hemorrhoids.
RADIONUCLIDE STUDIES
• Radionuclide scanning using 99mTc-pertechnetate-
labeled red blood cells is often used to localize LGI
bleeding. Nuclear scan can detect bleeding rates as
low as 0.1 mL/min and repeat imaging may be per-
formed within the 48-hour stability of the tagged red
blood cell.
• Nuclear scanning has a high sensitivity but low speci-
ficity for precise localization compared to positive
endoscopy or angiography.
• A positive scan localizes the bleeding only to an area
of the abdomen and should be used to direct attention
to specific sites to be examined by angiography or
repeat endoscopy. Surgical intervention should not be
based on nuclear scan alone.
ANGIOGRAPHIC THERAPY
• Angiography with therapeutic intent is the pre-
ferred treatment in the setting of massive bleeding
that precludes colonoscopy or after a nondiagnostic
colonoscopy.
• Overall diagnostic yield ranges from 40 to 78% with
diverticular disease and angiodysplasia being the most
common findings. Initial hemostasis using intra-
arterial vasopressin or embolization ranges from 60 to
100% although recurrent bleeding can be as high as
50% following vasopressin therapy.
• Intra-arterial vasoconstrictive therapy is associated with a
major complication rate of 10–20% and includes arrhyth-
mias, ischemia, and pulmonary edema. Transcatheter
embolization with gelatin sponges and microcoils is a
more definitive means of controlling bleeding but carries
up to a 20% risk of intestinal infarction.
• In the absence of localization via nuclear imaging, the
superior mesenteric artery is examined first followed
by the inferior mesenteric and celiac vessels.
• If therapeutic angiography does not achieve perma-
nent homeostasis, emergent surgical therapy is indi-
cated. Angiography can also be used to temporarily
control bleeding and allow surgical intervention in a
controlled setting with improved operative mortality.
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SURGICAL THERAPY
• Surgical therapy should be reserved for hemorrhage
that is refractory to nonsurgical interventions. The
patient who is exsanguinating from LGI bleed, how-
ever, should undergo emergent subtotal colectomy.
• Preoperative localization by angiography or colonoscopy
is crucial to avoid extensive surgical resection and
ensure that the bleeding is truly arising from a lower
source. Exploratory laparotomy with intraoperative
endoscopy can be used to localize the source, espe-
cially in the small intestine.
• Once the source is identified, segmental colectomy can
be performed. A subtotal colectomy is indicated for the
exsanguinating patient or patient with persistent hem-
orrhage without a source and involves resection from
the cecum to proximal rectum with an ileoproctostomy.
OBSCURE BLEEDING AND SMALL BOWEL
EVALUATION
• Occasionally, patients undergo nondiagnostic evalua-
tions for GI bleeding but clinically stabilize. Emergent
surgical exploration and intraoperative endoscopy may
not be indicated and they should undergo further eval-
uation directed at the small bowel.
• Novel endoscopic modalities exist that can visualize
more distal portions of the small bowel. Push
enteroscopy uses a pediatric endoscope passed beyond
the ligament of Treitz to visualize the proximal 60 cm
of jejunum and allows biopsy or therapy of visualized
lesions. Diagnostic yield is 50% with angiodysplasia
being the most common lesion. Sonde enteroscopy
should be considered if push enteroscopy is negative. It
is performed by passing a long flexible enteroscope
passively by intestinal peristalsis but does not allow
biopsy or therapy of the lesions. Wireless capsule
endoscopy provides a noninvasive method of examin-
ing the entire small bowel via peristaltic propulsion of
an endoscopic capsule. Approximately 50,000 images
are taken as it traverses the small bowel over 12–15 hours
but biopsy and therapeutic interventions cannot be per-
formed. Enteroclysis radiology is a double contrast
study performed by injecting barium, methylcellulose,
and air via a tube in the proximal small bowel. It has a
yield of only about 10% but is considered superior to
standard small bowel follow through studies.
• Small intestinal angiodysplasia accounts for the
majority of lesions associated with obscure bleeding.
End-stage renal disease, von Willebrand disease, and
Osler-Weber-Rendu are all associated with increased
incidence of small bowel angiodysplasia.
• Hemobilia is bleeding from the liver, bile ducts, or
pancreas and usually results from blunt or sharp
trauma to the liver. Hemobilia should be considered
when melena occurs in conjunction with jaundice,
after blunt trauma or acute pancreatitis. Angiographic
therapy may allow temporary control of hemobilia but
generally definitive surgery is required.
• Aortoenteric fistula occurs rarely following abdominal
vascular surgery with synthetic graft placement. The
fistula arises from the proximal anastomosis of the graft
and communicates with the fourth portion of the duode-
num. Evaluation should begin with endoscopy and if
this fails to identify the source, angiography should be
performed.
• Meckel diverticulum should be considered in younger
patients with massive bleeding. 99mTc-pertechnetate
scan has a diagnostic sensitivity of 75% and surgical
resection provides definitive therapy.
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104 ACUTE HEPATIC FAILURE
D. Kyle Hogarth
KEY POINTS
• Fulminant hepatic failure (FHF) is defined as the
onset of hepatic oncephalopathy (HE) within 8 weeks
of the onset of liver-related symptoms.
• Common complications in patients with FHF include
encephalopathy, cerebral edema, cardiovascular insta-
bility, renal failure, and infection.
• Supportive management of FHF consists of (1) airway
protection, (2) ICP monitoring in the sickest patients,
and (3) treatment of complications and monitoring for
infection.
• Patient survival is inversely related to the number and
extent of extrahepatic organ dysfunction, so early
recognition and management of organ system deterio-
ration is mandatory.
• All FHF patients should be assumed to have an unpre-
dictable clinical course, which may require liver
transplantation.
• Orthotopic liver transplantation (OLT) is the only
definitive therapy for FHF. Among severe FHF
patients, expected recovery with medical management
is only 10–40%. Liver transplantation has survival
rates of 60–80% for FHF.
DEFINITIONS
• There are multiple ways to classify fulminant hepatic
failure (FHF), which are useful from a research and
retrospective analysis point of view. However, the
classification systems do not provide prospective
guidelines for initial management of FHF.
• FHF is defined as the onset of hepatic encephalopathy
(HE) within 8 weeks of the onset of liver-related
symptoms.
• HE is graded using the following scale:
 Grade 1: confused or has an altered mood
 Grade 2: somnolent or displays inappropriate
behavior
 Grade 3: stuporous but arousable or displays moder-
ately confused behavior
 Grade 4: the patient is unresponsive or comatose
ETIOLOGIES
• Careful history taking from the patient, family, and
significant others is mandatory and may provide valu-
able information in identifying the etiology of FHF.
• In the United States, acetaminophen toxicity has
replaced acute viral hepatitis as the most common
cause of FHF.
• Of the viral causes of FHF, hepatitis A and B are the
most common with hepatitis C rarely causing FHF.
Other viral causes include herpes simplex virus and
Epstein-Barr virus.
• Drugs other than acetaminophen causing FHF include
halothane, ampicillin-clavulanate, ciprofloxacin, eryth-
romycin, isoniazid, nitrofurantoin, tetracycline, sodium
valproate, phenytoin, lovastatin, tricyclic antidepres-
sants, gold, flutamide, dipyridium, Antabuse, cyclophos-
phamide, methyldioxymethamphetamine (ecstasy),
loratadine, propylthiouracil, and troglitazone.
• FHF results from toxins including Amanita phal-
loides, organic solvents, herbal medicines, and bacte-
rial toxins (Bacillus cereus and Cyanobacteria).
• Miscellaneous rare causes of FHF include acute
Budd-Chiari syndrome (hepatic vein thrombosis),
hepatic ischemia from shock, Wilson disease, Reye
syndrome, acute fatty liver of pregnancy, heatstroke,
extensive hepatectomy, and autoimmune hepatitis.
INITIAL EVALUATION
AND MANAGEMENT
• Patients suspected of having FHF should be managed
in a critical care unit associated with an active liver
transplant program.
• A history of preexisting liver disease, toxin exposure
(e.g., alcohol, acetaminophen, and nonsteroidal anti-
inflammatory drugs [NSAIDs]), acute viral illness, or
predisposing medical condition should increase suspi-
cion of FHF in a patient presenting with altered
mental status, transaminase elevation, and synthetic
dysfunction.
• Synthetic function of the liver is best followed by the
international normalization ratio (INR) or prothrom-
bin time. A rising INR coincident with falling liver
transaminases is an ominous sign suggestive of non-
recoverable ongoing hepatic necrosis.
• Progression of FHF may lead to significant hemody-
namic instability. Often, the hemodynamic changes
resemble those associated with septic shock, and
include a hyperdynamic circulation and a decreased
systemic vascular resistance.
• Episodes of hypotension require aggressive evaluation
and correction to prevent cerebral hypoperfusion,
worsening injury to the blood-brain barrier, and mul-
tisystem organ failure.
• When the intracranial pressure (ICP) is being meas-
ured, cerebral perfusion pressure (CPP) serves as the
major parameter for titration of fluid and vasoactive
therapy (goal >60 mmHg), rather than the mean arte-
rial pressure (MAP).
MONITORING
• Among patients with grade 3 or 4 encephalopathy,
endotracheal intubation is necessary for airway pro-
tection, oxygenation, and control of respiratory
acidosis.
• ICP monitoring is strongly recommended for direct
measurement of ICP in patients with grade 3 or 4 HE.
Extradural catheter monitoring is preferred in this set-
ting for its safety and ease in placement.
WORKUP FOR ETIOLOGY AND
POSSIBLE TRANSPLANT
• The initial laboratory evaluation should try to deter-
mine the potential causes of FHF as well as evaluate
other organ system function in the patient.
• A complete blood count, platelet count, chemistries,
albumin, bilirubin, alkaline phosphatase, aspartate
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aminotransferase (AST), alanine aminotransferase
(ALT), prothrombin time (INR), arterial blood gas,
factor V level, blood glucose, and ammonia level are
required for initial evaluation and management.
• Possible causes of FHF are sought through serologic
assays for hepatitis A (anti-HAV IgM) and hepatitis B
(anti-HBV IgM, HBsAg, HBcAb) and serum assays
for ceruloplasmin, iron binding capacity, toxic sub-
stances, and acetaminophen. HIV testing should also
be performed.
• A right upper quadrant ultrasound is useful in provid-
ing information regarding the patency of hepatic ves-
sels, liver size, presence of ascites, and degree of
compression of the porta hepatitis by intra-abdominal
masses.
• The role for liver biopsy is controversial.
COMPLICATIONS
ENCEPHALOPATHY AND CEREBRAL EDEMA
• Dysfunction of cerebral blood flow autoregulation,
cerebral vasodilation, and a disrupted blood-brain bar-
rier all contribute to the accumulation of interstitial cere-
bral fluid, resulting in increased ICP in the FHF patient.
• In the acute setting, cerebral edema is clearly evident
in patients with grade 3 and 4 encephalopathy.
• Computed tomography (CT) has limited sensitivity in
detecting cerebral edema, therefore, repeated clinical
evaluation and grading of encephalopathy is required,
preferably by the same senior staff member.
• Other external variables that may contribute to wors-
ening encephalopathy include hypoglycemia, hypoxia,
electrolyte abnormalities, gastrointestinal bleeding,
and sepsis.
• Treatments normally effective in the encephalopathy
of decompensated chronic liver disease, such as selec-
tive gut decontamination, lactulose, and dietary nitro-
gen restriction, do not help in FHF.
• Initial management of cerebral edema in FHF should
include avoidance of unnecessary stimulation, includ-
ing respiratory suctioning in intubated patients, which
may cause acute elevations in ICPs.
• The head of the patient’s bed should be elevated to 30°
and the patient’s head should be maintained in a neu-
tral position.
• Brain blood flow is determined largely by the CPP, a
function of MAP and ICP: CPP = MAP − ICP. The
optimal CPP is between 60 and 80 mmHg.
• Mannitol can be used as medical therapy of cerebral
edema in FHF. Careful monitoring of the serum
osmolality should occur. When osmolality exceeds
320 mOsm/L, the mannitol should be held.
RENAL FAILURE
• Acute renal failure is a frequent occurrence in the
patients with FHF and is associated with a poor
prognosis.
• The incidence of renal insufficieny approaches 75%
among patients with acetaminophen-induced FHF and
30–50% among patients with FHF from other causes.
Prerenal azotemia, acute tubular necrosis, hepatorenal
syndrome, and nephrotoxic drugs may contribute to
renal dysfunction and should be investigated and treated.
• Continuous renal replacement therapies are the pre-
ferred modality for dialysis as significant fluctuations
in hemodynamic and ICP have been demonstrated
with intermittent hemodialysis.
RESPIRATORY FAILURE
• The onset of hypoxic respiratory failure is usually
associated with development of multisystem organ
failure and predicts an overall poor prognosis.
• Diagnostic and therapeutic bronchoscopy should gen-
erally be avoided in these patients because of the
potential to raise ICP dramatically.
• The presence of hypoxemia requiring >60% FiO2 is
likely to present difficulties with posttransplant man-
agement and survivability.
INFECTIONS
• Patients with FHF have a high incidence of bacterial and
fungal infections. Eighteen percent of all patients with
FHF ultimately die of infectious-related complications.
• Central venous catheters should be inserted using full
barrier precautions and maintained with sterile tech-
nique. When line sepsis is suspected, all lines must be
removed and replaced at alternative sites. Before a
new line is inserted, reassess if the patient truly needs
the central access.
• Urinary catheters can be removed from anuric patients
to limit the risk of an ascending urinary tract infection.
• Systemic infection usually contraindicates transplanta-
tion because of the high level of immunosuppression
subsequently required. However, this contraindication
is not absolute.
LIVER TRANSPLANTATION
• Liver transplantation for the treatment of FHF has
dramatically improved survival and should be consid-
ered the primary mode of therapy.
• The only factor consistently associated with poor out-
come was level of encephalopathy at the time of
admission.
• No consistent patient characteristic could be corre-
lated with survivability without liver transplantation.
OTHER THERAPEUTIC INTERVENTIONS
• Many other treatment options have been investigated,
and many showed early promise. However, none have
proven benefit. Potential treatment options in a research
setting include high volume plasma exchange, steroids,
prostaglandin E, auxiliary liver transplantation, and
extracorporeal liver support.
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105 CHRONIC LIVER DISEASE
Josh Levitsky
KEY POINTS
• Decompensation in patients with chronic liver disease
and cirrhosis often results from infection, bleeding,
and/or encephalopathy.
• Clinicians should have a low threshold for paracente-
sis in patients with chronic ascites and even modest
evidence of infection to clarify the potential diagnosis
of SBP.
• Massive ascites may compromise respiratory function
and lead to an abdominal compartment syndrome.
EPIDEMIOLOGY
• In 2000–2001, over 360,000 hospital discharges and
27,000 deaths in the United States resulted from com-
plications of chronic liver disease.
• Complications are related to the development of portal
hypertension.
• Most common diagnoses on ICU admission are:
sepsis, spontaneous bacterial peritonitis (SBP),
variceal hemorrhage, hepatic encephalopathy (HE),
massive ascites, and renal failure.
PATHOPHYSIOLOGY
• Portal hypertension = portal pressure gradient (pres-
sure difference between the portal vein and inferior
vena cava [IVC]) >5 mmHg; clinically significant
>10 mmHg (formation of gastrointestinal varices) or
>12 mmHg (risk of variceal hemorrhage).
• Portal hypertension leads to cirrhotic circulatory dys-
function, characterized by splanchnic vasodilation, acti-
vation of the renin-angiotensin and sympathetic nervous
systems, and subsequent systemic vasoconstriction.
• Renal failure due to portal hypertension (e.g., hepa-
torenal syndrome) is caused by systemic and intrarenal
vasoconstriction.
• Ascites develops with avid fluid and sodium retention
by the kidneys, excessive lymph formation, and
increased intrahepatic resistance.
• HE may be caused by portosystemic shunting of neu-
rotoxins (e.g., ammonia, endogenous benzodiazepines,
manganese, and gamma-aminobutyric acid [GABA]).
CLINICAL FEATURES
• Relative hypotension is important to confirm as hypoten-
sion (systolic blood pressure [SBP] ~80–90 mmHg) is
common at baseline.
• Tachypnea may be due to intrapulmonary (hepatic
hydrothorax, pulmonary edema, pneumonia) or extra-
pulmonary (tense ascites, metabolic acidosis due to
sepsis, cirrhotic cardiomyopathy, encephalopathy)
causes.
• Fetor hepaticus: sweet breath odor caused by
increased dimethylsulphide concentrations (portosys-
temic shunting).
• Neurologic: stage I HE: anxiety, short attention span,
sleep-wake reversal; stage II HE: lethargy, inappropri-
ate behavior, slurred speech, asterixis; stage III HE:
severe confusion, somnolent but arousable, hyper-
reflexia; stage IV HE: obtundation, loss of reflexes.
• Cardiovascular: hypotension, tachycardia, bounding
pulses.
• Pulmonary: tachypnea, small lung volumes from ascites,
decreased breath sounds, and dullness to percussion
from associated pleural effusions.
• Gastrointestinal: flank or shifting dullness, splenomegaly,
caput medusa, abdominal tenderness or rebound (SBP).
Hepatomegaly suggests posthepatic cause or infiltrative
disorder.
• Genital: testicular atrophy.
• Extremity: edema or anasarca, clubbing (often in pri-
mary biliary cirrhosis or hepatopulmonary syn-
drome), Dupuytren contracture (often in alcoholics),
Muehrcke (white bands separated by normal color) or
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Terry (proximal two-thirds of nail plate appears
white) nails.
• Dermatologic: jaundice, spider angiomata, palmar
erythema.
• Miscellaneous: gynecomastia, parotid hypertrophy
(often in alcoholics).
LABORATORY FEATURES
• Leukopenia: often due to hypersplenism.
• Thrombocytopenia: hypersplenism, decreased throm-
bopoietin levels from liver disease, alcoholism.
• Anemia: hypersplenism, anemia of chronic disease,
acute blood loss (bleeding or hemolysis), vitamin
deficiency, alcoholism, renal failure.
• Coagulopathy: elevated international normalized ratio
(INR), correlates with severity of liver disease, less
common disseminated intravascular coagulation
(DIC), fibrinolysis, dysfibrinogenemia.
• Liver tests: hypoalbuminemia (not specific for liver
disease), hyperbilirubinemia, aspartate aminotrans-
ferase (AST)/alanine aminotransferase (ALT) >1 often
seen in cirrhosis, >2 suggestive of alcohol-related liver
disease, elevated alkaline phosphatase and gamma-
glutamyltransferase in cholestatic disorders (primary
biliary cirrhosis, primary sclerosing cholangitis).
• Chemistry: hyponatremia, hyperkalemia (use of
potassium-sparing diuretics, renal failure), metabolic
alkalosis.
PRINCIPLES OF DIAGNOSIS
AND MANAGEMENT
• Infection (general): Pan-culture (blood, urine, peri-
toneal fluid if ascites present), chest x-ray (CXR). If
no obvious initial source, consider broad-spectrum
antibiotics until further data (culture or imaging results)
direct management.
• SBP: Diagnostic paracentesis for culture, Gram’s
stain, and cell count. Diagnosis made with a polymor-
phonuclear (PMN) count ≥250/µL. Organism isolated
in only 50–60% of cases. Start cefotaxime (2 g IV
every 6–8 hours) or ceftriaxone (2 g IV every 24 hours).
Albumin infusion at the time of diagnosis (1.5 g/kg)
and day 3 (1 g/kg) to reduce risk of renal dysfunction.
Repeat diagnostic paracentesis in 48–72 hours: if no
improvement in cell count, culture is polymicrobial,
or ascites glucose <50 mg/dL or ascites lactate dehy-
drogenase (LDH) >serum LDH, consider secondary
peritonitis.
• HE: Often precipitated by progression of liver disease,
missed scheduled medications, infection, gastrointestinal
blood loss, hypovolemia, sedative use, electrolyte
imbalances (hyponatremia, hypokalemia, hypo-
glycemia, alkalosis, renal failure), protein load, hepa-
tocellular carcinoma. Treat underlying cause +
lactulose (goal: 2–3 soft stools per day). If no resolu-
tion, consider other causes of encephalopathy.
• Variceal hemorrhage: Initial management—protect
airway (consider endotracheal intubation), consider
central venous catheter; resuscitate with fresh frozen
plasma, red blood cells, platelets, and/or saline. Avoid
excessive transfusions. Start octreotide (initial IV bolus
25–50 µg followed by 25–50 µg/h infusion) and
broad-spectrum antibiotic prophylaxis. Urgent upper
endoscopy for variceal sclerotherapy or banding. If
unsuccessful, balloon tamponade tube or urgent por-
tosystemic shunt (transjugular intrahepatic portosys-
temic shunt [TIPS]).
• Ascites: Exclude infectious peritonitis. Low sodium
diet and diuretics. Avoid >10 L paracentesis and give
8 g albumin/1 L ascites, 1/2 after paracentesis, and
1/2 6 hours later. Consider TIPS in refractory cases if
no contraindications (encephalopathy, severe hepatic
dysfunction).
• Renal failure: Evaluate for prerenal, intrarenal, and
postrenal causes. Assess volume status and evidence of
infection. Discontinue nephrotoxic drugs. Trial of 1.5 L
of normal saline or equivalent. Order urinalysis, urine
sodium, renal ultrasound. If no etiology or improve-
ment in 24–48 hours, likely hepatorenal syndrome:
avoid overzealous paracentesis, maintain volume
status, consider systemic vasoconstrictors (terli-
pressin, octreotide + midodrine). TIPS is considered
experimental.
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106 BLEEDING ESOPHAGEAL
VARICES AND TIPS
Sunana Sohi
KEY POINTS
• A large fraction of patients with cirrhosis will experi-
ence at least one episode of variceal bleeding.
• Without treatment, variceal bleeding has a high rate of
recurrence.
• Initial stabilization can be challenging given the
propensity for massive and rapid blood loss.
• In advance of diagnostic procedures, large-bore access
should be established, blood product and fluid resusci-
tation initiated, coagulopathy addressed, and in many
patients, intubation performed to protect the airway.
EPIDEMIOLOGY
• Liver cirrhosis affects approximately 3.6 out of 1000
adults in the United States.
• In the United States, alcohol abuse is the most
common cause of cirrhosis.
• Approximately 10% of upper gastrointestinal bleeds
are variceal in nature, and 25–40% of patients with
cirrhosis will develop a variceal bleed.
• One-third of all cirrhosis-related deaths are secondary
to variceal bleeds.
• A single variceal bleeding episode is associated with
a 30% mortality rate.
• Whereas approximately 90% of nonvariceal upper
gastrointestinal bleeds resolve spontaneously, less
than half of variceal bleeds resolve without treatment.
ETIOLOGY
• Varices develop as a result of portal hypertension,
which is caused by resistance to outflow from the
portal vein. This can happen at several levels:
 Presinusoidal (e.g., portal vein thrombosis and splenic
vein thrombosis)
 Sinusoidal (alcoholic cirrhosis being the most
common, but other causes include schistosomiasis,
the various hepatitides, Wilson disease, hemochro-
matosis, and alpha1-antitrypsin deficiency)
 Postsinusoidal (including Budd-Chiari syndrome
and inferior vena cava thrombosis)
• In cirrhosis, portal hypertension develops secondary to
sinusoidal obstruction and is associated with splanch-
nic vasodilation, which increases portal inflow.
• Varices form as portosystemic collaterals to divert
obstructed blood flow back to the systemic vascula-
ture, thus decompressing the portal system. This
happens when the pressure gradient between the two
systems exceeds 12 mmHg. The most significant
collaterals are the gastroesophageal varices, which
drain blood from the portal system into the azygous
vein.
• Increased expression of the vasoconstrictor endothe-
lin-1 has been related to the pathogenesis of varices;
endothelin-1 is produced by the hepatic sinusoids and
its vasoconstrictor effects serve to increase portal
pressure. Additionally, the cirrhotic liver sinusoids
have been shown to downregulate production of the
vasodilator nitric oxide. Together, these mechanisms
increase hepatic vascular resistance.
• Factors predicting variceal progression are similar to
those predicting bleed (see “Factors Predicting a
Variceal Bleed,” below). Varices are more likely to
progress if the patient has a higher Child-Pugh score
(Table 106-1), if they are a large size, and if they have
red wale signs (long erythematous streaks on the
varices) seen on endoscopy.
FACTORS PREDICTING
A VARICEAL BLEED
• A previous bleed: Almost 75% of patients will
rebleed.
• Size and appearance: Varices that are more likely to
bleed are larger and have endoscopic red signs: red
wale markings, cherry red spots (clearly demarcated
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TABLE 106-1 Child-Pugh Score∗
1 POINT 2 POINTS 3 POINTS
Total bilirubin <2 mg/dL 2–3 mg/dL >3 mg/dL
Serum albumin >3.5 g/dL 2.8–3.5 g/dL <2.8 g/dL
International normalized <1.7 1.7–2.2 >2.2
ratio (INR)
Ascites None Mild Moderate/severe
Encephalopathy None Mild Moderate/severe
∗Class A: 5–6 points; class B: 7–9 points; class C: 10–15 points.
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flat spots), hemato cystic spots (clearly demarcated
raised spots), or simply diffuse erythema.
• Child-Pugh score: As a marker of liver dysfunction,
those patients with Child class B or C are more likely
to bleed than those with Child class A.
• Alcohol intake: Patients still actively consuming alco-
hol are more likely to have a variceal bleed than those
who abstain.
• High variceal pressure: Variceal pressure can be
measured using an endoscopic gauge, and the higher
the pressure within the varices, the more likely they
are to bleed.
PROPHYLAXIS AGAINST A FIRST
VARICEAL BLEED
• Therapies are aimed at either decreasing portal pres-
sure or locally minimizing the varices.
• Nonselective beta-blockers: Nonselective beta-
blockers, such as propranolol, nadolol, and timolol,
are commonly used as prophylaxis against variceal
bleeds. They increase splanchnic vascular tone by
blocking beta-adrenergic-mediated vasodilation, and
they therefore decrease blood flow to the portal
system. Their use is associated with an approximately
50% risk reduction of hemorrhage, but they have not
yet been consistently proven to decrease mortality.
Nadolol is used most commonly as it is dosed once
per day. The typical starting doses are: nadolol 20–40 mg
PO qd. Alternative beta-blockers include propranolol
10 mg PO tid, and timolol 10–20 mg PO bid. Doses
are adjusted based on heart rate, with the aim being a
relative bradycardia.
• Nitrates: Long-acting nitrates, such as isosorbide
mononitrate, decrease portal pressure, but they have not
been demonstrated to decrease mortality when used as a
single agent, nor have they been shown conclusively to
prevent bleeding, even when used in conjunction with a
beta-blocker. Therefore, they are not used routinely.
• Sclerotherapy: Endoscopic sclerotherapy is an effec-
tive treatment of bleeding esophageal varices, but as
there are many risks to the procedure (see “Endoscopic
Sclerotherapy or Band Ligation,” below), is not cur-
rently recommended as prophylaxis against a first
variceal bleed.
• Band ligation: A meta-analysis of endoscopic band
ligation has shown the procedure to decrease the risk
of a first variceal hemorrhage and bleeding-related
mortality; however, it has not been shown to decrease
mortality overall. Additionally, as with sclerotherapy,
band ligation has risks, and does not permanently
remove varices. Currently, its use is limited to patients
with a high risk of hemorrhage who are unable to tol-
erate beta-blocker prophylaxis.
• Surgical portal decompression and TIPS (Transjugular
Intrahepatic Portosystemic Shunts): These treatments
are very effective at preventing variceal hemorrhage,
but their complications (see individual sections) pre-
clude their use as a prophylactic measure against a
first variceal bleed.
TREATMENT OF A VARICEAL BLEED
• Supportive measures are key in the treatment of a
variceal bleed, as patients can exsanguinate quickly.
Obtaining large-bore venous access is a first priority.
• The preferred first direct therapy for variceal bleeding
includes pharmacologic treatment with octreotide or
somatostatin, quickly followed by endoscopic scle-
rotherapy or band ligation.
• Treatment of a variceal hemorrhage is aimed at
addressing the bleed site directly, via sclerotherapy,
band ligation, or balloon tamponade, and decreasing
portal pressure, via pharmacotherapy, TIPS, or surgi-
cal shunt creation (Table 106-2).
SUPPORTIVE TREATMENT
• Hemodynamic support: Volume resuscitation with
normal saline should be initiated via two large-bore
peripheral IVs or a central line. Additionally packed
red blood cells may be transfused to replace blood
loss, and fresh frozen plasma may be needed to
replace clotting factors that may be deficient due to
the cirrhotic liver.
• Nasogastric (NG) tube placement: A NG tube should
be placed for decompression and to lavage the stom-
ach for greater visibility during endoscopy.
• Intubation: NG tube decompression may reduce
aspiration risk, but if there is a concern for aspira-
tion, the patient may require intubation for airway
protection.
TABLE 106-2 Treatment Modalities
Site-specific
Endoscopic sclerotherapy
Endoscopic band ligation
Balloon tamponade
Portal pressure reduction
Somatostatin
Octreotide
Vasopressin (rarely used)
Terlipressin (not available in the United States)
TIPS
Surgical shunt
PHARMACOTHERAPY
• Somatostatin and octreotide: Somatostatin and
octreotide, is long-acting synthetic analog, inhibit
glucagon and thus constrict the mesenteric vascula-
ture, which decreases portal pressure. Their effects on
the portal system are similar to that of vasopressin but
with fewer systemic side effects (see below). This
makes somatostatin and octreotide first-line pharma-
cotherapy for an acute variceal bleed, though they
have not been shown to decrease mortality.
• Vasopressin: Vasopressin constricts the splanchnic bed,
thereby decreasing portal inflow and thus portal pres-
sures. It may be beneficial in the initiation of hemosta-
sis, but as its vasoconstrictor effects are not limited to
the mesenteric system, it can increase mortality by
causing organ ischemia. In the past, it was used with
nitroglycerin in an attempt to counteract systemic vaso-
constriction, but with the development of somatostatin
and octreotide, its use has fallen out of favor.
• Terlipressin: Although not available in the United
States, terlipressin is a synthetic vasopressin analog
used commonly in Europe. It has a longer half-life
and can be given in IV boluses instead of continuous
infusion. It is the only pharmacologic agent associated
with decreased mortality.
ENDOSCOPIC SCLEROTHERAPY
OR BAND LIGATION
• Endoscopic treatment is diagnostic as well as thera-
peutic and has been shown to achieve hemostasis
80–90% of the time.
• Sclerotherapy: Sclerotherapy involves the injection of
a “sclerosant” (usually sodium tetradecyl sulfate or
sodium morrhuate) into the varices on visualization
during endoscopy. The procedure is associated with a
2% mortality rate. Complications include mucosal
ulceration, esophageal perforation, mediastinitis, and,
in the long term, approximately 15% of patients will
develop esophageal stricture.
• Band ligation: This involves the deployment of small
elastic bands around the varices, causing subsequent
strangulation and then fibrosis of the vessels. Its major
limitation is impaired visibility caused by the banding
attachment device, although this has improved with the
development of clear devices. Local complications, such
as esophageal stricture, are less common, but band liga-
tion is associated with rebleeding during the procedure.
• Both have fairly equivalent rates of hemostasis; utility
of one over the other is based on operator preference.
• If endoscopic treatment fails, balloon tamponade, sur-
gical treatment, or TIPS are second-line therapies.
BALLOON TAMPONADE
• Balloon tamponade, via the Sengstaken-Blakemore
tube, Minnesota tube, or Linton-Nachlas tube, is used
for short-term hemostasis if endoscopic treatment fails.
It is less likely to be successful if the patient has failed
pharmacotherapy or has developed early rebleeding.
• Generally, the tube is advanced through the orophar-
ynx, and placement is confirmed via endoscopy or a
radiograph or ultrasound. The balloon is then inflated
in the stomach and pulled up against the gastroe-
sophageal junction, compressing the varices. Tension
is held until hemostasis is achieved.
• Complications associated with balloon tamponade
include a high risk of rebleeding after the balloon is
deflated and a risk of esophageal rupture if the balloon
is overinflated. The procedure is associated with a risk
of aspiration pneumonia and thus the patient is com-
monly intubated for airway protection. Because of
these complications, tamponade is used primarily to
stabilize the patient briefly prior to a more definitive
treatment, such as TIPS or surgical shunt creation.
TRANSJUGULAR INTRAHEPATIC
PORTOSYSTEMIC SHUNTS
• Transjugular intrahepatic portosystemic shunts
involve the use of a metal stent to create a connection
between the hepatic vein and the intrahepatic portion
of the portal vein, thus decompressing the portal
system. It has the added benefit of decompressing the
hepatic sinusoids, thereby also decreasing ascites.
• TIPS is not first line in the treatment of acute variceal
bleeds. Endoscopic treatment is first line; however,
10–20% of patients may rebleed after endoscopic
therapy. Sclerotherapy or band ligation may be
attempted again, but if this fails again, TIPS may be
attempted. It is indicated in patients who rebleed and
are poor surgical candidates.
• TIPS has been associated with a lower rebleeding rate
compared with endoscopy, however, it is also associ-
ated with higher rates of hepatic encephalopathy and
liver failure, as well as a higher mortality rate.
MAJOR COMPLICATIONS ASSOCIATED WITH TIPS
• Rebleeding: The main causes of rebleeding after TIPS
include a recurrence of portal hypertension due to
stent thrombosis, kinking, or stenosis, and the devel-
opment of right heart failure.
• Stent stenosis: This is the most common complication
after TIPS and is caused by pseudointimal hyperplasia,
or growth of the liver tissue into and around the lumen
of the stent. Almost 50% of patients will occlude their
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shunts within 1 year of the procedure, thus surveil-
lance Dopplers or angiograms are standard.
• Stent thrombosis: Anticoagulation carries with it such
a high risk of bleeding in this patient population that it
is not used as a prophylactic measure. Approximately
8% of patients will develop stent, portal vein, or
splenic vein thrombosis, usually within 1–2 months of
the procedure. If this develops, thrombolytics, antico-
agulation, or suction thrombectomy are used; liver
transplant is the definitive treatment.
• Procedural complications: Patients must be moni-
tored for cardiac arrhythmias as the catheter is passed
through the heart. There is also a risk of fatal hemo-
peritoneum if the liver capsule is punctured, if a TIPS-
biliary fistula is created, or if the portal vein is
punctured in the extrahepatic region.
• Complications of shunt creation: These complications
also apply to the creation of surgical shunts. Twenty-
five percent of patients develop portosystemic
encephalopathy within 2–3 weeks of the procedure.
They present with altered sleep, confusion, or hepatic
coma. Portosystemic encephalopathy is also associ-
ated with a high ammonia level, although the level is
not correlated with the severity of the encephalopathy.
Patients should be treated with lactulose while other
causes for encephalopathy, such as infection, subclin-
ical bleed, metabolic and acid-base disturbances, are
ruled out.
SURGICAL PORTAL DECOMPRESSION
• There are three types of surgical shunts. The side-to-
side portocaval shunts decompress the entire portal
tree and are thus nonselective; the selective distal
splenorenal shunt decompresses the varices while
keeping pressure in the superior mesenteric artery
high; and the partial shunts only partially decompress
the portal tree while maintaining some amount of liver
perfusion.
• Surgical shunts are very successful at creating hemo-
stasis but they interfere with the potential for future
liver transplant. As with TIPS, they are associated
with about a 50% encephalopathy rate.
• They may be used in patients who are good surgical
candidates and fail emergent endoscopic treatment.
RECURRENT BLEEDING EPISODES
• The greatest likelihood of rebleeding occurs within
the first 2–3 days after stabilization, but the patient is
still considered high risk for approximately 6 weeks
after treatment.
• Survivors of an acute variceal bleed have a 70% risk
of recurrent hemorrhage within 1 year. Up to one-
third of these events are fatal.
• Risk factors for a rebleeding episode include age >60,
the presence of renal failure, large variceal size, and a
severe initial bleed (hemoglobin <8 when admitted).
PREVENTION OF RECURRENCE
• Data regarding a first-line treatment for the prevention
of recurrence of variceal bleeds has not been consistent.
Currently, the American College of Gastroenterology
recommends endoscopic band ligation as a primary
treatment.
• Surveillance endoscopy should be performed every
6 months for the first year after the bleeding episode,
and then every year thereafter, to monitor for recurrent
varices.
• Many of the medications used for the prevention of
variceal bleeding are also used in the prevention of
recurrence. Nonselective beta-blockers, with or without
the addition of a long-acting nitrate, are commonly
administered.
• Treatment choices are based on Child-Pugh class.
Clinicians are more likely to attempt medical manage-
ment on patients with Child’s score A, while patients
with Child’s score C would benefit from repeat endo-
scopic sclerotherapy or band ligation, with consideration
for TIPS or surgical shunt creation as salvage therapy if
patients continue to rebleed. Additionally, Child’s score
C patients should be listed for liver transplant.
• Liver transplantation is the only long-term treatment
that reliably prevents against rebleeding, with survival
rates of 80–90% at 1 year posttransplant and 60% at
5 years after transplant.
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107 ACUTE PANCREATITIS
Maria Dowell
KEY POINTS
• The most common causes of pancreatitis causing
admission to the ICU include alcohol and biliary
obstruction; the most common causes of pancreatitis
arising during other critical illness include direct sur-
gical trauma, hypoperfusion, and drugs.
• Severe pancreatitis causes a generalized Systemic
Inflamatory Response Syndrome (SIRS) with a high
risk of evolution of other organ failures.
• Fluid requirements may be large early in the course,
with risks of low pressure pulmonary edema and large
intra-abdominal fluid collections.
• Carefully timed imaging of the abdomen is crucial to
assess for anatomic complications of pancreatic
inflammation.
BACKGROUND AND ETIOLOGY
• Often a self-limiting disease but 10% can develop
severe form that carries a 30–40% mortality rate.
• Many causes with the most common being alcohol
and gallstones. Other causes include postcardiopul-
monary bypass, abdominal aortic aneurysm repair,
posttransplantation of organs including the heart,
kidney, and liver.
• Regardless of initiating cause, common pathogenetic
mechanisms involve an intense systemic inflamma-
tory response syndrome (SIRS) and hypoperfusion
injury. The exact mechanism of injury is not known
and is likely multifactorial.
DIAGNOSIS
• Clinical signs and symptoms are notoriously variable
and may include abdominal pain, nausea, vomiting,
leukocytosis, fever, and hemodynamic instability.
Serum lipase may be more reliable and specific than
amylase.
• Abdominal and chest radiographs should be used to
rule out perforation and intestinal obstruction. X-rays
may suggest pancreatitis by demonstrating pleural
effusions, local ileus, widened duodenal loop, gall-
stones, absent psoas shadow, free intraperitoneal
fluid, or pancreatic calcifications.
• Computed tomography (CT) scan (IV contrast if pos-
sible): The gold standard for assessing retroperitoneal
morphology and recommended in the presence of
diagnostic uncertainty at the time of initial presenta-
tion. Can be useful to have a baseline scan but critical
value is in detection and follow-up of pancreatitis
complications. It is recommended that CT for detec-
tion of local complications be delayed for 48–72 hours
when possible, as necrosis may not be visible earlier.
• Ultrasound: The most available and convenient bed-
side test for edematous pancreatitis that responds rap-
idly to supportive therapy and monitoring resolution
of pseudocysts. Results may be hampered by obesity
and ileus.
SEVERITY OF DISEASE
• Ranson criteria were used extensively in the past but
several scoring systems employing clinical, biochem-
ical, and radiologic features are currently available.
These models should not replace frequent serial clini-
cal assessments. Many centers use the Atlanta classi-
fication, based on the patient’s presentation, Ranson
score, APACHE (Acute Physiology and Chronic
Health Evaluation) II score, and organ dysfunction.
The Balthazar score is based on CT findings.
TREATMENT
• The mainstay of initial treatment is fluid resuscitation,
respiratory and nutritional support, as well as atten-
tion to the primary disease state. Current sepsis guide-
lines should be initiated once the presence of infection
is suspected and sepsis physiology is present.
• Metabolic and hemodynamic effects: Close clinical
observation is required as patients usually require
early and aggressive fluid resuscitation (may be up to
10 L isotonic fluid). Monitoring should focus on
intravascular volume assessment (examination, urine
output, acid-base status, central venous pressure) and
pulmonary function. Use of pulmonary artery
catheters remains controversial.
• Respiratory and renal support: Increased capillary
permeability related to serotonin release, breakdown
of surfactant by pancreatic phospholipase A, or acti-
vation of complement cascade are all mechanisms
implicated in development of acute respiratory dis-
tress syndrome (ARDS) in acute pancreatitis.
Ventilatory support is often required. Acute tubular
necrosis and resulting renal insufficiency or failure
usually results from hypoperfusion injury.
• Nutrition: Enteral nutrition via nasojejunal or percuta-
neous jejunal tube is recommended in preference to
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parenteral nutrition. Infusion into the proximal
jejunum bypasses stimulatory effects of feeding on
pancreatic secretion, has fewer complications, is less
costly than total parenteral nutrition (TPN), helps
maintain mucosal function, and limits absorption of
endotoxins and cytokines from the gut. TPN should
only be used after 5–7 days’ trial if enteral nutrition
has failed.
• Control of pancreatic enzyme secretion: Numerous
strategies attest to the failure of most of them to alter
the course of the inflammatory process.
LOCAL COMPLICATIONS OF
NECROTIZING PANCREATITIS
• Uncommon but potentially lethal intra-abdominal
hemorrhage may occur. Necrosis, abscess, pseudo-
cyst, perforation, and abdominal compartment syn-
drome may occur due to further hypoperfusion injury
to the pancreas.
• Pancreatic and peripancreatic necrosis: Patients who
die from necrotizing pancreatitis usually do not die in
the early resuscitation phase. The patchy devitaliza-
tion of the pancreas develops days to weeks after the
onset of inflammation and may occur with or without
infection of this tissue. Abdominal pain, persistent
fever, leukocytosis, and radiologic evidence are useful
in making the diagnosis. Ultrasound or CT-guided
fine needle aspiration (FNA) with Gram’s stain should
be done to discern sterile from infected necrosis.
Debridement and/or drainage are not recommended
for sterile necrosis.
• Infected necrosis and pancreatic abscess: Debridement
or drainage should be performed with infected necrosis
or abscess confirmed by radiologic gas or FNA culture
to avoid the sequelae of systemic infection.
• Antibiotic therapy: Although the latest consensus rec-
ommends against routine prophylactic systemic
antimicrobial or antifungal agents or selective decont-
amination of the gastrointestinal (GI) tract in patients
with necrotizing pancreatitis, it remains common prac-
tice. There may be a subset of patients (posttransplant,
immunocompromised) identified by future investiga-
tions who may benefit from use of these agents.
• Surgical debridement: The gold standard is open
operative debridement. Whenever possible, necrosec-
tomy and/or drainage should be delayed 2–3 weeks to
allow for demarcation of the necrotic pancreas; how-
ever, the clinical picture should be the primary deter-
minant of when the patient needs to proceed to the
operating room.
• Gallstone pancreatitis: In the setting of obstructive
jaundice, urgent endoscopic retrograde cholangiopan-
creatography (ERCP) should be performed within
72 hours of onset of symptoms or, if ERCP unavail-
able, alternative methods of biliary drainage must be
considered.
• Pseudocysts: Persistence of lesser sac fluid implies
communication with pancreatic duct system. Cysts do
not mandate immediate treatment unless they become
symptomatic, infected, rupture, or grow quickly.
Percutaneous decompression or endoscopic drainage
is often employed. Surgery is required for bleeding or
free rupture.
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108 MESENTERIC ISCHEMIA
Joseph Levitt
KEY POINTS
• Acute mesenteric ischemia is rare but often fatal when
diagnosis is delayed and thus a high index of suspi-
cion is necessary in at-risk patients.
• Presentation can vary from a dramatic acute abdomen
and shock in acute embolic events to vague nonspe-
cific abdominal pain and changed bowel habits with
chronic ischemia or venous thrombosis.
• Mesenteric angiography is the investigation of choice
and may offer therapeutic options. CT angiography is
commonly used and widely available and allows
insight into status of the bowel.
• Treatment is generally surgical with restoration of
blood flow via endarterectomy or bypass and resec-
tion of nonviable bowel.
• Prognosis remains poor even at specialist centers with
diagnostic delay being the greatest hurdle to improved
outcomes.
ANATOMY AND PATHOGENESIS
• The bowel is supplied by three branches of the aorta.
The celiac artery supplies the foregut and hepatic and
splenic circulations. The superior mesenteric artery
(SMA) supplies the midgut and the inferior mesenteric
artery (IMA) supplies the hindgut. With chronic
ischemia significant collateral circulation can develop.
• At baseline, the intestine receives 20–30% of cardiac
output, which can increase to 50% after meals.
• Acute drops in cardiac output cause intense vasocon-
striction of the mesenteric circulation that can be out
of proportion to the fall in cardiac output.
• Decreases in blood supply to the mesentery lead to an
increased O2 extraction by the bowel, thus lowering
the O2 content of the portal circulation and increasing
the risk of hepatic ischemia.
• The mucosal layer receives 70% of intestinal blood
supply and is the most sensitive to ischemia. Twenty
minutes of ischemia can lead to injury and loss of
mucosal villi. Prolonged ischemia will progress to
mucosal sloughing (which presents as bloody diarrhea)
and eventually transmural infarction with perforation
and septic peritonitis.
• Reperfusion after prolonged ischemia can release a
host of metabolic byproducts into systemic circulation
causing an intense systemic inflammatory response
syndrome (SIRS) or promote translocation of intes-
tinal bacteria and sepsis.
PRESENTATION
• It is important to be able to recognize the signs and
symptoms of both acute and chronic mesenteric
ischemia as they can have very different presentations
and therapies but the same catastrophic result if not
recognized early.
• Chronic ischemia may be subtle and presents with the
classic triad of weight loss, intestinal angina (pain after
eating and food phobia), and a change in bowel habits.
• Acute ischemia has a range of presentations depend-
ing on its cause:
 Embolic (usually to SMA)—severe abdominal pain
(often out of proportion to the physical examination
because of poor localization of pain to palpation) with
nausea, vomiting, and diarrhea. Patients may choose a
“chin to knee” position and be restless from the pain.
As ischemia progresses to perforation, patients may
develop peritonitis and a more acute abdominal
examination. History should focus on predisposing
factors such as atrial fibrillation, dilated cardiomy-
opathy, or recent aortic instrumentation.
 Thrombotic—usually presents in the setting of
acute-on-chronic ischemia where collateral circula-
tion allows for a more subtle onset of vague pain
and a change in bowel habits. However, due to dif-
fuse disease of all three major circulations, it may
progress to massive infarction. History should focus
on occult symptoms of chronic ischemia and other
sites of atherosclerosis (i.e., stroke, coronary, or
peripheral vascular disease).
 Nonocclusive mesenteric ischemia (NOMI)—occurs
in setting of shock and use of vasopressors with a non-
specific presentation of persistent ileus, abdominal
distention, melena or hematochezia, and occult sepsis.
 Mesenteric vein thrombosis—onset may be acute or
delayed with several weeks’ history of vague pain
and changed bowel habits. Risk factors include prior
abdominal surgery, thrombophilia, history of
mesenteric or deep venous thrombosis, malignancy,
and cirrhosis.
 Miscellaneous causes—include aortic surgery or
dissection, trauma, aneurysms, arteritis or extrinsic
compression (low pressure veins are more suscepti-
ble and may be seen with severe intestinal distention,
volvulus or intussusception, or by tumor).
DIAGNOSIS
• Early diagnosis requires a high index of suspicion and
early utilization of appropriate diagnostic testing.
• Clinical presentation can vary from vague abdominal
discomfort with a benign examination to overt shock.
Laboratory studies are generally not helpful.
Leukocytosis is nearly universal but nonspecific while
lactate has poor sensitivity and should not delay more
definitive diagnostic testing.
• Mesenteric angiography remains the definitive diag-
nostic test and may provide therapeutic options but is
invasive and not always readily available.
 Emboli are seen as rounded filling defects at arterial
branch points.
 Thrombosis appears as abrupt cutoffs usually near
the ostia of larger vessels in the setting of extensive
collaterals.
 NOMI shows diffuse narrowing with a “sausage
string” appearance and should have an acute response
to papaverine infusion.
 Venous thrombosis shows decreased portal vein fill-
ing in the late phase of infusion.
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• Computed tomography (CT) angiography is often the
first test of choice in the algorithm of abdominal pain
and has the advantage of wide availability and high
diagnostic yield but may not be as sensitive or specific
as invasive angiography. CT also has the added bene-
fit of evaluating to the condition of the bowel, which
has important treatment implications and is not pro-
vided by angiography.
• Ultrasound with duplex is the test of choice in chronic
ischemia with diagnostic criteria being based on
velocity of flow in SMA and celiac artery. In acute
ischemia, potential findings of ileus and bowel wall
thickening are nonspecific.
• MRI has gained acceptance in diagnosing chronic
ischemia but currently is not indicated in the acute
setting.
• Abdominal x-ray is insensitive and nonspecific.
Supportive information may include ileus, luminal
distention, or diffuse calcification of mesenteric vas-
culature. Classic findings of intestinal wall thickening
(“thumbprinting”), pneumatosis intestinalis, and free
air are very late findings.
TREATMENT
• First-line therapy is supportive and should always start
with the ABCs (airway, breathing, circulation) of resus-
citation. Correction of electrolyte abnormalities, place-
ment of a nasogastric tube to decompress the bowel,
broad-spectrum antibiotics, and full-dose heparin are
also recommended. Analgesia should not be withheld
while workup proceeds.
• If no evidence of infarct exists, then angiography may
have therapeutic implications. In NOMI, papaverine
infusion into the SMA for 24 hours is the treatment of
choice. For occlusive etiologies, surgery is still the
standard of care but percutaneous procedures includ-
ing clot suctioning, angioplasty, and stenting and
thrombolysis are gaining ground at specialized
centers.
• When concern for bowel infarction exists, urgent
laparotomy should be performed to evaluate intestinal
viability. This can be confirmed with good sensitivity
by the character of pulsation of the mesenteric arcade
vessels (either manually or with sterile Doppler
probe), bleeding, color, and peristalsis.
• Revascularization should be attempted by endarterec-
tomy or, if not successful, bypass. If >6 ft of small
bowel is clearly viable then liberal excision of suspect
portions may be performed with primary anastomosis.
With more extensive involvement, bowel-sparing proce-
dures with delayed reanastomosis may be necessary to
prevent long-term dependence on parenteral nutrition.
A second exploration within 48 hours will often be
necessary to confirm viability of all remaining bowel
segments.
• Postoperative care should always be in an intensive
care unit. Reperfusion may cause severe SIRS or overt
sepsis requiring aggressive fluid resuscitation and
vasoactive drugs. Attention should be paid to the risk
of developing abdominal compartment syndrome due
to bowel edema and massive third spacing of fluid.
Parental nutrition may be necessary for prolonged
periods. Heparin should be continued and transitioned
to warfarin when enteral feeding resumes.
• Further diagnostic testing may include transthoracic
or transesophageal echocardiography to look for an
embolic source or laboratory testing to rule out a
thrombophilia.
PROGNOSIS
• Prognosis is generally poor, with perioperative mor-
tality ranging from 22 to 96% in different case series
and is related to the etiology of the ischemia. Venous
thrombosis and arterial embolism have better progno-
sis (postsurgical mortality of 32% and 54%, respec-
tively) compared to arterial thrombosis and NOMI
(postsurgical mortality 77% and 73%, respectively).
• These differences are likely related to greater comor-
bidities associated with the latter two etiologies as
well as a more subtle presentation leading to delayed
diagnosis and greater bowel involvement at time of
intervention.
• For those who survive the perioperative period, they
are generally able to return to preoperative levels of
function but significant late mortality persists, related
to underlying comorbidities.
• Poor prognosis should dissuade pursuit of heroic
measures in the elderly: presence of significant
comorbidities, advanced shock, or extensive tumor
involvement.
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109 ABDOMINAL
COMPARTMENT
SYNDROME
Michael Moore
KEY POINTS
• Increases in abdominal pressure to a point compro-
mising local and systemic perfusion and impairing
pulmonary function can occur in a number of medical
and surgical contexts, a circumstance termed as
abdominal compartment syndrome.
• Clinicians must have a high index of suspicion for
this condition and if clarification is required, bladder
pressure can be measured at the bedside as a surro-
gate for IAP.
• Surgical decompression may be required in the most
severely affected patients.
INTRODUCTION AND DEFINITION
• Abdominal compartment syndrome (ACS) can be
defined as symptomatic organ dysfunction resulting
from increased intra-abdominal pressure (IAP). ACS
has been described in patients with multiple medical
and surgical conditions.
• ACS is often hard to diagnose because patients are
often critically ill and progressive organ dysfunction
may be attributed to other causes. Prompt recognition
of increased IAP before ACS develops may prevent
progressive tissue hypoperfusion, multiple organ dys-
function, and death.
• The reported mortality has been between 42 and
100%.
PATHOPHYSIOLOGY
• Intra-abdominal pressure is normally 0 mmHg.
• IAP is slightly positive in patients on positive pressure
ventilation and increases in direct relationship to body
mass index.
• As volume of the peritoneal cavity increases, the IAP
rises in proportion to the pressure-volume relationship
of the abdominal cavity.
• Once a “critical IAP” is reached, abdominal wall
compliance decreases and results in a rapid increase
in IAP.
• The increased IAP has two important physiologic
consequences:
 Decreased perfusion to the intra-abdominal vascular
beds (hepatic, splanchnic, and renal)
 Increased intrathoracic pressures via mechanical
coupling of the intra-abdominal and thoracic cavi-
ties through the diaphragm
• Compression of the intra-abdominal vascular beds
and increased juxtacardiac and pleural pressures lead
to decreased organ perfusion, interfere with cardiac
and respiratory function, and lead to clinical ACS.
• The compliance of the abdominal wall tends to limit
the rise of IAP and states that are associated with
increased compliance may protect against ACS (preg-
nancy, cirrhosis, morbid obesity).
RISK FACTORS
MEDICAL
• Massive volume resuscitation
• Bowel obstruction
• Pancreatitis
• Massive ascites
• Peritonitis
• Peritoneal dialysis
• Gastric over distention following endoscopy
• Pneumothorax (rare)
• Any condition that results in tissue edema, intraperi-
toneal or retroperitoneal bleeding, bowel distention,
or third spacing of fluids
SURGICAL
• Trauma patients who require massive volume
resuscitation
• Laparoscopy
• Postoperative edema
• Liver transplantation
• Abdominal wall restriction (abdominal burns with
fascial scaring, MAST [medical antishock trousers]
garments)
• Tight surgical closure following laparotomy
• Pneumoperitoneum
CLINICAL MANIFESTATIONS
• Abdominal compartment syndrome can compromise
the function of every organ system and organ dys-
function is further exacerbated by the presence of
hypotension and shock.
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CARDIOVASCULAR
• Direct compression the heart resulting in decreased
ventricular compliance and contractility resulting in a
decreased cardiac output.
• Elevated IAP decreases venous return by compressing
the inferior vena cava (IVC) resulting in peripheral
edema, increased risk of venous thrombosis, and
decreased cardiac output from the lower venous return.
PULMONARY
• Hypoxemia and hypercarbia are common.
• Extrinsic compression of the pulmonary parenchyma
results in atelectasis, decreased oxygen transport,
increased intrapulmonary shunt fraction, and increased
alveolar dead space.
• Increased peak and mean airway pressure in mechani-
cally ventilated patients.
• Decreased chest wall compliance and tidal volumes
result in V/Q mismatching and increased work of
breathing.
• Increased risk of pneumonia.
RENAL
• Progressive decline in glomerular filtration rate
(GFR) and urine output directly related to IAP.
• Oliguria develops at IAP of 15 mmHg.
• Anuria develops at IAP of 30 mmHg.
• Results in “prerenal” picture with FENa (fractional
excretion of sodium) <1%.
• Mediated via increased venous resistance and arterial
vasoconstriction mediated by sympathetic and renin-
aldosterone systems.
GASTROINTESTINAL
• Gastrointestinal (GI) system is the most sensitive to
changes in IAP.
• Mesenteric blood flow is compromised at relatively
low levels of IAP and results in intestinal mucosal
ischemia.
• IAP causes compression of mesenteric veins promot-
ing venous hypertension and edema.
• Intestinal edema further increases IAP and can result
in a vicious cycle of worsening hypoperfusion and
ischemia.
• Gut hypoperfusion results in loss of mucosal barrier
which may contribute to bacterial translocation, sepsis,
and multisystem organ failure.
HEPATIC
• Decreased hepatic perfusion
• Decreased lactate clearance
CENTRAL NERVOUS SYSTEM
• Increased IAP increases central venous pressure (CVP)
and will increase intracranial pressure.
• High CVP in setting of hypotension may result in
decreased cerebral perfusion pressure and progressive
cerebral edema.
DIAGNOSIS
• Suspect diagnosis with clinical syndrome of tense
abdominal distention with the signs and symptoms of
splanchnic hypoperfusion, systemic hypoperfusion, or
increased work of breathing.
• Physical examination findings have sensitivity of only
40%.
• Chest x-ray (CXR) findings of small lung volumes,
atelectasis, and elevated hemidiaphragms are suggestive.
• Computed tomography (CT) findings include tense
infiltration of the retroperitoneum out of proportion to
peritoneal disease, extrinsic compression of the IVC,
massive abdominal distention, direct real compression
or displacement, bowel wall thickening, and bilateral
inguinal herniation.
• Neither physical examination nor imaging studies are
adequate for diagnosis.
• The gold standard is to indirectly measure the IAP by
transducing the intra-abdominal bladder pressure (IAPB).
INTRA-ABDOMINAL BLADDER PRESSURE
MEASUREMENT
• Bladder acts as a passive reservoir that can transmit
IAP using the bladder wall as a transducing membrane.
• IABP is well correlated with directly measured IAP
(Fig. 109-1).
• Technique:
 Instill 50 mL of sterile water into the bladder via a
Foley catheter with the drainage tube clamped.
 Insert an 18-gauge needle connected to a pressure
transducer into the aspiration port of the catheter.
 Measure the pressure with the transducer zeroed at
the level of the pubic symphysis.
• Certain clinical states may interfere with accurate
measurements:
 Intraperitoneal adhesions
 Pelvic hematomas
 Pelvic fractures
 Abdominal packing
 Neurogenic bladder
• Certain clinical states associated with chronic intra-
abdominal hypertension (IAH) (pregnancy, morbid
obesity, and ascites) complicate the diagnosis of ACS
while small increases in IAP in this setting may be tol-
erated less well.
• The critical IAP varies from patient to patient and
within patients based on severity of illness so no single
value in individual patients can accurately diagnose
ACS.
• In general, an IABP ≤10 mmHg rules out ACS and
>25 mmHg rules in ACS.
TREATMENT
• Successful management requires attention to preven-
tion, maintaining a high index of suspicion, and early
recognition with prompt decompression.
• Preventative techniques include temporary abdominal
closure following laparotomy in surgical patients and
avoiding supranormal resuscitation of critically ill
medical patients.
• Low threshold for checking bladder pressures in patients
at risk for or suspected of having ACS.
• Follow patients with elevated IAP with serial
measurements.
• ACS secondary to tense ascites may be managed with
serial or large volume paracentesis.
• Supportive care including endotracheal intubation and
mechanical ventilation.
• When positive end-expiratory pressure (PEEP) is
required to maintain adequate oxygenation, use the
least PEEP associated with a nontoxic FiO2.
• Volume resuscitation will, at least temporarily, improve
cardiac output, pulmonary function, renal function, and
visceral perfusion but may also be associated with worse
outcome.
• Definitive management for ACS is surgical decom-
pression and maintenance of an open abdomen with
temporary wall closure.
• The critical IAP that identifies the need for decom-
pressive laparotomy, the timing, and procedure of
choice are not well defined.
BIBLIOGRAPHY
Balogh Z, McKinley BA, Cocanour CS, et al. Patients with
impending abdominal compartment syndrome do not respond
to early volume loading. Am J Surg 2003;186:602–607.
322 SECTION 8 • GASTROINTESTINAL DISORDERS
FIG. 109-1 Bladder transduction system. Using a patient Foley catheter with clamped
drainage tube, 50–100 mL sterile water is infused into the bladder via a three-way stopcock
system. The bladder pressure measured with a transducer correlates well with directly meas-
ured IAP.
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110 INFLAMMATORY BOWEL
DISEASE
Timothy L. Zisman
KEY POINTS
• Inflammatory bowel disease consists of two separate
but related diseases of the bowel, Ulcerative Colitis
(UC) and Crohn’s Disease (CD).
• IBD can have serious complications associated both
with the underlying disease process as well as the dis-
ease treatments.
• Complications of the GI tract include massive hemor-
rhage, toxic megacolon, bowel obstruction, fistula for-
mation, intra-abdominal abscess, and bowel perforation.
• Immunosuppressive and cytotoxic medications used
to treat IBD can predispose patients to a variety of
infectious complications.
• Extraintestinal manifestations of IBD include periph-
eral and axial arthritis, ocular disease, aphthous
ulcers, erythema nodosum, pyoderma gangrenosum,
PSC, venous thrombosis, and pulmonary fibrosis.
EPIDEMIOLOGY AND GENETICS
• Crohn disease (CD) has an annual incidence of
approximately 3–8 per 100,000 persons, with a preva-
lence of 1 in 1–2000. Ulcerative colitis (UC) has an
annual incidence of 2–12 per 100,000 persons, with a
prevalence of 1 in 1–2000.
• Disease onset occurs in a bimodal distribution, with
the largest peak at age 15–25 and a second smaller
peak later in life at age 50–80.
• The incidence of inflammatory bowel disease (IBD) is
much higher in developed countries than in the devel-
oping world. Within a given country the incidence
appears to be higher in the northern regions.
• IBD is more common in Jewish than non-Jewish popu-
lations. Prevalence amongst whites and blacks is higher
than among Asians, Hispanics, and Native Americans.
• CD is slightly more common in women, whereas UC
is slightly more common in men.
• Familial aggregation of IBD has been well estab-
lished. Approximately 20% of IBD patients are able to
identify another family member with IBD. Amongst
monozygotic twins, the concordance rate is 58% for
CD and 6–18% for UC.
• Interestingly, tobacco use appears to offer a sympto-
matic protective effect for patients with UC. Disease
onset is often associated with smoking cessation, in
many cases as far as a few years after stopping smoking.
• Investigations into the genetics of IBD have identified
mutations in the NOD2 gene on chromosome 16
which appear to confer susceptibility to ileal and stric-
turing CD.
CLINICAL FEATURES
ULCERATIVE COLITIS
• The inflammation in UC invariably involves the rectum,
with extension of disease proximally in a contiguous
distribution. Approximately 50% of patients have dis-
ease limited to the rectum and sigmoid colon, 30% have
involvement of the descending colon as well, and 20%
have extensive involvement of the entire colon.
• Bowel inflammation outside the colon does not occur
in UC, with the exception of “backwash ileitis,” an
inflammation of the distal terminal ileum seen in some
patients with extensive colitis.
• Patients with UC often report hematochezia, diarrhea
associated with urgency and nocturnal awakenings,
abdominal cramping, bloating, poor appetite, and weight
loss.
• Physical examination may reveal fever, tachycardia,
dehydration, and signs of anemia. A tender and dis-
tended abdomen with absent bowel sounds may sug-
gest toxic dilatation of the colon.
• Serologic studies may demonstrate anemia, an elevated
erythrocyte sedimentation rate, and hypoalbuminemia.
• Stool analysis will reveal gross blood with presence of
fecal leukocytes. Stool culture and examination for
ova and parasites will be negative.
• Endoscopic findings may show edematous, granular,
erythematous, and friable mucosa with areas of gross
ulceration. Dysplasia in UC often appears as flat
lesions and may be difficult to identify. Although not
done routinely, colonoscopy can be safely performed
in patients with acute severe colitis.
• Biopsy of the colon demonstrates superficial inflam-
mation involving only the mucosa. Common findings
include alteration of crypt architecture with neu-
trophilic infiltrate and crypt abscesses (Table 110-1).
CROHN’S DISEASE
• Crohn disease is an inflammatory condition of the
bowel that can occur anywhere along the gastroin-
testinal (GI) tract from mouth to anus. Thirty percent
of patients have disease confined to the small bowel,
25% have only colonic involvement, and 40% have
both small and large bowel inflammation.
• Patients frequently report abdominal pain and cramp-
ing, diarrhea, low-grade fever, poor appetite, and weight
loss. Hematochezia is less common than with UC.
• Physical examination may be significant for weight
loss, dehydration, abdominal tenderness, and a right
lower quadrant mass. Perianal examination may show
skin tags, fissures, enterocutaneous fistula tracts, or
perirectal abscesses.
• High-grade fever and a tender abdominal mass may
represent intra-abdominal abscess and should prompt
further investigation.
• Laboratory studies may show leukocytosis, anemia
(from iron deficiency, chronic disease, or vitamin B12
deficiency), hypoalbuminemia, and elevated acute
phase reactants.
• Patients with extensive small bowel involvement may
have steatorrhea with consequent vitamin deficien-
cies. Laboratory findings in these patients may reveal
hypocalcemia, prolongation of the prothrombin time,
and hyperoxaluria with nephrolithiasis.
• Endoscopic features characteristically include dis-
crete ulcers in normal mucosa, linear ulcerations,
discontinuous areas of involvement, rectal sparing,
strictures, and “cobblestoning.”
• Classic histologic findings include aphthoid ulcers
overlying lymphoid follicles, lymphoid aggregates
and fibrosis of the bowel wall, and granuloma
formation.
• Radiologic studies may aid in diagnosis or in assess-
ment of extent and severity of disease. Computed
tomography (CT) often reveals bowel wall thickening
with adjacent fat stranding, and is superior to ultra-
sound for identifying intra-abdominal abscesses.
Small bowel series may be useful in identifying areas
of stricture or fistula tracts (Table 110-1).
DIAGNOSIS
• Both UC and CD are diagnosed clinically, taking into
consideration the sum of available evidence, including
the patient’s signs and symptoms, as well as endo-
scopic, histologic, and radiologic features.
• Anti-Saccharomyces cerevisiae antibodies (ASCA)
and perinuclear antineutrophil cytoplasmic antibodies
(p-ANCA) have been proposed as serologic tests for
CD and UC, respectively. However, due to inadequate
sensitivity and specificity these tests are not currently
recommended for routine use as either a screening or
diagnostic tool.
EXTRAINTESTINAL MANIFESTATIONS
• Ocular findings include uveitis and iritis, which tend
to occur independent of bowel disease activity, and
episcleritis, which is more coincident with active
bowel symptoms.
• Cutaneous manifestations include oral aphthous ulcers,
erythema nodosum, and pyoderma gangrenosum.
• Peripheral arthritis is a common feature of IBD that
occurs in approximately 20% of patients, and the
severity of joint inflammation correlates with the
activity of bowel disease. Typically, the large joints are
involved, especially knees ankles, hips, and shoulders.
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TABLE 110-1 Clinical Features of CD and UC
CD UC
Pattern of distribution Patchy, discontinuous areas of inflammation Contiguous from rectum, extending proximally
Involved bowel Anywhere from mouth to anus, most commonly Large intestine only
in terminal ileum
Thickness Transmural Mucosa only
Endoscopic findings Ulcers in otherwise normal mucosa, cobblestoning Friable mucosa, ulcers only in inflamed mucosa
Biopsy Granulomatous inflammation Neutrophilic infiltrate, crypt abscesses
Major complications Fistulas, strictures, abscesses, bowel obstruction Massive hemorrhage, toxic megacolon, bowel perforation
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IBD patients are also at increased risk for an axial
arthritis akin to ankylosing spondylitis, which occurs
in 3–5% of patients and is independent of bowel dis-
ease activity.
• Bronchopulmonary disease is uncommon in IBD but is
becoming increasingly recognized. Inflammations of
the airways, pulmonary parenchyma, and pleura have
all been reported and are attributed both to the disease
itself as well as the medications used to treat IBD.
• Hepatobiliary manifestations in patients with UC
include primary sclerosing cholangitis (PSC) which
may progress to liver failure or be complicated by
cholangiocarcinoma. Crohn patients are predisposed
to develop cholelithiasis which results from depletion
of bile salts in patients with inflammation or surgical
resection of the terminal ileum.
• Anemia is quite common in IBD patients and may be
multifactorial in etiology. Chronic blood loss can lead
to iron deficiency, whereas chronic inflammation can
result in anemia of chronic disease. CD patients may
also have vitamin B12 deficiency with consequent
megaloblastic anemia.
• Hypercoagulability associated with IBD predisposes to
venous, and occasionally arterial, thromboembolism.
• Osteopenia and osteoporosis are common in IBD and
are related both to calcium malabsorption and chronic
steroid use. Low body weight may exacerbate prob-
lems with decreased bone mineral density.
• Nephrolithiasis, particularly with calcium oxalate
stones, may complicate CD. Impaired reabsorption of
bile salts may result in intraluminal chelation of cal-
cium, with consequent increased absorption of oxalate.
• Immunosuppression is a common side effect of many
of the medications used to treat IBD, particularly glu-
cocorticoids, azathioprine (AZA), 6-mercaptopurine
(6-MP), infliximab, and cyclosporine. Consequently,
patients are at increased risk for a variety of infections
with ordinary pathogens and opportunistic organisms.
BOWEL COMPLICATIONS
FULMINANT COLITIS AND TOXIC
MEGACOLON
• Approximately 10–15% of UC patients develop ful-
minant colitis, characterized by severe diarrhea (>10
bowel movements daily), hemorrhage requiring trans-
fusion, high fever, tachycardia, dehydration, marked
abdominal tenderness, and leukocytosis.
• A severely dilated colon of more than 6 cm on abdom-
inal x-ray, associated with absent peristalsis, an acute
abdomen, and signs of systemic toxicity are worri-
some findings suggestive of toxic megacolon.
• Development of toxic megacolon may be precipitated
by hypokalemia or by the use of narcotic, antidiar-
rheal, or anticholinergic medications in patients with
fulminant colitis.
• Abdominal radiograph may show “thumbprinting”
from bowel wall edema or pneumatosis.
• In addition to supportive care with fluids, electrolytes,
and blood products, initial management should include
serial abdominal examinations and radiographs, and
decompression of the bowel with nasogastric suction.
• Intravenous corticosteroids should be continued and
may mask signs of systemic toxicity.
• Broad-spectrum antibiotics with sensitivity against
gram negatives and anaerobes should be administered
in anticipation of possible peritonitis or perforation.
• Signs of decreasing peristalsis or worsening bowel
dilatation may indicate impending perforation that
should prompt urgent surgical evaluation. Likewise,
failure to improve within 48–72 hours despite aggres-
sive medical therapy is an indication for surgical inter-
vention. Free air under the diaphragm on upright chest
radiography indicates perforation and requires urgent
surgical intervention.
• With prompt recognition, close monitoring, and aggres-
sive medical and surgical therapy, the mortality rate
associated with fulminant colitis and toxic megacolon
has been reduced to 6%.
COLON CANCER
• Colorectal carcinoma is a well-established long-term
complication of UC. The association between CD and
cancer has been increasingly reported and is now
accepted as well.
• The risk of cancer in UC increases with the duration
of disease and is estimated to be 2% at 10 years of dis-
ease, 8% at 20 years, and 18% at 30 years.
• Factors associated with an increased risk of colon
cancer include longer duration of disease, younger
age at diagnosis, greater extent of disease, family his-
tory of colorectal cancer (independent of a history of
IBD), and the presence of PSC.
• Evidence from observational studies suggests that reg-
ular use of 5-aminosalycylate medications and folate
may provide chemoprotection against colon cancer.
• Unlike in sporadic colorectal carcinoma, malignant
lesions in IBD do not arise from polyps, but rather
from areas of dysplasia in flat mucosa.
• Patients with IBD should undergo periodic surveil-
lance colonoscopies beginning 8–10 years after dis-
ease onset with the goal of identifying potentially
malignant lesions at a precancerous stage when surgi-
cal cure is still feasible.
• Patients with low-grade or high-grade dysplasia on
colonoscopy should be referred for surgery because of
the high rate of progression to frank carcinoma.
FISTULAS/ABSCESSES
• The transmural inflammation in CD can lead to fistula
tracts between the bowel and adjacent anatomic struc-
tures. Fistulas and abscesses are not part of the clini-
cal picture in UC.
• Enterovesical or enterovaginal fistulas can lead to
recurrent infections.
• Enteroenteric or enterocolic fistulas may result in bac-
terial overgrowth with consequent diarrhea, malab-
sorption, and weight loss.
• Fistulas to the mesentery may cause intra-abdominal
abscesses that typically manifest as fever and a tender
abdominal mass.
• Computed tomography is more sensitive than ultra-
sound for identifying abscesses.
• Abscesses, if present, require percutaneous or surgical
drainage as well as antibiotic therapy.
BOWEL OBSTRUCTION
• Obstruction may complicate stricturing CD, espe-
cially of the small bowel.
• Patients often present with postprandial crampy
abdominal pain, bloating, and distention.
• Nasogastric tube insertion with low intermittent suc-
tion is advised to decompress the bowel.
• Although medical therapy may be attempted, most
patients will require surgery to alleviate their obstruction.
HEMORRHAGE
• Severe hemorrhage requiring transfusion can be seen
in 10–15% of UC patients. The incidence in CD is
much lower.
• Initial management of massive hemorrhage is similar
to non-IBD patients, and involves immediate resusci-
tation and correction of coagulopathy with intra-
venous fluids and blood products.
MALABSORPTION
• Loss of bile salts may occur in Crohn patients with
active inflammation or prior resection of the terminal
ileum, leading to malabsorption and steatorrhea.
• Patients may develop nutritional deficiencies, espe-
cially from poor absorption of fat-soluble vitamins.
• Loss of fluids can result in profound dehydration and
electrolyte disturbances, especially hypokalemia.
• Surgical resection of the small bowel decreases the
absorptive area of the gut and, if extensive, can result
in the short gut syndrome with consequent malnutri-
tion and weight loss. Total parenteral nutrition may be
necessary to meet metabolic requirements.
COMPLICATIONS OF
EXTRAINTESTINAL DISEASE
PULMONARY DISEASE
• Involvement of the respiratory system in IBD is rela-
tively uncommon, but is being increasingly recog-
nized, especially in association with UC.
• Pulmonary involvement may manifest as airway
inflammation, lung parenchymal disease, or pleuritis.
• Airway inflammation can occur in the large or small
airways, and often presents as cough with or without
sputum production and wheezing.
• Bronchiolitis obliterans with organizing pneumonia
(BOOP) presents as fever, cough, shortness of breath,
and pleuritic chest pain.
• Interstitial lung disease may manifest as dyspnea.
Chest CT may show interstitial opacities.
• Sulfasalazine, one of the mainstays of pharmacother-
apy for IBD, has been associated with eosinophilic
pulmonary infiltrates.
PRIMARY SCLEROSING CHOLANGITIS
• Primary sclerosing cholangitis is an idiopathic inflam-
matory condition of the biliary tree that leads to fibrosis
and stricturing of the intra- and extrahepatic bile ducts.
• PSC occurs in only 1–4% of UC patients. However, 70%
of patients with PSC have IBD, predominantly UC.
• Patients may present with signs or symptoms of obstruc-
tive jaundice, or they may have asymptomatic eleva-
tion of alkaline phosphatase on routine labs.
• Serious long-term complications of PSC include pro-
gression to biliary cirrhosis, and development of cholan-
giocarcinoma in up to 15% of patients.
• Medical therapy with ursodeoxycholic acid may pro-
vide symptomatic benefit but does not alter the pro-
gression of disease.
• Biliary stricturing may be managed with endoscopic
dilatation and stent placement initially. However, liver
transplantation is the procedure of choice once cirrho-
sis develops.
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IMMUNOSUPPRESSION
• Many of the medications used to treat IBD can cause
serious immunosuppression that places patients at
risk for infections with typical and opportunistic
pathogens.
• The differential diagnosis and empiric antibiotic cov-
erage should remain broad for IBD patients on
immunosuppressive medications who appear infected.
MEDICAL THERAPY
5-AMINOSALICYLATES
• Mesalamine, sulfasalazine, olsalazine, and balsalazide
are all derivatives of 5-aminosalicylic acid (5-ASA),
and are considered the mainstay of therapy for patients
with IBD.
• 5-ASA medications are first-line agents for both induc-
tion of remission and maintenance in mild to moder-
ately active UC and CD.
• Regular use of 5-ASA products may reduce the risk
colorectal carcinoma in patients with IBD, suggesting
an additional role for these medications as chemopre-
ventive agents.
• While the sulfapyridine moiety in sulfasalazine is
associated with a fair amount of adverse effects, the
other 5-ASA medications are generally well tolerated
with only minor side effects.
CORTICOSTEROIDS
• Corticosteroids are highly effective in inducing remis-
sion for both UC and CD, however, the side effects
associated with chronic therapy preclude their use as
maintenance medications.
• Ideally, steroids should be initiated for disease flares
and then be tapered after 2–3 weeks. Many patients,
however, are unable to withdraw completely from
steroids. In these patients, it is appropriate to initiate
steroid-sparing agents such as AZA or 6-MP.
• Budesonide is an oral steroid that acts topically in
the gut, and subsequently undergoes significant first-
pass metabolism in the liver, thereby limiting sys-
temic effects. It is effective for inducing remission in
ileal CD, but should not be used as maintenance
therapy.
• Intravenous corticosteroids should be reserved for
patients with severe disease requiring admission to the
hospital. After symptomatic improvement, patients can
transition to oral steroids and begin a taper.
IMMUNOMODULATORS
• Azathioprine is a prodrug that is metabolically con-
verted to 6-MP. Both AZA and 6-MP therapy have a
role as steroid-sparing agents in the long-term man-
agement of patients who are unable to taper com-
pletely off of oral corticosteroids.
• These medicines take 3–6 months for peak effect and
should therefore be started well before steroid taper-
ing is undertaken.
• Approximately 1 in 10 patients will have to discon-
tinue these medications due to significant side effects
including bone marrow suppression, hepatitis, pancre-
atitis, rash, or infections.
• Deficiency of thiopurine-S-methyltransferase (TPMT),
the enzyme that metabolizes AZA and 6-MP, is present
in 1 in 300 people and can predispose to life-threatening
bone marrow suppression.
• Methotrexate has also been shown to be effective in
inducing remission, but its use is mainly limited by
side effects and the greater convenience of other
immunomodulatory drugs.
CYCLOSPORINE
• Cyclosporine should be reserved for patients with
severe or fulminant colitis who fail to respond to an
appropriate course of intravenous steroids.
• Although initial clinical response to cyclosporine is
good, many of these patients will go on to have relapse
of colitis that ultimately requires colectomy.
ANTIBIOTICS
• Antibiotics may be helpful as adjuvant therapy in the
management of CD patients with active colonic involve-
ment or with fistulizing disease.
• Ciprofloxacin and metronidazole are the best-studied
antibiotics, although rifaximin is being increasingly
studied with encouraging results.
TUMOR NECROSIS FACTOR-ALPHA INHIBITORS
• Infliximab is a chimeric monoclonal antibody
directed against human tumor necrosis factor-alpha
(TNF-alpha).
• TNF-alpha has been implicated as a key mediator in
the inflammatory cascade of CD, and inhibition of
TNF-alpha with infliximab has been shown to
improve endoscopic and histologic inflammation in
CD patients.
• Infliximab is currently recommended for both induc-
tion and maintenance of remission in CD patients
with moderate to severe disease activity, or with fis-
tulizing disease, who fail to respond to conventional
therapy.
• Common side effects include acute infusion reactions
(shortness of breath, hypotension, urticaria, fever),
delayed hypersensitivity reactions, drug-induced
autoantibodies, arthralgias, rash, GI upset, and minor
infections.
• Serious adverse effects include severe or life-threatening
infections (4%), bone marrow suppression, hepato-
toxicity, and a possible association with lymphoma
(Table 110-2).
SURGICAL MANAGEMENT
ULCERATIVE COLITIS
• Surgical removal of the colon should be considered
for patients with disease refractory to medical treat-
ment or for those who develop massive hemorrhage,
perforation, toxic megacolon, dysplasia, or frank ade-
nocarcinoma of the colon.
• Approximately one in four patients with UC will even-
tually require surgery.
• Surgery, if undertaken, should consist of total abdom-
inal colectomy, and is considered curative.
• In the majority of cases, patients are able to maintain
intestinal continuity with the construction of an ileal
J-pouch that is anastomosed to the anal canal. These
patients typically will have 4–6 soft bowel movements
daily with normal bowel continence.
• Approximately 50% of these patients will develop an
inflammatory condition of the ileal pouch called “pou-
chitis” that symptomatically mimics their UC and is
usually responsive to antibiotic therapy with either
ciprofloxacin or metronidazole.
• In patients who are unable to have ileal pouch anal
anastomosis, an ileostomy is created. The major compli-
cation of ileostomy formation is local skin breakdown.
CROHN DISEASE
• Surgery should be considered in patients with
intractable symptoms despite medical therapy, stric-
tures with obstruction, enterovesical or enterovaginal
fistula formation, intra-abdominal abscesses, massive
hemorrhage, or colorectal carcinoma.
• Approximately three of four patients with CD will
eventually require surgical intervention.
• Surgery is not curative for CD, and every effort should
be made to spare as much bowel as possible from
resection. Techniques such as stricturoplasty can be
employed to limit the need for resection.
• Surgical anastomoses are often sites of disease
recurrence.
• Complications of surgery include short gut syndrome
with consequent nutritional deficiency.
• Following surgical resection of diseased bowel,
patients should be placed on medication for mainte-
nance of remission.
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TABLE 110-2 Major Side Effects of Medications Used to Treat IBD
MEDICATION MAJOR SIDE EFFECT
Sulfasalazine Nausea, headache, fever, rash, male infertility, hypersensitivity reaction (in sulfa-allergic patients), pancreatitis,
agranulocytosis, pericarditis, pneumonitis
5-Aminosalicylates Fever, rash, pancreatitis, pneumonitis
Corticosteroids Lymphopenia, osteopenia, avascular necrosis, impaired wound healing, gastritis, hyperglycemia, hypertension (HTN),
accelerated atherosclerosis
AZA and 6-MP Fever/rash, pancreatitis, nausea, bone marrow suppression, hepatitis, infections
Methotrexate Nausea, abdominal pain, joint pain, myelosuppression, hepatotoxicity 
Cyclosporine Nephrotoxicity, HTN, hyperglycemia, infections, neurotoxicity
Infliximab Infusion reactions, immunosuppression, life-threatening infections, hepatotoxicity, possible lymphoproliferative disorder
111 ACUTE ABDOMEN
Nina M. Patel
KEY POINTS
• Intra-abdominal crises may present in subtle ways in
patients in the ICU.
• Early diagnosis is essential to optimize outcome.
• A low threshold for imaging the abdomen with ultra-
sonographic or CT techniques should exist.
• A patient with signs and symptoms of sepsis and who
does not have a plausible source identified outside of
the abdomen should be evaluated for the possibility of
an intra-abdominal source.
DEFINITION
• The “acute abdomen” is defined as the sudden onset
of severe abdominal pain.
CLINICAL FEATURES
• Patients in the ICU are often unable to verbally
express pain due to endotracheal intubation, sedation,
and/or compromised mental status. Consequently, the
clinical presentation of the acute abdomen in an ICU
patient is vastly different than that in an outpatient.
• Nonspecific findings, including fever, hemodynamic
instability, abdominal distention, and unexplained
sepsis may be surrogate markers of an acute abdomen.
• If clinical suspicion for an abdominal emergency is
present, prompt diagnostic evaluation should be
effected with radiologic imaging (generally abdomi-
nal computed tomography [CT] or ultrasound [US])
and/or gastroenterologic and surgical consultation.
DIFFERENTIAL DIAGNOSIS
• Traditional causes of the acute abdomen can be clas-
sified into categories based on the etiology and qual-
ity of the pain: inflammatory (e.g., appendicitis and
diverticulitis), colicky (e.g., biliary or renal), vascular
(e.g., mesenteric ischemia), urologic/gynecologic, or
related to systemic disease (e.g., sickle cell crisis).
• This chapter will focus on a number of causes of intra-
abdominal sepsis (IAS) that are specific to the ICU
setting:
 Primary peritonitis
 Secondary peritonitis
 Biliary sepsis
 Intra-abdominal abscess—intravisceral or extravisceral
 Occult IAS
PATHOPHYIOLOGY, DIAGNOSIS,
AND THERAPY
• Primary peritonitis is a spontaneous phenomenon that
occurs most frequently in patients with ascites due to
congestive heart failure, cirrhosis, or renal failure. It
can also occur consequent to more esoteric causes
(e.g., tuberculosis [TB] peritonitis).
 It is speculated that infection results from a
hematogenous source or from bacterial transloca-
tion across the intestinal wall.
 Diagnosis is based on clinical suspicion and para-
centesis. Ascites fluid reveals a neutrophil count of
>250 and/or a positive culture. Aerobic, enteric
organisms are the most commonly isolated infec-
tious agents.
 Empiric antibiotic therapy should be initiated while
awaiting culture results, with either an aminoglycoside,
a third-generation cephalosporin, or ciprofloxacin +
enterococcal coverage (e.g., ampicillin). A response
to therapy is marked by a decline in the ascitic neu-
trophil count.
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• Secondary peritonitis results from inflammation of
the peritoneal lining secondary to polymicrobial
infection and/or chemical irritation of the peritoneal
lining (e.g., bile). Visceral inflammation and/or perfo-
ration (e.g., bowel infarction and gallbladder perfora-
tion), retroperitoneal pathology (e.g., infected
pancreatic pseudocyst), and postoperative complica-
tions (e.g., wound dehiscence) are frequent causes of
secondary peritonitis.
 Patients may experience substantial fluid shifts into
the abdomen with subsequent hypovolemia.
 A plain film of the abdomen should be performed in
the initial evaluation, as a rapid means of assessing
for the presence of free air under the diaphragm.
 Rapid intervention with surgical treatment, how-
ever, is frequently the only way to diagnose and/or
correct the primary process. As such, patients often
proceed to laparoscopy prior to obtaining imaging
studies.
 Although few patients will respond to medical
therapy alone, broad-spectrum antibiotic coverage
(gram-negative, gram-positive, and anaerobic organ-
isms) is necessary as adjunctive therapy pre-, peri-,
and postoperatively to treat IAS and/or systemic
bacteremia.
 Aggressive supportive care with antibiotic therapy,
intravenous fluid (IVF) hydration and hemody-
namic support, enteral feeding (as tolerated), and
renal replacement therapy (if necessary) are essen-
tial components of the intensivist’s care.
 If fever, bandemia, or ileus fail to regress with appro-
priate surgical and medical therapy, postoperative
complications (e.g., wound dehiscence, abscess, and
enterocutaneous fistula) or the possibility of
extraperitoneal infection should be considered.
 Prior to postoperative days 5–7, repeat surgical explo-
ration is necessary if clinical symptoms and abdomi-
nal examination are not regressing. Abdominal CT
may be helpful in delineating complications after this
time point.
 Risk of wound dehiscence is greatest at postopera-
tive days 4–8.
• Biliary sepsis is a consequence of (a) acute calculous
cholecystitis, (b) ascending cholangitis, and (c) acal-
culous cholecystitis.
 Diagnosis of biliary sepsis may first be inferred by
the presence of jaundice and hyperbilirubinemia.
Appropriate initial triage includes liver function
testing (LFT) and right upper quadrant (RUQ) US.
Acute calculous cholecystitis seldom necessitates
ICU intervention.
 Acute cholangitis, characterized by fever, RUQ
pain, and jaundice, is an infection within the biliary
ductal system due to biliary obstruction and stasis.
If RUQ US does not demonstrate biliary ductal
dilatation in the appropriate clinical setting, patients
may require endoscopic retrograde cholangiopan-
creatography (ERCP) or percutaneous transhepatic
cholangiography (PTC) for diagnosis. Biliary
decompression is the definitive therapy and should
be pursued emergently with sphincterotomy, stent
placement, or T-tube placement. Patients should be
concurrently treated with broad-spectrum antibiotic
coverage (gram negatives, Enterococcus species).
 Acalculous cholecystitis is an indolent process that
occurs in 0.5–1.5% of patients who are hospitalized
in the ICU for >1 week.
 It is characterized by gallbladder wall inflammation
and infection with enteric organisms as well as
cystic duct edema and functional occlusion due to
increased viscosity of bile.
 Preventive measures are limited as the pathophys-
iology of this process is not well understood.
 The utility of most diagnostic tests is limited in acal-
culous cholecystitis. LFTs do not aid in diagnosis,
and US or CT may show a thickened gallbladder
wall, pericholecystic fluid, or intramural gas.
Hydroxy iminodiacetic acid (HIDA) scan can be
helpful by ascertaining patency of the cystic duct.
 Unrecognized acalculous cholecystitis will pro-
ceed to complete gallbladder necrosis. Therefore,
if clinical suspicion is high, patients should pro-
ceed rapidly to the operating room (OR) for chole-
cystectomy. If deemed too ill for the OR,
percutaneous drainage can be performed as a tem-
porizing measure.
• Intra-abdominal abscesses may be visceral or
extravisceral.
 Visceral abscesses (e.g., hepatic or splenic) may
result from hematogenous seeding or direct exten-
sion of an infectious process.
 Extravisceral abscesses are most often due to post-
operative complications, though they also can
develop from direct extension.
 Presentation tends to be nonspecific, with fever,
ileus, and occasionally abdominal pain or peritoneal
signs.
 Abdominal CT or US are the diagnostic tests of
choice, and US the preferred test to visualize pelvic
fluid collections.
 Therapy consists of broad-spectrum antibiotic cover-
age with percutaneous or surgical drainage/resection
of the fluid collection.
• Occult IAS
 Microabscesses, short segments of infarcted bowel,
or bacterial translocation from the gastrointestinal
(GI) tract are all postulated etiologies of IAS of
unknown cause.
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 Radiologic imaging is likely to be unhelpful in
making a diagnosis of occult IAS. Similarly, blind
laparoscopy to seek out a cause of IAS is also unlikely
to improve patient outcome.
CONCLUSIONS
• Intensivists must maintain a high level of suspicion to
diagnose an acute abdomen in the ICU.
• Diagnosis is often challenging and necessitates a low
threshold to proceed to radiologic imaging and/or
surgical consultation.
• Treatment consists of supportive medical therapy and
broad-spectrum antibiotic coverage, often in concert
with percutaneous drainage and/or surgical intervention.
• If a patient’s clinical course is not improving follow-
ing “definitive” therapy, the intensivist should pursue
evaluation of postoperative complications.
• If no intra-abdominal source of sepsis is found and
extra-abdominal sepsis has been effectively ruled out,
occult sources of IAS should be considered.
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112 COMPLICATIONS OF
SOLID ORGAN
TRANSPLANTATION
Nathan Sandbo
KEY POINTS
• The immunosuppressive regimens used for solid
organ transplantation result in a high incidence of
infectious complications in certain patient groups, and
the time from transplant is useful to consider potential
infecting organisms.
• Each transplanted organ has a characteristic pattern of
rejection, which is generally characterized as acute or
chronic, with adjustment of immunosuppression
determined in part by the time course.
GENERAL ASPECTS
• Over 25,000 solid organ transplants (kidney, liver,
heart, lung, pancreas, small intestine) were performed
in 2003, with 1 year survival at ~90% for most recip-
ients, with the exception of lung (~70%).
• Immunosuppressive agents usually fall into four main
categories, each with unique toxicities.
 Corticosteroids, which are commonly used in high
doses in the initial posttransplant period, and then
are slowly tapered. They are also commonly used in
pulse doses to treat episodes of acute rejection. The
most common side effects include insulin resistance,
impaired wound healing, and adrenal insufficiency.
 Calcineurin inhibitors, which are commonly part of
the initial immunosuppression regimen. Cyclosporine
is the founding member of this class, but tacrolimus is
a more recent agent, which is often employed to treat
acute rejection. The most common side effects of each
of these agents include nephrotoxicity, hypertension,
neurotoxicity, and tremors.
 Antiproliferative agents, such as azathioprine, and
more recently, mycophenolate mofetil (MMF).
Usually one of these agents is initially included in
the induction and maintenance of immunosuppres-
sion, with MMF often reserved for the treatment of
rejection. The most common toxicities are bone
marrow suppression and hepatotoxicity.
 Antilymphocyte antibodies, such as OKT3, antilym-
phocyte globulin (ALG), and antithymocyte anti-
body (ATG). Most often these agents are employed
only for therapy-resistant acute rejection, as their
toxicity is high. OKT3, for instance, can result in
lymphokine-mediated toxicity, anaphylaxis, pul-
monary edema, and fevers.
• Induction therapy is generally based on cyclosporine
and corticosteroids, with addition of one antiprolifer-
ative agent, most typically, azathioprine. Dosing is
generally high in the perioperative period, with subse-
quent tapering to maintenance doses after allograft
implantation.
PERIOPERATIVE CONSIDERATIONS
• Perioperative complications are similar to those found
with any large intra-abdominal or intrathoracic sur-
gery, but also includes pulmonary edema from fluid
overload, electrolyte abnormalities, engraftment syn-
drome, and hypotension secondary to hypovolemia,
and graft dysfunction due to surgical technique or pri-
mary graft failure of any transplanted organ. The risk of
primary graft failure increases with cold ischemic time.
SPECIFIC ORGAN CONSIDERATIONS
• Renal: Initial organ function is characterized by urine
output in the immediate postoperative period, and
adequate circulating intravascular volume is impera-
tive. Special attention is needed to identify and treat
hyperkalemia, acidosis, and fluid overload.
• Liver: The monitoring of organ function and detection
of abdominal hemorrhage are paramount in the post-
transplant period, as both can lead to rapid deteriora-
tion and death in the organ recipient.
• Heart: Denervated heart lacks the ability to manifest
reflex tachycardia in response to hypovolemia, thus
maintenance of euvolemia is important. Similarly,
normal neuroendocrine responses are not present in
the immediate posttransplant period, such that sys-
temic hypertension is a common finding.
• Lung: Pulmonary edema from volume expansion, or
ischemia-reperfusion injury is a common finding.
Lung protective ventilator strategies and moderation in
volume repletion are important considerations during
this time.
REJECTION
HYPERACUTE REJECTION
• Rarely seen—results from ABO incompatibility of
donor organ. Within hours of transplant, there is rapid
onset of complete dysfunction in the transplanted
organ and the presence of a systemic inflammatory
response syndrome, progressing to shock and death.
ACUTE CELLULAR REJECTION
• A T-cell-mediated phenomenon occurring between
1 week and 1 year. Often characterized by fever,
leukocytosis, or organ dysfunction and requires lab
studies of physiologic function of grafted organ and
tissue biopsy to ascertain diagnosis. Treatment usually
consists of increased immunosuppression, often with
pulsed corticosteroids, the administration of second-
line immunosuppressives (such as tacrolimus), or the
initiation of salvage immunosuppression with anti-
lymphocyte antibodies (OKT3, ALG).
CHRONIC REJECTION
• Characterized by a slowly progressive, angiocentric
fibroproliferative response that is generally resistant
to treatment with immunosuppressive agents, and is
characterized by a slow deterioration of organ func-
tion. Early posttransplant infections (especially viral)
may be a risk factor for the early development of clin-
ically significant chronic rejection.
INFECTIOUS COMPLICATIONS
THE FIRST MONTH (PERIOPERATIVE PERIOD,
ASSOCIATED WITH HIGH LEVELS OF
IMMUNOSUPPRESSION)
• Approximately 90% of infections during this period are
bacterial infections related to surgery. Common sites
include intravascular catheter-related sepsis, wound
infections, and hospital-acquired pneumonias. The
overall risk is dependent on the integrity of mucocuta-
neous barrier (presence of indwelling devices), degree
of immunosuppression, and coexistent morbidities.
• Viral infections may begin to present late in this
period. Reactivation of herpes simplex virus (HSV) is
the most common etiology, however the prophylactic
use of acyclovir may decrease its incidence.
Exacerbation of chronic hepatitis B or C (in liver trans-
plant patients) may also present during this period.
• Fungal infections usually do not present during this
early period, with the exception of candidal infections
related to hospitalization (indwelling catheters). In
addition, pulmonary aspergillosis may occasionally
present during this early period.
1–6 MONTHS (EMERGENCE OF
OPPORTUNISTIC INFECTIONS)
• This period is characterized by the onset of the “classic”
post-transplant-related viral infections.
 Cytomegalovirus (CMV) is the most common viral
illness encountered during this period.
 Occurs either by reactivation or through de novo
acquisition from the graft, with de novo infections
tending to be most severe. Antilymphocyte globu-
lin (ALG) treatment increases the risk and sever-
ity of infection.
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 Symptoms classically include a mononucleosis-
like syndrome of fever, malaise, and leukopenia, as
well as concurrent end-organ involvement (pneu-
monitis, hepatitis, chorioretinitis, gastroenteritis).
 Active CMV infection is thought to result in fur-
ther systemic immunosuppression, and often her-
alds subsequent infectious complications later in
the posttransplant period.
 CMV infection also is associated with an increased
risk for the development of Epstein-Barr virus
(EBV)-related posttransplant lymphoproliferative
disorder (PTLD) and chronic rejection.
 Other viral illness include EBV (usually only seen
in seronegative recipients receiving a seropositive
graft), varicella-zoster virus (VZV) reactivation
(shingles), respiratory syncytial virus (RSV, associ-
ated with risk of chronic rejection, bronchiolitis
obliterans syndrome [BOS], in lung transplant
recipients), adenovirus, and influenza.
• Opportunistic bacterial infections
 Nocardia, most often presenting as pulmonary infil-
trates. However, this is less common in the era of
pneumocystis pneumonia (PCP) prophylaxis with
trimethoprim/sulfamethoxazole.
 Listeria—frequent cause of central nervous system
(CNS) infection.
 Mycobacterial disease
 Tuberculosis (TB) usually is due to reactivation
rather than primary infection. Presenting symp-
toms typically include fever, with other constitu-
tional symptoms. Half of patients have lung
involvement alone, one-third dissemination with
lung involvement, and one-sixth extrapulmonary
TB alone. Mortality is 25–40%, even in modern
treatment era.
 Nontuberculous infection is also a cause of pul-
monary infiltrates in the posttransplant period (espe-
cially in lung transplant). Mycobacterium-avium
complex accounts for the majority of infections.
• Opportunistic fungal infections
 Aspergillus
 Incidence is as high as 5% in heart, lung, and liver
transplants, but lower in kidney. Usually presents
as invasive disease in the lung, with fever, cough,
chest pain, and hemoptysis.
 Radiographically presents with one or more nodu-
lar opacities, which often cavitate.
 Diagnosis can be difficult to obtain, empiric therapy
with either liposomal amphotericin B or voricona-
zole is the current standard of care.
 Cryptococcus—also a frequent cause of meningitis
and brain abscess
 PCP
 Incidence is now decreasing due to effective prophy-
lactic therapy with trimethoprim/sulfamethoxazole.
 Endemic fungi should be considered in any trans-
plant patient who has lived in an appropriate geo-
graphic area:
 Histoplasmosis (Ohio and Mississippi river val-
leys), coccidioidomycosis (Southwestern United
States), and blastomycosis (Midwest).
 Disease most often is due to reactivation and is
more likely to present with dissemination in solid
organ transplant patients.
• Opportunistic parasitic infections
 Toxoplasma accounts for the majority of parasitic
infections, with CNS infection (abscess, meningitis)
the most common site.
>6 MONTHS POSTTRANSPLANT
(MAINTENANCE IMMUNOSUPPRESSION)
• This period is characterized by tapering to mainte-
nance immunosuppression, and, consequently, a shift
in the epidemiology of infections to community-
acquired pathogens.
• Indolent viral infections can become apparent, such as
BK virus in renal transplants and reactivation of vari-
cella virus (herpes zoster).
• Chronic rejection may become apparent, especially in
patients with previous viral infections or acute
rejection.
• Vascular insufficiency due to stenosis of anastomoses
can lead to progressive deterioration of organ function.
POSTTRANSPLANT
LYMPHOPROLIFERATIVE DISORDER
• Comprises several EBV-driven disorders including
uncomplicated EBV posttransplant infection (mononu-
cleosis), to true malignancy with clonal chromosomal
abnormalities. Historically, mortality ranges between
50 and 80% in patients with the monoclonal-derived
malignancy.
• Risk factors include EBV infection in the early post-
transplant period, CMV disease, type and intensity of
immunosuppression, and type of solid organ trans-
plant (lung, heart; due to degree of immunosuppres-
sion). Importantly, EBV seronegative recipients have
a 10–76% greater likelihood of developing PTLD
early in the transplant period.
• Diagnosis is based on histologic criteria, with a gold
standard of pathologic examination of either surgical
or needle biopsies.
• Therapy consists of reduction of immunosuppressive
therapy, consideration of local resection for isolated
lesions, consideration for use of anti-CD20 antibodies
(rituximab), and consideration of antiviral agents or
interferon-α for selected patients.
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113 CARE OF THE
MULTISYSTEM TRAUMA
PATIENT
William Schweickert
KEY POINTS
• Mortality from trauma has a trimodal distribution—a
first peak (seconds to minutes after the traumatic
event) produced by essentially lethal injuries; a second
peak (minute to hours after the traumatic event) pro-
duced by injuries of potentially lethal nature (usually
neurologic injury and hemorrhage); and a third peak
(days or weeks) due to sepsis and multiple system
organ failure. The intensivist can help to intervene in
the latter instances, especially the third peak, utilizing
medical knowledge, resources, persistence, and atten-
tion to detail to reduce the impact.
• On admission to the ICU, patients usually have been
previously evaluated (emergency physician, trauma/
general surgeon); however, patients remain at risk for
deterioration due to unrecognized injuries, iatrogenic
complications of initial diagnostic studies and therapy,
and general complications of critical care.
STEP 1: REASSESSMENT OF THE
PRIMARY SURVEY
AIRWAY (A)
• If the patient is intubated, the patency and position of
the endotracheal tube should be assessed, especially
given risk of dislodgement during transport.
• If the patient is spontaneously breathing, verify that
the oral cavity is clear without evidence of airway
obstruction from the loss of tone of the musculature
supporting the tongue or foreign material.
• In the multisystem trauma patient, particularly with
blunt injuries above the clavicle, a cervical spine
injury should be assumed and immobilization must be
maintained until proven otherwise.
BREATHING (B)
• Inspect patient for asymmetric/paradoxical chest wall
movement and/or tracheal deviation.
• Auscultate and percuss the chest for hyperresonance
or dullness suggesting pneumo- or hemothorax.
• Hypoxemia should be rapidly addressed with either
supplemental FiO2 via face mask or in concert with
positive end-expiratory pressure (PEEP) via a ventila-
tor to ensure an oxygen saturation goal of >95%.
CIRCULATION (C) AND HEMORRHAGE
CONTROL
• Verify adequate resuscitation, seeking weak pulses, cool/
clammy skin, and delayed capillary refill to indicate fur-
ther needs. Tachycardia with cool extremities suggests
hypoperfusion until proven otherwise. This is usually as
a result of hemorrhage, although other causes of hypo-
perfusion (tension pneumothorax, cardiac tamponade,
myocardial contusion, open pneumothorax, flail chest,
and limb vascular injury) must be considered.
• Intravascular access should be reviewed. Such trau-
mas require at least two large-bore (14- to 16-gauge)
intravenous catheters; central venous catheters should
be directed to large bore, number 8 French introducers
(over a multilumen catheter) for the ability to achieve
high flow rates. All catheters should have confirmed
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patency and appropriate placement. Replace any
unsterile lines once stabilized.
• Review the total volume of intravenous (IV) fluids
administered since presentation. If normalization of
blood pressure is not accomplished after ~50 mL/kg
of crystalloid, blood should be administered (un-
crossmatched group O if necessary). All blood products
and IV fluids must be prewarmed when administered in
massive quantities or at rapid infusion rates to prevent
or correct hypothermia.
NEUROLOGIC DISABILITY (D)
• A full neurologic evaluation, including level of con-
sciousness, mentation, and pupillary size and reaction
must be performed on arrival and compared to previ-
ous examination results.
• Any significant deterioration mandates a more
detailed examination, including oxygenation, ventila-
tion, and perfusion, and investigation of intracranial
pathology with immediate brain computed tomogra-
phy (CT) scan without contrast.
EXPOSURE (E)
• The patient MUST be completely (RE)exposed to
evaluate external injuries.
STEP 2: REVIEW THE TRAUMA
EVENT’S HISTORY AND MEDICAL
HISTORY CLOSELY
• Trauma details: mechanism of injury, event, and envi-
ronment related to the accident, details of the prehos-
pital course. Think about the possible intentional drug
overdose prior to injury.
• Medical history (often obtained from family/friends):
medications, allergies, and especially any history of
drug or alcohol use. Ongoing drug or alcohol depend-
ence is present in over 30% of patients admitted for
complications of trauma. These patients have higher
risks of complications, including withdrawal.
STEP 3: EXCLUDE UNDIAGNOSED
INJURIES
• The incidence of missed injuries despite complete pri-
mary and secondary surveys has been estimated to be
as high as 10% in patients with blunt injury. Reasons
for injuries to be missed: altered mental status due to
head injury or alcohol intoxication, severe multiple
injuries, instability requiring immediate operation, lack
of symptoms on admission, and low index of suspicion.
• Potentially life-threatening injuries that may have
been missed include head injury (especially intracra-
nial hemorrhage), aortic injury, intra-abdominal
injury, and rhabdomyolysis. These require careful ini-
tial radiographic interpretations and serial neurologic
examinations. Intra-abdominal injury should be con-
sidered in all patients with blunt or penetrating trauma
and evidence of ongoing unexplained blood loss.
Rhabdomyolysis is evidenced by the clinical history,
elevated creatine kinase, and should be managed with
fluids, maintenance of high urine output, and consid-
eration for intravenous bicarbonate-containing fluids.
STEP 4: AVOIDANCE OF IATROGENIC
AND GENERAL COMPLICATIONS OF
CRITICAL ILLNESS
• Transfusion-related complications. Avoid hypothermia
by warming blood, dilutional coagulopathy by follow-
ing coagulation studies and replacing platelets and/or
fresh frozen plasma, monitor and treat hypocalcemia.
Recognize that massive transfusion may lead to acute
lung injury independently.
• Venous thromboembolic disease (due to prolonged
immobilization, pelvic and lower extremity injuries, and
direct vascular injuries). Utilize antiembolism stock-
ings, sequential compression devices. Anticoagulation
or inferior vena cava filter placement may be necessary
in high-risk situations.
• Stress ulcers. Recommend prophylaxis via acid inhibi-
tion (either antihistamine or proton pump inhibitors).
• Contrast nephropathy. Maintenance of renal perfusion,
euvolemia, and urinary flow are necessary. Adjunctive
N-acetylcysteine or intravenous sodium bicarbonate
has been shown to improve outcomes in selected
populations.
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114 SPINE INJURIES
D. Kyle Hogarth
KEY POINTS
• In any trauma setting, spinal injury should always be
assumed to be present until appropriate assessment has
ruled it out.
• All spinal injuries must be considered unstable until
they are thoroughly evaluated.
• Spinal cord injury can be minimized by limiting the
secondary ischemic phase and maintaining appropri-
ate spinal immobilization.
• Complete spinal cord injuries have no potential for
functional recovery.
• Incomplete injuries have recovery potential, which
must be maximized.
• Rehabilitation must be initiated at the beginning of the
hospitalization.
GENERAL THOUGHTS
• Life-threatening injuries from trauma requiring ICU
admission can potentially delay the diagnosis and
management of spinal injury as the team focuses on
the immediate obvious injuries.
• It is estimated that approximately 20% of patients sus-
taining multiple injuries have associated spinal column
injury.
• The possibility of cervical spine injury must be con-
sidered in anyone who has suffered significant
injuries to the face or head, especially those uncon-
scious from trauma.
• Furthermore, patients with preexisting conditions that
put them at risk for spinal injury, such as ankylosing
spondylitis, may suffer serious neck injury from appar-
ently “minor” traumatic events.
NEUROLOGIC INJURY
• Physical disruption of the spinal cord results in com-
plete, irreversible loss of function.
• The effect and extent of injury is directly related to the
magnitude of the force applied and the length of time
it was applied.
• The management goal for a spine injury is to prevent
further force being applied to the injured area. This is
accomplished via immobilization and then relief of
the compression on the spine from displaced bony
fragments and discs.
SPINAL CORD SYNDROMES
ANTERIOR CORD SYNDROME
• Complete motor loss below the level of injury.
• Loss of light touch sensation below the level of injury.
• Preservation of position, vibration, and deep touch
sensation.
CENTRAL CORD SYNDROME
• Motor loss in the extremities: the upper extremities
experience greater loss than the lower extremities.
• Sensation is variably altered.
• Caused by central hemorrhage in the cord.
BROWN-SÉQUARD SYNDROME
• Motor is lost on the ipsilateral side of injury.
• Pain and temperature are lost on the contralateral side,
one or two segments below the level of the injury.
CAUDA EQUINA SYNDROME
• The degree of neurologic loss with this syndrome
varies greatly, depending on the extent of nerve root
damage.
• The motor and sensory loss is symmetrical.
• May have loss of bladder and bowel control.
SPINAL SHOCK
• There can be a physiologic block to conduction from any
force applied to the spine. This is clinically manifested as
complete cessation of all neurologic function—motor,
sensory, and autonomic—below the level of the injury.
• Spinal shock and complete block to conduction can
last from minutes to weeks.
INITIAL CLINICAL ASSESSMENT
• A history of the mechanism of injury is helpful in pre-
dicting the type of neurologic injury.
• Any evidence of head or facial trauma (i.e., bruises, lac-
erations, or abrasions) can suggest the direction from
which the force was applied and can help predict injury.
• Evaluate for asymmetry of the head position and ten-
derness along the sternomastoids.
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• Examine the chest for the presence of a paradoxical
pattern of respiration.
• A detailed neurologic examination should be per-
formed and recorded on a flow sheet to allow for serial
examination.
• The patient who is stabilized in a cervical collar and is
manually secured in traction may be slowly log-rolled
to allow examination of the back for the following:
tenderness, malalignment of the spinous processes, a
boggy gap in the supraspinous ligament, sensation in
the perianal area, rectal examination, and testing of
the bulbocavernosus reflex.
RADIOLOGY
• The initial films that should be done are lateral cervi-
cal spine films and an anteroposterior view of the
chest and pelvis.
• Other x-ray views, such as oblique and swimmer’s
may help visualize the spine.
• Computed tomography (CT) allows for routine, coro-
nal, sagittal, and three-dimensional reconstructions of
the spine. CT requires only a single transfer of the
patient: this is done with a spine board.
• Myelography should only be done in three different
clinical scenarios:
 The extent of the injury cannot be explained by the
plain films or CT.
 Increasing neurologic loss without severe encroach-
ment on the neural canal.
 When demonstration of defects or avulsed nerve
roots needs to occur.
• Magnetic resonance imaging (MRI) can be used to
assess soft tissue and ligamentous injury in the spine,
but surprisingly the results have not shown much
advantage compared to conventional films and CT.
• MRI has a very high negative predictive value for sig-
nificant soft-tissue injury.
IMMEDIATE GENERAL
MANAGEMENT
• Patients with spinal injuries should be taken directly
to a level 1 tertiary care center.
• The advanced cardiac life support (ACLS) require-
ments for management of airway, breathing, and cir-
culation do not change even in the presence of a spinal
injury.
• Spinal immobilization should continue until the
patient has either been cleared or appropriate manage-
ment of the injury has occurred.
• The arterial PaO2 should be at least 100 mmHg.
Supplemental oxygen should be delivered to ensure this.
• The blood pressure should be at least 100 mmHg
systolic.
MANAGEMENT OF NEUROGENIC
SHOCK
• Patients with neurogenic shock will be hypotensive
and bradycardic secondary to increased vagal tone
and peripheral vasodilation. This is treated with crys-
talloid infusion.
• Placement of a central line for monitoring of the cen-
tral venous pressure should occur.
• Small doses of vasopressors can be used.
OTHER MANAGEMENT ISSUES
• Respiratory complications after cervical spinal cord
injury occur in 60% of patients.
• Loss of phrenic nerve function occurs in spinal lesions
above C5.
• Acute spinal cord injury may be associated with pul-
monary edema.
• Almost all spine injury patients develop a transient
ileus.
• 50% of patients with spinal cord injuries develop deep
vein thrombosis and prophylaxis with low-dose heparin
appears ineffective. Calf compression and low-molecular
weight heparin seem to be more effective.
• Care should be taken to avoid decubitus ulceration of
the skin.
• Spinal injury patients become catabolic. As soon as
the ileus resolves, eating should resume.
SURGICAL MANAGEMENT
• Indications for surgical decompression of spinal cord
are:
 Progressive neurologic loss
 Failure or anticipated failure of nonoperative decom-
pression (owing to retained bone or disc fragments)
 Incomplete cord and/or cauda equina lesions with
residual compression
• Contraindications for surgical decompression as it
will not benefit or may even harm:
 A complete spinal cord lesion in a patient out of
spinal shock
 Progressive neurologic loss due to ischemia, with no
blockage or significant residual compression as seen
on myelography
STEROIDS
• Glucocorticoids (e.g., dexamethasone) are presumed
to help in spine injury by decreasing modulating cate-
cholamines, stabilization of cell membranes, and pre-
vention of immune cell release of lysosomal enzymes
and prevention of complement activation.
• Controversy exists regarding the effectiveness of
steroids.
COMPLICATIONS OF SPINAL
CORD INJURY
• Hypothermia secondary to lack of vasoconstriction
due to loss of thoracic sympathetic outflow as well as
being unable to shiver to maintain core temperature
can lead to hypotension and bradycardia.
• Autonomic dysreflexia can occur in patients with
injuries above T6 at any time after the stage of spinal
shock. Symptoms include hyperhidrosis, headache,
and vasodilation above the level of the neurologic loss
with nasal stuffiness. The cardinal sign of autonomic
dysreflexia is paroxysmal hypertension. Typical pre-
cipitating events are distention or manipulation of the
bladder or rectum or intra-abdominal pathology.
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115 TORSO TRAUMA
Kaveeta P. Vasisht
KEY POINTS
• Torso trauma can occur due to blunt or penetrating
trauma.
• The critical care physician needs to be prepared for
any injury to a thoracic or abdominal organ when
treating a patient who has trauma to the torso.
• Careful history and examination of a torso trauma patient
can allow quick identification of a life-threatening injury.
OVERVIEW
• Generally, torso trauma is classified as blunt versus pen-
etrating. Clinically, it is useful to differentiate injuries
that are immediately life threatening versus injuries in a
hemodynamically stable person. This chapter will focus
on the potentially life-threatening injuries where lifesav-
ing skills are within the realm of practicing intensivists.
TENSION PNEUMOTHORAX
• Pathophysiology: Injury to the lung results in gas
accumulation in the pleural space which is normally
apposed by the parietal and visceral pleura. A one-
way valve mechanism is created by which air enters
the pleural space with each respiratory cycle but
cannot escape. Eventually, the intrathoracic pressure
becomes increased such that the ipsilateral lung is
compressed and displaced to the opposite side. This
rise in intrathoracic pressure will cause impedance of
venous return. In addition, mediastinal shifting
occurs, which may cause occlusion of the major ves-
sels resulting in worsening venous return.
• Diagnosis: The diagnosis is made clinically. Patients
may present with severe dyspnea, tachypnea, hyper-
resonance, and absent or decreased breath sounds on
the affected side. The trachea may be shifted away
from the side of the tension pneumothorax.
• Treatment: Immediate needle decompression with a
large-bore needle in the second intercostal space, mid-
clavicular line. This action is then followed by tube
thoracostomy placement.
OPEN PNEUMOTHORAX
• Pathophysiology: Free communication between the
pleural space and the atmosphere through a chest wall
wound. This results in collapse of the ipsilateral lung.
• Diagnosis: Generally, there is a visible wound and
audible noise from atmospheric air entry into the
pleural space.
• Treatment: Occlusion of the open wound, which can usu-
ally be accomplished by occlusive gauze dressings. This
should be followed by tube thoracostomy placement.
MASSIVE PNEUMOTHORAX
• Pathophysiology: Persistent pneumothorax despite an
adequately functioning chest tube with respiratory
instability is a sign of a large pulmonary defect. The
air is leaving the pulmonary system faster than the
chest tube can remove it from the thorax.
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• Diagnosis: This is a clinical assessment. A massive
pneumothorax suggests a large airway laceration.
• Treatment: 100% oxygen and immediate surgical
intervention.
MASSIVE HEMOTHORAX
• Pathophysiology: Blunt or penetrating trauma results
in injury to a major central vascular structure or lacer-
ation of a systemic artery.
• Diagnosis: Severe hypotension from blood loss followed
by hypoxemia from lung collapse secondary to mass
effect of blood in the thoracic cavity. Dullness to percus-
sion on affected side. Diagnosis is confirmed if after
chest tube placement a large volume of blood is drained.
• Treatment: Volume resuscitation, chest tube placement.
If blood continues to drain at 100 cc/h the patient needs
surgical intervention.
FLAIL CHEST
• Pathophysiology: Chest trauma results in rib fractures,
which result in a segment of the chest wall moving
paradoxically. During inspiration the flail segment
moves inward with negative pleural pressure and out-
ward with expiration.
• Diagnosis: The diagnosis is often difficult to make clin-
ically. On chest x-ray (CXR), the presence of multiple
adjacent rib fractures involving the same rib in different
segments of the CXR would suggest flail chest.
• Treatment: A hemodynamically unstable patient
requires positive pressure ventilation (PPV) and chest
tube placement on the involved side to prevent tension
pneumothorax on institution of PPV. Liberation from
mechanical ventilation can occur once the gas
exchange abnormality is corrected. However, if there
is no hemodynamic compromise, not all flail chest
patients need to be mechanically ventilated.
CARDIAC TAMPONADE
• Pathophysiology: Blood accumulation in the pericar-
dial sac secondary to trauma resulting in impaired
cardiac filling and reduced stroke volume and cardiac
output.
• Diagnosis: Requires a high index of clinical suspicion
in anyone who has had blunt or penetrating trauma to
the chest and is hypotensive without obvious signs of
blood loss.
 Beck triad includes hypotension, decreased heart
sounds, and jugular venous distention. However, this
is not always present.
 Pulsus paradoxus (the difference between systolic
blood pressure during inspiration and expiration)
above 10 mmHg may also be evident.
 One should note that distended neck veins and
hypotension are present in both tension pneumotho-
rax and cardiac tamponade. If there is a doubt to the
diagnosis always treat tension pneumothorax first.
• Treatment: If available in the emergency setting ultra-
sound probe placement is helpful in the diagnosis of
hemopericardium. The initial treatment involves IV
fluid administration and prompt pericardiocentesis.
TRAUMATIC AIR EMBOLISM
• Pathophysiology: Systemic air embolism occurs when
a direct communication exists between the air pas-
sages and the blood vessels. In chest trauma, scattered
loss of integrity of the pulmonary blood vessels, air
passages, and alveoli creates such a pathway.
• Diagnosis: High index of clinical suspicion in anyone
that suffers sudden cardiovascular collapse after chest
trauma who demonstrates a neurologic deficit, espe-
cially after PPV. May see bubbles in arterial puncture
(need to make sure the syringe connector is not loose
and giving bubbles via this mechanism).
• Treatment: Left lateral decubitus positioning of the
patient. Maintenance of high systemic pressures (with
alpha agonists if needed) may limit gradient for air
entry at some vascular sites.
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116 PELVIC AND EXTREMITY
TRAUMA
Shashi Kiran Bellam
KEY POINTS
• Pelvic and extremity trauma require a careful evalua-
tion for neurologic and vascular injury.
• Serial examination of the traumatic area, and areas
distal to the injury, should be performed after initial
stabilization with careful attention to the neurovascu-
lar examination.
• Early consultation with surgical colleagues should be
sought for trauma patients.
• Long-bone injuries can lead to local complications,
such as compartment syndrome, bleeding, and neuro-
logic injury.
• Long-bone injuries can also lead to distant complica-
tions, such as fat embolism.
EXTREMITY INJURIES
COMPARTMENT SYNDROME
• Compartment syndrome is defined as an elevation of
the interstitial pressure in a closed osseofascial com-
partment, resulting in microvascular compromise, and
occurs after prolonged external pressure, direct
trauma, and vascular injury, commonly in the forearm
or leg, less commonly in the hand, foot, or thigh.
• Physiologically, compartment syndrome involves the
accumulation of fluid in a nondistensible compart-
ment leading to increased absolute compartment pres-
sure, decreased venous blood exit, decreased capillary
flow, tissue hypoperfusion, and eventually, anaerobic
metabolism. Muscle and nerve necrosis may occur
while distal pulses are still maintained.
• Clinical signs and symptoms in a conscious patient
include: pain disproportionate to the known cause of
pain; swelling and tenderness over the involved com-
partment; hypesthesia in the cutaneous nervous distri-
bution for nerves within the compartment; and severe
weakness of involved muscles. In an unconscious
patient, a greater degree of physician awareness for a
possible compartment syndrome is required.
• Measurement of the intracompartmental pressures can
be helpful. The pressure should be below 30 mmHg,
but the degree of injury is related to both the absolute
pressure and the duration of increased pressure.
Compartment syndrome may occur at lower intra-
compartmental pressures in the face of hypotension
due to decreased tissue perfusion pressures.
• Nonoperative management of compartment syndrome
is only appropriate in the earliest stages and consists
of removal of all external sources of pressure, elevat-
ing the limb to the level of the heart to maintain per-
fusion but limit edemagenesis. If nonoperative
management is successful, there should be complete
resolution of signs and symptoms within 1 hour.
• Surgical management involves an open release of the
entire compartment involved, stabilization of underlying
fractures, fasciotomy incisions packed to allow second-
ary suturing, or skin grafting within 4–7 days. Immediate
skin grafting of the incision site is also acceptable.
• Secondary complications of compartment syndrome
include myoglobinuria and acute renal failure, infection
of the fasciotomy wound, loss of range of motion of
affected joints, and muscular weakness and contracture.
PERIPHERAL NERVE INJURY
• A detailed neurologic examination with attention to
extremities with known injury should be done by
identifying the nerve to be tested, examining sensa-
tion in the distribution of cutaneous innervation of that
nerve, and examining motor activity in a muscle that
is most distal, least cross-innervated, and not inhibited
by pain.
• Once peripheral nerve injury is documented, expected
recovery is 1 mm/day after a 1-month delay at the site
of injury, followed by monitoring Tinel sign (pain or
paresthesia in the distribution of the nerve elicited by
tapping over the course of the nerve distal to the
injury). If serial examination shows that Tinel sign is
progressing distally, nerve regeneration is occurring. If
serial examination does not show that Tinel sign is pro-
gressing distally, then structural disruption of the nerve
is likely present and nerve repair should be considered.
VASCULAR INJURIES
BLUNT
• If an open vascular injury due to penetrating or blunt
trauma occurs, operative repair is essential and post-
operative management for shock or reperfusion injury
in the ICU may be required.
• Multiple trauma patients may be initially evaluated in
the ICU for assessment and management.
• Arterial occlusion with hypotension will lead to ischemic
injury to muscles and nerves in the affected region.
Muscle cell death occurs after 6 hours of ischemia.
Revascularization must be accomplished within this time
frame to preserve the function of the limb.
• Traction injuries to the shoulder girdle may be associ-
ated with brachial plexus palsy and innominate, sub-
clavian, or axillary artery injury.
• Injuries above the knee may be associated with
popliteal artery occlusion.
• Clinical signs of extremity ischemia should be sus-
pected in the traumatized extremity and are summa-
rized by the 5 P’s: pain, pallor, paresthesias, paralysis,
and pulselessness. Pulselessness with hemodynamic
stability should be presumed to be due to arterial
occlusion and an arteriogram should be performed.
Angiographic documentation of patent circulation
allows continued management by observation alone.
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• Compromised arterial circulation should be repaired
operatively. Supportive therapies include protection
from additional trauma, occlusive dressings on
wounds, and stabilization of fractures. Concomitant
venous repair is usually performed. In the absence of
multiple injuries, systemic heparinization should be
instituted preoperatively if the limb is ischemic.
Concomitant fasciotomy should be performed if
ischemia has lasted more than 6 hours or if there is
evidence of compartment syndrome before or after
revascularization.
PENETRATING
• Penetrating vascular injuries may or may not present
with the 5 P’s (see above). Some arterial injuries do
not cause ischemia. Venous injuries do not cause
ischemia. Evidence of massive blood loss is sufficient
to warrant either exploration or angiography. Arterial
injuries may present with a pulsating or expanding
hematoma. Antibiotic and tetanus prophylaxis should
be given perioperatively.
FRACTURES
• Fractures and joint injuries may pose a life-threatening
problem via sepsis, hemorrhage, or fat embolism.
• Definitive management of fractures involves reduc-
tion, maintenance, and rehabilitation.
• Immediate operative management of fractures in multi-
system trauma can reduce the incidence of many com-
plications that can occur with more conservative
management (fat embolism, pulmonary failure, sepsis).
• Early nutrition is also likely to improve outcomes.
• Compound fractures are frequently complicated by
infection and patients should receive prophylactic
antibiotics to cover common skin pathogens as well as
any specific pathogens related to the injury (e.g.,
Clostridium in farmyard injuries).
• Early cleaning and debridement of compound frac-
tures is a surgical emergency and failure to perform it
within 8 hours will turn a contaminated wound into an
infected one.
PELVIC FRACTURES
• The mortality rate from major pelvic injury is approx-
imately 10%.
• Pelvic instability is implied when there is obvious
pelvic displacement, a compound wound, injury to neu-
rovascular structures, or marked tenderness or bruising
posteriorly.
• Palpation and manipulation of the pelvis may also
demonstrate instability.
• Bleeding at the urethral meatus indicates a urethral
tear.
• Standard radiologic assessment includes a routine
anteroposterior view; an inlet view may show posterior
displacement; an outlet view shows superior migration
or rotation. Computed tomography (CT) may be the
most helpful study.
• Initial management includes massive fluid replace-
ment, type and screen for packed red blood cell (RBC)
transfusion, and stabilization of the fracture via appli-
cation of an external frame or clamp.
• Bleeding or hemodynamic instability may warrant
angiography. Diagnostic peritoneal lavage is frequently
positive due to transperitoneal leakage of a pelvic
hematoma.
• Definitive stabilization may be delayed up to 1 week
after the injury to allow for the patient’s generalized
condition to be stabilized.
• Major complications include: massive hemorrhage,
visceral and soft-tissue injuries, and deep venous
thrombosis.
FAT EMBOLISM
• Criteria for the diagnosis of fat embolism syndrome
(FES) include respiratory insufficiency, cerebral
involvement, and a petechial rash. Minor features
include fever, tachycardia, anemia, thrombocytopenia,
and lipiduria.
• FES usually occurs 48–72 hours following injury and
initially can present with disorientation, lethargy, or
irritability. Petechiae are present in 60% of cases, usu-
ally in the upper trunk, axillary folds, conjunctiva, or
fundi.
• There is usually a fall in hemoglobin of 3–4 g/dL.
There is usually thrombocytopenia and increased fibrin
degradation products, but rarely clinical bleeding.
• Chest x-ray (CXR) may show a diffuse infiltrate.
• Management is primarily preventive (early fracture
stabilization and splinting) and supportive (mechani-
cal ventilation as needed).
• There is no proven role for corticosteroids.
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117 ELECTRICAL TRAUMA
Steven Q. Davis, Chris E. Keh
KEY POINTS
• The extent of electrical injury is dependent on duration,
voltage, resistance, type of current, and distribution.
• Initial examination may be normal, but this does not
rule out serious complications as delayed and subtle
injuries can occur.
• The extent of injuries can include most organ systems,
including cardiac, neurologic, and musculoskeletal
injuries.
PHYSICS OF ELECTRICAL INJURY
• Ohm’s law (I = V/R) describes the relationship of cur-
rent (I), voltage (V), and resistance (R).
• The duration of contact with the power source, the
type of current, the voltage/resistance, and the distri-
bution of current throughout the body determine the
extent of injury. Prediction of the amount of heat pro-
duced from current flow can be calculated from
Joule’s law, energy = (V2 × time)/R.
• Alternating current (ac) is found in household current
and is defined by a current that changes the direction of
electron flow in a cyclical manner. Direct current (dc),
in which the direction of electron flow is constant, is
found in batteries, electronics, and lightning.
• Current density is usually greatest at the contact
points with the power source.
• Nerve and blood vessels have the least electrical resist-
ance (good conductor of electricity), while bone has
the highest resistance (poor conductor of electricity).
Muscle has resistance that is intermediate between
the two.
CLASSIFICATION OF INJURY
• Low-voltage injuries: Most often domestic electricity,
in which there is often an entry and exit point.
Cutaneous burns are often minor or absent, although
ac has the potential to interfere with cardiac cycle
leading to ventricular fibrillation.
• High-voltage injuries: Found in power lines and light-
ning. Minimal contact results in severe cutaneous burns.
 True high tension: Occurs at voltage ≥1000 V. This
type of injury is associated with massive tissue
damage and aggressive monitoring and resuscitation
is often needed.
 Flash (arc): Occurs when an arc of current strikes
or affects the skin, but does not pass through the
body.
 Lightning: The arc temperature of a lightning strike
is approximately 3000°C. A direct lightning strike is
most often fatal. Survivors of lightning strike were
most likely in the vicinity of a surface strike and
experience surface burns and arc effects.
CELLULAR RESPONSE TO
ELECTRICAL TRAUMA
• Tissue destruction occurs both by thermal injury and
nonthermal electroporation (production of holes in
cell membranes).
• If the victim is holding the power source, muscles will
initially have involuntary spasms, then tetanic con-
traction. This leads to the “no-let-go” phenomenon,
when the victim is unable to let go of the power
source when held in the hand because of strong con-
tractions of the hand and forearm flexor muscles.
• If the victim is close to but not touching the power
source, muscle contractions generally push the victim
away from the source. High-voltage contacts will also
tend to throw the victim from the source, due to a
single strong muscle contraction.
CLINICAL PRESENTATION
• Cardiac: Ventricular arrhythmias account for a signif-
icant portion of the initial morbidity and mortality
from electrical injury.
 Low-voltage ac often produces ventricular fibrilla-
tion, while high-voltage ac and dc can produce asys-
tole and other cardiac arrhythmias.
 Approximately half of victims have electrocardio-
graphic (ECG) or rhythm disturbances. Most com-
monly these are nonspecific ST-T-wave changes and
sinus tachycardia, both of which usually resolve
over time.
 Because of the extensive muscular damage in an
electrical injury, determination of cardiac damage
by biochemical markers can be difficult. Because
ECG changes usually revert to normal, these are
also unreliable for the diagnosis of ischemia.
 Generally, as typical victims tend to normally be
active and healthy, preexisting cardiac disease is
usually not present and treatment (including sur-
gery) may proceed. Any history of cardiac disease
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should raise concern for myocardial damage during
the electrical injury and may warrant more dedi-
cated investigation.
• Renal: Roughly 10% of victims will develop renal dys-
function, which is most commonly due to hypo-
volemia secondary to extravascular extravasation of
fluid. Creatine phosphokinase (CPK) isoenzymes and
urine myoglobin should be measured frequently. If
myoglobin fails to clear or enzymes continue to rise,
an occult focus of muscle injury should be sought.
• Musculoskeletal: Soft-tissue injuries should always be
assumed to be worse than is superficially apparent.
Compartment syndromes are common and lead to sig-
nificant morbidity if not addressed rapidly. Pain with
passive movement is an early finding of compartment
syndrome. A fluid pressure >30 mmHg in a compart-
ment indicates the need for fasciotomy. All nonviable
tissue should be debrided.
• Skin: Injury can range from first-, second-, or third-
degree burns. The amount of cutaneous injury can
severely underestimate the amount of internal injury.
Lightning injury can present with characteristic cuta-
neous markings.
• Neurologic: Effects may be transient or permanent,
immediate or delayed.
 Up to 65% of patients lose consciousness secondary
to neuronal depolarization in the brain.
 Ischemic brain damage can occur if respiratory
movement is compromised.
 Acute deficits of the spinal cord tend to resolve rel-
atively quickly; delayed onset spinal cord injuries
are much less likely to resolve.
 Median nerve damage is the most common mani-
festation of peripheral nerve injuries. Immediate
decompression of the compartments of the arm may
prevent significant functional decline and permanent
injury.
 Long-term sequelae include headache, dizziness, ver-
tigo, seizure activity, mood or personality changes,
and impotence. Cognitive decline has also been doc-
umented. Sensorimotor neuropathies, paresthesias,
dysesthesias, reflex sympathetic dystrophy, and cold
intolerance may manifest long after the injury is sus-
tained and may last several years or remain perma-
nent. Paraplegia and quadriplegia have occurred
years after the injury.
• Pulmonary: Pulmonary dysfunction is usually related
to central nervous system (CNS) damage or injury to
the chest wall. If the current path traverses the upper
airway, particular attention should be paid to the poten-
tial for life-threatening airway edema. Furthermore,
inhalation injuries from chemical toxins (ozone) or
carbon monoxide can occur in arc injuries, explosions,
or fires.
MANAGEMENT
• As with any major trauma, attention must first be paid
to the airway, breathing, and circulation (ABCs).
Advanced trauma life support (ATLS) guidelines
should also be followed, with special attention to cer-
vical spine immobilization and possible airway burns
or smoke inhalation.
• A careful examination should be performed to look
for contact points. Obvious cutaneous injury often
represents a small fragment of the total injury.
• If cardiopulmonary arrest occurs, resuscitation
attempts should be aggressive and prolonged if neces-
sary. Anecdotal evidence reports survival after several
hours of resuscitation. All patients should have close
hemodynamic and cardiac monitoring with ECG on
presentation.
• Laboratory evaluation with complete blood count,
serum electrolytes including creatinine, and urine analy-
sis in patients with more than minor injury.
• Assess the amount of muscle necrosis by obtaining
CPK or urine/serum myoglobin. Suspicion for com-
partment syndrome should be high and consultation
with surgeons for possible fasciotomy or escharotomy
should occur early.
• Large volumes of isotonic fluid should be used during
resuscitation.
 The goal for urine output is 0.5–1 mL/kg/h, which
increases to 1.5–2 mL/kg/h if myoglobin or free
hemoglobin is found in the urine. Alternatively,
initial intravenous fluid rate can be started at
20–40 mL/kg/h with reassessment after the first
hour.
 Mannitol (12.5 mg IV) may be necessary to
achieve the large amounts of diuresis. If myoglo-
binuria persists, a continuous infusion of 12.5 g/h
may be used or alkalinization of the urine may be
considered.
• Any change in the level of consciousness requires a
thorough evaluation given the high coincidence of
head trauma. Tests to be considered include electroen-
cephalogram, arterial blood gas, and toxicology
screen. Only after other causes have been ruled out
can a change in the level of consciousness be attrib-
uted to the electrical injury itself.
• Imaging with chest radiographs, bone radiographs to
rule out fractures (due to tetanic muscle contractions
and falls), or computed tomography may be initiated
according to risk for secondary injuries.
• Prophylaxis against streptococcal and clostridial
organisms should be considered, along with adminis-
tration of tetanus vaccine.
• Those with lightning injury should have evaluation for
cataract formation and otoscopic abnormalities.
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118 BURNS
Maria Dowell
KEY POINTS
• The morbidity and mortality of burns is determined by
the wound surface area, wound depth, age, and asso-
ciated injuries.
• Early resuscitation of the burn victim involves aggres-
sive fluid administration and attention to respiratory
compromise if present.
• The intermediate phase of burn management is charac-
terized by a hypermetabolic state, need for nutritional
support, and a growing risk of infectious complications.
• The late phase of burn management, extending
through the period of wound closure, is marked by
continued risk of infection as well as other general
complications of critical illness.
PATHOPHYSIOLOGY
• Burn patients are trauma patients and their condition
changes significantly over the course of the injury.
• First-degree burns involve only the thin outer epider-
mis, appear as erythema, produce mild discomfort,
and heal rapidly. Second-degree burns are defined as
injury to the entire epidermis and variable portions of
the dermis. Third-degree burns destroy the entire epi-
dermis and dermis leaving no residual epidermal cells
to repopulate the area. Skin grafting is often required.
• Estimating the size of the burn is guided by the rule of
nines. The head and each arm are 9% while the
chest/abdomen, back, each lower extremity are 18% of
the total body surface (TBS). The Lund and Browder
chart is more accurate and should be used for precise
calculation.
• The morbidity/mortality is based on the wound size
and depth, patient’s age, and associated injuries.
• Physiologic and metabolic parameters substantially
change due to the cardiopulmonary instability, onset
of intense wound inflammation, immunosuppression,
and infection.
• Treatment is based on clear understanding of differ-
ences in the postburn phases.
INITIAL RESUSCITATION
PERIOD (0–36 HOURS)
• This phase is characterized by cardiopulmonary insta-
bility including life-threatening airway and breathing
problems and hypovolemia due to plasma volume
loss.
• Pulmonary insufficiency caused by heat and smoke is
the major cause of mortality and accounts for >50% of
fire-related deaths.
• Carbon monoxide (CO) toxicity symptoms usually
appear when the CO concentration exceeds 15% and
are manifested as neurologic changes and metabolic
acidosis. Hydrogen cyanide exposure is a well-
recognized byproduct of burning synthetics such as
polyurethane and presents in a similar fashion.
Persistent metabolic acidosis despite adequate volume
resuscitation suggests CO or cyanide inhalation even
though the PaO2 remains normal. Toxicology screen is
warranted as ethyl alcohol (EtOH) and drugs can cause
similar neurologic dysfunction. CO toxicity requires
early administration of 90–100% O2 to displace CO
from hemoglobin. Hyperbaric O2 is best reserved for
severe neurologic compromise with high CO level.
Cyanide toxicity treatment involves administration of
sodium nitrite followed by sodium thiosulfate to help
clear the cyanide.
• Upper airway obstruction from airway edema after
heat exposure may not occur for 12–18 hours. The
external burn edema and airway edema have a parallel
time course and local edema can resolve in 4–5 days.
Inspection of the oropharynx for soot or heat injury
should be routine. Intubation should occur if there is
significant inhalation injury, deep facial burns, respira-
tory distress, hemodynamic instability, impaired con-
sciousness, or indecision. Use the largest endotracheal
tube (ETT) possible as very thick secretions develop.
• Chemical burns of the upper and lower airway from
toxic gases may become evident only after 24–48 hours.
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Breath-holding and laryngospasm are protective
measures in the conscious patient, however, the
unconscious patient loses this protection and sustains
more injury to the lower airway. Early bronchospasm
and edema from the irritant gases result in decreased
dynamic lung compliance and ventilation-perfusion
mismatching. Initial treatment consists of mainte-
nance of small airway patency (with positive end-
expiratory pressure [PEEP]) as well as removal of
secretions. Increased airway resistance >18–24 hours
after the injury is due to bronchiolar edema and plug-
ging more than bronchospasm.
• Hemodynamic instability and impaired O2 delivery
can occur with massive fluid shifts during resuscita-
tion. Increased vascular permeability, increased
osmotic forces in burned tissue, and cellular swelling
contribute to intravascular volume loss into burned
and nonburned tissues. The fluid and protein shifts are
the greatest in the first several hours. The quantity of
edema depends on the adequacy of fluid resuscitation.
Major protein losses in the first 6–8 hours can result
in severe hypoproteinemia. Edema may take days to
weeks to resolve depending on the restoration of lym-
phatic patency. Cardiac output is depressed primarily
due to hypovolemia but myocardial edema can be
seen with third-degree burns >40% of the TBS.
Afterload is increased due to increased systemic vas-
cular resistance (SVR) from catecholamines.
 Intravenous access should be through peripheral vein
catheters in nonburned tissue to avoid line sepsis
(older patients with massive burns or inhalation injury
are typically monitored with a central catheter).
 Parameters of perfusion to monitor include a mean
arterial pressure >85 mmHg, heart rate <130, urine
output 0.5–1 mL/kg/h, trends in base deficit as indi-
cator of adequacy of restoration of perfusion, and
avoidance of hypothermia.
 Use crystalloid without glucose (except in small
children) initially and colloid about 8–12 hours later
for protein restoration. The total 24-hour volume is
calculated as (4 mL)(% burn)(body weight in kg)
and 50% of this is generally given in the first 8 hours.
 This general guideline should be modified by serial
clinical assessments of the intravascular volume.
• Hematologic disorders to look for after major burns
include hemolysis due to red cell fragility, early
leukocytosis, thrombocytopenia, and hypercoagula-
bility from consumption of clotting factors.
• Pain and anxiety management should begin soon after
the injury to avoid excessive stress response. A con-
tinuous background of narcotics and low doses of
benzodiazepines are commonly used.
• The burn itself is a low priority for initial care.
POSTRESUSCITATION PHASE
(2–6 DAYS)
• This phase is a period of transition from the shock
phase to the hypermetabolic phase.
• Five major pulmonary abnormalities impair pulmonary
function during this period.
 Upper airway and facial edema from heat-induced
damage begins to resolve between days 2 and 4.
 Impaired chest wall compliance may occur, espe-
cially in circumferential third-degree burns and is
improved, but not eliminated, by escharotomy.
 Mucosal irritation and ciliary dysfunction from a
chemical burn to the airways cause bronchorrhea,
cough, increased mucus production, and may
progress to bacterial tracheobronchitis and diffuse
bronchopneumonia.
 If infection can be controlled, the acute process will
resolve over 7–10 days.
 Pulmonary edema and surgical anesthesia-related
pulmonary dysfunction may also be present.
• Maintaining hemodynamic stability can be challeng-
ing. Fluid losses from surface evaporation, increases
in intravascular fluid from absorption of edema and
decreases in hematocrit from red cell membrane
damage, and low production all contribute.
• Persistently elevated catecholamines from the hyper-
metabolic state give tachycardia.
• O2 consumption peaks around 5–7 days postburn.
• Release of pyrogens from the wound increases body
temperature by 1–2°F.
• Rate of protein loss is massive as a result of increased
catecholamines and cortisol as well as inflammatory
cytokines that stimulate gluconeogenesis and protein
breakdown. Muscle loss of 1 kg/day is common with
large burns. All of this contributes to reduced wound
healing and immune dysfunction.
• A common error is continued infusion of isotonic
crystalloid in the absence of major sodium losses. A
5% glucose-containing solution with low sodium
and increased potassium is the primary replacement
fluid for evaporative and urinary losses during
this phase. Initiation of nutrition, preferably enteral,
is essential.
• Care of the burn wound becomes increasingly impor-
tant. Burn wounds are never sterile. Many of the early
colonizing bacteria originate from the heat-injured
skin, nares, oropharynx, perineum, and stool. Silver
sulfadiazine is the most common and least toxic top-
ical antibiotic used. Mafenide (carbonic anhydrase
inhibitor) is more potent but reserved for deep infec-
tions. Infection of the wound indicates invasion
of viable tissue and may lead to sepsis. Diagnosis
is difficult and may require biopsy. Staphylococcus
aureus is common in the first week with gram-
negative organisms more evident after the first week.
Enterococcus and Candida albicans are present in 50%
of wounds.
• Surgical excisions should begin as soon as the patient
is hemodynamically stable, to avoid having extensive
burns still in place when the infection-inflammation
phase begins.
INFLAMMATION-INFECTION PHASE
(DAY 7 TO WOUND CLOSURE)
• This is the most complicated phase of management
evidenced by marked catabolism with loss of body
protein, increased metabolic rate, bacterial coloniza-
tion of the wound, and concern for wound sepsis.
Intense inflammation is seen at 7–10 days in deep
burns.
• Sepsis is the leading cause of morbidity/mortality
during this period with the most common sites being
the lungs, burn wound, and vascular catheters.
Respiratory failure and pneumonia surpass burn
wound sepsis as causes of mortality. Approximately
50% of burn patients with both inhalation injury and
major body burn develop pneumonia. Both the
immunocompromised state and high incidence of vir-
ulent organisms in the ICU contribute to the risk.
Prevention of pneumonia is important as eradication
of established pneumonia is difficult.
• The antimicrobial doses required to obtain adequate
tissue levels are much higher in hypermetabolic burn
patients.
• Consider tracheostomy early if there is a persistent
need for intubation.
• Evaporative water and protein losses from the wound
remain increased until wound closure. The
hypermetabolic-catabolic state persists with elevated
catecholamine levels, increased O2 consumption,
hepatic gluconeogenesis requiring rapid body protein
breakdown, suboptimal nutrition, growth hormone
decrease, and reduced antioxidants.
• It is important to control the source of the stress
response and increase the process of anabolism through
nutrition, nutritional adjuvants, and increased muscle
activity. Liberal use of analgesics, anxiolytics, and
other methods to control stress are required. Relative
adrenal insufficiency has also been reported.
• Parenteral nutritional support is preferred and 30–35
cal/kg/day are required for burns >30% TBS.
Increasing carbohydrate intake reduces gluconeogen-
esis and proteolysis. Protein requirements are two to
three times the recommended daily allowance and
supplements are often necessary. Glutamine replace-
ment as well as vitamin and mineral replacement are
essential. Occasionally, growth hormone and the
testosterone analog, oxandrolone, are used to increase
anabolic activity.
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119 CARE OF THE
POSTCARDIAC SURGERY
PATIENT
J. Matthew Brennan
KEY POINTS
• Hypotension following cardiac surgery has a broad
differential diagnosis that is informed by chest radi-
ography, measurement of central venous pressure,
monitoring of chest drains, and echocardiography.
• Respiratory dysfunction may be caused by pulmonary
edema, consequences of cardiopulmonary bypass,
transfusion (transfusion-related acute lung injury,
TRALI), and phrenic nerve injury.
• Renal dysfunction complicates 30% of patients fol-
lowing bypass grafting and, when nonoliguric, gener-
ally resolves quickly.
• Operative complications (tamponade, hemorrhage,
acute graft failure) are uncommon but require prompt
diagnosis and treatment.
• Atrial fibrillation is common: rate or rhythm control
are equally effective.
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GENERAL MANAGEMENT ISSUES
HYPOTENSION
• See Table 119-1 for details.
RISK FACTORS
• Decreased left ventricular (LV) function
• Diastolic dysfunction
• Increased cardiopulmonary bypass (CPB) duration
• Periop acute myocardial infarction (AMI)/graft failure
• Coronary artery air embolism
MECHANICAL SUPPORT
• Intra-aortic balloon pump (IABP): most placed in
the operating room if blood pressure (BP) unstable
following CPB. A survival benefit has been noted
with IABP use.
TABLE 119-1 Hypotension—Diagnosis and Treatment
TREATMENT
CVP DDX CLINICAL FEATURE (IN ORDER OF PREFERENCE) COMMENT
High LV failure Decreased EF with Dobutamine Increased contractility
pulmonary edema 1–20 µg/kg/min with decreased SVR
Need central IV access for doses
above 5–10 µg/kg/min
Milrinone Increased contractility
Loading dose: 50 µg/kg with decreased SVR
Maintenance: 0.4–0.5 µg/kg/min Need central IV access
IABP Decreased afterload with
increased coronary perfusion
See below for details
Epinephrine Increased contractility
0.05–0.25 µg/kg/min and SVR
Need central IV access
Norepinephrine Vasoconstrictor
0.05–0.25 µg/kg/min Need central IV access
Dopamine Vasoconstrictor
2.5–20 µg/kg/min >6 µg/kg/min increases SVR
Need central IV access
VAD See text for details
Diastolic dysfunction Normal EF with IVF (goal: MAP 15–20 mmHg) Secondary to long-standing HTN
pulmonary edema or myocardial stunning postinfarction
RV failure Dilated/hypocontractile Sildenafil (Viagra) if PE vs. pulmonary vasoconstriction
RV with dry lungs increased pulmonary
vascular resistance
Dobutamine
Vasopressin
0.02–0.04 units/min
Norepinephrine
Epinephrine
VAD
Tamponade See Chap. 135 Surgical correction TTE often shows RV/RA dimpling
Elevated and equalized RAP, RVEDP,
PA diastolic pressure and PCWP
Tension PTX Decreased breath sounds; Chest tube or Angiocath Diagnosed by physical examination
mediastinal shift away (2nd intercostal space, and CXR
from PTX midclavicular line)
Mechanical dysfunction New, loud systolic murmur Surgical repair Papillary muscle rupture, VSD
Arrhythmia Bradycardia Atrial, AV, or ventricular pacing, Determine if cause is sinus node or AV
atropine nodal dysfunction by ECG
Tachyarrhythmias See appropriate sections
for management
Low Hypovolemia Cold skin IVF and blood products, as needed Vigorous LV function on TTE
Vasodilatory Warm skin Vasopressin CPB effect with cytokine release,
0.04 units/min sepsis or adrenal insufficiency
Norepinephrine
ABBREVIATIONS: CVP, central venous pressure; dDx, differential diagnosis; EF, ejection fraction; PTX, pneumothorax; IVF, intravenous fluid; MAP,
mean arterial pressure; SVR, systemic vascular resistance; HTN, hypertension; PE, pulmonary embolism; RV, right ventricle; RA, right atrium; RAP,
right atrial pressure; RVEDP, right ventricular end-diastolic pressure; PA, pulmonary artery; PCWP, pulmonary capillary wedge pressure; CXR, chest
x-ray; VSD, ventricular septal defect.
 Mechanism of Action (MOA): increase coronary
perfusion and decrease afterload
 Indications:
 Decreased cardiac output with optimization of
preload/afterload/heart rate
 Moderate dose dopamine (10 µg/kg/min) or equiv-
alent dobutamine/epinephrine with hemodynamic
(HD) instability
 Initially 1:1 ratio (60–100 cycles/min); then, titrated
to 1:3 as cardiac output improves
• Ventricular assist devices (VADs): placed in the oper-
ating room if BP unstable following CPB despite
IABP use
 Indications:
 Decreased cardiac index (<1.5 L/min/m2) despite
IABP and moderate dose inotropic support fol-
lowing discontinuation of CPB, and
 If myocardial dysfunction expected to resolve in
course of a few days, or if patient <65–70 years
old (y/o) and transplant candidate
 Short- and long-term devices are available
PULMONARY DYSFUNCTION
RISK FACTORS
• Age: <2 y/o or >60 y/o
• Chronic obstructive pulmonary disease (COPD)
• Preop use of amiodarone
• Oxygenators other than membrane type
• Increased CPB duration
• Increased left atrial pressure
• If reintubation is necessary, consider tracheostomy at
7 days postop
CARDIOPULMONARY BYPASS EFFECTS
Treatment
• Noninvasive positive pressure ventilation (NIPPV)
• Judicious use of diuretics
• Oxygen
• Chest physiotherapy (PT)
• Steroids
PHRENIC NERVE PALSY
Epidemiology
• 11% of patients with left lower lobe atelectasis
in the postop period suffer from phrenic nerve
palsies.
Risk Factors
• The major risk factor is use of ice slush rather than
cold saline for cardioplegia.
Treatment
• Spontaneous recovery occurs within 6 months in the
majority of patients.
RENAL FAILURE
EPIDEMIOLOGY
• Renal dysfunction is defined as an increase in serum
creatinine by >50% above the baseline, and renal fail-
ure is an acute increase in serum creatinine ≥2 times
the baseline value.
• Renal dysfunction is present in ~30% of patients post-
coronary artery bypass graft (post-CABG).
• In adults with normal preop renal function, there is a
1% incidence of renal failure with rare progression to
HD. However, in patients with abnormal preop renal
function the incidence may be as high as 16–20% with
nearly 1 in 5 progressing to acute dialysis.
• Oliguric acute renal insufficiency (ARI) often occurs
within 12–18 hours postop, is recalcitrant to
dopamine and diuretics, but resolves completely in
the majority of patients. In contrast, nonoliguric ARI
may occur as late as 3–4 days with a blood urea nitro-
gen (BUN) and creatine peak around days 7–10, and
is only associated with a 75% rate of resolution.
• Nonoliguric ARI is associated with a 90% survival
rate; however, among patients with acute renal failure
progressing to end-stage renal disease (ESRD), there
is a 50% in-hospital mortality rate.
• Aprotinin causes renal artery stenosis and oliguric
azotemia resolving in 1–2 days.
• The possible utility of nesiritide in the treatment of
hypervolemia is controversial due to its association
with renal dysfunction.
RISK FACTORS
• Preop chronic kidney disease (CKD)
• Diabetes
• Renal artery stenosis
• Emergent operations
• Re-exploration for bleeding
• Advanced atherosclerosis
• Class III/IV heart failure
• Cyanotic heart disease
• Old age (>70 y/o)
• Increased time of CPB
• CPB prime with whole blood (instead of hemodilution)
• Increased plasma hemoglobin (>40) during and fol-
lowing CPB
• Acute postop decrease in cardiac output
• Preop use of radiocontrast dye
• Use of certain antibiotics (especially gentamicin)
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PATHOPHYSIOLOGY AND DIAGNOSIS
• See Chap. 79 for details.
Prerenal
• Most frequently an issue of volume status or cardiac
output.
• If not receiving loop diuretics (i.e., furosemide):
check serum and urine sodium and creatinine; FeNa
<1% indicates prerenal etiology, >2% indicates intrin-
sic renal dysfunction.
• If receiving loop diuretics: check serum BUN and
creatinine and urine urea and creatinine; FeUrea
<35% indicates prerenal etiology, >35% indicates
intrinsic renal dysfunction.
Renal
• Most often due to acute tubular necrosis (ATN), acute
interstitial nephritis (AIN), or pyelonephritis.
• Check urine for eosinophils (AIN), casts (ATN), or
bacteria and WBCs (pyelonephritis).
Postrenal
• Most often due to Foley catheter dysfunction.
• Flush and/or replace Foley catheter if high suspicion.
PREVENTION AND TREATMENT
• The cornerstone of prevention involves appropriate fluid
management and maintenance of a good cardiac output.
• Treatment initially involves optimizing preload and
afterload.
• Dopamine 2.5 µg/kg/min may increase glomerular fil-
tration rate (GFR), but is controversial.
• Fenoldopam 0.01 µg/kg/min may increase GFR, but
is controversial.
• Some centers use furosemide q 6-12 h × 3 days in
escalating doses with or without albumin to increase
tubular flow and help manage fluid status. This does
not aid recovery of kidney function.
• “Renal Cocktail” infusion (400 mg furosemide + 100 mL
20% mannitol) at 1 mg/kg/h furosemide rate, alternating
4 hours “on” and 4 hours “off” has also been used by
some. Serum osmolarity must be monitored frequently
and the infusion is stopped if >310 mOsm/L.
• Early HD/continuous venovenous hemodialysis
(CVVHD)/slow continuous ultrafiltration (SCUF);
CVVHD associated with decreased ventilator days,
decreased ICU stay, and increased renal recovery rate.
CARDIOVASCULAR ACCIDENT
EPIDEMIOLOGY
• Rates of postop cardiovascular accidents (CVAs) lead-
ing to hemiplegias or hemiparesis are age dependent:
5% in patients >65 y/o, 8% in those >75 y/o. They
occur in up to 16% of all patients undergoing com-
bined CABG and intracardiac procedures.
• Approximately 12% of patients with periop CVAs die.
RISK FACTORS
• Increased age
• Prior CVA/transient ischemic attack (TIA)
• Severe ascending aortic atherosclerosis
• Increased CPB duration
• Decreased postop cardiac output
DIAGNOSIS AND TREATMENT
• Head computed tomography (CT) with and without
IV contrast
• Maintain systolic blood pressure (SBP) between 130
and 160 mmHg to prevent extension of infarct
PANCREATITIS
EPIDEMIOLOGY
• Postop increases in serum amylase are noted in
25–30% of patients; however, most is thought to be
secondary to salivary amylase production. An increase
in lipase is seen in only 10% of patients. Clinical signs
of pancreatitis are far less common (0.04–1%).
PREVENTION
• Administration of calcium chloride is associated with
an increased risk of postop erative pancreatitis.
TREATMENT
• Symptomatic pancreatitis is treated with bowel rest
(often with intermittent nasogastric [NG] tube suction)
and opioid analgesics. Enteral nutrition improves out-
come in severe pancreatitis.
HYPERTHERMIA
• Postcardiac surgery patients frequently experience
noninfectious fevers for 4–5 days after surgery persist-
ing for up to 2 weeks without active infection. Some
have attributed this phenomenon to the release of inter-
leukins associated with the damaging effects of CPB.
HYPERGLYCEMIA
• Post-CABG blood glucose levels >175 mg/dL lead to
increased mortality, deep sternal wound infections,
length of hospital stay, and cost of hospitalization.
• Blood glucose levels >110 mg/dL in a general ICU
population leads to increased mortality rates.
TREATMENT
• Goal: 80–175 mg/dL (80–110 mg/dL is likely most
beneficial)
• IV insulin drips are most effective means to tight
glycemic control
SPECIFIC POSTOP COMPLICATIONS
POSTOP HEMORRHAGE
CLINICAL FEATURES
• Excessive bleeding:
 There is no accepted standard.
 500 mL/h in 1st hour; 400 mL/h in first 2 hours;
300 mL/h in first 3 hours; 200 mL/h in first 6 hours;
or increasing bleeding rate at any postop time.
 Others use 200 cc/h over first 3 hours or >1 L over
24 hours.
EPIDEMIOLOGY
• 30% of patients require postop transfusions; however,
only 3–5% have severe bleeding (>10 U packed red
blood cells [PRBC]).
RISK FACTORS
• Low preop hemoglobin
• Low weight
• Older age
• Female gender
• Emergency operation
• Open heart procedure
• Aortic operation
DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS
• Increased partial thromboplastin time (PTT) and acti-
vated clotting time (ACT): heparin effect
• Increased prothrombin time (PT)/international nor-
malized ratio (INR): shock liver
• Decreased platelet count: hemodilution or dissemi-
nated intravascular coagulation (DIC)
• Decreased factor VIII level: DIC
• Normal coagulation profile, platelet count, factor VIII
levels: mechanical vascular dysfunction (i.e., anastomotic
failure)
• High-risk anatomic sites:
 Graft anastomosis or side branch
 Cannulation sites
 Aortotomies/cardiotomies
 LV aneurysm resection lines
 Pericardial edges
 Coronary sinus
 Sternal wire sites
 Pleural/pericardial fat pad
• CPB effect:
 Fibrinolysis—risk increases with increased CPB times
• Meds:
 Aspirin and Clopidogrel lead to platelet dysfunction
 Heparin
• Hemodilution of clotting factors and platelets
• Hypothermia and CPB effects lead to platelet
dysfunction
TREATMENT
• Fibrinolysis:
 Transexemic acid
 Epsilon-aminocaproic acid
• Reverse heparin with protamine (amount is based on
ACT level).
• Replace fibrin with fresh frozen plasma (FFP,
500 mg/U) or cryoprecipitate (150 mg/U) if fibrinogen
level <100 mg/dL.
• NovoSeven can be used if factor VIII or IX levels are
decreased due to hemophilia, DIC, or hemodilution or
if inhibitors to factors VIII or IX are present.
• Some centers suggest increasing positive end-expiration
pressure (PEEP) to 10–15 cmH2O to tamponade
hemorrhage.
• If continued hemorrhage despite correction of coagu-
lation cascade, consider a mechanical dysfunction
(i.e., anastomotic failure) and return patient to OR.
PERICARDIAL TAMPONADE
CLINICAL FEATURES
• See Chap. 135 for details.
EPIDEMIOLOGY
• 84% of postop patients have pericardial effusions on
transthoracic echocardiography (TTE).
• 30% have large effusions by postop days 4–10, mostly
found in cardiac transplant patients and those with
excessive postop hemorrhage. Most effusions regress
starting on day 10.
• Clinical tamponade is present in only 1% of patients,
but can develop up to 4 months after cardiac surgery.
DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS
• See Chaps. 13 and 135 for details.
TREATMENT
• Reentry into the chest
ACUTE GRAFT FAILURE/PERIOP MYOCARDIAL
INFARCTIONS
EPIDEMIOLOGY
• Seen in 2–5% of post-CABG patients
• Associated with increased inpatient mortality (9.7%
vs. 1.0%)
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RISK FACTORS
• Cardiomegaly
• Increased CPB time
• Repeat CABG
• CABG plus other open heart surgery (OHS)
PATHOGENESIS
• Acute graft failure may occur as a result of graft
thrombosis (32%), poor distal run-off (17%), graft
stenosis (7%), and anastomotic stenosis (5%).
DIAGNOSIS
• Periop AMI is defined by the presence of new Q waves
on a postop ECG or CK-MB increasing to >5 times the
upper limits of normal 8–16 hours postop.
• Troponin elevation is considered the most reliable
marker by some.
TREATMENT
• The mainstay of treatment involves postop coronary
catheterization with rescue percutaneous coronary inter-
vention (PCI) or reoperation (see Chap. 18).
POSTOP ATRIAL FIBRILLATION
EPIDEMIOLOGY
• The risk of postop atrial fibrillation (AF) depends on
the surgical procedure performed; 15–40% incidence
following CABG; 37–50% postvalve surgery; 60%
with combined valvular and CABG surgery; 11–24%
following cardiac transplant.
• Peak risk occurs at 2–3 days postop.
• Most postop AF is transient, and converts to normal
sinus rhythm (NSR) within 2–3 days with treatment
(unless chronic preop AF). If no prior history, 15–30%
convert to NSR within 2 hours, 80% within 24 hours;
however, 43% of patients experience recurrent episodes.
• New-onset postop AF leads to increased morbidity,
length of stay, and cumulative cost.
RISK FACTORS
• Prior AF
• Discontinuation of periop beta-blockers
• Age: 4% <40 y/o, 18% <60 y/o, 30% >70 y/o, 52%
>80 y/o
• COPD
• CKD
• Mitral valvular disease (esp. stenosis)
• Left atrial enlargement (LAE), cardiomegaly
• Increased CPB
• Prior OHS
• Elevated preop brain natriuretic peptide (BNP)
• Right coronary artery (RCA) stenosis
• Risk prediction models have been developed
PREVENTION AND TREATMENT
• The cornerstone of prevention involves the use of
periop beta-blockers beginning on the morning follow-
ing surgery. Angiotensin-converting enzyme (ACE)
inhibitors have also been shown to decrease the risk of
recurrent postop AF. Postop beta-blockers should be
continued at least until 1st postop clinic visit.
• Postop biatrial pacing is the most effective form of
prevention.
• Treatment strategies consist of either rate or rhythm
control. No difference in time to NSR, AF relapse,
proportion of patients in NSR at 2 months has been
shown between the two strategies.
 Hemodynamic instability:
 Rhythm control:
• Pacing via biatrial pacing wires
• External defibrillation
• Amiodarone 5 mg/kg IV bolus; then 0.25–0.5
mg/min infusion with conversion to PO when
stable
 Hemodynamically stable:
 Rate control:
• IV beta-blocker with conversion to PO meds
when clinically stable
 Anticoagulate with warfarin is only necessary if
AF >48 hours and acceptable bleeding risk with
target INR = 2–3
MEDIASTINITIS
CLINICAL FEATURES
• Characterized by sternal instability, retrosternal fluid
collections identified on CT scan, and retrosternal
purulent drainage.
EPIDEMIOLOGY
• Mediastinitis develops in 0.8–1.5% of post-CABG
patients and 2.5–7.5% of posttransplant patients.
• There is an increased risk with VADs, and in patients
not given periop prophylactic antibiotics (50% infec-
tion rate).
• 83% of sternal wound infections are monomicrobial.
• 57% are associated with bacteremia.
• The median time to onset is 7 days with two-thirds of
cases occurring within 2 weeks.
• They are associated with an increased length of stay by
38–51 days extra with 2–3 times increased cost of
care.
• A wide range of mortality rates has been reported
from 6 to 70%, but current series support a likely rate
of 5–10% with early treatment.
• Favorable outcomes are typical with appropriate antibi-
otic therapy.
RISK FACTORS
• Retrosternal hematoma
• Increased operative time
• Incomplete sternal closure
• New York Heart Association (NYHA) class IV con-
gestive heart failure (CHF)
• Prior OHS
• Obesity
• Smoking
• Diabetes
• COPD
• Male sex (possibly secondary to practice of chest
shaving on day prior to surgery)
• Prolonged postop ventilation
• Steroid use
• Pre- and periop hyperglycemia
• Bilateral IMA use (secondary to decreased sternal
blood supply)
• Of note, reoperation has not been shown to be an inde-
pendent risk factor for mediastinitis
PATHOPHYSIOLOGY
• Organism isolates <30 days postop:
 Methicillin-susceptible Staphylococcus aureus
(MSSA) 45%
 Methicillin-resistant S. aureus (MRSA) 16%
 Gram-negative bacilli 17%
 Coagulase-Negative Staphylococcus species (CoNS)
13%
 Streptococci 5%
 Candida albicans also cultured
DIAGNOSIS
• Computed tomography scan is the best diagnostic
modality, but its sensitivity and specificity vary accord-
ing to the timing of the scan (100% sensitive, 33% spe-
cific if performed before 14 days; 100% sensitivity and
specificity if performed >14 days). Overall sensitivity
and specificity have been reported as 67% and 83%,
respectively.
PREVENTION AND TREATMENT
• Prophylactic antibiotics with one dose prior to anes-
thesia, one prior to CPB, and one post-CPB; continu-
ing until postop day 2 or until last IV/ET tube is
removed. Longer durations have not been shown to
decrease rates of infection. Recommended regimens:
 Cefazolin 1 g if <80 kg or 2 g if >80 kg
 Cefuroxime 1.5 g
 If penicillin (PCN) allergy: vancomycin 10–15 mg/kg
or clindamycin 600–900 mg
• Tight glycemic control
THERAPY
• Surgical management
POSTCARDIOTOMY SYNDROME
CLINICAL FEATURES
• Pleuritic and pericardial chest pain occurring usually
>2 weeks following surgery with a peak incidence at
4 weeks postop. Pericardial and pleural friction rubs
are often present, and it is occasionally associated
with tamponade.
• Fever, pleural/pericardial pain with associated
eosinophilia and atypical lymphocytosis.
EPIDEMIOLOGY
• Median duration is 22 days (range 2–100 days), and
there is a 21% recurrence rate by 30 days.
PATHOPHYSIOLOGY
• It is thought to be secondary to heart-reactive
antibodies.
TREATMENT
• Treatment is with high-dose aspirin or nonsteroidal
anti-inflammatory drugs (NSAIDs) unless the patient is
taking diuretics. If pain persists and infection has been
ruled out or if patient is on diuretics, prednisone (40 mg
daily with a 4–8 weeks taper) has been advocated.
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120 PREGNANCY IN THE ICU
D. Kyle Hogarth
KEY POINTS
• The most common causes of ICU admission in preg-
nancy are complications of cesarean section, preeclamp-
sia or eclampsia, and postpartum hemorrhage.
• The most common risk factors associated with ICU
mortality include pulmonary complications, shock,
cerebrovascular events, and drug dependence.
• A multidisciplinary team consisting of intensivists,
high-risk obstetricians, anesthesiologists, and neona-
tologists should manage the gravid patient in the ICU.
PHYSIOLOGY OF PREGNANCY
• Blood volume increases with a decrease in albumin
and hematocrit and hemoglobin.
• Heart rate, stroke volume, and cardiac output all
increase while blood pressure decreases. Overall, the
systemic and pulmonary vascular resistances decrease.
• Minute ventilation increases, as does oxygen consump-
tion. Overall, the pregnant patient will have diminished
PCO2 with a decrease in HCO3, giving the patient a
compensated respiratory alkalosis. Understanding that
a pregnant patient at baseline has a respiratory alkalo-
sis with a compensatory metabolic acidosis is very
important when interpreting the acid-base status of the
patient during acute illness.
• A majority of pregnant patients will have a physiologic
third heart sound, and this finding on examination
cannot be interpreted as indicating ventricular failure
with certainty.
THE FETO-PLACENTAL UNIT
• The fetus is very sensitive to changes in oxygen deliv-
ery, and pathologic changes in maternal physiology
can quickly lead to diminished oxygen delivery.
• At baseline, the uterine artery is maximally dilated, so
increased flow from local autoregulation cannot
occur.
• Any condition leading to maternal general vasocon-
striction will diminish oxygen delivery to the fetus.
Worsening maternal alkalemia will also lead to
vasoconstriction.
• The delivery of oxygen to the fetus is dependent on
maternal cardiac output, as the oxygen-carrying
capacity of the mother is diminished secondary to the
lower level of hemoglobin.
• Monitoring fetal well-being through fetal heart rate is
nonspecific, and fetal pH requires rupture of mem-
branes. In general, the maternal acid-base status and
parameters of oxygen delivery are adequate surro-
gates for fetal well-being.
• Maternal anemia sometimes needs to be corrected if
oxygen delivery is compromised.
SHOCK IN PREGNANCY
• The approach to the hypoperfused pregnant patient is
essentially the same for the nonpregnant patient. The
initial management includes distinguishing between
low flow and high flow states and assessing the
volume status of the patient, keeping in mind the
normal changes in physiology.
• If a right heart catheter must be placed, then the
femoral position is relatively contraindicated sec-
ondary to vena caval obstruction by the gravid uterus
and the possible need for emergent delivery of the
fetus.
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HYPOVOLEMIC SHOCK
IN PREGNANCY
• The management of the pregnant patient with hypov-
olemic shock is essentially the same as the nongravid
patient. While delivering the necessary volume to
ensure adequate perfusion, a careful assessment of the
cause of hypovolemia is undertaken.
• While assessing for causes of hemorrhage related to
the gravid state, care must be taken to evaluate for
nongravid causes of blood loss (i.e., gastrointestinal
blood loss and hemolysis). Furthermore, critically ill
gravid patients can frequently develop disseminated
intravascular coagulation (DIC), so any massive
bleeding should prompt a coagulopathy workup.
• Management of hemorrhage in pregnancy requires
immediate intravenous access with two large-bore
(16-gauge or larger) catheters. Resuscitation with crys-
talloid or colloid should be instituted until blood can be
administered. The patient should be placed in the left
lateral decubitus position. In patients receiving massive
transfusions, a survey for resultant DIC should be
undertaken. Patients should also be monitored for a sec-
ondary thrombocytopenia resulting from consumption.
SEPTIC SHOCK IN PREGNANCY
• Sepsis in an important cause of hypoperfusion in
pregnancy, as it accounts for up to 15% of all mater-
nal deaths.
• Normal pregnant circulatory physiology somewhat
resembles early sepsis (high cardiac output, low vas-
cular resistance), and sepsis can be difficult to diag-
nose in the febrile gravid patient.
• Chorioamnionitis or intra-amniotic infection occur in
1–4% of pregnancies and most commonly occur after
prolonged rupture of membranes, prolonged labor, or
postinvasive procedures such as amniocentesis or cervi-
cal cerclage. Patients typically have fever, tachycardia,
uterine tenderness, and foul smelling amniotic fluid.
• The management of the septic gravid patient is simi-
lar to the nongravid patient.
• Cultures of blood, urine, and pelvic sites should be
obtained. Empiric coverage with broad-spectrum
antibiotics for polymicrobial infection should be initi-
ated. If possible, aminoglycosides should be avoided
in the gravid patient secondary to the risk of fetal
nephrotoxicity and ototoxicity.
• The principles of assuring adequate venous return,
cardiac filling pressures, and mixed venous oxygen
saturation guide the ICU physician during the man-
agement of the gravid patient in a manner similar to
the nongravid patient.
• Septic shock should be managed with early goal-
directed therapy for a central venous pressure (CVP)
of 10 mmHg and a mixed venous oxygen saturation of
at least 70%. Inotropes to ensure adequate cardiac
output and adequate mixed venous saturation are pre-
ferred over vasoconstrictors that may alter placental
blood flow. However, if there is refractory hypotension
after ensuring adequate filling pressures and mixed
venous saturation, then vasoactive drugs should be
employed.
• The role of drotrecogin alpha (activated) has not been
defined in the pregnant population with sepsis. These
patients were excluded in the original study. Pregnancy
should be considered a relative contraindication for the
use of activated protein C.
CARDIOGENIC SHOCK IN PREGNANCY
• Hypoperfusion secondary to cardiac dysfunction
during pregnancy is often from preexisting conditions,
such as valvular abnormalities, that emerge during the
increased physiologic demands of pregnancy.
• Peripartum cardiomyopathy is an acquired cause of
cardiac dysfunction that occurs with an incidence
of 1/1300 to 1/4000 deliveries. Maternal mortality of
patients with class III or IV heart failure is around 7%.
• This acquired heart failure of pregnancy usually
occurs during the last month of pregnancy or during
the first 6 months postpartum. Risk factors include
African American race, older age, twin gestation,
preeclampsia, and postpartum hypertension.
• Pregnant patients also have an increased risk for aortic
dissection, possibly secondary to the increased shear
stress from the elevated cardiac output. Dissection
tends to present in the last trimester as a tearing sen-
sation around the scapula.
• Risk factors for dissection include hypertension,
increased age, multiparity, trauma, Marfan syndrome,
Ehlers-Danlos syndrome, coarctation of the aorta, and
bicuspid aortic valve. History and a widened medi-
astinum on chest x-ray should raise the suspicion for
dissection. The diagnosis can be made with infused
chest computed tomography (CT) or with trans-
esophageal echocardiogram.
• Adequate preload needs to be ensured, and having the
patient in the left lateral decubitus position is extremely
important. If shock persists despite adequate preload,
then management options include inotropic support
and maximizing reduction in afterload.
• Dobutamine is the drug of choice for inotropic sup-
port, but it should be reserved for life-threatening sit-
uations because it has been shown in animal models to
decrease placental blood flow.
356 SECTION 10 • SPECIAL PROBLEMS IN THE ICU
CHAPTER 120 • PREGNANCY IN THE ICU     357
• Afterload reduction with nitroprusside or nitroglycerin
can be initiated if inotropic support does not correct the
shock state. Nitroprusside can only be used for
extremely brief periods of time because of the risk of
cyanide and/or thiocyanate toxicity to the fetus. The
dose and duration should be minimized, and the patient
converted to oral hydralazine as soon as possible.
• Angiotensin-converting enzyme (ACE) inhibitors are
absolutely contraindicated as they cause oligohy-
dramnios and anuric renal failure in the fetus exposed
in utero.
• When the patient with cardiogenic shock delivers, this
should be an assisted vaginal delivery in the left lateral
decubitus position with epidural anesthesia to minimize
the tachycardic and hypertensive response to pain.
PREECLAMPSIA
• Preeclampsia is a circulatory disorder unique to preg-
nancy that occurs in 5–10% of pregnancies. It occurs
usually after the 20th week of pregnancy, but may
happen postpartum.
• It is characterized by the triad of hypertension, edema,
and proteinuria. However, all three characteristics
need not be present, and in some cases the manifesta-
tions may be mild.
• Risk factors for the development of preeclampsia
include chronic hypertension, preexisting renal dis-
ease, diabetes, multiple gestations, hydatidiform
mole, and the antiphospholipid antibody syndrome.
• Management of preeclampsia includes early diagnosis,
close medical observation, and timely delivery. In
most cases of preeclampsia, delivery is curative. In
cases of severe preeclampsia, impending eclampsia,
multiorgan involvement, or gestational age >34 weeks,
immediate delivery is recommended.
• Conservative management involves close blood pres-
sure control. A diastolic blood pressure of 110 mmHg or
greater should be treated with the goal of maintaining a
mean arterial pressure between 105 and 126 mmHg,
with the diastolic between 90 and 105 mmHg. The goal
of blood pressure management is to prevent the devel-
opment of encephalopathy and lower the risk of cere-
bral hemorrhage.
ECLAMPSIA
• Eclampsia is a syndrome characterized by convul-
sions and increased risk for death in the setting of
preeclampsia.
• The seizures of eclampsia can be controlled with mag-
nesium, benzodiazepines, or phenytoin. Meta-analysis
has suggested that magnesium is superior for control
and prevention of further eclamptic seizures.
• No study has convincingly demonstrated prophylactic
magnesium to be superior to blood pressure control in
preventing eclampsia. However, magnesium and blood
pressure control are superior to phenytoin in prevent-
ing eclampsia.
• Magnesium should be given for a minimum of 24 hours
postdelivery in any woman with eclampsia.
HELLP SYNDROME
• An extremely fulminant complication of preeclampsia
is the HELLP syndrome (Hemolytic anemia, Elevated
Liver enzymes, Low Platelets), which occurs in 0.3%
of deliveries.
• The HELLP syndrome is characterized by multiorgan
system dysfunction arising from an unclear endothe-
lial abnormality that results in secondary fibrin depo-
sition and organ hypoperfusion.
• In up to 30% of patients who develop HELLP, the dis-
ease manifests 48 hours postpartum. Maternal mortal-
ity ranges from 0 to 24%, with fetal mortality ranging
from 8 to 60%.
• The diagnosis is made based on laboratory values that
demonstrate dropping platelets and elevated liver
transaminases in the setting of a consumptive microan-
giopathic hemolytic anemia. Management is support-
ive and requires delivery of the fetus.
RESPIRATORY DISORDERS
OF PREGNANCY
• The lower functional residual capacity of the lungs
during pregnancy secondary to the enlarging abdomen
can complicate chronic respiratory disorders such as
asthma, cystic fibrosis, or chest wall restrictive lung
disease (scoliosis).
• Tocolytic-induced pulmonary edema, amniotic fluid
embolus, air embolus, aspiration, or pneumonia can
complicate pregnancy.
• Management of many of these problems is supportive,
and similar to the nonpregnant patient.
MECHANICAL VENTILATION
OF PREGNANT PATIENTS
• The indications for intubation of a pregnant patient are
no different than the nonpregnant patient. Noninvasive
ventilation has not been studied extensively in this
population.
• The guiding principle of ventilating the pregnant patient
is ensuring adequate oxygen delivery. The goal is a
PaO2 of >90 mmHg.
• Positive end-expiratory pressure (PEEP) should be
applied to keep the FiO2 <60%, but the patient should
be kept in the left lateral decubitus position to mini-
mize the effect of PEEP on venous return. Ensuring
adequate preload with intravenous fluids can also
minimize the hemodynamic effects of PEEP and
mechanical ventilation.
• Pregnant patients with ventilatory failure (e.g., from
drug overdose and neuromuscular weakness) and
without diffuse lung injury should have a target PaCO2
of 27–30 mmHg, a eucapnic level during pregnancy.
• Pregnant patients with acute lung injury have not
been well studied. Permissive hypercapnia, a strat-
egy used in acute lung injury, may lead to fetal dis-
tress. If higher PaCO2 levels are being sustained in
the pregnant patient, then continuous fetal monitor-
ing is required.
• In patients requiring neuromuscular blockade, short-
term use of nondepolarizing agents such as pancuro-
nium, vecuronium, and atracurium are safe for the
fetus.
• Sedation with propofol and opioid drugs are safe,
though the fetus may need to be intubated on delivery
as these drugs cross the placenta.
• Benzodiazepines should be avoided as they have been
shown to increase the incidence of cleft palate.
• Higher than normal peak and plateau airway pressures
can be expected on the ventilator: compression of the
diaphragm by the gravid uterus will increase respira-
tory system elastance.
• Fetal viability can be maintained while a patient is on
mechanical ventilation, even during maternal brain
death. Delivery or termination of pregnancy does not
seem to improve the respiratory status of the mother,
and therefore is not recommended.
CARDIOPULMONARY ARREST
• A pregnant patient requiring chest compressions
should have a Cardiff Wedge or other device achiev-
ing approximately a 30° tilt placed under her back.
This allows the patient to have adequate support of the
torso for cardiopulmonary resuscitation (CPR) but
also minimizes compression of the inferior vena cava
(IVC). A backboard with rolled up towels or pillows
under one side can substitute.
• The pregnant patient can safely undergo direct current
cardioversion, both synchronized and unsynchro-
nized. Drugs such as lidocaine, procainamide, adeno-
sine, and quinidine can be safely used in the gravid
patient. Amiodarone is contraindicated secondary to
the possible effects on fetal thyroid development.
• It is possible for an emergent cesarean section to be
performed during CPR.
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121 RHEUMATOLOGY
IN THE ICU
Janelle Laughlin
KEY POINTS
• Rheumatology patients are at increased risk for infection.
• Hypotension may be caused by adrenal insufficiency
related to prior corticosteroid use without adequate
stress dosing.
• Many rheumatologic diseases will present with pul-
monary complications.
• Rheumatoid arthritis and lupus patients are at increased
risk for coronary artery disease.
• Rheumatoid arthritis patients may have cervical neck
instability.
EPIDEMIOLOGY
• Approximately one-third of patients admitted to the
hospital with rheumatic disease require intensive care.
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• 50% of intensive care unit (ICU) admissions are
related to infection, and 25–35% are related to exac-
erbation of the rheumatic disease.
• Of the rheumatic diseases, rheumatoid arthritis (RA),
systemic sclerosis (SSc), and systemic lupus erythe-
matosus (SLE) account for more than 75% of admis-
sions to the ICU.
IMMUNE STATUS OF THE RHEUMATIC
PATIENT AND RISK FOR INFECTION
• Patients with rheumatic disease are often immuno-
compromised either due to the disease itself or thera-
pies employed. 
• For example, patients with SLE have impaired cellu-
lar immunity, altered phagocytic function, low com-
plements, decreased production of immunoglobulin,
and an impaired reticuloendothelial system necessary
for organism elimination.
• Corticosteroids decrease phagocytic function as well
as impair cell-mediated immunity. 
• The incidence of infectious complications with corti-
costeroids increases with dose and duration over
4 weeks.
• Other immunosuppressives used can result in neu-
tropenia, lymphopenia, T-cell signaling abnormalities,
and other defects in immune response.
• Newer biologic therapies play a role in immunosup-
pression. These include monoclonal antibodies to tumor
necrosis factor-alpha (TNF-α) (e.g., infliximab, etaner-
cept, and adalimumab) and CD20 (e.g., rituximab).
• The TNF-α agents have been associated with infec-
tions with Mycobacterium tuberculosis, histoplasmo-
sis, Pneumocystis carinii, coccidioidomycosis, and
cryptococcus.
• Anti-CD20 therapies result in B-cell depletion and
decrease production of immunoglobulins.
SYSTEMIC LUPUS ERYTHEMATOSUS
• Systemic lupus erythematosus is a systemic inflam-
matory disease, which can present in a variety of ways
to the ICU.
• Pulmonary disease was the most common cause of
admission in a series of 48 patients, occurring in
18 patients (37.5%). Other manifestations include
neurologic and hematologic phenomena.
• Pulmonary manifestations of SLE include the
following:
 Pulmonary embolism
 Pneumonia
 Pneumonitis
 Pulmonary hemorrhage
 The mortality rates for lupus pneumonitis and pul-
monary hemorrhage are high (up to 50%).
 Patients may present with fever, tachypnea, and
chest pain.
 Hemoptysis does not need to be present.
 Workup includes bronchoscopy or lung biopsy
and markers of disease activity including comple-
ment levels, double stranded DNA antibodies, and
markers of inflammation.
 Infection must be ruled out.
 Treatment should be aggressive although no con-
sensus exists. Therapy includes pulse methyl-
prednisolone 500–1000 mg intravenously for
3–5 days and/or intravenous cyclophosphamide.
Plasmapheresis has been used as a temporizing
measure although there are no controlled trials of
its efficacy.
• Central nervous system (CNS) lupus ranges from cog-
nitive dysfunction or peripheral neuropathy to
seizures, psychosis, septic and aseptic meningitis,
mononeuritis, and rarely transverse myelitis.
• Anemia and thrombocytopenia are common in SLE
and can be refractory to therapy.
• It can be difficult to differentiate active SLE from
thrombotic thrombocytopenic purpura (TTP) as these
have been reported to coexist.
ANTIPHOSPHOLIPID SYNDROME
• Antiphospholipid syndrome (APS) is characterized by
venous or arterial thrombosis and/or pregnancy mor-
bidity in the setting of positive lupus anticoagulant,
anticardiolipin antibodies, or anti-β2-glycoprotein I
antibodies.
• APS can present independently or along with other
connective tissue disease.
• Less than 1% of APS patients present with life-
threatening multiple-organ thrombosis and failure
defined as catastrophic APS (CAPS).
 CAPS is characterized by rapid diffuse small vessel
ischemia and thrombosis affecting parenchymal
organs.
 Conditions associated with CAPS include malignant
hypertension, acute respiratory distress syndrome,
disseminated intravascular coagulation, microan-
giopathic hemolytic anemia, schistocytes, and
thrombocytopenia.
 “Trigger factors” such as recent surgical procedures
or medications such as oral contraceptives have
been described.
 CAPS is fatal in approximately half of all patients
despite treatment.
 First-line treatment consists of immediate anticoag-
ulation with unfractionated or low-molecular weight
heparin and high-dose corticosteroids.
 Corticosteroids are used to inhibit the excessive
cytokine response but does not prevent further
thrombotic events. 
 Intravenous pulse methylprednisolone (1000 mg/day)
for 3–5 days followed by high-dose methylpred-
nisolone (1–2 mg/kg) is most commonly used.
Second-line therapies include IVIg (in patients who
are not IgA deficient) and plasma exchange with or
with out fresh frozen plasma.
SCLERODERMA
• Life-threatening complications of SSc include renal
crisis, undiagnosed or decompensated pulmonary
artery hypertension (PAH), aspiration, alveolar hem-
orrhage, cardiac or gastrointestinal involvement.
• Scleroderma renal crisis presents with malignant
hypertension and can progress to renal failure if treat-
ment is not initiated.
 There is an association with antecedent high-dose
corticosteroids.
 Laboratory data may show proteinuria, increased
serum creatinine, and elevated plasma renin activity.
 A microangiopathic hemolytic anemia may also be
present.
 Treatment includes the early use of angiotensin-
converting enzyme (ACE) inhibitors and hemodialysis.
• SSc patients with PAH may present with symptoms of
right ventricular failure.
 Causes for decompensation should be investigated
including but not limited to infection, thromboem-
bolic disease, acute myocardial infarction, and car-
diac tamponade.
 Initial management should include administration of
oxygen, use of pulmonary vasodilators, cardiac
inotropes, and diuretics.
 Diuresis can improve symptoms, however patients
should be monitored carefully because of preload
dependence.
 Nitric oxide can be used to decrease pulmonary artery
pressure without the risk of systemic hypotension.
 Epoprostenol will reduce right ventricular afterload,
however patients must be monitored for systemic
hypotension. This should be administered in the ICU
with the guidance of a pulmonary artery catheter.
RHEUMATOID ARTHRITIS
• Acute infection is the predominant reason for admis-
sion to the ICU in patients with RA.
• Standard evaluation for infectious source should
include a thorough joint examination as RA patients
are at increased risk for septic arthritis.
• Joint aspiration and culture should be performed espe-
cially if there is asymmetric swelling, redness, and
warmth. The most common pathogen is Staphylococcus
aureus.
• Patients with RA may present with respiratory failure.
 Causes for respiratory failure are similar to those in
the general population, but also include interstitial
lung disease associated with RA, acute laryngeal
stridor, and cricoarytenoid arthritis.
 Airway management in these patients poses a spe-
cial challenge. Obstacles in airway management
include temporomandibular joint involvement,
hypoplasia of the mandible, laryngeal or cricoary-
tenoid arthritis, as well as cervical spine disease
including instability at the atlantoaxial joint. 
 For these reasons caution must be maintained for
endotracheal intubation. It is important to avoid flex-
ion of the neck. The cervical spine should be stabi-
lized prior to intubation and intubation should occur
under fiberoptic visualization. Continued neurologic
monitoring for spinal cord dysfunction should be
performed while patient remains intubated.
INFLAMMATORY MYOPATHY
• Dermatomyositis and polymyositis are idiopathic
inflammatory muscle diseases presenting with proxi-
mal muscle weakness, which may include respiratory
muscles and/or bulbar muscles.
• Severe disease may result in respiratory failure and/or
aspiration.
• Patients who cannot protect their airway or who have
difficulty adequately ventilating may require endotra-
cheal intubation.
• Patients with dysphagia may require an enteral feed-
ing tube to lessen aspiration risk. 
• Electromyogram (EMG) and muscle biopsy are help-
ful in the diagnosis as well as laboratories for muscle
enzymes and pulmonary function tests to diagnose
respiratory muscle weakness.
• Respiratory muscle strength can be assessed at bedside
via measurement of the negative inspiratory force.
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KEY POINTS
• Observation and description of the lesions (morphol-
ogy, distribution, feel) are important in developing a
differential diagnosis.
• Mucous membranes (oral, ocular, nasal, genital, and
perianal) should be examined in all patients.
• The skin may provide clues to an underlying, life-
threatening condition, such as endocarditis, GVHD,
bacterial sepsis, TSS, systemic vasculitis, or compli-
cations of HIV infection.
• Drug-related dermatoses are prevalent in the intensive
care unit. Clues include a rapidly developing eruption;
generalized, symmetrical, predominantly truncal dis-
tribution; maculopapular, urticarial, or acneiform
morphology; and accompanying pruritus.
• Extensive skin disease can cause important fluid, elec-
trolyte, and protein losses and predisposes the patient
to life-threatening infection.
CHARACTERIZING THE LESION
• In approaching a patient with skin disease, careful
observation, palpation, and description are critical in
developing a differential diagnosis.
• Morphology may be flat (macule), elevated (papule,
nodule, plaque, cyst, vesicle, bulla, pustule, hyperker-
atosis), or depressed (ulcer, atrophy).
• Shape, margination (well or poorly defined borders),
and arrangement of the lesions are important.
• Color may be white (leukoderma, hypomelanosis); red
(erythematic); pink; violaceous (purple); brown (hyper-
melanosis, hemosiderin); black; blue; gray; yellow.
• Particular attention should be given to the distribution
of the eruption (e.g., localized, systemic, truncal, acral,
unilateral, or intertriginous).
• Palpation will help determine consistency, tempera-
ture, mobility, tenderness, and depth of lesion.
• When various lesions are present, one should attempt
to identify the primary lesion.
INITIAL APPROACH
• Clinical history is an important part of any diagnosis.
Symptoms (fever, malaise, arthralgias, myalgias, and
so forth) should be questioned with particular attention
paid to cutaneous symptoms (pruritus, pain, tender-
ness, burning, stinging). Careful medication history,
including alternative and herbal remedies, is essential.
• Time course of the skin lesions should be determined
and correlated with recent illness and medications.
• Common diagnostic aids include: skin biopsy for
hematoxylin and eosin (H&E) or other special stain-
ing, direct immunofluorescence (DIF), or culture;
potassium hydroxide (KOH) preparation (for der-
matophytic infections); mineral oil mounts (for sca-
bies); Gram’s stain (for bacterial infections); fluid
cultures; and Tzanck smears (for herpes simplex and
varicella zoster virus infections).
DRUG REACTIONS
• Cutaneous drug reactions are the most common type
of adverse drug reaction, and occur in 2–3% of hospi-
talized patients with 1 out of 1000 patients having a
serious reaction.
• Multiple medications and delayed onset can make deter-
mination of the offending agent difficult in the ICU set-
ting. Commonly identified agents include antiepileptics
(e.g., phenytoin and carbamazepine), antibiotics (e.g.,
amoxicillin, penicillin, fluoroquinolones, sulfonamides,
and cephalosporins), nonsteroidal anti-inflammatory
agents (NSAIDs), and other analgesics.
• Morphology may be maculopapular, morbilliform,
urticarial, fixed drug, or acneiform.
• Eruptions generally develop very rapidly and may be
accompanied by pruritus.
• Onset is usually 1 week after exposure but may be sig-
nificantly delayed, particularly with antibiotics.
• While usually benign, adverse reactions can progress
to toxic epithelial necrolysis (TEN) or the Stevens-
Johnson syndrome. Signs indicative of serious skin
problems include mucosal involvement, blistering
lesions, and a positive Nikolsky sign (sheering of epi-
dermis when lateral pressure is applied to the skin).
• Systemic manifestations include hepatitis, fever,
eosinophilia, glomerulonephritis, anaphylaxis, and
angioedema.
SERIOUS CUTANEOUS DRUG REACTIONS
CHEMOTHERAPEUTIC AGENTS
• Stomatitis occurs in 40% of patients and can lead to
significant discomfort and even difficulties with oral
nutrition. Treatment consists of oral hygiene and
topical regimens consisting of magnesium/aluminum
hydroxide, diphenhydramine elixir, and viscous lido-
caine/benzocaine solutions.
• Care should be taken to distinguish stomatitis from
candidiasis (white adherent velvety plaques) and vari-
cella and herpes zoster (lip and intraoral ulcers) infec-
tion. KOH preparations and Tzanck staining should be
diagnostic in ambiguous situations.
• Extravasation of peripherally infused agents start as
painful erythema and can lead to significant local
tissue necrosis. Treatment consists of elevation of the
effected limb, hot or cold packs, and if necessary sur-
gical debridement. Specific antidotes to some agents
exist and should be used early to prevent progression.
• Acral erythema occurs in 6–24% of patients and con-
sists of painful erythema and edema of the palms and
soles. Symptoms usually resolve within 4 weeks of
discontinuation of offending agent.
ANTICOAGULANT AGENTS
• Subcutaneous heparin on rare occassion is associated
with local delayed type reaction at the injection site
manifested by erythema and vesicular pruritic plaques
(2–5 days) and local skin necrosis (5–10 days).
Reactions are associated with increased risk of
heparin-induced thrombocytopenia. Reports of cross-
reactivity with low-molecular weight heparins and
heparinoids have been reported and thus these agents
should be avoided.
• Warfarin necrosis occurs on rare occasions on initia-
tion of therapy as protein C and S levels decline prior
to fall in procoagulant factors. Lesions, involving the
breast, abdomen, and thighs, start as blue/black
plaques with hemorrhagic bullae that necrose and form
a central eschar. Predisposing factors include protein C
deficiency and factor V Leiden mutations. Surgical
debridement is often necessary but significant mor-
bidity and mortality (15%) persists.
VASOPRESSOR AGENTS
• Extravasation of peripherally infused α1-agonists and
vasopressin can cause severe local ischemic tissue
necrosis. Even with when centrally delivered, high
doses in low flow states (shock) can lead to necrosis
of distal digits and diffuse ischemic skin lesions.
STEVENS-JOHNSON SYNDROME AND
TOXIC EPITHELIAL NECROLYSIS
• Histologically identical lesions, these syndromes are
distinguished by amount of body surface area involved
(SJS <10% and TEN >30%). Erythema multiforme
shares similar histology but is limited to annular ery-
thematous plaques with central areas of blistering and
necrosis (target lesions) involving mucosal and
extremity extensor surfaces.
• Fever, sore throat, and burning eyes may precede erup-
tion of a painful erythematous maculopapular rash.
Early stages may be indistinguishable from benign
drug reactions, but lesions rapidly coalesce, progress
to blisters and epidermal detachment in hours to days.
Mucosal surfaces are involved in 85–95% of cases
and, when present early, suggest a more serious reac-
tion. Ocular and airway and gastrointestinal epithelial
involvement are associated with increased morbidity.
• Anticonvulsants (phenytoin, valproic acid, phenobar-
bital, carbamazepine), antibiotics (sulfonamides,
aminopenicillins), NSAIDs, chlormezanone, allopuri-
nol and, paradoxically, corticosteroids are the most
commonly implicated medications. Reactions occur
more commonly in patients with HIV.
• Treatment is largely supportive and consists of nonad-
herent wrapping of affected areas to limit fluid losses.
Silver or antibiotic (except sulfonamides) impregnated
wraps may help to reduce infection. Airway involve-
ment may require endotracheal intubation and aggres-
sive fluid and electrolyte replacement may be necessary.
Case reports have suggested benefit with early use of
corticosteroids but multiple retrospective series imply a
worse outcome and they are generally considered con-
traindicated. IVIg and plasmapheresis may be beneficial
but no consensus exists on their utility.
MEDICAL DERMATOSES
ERYTHRODERMA
• Erythroderma or exfoliative dermatitis is a descriptive
term for a clinical condition characterized by total
body diffuse erythema and scaling, often accompa-
nied by fever, chills, and lymphadenopathy.
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• Loss of the percutaneous absorption barrier increases
blood flow to the skin and may lead to hypoalbumine-
mia, peripheral edema, loss of muscle mass. High output
cardiac failure may result with as much as 8% of cardiac
output directed to the inflamed cutaneous vasculature.
• Risk factors for erythroderma include inflammatory
conditions (psoriasis, atopic dermatitis, contact der-
matitis, and pityriasis rubra pilaris), drug eruptions,
cutaneous T-cell lymphoma, and systemic neoplasms.
• Treatment consists of careful attention to fluid and
electrolyte balance, temperature regulation, and nutri-
tional status. Topical therapies include medium potency
steroid ointments covered with a bland ointment, such
as zinc oxide ointment and wrapped with clean cloths,
or topical steroids applied directly under a plastic sauna
suit. Topical irritant agents, such as tar containing oint-
ments, should be avoided. Wet dressings may help
weeping or crusted areas. Pruritus and anxiety typically
respond to the sedating antihistamines.
PURPURA
• Purpura results from the extravasation of blood into
surrounding tissues and is associated with many condi-
tions. Lesions are placed into two main categories, pal-
pable or nonpalpable. Assessment of purpura includes
evaluation of the patient’s underlying conditions;
potential precipitating events, current and past labora-
tory values, and medication history are analyzed.
• Nonpalpable (macular), nonblanching purpura arises
from simple hemorrhage into tissue. Petechiae are
lesions <0.2 cm in diameter that result from superfi-
cial vascular hemorrhage. Larger areas are termed
ecchymoses. Nonpalpable purpura is most commonly
attributed to fragility of the vascular tissue or defects
in hemostasis. Examples include platelet disorders
(thrombocytopenia, thrombocytopathia, and thrombo-
cytosis), disseminated intravascular coagulation
(DIC), and warfarin-associated necrosis. Skin biopsy
may be helpful in diagnosis, especially in neutropenic
patients who are unable to mount the immune response
to cause dermal inflammation.
• Palpable purpura indicates underlying vasculitis (also
called cutaneous necrotizing venulitis or leukocytoclas-
tic vasculitis) resulting from segmental vascular inflam-
mation, swelling, and necrosis of endothelial cells, and
neutrophilic infiltration of vessel walls. For the first
24–48 hours, the lesions are a deep erythematous color
that eventually becomes violaceous. Precipitating fac-
tors include infections, drugs, autoimmune diseases,
and immunoglobulin-mediated complement activation.
Common infectious agents include Staphylococcus
aureus, hepatitis B, and hepatitis C. Drugs commonly
associated with vasculitis include ampicillins, thiazides,
phenytoin, sulfa-containing compounds, allopurinol,
hydralazine, and propylthiouracil.
• Workup includes identification of a potential primary
cause and evaluation for systemic involvement. In addi-
tion to a biopsy, a complete blood count, chemistry panel,
liver function tests, urinalysis, stool guaiac, hepatitis B
and C viral serologies, cryoglobulins, and complement
levels are evaluated. Antinuclear antibody (ANA) titers
are evaluated in patients with suspected connective tissue
diseases. In patients with a fever and heart murmur, blood
cultures and echocardiography should be performed.
GRAFT-VERSUS-HOST DISEASE
• Graft-versus-host disease (GVHD) is a complex syn-
drome following allogeneic bone marrow transplanta-
tion. The skin is often the first and is the most frequent
organ involved in GVHD. Biopsy may help distin-
guish GVHD from other causes of erythema such as
drug eruptions or viral exanthems. Acute GVHD usu-
ally occurs between days 10 and 30 after transplanta-
tion, but may appear anytime up to day 100.
• Skin changes consist of a generalized morbilliform erup-
tion progressing to extensive redness, blistering, or skin
necrosis. The earliest sign is pruritus and tenderness of
the palms and soles with reddening of the dorsal aspects
of the fingers followed by diffuse erythema of the hands
and feet. Blisters (with a positive Nikolsky sign) and
generalized desquamation portend a poor prognosis.
• Factors associated with developing GVHD include
recipient cytomegalovirus seropositivity, pretrans-
plant seropositivity for three to four different herpes
viruses in the donor, early engraftment (<15 days),
increased tumor necrosis factor (TNF) during condi-
tioning, and prophylactic monotherapy.
• Treatment for acute GVHD includes continuing the
original immunosuppressive prophylactic regimen
(cyclosporine, tacrolimus, mycophenolate mofetil) and
adding methylprednisolone at 2 mg/kg. Treatment pro-
tocols differ and may include antithymocyte globulin
and monoclonal antibodies. Topical treatment is mainly
supportive with emollients and topical steroids.
INFECTIONS
BACTERIAL INFECTIONS
NECROTIZING FASCIITIS
• This results from a suppurative bacterial infection of the
superficial and soft tissues. Proximal spread along deep
fascial planes can lead to rapid progression to gangrene,
sepsis, and death. Although classically described with
group A streptococcus alone or in combination with
anaerobes, numerous organisms can be implicated
depending on the clinical setting.
• Risk factors include any break in the skin (superficial
infections, surgical procedures, cuts, burns, indwelling
catheters, child birth), obesity, diabetes, cirrhosis, and
immunosuppression (steroids, NSAIDs, TNF-alpha
inhibitors).
• Patients present with erythema, edema, warmth, and
severe tenderness often limited to one limb which may
rapidly progress to a bluish hue with bullae forma-
tion. The diagnosis is primarily clinical. Necrotizing
fasciitis (NF) is distinguished from cellulitis by rapid
progression and the severity of pain on presentation.
Computed tomography (CT) scans may help identify
the extent of involvement, but should not delay or
discourage definitive surgical exploration. Plain radi-
ographs may show air in the soft tissues with con-
comitant anaerobic infections. Measurement of
compartment pressures may help confirm the diagno-
sis. Superficial biopsies and cultures are not useful.
• Treatment consists of antibiotics and emergent fas-
ciotomy and surgical debridement. Antibiotics alone
are ineffective due to the vascular occlusion in
effected areas. There is theoretical support for adding
clindamycin for its disruption or protein synthesis
since much of the intense inflammation is toxin
mediated.
TOXIC SHOCK SYNDROME
• Toxic shock syndrome (TSS) is characterized by fever,
shock, desquamating rash, and multiorgan system fail-
ure in association with toxins mediated from both
group A streptococcal and S. aureus infections.
• Streptococcal TSS usually occurs in association with
soft tissue infections, but less apparent portals can
occur via the vagina or pharynx. Toxins may function
as superantigens, binding directly to major histocom-
patibility complex (MHC) II cells and inducing a mas-
sive T-cell reaction.
• In Staph TSS diagnostic criteria include the presence
of a normal to high normal WBC with extreme left
shift, acute renal failure, hypotension, hypoalbumine-
mia, hypocalcemia, thrombocytopenia, hematuria,
and elevated creatine kinases (CKs). Interestingly,
renal failure often precedes the onset of hypotension.
• Staph TSS occurs in association with overgrowth of
occluded mucosal surfaces (superabsorbent tampons
and nasal packing) and presents with a scarlatiniform
eruption with flexural accentuation. Erythema and
edema of the palms and soles, hyperemia of conjunc-
tiva and mucous membranes, and a strawberry tongue
may also be present.
• Treatment is supportive and consists of penicillin and
clindamycin and vasoactive drugs. IVIg may be of ben-
efit when hypotension is present. Plasmapheresis and
hyperbaric oxygen have also been used in Strep TSS.
STAPHYLOCOCCAL SCALDED SKIN SYNDROME
• A desquamative exanthem that occurs in conjunction
with infection by toxin producing S. aureus. The
majority of patients are under age 5 and adults are only
rarely affected. The major risk factors for developing
staphylococcal scalded skin syndrome (SSSS) in
adults are renal failure (owing to decreased filtration of
toxin), hematologic malignancies, and immunosup-
pression. The concurrent use of NSAIDs may predis-
pose to SSSS.
• Patients may have a preceding upper respiratory infec-
tion with rhinorrhea, pharyngitis, and conjunctivitis.
The exanthem begins abruptly with diffuse tender ery-
thema and subsequent superficial desquamation. Intact
bullae are rarely seen but when present, may have a
positive Nikolsky sign. Biopsy of the blister border
may be necessary to distinguish from TEN.
• Treatment consists of appropriate antibiotics (naf-
cillin, methicillin, dicloxacillin, or a first-generation
cephalosporin) and vigilant monitoring of fluids and
electrolytes. Monotherapy is usually adequate, since
multiresistant strains of S. aureus are rarely encoun-
tered among the toxigenic strains. Healing generally
occurs in 7–10 days.
PSEUDOMONAS BACTEREMIA
• A variety of skin manifestations of Pseudomonas bac-
teremia have been described. Ecthyma gangrenosum,
usually found in the anogenital region, buttocks, or
axilla, occurs in 5% of patients and is characterized by
a localized, erythematous, tender plaque or bulla
which subsequently develops central necrosis leaving
a gangrenous eschar with an erythematous annular
border.
• Vesicles or bullae may occur anywhere either singly or
in clusters. Lesions frequently become hemorrhagic
and may resemble ecthyma gangrenosum lesions
when ruptured.
• Cellulitis, which in contrast to that caused by staphy-
lococcal or streptococcal infections, tends to have
sharply demarcated borders.
• Cellulitis may also form as small pink, round plaques
or subcutaneous nodules concentrated on the trunk
and proximal extremities which when incised and
drained, grow Pseudomonas aeruginosa in culture.
MENINGOCOCCEMIA
• Acute infection with the gram-negative diplococcus
Neisseria meningitidis is associated with petechiae,
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ecchymoses, or palpable purpura, which may herald a
rapidly progressive fatal disease. Petechiae may be
preceded by an urticarial, rubella-like, papular or gen-
eralized scarlatiniform eruption for 2 days.
• Lesions may result from thrombosis precipitated
directly by meningococcus, fibrin, and leukocytes
with a corresponding leukocytoclastic vasculitis or
DIC precipitated by meningococcal endotoxin result-
ing in microvascular fibrin thrombi.
• Differential diagnosis includes gonococcemia, Rickettsial
infection, allergic vasculitis, and bacterial endocardi-
tis. Gonococcemia is usually associated with arthritis
and tenosynovitis. Petechiae of the palms and soles
suggest Rocky Mountain spotted fever (infection with
Rickettsia rickettsii).
• Rapid recognition and prompt antibiotic treatment is
essential to reduce mortality which may be as high as
70% when progressing to shock.
INFECTIVE ENDOCARDITIS
• Petechiae, secondary to microemboli, are found in
approximately 30% of patients. Roth spots may appear
on conjunctiva, buccal mucosa, palate, and retina.
Petechiae on fingers or proximal nail beds manifest as
red to brown streaks termed splinter hemorrhages.
• Petechiae occurring on the palms and soles with a
nodular character are termed Janeway lesions. Lesions
are characteristically nontender and result from septic
emboli consisting of bacteria, neutrophilic infiltration,
and subcutaneous hemorrhage.
• Osler nodes are small 2–15 mm, painful nodules com-
monly found on the pads of the fingers, toes, or thenar
eminences. Osler nodes are seen in 5–15% of patients
with streptococcal-induced infective endocarditis but
may also be seen in systemic lupus erythematosus, endo-
carditis due to fungal or gram-negative bacilli, typhoid
fever, gonococcemia, and in the arms of patients with
cannulated radial arteries.
VIRAL INFECTIONS
HERPES SIMPLEX
• Cutaneous herpes infection, associated with herpes
simplex virus (HSV) types 1 and 2 appear as clusters
of vesicles or shallow erosions, usually over the lips,
genitals, and lumbosacral region but can occur on any
cutaneous area. When vesicles to go undetected, the
patient may present with punched-out erosions or
shallow ulcerations. Chronic perianal HSV ulcers are
easily mistaken for decubitus ulcers. Scalloped bor-
ders and small circular ulcerations at the periphery of
the ulcer may be helpful distinguishing signs.
• Rapid diagnosis may be done by DIF on cells smeared
on a glass slide, or by direct fluorescent antibody
(DFA) testing with monoclonal antibodies on cultured
specimens. Bedside diagnosis can be made with a
Tzanck smear by scraping the base of an unroofed
vesicle with a blade or glass slide revealing multinu-
cleated giant and/or balloon cells.
• All infections encountered in the ICU should be
treated promptly with an antiviral agent such as acy-
clovir, famciclovir, or valacyclovir usually intra-
venously although the medications are effective
orally.
VARICELLA ZOSTER
• Classic cutaneous findings consist of a generalized
eruption of discrete vesicles on an erythematous base
(“dewdrop on a rose petal”) associated with prodro-
mal symptoms of fever and malaise.
• Lesions, which first appear on the trunk and spread to
the extremities, progress from an erythematous papule
to a vesicle to a hemorrhagic crust and may be at var-
ious stages of development at any one time (in con-
trast to small pox in which lesions start centripedally
and all are in the same stage of development).
• Patients are contagious from 2 days prior to the erup-
tion until all lesions have crusted.
• While usually self-limited, infections in adults and the
immunosuppressed can be life threatening. Encephalitis
may be seen in patients with a persistent viremia. An
immune complex vasculitis may lead to pancreatitis,
myocarditis, arthritis, and palpable purpura.
• Zoster (shingles), a recrudescence of latent infection
lying dormant in nerve roots, presents with a pro-
drome of intense pain followed by eruption of lesions
in dermatomal pattern (thoracic 55% and trigeminal
nerves 15–20%).
• Involvement of the eye, caused by infection of the oph-
thalmic branch of the trigeminal nerve, may lead to con-
junctivitis, keratitis, and iridocyclitis. Ophthalmologic
consultation is mandatory.
• In immunosuppressed patients, disseminated herpes
zoster may occur and should be treated with full doses
of intravenous antiviral therapy.
SUPERFICIAL FUNGAL INFECTIONS
• Primary cutaneous infection with Candida albicans is
the most common fungal infection in the ICU.
Lesions consist of bright red, moist plaques with
satellite pustules occurring in moist, warm environ-
ments such as intertriginous areas. Associated skin
breakdown may predispose to secondary bacterial
infections.
• Candidemia, once rare, is a growing concern in ICUs.
Usually associated with central venous lines, neutrope-
nia, or multiorgan failure, candidemia is associated
with a 30% mortality rate despite antifungal therapy.
• The diagnosis is supported by the typical pseudohy-
phae on KOH mount or culture of scales but visual
inspection is often sufficient to begin topical therapy.
PRESSURE ULCERS
• Continuous pressure over a bony site obstructs micro-
circulation, leading to tissue ischemia and necrosis.
Pressure ulcers constitute a major problem in the ICU,
with reported prevalences as high as 40% (two- to
threefold higher than other hospitalized patients).
• Risk factors include the duration of previous surgeries
and number of operations, preoperative protein and
albumin concentrations, skin moisture, use of inotropic
drugs, fecal incontinence or diarrhea, altered circulatory
status, diabetes mellitus, decreased mobility, and high
Acute Physiology and Chronic Health Evaluation II
(APACHE II).
• Ulcers are classified in four grades:
 Stage I: An observable pressure-related alteration
(redness, skin temperature, tissue consistency, and/or
sensation) of intact skin.
 Stage II: Partial thickness skin loss involving epi-
dermis, dermis, or both. The ulcer is superficial and
presents clinically as an abrasion, blister, or shallow
crater.
 Stage III: Full thickness skin loss involving damage
to, or necrosis of, subcutaneous tissue that may
extend down to, but not through, underlying fascia.
The ulcer presents clinically as a deep crater with or
without undermining of adjacent tissue.
 Stage IV: Full thickness skin loss with extensive
destruction, tissue necrosis, or damage to muscle,
bone, or supporting structures (e.g., tendon and joint
capsule). Undermining and sinus tracts also may be
associated with stage IV pressure ulcers.
• Pressure ulcers lead to increased mortality rates,
costs, and lengths of hospital stays and preventive
strategies (risk assessment scales, repositioning the
patient every 2 hours, the provision of dynamic or
static support surfaces that redistribute pressure, and
proper nutrition) should be implemented from the
moment of entry into the ICU.
• Topical treatment consists of maintenance of a moist
environment via one of many different dressings (trans-
parent films, hydrocolloids, alginates, foams, hydro-
gels, or hydrofibers). These dressings require few
changes and result in less need for nursing care, faster
healing, and decreased infection. Gauze dressings,
particularly wet to dry dressings, should be avoided.
Surgery may be required for recalcitrant, full-thickness
ulcers, however, recurrence rates are high.
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123 TOXICOLOGY IN ADULTS
Michael Moore
KEY POINTS
• Supportive management is the most important aspect
of treating most intoxications, although specific anti-
dotes should be considered when indicated.
• Patients with depressed mental status should all receive
empiric therapy with oxygen, dextrose, thiamine, and
naloxone while evaluation is ongoing.
• Identification of toxidromes, guided largely by vital
signs, pupillary findings, and aspects of autonomic
function often helps to identify the class of agents that
may be part of the poisoned patient.
• Poison control center consultation is an extremely useful
source of information.
• An osmolal gap of large magnitude coupled to an anion
gap acidosis suggests methanol or ethylene glycol
poisoning.
EPIDEMIOLOGY
• In 2001, >2 million toxic exposure cases were reported
to poison control centers in the United States.
• 85% were unintentional and 92% involved a single
substance.
• Toxic exposures account for 5–10% of emergency
department (ED) visits and >5% of all adult ICU
admissions.
• Most common exposures: analgesics (10.6%), clean-
ing substances (9.5%), cosmetics (9.2%), foreign
bodies (5.1%), plants (4.7%), sedative-hypnotics
(4.4%), and cough/cold preparations (4.3%).
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• Substances most associated with fatalities: carbon
monoxide (CO), analgesics, sedative-hypnotics,
antipsychotics, antidepressants, street drugs, cardio-
vascular drugs, or alcohols.
GENERAL APPROACH
DIAGNOSIS
• Suspect the diagnosis in patients with the clinical fea-
tures found in Table 123-1.
• The history is paramount but may be missing or
incomplete.
• Look for specific “toxidromes” (see Table 123-2).
• Physical examination:
 Vital signs: tachycardia, bradycardia, hypo/hyperthermia
 Ocular findings: mydriasis versus miosis, horizontal
versus other nystagmus
 Mental status/behavior: depressed mentation, agita-
tion, delirium/confusion
 Muscle tone: dystonias, dyskinesias, rigidity
• Urine toxicology screen can help confirm or refute
exposure but is unlikely to alter early management.
• Measure the anion gap, osmolal gap, and oxygen sat-
uration gap.
• Contact local poison control center for additional help
in suspected poison cases and to help guide initial
management.
MANAGEMENT
• Initial support measures require attention to the “ABCs”
(airway, breathing, circulation).
ELIXIR OF CONSCIOUSNESS
• Administer a combination of thiamine 100 mg IV, dex-
trose 50 g IV, and naloxone (initial dose of 0.2–04 mg
IV) to patients who present with change in mental status.
• Consider administration of flumazenil for suspected
cases of benzodiazepine overdose.
DECONTAMINATION
GENERAL
• Decontaminate skin by removal of toxin with soap and
water. Remove contaminated clothing and store in ade-
quate container to limit ongoing exposure to patient
and health care providers.
• Ocular decontamination may require prolonged irri-
gation with normal saline solution.
EMESIS
• Can be considered for fully awake patient but rarely
used since these patients usually have not ingested
highly toxic substances or quantities.
• Contraindicated in patient at high risk for seizures, or poi-
soning with corrosives, petrolatum products, or antiemet-
ics. Avoid in patients who are at risk for seizures.
• Dose 30 mL followed by 16 oz of water. Can be
repeated in 30 minutes if no effect.
GASTRIC EMPTYING
• Large-bore (Ewald) tubes 37–40 F may be needed to
remove gastric debris.
• Technique: Inspect mouth and clear off foreign mate-
rial. Have suctioning equipment ready. Insert tube and
confirm placement. Immediately withdraw as much
of the gastric contents as possible. Instill 200 mL
bolus of warmed water and aspirate gastric contents.
Repeat until gastric aspirate is clear. This method of
tube placement should not be used in patients with
TABLE 123-1 Clinical Features Mandating Consideration
of Toxic Ingestion
History of drug overdose or substance abuse
Suicidal ideation or prior suicide attempts
History of other psychiatric illness
Agitation and hallucinations
Stupor and coma
Rotary nystagmus
Delirium or confusion
Seizures
Muscle rigidity
Dystonia
Cardiopulmonary arrest
Unexplained cardiac arrhythmias
Hyper/hypotension
Ventilatory failure
Aspiration
Bronchospasm
Liver failure
Renal failure
Hyper/hypothermia
Rhabdomyolysis
Osmolal gap
Anion gap acidosis
Hyper/hypoglycemia
Hyper/hyponatremia
Hyper/hypokalemia
Polypharmacy
SOURCE: Adapted from Corbridge TC, Murry P, Mokhlesi B. Toxicology
in adults. In: Hall JB, Schmidt GA, Wood LDH, eds., Principles of
Critical Care, 3rd ed. New York, NY: McGraw-Hill; 2005: 1506.
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TABLE 123-2 Common Toxidromes
TOXIDROME FEATURE DRUG/TOXIN DRUG TREATMENT
Anticholinergic Mydriasis Antihistamines Physostigmine (do not use in cyclic
“Hot as a hare, dry as a beet, Blurred vision Atropine antidepressant overdose)
mad as a hatter” Fever Baclofen Sodium bicarbonate in cyclic antidepressant
Dry skin Benztropine overdose
Flushing Cyclic antidepressants
Ileus Phenothiazines
Urinary retention Propantheline
Tachycardia Scopolamine
Hypertension
Psychosis
Coma
Seizures
Myoclonus
Cholinergic Salivation Carbamate Atropine
“SLUDGE” Urination Organophosphates Pralidoxime for organophosphates
Diarrhea Physostigmine
GI cramps Pilocarpine
Emesis
Wheezing
Diaphoresis
Bronchorrhea
Bradycardia
Miosis
Beta-adrenergic Tachycardia Albuterol Beta-blockade (caution in asthmatics)
Hypotension Caffeine
Tremor Terbutaline
Theophylline
Alpha-adrenergic Hypertension Phenylephrine Treat hypertension with phentolamine
Bradycardia Phenylpropanolamine or nitroprusside; not with beta-blockers alone
Mydriasis
Beta- and alpha-adrenergic Hypertension Amphetamines Benzodiazepines
Tachycardia Cocaine
Mydriasis Ephedrine
Diaphoresis Phencyclidine
Dry mucus membranes Pseudoephedrine
Sedative/hypnotic Stupor and coma Anticonvulsants Naloxone for opiates
Confusion Antipsychotics Flumazenil for benzodiazepines
Slurred speech Barbiturates Urinary alkalinization for phenobarbital
Apnea Benzodiazepines
Ethanol
Meprobamate
Opiates
Hallucinogenic Hallucinations Amphetamines Benzodiazepines
Psychosis Cannabinoids Haloperidol
Panic Cocaine
Fever LSD
Mydriasis Pneumocystis pneumonia
Hyperthermia (PCP)
Extrapyramidal Rigidity/tremor Haloperidol Diphenhydramine
Opisthotonos Phenothiazines Benztropine
Trismus
Hyperreflexia
Choreoathetosis
Narcotic Altered mental status Dextromethorphan Naloxone
Slow respirations Opioids
Miosis Pentazocine
Bradycardia Propoxyphene
Hypotension
Hypothermia
Decreased bowel sounds
(Continued)
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depressed level of consciousness unless intubation
has been performed, since retching and vomiting is
common.
• Indications: American Academy of Clinical Toxicology
does not recommend routine use of gastric lavage (GL)
unless the patient has ingested a potentially life-
threatening amount of a poison and the procedure can
be performed within 60 minutes of ingestion. The
time to perform GL may be increased if the toxin is
known to delay gastric emptying.
• Contraindications: Obtunded, comatose, or convuls-
ing patients. Also ingestion of sustained-release or
enteric-coated tablets and probably caustic liquids to
avoid aspiration-induced lung injury.
ACTIVATED CHARCOAL
• Activated charcoal is a nontoxic, inert, nonspecific
adsorbent that binds intraluminal drugs and decreases
systemic absorption.
• Very effective for high molecular weight substances.
• Indications: As sole decontaminate or used after GL
or ipecac-induced emesis.
• Contraindications: Patients unable to protect airway
or during seizures.
• Complications: pneumonia, bronchiolitis obliterans,
acute respiratory distress syndrome (ARDS), death.
• Dosing: If quantity of toxin known, give 10:1 charcoal:
toxin ratio; can dose by weight 1 g/kg.
WHOLE-BOWEL IRRIGATION
• Polyethylene glycol (Colyte®) or potassium chloride
(Golytely®) can be used to clear gastrointestinal (GI)
tract of tablets or packages.
• Usual dose is 1–2 L/h.
• May be particularly effective in cases of ingestion of
sustained-release tablets, drugs where activated charcoal
is not effective (iron, lithium), or in cases of “body
packing.”
• Contraindications: ileus, GI hemorrhage, bowel
perforation.
ENHANCEMENT OF ELIMINATION
MULTIPLE-DOSE ACTIVATED CHARCOAL
• Can enhance elimination of drugs that have already
been absorbed.
• Interrupts enterohepatic/enterogastric circulation or
binds drugs that can diffuse from circulation into
gut lumen.
• Dose: initial 1 g/kg followed by 0.5 g/kg every 2–4
hours for at least 3 doses.
• Contraindications: inability to protect airway.
• Avoid cathartics to avoid hypernatremia, hypokalemia,
and hypermagnesemia.
• Not studied in clinical trials; not shown to decrease
morbidity or mortality.
• Should be reserved for life-threatening ingestion of
carbamazepine, dapsone, phenobarbital, quinine, or
theophylline.
HEMODIALYSIS
• Effective for removal of certain toxins and drugs (low
molecular weight, water soluble, low protein binding,
and small volume of distribution).
• Consider in cases where clearance is expected to be
delayed or insufficient secondary to renal or hepatic
insufficiency, toxin produced toxic metabolites, or
when delayed toxicity is characteristic.
• Early use of hemodialysis (HD) is recommended for
intoxication with methanol, ethylene glycol, boric
acid, salicylates, and lithium.
• Effective for use in heavy metal intoxication in
patients with renal failure.
TABLE 123-2 Common Toxidromes (Continued)
TOXIDROME FEATURE DRUG/TOXIN DRUG TREATMENT
Serotonin syndrome agents Irritability Fluoxetine Benzodiazepines
Hyperreflexia Meperidine
Flushing Paroxetine
Diarrhea Sertraline
Diaphoresis Trazodone
Fever
Trismus
Tremor
Myoclonus
SOURCE: Corbridge TC, Murry P, Mokhlesi B. Toxicology in adults. In: Hall JB, Schmidt GA, Wood LDH, eds., Principles of Critical Care, 3rd ed.
New York, NY: McGraw-Hill; 2005: 1507.
HEMOPERFUSION
• Blood is pumped through an adsorbent system (usu-
ally a charcoal canister).
• Has been effectively used for intoxications with theo-
phylline, phenobarbital, phenytoin, carbamazepine,
paraquat, and glutethimide.
• Less effective for lithium, ethanol, methanol, CO,
cocaine, and phencyclidine.
• Complications: cartridge saturation, thrombocytope-
nia, hypoglycemia, hypocalcemia, hypothermia, char-
coal embolization.
HEMOFILTRATION
• Utilizes a highly porous membrane to remove drugs
and toxins by convection.
• Potentially useful for removal of toxins that have a
large volume of distribution, slow intracompartmental
transfer, or extensive tissue binding.
• Specific hemofiltration cartridges can be used to effec-
tively remove digoxin-Fab complexes, deferoxamine-
iron complexes, and aluminum.
INDICATIONS FOR ADMISSION
TO INTENSIVE CARE UNIT
• Based on observed and predicted severity of toxicity.
• Patients with mild toxicity or low predicted severity
can be observed in the ED until asymptomatic.
Patients with observed or predicted moderate toxicity
should be admitted to an appropriate observation unit.
• One study retrospectively identified eight clinical
risk factors in poisoned patients who are likely to
require ICU interventions: PaCO2 >45 mmHg, need
for endotracheal intubation, toxin-induced seizures,
cardiac arrhythmias, QRS duration ≥0.012 seconds,
systolic blood pressure (BP) <80 mmHg, second- or
third-degree AV block, unresponsiveness to verbal
stimuli.
• See Table 123-3 for list of ICU admission criteria.
SELECTED SPECIFIC INTOXICATIONS
(LISTED ALPHABETICALLY)
ACETAMINOPHEN
• Most common overdose reported to poison control
centers.
• Rapid oral absorption with peak levels in <1 hour.
• The toxic threshold is 150 mg/kg or 7.5–10 g in
adults.
• There are four phases of toxicity:
 Phase 1: first 24 hours: malaise, pallor, diaphoresis,
nausea, and vomiting
 Phase 2: 24–48 hours: onset of right upper quadrant
(RUQ) pain and liver function test abnormalities.
Initial symptoms may improve
 Phase 3: 48–96 hours: encephalopathy, hypo-
glycemia, and coagulopathy. Aspartate transaminase
(AST)/alanine transaminase (ALT) levels usually
peak (≥10,000 IU/L) with severely abnormal pro-
thrombin time and total bilirubin levels. Rare phase
3 complications include acute renal failure, hemor-
rhagic pancreatitis, and myocardial necrosis
 Phase 4: >96 hours: full recovery or death
• The modified Rumack-Matthew nomogram allows
stratification of risk based on acetaminophen level
and time since ingestion (see Fig. 123-1).
• Successful use of the Rumack-Matthew nomogram
requires attention to its limitations:
 Less useful when patients present early (<4 hours)
or late (>24 hours)
 Chronic ingestion or ingestion with extended-release
products
 Nomogram does not take into account patients at
high risk of toxicity (chronic alcohol users or
patients with induced cytochrome P-450 system)
• Activated charcoal is the treatment of choice for gas-
tric decontamination. GL is reasonable if adminis-
tered within 1 hour of ingestion.
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TABLE 123-3 Indications for Admission to ICU
Respiratory depression (PaCO2 >45 mmHg)
Seizures
High-degree AV block
Systolic BP <80 mmHg
Glasgow Coma Scale <12
Need for emergent HD, hemoperfusion, or extracorporeal membrane
oxygenation (ECMO)
Increasing metabolic acidosis
Hypo- or hyperthermia
Tricyclic or phenothiazine overdose with anticholinergic signs, neurologic
abnormalities, or prolonged QRS/QT
Body packers
Drug bezoars
Need for naloxone by continuous infusion
Digitalis overdose and hypokalemia
Antivenom for envenomations
SOURCE: Adapted from Mokhlesi B, Leiken JB, Murry P. Adult
toxicology in critical care. Part I. General approach to the intoxicated
patient. Chest 2003;123:589.
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• Indications for N-acetylcysteine (NAC) include:
 Possible or probable risk of hepatic toxicity based
on Rumack-Matthew nomogram
 Acetaminophen level >5 µg/mL if time since inges-
tion unknown
 Evidence of hepatotoxicity
 Serum acetaminophen levels unavailable
• NAC is given as a 5% solution in juice with oral load-
ing dose of 140 mg/kg followed by maintenance dose
of 70 mg/kg q 4 h for 17 doses. Antiemetics can be
given with repeat doses if patient vomits.
• IV dosing is now Food and Drug Administration
(FDA) approved.
• Poor outcomes are seen in patients who present late or
whose course is complicated by grade 3 or 4
encephalopathy, prolonged prothrombin time (PT),
renal dysfunction, sepsis, or cerebral edema.
ALCOHOLS
• Ethylene glycol, methanol, and isopropanol are the most
commonly ingested nonethanol alcohols. Intoxication
suggested by signs and symptoms of inebriation with
low or undetectable ethanol levels. Elevated anion gap
and/or elevated osmolal gap are cardinal features of
methanol and ethylene glycol intoxication. All are rela-
tively weak toxins but all have toxic metabolites.
ETHYLENE GLYCOL
• Odorless and sweet tasting.
• Contained in antifreeze, deicers, and industrial solvents.
• Has a positive urinary fluorescence under a Wood
lamp because of added dye.
• Metabolized eventually to oxalic acid.
• Precipitation of oxalic acid to calcium oxalate in the
renal tubules produces calcium oxalate crystals. This
contributes to development of acute tubular necrosis.
• Other complications include hypocalcemia and
myocardial dysfunction.
• Ingestion of 100 mL can be lethal with significant tox-
icity at serum levels of >50 mg/dL.
• Clinical course:
 Stage I: 30 minutes to 12 hours postingestion: ine-
briation, ataxia, seizures, variable levels of elevated
anion gap metabolic acidosis with Kussmaul breath-
ing, elevated osmolal gap, crystalluria, hypocal-
cemia; death or coma can occur from cerebral edema
 Stage II: 12–24 hours postingestion: myocardial dys-
function, high or low pressure pulmonary edema;
death can occur from myocardial dysfunction or
aspiration pneumonia
 Stage III: 2–3 days postingestion: acute renal failure
 Late: 6–18 days postingestion: neurologic sequelae
• Treatment:
 Inhibition if alcohol dehydrogenase and dialytic
removal is cornerstone of therapy.
 Supportive therapy includes GL in the first hour
postingestion, thiamine, folate, and pyridoxine.
Correct hypoglycemia and hypocalcemia.
 Inhibition of formation of toxic metabolites:
 Fomepizole: does not require blood monitoring;
15 mg/kg loading dose followed by a 10 mg/kg IV
bolus q 12 h; after 48 hours, increase bolus dose to
15 mg/kg q 12 h. Continue therapy until levels
<20 mg/dL.
 Ethanol: can be given PO or IV to maintain serum
levels between 100 and 200 mg/dL. Exacerbates
inebriated state and requires monitoring of levels.
 Indications for HD include ethylene glycol level
>50 mg/dL, significant and refractory metabolic
acidosis, or evidence of end-organ damage.
METHANOL
• Colorless, odorless, bitter tasting, and highly volatile.
• Commonly found in paint removers, duplicator fluid,
gas-line antifreeze, windshield washing fluid, and
canned solid fuel.
• Lethal doses can be as little as 150–240 mL of a 49%
solution.
• Intoxication can occur via ingesting, inhalation, or
dermal absorption.
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FIG. 123-1 Rumack-Matthew Nomogram.
SOURCE: Reproduced with permission (pending) from Rumack
BH. Acetaminophen overdose in children and adolescents.
Pediatr Clin North Am 1986;33:691.
• Metabolized by alcohol dehydrogenase to formalde-
hyde which is subsequently converted to formic acid
by aldehyde dehydrogenase. Formic acid is primarily
responsible for metabolic and ocular toxicity.
• Clinical course:
 Initially: headache, inebriation, dizziness, ataxia, and
confusion.
 Formic acid accumulates over 6–12 hours, the anion
gap increases, visual symptoms become more
prominent; other complications include pancreatitis.
• Treatment:
 Similar to ethylene glycol intoxication.
 HD is indicated for serum levels >50 mg/dL, sus-
pected ingestion of lethal dose, significant and refrac-
tory metabolic acidosis, or evidence of end-organ
damage.
 Continue HD until acidosis resolves and level is
<25 mg/dL.
ISOPROPANOL
• Colorless, bitter tasting, with smell of acetone or
alcohol.
• Commonly found in rubbing alcohol, skin lotions,
hair tonics, aftershave, deicers, and glass cleaners.
• Isopropanol is metabolized by alcohol dehydrogenase to
acetone. Acetone is eliminated via the kidneys and lungs.
• Diagnosis of isopropanol exposure is suggested by the
combination of ketonemia, ketonuria, sweet-smelling
breath, and absence of anion gap or metabolic acido-
sis along with hemorrhagic gastritis and an elevated
osmolal gap. Diagnosis is confirmed by measuring
serum levels.
• Treatment:
 Supportive measures; GL in first hour postingestion.
 HD is indicated when lethal doses have been
ingested (150–240 mL of a 40–70% solution), lethal
level detected in serum (>400 mg/dL), refractory
shock, or prolonged coma.
AMPHETAMINES
• Includes illicit drugs like methamphetamine (“crank”),
3,4-methylenedioxy-methamphetamine (“ecstasy”),
prescription stimulants: methylphenidate, dextroam-
phetamine, pemoline, and prescription anorexiants:
diethylpropion and phentermine.
• Toxicity occurs via central nervous system (CNS)
stimulation, peripheral release of catecholamines,
inhibition of reuptake of catecholamines, or inhibition
of monoamine oxidase.
• Low therapeutic index.
• Signs and symptoms of overdose: confusion, irritability,
tremor, anxiety, agitation, mydriasis, tachyarrhythmias,
myocardial ischemia, hypertension, hyperreflexia,
hyperthermia, rhabdomyolysis, renal failure, coagu-
lopathy, seizures.
• Death can result from hyperthermia, arrhythmias,
status epilepticus, intracranial hemorrhage, fulminant
liver failure, or aspiration pneumonia.
• Treatment is supportive with attention to specific
signs and symptoms:
 Hypertension: phentolamine or nitroprusside
 Tachyarrhythmias: esmolol or propranolol
 Agitation/violent behavior/psychosis: haloperidol,
droperidol, benzodiazepines, or phenothiazines
 Hyperthermia: cooling measures if temperature >40°C
• GL is effective if performed within 1 hour of ingestion.
• HD and hemoperfusion are not effective.
BARBITURATES
• Phenobarbital is prototypical agent.
• Mild-to-moderate overdose is characterized by decreased
level of consciousness, slurred speech, and ataxia.
• Higher doses cause hypothermia, hypotension, brady-
cardia, flaccidity, hyporeflexia, coma, and apnea.
• Severe overdose can result in the appearance of brain
death with absent electroencephalogram (EEG) activity.
• Cardiovascular and respiratory depression result in a
hypotensive, hypercapnic, and hypoxemic state.
• Diagnosis is made clinically with confirmation of bar-
biturate exposure by routine toxicology screen. Serum
levels correlate with severity but usually do not
change management.
• Treatment:
 Supportive
 No antidote available
 GL is useful for acute massive overdose within the
first hour
 Multiple-dose activated charcoal, charcoal hemop-
erfusion, and urinary alkalinization (phenobarbital
only) enhances elimination
• If CNS depression persists, other etiologies should be
considered.
BENZODIAZEPINES
• Common therapeutic agents used as hypnotics, anxi-
olytics, muscle relaxants, and sedatives.
• Frequently involved in single and multiple drug
overdoses.
• Symptoms range from slurred speech and lethargy to
respiratory arrest and coma.
• Benzodiazepines increase the inhibitory effects of
gamma-aminobutyric acid (GABA) and cause general
CNS depression.
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• Diagnosis is clinical with confirmation of exposure by
routine urine toxicology.
• Benzodiazepine coma patients present with hypore-
flexia and small-to-midsize pupils.
• Treatment:
 Supportive measures initially
 Gastric emptying if performed within the first hour
postingestion
 Activated charcoal
 No role for forced diuresis, dialysis, or hemoperfusion
 Consider antidote flumazenil
• Flumazenil is a specific benzodiazepine antagonist:
 Helpful as diagnostic challenge as it does not antag-
onize the effects of other CNS depressants.
 May precipitate seizures in patients with mixed ben-
zodiazepine and tricyclic antidepressant overdose or
unmask seizure from any cause.
 Avoid in patients taking benzodiazepines for control
of seizures or increased intracranial pressure.
 Can precipitate acute withdrawal in patients chroni-
cally exposed to these agents.
 Initial dose is 0.2 mg IV over 30 seconds, repeat
with 0.3 mg if no effect seen in 30 seconds.
Additional doses can be given at 1-minute interval
to a total loading dose of 3 mg.
 Monitor for resedation which may occur 1–2 hours
after administration.
BETA-BLOCKERS
• Competitive antagonists of beta-receptors found in the
heart (β1) and bronchial tree (β2).
• Clinical features are variable but toxicity is increased
in patients exposed to other cardioactive drugs and
beta-blockers with membrane stabilizing effects (ace-
butolol, betaxolol, pindolol, propranolol).
• Diagnosis is clinical. Serum levels are available but do
not correlate well with toxicity.
• Cardiovascular toxicity is usually seen within 4 hours
postingestion. Asymptomatic patients with normal
ECGs after 6 hours do not require ICU monitoring.
• Signs and symptoms of toxicity include hypotension,
bradycardia, atrioventricular blocks, and congestive
heart failure (CHF) with or without pulmonary edema.
Other effects include bronchospasm, hypoglycemia,
hyperkalemia, lethargy, stupor, coma, and seizures.
There is an increased risk of seizures and cardiac arrest
with propranolol.
• Treatment:
 Supportive measures are indicated initially.
 Induced emesis is contraindicated.
 GL and activated charcoal if performed within 1 hour
of ingestion.
 Cardiovascular manifestations can be treated with
IV fluids, vasopressor therapy, transvenous pacing,
and glucagon.
• Glucagon as antidote:
 Positive inotropic and chronotropic effects mediated
via increases in cyclic adenosine monophosphate
(cAMP).
 Bolus dose of 5–10 mg IV over 1 minute followed
by maintenance infusion of 1–10 mg/h.
 Dilute in normal saline of dextrose solution to pre-
vent phenol toxicity.
CALCIUM CHANNEL BLOCKERS
• Selectively inhibit calcium flux in cardiac and vascu-
lar smooth muscle.
• Cardiovascular effects are dependent on class effects.
Dihydropyridine causes peripheral vasodilatation.
Verapamil and diltiazem have negative inotropic effects,
depress the sinus node, and slow conduction through the
AV node.
• Signs and symptoms of toxicity including hypoten-
sion (most common) generally occur within 6 hours
with immediate release and 12 hours with sustained-
released formulations. Other effects may include
hyperglycemia, lethargy, confusion, and coma.
• Treatment:
 Poisoning with sustained-release products may be
treated with GL up to 8 hours postingestion and
whole-bowel irrigation.
 Multiple-dose activated charcoal and HD are not
usually helpful.
 In hepatic dysfunction, verapamil overdose has been
treated with charcoal hemoperfusion.
 Hypotension is managed with IV fluid.
 Refractory hypotension can be treated with calcium
gluconate and/or glucagon.
CARBON MONOXIDE
• Nonirritating, colorless, tasteless, and odorless gas
produced by incomplete combustion of carbon
fuels.
• Toxicity is usually seen in setting of smoke inhalation,
attempted suicide from automobile exhaust, and poorly
ventilated charcoal or gas stoves.
• Most common cause of death by poisoning in the
United States.
• Mechanism of CO toxicity:
 Has 240 times greater affinity for hemoglobin versus
oxygen.
 Decreases oxyhemoglobin and oxygen-carrying
capacity.
 Results in tissue hypoxia and directly inhibits
cellular respiration via cytochrome oxidase
blockade.
• Diagnosis:
 Have a high level of suspicion especially during cold
months.
 Historical clues include symptomatic coinhabitants,
suspect heating devices, and problems with forced-
air heating systems.
 Carboxyhemoglobin (COHb) levels are determined
by co-oximetry.
 Pulse oximetry does not differentiate between
COHb and oxyhemoglobin and overestimates oxy-
hemoglobin levels.
• Clinical features:
 COHb levels up to 5% are generally well tolerated.
 Mild toxicity (COHb 5–10%): headache, mild dys-
pnea. These levels can be seen in heavy smokers and
commuters on polluted roads.
 Moderate (COHb 10–30%): headache, dizziness,
weakness, dyspnea, irritability, nausea, and vomiting.
 Severe (COHb 10–30%): coma, seizures, cardiovas-
cular collapse, and death.
 COHb levels do not always correlate well with clin-
ical severity.
 Delayed neuropsychiatric sequelae (DNS):
 10–30% of survivors of CO intoxication.
 Symptoms include persistent vegetative state,
short-term memory loss, behavioral change, hear-
ing loss, incontinence, and psychosis.
 Most patients (50–70%) will have full recovery at
1 year.
• Treatment:
 Administration of 100% oxygen decreases the half-
life of COHb from 5 to 6 hours in ambient air to
40–90 minutes.
 Hyperbaric oxygen therapy can additionally
decrease the half-life to 15–30 minutes.
COCAINE
• Can be snorted nasally, orally ingested, smoked (crack
cocaine), or injected IV.
• Toxicity stems from excessive CNS stimulation and
inhibition of neural uptake of catecholamines.
• Onset of effects depends on route of administration,
dose, and patient tolerance.
• Coingestion is common with heroin, phencyclidine,
and alcohol.
• Toxicity:
 CNS: euphoria, anxiety, agitation, psychosis, delirium,
seizures
 Cardiovascular: chest pain, myocardial ischemia,
infarction, sudden death, arrhythmias, CHF, pul-
monary hypertension, endocarditis, aortic dissection
 Respiratory:
 Status asthmaticus, upper airway obstruction, baro-
trauma, pulmonary edema, alveolar hemorrhage
 Acute pulmonary syndrome associated with crack
cocaine and characterized by dyspnea, diffuse
infiltrates, and hemoptysis
 Renal: acute rhabdomyolysis
 Other: hyperthermia, muscle rigidity, disseminated
intravascular coagulation (DIC), multiple system
organ failure (MSOF)
• Treatment:
 ABCs with immediate treatment of seizures, hyper-
thermia, or agitation
 Decontamination with activated charcoal for oral
ingestion
 Enhanced elimination: HD and hemoperfusion
ineffective
 Avoid unopposed beta-blockade
 Symptom-based:
 Hyperthermia: active and passive cooling
 Agitation: benzodiazepines
 Chest pain: nitrates and calcium channel blockers
 Bronchospasm: bronchodilators and corticosteroids
CYANIDE
• Found in a variety of materials including plastics, glue
removers, wool, silks, various seeds, and plants.
• Poisoning usually occurs through inhalation of hydro-
gen cyanide gas when cyanide-containing products
are burned. May also occur with nitroprusside infu-
sion or when absorbed through skin from cyanide-
containing solutions.
• Mechanism: inhibits cellular cytochrome oxidase and
interferes with aerobic oxygen consumption.
• Toxicity:
 Early signs include anxiety, headache, confusion,
tachycardia, and hypertension.
 Rapidly progresses to include stupor, coma, seizures,
fixed and dilated pupils, hypoventilation, bradycar-
dia, heart block, ventricular arrhythmias, and cardio-
vascular collapse.
• Diagnosis:
 Usually made clinically based on history of smoke
inhalation.
 Rapid onset of coma, seizures, cardiovascular dys-
function in setting of severe lactic acidosis.
 Blood level >0.5 mg/L is toxic.
 Other hints include “arterialization” of venous
blood seen on ophthalmoscopic examination or
bitter almond smell of hydrogen cyanide gas.
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• Treatment:
 Most efficacious if started early.
 Gastric emptying followed by activated charcoal
appropriate for acute ingestions.
 Immediate 100% oxygen therapy via mask or endo-
tracheal tube (ETT).
 Induce methemoglobinemia to scavenge unbound
cyanide with amyl or sodium nitrite:
 Amyl nitrite: inhaled by crushable pearls for
15–30 seconds with 30 seconds breaks in between
inhalations
 Sodium nitrite: 300 mg over 3 minutes IV
 Induced methemoglobin levels usually <20%
 Avoid methylene blue to treat methemoglobinemia
 Sodium thiosulfate enhances conversion of cyanide
to thiocyanate:
 12.5 mg IV over 10 minutes
 May repeat 1/2 dose after 2 hours
 HD is effective for possible thiocyanate toxicity
CYCLIC ANTIDEPRESSANTS
• Tricyclic antidepressants responsible for majority of
antidepressant-related fatalities.
• Mechanism of toxicity is related to anticholinergic
effects, inhibition of neurotransmitter reuptake, periph-
eral alpha-blockade, and cardiac membrane depressant
effects.
• Clinical presentation:
 Anticholinergic effects: mydriasis, blurred vision,
fever, dry skin/mucus membranes, lethargy, delirium,
coma, tachycardia, ileus, myoclonus, urinary retention
 Cardiovascular:
 Sinus tachycardia with prolongation of QRS,
QTc, PR intervals
 Ventricular tachycardia
 QRS interval (limb lead) >0.10 seconds predicts
seizures
 QRS duration >0.16 seconds associated with ven-
tricular arrhythmias
 Atrioventricular block
 Hypotension
 Neurologic: seizures, mental status changes
• Diagnosis:
 Can be made when there is a compatible history and
consistent clinical features.
 Suspect in all patients with a prolonged QRS
duration.
 Confirm exposure with urine toxicology screening.
 Blood levels are available but not necessary as ECG
findings adequately predict severity.
• Treatment:
 Supportive while identifying potentially life-
threatening complications
 Immediate serum alkalinization if QRS prolonged:
 Sodium bicarbonate 1–2 meq/kg IV
 Continue until QRS interval normalizes or pH >7.55
 Hyperventilation in intubated patients
 Decontamination:
 GL (within 2 hours postingestion)
 Single-dose activated charcoal
 Induced emesis contraindicated
 Dialysis and hemoperfusion not effective
 Specific complications:
 Refractory ventricular arrhythmias: lidocaine drug
of choice
 High-grade AV block: temporary ventricular
pacing
 Hypotension: fluids, vasopressors
 Seizures: benzodiazepines, phenobarbital
 Refractory seizures: phenytoin, paralysis, or deep
sedation
 ICU monitoring for mental status changes, seizures,
hypotension, metabolic acidosis, or cardiac arrhythmias
γ-HYDROXYBUTYRATE
• Drug of abuse also known as liquid ecstasy, liquid G,
date-rape drug, fantasy.
• Mechanism: derived from GABA and may act as an
inhibitory neurotransmitter through γ-hydroxybutyrate
(GHB) receptors or via GABA receptors.
• Not used clinically; banned by FDA outside of clini-
cal trials.
• Toxicity:
 Tolerance and dependence has been reported
 Delirium and psychosis after abrupt withdrawal
 Low doses result in euphoria, emesis, hypothermia,
symptomatic bradycardia, hypotension, respiratory
acidosis
 High doses can result in deep coma and death
• Treatment:
 Supportive
 Expect coingestions
 Decontamination: not reported
 Antidotes: no role for naloxone
 Patients usually will regain consciousness sponta-
neously after 5 hours
• Diagnosis:
 No readily available diagnostic tests
 Can be detected in blood and urine by specialized
laboratories
LITHIUM
• Monovalent cation used in the treatment of bipolar
affective disorders.
• Low therapeutic index.
• Poisoning most often accidental in patients on chronic
therapy or deliberate overdose with suicidal intent.
• Risk factors for toxicity in chronic users:
 Elderly
 Long-term therapy increases half-life of lithium
 Volume depletion
 Renal insufficiency
• Toxicity:
 Mild:
 <2.5 meq/L
 Tremor, ataxia, nystagmus, choreoathetosis, pho-
tophobia, lethargy
 Moderate:
 2.5–3.5 meq/L
 Agitation, fascicular twitching, confusion, nausea,
vomiting, diarrhea, signs of cerebellar dysfunction
 Severe:
 >3.5 meq/L
 Seizures, coma, sinus bradycardia, hypotension
 Levels do not correlate well with symptoms in acute
toxicity
 Chronic or acute-on-chronic toxicity:
 Levels better correlated with symptoms
 Severe symptoms may occur at lower serum levels
 Associated with diabetes insipidus, renal insuffi-
ciency, hypothyroidism, and leukocytosis
• Treatment:
 Supportive including treatment of seizures and
hypotension with vasopressors
 Decontamination:
 GL
 Activated charcoal not indicated
 Sodium polystyrene: monitor for hypokalemia
 Whole-bowel irrigation for sustained-release tablets
 Enhanced elimination:
 HD
• Prototypical dialyzable intoxicant
• Indications:
 Acute intoxication serum level >3.5 meq/L
 Chronic intoxication, renal insufficiency, or
symptomatic patients with level >2.5 meq/L
 Any serum level after large ingestion
• May need to repeat HD secondary to drug
redistribution
 Multidose sodium polystyrene may result in GI
dialysis
 Saline and forced alkaline diuresis are not
indicated
METHEMOGLOBINEMIA
• Formed by oxidation of reduced hemoglobin (Fe2+) to
methemoglobin (Fe3+).
• Pathophysiology:
 Cannot bind and transport oxygen
 Shifts oxyhemoglobin dissociation curve to left
• Etiology:
 Includes hereditary, dietary, drug-induced, idiopathic
 Acquired methemoglobinemia is usually oxidant
drug or toxin exposure induced
 Many drugs are associated:
 Antibiotics: dapsone, chloroquine, primaquine,
sulfonamides
 Anesthetics: lidocaine, benzocaine, bupivacaine
 Nitrates: isosorbide dinitrate, nitric oxide, nitro-
glycerine, nitroprusside
• Clinical features:
 Mild:
 MetHb <15%
 May see cyanosis but usually asymptomatic
 May be significant in setting of critical coronary
artery stenosis
 Moderate:
 MetHb 15–60%
 Dyspnea, headache, weakness
 Severe:
 MetHb >60%
 Confusion, seizures, death
• Diagnosis:
 Co-oximetry: can accurately measure both MetHb
and oxygen saturation levels
 Pulse oximetry: cannot directly measure MetHb levels
and may over- or underestimate the true oxygen
saturation
 “Chocolate” color of blood that does not change on
exposure to air
• Treatment:
 General supportive care and removal of inciting agent
 Decontamination with GL followed by activated
charcoal
 Antidote:
 Methylene blue:
• Increases conversion of MetHb to Hb
• Consider use in symptomatic patients
• Dose 1–2 mg/kg IV over 5 minutes, repeat after
60 minutes
• Contraindications:
 Glucose-6-phosphate dehydrogenase deficiency
 Renal failure
 Failure to respond suggests cytochrome b5
reductase deficiency, glucose-6-phosphate dehy-
drogenase deficiency, or sulfhemoglobinemia
OPIOIDS
• Produce generalized depression of CNS via opioid
receptor.
• Coingestions are common.
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• Toxicity:
 Severity depends on dose, drug type, and patient
tolerance
 Mild or moderate overdose:
 Lethargy, miosis, hypotension, sinus bradycardia,
diminished bowel sounds, flaccid muscles
 Severe overdose:
 Respiratory depression, apnea, coma
 Death is usually a result of respiratory failure
 Respiratory failure may be multifactorial:
 Alveolar hypoventilation
 Aspiration pneumonitis
 Low pressure pulmonary edema:
• Often presents after resuscitation
• Idiopathic response
• Complication of naloxone
 Seizures are most likely to be seen after overdose
with propoxyphene and meperidine
• Diagnosis:
 Usually made on clinical grounds.
 Rapid response to naloxone supports diagnosis but
is neither sensitive nor specific.
 Urine toxicology screening confirms opioid exposure.
 Blood toxicology screening is more sensitive.
• Treatment:
 Initial supportive measures
 Naloxone is specific opioid antagonist:
 Reverses sedation, hypotension, and respiratory
depression
 Administration:
• Initial dose 0.2–0.4 mg IV
• Repeat 1–2 mg IV if no response after 2–3 min-
utes to total dose of 10 mg
• Half-life 45–90 minutes and may need to
repeat every 20–60 minutes to maintain clinical
response
• Continuous infusion at 0.4–0.8 mg/h can be
used
• Side effects include pulmonary edema and
seizures
 In general, if no response after 10 mg opioid over-
dose can be ruled out
 Supplemental oxygen and mechanical ventilation
may be required to treat alveolar hypoventilation
and hypoxemia
 Decontamination:
 GL (if oral intoxication), followed by
 Activated charcoal
 Time when GL useful; increased secondary to
delayed gastric emptying
 Ensure adequate airway protection prior to lavage
or activated charcoal
 Enhanced elimination: no role for HD, hemoperfu-
sion, or forced diuresis secondary to large volume of
distribution
ORGANOPHOSPHATES/CARBAMATE
INSECTICIDES
• Widely used as insecticides in the United States.
• Organophosphates also used as nerve agents in chem-
ical warfare.
• Exert toxicity by inhibiting acetylcholinesterase.
• Reversible (carbamates) or irreversible (organophos-
phates) inhibition of acetylcholinesterase causes the
accumulation of acetylcholine at parasympathetic
synapses leading to the cholinergic syndrome.
• Exposure is usually through the GI tract but sub-
stances can also be absorbed through the skin, con-
junctiva, and respiratory tract.
• Exposure is usually accidental but occasionally with
suicidal intent.
• Clinical features:
 Symptoms are the result of overstimulation of mus-
carinic, nicotinic, and CNS receptors
 Muscarinic: characterized by SLUDGE (Salivation,
Lacrimation, Urination, Diarrhea, GI cramps, and
Emesis). Also blurred vision, miosis, bradycardia,
and wheezing
 Nicotinic: muscle fasciculations and weakness;
severe overstimulation of nicotinic receptors results
in hypertension, tachycardia, paresis, paralysis, and
respiratory failure
 CNS: organophosphates (not carbamates) enter the
CNS and induce anxiety, confusion, seizures, psy-
chosis, and ataxia
• Diagnosis:
 Based on history of exposure and characteristic
signs and symptoms
 Cholinesterase activity:
 Normal levels vary widely and do not correlate
well with clinical symptoms
 Severe intoxications: levels <20–50%
 Serial postexposure levels may help confirm the
diagnosis
• Treatment:
 Initial supportive care with special attention to res-
piratory function secondary to risk of respiratory
failure from wheezing, excess secretions, muscle
weakness, and mental status changes
 Take precaution to remove patient and staff from
exposure from contaminated clothing and cleanse
the skin and hair
 Decontamination:
 Activated charcoal
 GL if immediately postingestion
 Specific drugs and antidotes:
 Atropine:
• Indicated for all symptomatic patients
• Competitively blocks acetylcholine at muscarinic
receptors
• Dose required to achieve “atropinization”
(mydriasis, dry mouth, increased heart rate) is
highly variable:
 Initial dose is 2 mg IV (6 mg if life threaten-
ing) followed by 2 mg every 15 minutes until
atropinization
 Large doses up to 100 mg/day may occasion-
ally be required
 Pralidoxime:
• Reverses muscarinic and nicotinic effects by
reactivating phosphorylated cholinesterase
enzyme and protects it from further inhibition
prior to irreversible inactivation
• Effectiveness best within first 6 hours but useful
for 24–48 hours postexposure
• Dosing:
 Initial dose is 1–2 g IV over 10–20 minutes
 Start continuous infusion (200–500 mg/h)
titrated to effect
 Duration dependent on half-life of toxin but
may require >24 hours before tapering infu-
sion while monitoring for signs or recurrent
weakness
• Generally not necessary for carbamate toxicity
PHENCYCLIDINE
• Dissociative anesthetic with properties similar to
ketamine.
• Also known as “angel dust” and can be snorted,
smoked, ingested orally, or injected IV.
• Coingestions with THC (delta-9-tetrahydrocannabinol),
alcohol, and lysergic acid diethylamide (LSD) are
common.
• Variable anticholinergic, opioid, dopaminergic, CNS
stimulant, and alpha-adrenergic effects.
• Clinical presentation:
 Mild intoxication: lethargy, euphoria, hallucina-
tions, occasional bizarre or violent behavior, nystag-
mus: vertical and horizontal
 Severe intoxication: hypertension +/− hypertensive
crisis, rigidity, hyperthermia, tachycardia, diaphore-
sis, seizures, coma, rhabdomyolysis, acute renal
failure, and apnea
• Diagnosis:
 Suspect in patients with fluctuating behavior, sym-
pathomimetic overstimulation, and nystagmus
 Pinpoint pupils in an agitated patient is suggestive
 Exposure is confirmed by urine toxicology
screening
• Treatment:
 Initial supportive measures
 Decontamination:
 No role for emesis or GL
 Activated charcoal
 No specific drugs or antidotes
 Enhanced elimination not effective secondary to large
volume of distribution, avoid urinary acidification
 Violent or psychotic behavior:
 Decrease stimulation
 Haloperidol drug of choice
 Can add a benzodiazepine
 Severe hypertension:
 Drug therapy if calming strategies fail
 Nitroprusside or labetalol
 Avoid beta-blockers alone; secondary to risk of
unopposed alpha stimulation
SALICYLATES
• Common ingredients in prescription and nonprescrip-
tion drugs.
• Pathophysiology:
 Acetylsalicylic acid is converted to salicylic acid.
 Salicylic acid is readily absorbed form stomach and
small bowel.
 Uncouples oxidative phosphorylation and interferes
with Krebs cycle.
• Clinically features:
 Acute:
 Mild intoxication 150–200 mg/kg
 Severe intoxication 300–500 mg/kg
 Initially present with vomiting followed by hyper-
pnea, tinnitus, and lethargy
 Respiratory alkalosis and metabolic acidosis
 Severe intoxication can result in coma, seizures,
hypoglycemia, hyperthermia, and pulmonary
edema
 Chronic:
 Usually young children or elderly
 Presentation nonspecific with confusion, dehydra-
tion, metabolic acidosis that may be attributed to
other conditions
 Cerebral and pulmonary edema more common
 Toxicity seen at lower salicylate levels
• Diagnosis:
 May be easy if history of acute ingestion
 Arterial blood gas (ABG) is suggestive: respiratory
alkalosis and metabolic acidosis
 Salicylate levels:
 Prognostic in acute intoxications
 Measure serial levels
 No clinical value
• Treatment:
 Emergent and supportive care
 Decontamination:
378 SECTION 10 • SPECIAL PROBLEMS IN THE ICU
CHAPTER 123 • TOXICOLOGY IN ADULTS     379
 Not indicated for chronic intoxications
 GL with activated charcoal
 Enhanced elimination:
 Urinary alkalinization
 HD:
• Very effective to remove salicylate and correct
acid-base and fluid abnormalities
• Indications:
 Serum level >120 mg/dL acutely
 Serum level >100 mg/dL 6 hours postingestion
 Refractory acidosis, coma, seizures, noncar-
diogenic pulmonary edema, volume overload,
and renal failure
 Symptomatic chronic intoxication with level
>60 mg/dL
 Hemoperfusion effective but does not address
acid-base abnormalities
 Multiple-dose activated charcoal is controversial
 Specific treatments:
 Sodium bicarbonate:
• Increase urinary elimination
• Prevent acidemia which increases CNS salicy-
late levels
• Goals of therapy:
 Systemic pH 7.45–7.5
 Urinary pH approximately 7–8
• Avoid hypokalemia
SELECTIVE SEROTONIN REUPTAKE INHIBITORS
(SEROTONIN SYNDROME)
• May become more common cause of overdose or
intoxication secondary to increased popularity.
• Combination of a selective serotonin reuptake
inhibitor (SSRI) with tryptophan, monamine oxidase
(MAO) inhibitor, or other serotomimetic antidepres-
sant can result in the serotonin syndrome and death.
• Pathophysiologic mechanism is presumed to be brain
stem and spinal cord activation of 1A serotonin
receptor.
• Long half-life may delay onset of symptoms.
• Clinical manifestations:
 Can be mild, moderate, or severe
 Mental status changes, restlessness, myoclonus,
hyperreflexia, diaphoresis, shivering, tremor, flush-
ing, fever, nausea, and diarrhea
 Severe symptoms include DIC, seizures, coma,
muscle rigidity, myoclonus, autonomic instability,
orthostatic hypotension, and rhabdomyolysis
• Diagnosis:
 Consider in any patient with history of depression,
use of serotonergic drugs, and compatible clinical
features at presentation
 Blood and urine assays are not commonly available
and not part of routine toxicology screen
• Treatment:
 Stop suspected serotonergic agent and provide sup-
portive care
 Decontamination:
 GL if 1 hour postingestion
 Activated charcoal
 Enhanced elimination techniques not effective
 Specific drugs:
 Serotonin antagonists have not been adequately
evaluated
 Chlorpromazine, diphenhydramine, and benzodi-
azepines have been used
THEOPHYLLINE
• Dimethyl xanthine used in management of obstructive
lung disease.
• Low therapeutic index.
• Patient noncompliance, physician prescribing errors,
and altered drug metabolism can result in toxicity.
• Intoxication:
 Acute and chronic
 Mild toxicity can occur within therapeutic range
 Drug levels:
 Toxicity usually when >25 mg/L
 Seizure:
• Acute 80–100 mg/L
• Chronic 35–70 mg/L
 Tachyarrhythmia 20–30 mg/L
 Cardiovascular collapse >50 mg/L
 Cardiovascular: tachycardia, supraventricular and
ventricular arrhythmias, cardiovascular collapse
 Neurologic: nervousness, insomnia, agitation, rest-
lessness, headache, tremor, seizures
 Metabolic: hypokalemia, hypomagnesemia, hyper-
glycemia, hypophosphatemia, hypercalcemia, respi-
ratory acidosis
• Treatment:
 Decontamination:
 GL followed by activated charcoal
 Emesis is contraindicated
 Enhanced elimination:
 Multiple-dose activated charcoal
 Extracorporeal (see below):
• Charcoal hemoperfusion
• HD
 Follow levels every 2–3 hours
 Specific complications:
 Seizure:
• Benzodiazepines
• Phenytoin may worsen seizures and should be
avoided
• Phenobarbital for refractory cases
 Hypotension:
• Fluids and phenylephrine
 Arrhythmias:
• Supraventricular tachycardia (SVT):
 Best treated with β1 cardioselective beta-
blockers
 Use caution in patients with obstructive lung
disease and avoid if active bronchoconstric-
tion present
 Calcium channel blockers for sustained SVT
• Ventricular:
 Lidocaine or other appropriate agent
 Severe intoxication with life-threatening compli-
cations should be considered for extracorporal
drug elimination:
• Other indications include plasma level >100 mg/L
in acute intoxication after initial charcoal therapy
• Level >50 mg/L after chronic ingestion
• 2 hours level >35 mg/L associated with clinical
instability or high risk of adverse outcome
and/or prolonged intoxication
• High-risk characteristics include chronic intoxi-
cation, intolerance to charcoal or intractable
vomiting, decreased theophylline metabolism
(CHF, cirrhosis, severe hypoxemia), poor cardio-
vascular reserve, seizures, and respiratory failure
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124 CHEMICAL WEAPONS
D. Kyle Hogarth
KEY POINTS
• Initial management of all chemical weapon victims is
to protect YOURSELF with respirators and protective
clothing.
• Nerve Agents work by inhibiting acetylcholinesterase.
They can be odorless, but may smell like bitter
almonds.
• Signs and Symptoms of Nerve Agents can be remem-
bered using “SLUDGE and the Killer Bs” for mus-
carinic signs: Salivation, Lacrimation, Urination,
Defecation, Gastroenteritis, Emesis, Bradycardia,
Bronchorrhea, Bronchospasm. Nicotinic signs of
nerve agents can be remembered using: “MTWHF”:
Mydriasis, Tachycardia, Weakness, Hypertension,
Fasciculations.
• Atropine is used to treat the muscarinic effects of the
agent: 2 mg IVP (1 mg for age 2–12, 0.5 mg for under 2),
repeat q 5 min, titrate until effective in controlling
symptoms. Average dose given is 6–15 mg.
MANAGEMENT
• Immediate management of all patients involves pro-
tecting yourself first. Ensure proper personal protec-
tive equipment (PPE), including respiratory protection
with at least an organic vapor/P1 cartridge respirator.
Higher exposures require pressure demand supplied
air respirator and escape self-contained breathing
apparatus (SCBA).
• Splash-protective chemical resistant suit and gloves/
boots should be worn by all people involved in the initial
care/assessment.
• Remove the patient’s clothing quickly and seal in
plastic impervious bags and save for authorities.
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• Wash the skin of the patient with shampoo and copious
water. Rinse, soap, rinse, wait 1 minute, and repeat for
20 minutes. As always, follow basic life support and
attend to the ABCs (airway, breathing, circulation) of
emergency care and quickly obtain as much history as
possible.
• Other immediate issues need to be attended to as well.
Call Local Health Director, Police, Federal Bureau
of Investigation (FBI), and hazardous materials
(HAZMAT). All can be reached via 911. Also contact
Poison Control (800-222-1222).
• Domestic Preparedness National Response Hotline
(800-424-8802).
• Centers for Disease Control and Prevention (CDC)
emergency response (770-488-7100).
• U.S. Army Chemical Casualty Care Handbook:
http://ccc.apgea.army.mil.
TYPES OF AGENTS
NERVE AGENTS
• The G agents were synthesized in 1936 by Germany.
The V agents were synthesized in the United
Kingdom in 1952. Iraq used Sarin and Tabun against
Iran and Iraqi Kurds between 1983 and 1988. Japan
was victim of Sarin gas attack by Aum Shinrikyo Cult
in 1994 and 1995.
• Types of nerve agents include: GA (Tabun), GB
(Sarin), GD (Soman), GF, VX (methylphosphonoth-
ioic acid), and VR.
• Nerve agents are usually colorless and odorless, but
may have a fruity smell like bitter almonds.
• They are all liquids, but Tabun, Sarin, and Soman have
high volatility and easily become gas. These agents are
usually absorbed via the respiratory system. VX and
VR are usually absorbed dermally as they have a low
volatility and tend to remain in liquid form.
• Each nerve agent essentially causes a syndrome of
organophosphates toxicity as they are very potent
acetylcholinesterase inhibitors.
• Each nerve agent has different characteristics in
regards to ease of production, volatility, persistence,
and onset of symptoms. For example, VX has a very
low volatility, and therefore will persist in an environ-
ment for a very long time. It is also a liquid, while the
others become gaseous at ambient temperature.
SIGNS AND SYMPTOMS
• Muscarinic signs of nerve agents can be remembered
using “SLUDGE and the Killer Bs”: Salivation,
Lacrimation, Urination, Defecation, Gastroenteritis,
Emesis, Bradycardia, Bronchorrhea, Bronchospasm.
• Nicotinic signs of nerve agents can be remembered
using: “MTWHF”: Mydriasis, Tachycardia, Weakness,
Hypertension, Fasciculations.
• The nicotinic signs often predominate early in the
course, but both can be found. Later, the muscarinic
signs and symptoms predominate. Severe exposure
can have both of the worst effects at the same time.
• Typical symptoms of moderate exposure to nerve agents
include diffuse muscle cramping, especially abdominal
muscles with nausea, vomiting, and occasionally diar-
rhea. Rhinorrhea and difficulty breathing often present,
as well as sweating. Eye pain and frontal headache, as
well as blurry vision are often present (of the 15 physi-
cians secondarily exposed to Sarin vapors in Tokyo,
73% complained of dimmed vision). Tremors, palpita-
tions, and fasciculations are often noted.
• Typical symptoms of high exposure to nerve agents
include seizures and flaccid paralysis. Acute respira-
tory failure is the primary cause of death in acute poi-
sonings with acetylcholinesterase inhibitors.
• Aerosol attack will give symptoms in seconds to min-
utes. Liquid attack (skin, conjunctival exposure) will
give symptoms in minutes to hours. Head/neck expo-
sure to liquid gives symptoms quicker than extremities,
which is quicker than torso exposure. Oral ingestion
can take hours (a study of volunteers who drank water
with VX showed a 22% drop in cholinesterase activity
after 400 µg/70 kg body weight 2–3 hours postinges-
tion. A full stomach increased the absorption).
DIAGNOSTIC TESTS
• RBC or serum cholinesterase on whole blood sample is
useful, but typically is a “send-out” lab. Sent in a
heparinized green-top tube. The diagnosis is made clin-
ically and with a good history and physical examination.
THERAPY
• Wash patient with 1 part household bleach, 9 parts water
solution (0.5% sodium hypochlorite). The Sarin half-
life in water is 5.4 hours: at pH 9, it’s only 15 minutes.
• Atropine is used to treat the muscarinic effects of the
agent: 2 mg IVP (1 mg for age 2–12, 0.5 mg for
under 2), repeat q 5 min, titrate until effective in con-
trolling symptoms. Average dose given is 6–15 mg.
• Pralidoxime chloride (2-PAM) can also be given,
600–1800 mg IM or 1 g IV over 20–30 minutes. This
drug reacts with the nerve agent inhibited cholinesterase
enzymes to remove the nerve agent from the enzyme.
Timing is very important. Once the binding of the agent
to the enzyme becomes irreversible, 2-PAM will not
work. This is called “aging.” Soman ages in <10 min-
utes, while VX takes several hours.
• Nebulized ipratropium may provide some benefit and
can be attempted.
• Hemofiltration (4 hours) and hemoperfusion was used
successfully in one patient in Tokyo during the Sarin
attacks.
PROPHYLAXIS
• Pyridostigmine bromide, 30 mg tid, for up to 7 days
can be taken. This was used in Operation Desert
Storm. Half of the troops who took the drug noted
mild abdominal symptoms (flatus, cramps, loose
stools). Discontinuation rate of 0.07% of the 41,650
troops who took the drug.
• Fluoroakylpolyether and polytetrafluoroethylene,
commonly called “SERPACWA” by the military (Skin
Exposure Reduction Paste Against Chemical Warfare
Agents) can also be applied to health workers after an
attack. SERPACWA has been shown to decrease toxi-
city of sulfur mustard, VX, and Soman in animal
studies.
BLISTER AGENTS
• First developed and used by the Germans in 1917
during World War I, but also used by the Italians
against Ethiopia from 1935 to 1940. Egypt employed
these agents in support of South Yemen during the
Yemeni Civil War. Iranian soldiers attacked by the
Iraqi army during the Iran-Iraq war (1983–1988) used
blistering agents.
• Types of blister agents include: sulfur mustard (Yperite),
nitrogen mustard, Lewisite, and phosgene oximine.
CHARACTERISTICS
• These agents are often odorless and colorless, depend-
ing on purity.
• An exposed patient’s skin may smell of garlic, horse-
radish, or mustard.
• They can cause symptoms within minutes (Lewisite),
but many don’t cause symptoms for up to 12 hours
(mustards).
• The agents are often nonfatal, but designed to inca-
pacitate and to overutilize an opponent’s resources
and to hamper an ability to fight as the soldier takes
precautions with gear/respirators.
SIGNS AND SYMPTOMS
• Blister agent victims describe their skin as burning,
and pruritic. The skin is erythematous and develops
thin walled blisters. They often have watery, swollen
eyes. Many develop upper airway sloughing, with pul-
monary edema and respiratory compromise.
• Mucosal irritation with lacrimation, conjunctival irri-
tation, and erythema are present. Typically, patient
will notice shortness of breath and experience nausea
and vomiting.
• Can see neutropenia and sepsis, late in course, and
often with sulfur mustard (of note, melphalan and
cyclophosphamide are nitrogen mustards).
DIAGNOSTIC TESTS
• Patients will often have a distinct smell of garlic,
horseradish, or mustard. Oily droplets present on the
skin can be sent for testing.
• Urine can be sent for thiodiglycol (breakdown product
of blistering agents). In animal studies and human
volunteers, significant urine excretion of thiodiglycol
occurred within 24 hours of exposure.
• Tissue biopsy can be obtained and samples sent to
USAMRICD (United States Army Medical Research
Institute of Chemical Defense) for analysis and
confirmation.
TREATMENT
• Mustards have no antidote, and treatment is supportive.
• Patients should be managed similar to thermal bum
patients, with careful attention to fluids, skin care, and
need for antibiotics.
• Amifostine and some new analogues seem to offer
prophylactic protection from the effects of mustards,
but have no effect after exposure.
• For Lewisite exposure, British anti-Lewisite
(Dimercaprol) given IM can help, but it is often not
available. In animal studies, a parenteral combination
of sodium thiosulfate (3 g/kg), vitamin E (20 mg/kg),
and dexamethasone (8 mg/kg) improved survival
and reduced organ damage after exposure to mus-
tard gas.
CHOKING AGENTS
• These agents were developed and used during World
War I. Phosgene was first used in 1915 and accounted
for 80% of all chemical fatalities during the war. They
work by primarily causing sudden, severe, massive
pulmonary edema. Used by the Italians against
Ethiopia in 1935–1940 and by the Japanese in China
from 1937 to 1945 and in Yemen during 1963–1967
civil war.
• They are all in gas form and are heavier than air. They
are typically odorless, but may smell of moldy or cut
hay. They react with multiple different macromole-
cules in tissue to increase capillary permeability.
• Types of choking agents include: phosgene, diphos-
gene, chlorine, chloropicrin, oxides of nitrogen, and
sulfur dioxide.
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SIGNS AND SYMPTOMS
• Mucosal irritation with pulmonary infiltrates and pul-
monary edema are seen.
• The patients note shortness of breath, chest tightness,
wheezing, and laryngeal spasm.
ONSET OF ACTION
• Effects are seen from 1 to 24 hours after exposure, and
rarely up to 72 hours.
• Typically, the patient may be asymptomatic for many
hours after exposure.
DIAGNOSTIC TESTS
• None.
THERAPY
• No antidote. Management is supportive through control
of secretions, oxygen supplementation, and positive
end-expiratory pressure (PEEP) via mask ventilation or
intubation.
• High-dose steroids for oxides of nitrogen agents may
prevent the pulmonary edema, but this has not been
proven in a clinical trial.
• Oral Zafirlukast 40–80 mg q12 for initial 48 hours and
glutathione may lessen the respiratory damage after
phosgene poisoning.
BIBLIOGRAPHY
Ben Abraham R, Rudick V, Weinbroum AA. Practical guidelines
for acute care of victims of bioterrorism: conventional injuries
and concomitant nerve agent intoxication. Anesthesiology
2002;97(4):989–1004.
Davis KG, Aspera G. Exposure to liquid sulfur mustard. Ann
Emerg Med 2001;37(6):653–6.
Evison D, Hinsley D, Rice P. Chemical weapons. Bmj
2002;324(7333):332–5.
Kadivar H, Adams SC. Treatment of chemical and biological war-
fare injuries: insights derived from the 1984 Iraqi attack on
Majnoon Island. Mil Med 1991;156(4):171–7.
Leikin JB, Thomas RG, Walter FG, Klein R, Meislin HW. A review
of nerve agent exposure for the critical care physician. Crit Care
Med 2002;30(10):2346–54.
Munro NB, Watson AP, Ambrose KR, Griffin GD. Treating expo-
sure to chemical warfare agents: implications for health care
providers and community emergency planning. Environ Health
Perspect 1990;98:205–15.
Vijayaraghavan R, Kumar P, Joshi U, et al. Prophylactic efficacy of
amifostine and its analogues against sulphur mustard toxicity.
Toxicology 2001;163(2–3):83–91.
White SM. Chemical and biological weapons. Implications for
anaesthesia and intensive care. Br J Anaesth 2002;89(2):306–24.
ccc.apgea.army.mil/products/handbooks/books.htm. Accessed Feb
22, 2007. Free registration required.
125 ANAPHYLAXIS
Nina M. Patel
KEY POINTS
• Anaphylactic and anaphylactoid reactions are rela-
tively rare, life-threatening events that are mediated
largely by mast cell and basophil cell activation.
• Common triggers include antibiotics, contrast media,
blood products, colloids, latex, envenomations, and
severe food allergies.
• In most circumstances symptoms are immediate but on
very rare occasion can be delayed up to several hours.
• Cardiovascular and respiratory instability are hall-
marks, often preceded by a subjective sense of
impending catastrophe.
• Mainstays of therapy include supportive management
with oxygen, airway protection and maintenance,
volume resuscitation, and epinephrine.
• Tryptase assay may help distinguish anaphylactic
from anaphylactoid or other reactions.
EPIDEMIOLOGY
• No comprehensive studies of the incidence, preva-
lence, and morbidity of drug allergy and anaphylaxis
in the general population have been performed.
• Anaphylaxis is estimated to occur in 1/5100 hospital
admissions.
• Anaphylaxis occurs at a rate of 1/10,000 to 1/20,000
during anesthesia.
• Drugs (antibiotics, neuromuscular blocking agents
[NMBA], or protamine commonly), radiocontrast
media (RCM), blood products, colloids, latex, and
preservatives are agents frequently involved in ana-
phylaxis in a hospital setting.
• Penicillin is the most common causative agent in ana-
phylaxis in humans.
• Anaphylaxis occurs in 1–2% of procedures involving
RCM.
• The overall incidence of anaphylaxis is similar between
men and women.
PATHOPHYSIOLOGY
• Anaphylaxis is a severe, acute systemic allergic reac-
tion resulting from the binding of a foreign antigen
to surface IgE on mast cells and/or basophils, with
subsequent activation of these cells and release of
chemical mediators.
• Anaphylactoid reactions have a similar clinical pres-
entation (though sometimes less severe), but are not
immune-mediated and result from direct drug or anti-
gen activation of mast cells and basophils.
• The major known mediators of anaphylactic and ana-
phylactoid reactions are histamine, eosinophilic
chemotactic factor of anaphylaxis (ECF-A), slow react-
ing substance of anaphylaxis (SRS-A), prostaglandins,
platelet-activating factor (PAF), and kinins.
• Mediators of anaphylaxis induce an array of systemic
physiologic perturbations, which include: decreased sys-
temic vascular resistance, systemic vasodilation, increased
capillary permeability, bronchospasm, mucosal edema,
mucus secretion, and platelet aggregation.
• The aggregate effects of mediators of anaphylaxis are
significant respiratory and cardiovascular compro-
mise, often leading to shock, due to decreased effec-
tive plasma volume and systemic vasodilation.
CLINICAL FEATURES
• Symptoms arise within minutes of administration of
the offending agent but can be delayed up to 2.5 hours.
Five to twenty percent of patients experience biphasic
anaphylaxis and will have recurrence of symptoms 1–8
hours after regression of the initial reaction.
• Patients with anaphylaxis often complain of an
impending “sense of death.”
• 30% of patients develop cardiovascular collapse and
shock.
• Cardiovascular: Patients commonly complain of
dizziness and exhibit tachycardia and hypotension. A
number of ECG changes have been described, includ-
ing nonspecific ST- and T-wave changes, multifocal
premature ventricular contractions, electromechanical
dissociation, asystole and ventricular fibrillation.
Cardiac output is generally elevated, though some
patients manifest myocardial depression as well as
myocardial ischemia and chest pain.
• Respiratory: 50% of patients develop respiratory man-
ifestations of anaphylaxis. Tachypnea, shortness of
breath, wheezing, stridor, and chest tightness consti-
tute the most common symptoms. Patients may exhibit
a decline in forced expiratory volume in 1 second
(FEV1) and intubated patients may display an increase
in peak airway pressures. Acute respiratory distress or
asphyxiation can ensue due to severe bronchospasm
(particularly in asthmatic patients) and bronchorrhea
and/or severe laryngeal or glottic edema.
• Skin: Typical complaints are of pruritus, flushing,
warmth, erythema, and minor edema. Rash, urticaria,
and angioedema occur in 88% of individuals. Skin
rash often resolves with antihistamine therapy. The
degree of cutaneous involvement does not correlate
with the extent of hemodynamic derangement.
Cutaneous involvement is not requisite in establishing
the diagnosis of anaphylaxis.
• Gastrointestinal: Patients may experience nausea,
vomiting, diarrhea, abdominal pain, and cramping.
• Neurologic: Seizures have been described to occur
very infrequently.
• Ophthalmologic: Excessive lacrimation and conjunc-
tival injection.
DIFFERENTIAL DIAGNOSIS
• The diagnosis of anaphylaxis must be considered in
any patient who develops hypotension in the operative
or perioperative period.
• Vasovagal syncope, systemic mastocytosis, carcinoid
syndrome, hereditary angioedema, pheochromocy-
toma, status asthmaticus, foreign body aspiration,
scombroidosis, monosodium glutamate (MSG) syn-
drome, seizures, hyperventilation syndrome, and
panic attacks constitute a few of the extensive number
of syndromes which can produce clinical manifesta-
tions similar to anaphylaxis.
• The diagnosis of anaphylaxis rests upon a correlation
in time between exposure to a known agent of ana-
phylactic or anaphylactoid reactions in concert with
characteristic clinical features.
• Identification of the offending agent through allergy
history, history of prior anaphylaxis, time frame to
onset of symptoms, and route of administration of the
putative causative agent is essential.
• Tryptase is a protease released during IgE-mediated mast
cell activation. Tryptase levels >25 µg/L are suggestive
of an immune rather than chemically mediated reaction.
The sensitivity and specificity of tryptase in diagnosing
anaphylaxis are 64% and 89.3%, respectively.
• Histamine levels are sometimes measured, but the
highly labile nature of this molecule in plasma limits
its clinical utility. The sensitivity and specificity of
elevated plasma histamine levels (>9 nM) are 75%
and 51%, respectively.
• If a potential causative agent is identified, skin prick,
intradermal titration, RAST (radioallergoabsorbent
test), and in rare cases, in vivo provocation, can be
used to confirm the presence of IgE antibodies.
PREVENTION AND TREATMENT
• Extensive preoperative and preprocedure evaluation for
history of allergic symptoms to NMBAs, hypnotics,
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opioids, antibiotics, NSAIDs (nonsteroidal anti-
inflammatory drugs), latex, RCM, blood products,
colloids, or any other agents is imperative.
• Once an anaphylactic/anaphylactoid reaction has begun,
a number of swiftly coordinated actions must ensue.
• Any and all suspected offending agents should be dis-
continued as well as any sedative or vasodepressor
agents.
• A definitive airway should be established with admin-
istration of supplemental oxygen (100%). Aerosolized
or inhaled β2-adrenergic agents can be utilized addi-
tionally in patients with bronchospasm.
• Intravenous access should be secured with two large-
bore (14- or 16-gauge) intravenous catheters.
• Epinephrine (IM) at 0.3–0.5 mL (1:1000) q 5-15 min
to titration of effect is the principal therapy in patients
with hypotension or severe bronchospasm due to its
α1-adrenergic, β1- and β2-adrenergic effects. In
patients with life-threatening hypotension, epinephrine
should be administered intravenously in cardiopul-
monary resuscitation doses (0.01 mg/kg to max of 1 mg
per dose).
• Intravascular volume expansion with crystalloid or
colloid should be pursued aggressively. Persistent
hypotension may require further support with continuous
infusion of vasopressors such as epinephrine (1–2
µg/min) or norepinephrine (0.5–30 µg/min).
• Administration of antihistamines is considered a
mainstay of therapy, though it is uncertain if these
drugs have any potential to reverse the effects of his-
tamine once it has been released. Recommended
agents are diphenhydramine (1 mg/kg q 4-6 h) and
cimetidine (4 mg/kg q 8 h).
• IV corticosteroids are recommended in patients with
severe cardiopulmonary dysfunction and also to pre-
vent biphasic anaphylactic reactions. A clear dose is
not established. Methylprednisolone 125 mg IV q 6 h
is a reasonable starting steroid regimen.
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126 HYPOTHERMIA
Melanie L. Brown
KEY POINTS
• Most organ systems can withstand severe hypother-
mia with return of function if intervening insults such
as hypoxia have not occurred.
• Cardiac arrhythmias are common during profound
hypothermia and during the warming phase.
• The methods of rewarming the patient should be
selected on the basis of the severity of the hypothermia.
• Volume resuscitation is most often required during
rewarming.
OVERVIEW
• The body functions optimally at its normal tempera-
ture (36.2–38.2°C).
• In the unimpaired adult three compensatory mecha-
nisms function to maintain normal body temperature:
 Heat exchange with the environment
 Change in metabolic rate
 Behavioral responses
• Homeothermic responses to cold are regulated by the
hypothalamus. The mechanisms of heat loss/exchange
with the environment include the following:
 Radiation
 Conduction
 Convection 
 Evaporation
• Hypothermia presentations range from the obvious
cold water or winter exposures to the more subtle pre-
sentations such as an elderly person or drug intoxi-
cated person with depressed mental status and those
returning to the floor after a prolonged operative pro-
cedure (Table 126-1).
• Some sources have reported that 70% of the severe
hypothermia cases result in death.
CLINICAL MANIFESTATIONS
SIGNS AND SYMPTOMS
OF MILD HYPOTHERMIA
• Patient has core body temperature between 32.2 and
35°C (90–95°F)
• Awake 
• Alert
• Hemodynamically stable
• Shivering
SIGNS AND SYMPTOMS OF MODERATE
HYPOTHERMIA
• Patient has core temperature between 26.7 and 32.2°C
(80–89°F)
• Dilated pupils
• Hemodynamic instability
• Prone to ventricular dysrhythmia
• Muscles are rigid
• Shivering ceases
• J or Osborne wave on ECG (Fig. 126-1)
SIGNS AND SYMPTOMS
OF SEVERE HYPOTHERMIA
• Patient has core temperature <26.7°C (<80°F)
• Coma
• Poor muscle tone
• Apnea
• Asystole or frequent spontaneous fibrillation
EFFECTS OF HYPOTHERMIA
ON ORGAN SYSTEMS
• All organ systems are affected by hypothermia.
• To care for hypothermia, it is critical to understand the
intravascular volume shifts during resuscitation, the
cardiac physiology during hypothermia, and the effects
on other organ systems.
• It is important to note that many of the secondary
organ system derangements of hypothermia are cor-
rected by rewarming and should be dealt with cau-
tiously unless they are immediately life threatening.
• Conduction disturbances can be particularly refrac-
tory to treatment and are common particularly during
the rewarming phase.
• As many as 80% of patients with moderate hypother-
mia have a J or Osborne wave. This wave is found on
the ECG at the J point immediately following the
QRS complex (Fig. 126-1).
• With worsening hypothermia QRS and ST lengthen-
ing occur.
 Below 33°C, atrial fibrillation is common.
 At 28°C the heart is particularly prone to ventricular
fibrillation (VF). The VF can be precipitated by any
irritation such as line placement or rewarming, and
may be refractory to all treatments until the core
body temperature reaches 30°C.
 As the heart becomes increasingly more hypother-
mic, cardiac output decreases leading to eventual
asystole. Asystole generally occurs below a core
body temperature of 20°C.
• Cold can be protective to the brain in cases of
ischemic, hypoxic, and traumatic injury.
• For each degree that body temperature decreases,
cerebral blood flow (and metabolic rate) decreases by
7–10%.
 At approximately 34°C, intellectual function is
impaired.
 Progressive somnolence occurs, leading to coma
below 28°C.
 Temperatures of <20°C are well tolerated by the brain.
 Circulatory arrest at these temperatures has been
tolerated for more than 1 hour without deficits on
rewarming.
• Other effects of severe hypothermia include hyper-
glycemia, platelet dysfunction with coagulopathy,
metabolic acidosis, hyperkalemia, and a brisk diure-
sis. These resolve with rewarming.
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FIG. 126-1 ECG in hypothermia.
TABLE 126-1 Causes of Hypothermia
Increased heat loss (environment, vasodilation, burns, cold infusion)
Decreased heat production (endocrine disorder, malnutrition)
Impaired peripheral regulation (peripheral neuropathy, diabetes, spinal 
cord transection)
Impaired central regulation (strokes, Parkinson disease, hypothalamic 
disorders, anorexia, drugs)
Other (sepsis, pancreatitis, uremia)
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MANAGEMENT
• As always in an emergency situation, the first steps of
treatment are: airway, breathing, and circulation.
• The patient should be removed from the cold environ-
ment and any cold/wet clothing should be removed.
• Treatment goals are to rewarm appropriately for level
of hypothermia while anticipating any potential car-
diac instability.
• Cardiopulmonary resuscitation (CPR) should be initi-
ated for pulselessness unless body temperature is
below 28°C.
• When the core temperature is more than 32°C,
rewarming with blankets and warmed IV fluids
(40–42°C) is the treatment of choice.
• When the body temperature is below 32°C, rewarm-
ing must be more aggressive.
• An arterial line will likely be necessary as the pulse ox
will be unreliable. Blood gas interpretation should be
done without blood gas temperature correction as
regards acid-base balance.
• Adults have a low body surface area:mass ratio relative
to children and conductive surface warming (e.g., blan-
kets) may be ineffective at low temperatures. In this
case, active core rewarming is required. Active core
rewarming can be accomplished by a warm air circu-
lating system (Bair hugger), body cavity warm water
lavage with 40–42°C isotonic saline, heated counter-
current hemodialysis, and cardiopulmonary bypass.
• Volume resuscitation during rewarming is critical to
preventing circulatory collapse.
• There is a higher incidence of ventricular arrhythmias
as the patient is warmed from 28 to 32°C. Below
30°C, the arrhythmia will likely be refractory to all
treatment.
• Core body temperatures of <25°C or a core tempera-
ture below 30°C with cardiac arrest are indications for
extracorporeal membrane oxygenation (ECMO).
• The following therapies are ineffective or possibly
dangerous: warm inspired air >60°C (can cause burns
to airway epithelium), warm blankets (see above),
warm water emersion (impractical in a resuscitation
situation).
• Remember, death cannot be determined until resusci-
tation attempts fail at 35°C or above!
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127 SEVERE HYPERTHERMIA
Nathan Sandbo
KEY POINTS
• Severe hyperthermia is defined as a core body tem-
perature >40.0°C, which is not primarily due to the
body’s immunologic response to infection, but rather
dysregulation of temperature homeostasis.
• Severe nonimmunologic hyperthermia is primarily
defined by three syndromes: environmental hyper-
thermia, malignant hyperthermia, and NMS.
• CNS abnormalities in heatstroke may include inap-
propriate behavior, delirium, and confusion and may
progress to seizures and coma.
• Management of heatstroke includes cooling the
patient and administration of intravenous fluids for
hypovolemia. Avoid use of vasopressor agents (alpha-
agonists) for hypotension, as they inhibit normal cool-
ing mechanisms.
• Heatstroke alone has caused over 7000 deaths in the
United States in the past 20 years, and mortality can
range up to 20%.
• For malignant hyperthermia, immediately give dantro-
lene IV push (2.5 mg/kg), repeating every 5 minutes
until symptoms subside or maximal dose (10 mg/kg)
has been reached. Dosing should be continued at
1 mg/kg every 4–6 hours for 36–48 hours.
PATHOPHYSIOLOGY
• Elevation in core body temperature is signaled to the
preoptic nucleus of the anterior hypothalamus which
in turn directs the body’s physiologic response. This
includes cutaneous vasodilation, decreased muscle
tone, and increased sweating.
• Environmental hyperthermia results from the combi-
nation of elevated endogenous heat production
and/or an inability to adequately unload heat due to
high ambient temperatures with or without high
humidity.
 Pharmacologic agents may predispose to the devel-
opment of environmental hyperthermia via inhibi-
tion of normal adaptive responses to elevated body
temperature.
 Sympathomimetics (cocaine, amphetamine,
ecstasy) increase heat production and may disrupt
thermoregulation.
 Anticholinergics (tricyclic antidepressants [TCAs],
antihistamines, antipsychotics) inhibit sweating
and disrupt hypothalamic function.
 Ethanol, beta-blockers, dehydration, obesity, and
head injury may all contribute to hyperthermia.
 Heatstroke is characterized by the presence of an
acute phase inflammatory response that is charac-
terized by the presence of elevated levels of circu-
lating inflammatory cytokines, endothelial cell
dysfunction, and activation of the clotting cascade.
 The combination of thermoregulatory dysfunction
and systemic inflammatory response may lead to the
development of life-threatening multisystem organ
dysfunction.
• Malignant hyperthermia is a syndrome of hyperther-
mia, muscle contractions, and cardiovascular instabil-
ity usually triggered by the administration of volatile
anesthetics, such as halothane, or depolarizing para-
lytic agents, such as succinylcholine in a genetically
susceptible host. In these patients, exposure to these
agents leads to a marked intracellular calcium release
from the sarcoplasmic reticulum in skeletal muscle,
resulting in a hypermetabolic and hypercontractile
state in skeletal muscle.
• Neuroleptic malignant syndrome (NMS) is an idio-
syncratic reaction to the administration of neuroleptic
drugs or withdrawal of dopaminergic drugs. It is
characterized by hyperthermia, muscle rigidity, alter-
ation in mental status, autonomic dysfunction, and
rhabdomyolysis.
CLINICAL FEATURES
• Environmental hyperthermia:
 Heat injury is a spectrum of disease.
 Heat cramps are the mildest form, and are most
often seen in younger individuals performing exer-
tional activities in hot environments. Usually treated
as an outpatient with oral hydration and relocation
to a cool environment.
 Heat exhaustion is characterized by mildly elevated
core temperature and systemic complaints (malaise,
weakness, nausea), but does not include any severe
central nervous system (CNS) dysfunction.
 Heatstroke is characterized by high body tempera-
ture (usually > 40°C and the presence of severe CNS
dysfunction. Patients have a history of exposure to a
heat load (internal or external).
 Two syndromes of heatstroke are: classical (nonex-
ertional) and exertional.
 Nonexertional heatstroke affects the elderly and
chronically ill in the presence of sustained (days)
heat stress as is seen in heat waves. Risk factors
include immobility, social isolation, obesity,
dehydration, and extremes of age.
 Exertional heatstroke is typically seen in young,
healthy individuals who undergo strenuous exer-
cise in hot environments for a short period of time
(military recruits, marathon runners).
 CNS abnormalities may include inappropriate
behavior, delirium, and confusion and may progress
to seizures and coma. Occasionally, cerebellar dys-
function or decerebrate posturing may be seen.
Lumbar puncture may reveal increased protein, xan-
thochromia, and lymphocytic pleocytosis.
 Cardiovascular findings almost always include
tachycardia and occasionally supraventricular
tachycardias (SVTs). Peripheral vasodilation is usu-
ally present, and hypotension results if cardiac
output cannot be augmented due to hypovolemia or
myocardial dysfunction.
 Lab findings may include metabolic lactic acidosis
from either hypoperfusion or sustained anaerobic
metabolism by skeletal muscle (exertional hyperther-
mia), respiratory alkalosis secondary to hyperventila-
tion, hypoglycemia, rhabdomyolysis, renal failure,
hyper- or hypokalemia, leukocytosis, disseminated
intravascular coagulation (DIC) (usually hours to
days after presentation), and thrombocytopenia.
• Clinical signs of malignant hyperthermia usually
present within 30 minutes of administration of anes-
thesia (succinylcholine or volatile inhaled anesthet-
ics), but may be delayed up to 11 hours.
 Spectrum of disease from mild symptoms to fulmi-
nant crisis.
 Muscle rigidity is an early manifestation and often
begins in extremities or chest with halothane, and in
the jaw (masseter muscle) with succinylcholine.
 Capnography or arterial blood gas sampling may
reveal elevated CO2 levels due to elevated produc-
tion, and is often the first manifestation of the syn-
drome noted during the induction of anesthesia.
 Pronounced, continuous rise in core temperature,
without shivering is characteristic of the reaction,
but may be a later finding.
 Tachycardia, hypertension, tachypnea, diaphore-
sis, and mottling of the skin often occur. As the
syndrome progresses, metabolic acidosis, respira-
tory acidosis, ventricular arrhythmias, hypoten-
sion, and rhabdomyolysis may ensue. Rarely, the
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syndrome can be characterized by rhabdomyolysis
without fever.
• Neuroleptic malignant syndrome usually occurs 3–9 days
after initiating a neuroleptic agent or changing the
dose, and may last 1–3 weeks.
 Majority of cases associated with high potency neu-
roleptics such as haloperidol and thiothixene.
Estimated incidence is 0.2% of patients who receive
neuroleptic agents.
 Symptoms begin with mental status changes fol-
lowed in sequence by muscle rigidity, hyperther-
mia, and autonomic dysfunction characterized by
tachycardia, diaphoresis, blood pressure instability,
and arrhythmias.
 Changes in muscle tone usually include “lead pipe”
rigidity or tremors. Other manifestations may
include dysphagia, dysarthria, or dystonia. Altered
mental status (agitation, coma) occurs in 75%.
 Lab findings may include elevated creatine kinase
(CK) and myoglobinuria, leukocytosis, and evidence
of DIC.
DIAGNOSIS
• The diagnosis of a nonimmunologic hyperthermia syn-
drome should be in the differential of any febrile patient.
The list of syndromes incorporating fever in association
with mental status changes includes heatstroke, malig-
nant hyperthermia, NMS, meningitis, drug overdose,
thyroid storm, sepsis, toxic shock syndrome, and
febrile delirium. The diagnosis of environmental hyper-
thermia, malignant hyperthermia, or NMS is established
from the clinical history. Items suggesting infection,
drug exposure, or environmental exposure allow for dif-
ferentiation between fever-associated syndromes.
• Patients at risk for malignant hyperthermia often have
a family history of complications from anesthesia.
Screening for susceptibility is performed by muscle
biopsy with caffeine-halothane contracture test.
TREATMENT
• Environmental hyperthermia:
 Immediately cool with conductive (immersion in
cool water, ice water soaks) or evaporative (fine
mist spray and airflow). Other methods include peri-
toneal lavage, iced gastric lavage, and cardiopul-
monary bypass, but none have been adequately
tested in humans.
 Place thermistor probe (esophageal or rectal) to con-
tinuously monitor core temperature. Cooling should
be stopped at 38.0–38.8°C to prevent iatrogenic
hypothermia.
 Administer intravenous fluids for hypovolemia.
Avoid use of vasopressor agents (alpha-agonists)
for hypotension, as they inhibit normal cooling
mechanisms.
 Provide supplemental oxygen to all patients and
definitive airway control with endotracheal intuba-
tion if clinically indicated.
 If rhabdomyolysis is present, administer intravenous
fluids to achieve urine outputs of 100–200 cc/h.
 Consider invasive hemodynamic monitoring in
patients with refractory hypotension or cardiac
dysfunction.
 Monitor for seizures and treat with benzodiazepines
if needed.
 Aggressive supportive therapy and rapid cooling
results in >90% survival, with the majority of
patients having complete resolution of neurologic
dysfunction.
• Malignant hyperthermia:
 Discontinue inciting drug, administer 100% O2 to
correct hypoxemia, IV fluids, and ventilatory sup-
port to correct respiratory acidosis.
 Immediately give dantrolene IV push (2.5 mg/kg),
repeating every 5 minutes until symptoms subside
or maximal dose (10 mg/kg) has been reached.
Dosing should be continued at 1 mg/kg every 4–6
hours for 36–48 hours.
 Provide evaporative or conductive cooling if dantro-
lene is not fully effective.
 Monitor for and treat rhabdomyolysis.
 Mortality is now <10%, due to prompt recognition
and treatment.
• NMS:
 Admit to ICU and discontinue offending medication.
 Control temperature, providing external cooling if
needed.
 Consider dantrolene and dopaminergic agonists
(bromocriptine, amantadine, levodopa/carbidopa),
although efficacy is not well established for either
therapy.
 Optimize intravascular volume, monitor and treat
arrhythmias, ventilatory support if needed, and cor-
rect any metabolic derangements.
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128 NEAR DROWNING
Melanie L. Brown
KEY POINTS
• Alcohol is a major contributing factor to drowning
incidents in adults.
• Clinical consequences of drowning are usually sec-
ondary to hypoxic injury leading to multisystem dys-
function. Patients can suffer ARDS, brain injury,
cardiac arrest, and acute renal failure.
• Even small amounts of aspirated water can lead to
profound ventilation/perfusion mismatches.
• Initial management focuses on the ABCs with careful
attention to C-spine stabilization as many drownings
can be associated with diving accidents.
EPIDEMIOLOGY
• Males drown at five times the rate of females in the
United States.
• Alcohol is a contributing factor in greater than half of
the drowning incidents in adults.
• In scuba-related drowning incidents, entanglement or
running out of oxygen are the two most common factors.
PATHOPHYSIOLOGY
• Most of the consequences of near drowning are sec-
ondary to asphyxia and multisystem hypoxic injury.
• Most drowning victims do not aspirate any of the
drowning medium. This is likely secondary to reflex
laryngospasm. Only 10–15% of near-drowning vic-
tims aspirate a small amount of fluid.
• Even a small amount of aspirated seawater or fresh-
water can cause ventilation perfusion mismatch and
shunting which can lead to a more prolonged period
of hypoxemia.
• Large amounts of fluid are often swallowed. This can
lead to both electrolyte disturbances and vomiting
with aspiration of stomach contents.
END-ORGAN EFFECTS
LUNG
• The presentation can be variable. Patient’s presenta-
tion can vary from no complaints to florid pulmonary
edema and acute respiratory distress syndrome
(ARDS).
• Acute lung injury is usually due to the direct effect of
aspiration of the drowning fluid or due to aspiration of
gastric contents.
• Generally, the pulmonary edema is not cardiogenic in
origin.
• X-ray appearance does not always correlate with clin-
ical course and outcome.
• Management is similar to ARDS (see Chap. 35).
BRAIN
• Aggressive intracranial pressure (ICP) monitoring
and management has shown no benefit for the near-
drowning victim.
• Brain injury is secondary to the hypoxic insult (see
Chap. 71).
HEART
• Supraventricular tachycardia can be seen secondary to
hypoxemia and acidosis.
• Cardiac arrest is secondary to hypoxemia.
• The cardiac abnormalities are often responsive to car-
diopulmonary resuscitation (CPR).
KIDNEY
• Renal insufficiency secondary to hypoxemia and
acute tubular necrosis (ATN) can be seen.
• Rarely rhabdomyolysis and hemolysis with dissemi-
nated intravascular coagulation (DIC) can occur and
can complicate existing renal failure.
GENERAL MANAGEMENT
• Follow the ABCs of acute care: airway, breathing, and
circulation.
• Invasive blood pressure monitoring may be helpful in
some cases.
• Sedatives and alcohol used by the patient may com-
plicate sedation in the ICU.
• Causes of the near-drowning episode not related to
entanglement or alcohol use need to be considered
and ruled out quickly: cardiac arrhythmias, seizures,
and subarachnoid hemorrhage are all possible con-
tributing factors to a near-drowning episode.
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• Injuries to the spine and skull may be present, espe-
cially in diving injuries.
• In acute near-drowning episodes in seawater or swim-
ming pool water, antibiotics are not necessary.
Prophylactic antibiotics do not improve morbidity or
mortality.
• In the case of unexpected difficulty with mechanical
ventilation, a bronchoscopy may be warranted to look
for aspirated sand, gravel, or other debris.
• Experimental evidence suggests that routine steroid
use does not improve outcome, but it has been reported
that high-dose steroids might help near-drowning vic-
tims who present in pulmonary edema.
ADMISSION CRITERIA
• Patients should generally be admitted to the hospital if
they present with the following things (noninclusive
list):
 Abnormal blood gas (gas exchange abnormalities
are usually evident within 4–8 hours of the injury)
 Abnormal chest x-ray
 Any respiratory symptoms
PROGNOSIS
• 80% of near-drowning victim recover fully.
• Approximately 12% of near-drowning patients die.
• A lack of spontaneous respirations after resuscitation
is associated with increased risk of death or severe
neurologic impairment.
• Those who arrive to the hospital neurologically intact
are likely to survive without neurologic sequelae.
Outcome predictions are difficult if not impossible in
the presence of hypothermia.
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129 CARBON MONOXIDE
INTOXICATION
Michael A. Samara
KEY POINTS
• Carbon monoxide is the nonirritating, colorless, odor-
less, and tasteless gas produced by the incomplete
combustion of hydrocarbons.
• CO intoxication is among the leading causes of poi-
soning death in the United States resulting in over
5000 fatalities each year. The vast majority of these
are secondary to suicide attempts. Case fatality rates
are highly variable (0–30%).
• Unintentional CO poisonings demonstrate seasonal
and regional variation (peaking in winter months and
in colder climates) and are primarily secondary to
smoke inhalation.
 Other causes include malfunctioning residential fur-
naces; poorly ventilated kerosene, wood, and char-
coal heaters; and motor vehicle operation with
insufficient ventilation.
 Methylene chloride (an industrial solvent frequently
found in paint remover) undergoes hepatic metabo-
lism to CO and is a commonly overlooked cause of
poisoning.
• Clinical presentations vary greatly.
 During winter months, CO intoxication is important
to consider in patients presenting with influenza-
like signs/symptoms particularly when presenting in
cohabitants.
 CO intoxication should not be omitted from the dif-
ferential diagnosis in cases of unexplained syncope.
• Neuropsychiatric derangements are the most common
and best understood morbidities but CO intoxication
can present with any complication of tissue hypoxia
(e.g., myocardial infarction and bowel ischemia).
PATHOPHYSIOLOGY
• Carbon monoxide (CO) rapidly crosses the alveolar/
capillary membrane. Absorption varies with ambient
concentrations, minute ventilation, and the duration of
exposure. CO elimination is primarily via the lung as
an unchanged gas.
• CO’s affinity for hemoglobin and other iron moieties
is 200–250 times greater than that of oxygen.
 In addition to functioning as a competitive inhibitor
(effectively decreasing oxygen-carrying capacity), CO
binding results in a conformational change in hemo-
globin with a resultant left shift of the oxyhemoglobin
dissociation curve (decreased P50). This impaired
release of O2 is the principal mechanism by which CO
intoxication results in cellular hypoxia (Fig. 129-1).
 Binding to cardiac myoglobin results in myocardial
depression and hypotension thereby exacerbating
systemic tissue hypoxia.
• Non-hemoglobin-mediated toxicities (including
deranged oxidative phosphorylation, lipid peroxy-
genation, and numerous effects on platelets, leuko-
cytes, and endothelial cells) contribute to neurologic
and cardiac sequelae.
• Pregnant woman pose a unique clinical challenge. The
greater affinity of fetal hemoglobin for O2 and the cor-
responding accentuated leftward shift in fetal car-
boxyhemoglobin (HbCO) results in greater sensitivity
for the deleterious effects of CO in the fetus.
CLINICAL PRESENTATION
HISTORY
• While acute intoxications are readily apparent in the his-
tory (e.g., smoke inhalation and suicide attempts), the
presentation of chronic intoxications can be quite subtle.
SYMPTOMS
• Severity of symptoms range from mild constitutional
symptoms mimicking viral infection to respiratory
depression, seizures, syncope, and coma.
• While many of the acute effects of CO intoxication
vary with HbCO levels, the severity of most
delayed effects has no clear correlation with HbCO
levels.
• Nonlethal CO intoxication frequently presents with
the nonspecific symptoms of a viral illness resulting
in frequent misdiagnosis.
• Headache, dizziness, weakness, and nausea are the
most common presenting complaints occurring in
91%, 77%, 53%, and 47% of patients, respectively.
• 10–30% of victims have no acute neurologic symp-
toms but present days to months later with a delayed
neuropsychiatric syndrome (DNS) characterized by
cognitive deficits, personality changes, movement dis-
orders, and focal neurologic deficits. DNS may persist
for 1 year or longer but in most cases resolves.
 While DNS typically occurs within 28 days of
exposure, case reports exist of presentations up to
240 days after apparent recovery from the acute
exposure.
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FIG. 129-1 Effect of HbCO on oxygen capacity and unloading. With a
50% reduction in hemoglobin both arterial and venous (v) oxygen content
are reduced but the partial pressure at which hemoglobin is 50% saturated
(P50) is unchanged. In subjects with 50% HbCO both oxygen content and
the P50 are reduced.
SOURCE: Adapted from http://www.inchem.org/documents/ehc/ehc/ehc213.htm.
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DIAGNOSIS
• In inadvertent intoxications the best diagnostic tool is
a high clinical suspicion. The diagnosis is based on a
suggestive history, physical examination, and HbCO
measurements by co-oximetry.
• Signs
 Tachycardia and tachypnea (as markers of impaired
cellular oxygenation) are the most consistently
found physical signs.
 The classic findings of cherry-red lips, cyanosis, and
retinal hemorrhages are rare and should not be
relied upon for diagnosis.
 More severe intoxications can result in severe lactic
acidosis, ventricular arrhythmias, pulmonary edema,
and myocardial ischemia.
• Laboratory
 HbCO levels are important to obtain but may be
misleading.
 Serum levels of HbCO wane rapidly particularly if
oxygen therapy has been initiated and therefore
blood drawn in the field or ambient CO levels doc-
umented by emergency medical services (EMS)/fire
department are helpful.
 Chronic cigarette smokers may have baseline ele-
vations in HbCO to as high as 10%.
 HbCO must be measured with a spectrophotome-
ter or co-oximeter.
• HbCO absorbs light at the same wavelengths as
oxyhemoglobin and as a result most commercially
available pulse oximeters will overestimate the
oxygen saturation (though a linear decline will
occur).
• The pulse oximetry gap (the difference between
the oxygen saturation as determined by pulse
oximetry and the directly measured saturation)
is roughly equivalent to the HbCO.
 Cardiac enzymes and ECG
 Patients with underlying coronary artery disease
may experience worsening symptoms with mini-
mal levels of HbCO (5–10%).
 Young, healthy patients with no preexisting car-
diac disease may experience some myocardial
stunning with high-level exposures.
 Evaluation should also include basic chemistries, a
complete blood count (to assess for concomitant
anemia), an arterial blood gas (ABG), and a serum
lactate level (to assess for ongoing tissue ischemia).
• Imaging
 Except in their ability rule out structural causes of
neuropsychiatric derangements imaging offers little
to the evaluation in the acute setting.
 Computed tomography (CT), magnetic resonance
imaging (MRI), and positron emission tomography
(PET) imaging however may demonstrate deep
white matter abnormalities in patients with
DNS.
• It is of the utmost importance to document initial neu-
rologic/neuropsychiatric abnormalities. Dedicated
screening batteries exist (e.g., the Carbon Monoxide
Neuropsychological Screening Battery). The presence
of these abnormalities correlates well with the occur-
rence and severity of DNS and should in part govern
the decision of whether or not to treat with hyperbaric
oxygen (HBO; see Chap. 130).
TREATMENT
• Management begins with immediate removal from the
source and rapid initiation of the ABCs (airway,
breathing, circulation) of basic life support.
• High flow 100% oxygen should be administered
immediately and continued until HbCO levels are
below 10% (2% in patients with significant cardiopul-
monary comorbidities).
• Isocapnic hyperpnea (hyperventilation with O2 con-
taining ~5% CO2) is an alternative initial treatment in
the field and has been shown in dogs to double the rate
of HbCO elimination without the development of
hypocapnia.
• Patients who are comatose or have severe mental
status changes with concern for airway compromise
should be intubated without delay and ventilated with
100% oxygen.
• Continuous cardiac monitoring is essential.
• Once treatment is initiated it is important to consider
the use of HBO.
 The half-life of HbCO drops from 4–6 hours in
patients breathing room air, to 40–80 minutes in
patients breathing an FiO2 of 1.0, and to only 15–30
minutes in patients breathing HBO.
 Existing randomized-controlled trial (RCT) data are
limited, however, some consensus for when to
employ HBO is emerging:
 Coma, any preceding period of unconsciousness,
HbCO >40%, pregnancy with a HbCO level >15%,
signs of cardiac ischemia or arrhythmia, history of
coronary artery disease and HbCO >20%, and
symptoms not resolving with normobaric O2 after
4–6 hours.
 HBO has demonstrated the most efficacy in reduc-
ing the risk of DNS when multiple sessions at
2–3 atm are used within 24 hours of the primary
exposure.
 If not available in your institution immediately
notify the nearest HBO center for patients who are
comatose or unstable. This information is available
from Duke University’s Divers Alert Network hot-
line (919) 684-2948.
 A sample decision tree for when to employ HBO
(Fig. 129-2).
PREVENTION
• Safe operation of motor vehicles, residential furnaces,
and portable heaters.
• CO detectors have repeatedly demonstrated their effi-
cacy in minimizing unintentional exposures.
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130 HYPERBARIC OXYGEN
THERAPY
May M. Lee
KEY POINTS
• Hyperbaric oxygen has been recommended and used for
a wide variety of medical conditions with a varying evi-
dence base. The paucity of randomized-controlled trials
makes the efficacy of HBO in most diseases difficult to
assess.
• HBO therapy is currently used for patients with severe
CO poisoning, decompression sickness (DCS), and air
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Potential CO exposure victim
• Initiate 100 % NBO therapy
• Obtain CO-Hgb level
• ECG, ABG, CBC, chemistries
• Toxicology screen
Is any criterion present?
• Abnormal neurologic or cardiovascular 
 examination, including mini-mental 
 status examination
• Unconscious at scene or hospital
• History of transient neurologic deficit or
 mental status change
• Severe acidosis
• Pregnant woman
• Preexisting cardiovascular disease
• Age >60
• CO-Hgb >25 %
Refer for HBO therapy Headache, N/V, blurred vision,
or CO-Hgb >10 %
Discharge100 percent NBO therapy until CO-Hgb <10 percent and asymptomatic
Yes No
Yes No
FIG. 129-2 Algorithm for using normobaric and HBO following CO exposure.
SOURCE: Adapted from O’Brien C, Manakar S. Carbon monoxide and smoke inhalation. In: Hanson
CW, Lanken P, Manakar S, eds., The Intensive Care Manual. Philadelphia, PA: W.B. Saunders, in
press; http://Wwddw.Uptodate.Com.
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embolism, and as adjunctive therapy for the prevention
and treatment of osteoradionecrosis, clostridial
myonecrosis, and compromised skin grafts and flaps.
• HBO therapy is the treatment of choice in severe
anemia when transfusion is not an option because of
the physiologic effect of arterial oxygen content.
• HBO is expensive, not universally available, and not
without risks. Further research is needed to establish
its efficacy and safety in other conditions.
BACKGROUND
• Hyperbaric oxygen (HBO) therapy is a unique interven-
tion whose mechanism of action is not fully understood.
• It has been recommended for a wide range of medical
conditions (Table 130-1), but with a paucity of
randomized-controlled trials documenting its benefit.
• HBO is defined as a treatment in which a patient
breathes 100% oxygen while in a chamber where
the pressure is increased to greater than sea level
(or 1 atmosphere, atm). This may occur in a single
person chamber (monoplace) or multiplace chamber
(may hold two or more people). Breathing 100%
oxygen at 1 atm or exposing isolated parts of the body
to 100% oxygen does not constitute HBO therapy.
• The Undersea and Hyperbaric Medical Society
(UHMS) is the primary source of information for
diving and hyperbaric medicine physiology. Many of
the recommendations for the use of HBO come from
this organization.
PHYSIOLOGY
• The effects of HBO are based on the biologic and
physiologic effects of the gas laws (PV = nRT) and of
hyperoxia on the tissues. Thus, HBO is most com-
monly used to treat situations of tissue hypoxia or
conditions where gas bubbles obstruct blood flow, that
is, decompression sickness (DCS) or gas embolism.
 Increased oxygen delivery: Henry’s law states that the
amount of gas dissolved in a liquid or tissue is
directly proportional to its partial pressure. Most
oxygen carried by blood is bound to hemoglobin
(CaO2 = [1.39 × Hb (g/dL) × O2 saturation (%) +
0.0031 × PaO2]). That is, the proportion of oxygen
carried in solution is increased at increased pressure.
At 100% oxygen and 3 atm, arterial oxygen tensions
can increase to 2000 mmHg (from 100 mmHg) and
tissue oxygen tensions to around 500 mmHg (from
55 mmHg) allowing 60 mL of oxygen to be delivered
per liter of blood (compared to 3 mL/L at 1 atm).
 Reduction of bubble size: Boyle’s law states that at a
constant temperature, the volume of a gas is inversely
proportional to the pressure. That is, the volume of a
gas bubble at 3 atm is one-third that at sea level.
Furthermore, bubble dissolution is accomplished by
replacement of the gas inside the bubble with oxygen,
which is swiftly metabolized by the tissues.
 Increased generation of oxygen free radicals: Oxygen
free radicals oxidize proteins and membrane lipids,
damage DNA, and inhibit bacterial metabolic func-
tion. HBO alone is bactericidal for certain anaerobes,
including Clostridium perfringes, and bacteriostatic
for certain species of Escherichia and Pseudomonas.
 Improved wound healing: Amplifies oxygen gradi-
ents along the periphery of ischemic wounds and
promotes the oxygen-dependent collagen matrix
formation needed for angiogenesis.
 Reduction in reperfusion injury: Neutrophils have been
implicated as the major culprit in reperfusion injury by
adhering to the walls of ischemic vessels, releasing
proteases and free radicals leading to pathologic vaso-
constriction, and extensive tissue destruction. HBO has
been shown to inhibit neutrophil adherence and postis-
chemic vasoconstriction in ischemic rat tissue.
 Increased vasoconstriction: Hyperoxia in normal tis-
sues due to HBO causes quick and significant vaso-
constriction, but with increased plasma oxygen
carriage. Microvascular blood flow to ischemic tissue
is actually improved by HBO. This vasoconstriction
helps to reduce tissue edema, which contributes to the
treatment of compartment syndromes and burns.
 Antagonism of carbon monoxide (CO): CO binds to
hemoglobin at 200–250 times the affinity of oxygen.
Carboxyhemoglobin causes a marked decrease in the
oxygen-carrying capacity of blood and release of
oxygen in tissue. HBO at 2.5 atm reduces the
half-life of carboxyhemoglobin from 4 to 5 hours to
20 minutes or less in normal subjects.
TABLE 130-1 Possible Uses for HBO Therapy
Air or gas embolism
CO poisoning
CO poisoning complicated by cyanide poisoning
Clostridial myositis and myonecrosis (gas gangrene)
Crush injury, compartment syndrome, and other acute traumatic ischemias
DCS
Enhancement of healing in selected problem wounds
Exceptional blood loss (anemia)
Intracranial abscess
Necrotizing soft-tissue infections
Osteomyelitis (refractory)
Delayed radiation injury (soft-tissue and bony necrosis) 
Skin grafts and flaps (compromised)
Thermal burns
SOURCE: Adapted from http://www.UHMS.org.
ADMINISTRATION
• In order to be effective, HBO must be inhaled in the
atmosphere or through an endotracheal tube in a
monoplace chamber (Fig. 130-1), or through masks,
tight-fitting hoods, or endotracheal tubes in a larger,
multiplace chamber (Fig. 130-2). 
• Monoplace chambers are used for the treatment of
chronic medical conditions in stable patients.
Multiplace chambers allow closer monitoring of criti-
cally ill patients.
• Chamber pressures are usually maintained between
2.5 and 3 atm and last 45–300 minutes depending on
the indication.
• Typically, hyperbaric therapy is administered with
pressurized oxygen or air.
• Critical care monitoring and treatment, including
mechanical ventilation, should be readily available.
CLINICAL USES
CARBON MONOXIDE POISONING
• Carbon monoxide poisoning is the most common
cause of death by poisoning in the United States.
Severe poisoning is indicated by loss of consciousness
(syncope, seizures, and coma), neurologic deficits,
pulmonary edema, myocardial ischemia, and severe
metabolic acidosis. In addition to the acute toxic
effects, all victims of CO poisoning are at risk for
delayed neuropsychological sequelae. 
• The quality and results of clinical trials vary widely,
but numerous nonrandomized studies show that HBO
reverses both the acute and delayed effects of CO
poisoning.
• HBO is not routine or recommended in patients with
mild to moderate CO poisoning—treatment with
100% normobaric oxygen for 4–6 hours or until
symptoms abate should be adequate.
• Many authorities favor the use of HBO in the presence
of HbCO >40%, loss of consciousness, or in pregnant
women with HbCO >20%, because the prognosis for
these patients and exposed fetuses are sufficiently
poor with normobaric oxygen treatment.
• Patients with severe CO poisoning should receive at
least one treatment with HBO at 2.5–3 atm. Additional
treatments may produce greater improvement in neu-
ropsychological sequelae.
DECOMPRESSION SICKNESS
• Decompression sickness occurs mainly in recreational
divers breathing compressed air who return to the sur-
face too quickly, but can also affect aviators who
ascend above 5500 m (altitude DCS). 
• Bubble formation occurs when the partial pressure of
nitrogen dissolved in tissue and blood exceed the
ambient pressure. Bubbles can cause tissue deforma-
tion and vessel occlusion, impairing tissue perfusion
and oxygenation. Biochemical effects at the blood-gas
interface also cause endothelial damage, changes in
hemostasis, and activation of leukocytes.
• DCS manifests a range of severity from self-limited
rash to joint pain to paralysis, seizures, and even death.
• HBO is the definitive treatment for DCS, although no
randomized-controlled trials have compared it to nor-
mobaric oxygen treatment.
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FIG. 130-2 Multiplace chambers.
SOURCE: Adapted from http://www.sechristind.com/.
FIG. 130-1 Monoplace chamber. 
SOURCE: Adapted from http://www.sechristind.com/.
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• It is unclear whether the efficacy of HBO is due to
reduction in bubble size and relief of local hypoxia or
to the modulation of the pathologic effects mediated
by bubbles in the tissues and vessels.
• Patients with DCS should undergo HBO treatment as
soon as possible because a sharp decrease in the suc-
cessful treatment of cerebral air emboli has been
noted after a 4- to 5-hour delay.
• Patients should receive HBO at 2.5–3 atm for 2–4 hours,
with repeated longer treatment as necessary until they
are symptom free, or if there is no further clinical
improvement.
ARTERIAL GAS EMBOLISM
• Gas embolism occurs when gas bubbles enter or form
in the circulation. This can arise from pulmonary
overinflation during a dive, mechanical ventilation,
central venous catheter placement, hemodialysis, and
other sources.
• There are few clinical trials of HBO treatment in gas
embolism, but it is widely accepted as the only life-
saving treatment.
• Immediate therapy with HBO is typically at 2.5–3 atm
for 2–4 hours with repeated treatments until no further
clinical improvement is seen.
INFECTIONS
• Clostridial myositis and myonecrosis: The mainstay
of treatment has always been immediate surgical
decompression and excision and antimicrobials.
Adjunctive HBO therapy is known to have antibacter-
ial and antitoxin effects. There are many case reports
and clinical series showing combined treatment can
reduce the need for drastic surgery and amputation.
The UHMS recommends three 90-minute sessions at
3 atm for the first 25 hours, followed by twice-daily
treatments for 4–5 days until clinical improvement
is seen.
• Necrotizing fasciitis: This rapidly progressive infec-
tion of the skin and underlying tissue has a very high
mortality. Surgical debridement and antibiotics are
conventional therapies. Animal studies have shown
that HBO has a direct antibiotic effect, improves
oxygen tension, leukocyte function, and bacterial clear-
ance. HBO has been reported to improve mortality by
two-thirds. Patients should receive twice-daily treat-
ments for 90–120 minutes at 2–2.5 atm, reduced to
once daily when the patient stabilizes. Further treat-
ments may be given to reduce relapse.
• Refractory osteomyelitis: HBO is recommended in
localized and diffuse osteomyelitis, particularly if
there is vascular or immune compromise. HBO pro-
motes the formation of oxygen-dependent collagen
matrix needed for angiogenesis. It also directly and
indirectly kills anaerobes and promotes oxygen-
dependent osteoclastic resorption of necrotic bone.
HBO’s efficacy in osteomyelitis has been confirmed in
animal studies. Treatment varies with severity, but it is
recommended that HBO be given for 90–120 minutes
daily at 2–2.5 atm in conjunction with debridement,
antibiotics, and nutritional support.
• Intracranial abscess: In patients with severe infec-
tions, multiple, deep, or dominantly located abscesses,
or who are immune compromised, poor surgical can-
didates, or resistant to conventional treatment, adjunc-
tive HBO may be helpful. Clinical evidence is limited,
but patients may be treated once or twice daily at
2–2.5 atm for 60–90 minutes. Success is determined
by clinical and radiologic findings. The average
number of treatments is 13.
COMPROMISED SKIN GRAFTS
• Skin grafts and reconstructive flaps may fail because
of inadequate perfusion and hypoxia. 
• A number of animal and human studies have shown
improved survival of grafts with HBO. In skeletal
microcirculation models, HBO significantly reduced
endothelial leukocyte adherence and prevented with
progressive vasoconstriction of reperfusion injury.
Other mechanisms include fibroblast stimulation and
collagen synthesis.
• HBO should be considered when a graft or flap must
be placed over a capillary bed with poor circulation, in
an irradiated field, and especially if a previous recon-
struction in the same area was unsuccessful.
• Patients should receive twice daily treatments at 2–2.5
atm for 90–120 minutes reduced to once daily once the
graft or flap has stabilized.
PROBLEM WOUNDS
• Problem wounds, especially diabetic foot infections and
arterial insufficiency ulcers are among the most common
conditions treated with HBO in the United States.
Morbidity and mortality are high. HBO treatment has
been shown to improve healing and limb salvage.
• HBO has been reported to enhance oxygenation,
fibroblast proliferation, collagen synthesis, epithelial-
ization, and neovascularization, increase bactericidal
activity, and be toxic to anaerobes.
• A double-blind randomized-controlled trial in 2003
demonstrated improved healing and cost benefit with
adjunctive HBO treatment in diabetic ulcers com-
pared to a placebo group receiving hyperbaric air,
though the sample was small.
• HBO is very useful in the management of problem
wounds by promoting limb preservation and speedier
healing.
• Treatment at 2–2.5 atm for 90–120 minutes once or
twice daily combined with grafts and infection control
may be reasonable.
ANEMIA DUE TO EXCEPTIONAL BLOOD LOSS
• In hyperbaric conditions, the dissolved oxygen con-
tent in the blood can be sufficient to meet cellular and
metabolic demands without the contribution of
oxyhemoglobin.
• Hemorrhagic shock can be treated by HBO in patients
for whom suitable blood is not available, or who
refuse blood for religious or practical reasons.
• HBO is useful as a short-term temporizing measure,
but it is inconvenient and expensive, and the risks of
oxygen toxicity limit its treatment duration.
• It is recommended that patients be treated at up to 3 atm
for 2- to 4-hour periods, three to four times a day until
hypoxic symptoms have resolved and red blood cells
have regenerated.
RADIATION-INDUCED TISSUE INJURY
• Radiation therapy impairs restorative cellular prolifer-
ation, causing decreased vascularity, local hypoxia,
and eventually necrosis. This usually manifests itself
as edema, ulceration, bone necrosis, poor wound heal-
ing, and increased risk of infections, which can persist
for years after the initial insult. High doses of radia-
tion can result in spontaneous radionecrosis.
• HBO increases vascular density and oxygenation in
radiation-damaged tissues. Oxygen tension is
increased to normal levels enabling fibroblast prolif-
eration, collagen formation, angiogenesis at wound
edges, and re-epithelization. 
• Before HBO therapy was available, reconstruction of
previously irradiated mandibular tissue in patients
with oropharyngeal and other head and neck cancers
were often unsuccessful with complications including
osteonecrosis, soft-tissue radionecrosis, mucositis,
dermatitis, and laryngeal radionecrosis found in
50–60% of patients. The use of HBO has increased
success rates up to 93%.
• Successful treatment with HBO is also documented in
other postradiation damage including chest wall
necrosis, radiation-induced hemorrhagic cystitis, and
central nervous system (CNS) radiation damage.
• There is extensive, though not conclusive, evidence
for the use of HBO in radiation injury, particularly
mandibular osteoradionecrosis.
• Current protocols for the prevention and treatment of
osteoradionecrosis involve 30 preoperative HBO ses-
sions at 2.4 atm for 90 minutes each, followed by 10
sessions postoperatively.
THERMAL BURNS
• The proposed mechanisms of benefit to burn wounds
are decreased edema due to hyperoxic vasoconstriction,
collagen formation, and improved bacterial killing.
• Some studies have shown that HBO improves healing
time, hospitalization, and mortality compared to con-
trols and reduces the need for grafting. However,
other studies show no benefit.
• At this time, it is not clear that HBO confers any ben-
efit when added to the usual care given to patients at
burn centers.
• The UHMS recommends three sessions within 24 hours
of injury and 90-minute treatments twice daily there-
after at 2–2.4 atm.
ACUTE CRUSH INJURIES
• In acute traumatic crush injuries, extravasation of
intravascular fluid increases the diffusion difference
from capillary to cell, producing progressive, self-
perpetuating ischemia, edema, and inadequate healing.
• Surgical repair to maintain perfusion of tissues, blood
replacement, and anticoagulation are the mainstays of
management.
• HBO can improve tissue oxygen tension and increase
plasma-based oxygenation and increasing erythrocyte
deformability. 
• Hyperoxic vasoconstriction resolves edema without
impairing oxygen delivery and reverses the edema-
ischemia cycle.
• HBO also antagonizes lipid peroxidation by free rad-
icals thereby reducing reperfusion injury.
• Published research is limited, but a high-quality
randomized-controlled trial in 1996 demonstrated sig-
nificant improvements in healing with HBO.
• Patients should be treated within 4–6 hours of injury
at 2–2.5 atm once daily for several days.
OTHER
• A number of other potential uses for HBO have been
proposed, however remain poorly validated. Future
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indication for HBO are as disparate as malignant otitis
media, sports injuries, traumatic brain or spinal cord
injury, sickle cell disease, acute stroke, multiple scle-
rosis, tinnitus, sudden sensorineural hearing loss, the
systemic inflammatory response syndrome, and acute
myocardial infarction (MI). Further studies will need
to be done before HBO can be endorsed for these
potential indications.
COMPLICATIONS
• Hyperbaric oxygen therapy is safe when used accord-
ing to standard protocols with oxygen pressures not
exceeding 3 atm and with treatment sessions lim-
ited to 120 minutes. Some adverse effects may occur,
however.
 The most common side effect is reversible myopia,
caused by either direct toxicity of oxygen to the lens
or physical lens deformation. There is no evidence
for increased cataract formation.
 Middle ear and sinus barotraumas are preventable by
equalization techniques or tympanostomy tubes, and
otitis media can be prevented by pseudoephedrine.
Inner ear barotrauma is extremely rare but tympanic
rupture can result in permanent hearing loss, tinni-
tus, and vertigo.
 Inhaling highly concentrated and pressurized oxygen
may precipitate generalized seizures, but these are
self-limited and cause no permanent damage. HBO
has also been associated with hypoglycemia in some
patients with diabetes. Hypoglycemia should be
included in the differential for HBO-associated
seizures.
 Some patients have reversible tracheobronchial
symptoms with repeated exposure to HBO: chest
tightness, substernal burning, and cough, with
reversible decrements in pulmonary function.
 Critically ill patients who have required high con-
centrations of normobaric oxygen for a prolonged
period who then undergo repeated exposure to HBO
are at greater risk for toxic pulmonary effects.
 Psychological side effects such as claustrophobia,
especially in monoplace chambers, are common.
 There is no evidence for stimulation of malignant
growth with HBO therapy.
 Clinical evidence does not support claims of fetal
complications such as spina bifida or limb defects.
CONTRAINDICATIONS
• The only absolute contraindication to HBO therapy is
untreated pneumothorax.
• Relative contraindications include obstructive lung
disease, cardiac disease, impaired pressure equaliza-
tion, upper respiratory or sinus infections, recent ear
surgery or injury, fever, and claustrophobia.
• Patients with a history of seizure disorder, pneumoth-
orax, or chest surgery are at highest risk for compli-
cations related to barotraumas or CNS oxygen
toxicity.
COST
• On average, a single 90-minute HBO session can cost
between $300 and $400.
• The cost for 30–40 sessions for the treatment of
radionecrosis or problem wounds, therefore, can cost
from $9000 to $16,000. 
CONCLUSION
• Hyperbaric oxygen has been recommended and used
for a wide variety of medical conditions with a vary-
ing evidence base. The paucity of randomized-
controlled trials makes the efficacy of HBO in most
diseases difficult to assess.
• The discovery of beneficial cellular and biochemical
effects has strengthened the rationale for administering
HBO as primary therapy in patients with severe CO
poisoning, DCS, and air embolism, and as adjunctive
therapy for the prevention and treatment of osteora-
dionecrosis, clostridial myonecrosis, and compromised
skin grafts and flaps.
• The physiologic effect of HBO on arterial oxygen
content makes this therapy the treatment of choice in
severe anemia when transfusion is not an option.
• HBO is expensive, not universally available, and not
without its risks. Further research is needed to estab-
lish its efficacy and safety in other conditions.
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131 ACUTE ALCOHOL
WITHDRAWAL
Brian Klausner
KEY POINTS
• Alcohol abuse is prevalent in hospitalized population,
occurring in approximately 15–20% of patients.
• Alcohol withdrawal (AWD) symptoms can range
from mild agitation to life-threatening seizures and
delirium. Quick and adequate symptomatic control of
AWD decreases associated mortality from approxi-
mately 10–15% to <1%.
• Benzodiazepines are the first-line agents used to
treat withdrawal syndromes secondary to their cross-
reactivity with alcohol and their rapid onset of
action. Rapid and adequate control of agitation has
been shown to decrease mortality and duration of
symptoms.
PATHOPHYSIOLOGY
• Alcohol increases the binding of gamma-aminobutyric
acid (GABA), an important inhibitory neurotransmit-
ter, to its receptor while inhibiting the effects of the
excitatory neurotransmitter, N-methyl-D-aspartate
(NMDA), on its receptor. Over time, chronic exposure to
alcohol will lead to a compensatory decrease in GABA
receptor responsiveness and an upregulation of NMDA
receptors. As a result, sudden abruption of alcohol intake
in the chronic alcoholic leads to brain excitability and
withdrawal symptoms. Benzodiazepines, which are the
first-line agent for treatment, increase the affinity of
GABA to GABAA receptors, helping to counteract the
effects of alcohol withdrawal.
• With repeated detoxifications over time, there is
believed to be a “kindling effect” where an increase in
neuronal responsivity leads to worsening withdrawal
symptoms for individual patients.
CLINICAL MANIFESTATIONS
• Symptoms of hyperexcitability range from mild to
life-threatening and vary between patients and over
time for individual patients.
• Table 131-1 list the DSM-IV (Diagnostic and
Statistical Manual of Mental Disorders, Fourth
Edition) diagnostic criteria for alcohol withdrawal,
which include impairing symptoms of agitation and
excitability that occur in the context of alcohol cessa-
tion after prolonged use that cannot be explained by
other medical conditions. Alcohol withdrawal delir-
ium (AWD), commonly known as delirium tremens
(DTs) can be diagnosed when fluctuating changes in
cognition and consciousness occurs in the setting of
withdrawal symptoms.
• In general, minor withdrawal symptoms such as anxi-
ety, agitation, tremulousness, nausea, anorexia, palpi-
tations, and diaphoresis typically occur approximately
6–12 hours after the last drink, with more severe symp-
toms of hallucination (12–24 hours), tonic-clonic
seizures (typically 24–48 hours but can occur within
hours of cessation), and delirium (48–72 hours) occur-
ring later.
• The Clinical Institute Withdrawal Assessment for
Alcohol (CIWA-Ar) is a clinical scale used to assess
severity of the 10 most common withdrawal phe-
nomena and can be used to help guide treatment
(see Fig. 131-1).
EVALUATION
• History: duration, amount, and type of alcohol use;
any history of withdrawals, seizures, or other sub-
stance abuse.
• Physical: manifestations of liver disease, full neuro-
logic examination, signs of trauma (alcoholics often
present with evidence of falls or injuries). In the con-
text of mental status changes, head trauma often must
be ruled out as an etiology.
• Labs/imaging: liver function test, urine toxicology
screen, basic metabolic panel identifying hypo-
glycemia as well as magnesium and phosphate defi-
ciencies; possible head computed tomography (CT)
and lumbar puncture (LP) if indicated in patients with
seizures or delirium.
400 SECTION 10 • SPECIAL PROBLEMS IN THE ICU
TABLE 131-1 DSM-IV Criteria for EtOH Withdrawal
a. Cessation of EtOH use that has been heavy and prolonged
b. Two or more of the following:
Autonomic hyperactivity
Increased hand tremor
Insomnia
Nausea and vomiting
Hallucinations
Psychomotor agitation
Grand mal seizures
c. The symptoms of part b cause distress and impairment
d. The symptoms of part b are not due to a medication
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Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised (CIWA-Ar)
Patient:__________________________ Date: ________________ Time: _______________ (24 hour clock, midnight = 00:00)
Pulse or heart rate, taken for one minute:_________________________ Blood pressure:______
NAUSEA AND VOMITING -- Ask “Do you feel sick to your 
stomach? Have you vomited?” Observation.
0 no nausea and no vomiting
1 mild nausea with no vomiting
2
3
4 intermittent nausea with dry heaves
5
6
7 constant nausea, frequent dry heaves and vomiting
TACTILE DISTURBANCES -- Ask “Have you any itching, pins and 
needles sensations, any burning, any numbness, or do you feel bugs 
crawling on or under your skin?” Observation.
0 none
1 very mild itching, pins and needles, burning or numbness
2 mild itching, pins and needles, burning or numbness
3 moderate itching, pins and needles, burning or numbness
4 moderately severe hallucinations
5 severe hallucinations
6 extremely severe hallucinations
7 continuous hallucinations
TREMOR -- Arms extended and fingers spread apart. 
Observation.
0 no tremor
1 not visible, but can be felt fingertip to fingertip
2
3
4 moderate, with patient's arms extended
5
6
7 severe, even with arms not extended
AUDITORY DISTURBANCES -- Ask “Are you more aware of 
sounds around you? Are they harsh? Do they frighten you? Are you 
hearing anything that is disturbing to you? Are you hearing things you 
know are not there?” Observation.
0 not present
1 very mild harshness or ability to frighten
2 mild harshness or ability to frighten
3 moderate harshness or ability to frighten
4 moderately severe hallucinations
5 severe hallucinations
6 extremely severe hallucinations
7 continuous hallucinations
PAROXYSMAL SWEATS -- Observation.
0 no sweat visible
1 barely perceptible sweating, palms moist
2
3
4 beads of sweat obvious on forehead
5
6
7 drenching sweats
VISUAL DISTURBANCES -- Ask “Does the light appear to be too 
bright? Is its color different? Does it hurt your eyes? Are you seeing 
anything that is disturbing to you? Are you seeing things you know are 
not there?” Observation.
0 not present
1 very mild sensitivity
2 mild sensitivity
3 moderate sensitivity
4 moderately severe hallucinations
5 severe hallucinations
6 extremely severe hallucinations
7 continuous hallucinations
ANXIETY -- Ask “Do you feel nervous?” Observation.
0 no anxiety, at ease
1 mild anxious
2
3
4 moderately anxious, or guarded, so anxiety is inferred
5
6
7 equivalent to acute panic states as seen in severe delirium or 
acute schizophrenic reactions
HEADACHE, FULLNESS IN HEAD -- Ask “Does your head feel 
different? Does it feel like there is a band around your head?” Do not 
rate for dizziness or lightheadedness. Otherwise, rate severity.
0 not present
1 very mild
2 mild
3 moderate
4 moderately severe
5 severe
6 very severe
7 extremely severe
FIG. 131-1 CIWA-Ar clinical scale.
SOURCE: Adapted from Sullivan JT, Sykora K, Schneiderman J, et al. Assessment of alcohol withdrawal: the revised Clinical Institute
Withdrawal Assessment for Alcohol scale (CIWA-Ar). Br J Addict 1989;84:1353–1357.)
TREATMENT
• Goals of treatment: Alleviate and prevent progres-
sions of symptoms; treat underlying comorbidities.
• Benzodiazepines are first-line agents due to their
rapid absorption and cross-tolerance with alcohol.
Meta-analysis demonstrates that treatment with ben-
zodiazepines is associated with an improvement in
mortality and duration of symptoms and  with less
side effects than neuroleptics.
• Studies have demonstrated that symptom-based
treatment, where the CIWA score is calculated on an
hourly basis and treatment is administered when scores
are >8, is associated with a shorter treatment course
(9 hours vs. 68 hours) and total dosage (100 mg vs.
425 mg of chlordiazepoxide) compared to fixed
schedule regimens. Symptom-based treatment does
require extensive monitoring.
 Typical symptom-based treatment regimen:
diazepam (Valium) 5–10 mg or lorazepam (Ativan)
1–4 mg IV q 1-2 h as needed to maintain light seda-
tion or to keep CIWA-Ar scores below 8.
 Fixed dose regimen: Chlordiazepoxide (Librium)
50 mg PO q 6 h for four doses followed by 25 mg
PO q 6 h  for eight doses; doses held for excessive
somnolence or patient refusal. Additional doses of
25–100 mg doses given as needed hourly for CIWA
scores >8.
• There are no randomized, control studies looking at
long-acting versus shorter-acting benzodiazepines.
Long-acting provide a smoother withdrawal course
and are associated with less breakthrough symptoms
and seizures. Short-acting may be preferred in elderly,
patients with liver disease, or in patients who are
expected to require prolonged sedation.
• Other agents: Neuroleptics, such as haloperidol, have
been demonstrated to be inferior to benzodiazepines
as first-line agents, but are often used as adjunct treat-
ment to help control agitation and delirium. Beta-
blockers can be used to help control blood pressure,
tachycardia, and other symptoms of agitation, but
must be used with caution as they can worsen delir-
ium and mask withdrawal symptoms. Clonidine is
also often used to treat the autonomic symptoms of
withdrawal. Treatment with either clonidine or beta-
blockers should be considered in patients with known
coronary artery disease who might not be able to tol-
erate the cardiac autonomic strain of withdrawal.
• Supportive treatment: IV fluids with D5NS, 100 mg
IV thiamine (given before D5NS to prevent the sudden
onset or worsening of Wernicke encephalopathy that
can occur with thiamine deficiency), folate 1 mg, mul-
tivitamins, replace electrolytes as needed (magne-
sium, potassium, and phosphate deficiencies are
common in alcoholics).
ALCOHOL WITHDRAWAL DELIRIUM
(DELIRIUM TREMENS)
• On the spectrum of clinical manifestations, AWD is
the most severe and life-threatening, occurring in
approximately 5% of withdrawal patients. AWD
symptoms are typically first seen 48–72 hours after
the last drink and tend to peak 5 days after cessation
of alcohol. Risk factors for the development of AWD
include history of prior episodes or withdrawal
seizures, daily heavy alcohol use, concurrent medical
illness, older age, abnormal liver tests, and severe with-
drawal symptoms. All hospitalized patients undergoing
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AGITATION  -- Observation.
0 normal activity
1 somewhat more than normal activity
2
3
4 moderately fidgety and restless
5
6
7 paces back and forth during most of the interview, or 
constantly thrashes about
ORIENTATION AND CLOUDING OF SENSORIUM  -- Ask 
“What day is this? Where are you? Who am I?”
0 oriented and can do serial additions
1 cannot do serial additions or is uncertain about date
2 disoriented for date by no more than 2 calendar days
3 disoriented for date by more than 2 calendar days
4 disoriented for place/or person
Total CIWA-Ar  Score ______
Rater’s Initials ______
Maximum Possible Score 67
The CIWA-Ar is not copyrighted and may be reproduced freely. This assessment for monitoring withdrawal symptoms requires 
approximately 5 minutes to administer. The maximum score is 67 (see instrument). Patients scoring less than 10 do not usually need
additional medication for withdrawal. 
FIG. 131-1 (Continued)
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alcohol detoxification should be monitored closely for
evidence of AWD as the condition is associated with
a high mortality and necessitates aggressive treat-
ment. Any patient with clinical symptoms of AWD
should be monitored in an ICU setting.
• In patients with AWD, it is essential to obtain quick
and adequate control of agitation to a goal of light
sedation, defined as either the patient being asleep but
easily arousable, or awake but able to quickly fall
asleep without stimulation. With benzodiazepine
treatment, the mortality rate from AWD drops from
approximately 10–15% to 0–1%.
 Typical regimen: lorazepam 1–4 mg IV or diazepam
5–10 mg IV q 5-10 min as needed to control agita-
tion and achieve light sedation, and then additional
doses q 1-2 h as needed. Patients will often need
high doses to reach treatment goals.
• In addition to the adjunct treatments listed above,
propofol, a short-acting barbiturate, may be used in
severe cases of delirium/agitation that is refractory to
benzodiazepine treatment. Side effects of propofol
include hypotension, hypertriglyceridemia, and risk
of infection caused by the infusate medium. Patients
require an artificial airway and mechanical ventilation
in almost all cases.
• For withdrawal seizure, give 2 mg IV lorazepam;
repeat dose for subsequent seizures; correct any elec-
trolyte abnormalities or concurrent hypoglycemia.
Consider other possible etiologies in patients with
fever, history of trauma, focal seizures, or if their last
drink was over 48 hours prior to presentation. 
• Patients with seizures, severe impairment of con-
sciousness, or who are at high risk for aspiration may
require intubation for airway protection.
• Use physical restraints as needed for patient protection.
• Remember to monitor electrolytes and replace them as
needed. Magnesium, phosphate, and potassium defi-
ciencies commonly present in chronic alcoholics are
often exacerbated during episodes of withdrawal as
there is a shift of these electrolytes into the cells. Also,
monitor closely for evidence of rhabdomyolysis
which often occurs in the context of DTs.
BIBLIOGRAPHY
Al-Sanouri I, Dikin M, Soubani AO. Critical care aspects of alco-
hol abuse. South Med J 2005;98:372–381.
Bayard M, McIntyre J, Hill KR, et al. Alcohol withdrawal syn-
drome. Am Fam Physician 2004;69:1443–1450.
Lejoyeux M, Solomon J, Ades J. Benzodiazepine treatment
for alcohol-dependent patients. Alcohol Alcohol 1998;33:
563–575.
Mayo-Smith MF. Management of alcohol withdrawal delirium:
an evidence-based practice guideline. Arch Intern Med
2004;164:1405–1412.
Saitz R. Individualized treatment for alcohol withdrawal: a ran-
domized double-blind control trial. JAMA 1994;272:519–523.
This page intentionally left blank 
132 CENTRAL VENOUS
CATHETERIZATION
David R. Brush
KEY POINTS
• Careful consideration of the indication(s) for central
line placement helps dictate correct catheter choice
and site of cannulation.
• Patients with innate or iatrogenic coagulopathies
should have their coagulopathy corrected before central
venous catheter placement to reduce complications.
• Experience in the placement of central venous catheters
results in a substantial decrease in the rate of complica-
tions. Proper supervision should be provided to trainees.
• When no longer needed, central venous catheters
should be removed immediately to avoid long-term
complications of infection and/or thrombosis.
INDICATIONS FOR CENTRAL LINE
PLACEMENT
• To obtain measurements of central venous pressure
(CVP) via subclavian or internal jugular cannulation.
Femoral central venous catheters can be used to monitor
intra-abdominal pressure.
• In preparation for the placement of pulmonary artery (PA)
catheters.
• To provide rapid resuscitation with fluid or blood
products.
• To provide medications such as chemotherapy, vasoac-
tive drugs, and hyperalimentation that have the poten-
tial to cause phlebitis if not placed in central large
veins.
• To perform hemodialysis or plasmapheresis.
• To sample central venous oxyhemoglobin saturation.
• For patients requiring frequent blood draws, or if
peripheral access is unattainable.
• Cardiopulmonary resuscitation often calls for the emer-
gent placement of a central venous catheter. Under
these circumstances the femoral vein is most often can-
nulized due to ease of placement; however, breaks in
sterile technique are common. When the patient is sta-
bilized a new central line should be placed at another
site using sterile technique and the femoral catheter
should be removed. Any line placed emergently during
a code situation should be considered nonsterile.
• Intracardiac pacing can be accomplished with subcla-
vian and internal jugular venous catheters (Table 132-1).
GENERAL CONTRAINDICATIONS TO
CENTRAL VENOUS CANNULATION
• Generally, patients with platelets <50 × 103/µL, pro-
thrombin time >1.5 times the normal limit, or acti-
vated partial thromboplastin time >2 times the
normal limit are at increased risk of serious compli-
cations. Patients with blood coagulation disorders
should have their derangements corrected prior to
cannulation.
• For patients who have recently received therapeutic
anticoagulation (e.g., heparin, low-molecular weight
heparin, activated protein C, or tissue plasminogen
activator), a proper amount of time should be given
before proceeding with cannulation. The amount of
time needed to wait will depend on the half-life of the
medication.
• Uncooperative or delirious patients can be a significant
barrier to safe placement of a central venous catheter.
Short-acting parenteral benzodiazepines can be
employed but should be used with extreme caution in
patients with compromised cardiopulmonary or neuro-
logic function.
• Physician inexperience with central venous cannula-
tion is associated with increased mechanical and
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infectious complications. Close supervision is
required. Inexperienced physicians in training should
initially perform cannulations on sedated, mechani-
cally ventilated patients and only with senior super-
vising physicians.
SITE CHOICE
• Generally, the subclavian vein is the preferred site for
catheterization. It is associated with the lowest rates
of catheter infection and thrombosis when compared
to internal jugular and femoral cannulation. Aseptic
techniques, combined with operator expertise and cor-
rect site selection can minimize complications associ-
ated with central line placement.
• In general, it is advisable to avoid sites with poor
landmarks, anatomic defects, or recent surgery.
• If the patient is coagulopathic, consider femoral cannu-
lation to avoid bleeding from a noncompressible vessel.
• Consider jugular or femoral catheter placement in
patients requiring hemodialysis or plasmapheresis.
This protects the subclavian veins for later placement
of permanent catheters.
• If a PA catheter will be placed the preferred sites for
the introducer catheter are the left subclavian vein or
the right internal jugular due to the curved conforma-
tion of the PA catheter.
• Avoid subclavian and internal jugular cannulation in
patients with severe refractory hypoxemia.
• Do not place more than one central catheter at a single
site.
• Failed attempts for internal jugular or subclavian veins
should not proceed to the contralateral side for new
attempt until a chest x-ray (CXR) has been obtained
and confirmed no pneumothorax complication.
• Avoid sites with superficial skin lesions and infections.
• Avoid placement in vessels with known or suspected
thrombosis.
CATHETER SELECTION
SHORT, LARGE-BORE (8.5 F) INTRODUCER
CATHETER
BENEFITS
• Flow is inversely related to resistance described by
Poiseuille law: R = (8ηL/Pπ)r4, where η is fluid vis-
cosity, L is catheter length, and r is the radius of the
catheter lumen. Thus, short, large-bore (8.5 F)
catheters are the catheter of choice for extremely rapid
fluid resuscitation.
• Allows for introduction of a PA catheter through the
sheath introducer.
DRAWBACKS
• Not designed for long-term use >72 hours.
• Associated with increased risk of air embolism.
• Using a PA catheter through the sheath introducer is
associated with increased rates of catheter infection.
• Malfunction or accidental removal of the catheter by the
patient can cause rapid exsanguination. Thus, only to be
utilized in highly monitored settings such as in ICU.
LARGE-BORE, DOUBLE LUMEN
CATHETERS (QUINTON)
BENEFITS
• Best suited for hemodialysis or plasmapheresis.
DRAWBACKS
• Slower rate of flow than an 8.5 F catheter due to
decreased radius and increased catheter length.
• Can limit patient mobility.
TRIPLE LUMEN CATHETER
BENEFITS
• Allows for infusion of multiple agents.
• Can reduce the number of central venous catheters
needed.
DRAWBACKS
• Should not be used for fluid resuscitation or dialysis
due to high resistance and poor flow.
• A peripheral 16-gauge catheter can infuse fluids quicker
than a central triple lumen.
PREPARATION FOR CATHETER
PLACEMENT
• Obtain written informed consent for the procedure
from the patient or the patient’s surrogate. Consent
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TABLE 132-1 Indications for Central Venous Cannulation
Monitoring CVP or intra-abdominal pressure
Measuring central venous oxygen saturation
Placement of PA catheters
Extremely rapid fluid resuscitation
Hemodialysis
Plasmapheresis
Cardiopulmonary resuscitation
Administration of vasoactive drugs
Intracardiac pacing
Hyperalimentation
Administration of phlebitic medications (chemotherapy, potassium)
Inadequate peripheral access
Frequent phlebotomy
CHAPTER 132 • CENTRAL VENOUS CATHETERIZATION     407
should include discussion of the following risks:
possible pneumothorax and need for tube thoracos-
tomy, infection, bleeding, and thrombosis.
• Gather all materials necessary before proceeding with
the procedure.
• Supervising physicians should employ all sterile protec-
tive barriers (e.g., gloves and gown) so they can quickly
and safely assist during the procedure if needed.
• After employing sterile dress and gloves, arrange all
sterile materials according to operator preference
(Table 132-2).
• The catheter should always be examined under sterile
conditions for defects and flushed with sterile saline
to ensure proper function before placement.
INTERNAL JUGULAR CENTRAL
VENOUS CATHETER PLACEMENT:
CENTRAL APPROACH USING A
MODIFIED SELDINGER TECHNIQUE
• Locate the apex of the triangle formed by the two
bodies of the sternocleidomastoid muscle and their
insertion points into the clavicle. The internal jugular
vein, bound with the carotid artery in the carotid
sheath, runs deep to the sternocleidomastoid muscle
and emerges between the two heads of this muscle
before passing deep to the clavicle to join the subcla-
vian vein (Fig. 132-1A).
• Rotate the patient’s head approximately 45° to the con-
tralateral side and place the patient in Trendelenburg
position. This will increase the size of the vein to be can-
nulated and will also reduce the risk of air embolism.
• Sterilize the area and apply all sterile barriers.
• Place the index and middle finger of the nondominant
hand at the apex of the triangle directly over the carotid
pulse. With the dominant hand, insert a 25-gauge needle
with a syringe containing lidocaine just past the skin
surface immediately lateral to the carotid pulse. Apply
backpressure on the plunger, assuring there is no blood
return, then deliver lidocaine to create a wheal at the
skin surface.
• While applying gentle backpressure to the syringe,
advance the needle slowly in the direction of the ipsi-
lateral nipple, stopping frequently to deliver lidocaine
until sufficient anesthesia has been applied.
• Obtain a 22-gauge “finder” needle and an empty 10 cc
syringe. Continue to hold fingers over the carotid
pulse to help avoid puncturing the carotid artery.
Advance the needle and syringe along the same track,
lateral to the carotid pulse toward the ipsilateral nipple
at an angle of 20° to the skin surface. Draw back the
syringe during advancement to create negative pres-
sure within the syringe.
• The internal jugular vein is often located close to the
skin surface, so there is rarely a need to advance
needle more than 2 cm. When the vein is located,
venous blood will flow easily into the syringe.
• If the first pass is unsuccessful, withdraw the needle
close to the skin surface and redirect the needle more
medially on the next advancement.
• When the finder needle successfully locates the vein,
note the angle and depth of the needle.
• Withdraw the needle and insert an 18-gauge intro-
ducer needle and 10 cc syringe along the same path,
using the previous technique.
• When venous blood flow is again demonstrated, hold the
18-gauge needle steady in place and remove the syringe.
• Feed the guidewire through the 18-gauge introducer
needle. If the guidewire does not feed easily, remove
the wire and use the syringe to reconfirm blood flow.
Reposition the needle if needed.
• When the guidewire is in place, remove the 18-gauge
introducer needle over the wire.
• Guide an 18-gauge short tip intravenous catheter over
the guidewire. When the catheter is hubbed at the
proximal end, hold the catheter in place and withdraw
the wire entirely. Attach a transducer tube to the
catheter, and confirm venous pressure and venous
waveform. If venous access is confirmed, reintroduce
the guidewire to its previous position and remove the
18-gauge catheter over the wire. If arterial puncture is
suspected, do not reintroduce the guidewire. Instead,
remove the 18-gauge catheter and apply direct pressure
for 15 minutes. This additional step of confirming a
TABLE 132-2 Materials Necessary for Central Venous
Catheter Placement
Clean bouffant cap to prevent hair falling on the field
Clean mask with face shield
Sterile gown
Sterile gloves
Sterile towels
Large sterile drape with fenestration for site of insertion
500 cc sterile 0.9% normal saline in sterile bowl
Chlorhexidine skin antiseptic
At least one 5 mL ampule of HCl 1% lidocaine
25-Gauge injection needle c/ 5 cc syringe for lidocaine
22-Gauge “finder” needle c/ 10 cc syringe
18-Gauge introducer needle c/ 10 cc syringe
Guidewire
Short catheter: 18-gauge over 20-gauge introducer
#11 scalpel
Tissue dilator
Indwelling central venous catheter
Central line clamp fastener
4 × 4 gauze pads
Suture: straight needle and 3-0 silk
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venous pressure waveform has been shown to dramat-
ically reduce the incidence of accidental dilation and
cannulation of arteries.
• Once venous access has been confirmed, proceed to
cannulation. While holding the wire, insert the #11
blade along the wire to reduce skin tension. Next feed
the tissue dilator over the wire, withdraw the wire tip
from the dilator and advance the dilator to the hub.
Once this is complete, immediately remove the tissue
dilator over the wire and apply sterile 4 × 4 gauze pads
with pressure to reduce bleeding.
• Introduce the central venous catheter over the guidewire,
again withdraw the tip of the wire so it is not inadver-
tently pushed into the patient, then advance the catheter
to a length that approximates the catheter tip placement
in the correct position in the superior vena cava (SVC).
It is better to overestimate the length needed, as the
catheter can always be further withdrawn in a sterile
fashion, but obviously cannot be further advanced.
• Remove the guidewire, leaving the central venous
catheter in place. With a 5 cc syringe and 0.9% normal
saline, ensure that each port for the central line draws
blood and flushes appropriately.
• Reapply lidocaine below skin surface at the selected
suture site. Suture the catheter in place, and apply
appropriate sterile dressing.
• Order a CXR to check for complications and to con-
firm proper placement of the catheter tip 2–4 cm
above the junction of the SVC and atria.
SUBCLAVIAN CENTRAL VENOUS
CATHETER PLACEMENT:
INFRACLAVICULAR MIDDLE
APPROACH USING A MODIFIED
SELDINGER TECHNIQUE
• The subclavian vein lies directly underneath the clav-
icle and begins where the axillary vein crosses the lat-
eral border of the first rib. The anterior scalene muscle
separates the subclavian vein from the subclavian
artery, with the artery posterior (Fig. 132-1B).
• Rotate the patient’s head approximately 45° to the con-
tralateral side and place the patient in Trendelenburg
position.
• Place a small towel vertically between the patient’s
shoulder blades to widen the sternoclavicular angle.
• Identify landmarks by locating the midpoint of the
clavicle and the sternal notch. The finder needle will
be guided a few centimeters caudal to the midclavicu-
lar point angled parallel with the table and toward the
sternal notch.
FIG. 132-1 A Internal jugular placement.
SOURCE: McGee DC, Gould MK. Preventing complications of central venous catheteriza-
tion. N Engl J Med 2003;348:1123–1133.
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• Sterilize the area and apply all sterile barriers.
• Apply local anesthesia to the area in the expected path
described above. When the clavicle is encountered,
provide ample anesthesia to the periosteum.
• Obtain a 22-gauge “finder” needle and 10 cc syringe
c/ 5 cc of normal saline. Apply gentle suction to the
syringe while advancing the needle from the insertion
point inferior to the midclavicular point toward the
sternal notch at an angle parallel with the examin-
ing table. The needle should encounter the clavicle
around the junction between the middle and medial
thirds.
• While keeping the needle and syringe parallel with the
table, apply gentle downward pressure. While slightly
withdrawing and advancing the needle, carefully
guide the needle inferiorly along the clavicular sur-
face until the needle passes just under the inferior sur-
face of the clavicle.
• Advance the needle under the clavicle slowly applying
gentle backpressure. When the subclavian vein is
located, venous blood will flow easily into the syringe.
If this first pass is not successful, withdraw the needle
from under the clavicle and change the angle slightly
toward the patient’s head before readvancing.
• The internal jugular vein is often located close to the
skin, so there is rarely a need to advance the entire
length of the needle.
• When the finder needle successfully locates the vein,
note the angle and depth of the needle.
• Withdraw the needle and insert an 18-gauge introducer
needle and 10 cc syringe along the same path, using
the previous technique.
• When venous blood flow is again demonstrated, hold
the 18-gauge needle steady in place and remove the
syringe.
• Feed the guidewire through the 18-gauge introducer
needle. If the guidewire does not feed easily, remove
the wire and use the syringe to reconfirm blood flow
and reposition the needle if needed.
• When the guidewire is in place, remove the 18-gauge
introducer needle over the wire.
• Guide an 18-gauge short tip intravenous catheter over
the guidewire. When the catheter is hubbed at the
proximal end, hold the catheter in place and withdraw
Sternal
notch
First rib
Subclavian vein
and artery
Internal
jugular vein
Sternocleidomastoid
muscle
Common carotid
artery
(under muscle)
Clavicle
Syringe
FIG. 132-1 B Subclavian placement.
the wire entirely. Attach a transducer tube to the
catheter, and confirm venous pressure and venous
pulsation. If venous access if confirmed, reintroduce
the guidewire to its previous position and remove the
18-gauge catheter over the wire. If arterial puncture is
suspected, do not reintroduce the guidewire. Instead,
remove the 18-gauge catheter and apply pressure for
15 minutes.
• Once venous access has been confirmed, proceed as
described above for internal jugular catheter.
FEMORAL CENTRAL VENOUS
CATHETER PLACEMENT: APPROACH
USING A MODIFIED SELDINGER
TECHNIQUE
• Identify landmarks by locating the femoral artery and
the inguinal ligament. The femoral vein lies immedi-
ately medial to the femoral artery.
• Sterilize the area and apply all sterile barriers.
• With one hand, locate the femoral artery. Apply local
anesthesia to the area in the expected path, just medial
to the femoral artery 2–3 cm below the inguinal
ligament.
• Obtain a 22-gauge “finder” needle and 10 cc syringe
with 5 cc of normal saline Apply gentle suction to the
syringe while advancing the needle from the insertion
point toward the inguinal ligament parallel with the
arterial pulse at an angle approximately 20° from the
skin surface.
• When the vein is located, venous blood will flow
easily into the syringe. Note the angle and depth of the
needle.
• Withdraw the needle and insert an 18-gauge intro-
ducer needle and 10 cc syringe along the same path,
using the previous technique.
• When venous blood flow is again demonstrated, hold
the 18-gauge needle in place and remove the syringe.
• Feed the guidewire through the 18-gauge introducer
needle. One hand should be holding the guidewire at
all times to prevent guidewire embolization. If the
guidewire does not feed easily, remove the wire and
use the syringe to reposition the needle and reconfirm
blood flow.
• When the guidewire is in place, remove the 18-gauge
introducer needle over the wire.
• Guide an 18-gauge short tip intravenous catheter over
the guidewire. When the catheter is hubbed at the
proximal end, hold the catheter in place and withdraw
the wire entirely. Attach a transducer tube to the
catheter, and confirm venous pressure and venous pul-
sation. If venous access is confirmed, reintroduce the
guidewire to its previous position and remove the
18-gauge catheter over the wire. If arterial puncture is
suspected, do not reintroduce the guidewire. Instead,
remove the 18-gauge catheter and apply pressure for
15 minutes.
• Once venous access has been confirmed, proceed
as described above for internal jugular cathater.
MECHANICAL COMPLICATIONS
GENERAL
• Patient comfort should always be a concern. Local
anesthesia with agents such as lidocaine should be
used for every patient during every procedure.
• If arterial cannulation is suspected after tissue dilation
and/or central venous catheter has been placed, do not
remove the tissue dilator or catheter. Call for emergent
help from physicians with experience in vascular sur-
gery or percutaneous closure.
• Monitor patients in whom arterial puncture has
occurred for hematoma formation. Patients with coag-
ulation disorders are at increased risk. An expand-
ing hematoma can enlarge to compress adjacent
critical structures and is of particular concern during
internal jugular cannulation with damage to the
carotid artery.
• Symptoms of air embolism include acute mental
status changes and hypotension. Occasionally, a “cog-
wheel” murmur can be auscultated. If air embolism is
suspected the patient should immediately be placed in
a Trendelenburg left decubitus position. Provide
100% oxygen to increase the rate of resorption.
Skilled operators should attempt to aspirate the
embolized air if the catheter is in the heart.
• Guidewire and catheter embolization can be largely
prevented though vigilance. Catheters with any mal-
function or irregularity on inspection should never be
placed. Also, catheters should be removed with
extreme care. During cannulation, the operator should
always maintain visual control of the guidewire. If the
guidewire slips into the catheter during catheter place-
ment immediately clamp the catheter at the base and
attempt to remove the catheter and wire as a single
unit. Vascular surgery should be contacted immedi-
ately should embolization of a guidewire occur.
• Catheter tip misplacement is not uncommon.
Catheters advanced past the SVC into or near the
right atrium increase the risk for arrhythmias. This
should be promptly corrected by withdrawing the
catheter the appropriate length and resecuring the
catheter. Occasionally, the catheter will advance into
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an unintended vein (e.g., subclavian catheter with tip in
the internal jugular). Repositioning can be attempted
with the use of a guidewire and placement of a new
catheter (Table 132-3).
SUBCLAVIAN AND INTERNAL JUGULAR
CANNULATION
• Pneumothorax after cannulation can occur with both
subclavian and internal jugular cannulation, but is
more common with the subclavian approach. Severity
of the pneumothorax can range from small and
asymptomatic to rapid and catastrophic. CXR should
always be ordered after cannulation and inspected for
pneumothorax. Treatment can range from supportive
care to thoracostomy and chest tube insertion depend-
ing on the magnitude and rate of onset.
• Careful insertion at the internal jugular site with atten-
tion to not insert the needle “deep” can often prevent
pneumothorax. A frequent mistake junior operators
make is to “hub” the large-bore needle while attempt-
ing to find the vein.
• Myocardial or central vein perforation occurs infre-
quently and can manifest as a mediastinal hematoma
or pericardial effusion. Hemothorax is suggested by
symptoms similar to a pneumothorax and new effu-
sion on CXR. If the perforation is above the peri-
cardium a wide mediastinum may be seen on CXR.
• Thoracic duct laceration is a rare complication of left
internal jugular placement.
FEMORAL CANNULATION
• Arterial puncture or laceration is not uncommon
during femoral cannulation.
• The formation of a retroperitoneal hematoma should
be considered in patients with clinical or laboratory
evidence of blood loss after femoral cannulation.
Treatment in most cases involves correcting deficits in
coagulation and supportive care.
REDUCING MECHANICAL
COMPLICATIONS
• Experience: Physicians who have performed more than
50 cannulations have half the mechanical complication
rate of physicians with 50 or less.
• Ultrasound guidance has been shown to increase can-
nulation success rates and reduce mechanical
complications.
• The risk of mechanical complications increases sixfold
after the third unsuccessful pass of the needle. The oper-
ator should seek assistance if this third attempt fails.
• Arterial damage during central venous catheter place-
ment can be minimized by confirming venous blood
pressure and pulsation via short 18-gauge single
lumen catheter connected transducing tubing before
dilation over the guidewire.
• The chance of air embolism can be reduced substan-
tially by maintaining a closed system during catheter
placement. Needles should not be employed without
being attached to syringes filled with sterile saline.
All catheters should be promptly closed to air when
not in use.
• The use of soft catheters and slow introduction of the
catheter can reduce the risk of myocardial or central
vein perforation.
CATHETER-RELATED THROMBOSIS
• Considered a common long-term complication of cen-
tral vein cannulation.
• More common in femoral cannulation and least
common with subclavian cannulation.
• Should be suspected when clinical signs and symp-
toms of venous stasis are present corresponding
anatomically with the path of the catheter. Also can be
indicated by catheter occlusion or compromise.
• Confirmed by ultrasonography, computed tomogra-
phy (CT) scan with contrast, or contrast venogram.
• Treatment is anticoagulation for deep vein thrombosis
and removal of the catheter.
TABLE 132-3 Mechanical Complications
General
Pain
Bleeding
Hematoma
Arterial puncture
Air embolism
Guidewire or catheter embolization
Catheter tip misplacement
Complications associated with subclavian and internal jugular
Pneumothorax
Arrhythmia
Hemothorax
Mediastinal hematoma
Cardiac tamponade
Myocardial or central vein perforation
Thoracic duct injury
Complications from femoral cannulation
Retroperitoneal hematoma
CATHETER-RELATED INFECTIONS
HISTORY AND CLINICAL DIAGNOSIS
• Catheter-related infection should always be consid-
ered for patients demonstrating signs of infection or
sepsis without a confirmed source and who have a
central venous catheter in place for ≥3 days.
• Any signs of infection around the exit site demands
prompt removal of the catheter regardless of the pres-
ence or absence of other signs or symptoms. A new
site should be chosen for a new catheter and empiric
antibiotics should be provided.
• Resolution of signs and symptoms of infection
24–48 hours after catheter removal suggests the pres-
ence of a catheter-related infection regardless of culture
results in the absence of other sources for infection.
LABORATORY DIAGNOSIS
• Laboratory evidence of systemic infection or sepsis.
• Obtain two peripheral blood cultures to identify the
presence of bacteremia. Blood cultures should not be
drawn though the catheter due to greater opportunity
for contamination.
• Positive peripheral blood cultures with organisms
associated with central venous catheter infection (e.g.,
Staphylococcus epidermis) should raise concerns for
catheter-related infection.
• Strong clinical suspicion alone is enough to prompt
initiation of antibiotics and catheter removal.
MANAGEMENT
• Initiate empiric parenteral antibiotics that provide
adequate coverage for S. epidermis and S. aureus.
Broader empiric coverage should be initiated for
immunocompromised patients.
• Once antibiotics have been provided, and if there are
no signs of infection at the exit site, the catheter can
be changed over a guidewire and the tip sent for cul-
ture. All uncuffed catheters should be changed over
guidewire, replaced at a new site, or discontinued.
 A positive catheter tip culture with >15 colony
forming units (CFU): the catheter placed over the
guidewire should be removed and a catheter and
new site should be chosen.
 If the catheter tip culture is negative or with <15 CFU:
the replaced catheter can remain. Attempt to iden-
tify another infectious source.
• Monitor surveillance cultures for resolution of bac-
teremia after proper management. Persistent bacteremia
should prompt investigation into additional causes of
infection.
PREVENTION
• Quality assurance and continuing education should be
provided for standardization of aseptic care.
• Avoid placing catheters in the femoral area as it will
be difficult to maintain aseptic conditions.
• Oral or parenteral antibiotics have not been shown to
reduce incidence of catheter infections in adults.
• Routine line changes do not prevent catheter-related
infection and increase mechanical complications due
to multiple procedures.
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133 PULMONARY ARTERY
CATHETER INSERTION
Jennifer Sauk
KEY POINTS
• Recent randomized trials have not demonstrated ben-
efit to large patient populations receiving monitoring
with the PAC, but there may be patients who require
this intervention.
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• Serious complications from insertion are rare but
problems with recording artifact or misinterpretation
of data are common.
• While specific cardiac disorders can often be diag-
nosed or strongly suspected on the basis of the wave-
forms obtained by PAC, the right atrial pressure (RAP)
and pulmonary artery wedge pressure (PCWP) are in
and of themselves poor predictors of ventricular pre-
load and response to fluid resuscitation.
OBJECTIVES
• Understand indications for pulmonary artery catheter
(PAC) insertion.
• Understand preparation of the patient and the catheter
prior to the procedure.
• Understand the anatomy pertinent to PAC insertion.
• Be aware of potential complications associated with
the procedure.
• Understand pulmonary artery waveforms.
• Be aware of the hemodynamic calculations which can
be derived from PAC data.
INTRODUCTION
• A PAC, also known as a Swan-Ganz catheter, is a
balloon-tipped, four- or five-lumen polyvinyl chloride
catheter that can yield important hemodynamic data
such as pressures in the chambers of the right heart, car-
diac output (CO), and the pulmonary capillary wedge
pressure (PCWP), which reflects left atrial pressure.
Blood can also be sampled from the pulmonary artery
using this technique (Table 133-1; Fig. 133-1).
INDICATIONS AND
CONTRAINDICATIONS
• Much controversy exists regarding the use of the PAC.
Multiple studies suggest that large-scale, protocol-
driven trials would better define the role of the PAC.
TABLE 133-1 Hemodynamic Information That can be
Derived From PAC
DERIVED VALUE NORMAL PARAMETER
CO = VO2 (mL/min)/(10 × (CaO2 − CvO2)) 5 L/min
CI = CO/BSA (m2) 2–4 L/min/m2
SVR = (MAP − RAP) × 80/CO 900–1200 dyne-sec/cm5
PVR = (PAP − PCWP) × 80/CO 120–200 dyne-sec/cm5
ABBREVIATIONS: VO2, oxygen consumption; CvO2, mixed venous oxygen
saturation; CaO2, arterial oxygen saturation; CI, cardiac index; BSA,
body surface area; SVR, systemic vascular resistance; MAP, mean
arterial pressure; PVR, pulmonary vascular resistance; PAP, pulmonary
artery pressure.
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FIG. 133-1 Important hemodynamic waveforms to recog-
nize via PAC. (A) RAP tracing. Normal: 2–8 mmHg; A =
atrial contraction; C = tricuspid valve closure; V = atrial fill-
ing. (B) Right ventricular pressure tracing. Normal:
20–30/2–8 mmHg. Be aware of ventricular ectopy while in
the right ventricle. (C) PAP tracing. Normal: 20–30/8–15
mmHg. Monitored by distal port of PAC. Dicrotic notch:
represents closure of pulmonary valve. PA diastolic approx-
imates PAWP if no lung disease or mitral valve disease. (D)
PCWP tracing: (approx. left atrial pressure). Normal: 5–12
mmHg (mean). Since no valves between pulmonary artery
and mitral valve, PAWP approximates left atrial pressure, or
left ventricular end-diastolic pressure (LVEDP). A waves =
atrial contraction; V waves = atrial filling.
Large studies have not demonstrated a beneficial
effect with the use of PAC. However, PACs may be
useful in cases where hemodynamic data are needed
to establish a diagnosis or assist in management
(Tables 133-2 and 133-3; Fig. 133-2).
METHODS
PREPARATION
• Discuss risk: benefit of procedure with patient and
obtain written informed consent.
• Obtain all necessary equipment before the procedure
(Table 133-4).
• Insert an introducer catheter as described in Chapter 132.
FLOTATION OF PULMONARY ARTERY CATHETER
• Flush all catheter lumens with saline.
• Connect distal lumen to pressure transducer.
• Check balloon for proper inflation by injecting 1.5 cc
of air and looking for symmetry of balloon and absence
of leaks by immersing balloon in bowl of sterile saline.
Deflate balloon.
• Place PAC into PAC introducer and advance slowly to
20 cm mark.
• Inflate balloon with 1.5 cc of air.
• Maintain inflation with balloon lock.
• After inflation, advance catheter slowly to allow
blood flow to direct catheter through cardiac cham-
bers. If you meet resistance before reaching the pul-
monary artery, deflate the balloon, pull back, reinflate,
and attempt advancement. (See Table 133-5 for use of
PAC ports)
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TABLE 133-2 Possible Indications for Pulmonary Artery
Catheterization
Shock
Oliguric renal failure
Pulmonary disorders
Pulmonary hypertension
Pulmonary edema
Lactic acidemia
Cardiac disorders
Myocardial infarction (MI)—Catheter Consensus Conference
justified use in MI complicated by cardiogenic shock, right
ventricular infarction, or ventricular septal defect (VSD)/papillary
muscle rupture
Trauma
TABLE 133-3 Contraindications to Pulmonary Artery
Catheterization
Tricuspid or pulmonary valve stenosis
Prosthetic tricuspid or pulmonary valve
Right atrial or right ventricular mass
Cyanotic heart disease
Latex allergy
Complete left bundle branch block
Conduction abnormalities
Anticoagulation
IJ cannulation: previous carotid surgery
SVC obstruction
TABLE 133-4 Materials Needed for PAC
Other materials needed
Sterile drapes
Bouffant
Sterile gown
Sterile gloves
Sterile saline
Hexidine
1% lidocaine
Needles
25 gauge for lidocaine injection
21 gauge attached to 5 cc syringe as finder needle
18 gauge with catheter hub attached to 10 cc syringe used to pass
through
Seldinger J-wire
Scalpel
Vessel dilator
PAC introducer—9 F catheter
PAC catheter (described to the left)
Transducer pressure tubing
Suture
TABLE 133-5 Ports needed for PAC
PAC ports (refer to Fig. 133-2)
Proximal port
CVP monitoring since in SVC/RA
Inject thermodilution fluid or dye dilution for CO monitoring
Intravenous fluid (IVF) injection
Distal port
Monitor pressure waveforms during passage of the catheter
Assess PAPs when balloon inflated
Sample mixed venous blood
Never can be used for medication infusion
Thermistor port
Connects to CO monitor
Thermistor wire within measures blood temperature to estimate CO
Balloon port
<1 cm from tip of catheter
Inflates with air 0.8–1.5 cc
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• Observe pressure waveforms to determine catheter
location (Figs. 133-1B and C, 133-2, 133-3).
• Advance catheter until inflated balloon wedges (does
not move further) and observe fall in mean pressure.
Confirm placement with balloon deflation and obser-
vance of PA tracing. Reinflate and observe “PCWP”
tracings.
• Attach sterile sheath to introducer.
• Obtain chest x-ray to confirm placement of PA catheter.
• Appropriate damping of pressure transducer to ensure
adequate waveform readings >rapid flush test: open-
ing flush valve produces high pressures in normally
patent system. Close valve and observe rapid fall in
pressure before returning to PA wave.
• Calibration of PA catheter: open transducer to atmos-
pheric pressure while at the level of the left atrium.
• Once measurements are obtained, deflate the balloon
and secure PA catheter in the introducer hub.
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Infusion port
FIG. 133-2 Five-lumen PAC.
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FIG. 133-3 PA catheter waveforms.
COMPLICATIONS
INTRODUCTION OF CENTRAL
VENOUS CATHETER
• Pneumothorax 0.3–4.5%
• Arterial puncture 1.1–13%
• Air embolism 0.5%
FLOTATION OF PULMONARY ARTERY CATHETER
• Transient arrhythmia 4.7–68.9%
• Complete heart block (in patients with left bundle
branch block) 0–8.5%
• Pulmonary artery rupture 0.1–1.5%
• Pulmonary artery infarction 0.1–5.6%
• Catheter knotting
MAINTENANCE
• Similar to risks of central venous catheterization.
 Catheter-related infection 0.7–11.4%
 Thrombosis (higher after 36 hours of catheteriza-
tion) 0.5–66.7%
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134 THORACENTESIS
Adam P. Ronan
KEY POINTS
• Pleural effusions may be divided broadly into transu-
dates and exudates, with relatively simple chemistries
guiding this distinction.
• Identification of an empyema or complex parapneu-
monic effusion should lead to early consideration of
more definitive drainage.
• Ultrasound guidance can be extremely useful in
acquiring fluid when it is loculated.
• Careful attention to correcting coagulopathy and per-
forming thoracentesis at the upper margin of the rib
will minimize the chance of significant bleeding as a
complication.
PATHOPHYSIOLOGY
• A pleural effusion is a collection of fluid in the pleu-
ral cavity of which there are two broad categories:
 Transudative effusions: Form when there is an imbal-
ance between hydrostatic and oncotic pressures (e.g.,
increased hydrostatic pressure in the form of high
pulmonary capillary wedge pressures due to conges-
tive heart failure (CHF) or decreased oncotic pres-
sure due to cirrhosis or nephrotic syndrome).
 Exudative effusions: Form when there is an increase
in capillary permeability due to inflammation or
when there is a decrease in lymphatic drainage of the
pleural space (e.g., infection, malignancy, or autoim-
mune disorders).
INDICATIONS
• To obtain pleural fluid for diagnostic purposes.
• Therapeutic purposes to give the patient relief from
symptomatic effusions.
• Generally, all noncritically ill patients with pleural
effusions will need a thoracentesis unless the effusion
is extremely small (<10 mm thick on lateral decubitus
x-ray) and the clinical diagnosis is obvious (e.g., viral
pleurisy), or if the patient has a definitive diagnosis of
CHF with typical failures and is responding appropri-
ately to therapy.
• In critically ill patients, not all effusions need to be
tapped because the cause of the effusion is often known
and the results of the fluid analysis would not alter ther-
apy. In addition, coagulopathies and cardiopulmonary
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instability increases the risk for serious complication
(see Table 134-1).
RELATIVE CONTRAINDICATIONS
• Patient unable to cooperate
• Coagulation abnormalities or thrombocytopenia
• Patient on mechanical ventilation (greater risk for devel-
oping a tension pneumothorax or persistent air leak)
• Patient with severe cough or hiccups
• Bullous emphysema near site of effusion
COMPLICATIONS
• Pneumothorax
• Infection or empyema
• Localized bleeding or hemothorax
• Re-expansion pulmonary edema (if >1.5 L drained)
• Diaphragm injury
• Puncture of visceral organs (spleen or liver)
• Bronchopleural fistula
• Nerve injury
EQUIPMENT
• Adjustable table
• Skin cleansing materials (e.g., chlorhexidine solution)
• 25-Gauge needle, and a 20–22-gauge needle that is
1.5 in. long (longer for obese patients)
• Thoracentesis needle/catheter, or, if a such a catheter
is not available, a 14–18-gauge needle and clamp may
be used
• Scalpel
• Three-way stopcock
• Sterile drainage tube
• Fluid collection container (vacuum container or col-
lection bag)
• 12 cc syringe for anesthetization and larger syringe
(30–50 cc) for fluid withdrawal
• 1% lidocaine
• Sterile gloves, sterile gown, sterile drape, mask, and
eye protection
• Appropriate containers for laboratory tests
PROCEDURE
PREPARE PATIENT
• Obtain informed consent: letting the patient or
responsible party know the potential complications
which include pneumothorax, hemothorax, infection,
and pulmonary edema from re-expansion.
• If the patient is able, sit him/her straight upright on the
edge of the bed. (If the patient is unable to sit up in
this position, there are alternative approaches described
below.)
SELECT AND PREPARE SITE
• Identify the level of the effusion by gentle percussion
or ultrasound guidance.
• If the effusion is smaller than 10 mm on lateral decu-
bitus x-ray, or, if there is a concern that the effusion is
loculated (not freely moveable on lateral decubitus
x-ray), use ultrasound guidance to locate the effusion.
• Identify and mark the site for needle insertion:
 On the posterior thoracic wall, 5–10 cm lateral to
the spine, along the midscapular line.
 1 to 2 intercostal spaces below the superior margin
of dullness on percussion, thus overlying the effu-
sion (or as marked by ultrasound guidance).
 Overlying the middle of a rib just below the selected
intercostals space. One will not aim the needle at the
intercostal space during insertion but at the middle
of the rib. (The neurovascular bundle runs along
the inferior aspect of the rib, and, by directing the
needle into the midrib, this will be avoided).
 Alternative approaches in ICU patients: If the
patient must remain supine, the effusion can be con-
firmed by ultrasound marking and a catheter can be
inserted into the midaxillary or posterior axillary
lines in the 4th or 5th intercostal spaces. If the
patient can tolerate some elevation, the patient’s
weight can be supported by the hospital bed as the
head of the bed is elevated, and the effusion can then
be approached by the midaxillary or posterior axil-
lary line. Another option is to have the patient in a
lateral decubitus position (with the effusion side
down), with the head of the bed elevated, and the
effusion can be tapped by a posterior approach.
TABLE 134-1 ICU Indications for Thoracentesis
GENERALLY NEED GENERALLY DO NOT NEED
Effusion due to infection CHF
near pleura
(pulmonary, upper abdomen, Postesophageal sclerotherapy
mediastinal)
High-grade systemic sepsis Known malignancy diagnosis
Suspected malignancy Hepatic hydrothorax
Vasculitis Peritoneal dialysis
Pancreatitis Uremia
Drug-induced Central line complication 
(noninfectious) PE
• Cleanse the skin with the appropriate antiseptic
solution.
• Tape a fenestrated sterile drape on the patient’s back
with only a small area of skin exposed for the procedure.
ANESTHETIZE THE SITE AND ADVANCE
THE NEEDLE INTO THE EFFUSION
• Anesthetize the superficial dermis with the 1% lido-
caine using the 25-gauge needle inserted at a close
angle to the skin (<30°) to form a superficial weal
about 1 cm in diameter.
• Anesthetize the deeper structures using the 20–22-gauge
needle. Advance this needle perpendicular to the skin
surface aiming directly at the middle of the rib.
Remember to aspirate before each injection of the
lidocaine to avoid injecting the anesthetic intravascu-
larly. Maintain a negative pressure within the syringe
as you advance the needle forward.
• Advance the needle until it hits the rib. Be sure to
anesthetize the periosteum. Slowly “walk” the needle
up the rib until it slides over the superior margin of the
rib, thus avoiding the neurovascular bundle running in
the inferior margin. Continue gently advancing the
needle anesthetizing along the way—aspirating then
injecting lidocaine—until you are through the inter-
costal muscles and finally the pleura itself.
• Stop advancing the needle once you aspirate fluid.
This is a sign that the needle has been introduced into
the pleural cavity. Before removing the needle,
observe the depth and angle of the needle, as this will
be the same route you will take the larger thoracentesis
needle/catheter. You may consider placing a clamp on
the needle flush with the skin prior to withdrawing the
needle to mark the depth of needle insertion.
INSERTING THORACENTESIS DEVICE
AND REMOVING FLUID
• If you are using a thoracentesis catheter, then use the
scalpel to make a small nick into the skin to aid the
insertion of the catheter/needle.
• Attach the thoracentesis catheter/needle to the three-
way stopcock and large (30–50 cc) syringe. Make sure
the stopcock position only allows flow between the
needle and syringe, and is closed to the 3rd hub.
• Insert the thoracentesis catheter/needle into the punc-
ture following the same path as before, “walking”
over the superior rib margin, remembering to maintain
negative pressure in the syringe the entire time.
• When pleural fluid is aspirated, hold the needle in place
and carefully advance the catheter into the pleural space.
Withdraw the needle. Remember to never advance the
needle back into the catheter.
• If you are using a 14–18-gauge needle and no
catheter, then once the needle has been introduced
into the pleural cavity, place a clamp on the needle at
the level of the skin to keep the needle from slipping
further into the cavity.
• Attach the side arm of the three-way stopcock to the
drainage tubing and remove up to 1.5 L of fluid. Avoid
removing more than 1.5 L at any one time as this may
lead to re-expansion pulmonary edema and there is a
greater risk of pneumothorax.
• When finished removing the fluid, have the patient
Valsalva or hum while withdrawing the catheter.
POSTPROCEDURE
• Place bandage on site.
• Order necessary laboratory tests for fluid.
• Obtain an upright chest x-ray to check for pneumothorax
or signs of hemothorax if patient symptomatic or if pro-
cedure done in high-risk setting (critically ill patients).
LABORATORY ANALYSIS
• Send samples of the pleural effusion to the laboratory
for the following studies:
 Total protein
 Lactate dehydrogenase (LDH)
 Cell count and differential
 Gram’s stain and culture
 Glucose
 Others dictated by clinical suspicion:
 pH if infection, collagen vascular disease, or
esophageal rupture suspected
 Cytology if malignancy suspected
 Hematocrit (Hct) if effusion bloody
 Amylase if pancreatitis or esophageal rupture
suspected
 Acid fast smear if tuberculosis (TB) suspected
 Rheumatoid factor (RF) or antinuclear antibody
(ANA) if collagen vascular disease suspected
 Triglycerides and cholesterol if chylothorax
suspected
EXUDATES VERSUS TRANSUDATES
• Light criteria: Used to differentiate exudates from
transudates, these criteria are 98% sensitive and 83%
specific. If any of the following are true, then the effu-
sion is likely an exudate (see Tables 134-2 and 134-3):
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 Ratio of effusion total protein to serum total protein
>0.5 (TP
eff/TPserum >0.5) or
 Ratio of effusion LDH to serum LDH >0.6
(LDH
eff/LDHserum >0.6) or
 Effusion LDH greater than two-thirds of the upper
limit of normal serum LDH
DIFFERENTIAL DIAGNOSIS FOR EXUDATES
• Bacterial pneumonia (parapneumonic effusions and
empyema)
• Viral pneumonia (usually small)
• Other pulmonary infections (TB, fungal, parasites)
• Intraperitoneal or retroperitoneal infections
• Malignancy (primary lung, mesothelioma, metastases)
• Pulmonary embolism (75% are exudates)
• Collagen vascular disease (systemic lupus erythemato-
sus [SLE], rheumatoid arthritis [RA], dermatomyositis)
• Pancreatitis
TABLE 134-2 Summary of General Characteristics of
Exudates vs. Transudates
PARAMETER EXUDATE TRANSUDATE
TP
eff/TPserum >0.5 <0.5
LDH
eff/LDHserum >0.6 <0.6
TP (g/dL) >3.0 <3.0
LDH (IU/L) >200 <200
Cholesterol (mg/dL) >45 <45
Glucose <60 in complicated ≈Serum
parapneumonic
effusions, RA, 
esophageal rupture, 
and some malignancies
pH <7.3 in TB, complicated ≈7.4
parapneumonic
effusions, RA, 
esophageal rupture
WBC >1000 <1000
Appearance Serosanguinous, bloody, Clear to straw 
turbid, or purulent colored
TABLE 134-3 General Characteristics of Pleural Fluid
APPEARANCE WBC RBC GLUCOSE PH OTHER
Exudates
Uncomplicated Turbid Moderate to elevated, <5000 >40 >7.2 Negative Gram’s
parapneumonic ↑ polys stain, LDH <1000
Complicated Turbid or purulent Elevated <5000 <40 <7.2 Usually positive
parapneumonic (>10,000) ↑ polys Gram’s stain,
LDH >1000; need
complete drainage
Empyema Purulent Elevated <5000 <40 <7.0 Positive Gram’s
(20,000–100,000) stain, LDH >1000;
↑ polys need complete
drainage
TB Serosanguinous <10,000 ↑ lymphs 5000–10,000 <40–110 >7.2 Protein >4, + AFB,
ADA>70
Malignancy Turbid or bloody Variable Up to <40–110 >7.2 + Cytology
(usually <10,000) 100,000 Hct
↑ lymphs 1–20
RA Green or turbid Variable <1000 <60 7.2–7.3 ↑ RF
PE Straw or bloody Variable Up to >60 ≈Serum May be transudate
(often elevated) 100,000 Hct
1–20
Pancreatitis Turbid or Variable (often <10,000 >60 ≈Serum Left-sided, ↑ amylase
serosanguinous elevated) ↑ polys
Esophageal rupture Turbid or bloody Variable <10,000 40–70 <7 Left-sided, ↑ amylase
(often elevated)
Transudates
CHF Clear or straw <1000 lymphs <5000 ≈Serum ≈Serum Most common type;
colored usually bilateral;
may become
exudative after
aggressive diuresis
Cirrhosis Clear or straw <1000 <5000 ≈Serum ≈Serum Right-sided; often
colored massive
Nephrotic syndrome Clear or straw colored <1000 <5000 ≈Serum ≈Serum Usually bilateral, small,
or hypoproteinemia asymptomatic
ABBREVIATIONS: AFB, acid fast bacilli; ADA, adenosine deaminase; RA, rheumatoid arthritis; PE, pulmonary embolism.
• Drug reactions (nitrofurantoin, methysergide, practolol)
• Asbestosis
• Dressler syndrome
• Lymphatic disease/thoracic duct damage (if chylotho-
rax: expect triglycerides >110)
• Intra-abdominal abscess
• Esophageal rupture
• Uremia
• Sarcoid
• Iatrogenic causes
DIFFERENTIAL DIAGNOSIS FOR TRANSUDATES
• CHF
• Cirrhosis
• Nephrotic syndrome
• Hypoproteinemia
• Pulmonary embolism (25% are transudates)
• Peritoneal dialysis
• Superior vena caval obstruction
• Urinary obstruction (urinothorax)
• Atelectasis
• Myxedema
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135 PERICARDIOCENTESIS
J. Matthew Brennan
KEY POINTS
• The most common etiologies of pericardial effusions
include infection (viral, bacterial, TB), malignancy,
uremia, postinfarction inflammatory response, colla-
gen vascular disease, radiation, traumatic, iatrogenic,
and idiopathic.
• Bacterial, tuberculous, fungal, HIV-associated infec-
tions, malignancy, and hemorrhage are the most likely
to lead to cardiac tamponade.
• 80% of patients treated with pericardiocentesis
require no further drainage for effusions. However,
62% of malignant effusions redevelop within 7 days.
The treatment of recurrent pericardial effusions
involves surgical or balloon pericardiotomy.
• Cardiac tamponade can be diagnosed by physical
examination. However, ultrasound and right heart
catheterization (RHC) assessment is helpful in most
cases.
• On physical examination, the presence of pulsus para-
doxus (change in systolic blood pressure >10 mmHg
with inspiration), the loss of the “y” descent on the
venous waveform, as well as the triad of hypotension,
increased jugular venous pressure, and clear lungs are
suggestive of cardiac tamponade.
• Ultrasound criterion of tamponade include early dias-
tolic collapse of the right ventricle (specific) and right
atrium (sensitive), decrease in transmitral E wave >25%
with inspiration, and decrease in tricuspid E wave >40%
with inspiration.
• When RHC is performed in patients with cardiac tam-
ponade, high (10–30 mmHg) and equalized (within
4 mmHg) right atrial, RV middiastolic, pulmonary
artery diastolic, and pulmonary capillary wedge pres-
sures are found.
DIAGNOSTIC TESTS
• No consensus exists regarding the appropriate, cost-
effective workup for pericardial fluid samples.
However, the following have been suggested as high
yield in effusions of unknown etiology:
 Specific gravity
 Protein content
 White blood cell count with differential
 Gram’s stain
 Bacterial, fungal, tuberculosis (TB) cultures
 Acid fast bacilli (AFB) stain
 Adenosine deaminase (ADA)
 Cytology with pathology review
• Consider carcinoembryonic antigen (CEA), bilirubin,
and cholesterol (mostly found in traumatic, neoplastic
obstruction, or severe hypothyroidism) as other lower
yield tests.
PREPARATION
• A transthoracic echocardiogram (TTE) on the day of the
procedure has been shown to decrease complications.
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For greatest safety, anterior and posterior echo-free
space should be ≥10 mm. Intraprocedural echo guid-
ance has been recommended with small and regional
effusions.
• In the nonemergent situation, combining right heart
catheterization (RHC) and pericardiocentesis leads to
the highest yield workup. Approximately 40% of
medical patients with tamponade also have coexisting
causes of increased right atrial pressures diagnosed
on RHC.
• Computed tomography (CT) fluoroscopy guidance is
another option that some institutions utilize.
PROCEDURE
• Performance of this procedure in the cardiac cath lab
allows for RHC monitoring, fluoroscopic guidance,
and intrapericardial pressure monitoring which can
increase the diagnostic yield and safety of the proce-
dure. However, in the emergent situation, time con-
straints often make this option impractical.
• Continuous ECG monitoring is recommended
throughout the procedure.
• The attachment of an ECG lead to the puncture needle
is losing favor secondary to the cumbersome nature of
the technique and possible accidental arrhythmias,
which may be induced by improperly grounded leads.
• Several approaches exist; however, the most widely
used is the subcostal approach.
SUBCOSTAL APPROACH
• Place the patient at a 45° angle.
• Sterilize the subxiphoid area.
• 0.5 cm inferior to the xiphoid process, inject 1–2 cc
1% lidocaine.
• Using an 18-gauge, thin-walled needle puncture the
skin 0.5 cm inferior to the right costoxiphoid angle,
directing the needle posteriorly (perpendicular to the
skin) until below the costal margin (~1 cm).
• Holding the syringe with your dominant hand, walk
the needle under the xiphoid process while applying
downward pressure to the needle shaft with your non-
dominant hand and directing the needle cephalad
toward the patient’s left shoulder.
• Alternate aspirating and injecting small amounts of
1% lidocaine as the needle is advanced until the peri-
cardial space is entered or ST elevations are seen on
the ECG; if ST elevations are noted, withdraw the
needle and begin again.
• When the pericardial space is entered, aspirate a small
amount of fluid (2–3 cc) to ensure proper needle
placement.
• Advance a floppy tip guidewire through the needle
into the pericardial space.
• Remove the needle over the wire, leaving the wire in
place.
• Advance a pig-tailed catheter over the wire and into
the pericardial space, keeping control of the wire at all
times. When properly placed, the catheter should
wrap around the contour of the heart.
• Remove the wire, leaving the catheter in place.
• Aspirate pericardial fluid in no more than 1 L aliquots.
Often, a hemodynamic response will be seen with aspi-
ration of relatively small amounts of fluid (depending
on the chronicity of the fluid accumulation).
BLOOD VERSUS PERICARDIAL FLUID
• If the fluid aspirate appears hemorrhagic, place a few
drop of fluid on a sponge. Pericardial fluid typically
will leave a lighter stain than blood. Alternatively, place
~5 cc on the sterile drape and wait ~30 seconds; if the
fluid clots, it is blood—likely from a traumatic tap; if it
does not clot, it is likely pericardial fluid. Remember,
the pericardium has intrinsic fibrinolytic activity, which
prevents clotting; however, rapid hemorrhage into the
pericardium can overcome this fibrinolytic effect.
POSTPROCEDURE CATHETER CARE
• Fill the catheter with heparin or urokinase.
• Leave the catheter in place for 24–48 hours, flushing
q 1 h.
• Repeat TTE 24 hours postprocedure to determine
extent of fluid reaccumulation, if any.
COMPLICATIONS
• Coronary artery laceration
• Left ventricular (LV) puncture (very rarely leads to
significant bleeding)
• Right ventricular (RV) puncture (more bleeding than
the LV, but rarely serious)
 Look for an injury current on the ECG (ST eleva-
tion) in cases of LV or RV puncture
• Arrhythmia (induced by myocardial irritation from
the puncture needle, guidewire, or pig-tailed catheter)
• Puncture of the lung, liver, or stomach
• Pneumopericardium
• Pericarditis
• Acute LV failure with pulmonary edema (rare, but
increased risk if >1 L fluid removed)
• Acute RV dilation (rare)
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136 EMERGENT SURGICAL
AIRWAY
Kristopher M. McDonough
KEY POINTS
• Emergent surgical airways remain an important com-
ponent of the algorithms to be applied to patients with
evolving respiratory failure requiring mechanical
support.
• While the majority of patients with respiratory failure
will be managed with noninvasive mask ventilation or
translaryngeal intubation, on occasion an emergent
airway will be required.
• While all care providers attending to critically ill
patients cannot be expected to accrue a large experi-
ence with emergent surgical airways, the potential
need for such an intervention should be considered
when appropriate and each institution should provide
the means for staff and equipment to perform this
intervention to be assembled in a timely way.
BACKGROUND
• Emergent and nonemergent surgical airways are some
of the oldest surgeries documented. They were prac-
ticed as early as 3000 B.C. in Egypt and India. They
were popularized in Western medicine during the
nineteenth century when diphtheria and its resultant
upper airway obstruction were epidemic. The surgical
airway saw a re-emergence in the early twentieth cen-
tury when its champion, Chevalier Jackson, advocated
its application for a variety of conditions.
• Currently, there are a variety of techniques used to
introduce an artificial airway. For the purposes of this
chapter, cricothyroidotomy and tracheostomy will be
discussed in detail, as will be their emergent indications.
• Recall that there are a variety of chronic conditions
that necessitate or are improved by the placement of a
surgical airway. These are, by far, the majority of the
cases in which surgical airways are used.
• When an acute airway compromise arises, requiring
the placement of an artificial airway, endotracheal
intubation is possible and preferable in approximately
97% of cases. As such, endotracheal intubation should
always be the first choice for establishment of an
airway.
• Nevertheless, the placement of a surgical airway has
its indications, and in roughly 3% of airway emergen-
cies, is the procedure of choice.
ANATOMY
• An understanding of the regional anatomy of the
larynx and the trachea is essential to understanding
the procedure and its indications. For reference please
see Fig. 136-1.
• Recall that the airway is lined and supported by a
number of cartilaginous rings. The first of these is the
most identifiable anatomic landmark in the neck, the
thyroid cartilage. The thyroid cartilage contains and
protects most of the larynx including both the false
and true vocal cords.
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• Immediately inferior to the thyroid cartilage is the
cricoid cartilage. It should be palpable in most
patients, except for the very obese, and defines the
inferior aspect of the larynx. The fibrous structure
between the cricoid and thyroid cartilages is known as
the cricothyroid membrane.
• Below the larynx, the trachea begins. Cartilage rings
surrounding the trachea are numbered (e.g., first tra-
cheal cartilage, second tracheal cartilage, and so on).
• Below the thyroid cartilage the airway should be
largely free of interior structures to the level of the
branching into the right and left main stem bronchi,
known as the carina. This is important because surgi-
cal airways are largely indicated in cases were there is
obstruction at the level of the larynx or above.
• Overlying the larynx are the thyroid gland, its arterial
supply, and several nerves, including the recurrent laryn-
geal nerve, which supplies the muscles of the vocal cords.
PROCEDURES
• Generally, someone with extensive experience, espe-
cially in emergent situations, should perform these
procedures. This lessens the chance of poor outcome,
as well as decreasing the risk of both early and late
complications.
• Cricothyroidotomy is an incision made in the
cricothyroid membrane. This procedure requires an
identification of the relevant anatomic structures. This
is the most common method for establishment of the
surgical airway in the emergent setting.
• Tracheostomy is the classic surgical airway, and in the
past the most commonly used in emergent situations. It
is no longer the procedure of choice, however, as it is
time-consuming, requires more expertise, and is associ-
ated with twice as many complications in the emergent
setting. There are some emergency situations where tra-
cheostomy may be considered the procedure of choice,
as described in Indications below. The standard site for
tracheostomy is between the second and third tracheal
cartilages.
• The process of placing an airway via both cricothy-
roidotomy and tracheostomy is summarized in
Table 136-1.
INDICATIONS
• In general, indications for emergent surgical airway
placement are the same as those for any airway
FIG. 136-1 Anatomy of the larynx and sternal region.
Tracheal cartilages
Sternal notch
Sternum
Thyroid cartilage
Cricothyroid membrane
Cricoid cartilage
Clavicle
placement, but in the circumstance that endotracheal
intubation is not possible, or should not be performed.
• A list of indications for surgical airway is found in
Table 136-2. In general, cricothyroidotomy is the pro-
cedure of choice for urgent and emergent situations,
as noted above.
• Emergent tracheostomy should probably only be per-
formed if: (1) cricothyroidotomy fails; (2) the urgent
high-grade obstruction requiring airway is found at the
level of, or inferior to the site of cricothyroidotomy;
(3) massive neck swelling precludes identification of
necessary landmarks; or (4) other laryngeal injury is so
great that cricothyroidotomy is impossible.
• Notably, tracheostomy is the preferred procedure in a
patient with chronic need for a surgical airway.
• If tracheostomy rather than cricothyroidotomy is
required for the emergent case, there are recent data in a
variety of situations (especially traumatic injury) sug-
gesting that “high” tracheostomy should be performed
percutaneously. High percutaneous tracheostomy place-
ment is performed via needle into the membrane between
the first and second tracheal cartilages. This procedure, by
most accounts, is not yet universally accepted though it
may be in the future as experience grows.
COMPLICATIONS
• Even in the most experienced hands, emergency sur-
gical airways are associated with a high degree of
complications. Most studies report composite compli-
cation rates ranging from 18 to 32% for cricothy-
roidotomy. Emergent tracheostomy is associated with
an even higher risk of poor outcome.
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TABLE 136-1 Surgical Procedure for Placement of an Airway
CRICOTHYROIDOTOMY TRACHEOSTOMY
1. Position—neck should be hyperextended with the head supported 1. Position—neck should be hyperextended with the head supported by
by the table the table
2. Stabilization—the nondominant hand stabilizes the laryngeal 2. Cutaneous incision—is made 1–2 cm below the cricoid cartilage in the
cartilage with the index finger in the superior notch and the triangle formed by the heads of the sternocleidomastoid muscles and the
thumb and forefinger laterally cricoid cartilage
3. Cutaneous incision—is made in either a horizontal or vertical 3. Dissection—is performed to identify and separate strap muscles, transect
direction depending on landmark identification, skill of the the thyroid isthmus, and, if necessary, identify and avoid the recurrent
surgeon, and desire for future cosmetic appearance laryngeal nerves
4. Cricothyroid incision—is made as a horizontal stab incision 4. Tracheal incision—is made into the membrane between the 2nd to 3rd or
performed with the knife directed slightly cephalad to avoid 3rd to 4th tracheal cartilage with a midline division (not horizontal stab).
injury to the posterior tracheal wall The incision should not be more than 5 mm
5. Dilatation—is summarized by “Once in, stay in.” The blade 5. Cannulation—is performed using a tube that is approximately 50–75%
should be replaced by a dilator or hemostat before withdrawing of the diameter of the trachea, placed at a 90° angle and rotated caudally
6. Insertion—an appropriate-sized (usually 6 mm) tracheostomy, 6. Confirmation—of air and suction should be performed
endotracheal, or special cricothyroidotomy tube is inserted
7. Confirmation—of air flow and suction should be performed 7. Fixation—is performed using tracheal sutures and around the neck straps
8. Fixation—is assured with skin sutures, tape, or other means
TABLE 136-2 Indications for Emergent Surgical Airway Placement
INDICATION REASON
1. Failed intubation Regardless of the reason, failure to intubate (especially repeatedly) in a patient who needs emergent airway placement
is always an indication for surgical airway. 
2. Upper airway obstruction For purposes of classification, think of this as a “tube” problem. The tube can be blocked by anything in it, outside
of it, or the tube can block itself. As an example: obstruction can come from inside the airway (aspirated foreign
body), from the walls of the airway (laryngeal edema from angiotensin-converting enzyme [ACE] inhibitors),
or from external compression (traumatic cervical spine injury).
3. Cervical fracture/neck trauma Compromise of the cervical spine and structures supporting the head and neck may lead to compromise of the
upper airway. In addition, cervical fracture may predispose a patient to traumatic intubation and its attendant
complications.
4. Facial or nasal trauma As these conditions lead to a high likelihood of disruption of the normal anatomy of the naso- and oropharynx,
intubation is difficult or impossible.
5. Endotracheal tube Though this could be contained within #2 above, however, it deserves its own category. Recall that this type of
laryngeal injury condition often occurs when failed or difficult intubation is combined with any of the other indications listed.
Airway compromise can be from tissue, blood, or edema.
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• Adverse outcomes are often due to the poor condi-
tions surrounding most emergencies. An especially
common complicating factor is massive neck swelling
obscuring the thyroid cartilage.
• Complications range from minor to major or life
threatening, but more often fall toward the severe end.
This is largely due to the dire conditions in which we
find these patients.
• Complications can be grouped into those that occur
early, or immediate, and those that occur late.
• Possible complications include: subcutaneous or medi-
astinal emphysema, pneumothorax (especially common
with tracheostomy), hemorrhage, tube occlusion from
debris, tube misplacement (see below), infection of the
site, tracheobronchopulmonary infection, tracheobra-
chiocephalic artery fistula, and tracheal or subglottic
stenosis.
• Tube misplacement may occur in a variety of loca-
tions. It is the only complication more common in
cricothyroidotomy. Tube misplacement can result in a
fatal loss of airway control.
• Approximately one-third of malpositioning occurs
when the tube is placed into the pretracheal tissue. In
addition, the tube may commonly be passed upward
into the pharynx rather than downward into the tra-
chea. More rarely, the tube may be placed into the thy-
roid cartilage itself, into the pharynx, or even into the
esophagus.
• Complications are summarized in Table 136-3.
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TABLE 136-3 Complications of Emergent Surgical Airway
EARLY COMPLICATION LATE COMPLICATION
Hemorrhage Pneumonia
Pneumothorax (unilateral or bilateral) Paratracheal abscess
Tube misplacement Stomal infection
Posterior wall or other tissue ulceration Tube occlusion
Subcutaneous or mediastinal emphysema Tracheoesophageal fistula
Tube occlusion Tracheobrachiocephalic
artery fistula
Tracheomalacia
Tracheostenosis/subglottic
stenosis
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137 INFECTION CONTROL
IN THE ICU
Vidya Krishnan
KEY POINTS
• Nosocomial infections (NI) represent a huge burden
to patients and the health care system.
• The incidence of many NIs can be reduced by relatively
simple means—hand-washing, upright positioning
during feeding, strict barrier control for invasive catheter
placement—but compliance with such routine measures
requires constant effort.
• Tracking the microbiologic flora of the ICU can help
guide empiric antibiotic use.
EPIDEMIOLOGY
• Nosocomial infections afflict 5–35% of patients admit-
ted to ICUs, and contribute to increased mortality,
length of ICU and hospital stay, and medical care costs.
• More than 80% of NIs are caused by the following:
ventilator-associated pneumonia (VAP), catheter-
related bloodstream infections (BSI), surgical site
infections, and urinary catheter-related infections.
AIMS OF INFECTION CONTROL
IN THE INTENSIVE CARE UNIT
• The primary goal of infection control is to prevent
cross-contamination and to control potential sources
of pathogens that could be transmitted between
patients and from health care workers to patients.
• Another important goal is to direct appropriate use of
surgical antibiotic prophylaxis or empirical therapy
among vulnerable patient groups.
• When the source of the NI is identified, the imple-
mentation of specifically targeted measures against
various types of NIs is critical.
• Infection control also entails curtailing the emergence
of antibiotic-resistant microorganisms.
RISK FACTORS FOR INFECTION
• The greater the severity of underlying illness, the
greater the chance for the patient to develop an infec-
tion. Scoring systems, such as APACHE II/III, have
been used, but the consistency of these scores in pre-
dicting NIs has been limited.
• Prolonged length of stay in the hospital predicts
increased severity of illness and increases the oppor-
tunity for infection.
• The use of interventions that are common in the ICU,
including mechanical ventilation and vascular access,
increases the risk of infection.
• Understaffing of nurses and overcrowding in the ICU
(both resulting in high patient:nurse ratios) have both
been shown to increase NIs. Reasons for these find-
ings include lower compliance with hand hygiene and
increased colonization pressure.
• Use of multiple-dose vials for medications may promote
cross-contamination. Multidose vials of medications
have been independently associated with Enterobacter
cloacae carriage.
• Immunosuppression of patients, including neutropenia,
HIV, medications, and burn patients, results in higher
rates of infection.
INFECTION PREVENTION
AND CONTROL
• Hand hygiene. Hand hygiene by health care workers
is the simplest intervention that has the greatest poten-
tial of reducing NIs. Surveillance studies have shown
that the hands of over 75% of ICU health care workers
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carry infectious organisms, including gram-negative
bacilli and Candida spp. Alternative hand hygiene
agents (e.g., chlorhexidine gluconate) reduce hand
contamination more than hand-washing alone.
Alcohol-based treatments cause less skin drying and
damage and take less time to perform, resulting in
increased compliance.
• Isolation of patients. The isolation practices recom-
mended by the Health Care Infection Control
Practices Advisory Committee (HICPAC), which are
also available online at http:www.cdc.gov/ncidod/
hip/isolat/isolat.htm, are summarized in Table 137-1.
• Restriction of antibiotic use:
 Rational use of antibiotics. One of the critical factors
that are associated with outcome is time to appropri-
ate antibiotic therapy, resulting in frequent use of
broad-spectrum of antibiotics in the management of
critically ill patients. It is necessary, however, to
readdress the choice of antibiotics often, and narrow
the spectrum as possible. Antibiotic prescription
should be guided by a thorough, systematic approach.
 Is infection confirmed or likely to be present in the
patient?
 What is the infectious disease occurring in the
patient?
 Have diagnostic studies (such as blood cultures,
tissue biopsy, or noninvasive radiologic imaging
techniques) been performed to confirm the pres-
ence or persistence of infection?
 Prevention of wound infection. The use of antibi-
otics for wound infection prevention has been well
established prior to surgical procedures.
 Prevention of bacterial endocarditis. The use of
antibiotics for prevention of bacterial endocarditis
has not been well established by clinical trials.
Nonetheless, antibiotic prophylaxis is recommended
for patients with valvulopathy (congenital or
acquired) or prosthetic valves (bioprosthetic and
homograft valves) prior to certain procedures. The
1997 updated recommendations from the American
Heart Association for prevention of infectious endo-
carditis, which are available online at the American
Heart Association Web site (http://216.185.112.5/
presenter.jhtml?identifier=1729), are summarized in
Table 137-2.
 Topical antibiotics for sterile sites or clean skin
wounds. With the exception of sulfonamide creams
in the management of burn patients, all other meth-
ods of topical antibiotic application (endotracheal
nonabsorbable antibiotics, urinary bladder instilla-
tion of antibiotics, antibiotic creams for skin
wounds) have been ineffective, due to ineffective
prophylaxis of infection, development of resistance,
and/or superinfection.
 Selective decontamination of the digestive tract
(SDD). Because evidence of effectiveness in reduc-
ing morbidity and mortality is lacking, this method
is not recommended.
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TABLE 137-1 Diseases With Transmission-Based Precautions and Recommended Barrier Protection
PRECAUTION DISEASE∗ BARRIER
Standard universal All Gloves (for all anticipated contact with body fluid)
Gown, mask, eye protection recommended, if possible
splash or spray of body fluid
Airborne precautions Measles, VZV, TB, viral hemorrhagic fever Mask (N-95 standard certified-mask 170)
Droplet precautions Meningitis, pneumonia, epiglottitis, sepsis Mask
(Neisseria meningitidis, Haemophilus influenzae, Eye protection
diphtheria, Mycoplasma pneumoniae, Pertussis,
group A Streptococcus)
Serious viral infections (adenovirus, influenza, mumps,
parvovirus B19, rubella)
Contact precautions Resistant bacteria (MRSA, VRE, multiresistant Gloves
pseudomonal strains) Gown
Enteric infections (C. difficile)
Respiratory and enteral infections in young children
(syncytial virus, rotavirus, parainfluenza)
Highly contagious skin infections (diphtheria, HSV,
impetigo, uncovered abscess, pediculosis, scabies,
staphylococcal furunculosis, VZV)
Viral hemorrhagic fever
ABBREVIATIONS: VZV, varicella zoster virus; TB, tuberculosis; MRSA, methicillin-resistant Staphylococcus aureus; VRE, vancomycin-resistant
enterococcus; HSV, herpes simplex virus.
∗Includes common diseases, but not an exhaustive list.
SOURCE: Adapted from Garner JS. Guideline for isolation precautions in hospitals: the Hospital Infection Control Practices Advisory Committee. Infect
Control Hosp Epidemiol 1996;17:53–80.
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TABLE 137-2 Prophylaxis of Infectious Endocarditis
CARDIAC CONDITIONS BY RISK PROCEDURES FOR WHICH INFECTIOUS
OF INFECTIOUS ENDOCARDITIS ENDOCARDITIS PROPHYLAXIS IS RECOMMENDED
High-risk category: Endocarditis prophylaxis recommended:
Prosthetic cardiac valves, including bioprosthetic and homograft valves Dental procedures∗
Previous bacterial endocarditis Respiratory tract
Complex cyanotic congenital heart disease (e.g., single ventricle states, Tonsillectomy and/or adenoidectomy
transposition of the great arteries, and tetralogy of Fallot) Surgeries involving respiratory mucosa
Surgically constructed systemic pulmonary shunts or conduits Bronchoscopy with a rigid scope
Gastrointestinal tract†
Sclerotherapy for esophageal varices
Esophageal stricture dilation
ERCP with biliary obstruction
Biliary tract surgery
Surgeries that involve intestinal mucosa
Genitourinary tract
Prostatic surgery
Cystoscopy
Urethral dilation
Moderate-risk category: Endocarditis prophylaxis not recommended:
Most other congenital cardiac malformations (other than above and below) Respiratory tract
Acquired valvular dysfunction (e.g., rheumatic heart disease) Endotracheal intubation
Hypertrophic cardiomyopathy Bronchoscopy with a flexible scope
MVP with valvular regurgitation and/or thickened leaflets Tympanostomy tube insertion
Gastrointestinal tract
Transesophageal echocardiography
Endoscopy with or without biopsy
Genitourinary tract
Vaginal hysterectomy
Vaginal delivery
Cesarean section
In uninfected tissue:
Urethral catheterization
Uterine dilatation and curettage
Therapeutic abortion
Sterilization procedures
Intrauterine devices insertion/removal
Other
Cardiac catheterization
Implanted cardiac pacemakers, implanted defibrillators,
and coronary stents
Incision/biopsy of surgically scrubbed skin
Circumcision
Negligible-risk category (no greater risk than the general population)—
endocarditis prophylaxis not recommended:
Isolated secundum atrial septal defect
Surgical repair of atrial septal defect, ventricular septal defect, or patent ductus arteriosus (without residua beyond 6 months)
Previous coronary artery bypass graft surgery
MVP without valvular regurgitation
Physiologic, functional, or innocent murmurs 
Previous Kawasaki disease without valvular dysfunction
Previous rheumatic fever without valvular dysfunction
Cardiac pacemakers (intravascular and epicardial) and implanted defibrillators
ABBREVIATIONS: MVP, mitral valve prolapse; ERCP, endoscopic retrograde cholangiopancreatogram.
∗Refer to source article for detailed description of procedures.
†Prophylaxis is recommended for high-risk patients; it is optional for medium-risk patients.
SOURCE: Adapted from Adnan Dajani AS, Taubert KA, Wilson W, et al. Prevention of bacterial endocarditis. JAMA 1997;277:1794–1801. Copyright 1997
American Medical Association. All rights reserved.
• Surveillance programs should be designed to monitor
the rates of NIs, and detect the emergence of resistant
or unusual infectious organisms. Successful surveil-
lance programs require the teamwork of physicians,
nurses, and epidemiologists. A comprehensive sur-
veillance strategy requires both patient-directed (epi-
demiologic surveillance of resistant or unusual
organisms) and environment-directed (administrative
surveillance of health care workers, patients, and
medical equipment) interventions.
• Specific measures of intervention are warranted when
the source of the NI is identified. One universal meas-
ure that will reduce NIs is the liberation of the patient
from unnecessary devices and interventions. Examples
of other targeted measures include the following:
 BSI secondary to vascular access are the most
common type of ICU NI. Practices that reduce
catheter-related BSIs include consideration of the
best insertion site, observation of maximal barrier
precautions during insertion of the catheter, use of
chlorhexidine gluconate for insertion site skin anti-
sepsis, and use of antimicrobial-impregnated or
antibiotic-coated catheters (particularly when patient
risk is high or catheter use is expected to be at least
1 week).
 VAP is associated with significant morbidity and
mortality. Noninvasive ventilation should be used
when appropriate, since the risk of VAP is consider-
ably less with this intervention. Preventive strategies
to reduce the incidence of VAP include orotracheal
(nonnasal) route of intubation, semirecumbent
patient positioning, subglottic secretion suctioning,
optimal use of sedation (to reduce the duration of
mechanical ventilation), avoidance of large gastric
volumes, and promotion of patient oral hygiene (e.g.,
chlorhexidine mouth rinse). Prophylactic antibiotics
have not been shown to prevent VAP, but are being
considered in high-risk patient subsets (e.g., neu-
tropenia, HIV infection, and postabdominal surgery).
Once VAP is confirmed or suspected, the implemen-
tation of a rotating antibiotic schedule may reduce the
emergence of antibiotic-resistant organisms.
 Urinary tract infections (UTIs) develop in 5% of
patients with a urinary catheter per day of catheteri-
zation. Interventions that can reduce the risk of
catheter-related bacteriuria include use of suprapubic
or condom catheters (instead of urethral catheters),
and aseptic catheter insertion and maintenance.
 Clostridium difficile colitis is common among
patients receiving antibiotics. Restriction of antibi-
otic use and hand hygiene are the cornerstones in
prevention of C. difficile colitis.
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138 TRANSPORTING THE
CRITICALLY ILL
Joseph Levitt
KEY POINTS
• The goals of the transport of the critically ill patient
should include provision of all necessary monitoring
and emergent interventions to minimize risk during
this transition period.
• Each transport should weigh the risks and benefits of
moving the patient.
• While the physician sending the patient is responsible
for making the essential on-site evaluation of the
patient and determining the patient’s stability, guid-
ance from more specialized centers receiving the
patient should be sought as well.
BACKGROUND
• The movement of any critically ill or injured patient is
not without hazard. Though these patients may be
considered “stable,” their physiologic reserve is often
limited. Even minor adverse physiologic changes in
these patients during transport may cascade into life-
threatening complications. Rates of complications or
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serious physiologic derangements during intrahospital
transport have been reported as high as 45–75%.
• Transfers may be between hospitals (via ambulance,
helicopter, or airplane), within the hospital (from the
emergency department, to the operating rooms or radi-
ology), or simply between beds, gurneys, and so forth.
While each situation has unique features to address,
they all share potential hazards.
• In an effort to reduce patient risks, recommendations
have been published by the Transfer Guidelines Task
Force Committee of the Society of Critical Care
Medicine, the American College of Critical Care
Medicine, and the American Association of Critical
Care Nurses.
INTERHOSPITAL TRANSFERS
• Transfers from an emergency department are regu-
lated under the Emergency Medical Treatment and
Active Labor Act (EMTALA). While this act does not
specifically address other interfacility transfers, its
guidelines are generally applicable.
• When transferring between hospitals, utilizing appropri-
ately trained and experienced personnel to plan and
carry out the transfer is recommended. Direct physician-
to-physician contact and detailed communication
between receiving and accepting facilities is required.
• Federal law also has implications for receiving insti-
tutions. Hospitals with specialized services may not
refuse to accept an appropriate transfer if they have
the capacity to treat the individual. 
• A receiving hospital cannot refuse to accept the trans-
fer of a patient who is unstable or has an emergency
medical condition if they have the capacity and ability
to care for a patient.
• Excluding variation in road and weather conditions,
ambulances are generally the fastest mode of transport
for distances under 25 miles, with helicopters fastest
between 25 and 150 miles, and airplanes preferred for
distances beyond 150 miles.
PLANNING
• Careful assessment of risks and benefits should be per-
formed prior to deciding to attempt transfer with con-
sideration of alternatives when the risks are significant. 
• For unstable patients, it may be preferable for diag-
nostic studies (e.g., substituting portable ultrasound
and x-ray for a computed tomography [CT] scan) and
therapeutic or surgical procedures to be done at the
bedside in the ICU.
• When deteriorating status requires transfer to a more
acute care setting, assessment of the pace of deteriora-
tion and benefit of speed of transfer must be weighed
against delaying transfer while attempting to stabilize
the patient.
• Prior to all transfers, a brief assessment of the patient
and anticipation of potential complication is neces-
sary to ensure proper planning.
• Appropriate transport personnel and equipment should
be arranged prior to transfer.
AIRWAY
• Maintaining a patent airway and adequate oxygenation
and ventilation is the highest priority of any transfer.
• Patients with significant respiratory distress, especially
those receiving active therapy (noninvasive positive
pressure ventilation, heliox, continuous nebulizers)
which may not be possible during transfer, should be
intubated prior to transfer, even if they may not other-
wise require it.
• For intubated patients, position and security of the
endotracheal tube should be confirmed prior to trans-
fer. Particular attention must be paid to not dislodging
or advancing the tube. While ventilation can be per-
formed with either a manual bag-valve-mask or
portable ventilator, studies suggest portable ventila-
tors provide more constant and reliable ventilation.
• For patients requiring high levels of supplemental
oxygen, sufficient oxygen supply to last the duration
of transfer, including unexpected delays must be con-
firmed prior to departure.
• When patients require high levels of positive end-
expiratory pressure (PEEP), a bag-valve-mask or
portable ventilator capable of providing similar PEEP
levels should be used. For extremely unstable patients,
demonstrating adequate oxygenation and hemodynamic
stability during 10–15 minutes of manual bagging or
being connected to the portable ventilator prior to trans-
fer may be prudent.
CIRCULATION
• Securing an adequate vascular access is a necessity
prior to transfer of patients with unstable circulations. 
• Large-bore peripheral IVs are more prone to being
displaced during transfer and are not appropriate for
infusing many vasoactive medication.
• Transferring physicians should consider placing a
central venous catheter (CVC) in any patient whose
circulation may require infusion of fluids or vasoac-
tive medications during transfer.
• All nonessential medications should be discontinued
prior to during transfer to minimize risk of disrupt-
ing delivery of essential medication. Paralytics and
sedatives may be given by IV bolus during transport
rather than by continuous infusion. 
MEDICAL PERSONNEL
• The Transfer Guidelines Task recommended that all
critical care transports, both intrahospital and inter-
hospital, should be performed by dedicated, specially
trained transport teams.
• The guidelines recommend that all transported criti-
cally ill patients be accompanied by a minimum of
two people, one of which should be a critical care
nurse. They suggest that an accompanying physician
is necessary only for unstable patients.
• Physician presence during transfers has been shown to
reduce complications. 
EQUIPMENT
• Critically ill or injured patients require real-time mon-
itoring. Pulse oximetry and ECG monitoring can pro-
vide continuous oxygenation and cardiac assessment.
The blood pressure can be measured using an auto-
matic noninvasive blood pressure device if continuous
measurements via arterial line are not indicated. 
• Suitable transport monitors and equipment are portable,
durable, lightweight, and battery powered. Audible and
visible alarms for monitors, infusion pumps, and venti-
lators are required.
• Transport equipment should be compatible with the
lines, fittings, and power outlets at the destination unit
or in the transport vehicle. All transport equipment
should fit into elevators and transport vehicles, while
leaving enough room for transport personnel to
function.
• Transport personnel should familiarize themselves
with all equipment and an adequate supply of medi-
cation and battery charge for infusion pumps should
be confirmed prior to transfer.
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139 TELEMEDICINE
AND THE EICU
Jeremy Leventhal
KEY POINTS
• Current technology makes possible the import of
much of the bedside and hospital data concerning crit-
ically ill patients to a central location for physician
assessment.
• In theory, telemedicine would distribute a limited
resource (the critical care physician) over a large patient
population, particularly during time periods when direct
physician coverage was not available to the ICU.
• Further assessment will be needed to know if this
approach to care helps achieve the goals of standard-
ized care practices, enhanced operating effectiveness,
and improved patient outcomes.
BACKGROUND
• Since the birth of intensive care medicine in the 1950s,
a growing demand has arisen for its heavily monitored
setting.
• The advent of therapeutic modalities that include dial-
ysis and mechanical ventilation have resulted in the
prolongation of lives that would surely have been lost
in the past.
• With the increased use of intensive care units (ICU) in
hospitals, efforts of researchers have been directed at
ways to decrease the mortality rates amongst the
aggregate of unstable patients who normally populate
an ICU.
• In 2000, the Institute of Medicine published a report
citing that between 44,000 and 98,000 deaths have
been the result of medical errors. Because of the
acuity of a critically ill patient, the ICU is vulnerable
432 SECTION 12 • GENERAL ISSUES IN THE ICU
CHAPTER 139 • TELEMEDICINE AND THE EICU     433
to errors that will result in poor outcomes. A success-
ful effort to curb the amount of medical errors in the
ICU will surely result in a consequent decrease in
mortality.
• The role of the physicians making decisions in the
ICU has come into close scrutiny. Large purchasers of
health care in the United States formed the Leapfrog
group in 1998. Its purpose was to find ways to
increase the safety and value of health care delivered
in this country. One of its many recommendations
involved physician staffing in the ICU.
• The Leapfrog group hypothesized that by having cer-
tified intensivists more closely involved in the care of
the patients in the ICU, mortality could be decreased
by as much as 10%. The Leapfrog group has predicted
this intervention alone to result in the prevention of as
many as 50,000 deaths a year.
DATA
• A study in the Journal of the American Medical
Association supported this hypothesis. The JAMA
study identified 26 individual studies which were
then used to compare alternative staffing strategies in
the ICU. The unit physician staffing was grouped
into staffing categories as either low-intensity or
high-intensity.
 The low intensity group had either no staffing by an
intensivist or elective staffing only.
 The high-intensity group involved having either a
mandatory consultation by an intensivist, or having
care given in a closed unit where all the care was
directed by intensivists.
 The high-intensity staffing categories were found to
be associated with a decreased mortality in the ICU
as well as overall hospital mortality (61% and 71%,
respectively).
• A 2000 paper in JAMA commented that intensivists
were providing only 37% of care in the ICU.
• Furthermore, the same study in JAMA found that the
percentage of patients receiving high-intensity cover-
age by intensivists is as low as 10%.
• There are approximately 5500 intensivists now prac-
ticing in the United States. With increasing admis-
sions to ICUs, the demand for these subspecialists
will surely increase. The supply, however, is not pro-
jected to increase accordingly.
• The paper in JAMA projects this short supply to result
in a shortfall in intensivist hours by 22% in 2020 and
increase to 35% in 2030. A creative solution to
staffing ICUs with the limited supply of intensivists
available as well as designing systems that will help
decrease medical errors needed to be found.
THE eICU OR “TELEMEDICINE”
• In attempting to address the increased needs medical
advances have placed on the ICUs, the notion of an
electronic ICU (eICU) and telemedicine have arisen.
The notion of an eICU incorporates telemedicine.
• A Critical Care Medicine 2001 article on the subject
defined telemedicine as “the use of medical information
exchanged from one site to another via electronic com-
munication for health and education of the patient or
health care provider and for the purpose of improving
health care.” Put simply, telemedicine allows physicians
in remote locations to take in active role in evaluating
and guiding the care of patients in the ICU. The location
of the practitioner can include his/her home.
• What makes the eICU a true innovation is not just the
way it makes better use of a limited amount of inten-
sivists with telemedicine. Rather, the eICU refers to a
model that uses both the 24-hour decision-making
capability of a remote intensivist in conjunction with
a multidisciplinary team. This team benefits from the
preventive strategies, early computerized clinical
alarms, evidence-based medicine derived from previ-
ous outcomes data, and 24-hour access to an inten-
sivist’s clinical expertise and provides superior care to
the patient.
• The eICU model incorporates intensivists, housestaff,
nurses, physician’s assistants, respiratory therapists,
health care administrators, and information technolo-
gists in providing care to its patients.
 The intensivist can interact with members of the
team on-site by use of teleconferencing.
 This can allow for observation of the patient as well as
supervision of procedures performed on the patient.
 The teleconferencing can be used for interactions
amongst the staff and even for family interactions.
• Furthermore, the eICU works with data (lab values,
imaging), smart alarms, and computerized order entry
to potentially decrease the amount of medical errors.
• Outcome research can be automatically generated by
the data followed on the computer in order to constantly
upgrade the quality of care provided by an institution.
The data are immediately available to the multidiscipli-
nary team for interpretation and subsequent action.
• This availability, along with smart alarms that would
bring to attention concerning labs/vital signs, would
help handle or even prevent complications such as pneu-
monia, cerebral vascular accidents, and myocardial
infarctions. The amount of time that this eICU paradigm
would need to be in place depends on how often a spe-
cific hospital is adequately staffed with intensivists.
• eICUs can be linked to provide support to multiple
ICUs. For academic centers the amount of time where
eICU coverage is needed could be as little as 12 hours,
whereas more rural locations might require the eICU
model all the time to ensure the highest level of care.
• A study published in 2000 in Critical Care Medicine
journal supports the use of eICUs.
 The design was a triple-cohort study that took place
in the surgical ICU of an academically affiliated
community hospital where intensivist consultations
were available, but not on-site.
 The outcomes from the intervention time were com-
pared to outcomes from two separate periods of
equal time in the same ICU.
 Camera and data transmission equipment were
installed in both the ICUs as well as the intensivists’
homes.
 The intensivists all provided care exclusively from
their homes through teleconferencing with house-
staff and nursing.
• The study examined three different 16-week periods.
During only one of these periods was the telemedicine
intervention enacted. During the other 16-week peri-
ods, intensivists reviewed the charts to aid with triage.
If the need was there, they would act as consultants
(~30%) or assist in the management (5–10%).
 Data were gathered on ICU and hospital mortality
rates, complication rates, length of ICU stay, and
length of hospital stay.
 Throughout the intervention period, the intensivist
involved would formulate a plan while teleconfer-
encing with the on-site housestaff.
 Physiologic data from bedside monitors were
reviewed throughout the day, approximately every
2 hours except for the period between midnight and
6 in the morning.
 An intensivist was available 24 hours a day.
 The intensivists never actually physically examined
the patients.
• The results:
 Severity-adjusted ICU mortality, in comparison to the
two baseline periods, decreased by 68% and 46%.
 Rates of complications decreased by 44% and 50%.
 ICU length of stay decreased by 34% and 30%.
• The eICU is a fairly recent but increasingly necessary
response to adapting our ICUs to the inadequate
supply of intensivists while attempting to actuate pre-
viously proven methods of achieving improved out-
comes in the ICU.
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140 WITHHOLDING AND
WITHDRAWING LIFE-
SUSTAINING THERAPY
AND ADMINISTERING
PALLIATIVE CARE
Steven Q. Davis
KEY POINTS
• Most patients who die in the intensive care unit will
do so after conscious decisions are made to shift goals
from cure to palliative care.
• Ideally, agreement will be achieved among patients,
families, and care providers that further restorative
care would not be beneficial when such decisions are
made.
• Accordingly, palliative care is an essential part of crit-
ical care management, and the skill set to support
patients and families through this difficult process
should be part of all critical care physicians’ training
and clinical expertise.
DEFINITION
• Withholding and withdrawing life-sustaining therapy
or life support is a process by which various medical
interventions either are not given to or are taken away
from patients with the expectation that they will die
from their underlying illnesses.
• When applied to patients who are brain dead, life sup-
port should more appropriately be referred to as organ
support.
• Palliative care is the prevention or treatment of pain,
dyspnea, anxiety, and other kinds of suffering in dying
patients. It represents an attitude that includes open
communication between all caregivers and patients
and their surrogates and acknowledgement of the
emotional needs of all involved.
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ETHICAL ASPECTS
• A decision to withdraw a treatment is equivalent to
not initiating it, particularly since starting a ther-
apy may be necessary to evaluate the patient’s
condition.
• There are no ethical or moral differences between cat-
egories of treatment (cardiopulmonary resuscitation
[CPR], mechanical ventilation, vasoactive medica-
tions, nutrition, and so forth).
• The indefinite maintenance of a patient in a persistent
vegetative state raises ethical concerns both for the
patient’s dignity and appropriate health care resource
utilization.
• The wishes of an informed adult patient with decision-
making capacity should be the primary consideration
in treatment decisions.
• The patient’s needs during this process are to receive
adequate pain control, avoid prolongation of death,
achieve a sense of control over the dying process, and
to strengthen relationships with loved ones.
• The family’s needs are to be with the dying loved one,
to be helpful to them, to be informed of changes in the
patient’s condition, to understand therapy, to be assured
of the patient’s comfort, and to be comforted them-
selves, to express their emotions, to be assured that
their decisions were correct, to find meaning in the
death of the loved one, and to be fed and rested through
the dying process of their loved one.
• The critical care team’s needs are to establish con-
sensus regarding the goals and strategies for provid-
ing palliative care, to gain skills and knowledge in
palliative care, to be supported by their institution
and to have opportunities for bereavement after the
patient dies.
LEGAL ASPECTS
• Withholding and withdrawing care are justified by the
principles of informed consent and informed refusal,
both of which are derived from the patient’s right of
self-determination.
• All American courts recognize a competent adult’s
right to refuse life-sustaining care.
• When a patient is unable to make decisions for him-
self or herself, courts recognize the authority of a sur-
rogate decision maker. However, the standards used to
decide whether care will be withheld or withdrawn
vary by jurisdiction.
• The U.S. Supreme Court has described the distinction
between assisted suicide and withdrawal or withhold-
ing of care. “When a patient refuses life-sustaining
medical treatment, he dies from an underlying fatal
disease or pathology; but if a patient ingests lethal
medication prescribed by a physician, he is killed by
that medication.”
• The principle of double effect allows that medica-
tions that relieve pain and suffering (analgesics
and sedatives) are permissible even if they may
have the unintended consequence of hastening
death. The positive, morally acceptable reason
(limiting pain and suffering) must be the reason for
using the therapy that could produce an undesir-
able consequence.
CLINICAL ASPECTS
• In various surveys of intensive care units in the United
States, withholding or withdrawal of support was
involved in 75–90% of deaths.
• Prior to meeting with the patient or surrogate, all
involved caregivers, including the primary service and
any consultants, must arrive at a consensus. Otherwise,
the patient or family is very likely to be confused and
angered by the lack of consensus.
• Generally, surrogate decision makers eventually agree
with a physician recommending withdrawal or with-
holding of care. Effective and frequent communica-
tion with the surrogate is essential. A care provider
must be ready for the surrogate to not accept the deci-
sion and have a plan, usually involving the transfer of
care for the patient to another provider.
• While individual items may be discussed with the
patient or surrogate (CPR, mechanical ventilation,
vasoactive drugs, and so forth), it is preferable to pres-
ent these items more generally and grouped together
as interventions that will not benefit the patient and
will most likely cause harm or prolong death.
• Most families are not equipped to pick from a menu
of options to decide which therapies to withhold.
Also, this may create the impression that some of the
options may benefit the patient, making the decision
far more difficult to make.
• Adequate and aggressive sedation and analgesia are
an absolute requirement. In one study, prior to with-
holding care patients received approximately 3 mg/h
of morphine and 2 mg/h of diazepam. After withhold-
ing and withdrawal of support, this increased to
approximately 11 mg/h of morphine and 10 mg/h of
diazepam.
• If a family is unable to reach a decision due to dissen-
sion within the family, they must appoint one member
of the family to act as a spokesperson and to make
decisions for the group. When this happens, it is cru-
cial to have meetings that involve as many members
of the family as possible, so that everyone starts with
the same information about the patient’s clinical
condition.
• The patient and family should be assured that care
will be withdrawn expeditiously, with the primary
concern for the patient’s comfort.
• Extubation may be considered, but changing the venti-
lator to a FiO2 of 21% with no positive end-expiratory
pressure (PEEP) may be sufficient to provide comfort
and prevent gasping for air. Enough sedation and anal-
gesia must be used no matter what changes are made
to the ventilator.
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